

National Institutes of Health

Office of Financial Management

Royalties Semiannual Report -- Payments due to Inventors by IC -- Period ending: March 2020

CC

\$19,396.46

Baecher, Nicolai

(b) (3) (A), (b) (4),
(b) (6)

Gladwin, Mark T.

Harrison, Adam Patrick

Kwak, Jin Tae

Lay, Nathan Stephan

Liu, Jiamin

Lu, Le

Mollura, Daniel Joseph

Reinhard Roth, Holger

Summers, Ronald

Tsehay, Yohannes Kebede

Wang, Xiaosong

Wood, Bradford J

Xu, Sheng

Xu, Ziyue

Yao, Jianhua

CDC

\$270,590.65

Ades, Edwin W.

(b) (3) (A), (b) (4),
(b) (6)

Albarino, Cesar G.

Alisio, Carol H.

Aloisio, Carol H.

Amador, Manuel

Anderson, Burt E.

Anderson, Larry J.

Anderson, Raydel

Bagarozzi, Dennis Anthony

Barclay, Leslie

Barrera, Roberto

Beck, Eric T.

Bellini, William J.
Benitez, Alvaro J.
Bird, Brian H.
Bishop, Henry
Black, Charlotte M.
Black, Jodi B.
Bobick, Thomas G.
Boyer, Anne E.
Burns, Cara C.
Campagnoli, Raymond
Cantis, Douglas M.
Carlone, George M.
Carvalho, Maria Da Gloria
Castro, Arnold R.
Chang, Gwong-Jen J.
Chhabra, Preeti
Collins, Carlyn
Cox, Nancy J.
Cromeans, Theresa
Damon, Inger K.
Davis, Brent S.
Dawson, Jacqueline E.
Devos, Joshua R.
Diaz, Maureen
Dolan, Marc C.
Donis, Ruben O.
Donlan, Rodney M.
Edgell, Herbert D.
Erdman, Dean D.
Esposito, Joseph J.
Esswein, Eric J.
Fields, Howard A.
Fields, Patricia
Folks, Thomas M

(b) (3) (A), (b) (4), (b)
(6)

Freeman, Charlotte
Gagnon, MariBeth
Galland, Gale G.
Garcia Lerma, Jose Gerardo
Garcia-Lerma, J. Geraldo
Gentsch, Jon R.
George, Robert W.
Glass, Roger I.
Goldstein, Jason Marc
Granade, Timothy C.
Gregoricus, Nicole
Guo, Zhu
Hanlon, Cathleen
Harmon, Maurice
Hart, John C.
Hatcher, Cynthia P.
Heneine, Walid M.
Hierholzer, John C.
Hill, Vincent R.
Hummer, Jon
Janssen, Robert
Jiang, Baoming
Katz, Jacqueline M.
Kendal, Alan P.
Kennedy, Eugene R.
Kew, Olen M.
Khudyakov, Yury E
Kinney, Claire Huang
Kinney, Richard M.
Kirby, Wayne
Klimov, Alexander I.
Ksiazek, Thomas G.
Lange, James V.
Leaumont, Collette F.

(b) (3) (A), (b) (4),
(b) (6)

Lee, Tommy
Lewis, Daniel M.
Lindstrom, Stephen
Loftin, Lamorris
Lopez, Carlos
Lu, Xiaoyan
Mackay, Andrew J.
Maher, Kaija
Mark W. Reimer (b) (6)
Maupin, Gary O.
Mayer, Leonard W.
McDougal, Steve
McGee, Lesley
McKenzie, Eugene A.
McQuiston, John R.
Moore, Deborah D.
Morrill, William E.
Murga, Ricardo
Murphy, William J.
Narayanan, Jothikumar
Nichol, Stuart T.
O'Connor, Steven
Olson, Victoria Ann
Otten, Ronald
Pallansch, Mark A.
Parekh, Bharat S.
Pau, Chou-Pong
Pellett, Philip E.
Peret, Teresa C.
Phillips, Donald
Pohl, Jan
Pope, Victoria
Quay, Jacqueline
Quinn, Conrad P.

(b) (3) (A), (b) (4),
(b) (6)

Raudabaugh, William M.
Reimer, Charles B.
Roehrig, John T.
Rupprecht, Charles E.
Russell, Harold
Saluzzo, Jean-francious
Sampson, Jacquelyn S.
Sanchez, Anthony
Schmechel, Detlef
Shaw, Jing
Smith, Jean S.
Snawder, John E.
Sparks, Kansas
Stephenson, Mark R.
Stevens, James
Stockdale, Carol
Striley, Cynthia A.
Summer, John
Switzer, William
Tamin, Azibi
Tatti, Kathleen M.
Taylor, Roger
Tharpe, Jean A.
Theodore, Mary J.
Thibodeaux, Brett A.
Thomas, Jennifer D.
Tondella, Maria-Lucia
Tong, Suxiang
Tsou, Cecelia
Tuchman, Donald P.
Vinje, Jan
Volkwein, Jon C.
Wagar, Nicholas
Walls, Harriet

(b) (3) (A), (b) (4),
(b) (6)

Wang, Xin
Wang, Yuhuan
Wang, Zhongde
Wei, Xierong
Wells, Thomas
Wilson, Jason Ray
Winchell, Jonas M.
Wolff, Bernard
Wu, Xianfu
Yager, Pamela
Yamamoto, Masahiro
Yang, Chunfu (Dustin)
Yang, Yong
York, Ian Arthur
Youngpairoj, Ae Saekhou
Zheng, HaoQiang
Zhou, Zhiyong

CIT

Cheng, Ruida
McAuliffe, Matthew

FDA

Donnelly, Raymond P.
Falgout, Barry
Golding, Hana
Khurana, Surender
Markoff, Lewis
Norcross, Michael
Petricoin, Emanuel

NCATS

Alimardanov, Asaf R.
Auld, Douglas S.
Austin, Christopher P.
Bantukallu, Ganesha
Behnke, Mark L.

(b) (3) (A), (b) (4), (b)
(6)

\$54,884.15

(b) (3) (A), (b) (4),
(b) (6)

\$42,050.95

(b) (3) (A), (b) (4),
(b) (6)

Boxer, Matthew
Brimacombe, Kyle R.
Hall, Matthew D
Hu, Xin
Inglese, James
Jadhav, Ajit P.
Jiang, Jian-kang
Kouznetsova, Jennifer

(b) (4)

Liu, Ke
Maloney, David
Marugan, Juan J.
McKew, John C.
Mott, Bryan
Patnaik, Samarjit
Shen, Min
Simeonov, Anton
Skoumbourdis, Amanda P.
Southall, Noel T.
Swaroop, Manju
Thomas, Craig J.
Titus, Steven
Urban, Daniel
Xiao, Jingbo
Xu, Miao
Yang, Shyh Ming
Zhang, Ya-Qin
Zheng, Wei

NCI **\$9,054,356.69**

Aaronson, Stuart A.
Abrams, Scott I
Acquavella, Nicolas
Ahlers, Jeffrey D
Alimandi, Maurizio

(b) (3) (A), (b) (4),
(b) (6)

(b) (3) (A), (b) (4),
(b) (6)

Allegra, Carmen

(b) (4)

Antony, Paul A.

Aplan, Peter D.

Austin, Faye C.

Azimi, Nazli

Bagni- Beyer, Rachel K.

Bang, Sook-Hee

Barrett, J Carl

Barry, Todd

Bartlett, David L

Baskar, Sivasubramanian

Beers, Richard

Benter, Thomas

Bera, Tapan K

Bergamaschi, Cristina

Bernardo, Marcelino L.

Berzofsky, Jay A.

Bluestone, Jeffrey A

Blumberg, Peter M.

Bonner, William M

Bonomi, Carrie A.

Borgel, Suzanne D.

(b) (4)

Boyd, Michael R.

Brinkmann, Ulrich

Broadt, Trevor L.

Buck, Christopher

Burgess, Rebecca C.

Bustin, Michael

Cafri, Gal

Cao, Boliang (Brian)

Caplen, Natasha

(b) (4)

(b) (3) (A), (b) (4), (b) (6)

Chabner, Bruce A
Chang, Kai
Chang, Nancy T.
Chen, Weizao
Cheng, Sheue-Yann
Choyke, Peter L
Chung, Jae Wook
Colcher, David
Conrads, Thomas P
Copeland, Neal
Costantino, Nina
Court, Donald
Crowl, Robert
(b) (4)
Custer, Mary
Datta, Simanti
Deniger, Drew
Dimitrov, Dimiter S.
Doroshov, James H.
Dougherty, Kelly
Dubois, Sigrid
Dudley, Mark
Ellis, Hilary Moyed
Emmert-Buck, Michael R.
Erickson, John W.
Esposito, Dominic
Essand, Lars Magnus
(b) (6) Donald J. Giard
Felber, Barbara K.
Feldman, Steven A
Feng, Mingqian
Feng, Yang
Finch, Paul W.
Fisher, Amanda G.

(b) (3) (A), (b) (4), (b)
(6)

Fitzgerald, David J.
Fitzgerald, Peter C.
Fowler, Daniel
Franchini, Genoveffa
Fry, Terry
Gaitanaris, George A.
Gallo, Robert C.
Gao, Wei
Gartner, Jared
Gartner, Suzanne
Gazdar, Adi F.
Gelboin, (b) (6) Harry
(b) (4)
Giard, Donald
Giardina, Steven
Gillette, William K.
Goldman, Carolyn
Gonzalez, Frank J
Gottesman, Michael M.
Greer, Matthew D.
Greiner, John W.
Gress, Ronald E.
Gros, Alena
Grose, Carissa L.
Gulnik, Sergei V.
Gupta, Shanker Lal
Hahn, Beatrice
Hamilton, Thomas C
Hanada, Kenichi
Hand, Patricia H
Hathcock, Karen
Helman, Lee
Hinrichs, Christian S.
Ho, Mitchell

(b) (3) (A), (b) (4),
(b) (6)

Hodes, Richard
Hodge, Deborah
Hodge, James W.
Holderfield, Matthew T.
Hollingshead, Melinda G.
Hopkins, Ralph F.
Hurwitz, Arthur A.
Hwu, Patrick
(b) (4)
Irvine, Kari R.
Ise, Tomoko
Islam, S M Rafiqul
Issaq, Haleem J.
Jainchill, John L.
Janini, George
Jelinek, Ivett
Jenkins Copeland, Nancy A
Ji, Qingyong
Jiang, Guojian
Jin, Benjamin
Johnson, Bruce E
Johnston, Patrick G.
Jung, Sun-Hee
Jung, Unsu
Kalyanaraman, Vaniambadi S.
Kawakami, Yutaka
Kaye, Frederic J
Kebebew, Electron
Khanna, Chand
Kheif, Samir N.
Khleif, Samir N.
King, Charles R.
Kirnbauer, Reinhard
Kobayashi, Hisataka

(b) (3) (A), (b) (4), (b)
(6)

Kochenderfer, James N
Kraus, (b) (6) Matthias
Krausz, Kristopher W.
Kreitman, Robert J
Kuan, Chien-Tsun
Lacal, Juan C.
Lalani, Almin
Landry, Joseph W.
Lantz, Valerie A
Lapointe, Rejean
Laszlo, Gloria
Lee, Byungkook
Lee, E-Chiang
Leo, Oberdan
Liang, Chi-Ming
Lin, Ying-Wei
Liotta, Lance
Liu, Pentao
Lo, Winifred Margaret
Longo, Dan L
Lorenzi, Philipp
Lori, Franco C.
Lowy, Douglas R.
Lu, Yong-Chen W.
LUCIANO, MICHAEL
Lusso, Paolo
Makrigiannis, Andrew P.
Malekzadeh, Parisa
Mansfield, Elizabeth
Mariner Kilbourne, Jennifer
Markham, Phillip D.
Mason, Llewellyn H.
McCart, Judith Andrea
McMahon, James

(b) (3) (A), (b) (4), (b)
(6)

Mehta, Arpita I
Mertan, Francesca
Michie, Megan Suzanne
Minna, John D.
Misteli, Thomas
Mitra, Guatam (George)
Mitsunaga, Makoto
Mitsuya, Hiroaki
Moore, William
Morgan, Richard A.
Muchmore, Brian P.
Nagata, Satoshi
Nani, Roger R.
Nara, Peter L
Neckers, Leonard
Nourian, Saghar
Nutti, Marianna
O'Brien, Thomas R
O'Keefe, Barry
Oie, Herbert K
Onda, Masanori
Ortaldo, John R.
Ozols, Robert F
Palena, Claudia
Parkhurst, Maria
Parks, Wade P
Pasetto, Anna
Pass, Harvey I.
Pastan, Ira H
Pastrana, Diana V
Pavlakis, George N
Pearce, Larry V
Pendleton, Charles D.
Pierce, Jacalyn

(b) (3) (A), (b) (4), (b)
(6)

Pinto, Peter A
Ponraj, Prabakaran
Popovic, Mikulas
Porter-Gill, Patricia A.
Potter, (b) (6) Michael
Prokunina-Olsson, Ludmila
Qasba, Pradman
Qin, Haiying
Rader, Christoph
Ramakrishnan, Boopathy
RAY, UPASANA
Reddy, E. Premkumar.
Reitz, Jr., Marvin S.
Restifo, Nicholas P.
Risinger, John
Robbins, Paul F
Roberts, (b) (6) Anita
Roberts, Veronica Ann
Roden, Richard B
Rogakou, Efthimia P
Roop, Dennis R.
Rosenberg, Steven A.
Rosenwald, Andreas
Roukos, Vasileios
Roy, Krishnendu K.
Rubin, Jeffrey S
Rudloff, Udo
Sadaie, Mohammad Reza
Salahuddin, Syed Z.
Salvatore, Giuliana
(b) (4)
Sarngadharan, Mangalasseril
Sausville, Edward
Sawitzke, James

(b) (3) (A), (b) (4), (b)
(6)

Schiller, John T
Schlom, Jeffrey
Schnermann, Martin
Segal, David M.
Shaban, Samir H.
Sharan, Shyam K
Sharan, Shyam K.
Shaw, George M
Shirai, Mutsunori
Simone, Nicole L
Singh, Vinod
Slape, Christopher I.
Snader, Kenneth M
Sonalee Gaur, Sonia
Soppet, Dan
Soutoglou, Evi
Spiese, Paul J
Sporn, Michael B.
Stauber, Roland H.
Staudt, Louis M
Steeg, Patricia S.
Steinert, (b) (6) Peter M.
Stephens, Robert M.
Swaminathan, Srividya
Tamaoki, Naritaka
Tang, Zhewei
Todaro, George J.
Topalian, Suzanne L.
Toshiyuki, Mori
Tran, Eric
Tsang, Kwong-Yok
Turkbey, Ismail B.
Ueda, Kazumitsu

(b) (3) (A), (b) (4), (b)
(6)

(b) (4)

(b) (4)

(b) (3) (A), (b) (4), (b)
(6)

Uren, Aykut
Valentin, Antonio
Vande Woude, George
Varesio, Luigi
Vasmatzis, George
Veenstra, Timothy D
Vishnuvajjala, B. Rao
Vizcardo Sakoda, Raul Eduardo
Vos, Michele
Vournakis, John M.
Waldmann, Thomas A.
Wang, Ling-Mei
Wang, Qiong
Wang, Rong-fu
Wang, Xiaohong
Wang, Yan
Warming, Soren
Waugh, David
Weinstein, John N.
Weldon, John
Wiestner, Adrian
Wilkens, Kenneth L.
Willingham, Mark C.
Wilson, Wyndham H.
Wolfgang, Curt
Wong-Staal, Flossie
Wu, Carl
Wu, Yongzhong
Wunderlich, John
Xiang, Liaman
Xie, yueqing
Xu, Junfen

Yang, James C	(b) (3) (A), (b) (4), (b) (6)
Yang, Tian J.	
Yongzu Jin, Benjamin	
Yoseph, Rami	
Yoshimura, Teizo	
Young, Howard A.	
Yu, Daiguan	
Yu, Zhiya	
Yuspa, Stuart H.	
Zaharoff, David	
Zhang, Lisa Juan	
Zhang, ZhenHua	
Zhao, Chihao	
Zheng, Zhi-Min g (Thomas)	
Zheng, Zhili	
Zhu, Jianwei	
Zhu, Zhongyu	
Zhu, Ziqiang	
NEI	\$600,572.20
Bunce, George E.	(b) (3) (A), (b) (4), (b) (6)
Ferris III, Frederick L.	
Kinoshita, (b) (6) Jin H	
Li, Tiansen	
Smith, James Cecil	
Swaroop, Anand	
NHGRI	\$48,630.39
Chandler, Randy J.	(b) (3) (A), (b) (4), (b) (6)
Gispert-Sanchez, Suzana	
Goldin, Ehud M.	
Manoli, Eirini	
Motabar, Omid	
Nussbaum, Robert L.	
Pavan, William J	
Sidransky, Ellen	

Smith, Stephanie N.
Venditti, Charles P.
Westbroek, Wendy

(b) (3) (A), (b) (4),
(b) (6)

NHLBI

\$256,572.25

Adelstein, Robert
Al-Shami, Amin
Aletras, Anthony Homer
Amar, Marcelo A.

(b) (3) (A), (b) (4), (b)
(6)

(b) (4)

Berra, Lorenzo
Boehm, Manfred
Brewer, H. Bryan
Cannon, Richard O.
Cecchini, Sylvain
Chen, Guibin
Chen, Guokai
Chiorini, John A.
Combs, Christian A.
Demosky, Stephen J.
Derbyshire, John Andrew
Ding, Chuan-Tian
Ding, Chuantian
Finkel, Toren
Gladwin, Mark T.
Haque, Nazmul
Hogg, John Robert
Hunter, Christian J

(b) (4)

Kang, Dae-kyung
Kawamoto, Sachiyo
Keane-Myers, Andrea M.
Kelley, Christine A
Kellman, Peter
Kim, Kee Kwang

Knepper, Mark A
Kolobow, Theodor
Kotin, Robert M.
Larochelle, Andre
Leonard, Warren J.
Levine, Rodney L
Li, Lina
Lin, Jian-Xin
Lin, Yongshun

(b) (4)

McVeigh, Elliott R
Neufeld, Edward B.
Nezafat, Reza
Nirenberg, (b) (6) Marshall
Remaley, Alan T.
Smith, Richard H.
Spolski, Rosanna J
Stonik, John A.
Sviridov, Denis O.
Thomas, Fairwell

(b) (4)

Urabe Masashi

(b) (4)

Walsh, Frank
Wen, Han
Wolska, Anna
Yang, Yanqin
Zhu, Jun

NIA

Bagrov, Alexei
Doyle, Maire E


(b) (3) (A), (b) (4), (b) (6)

\$16,999.77

(b) (3) (A), (b) (4), (b) (6)

Egan, Josephine M
Falco, Geppino
Fedorova, Olga V.
Greig, Nigel H
Hodes, Richard
Hodes, Richard J
Holloway, Harold
Kim, Dong Seok
Ko, Minoru S.
Lakatta, Edward G.
Lee, Sung-Lim
Li, Yazhou
Matarin Jimenez, Maria Del Mar
Monti, Manuela
Perry, Tracy Ann
Sharova, Lioudmila V.
Shin, Soojung
Singleton, Andrew B.
Stanghellini, Ilaria
Zalzman, Michal

(b) (3) (A), (b) (4), (b)
(6)




NIAAA

\$5,920.50

Cinar, Resat
Iyer, Malliga R.
Kunos, George I

(b) (3) (A), (b)
(4), (b) (6)




NIAID

\$1,254,579.93

Abisola Abiona, Olubukola Mary
Akahata, Wataru
Akin, Cem
Alexander, Robert M.
Angermann, Bastian R
Barry, Clifton E
Baxa, Ulrich
Bennink, Jack R.
Bermingham, Alison

(b) (3) (A), (b) (4), (b)
(6)



Biacchesi, Stephanie
Blaney, Jr., Joseph E
Boyd, Lisa
Boyington, Jeffrey
Boyington, Jeffrey C.
Britt, William J.
Brock, Linda G.
Broder, Christopher
Buchholz, Ursula
Bukreyev, Alexander
Caldwell, Harlan D
Ceva Biomune
Chakrabarti, Bimal K
Chanock, (b) (6) Robert
Chen, Lei
Chen, Man
Chen, Man
Chen, Zhao Chun
Cheng, Cheng
Chesebro, Bruce
Cheung, Yiu Chong Gordon
Chuang, Gwo-Yu
Chuang, Gwo-Yu
Cohen, Jeffrey
Coligan, John
Collins, Peter L.
Connors, Mark
Conrad, John T.
Corbett, Kizzmekia
Cox, Josephine H
Datta, Sandip Kumar
Davey, Richard T.
DeVico, Angela M.
Doms, Robert W.

(b) (3) (A), (b) (4), (b)
(6)

Druz, Aliaksandr A.
Earl, Patricia L.
Eisenbarth, (b) (6) George
Emerson, Suzanne U.
(b) (6) Clement K. Asiedu
Evans, Leonard
Fauci, Anthony
Fink, Doran
Folks, Thomas M
Galen, Joseph Van
Garboczi, David
Georgiev, Ivelin S.
Germain, Ronald N.
Gorman, Jason
Graham, Barney
Graham, Barney S.
Green, Kim Y.
Guatam, Rejeev
Gupta, Pradeep K.
Hanley, Kathryn
Harriman, Gregory R.
Haynes, Barton F.
Hoshino, Yasutaka
Hsu, Su-Cheng Dana
Hu, Haijing
Huang, (b) (6) Yue
Huang, Jinghe
Hutchinson, Geoffrey Bain
Ishida, Elilse H.
Ishizuka, Andrew S
Jeang, (b) (6) Kuan-Teh
Jenkins, John P.
Joyce, Michael G.
Justement, Jesse S

(b) (3) (A), (b) (4),
(b) (6)

Kalinina, Olga V.
Kanekiyo, Masaru
Kang, Byong Ha
Kapikian, (b) (6) Albert Z
Kinter, Audrey L
Kirshenbaum, Arnold
Koh, Franklin
Kong, Wing-pui
Korty, Patricia E.
Krzewski, Konrad
Kubofcik, Joseph
Kunimoto, Dennis Y.
Kwon, Young Do
Kwong, Peter D.
Lai, Ching-Juh
Lantz, Larry
Lee, Ha Na
Lee, Richard E.
Leppla, Stephen H.
Leysath, Clinton E.
Liang, Bo
Long, Eric O.
Lujan, Hugo D
Luongo, Cindy L.
Mackett, Michael
Mangalampalli, Venkata R.
Margulies, David H
Marques, Adriana
Martin, Malcolm A
Mascola, John R
Mascola, John R.
McCarty, Thomas Charles
Mchugh, Rebecca S
McLellan, Jason Scott

(b) (3) (A), (b) (4),
(b) (6)

McTamney, Patrick
Meier-Schellersheim, Martin
Merritt, Joshua S.
Metcalf, Dean D
Milner, Joshua
Miyazawa, Masaaki
Moayeri, Mahtab
Moin, Syed M.
Morrison, Richard P.
Morse III, Herbert
Moss, Bernard
Mowatt, Michael
Munir, Shirin
Murphy, Brian R.
Myles, Ian
Nabel, Gary J
Nash, Theodore
Natarajan, Kannan
Nguyen, Hanh T.
Nishimura, Michael
Nutman, Thomas B.
Nutt, Anne S.
O'Brien, Daniel P.
OFEK, GILAD A
Ohara, Junichi
Ohta, Akio
Ou, Li
Pancera, Marie L.
Paul, (b) (6) William E.
Pesnicak, Lesley M
Phillips, Damilola D.
Pletnev, Alexander G
Pomerantsev, Andrei P
Porgador, Angel

(b) (3) (A), (b) (4), (b)
(6)

Powell, Douglas M
Purcell, Robert H
Putnak, J. Robert
Quasney, Judit A.
Rajagopalan, Sumati
Rao, Srinivas
Robertson, Michael N.

(b) (3) (A), (b) (4),
(b) (6)

(b) (4)

Rudicell, Rebecca S.
Rundlet, Emily
Sadjadpour, Reza
Sastry, Mallika
Schubert, Ulrich K
Schwartz, Richard M.
Seder, Robert
Shevach, Ethan M
Shi, Wei
Shingai, Masashi
Shukla Bajpai, Priyanka
Siebenlist, Ulrich
Silver, Jonathan E.
Sitkovsky, Michail V.
Skiadopoulos, Mario
Slayden, Richard A
Smith, Geoffrey L
Sosnovtsev, Stanislav V
Soto, Cinque
Srivatsan, Sanjay R.

(b) (4)

Stephens, Geoffrey L.
Stewart-Jones, Guillaume
Stewart-Jones, Guillaume BE
Strober, Warren

Sullivan, Nancy J	(b) (3) (A), (b) (4), (b) (6)
Sun, Peter D	
Thomas, Paul V.	
Tian, Lirjie	
Tilahun, Muluaelem	
Tsybovsky, Yaroslav	
Voss, Oliver	
Wang, Lingshu	
Ward, Lucy A.	
Wehrly, Kathryn	
Wei, Chih--Jen	
Whitehead, Stephen S.	
Whittle, James R R	
Wu, Xueling	
Wycuff, Diane L.	
Xu, Kai	
YANG, YONGPING	
Yang, Zhi-Yong	
Yassine, Hadi M.	
Yewdell, Jonathan W.	
Zhang, Baoshan	
Zheng, Anqi	
Zhou, Tongqing	
Zhou, Tongqing	
Zhu, Jiang	
Zhu, Yaling	
Zou, Zhongcheng	
NIAMS	\$10,309.40
Kinet, Jean-Pierre	(b) (3) (A), (b) (4), (b) (6)
Meylan, Francoise	
Plotz, Paul H.	
Raben, Nina	
Rao, Mahendra S	
Siegel, Richard	

Song, Yun-Jeong

(b) (3) (A), (b) (4),
(b) (6)

NIBIB

\$70,889.02

Chen, Xiaoyuan

(b) (3) (A), (b) (4),
(b) (6)

Parekh, Sapun

Phillips, Terence M

Shroff, Hari

Weiss, Orit Jacobson

York, Andrew G.

NICHD

\$116,406.90

Basser, Peter J

(b) (3) (A), (b) (4), (b)
(6)

Blithe, Diana L.

Bridson, William E.

Buonanno, Andres

Chou, Janice Y.

Chumakov, Ekaterina

Crouch, Robert J.

Dawid, Igor

Deligiannidis, Kristina M Galarneau

Dey, Anup K

Dressler, Gregory R.

Hertz, Roy

Horkay, Ferenc

Huang, Freesia

Huang, Kuo-Ping

Karavanov, Alex A. or Irina

Kingfield, Joyce G.

Klein, David C.

Kohler, Peter O

(b) (4)

McDonald, John

Moffett, John R

Mukherjee, Anil B.

Namboodiri, Aryan M

Nieman, Lynnette K.

Ozato Dawid, Keiko
Pierpaoli, Carlo
Robbins, John B.
Romero, Roberto
Roseboom, Patrick
Rouault, Tracy
Sarkar, Chinmoy
Schneerson, Rachel
Vullhorst, Detlef
Weller, Joan
Woodgate, Roger
Zhang, Gary Zhongjian

(b) (3) (A), (b) (4), (b) (6)

NIDA

\$33,816.42

Backman, Christina M
Cao, Jianjing
Cyriac, George C.
Grundt, Peter
Kumar, Vivek
Newman, Amy H.
Rice, Kenner C.
Shaik, Anerbasha
Tomas, Andreas C

(b) (3) (A), (b) (4), (b) (6)

(b) (4)

Wise, Roy A
Zangen, Abraham

NIDCD

\$13,601.55

Canseco De Kalinec, Gilda Mabel
Chen, Zhong
Cheng, Hui
De Kalinec, Gilda Mabel Canseco
Griffith, Andrew J.
Kalinec, Federico
Labay, Valentia
Makishima, Tomoko

(b) (3) (A), (b) (4), (b) (6)

Montcouquiol, Mireille
RJ Wenthold, (b) (6)

Saleh, Anthony
Van Waes, Carter

NIDCR

Adler, Jon Elliot
Akiyama, Steven
Burbelo, Peter D.
Chiorini, John A.
Elkin, Michael
Erlenbach, Isolde
Fisher, Larry
Gronthos, Stan
Hoon, Mark
Hsu, Su-Cheng Dana
Iadarola, Michael J.
Kaludov, Nikola
Keith, Jerry M
Kleinman, Hynda
Kulkarni, Ashok
Leppla, Stephen H.
Merkel, Todd J.
Miura, Masako
Ohshima, Toshio
Pasquale, Giovanni Di
Philp, Deborah
Robey, Pamela G.
Rosovitz, Mary Jo
Ryba, Nicholas
Seo, Byoung-Moo
Shi, Songtao
Siraganian, Reuben
Yamada, Kenneth
Yamada, Susan Sleeper

(b) (3) (A), (b) (4),
(b) (6)

\$141,203.66

(b) (3) (A), (b) (4),
(b) (6)

Yang, Xiaoming	(b) (3) (A), (b) (4), (b) (6)
NIDDK	\$49,102.14
Appella, Daniel H	(b) (3) (A), (b) (4), (b) (6)
Chandramohan, Dhruva	
Chou, Carson C.	
Daly, (b) (6) John W	
Englund, Ethan A.	
Gavrilova, Oksana Fedorovna	
Ge, Kai	
Gershengorn, Marvin	
Goldsmith, Paul K	
Hall, Kevin	
Huang, Wei	
Jacobson, Kenneth A	
Kopp, Jeffrey B	
Lee, Ji-Eun	
Micklitsch, Christopher	
Neumann, Susanne	
Oquare, Bereket	
Oral, Elif A.	
Proia, Richard L	
Raaka, Bruce	
Ramirez, Delia	
Rehermann, Barbara	
Reitman, Marc Lionel	
Rosshart, Stephan Patrick	
Schechter, Alan N.	
Shiloach, Joseph	
Simonds, William F.	
Spiegel, Allen M.	
Taylor, Simeon	
Tosh, Dilip K.	
Wang, Deyun	
Zhang, Jianhua	

Zhang, Ning

Zhao, Chao

NIEHS

(b) (4)

Beckley, Amy J.

Blackshear, Perry J

Bradbury, Jennifer Alyce

Cidlowski, John A.

DiAugustine, Richard P

(b) (4)

Eddy, Edward

Ehrenshaft, Marilyn I

Graves, Joan P.

Kennington, Elizabeth A.

Mason, Ronald P.

Mishina, Yuji

Moore, Rickie

Negishi, Masahiko

Oakley, Robert

Ray, Manas K.

Scott, Gregory J.

Summers, Fiona A.

Teng, Christina T.

Wetsel, William

Zeldin, Darryl C

NIMH

Cohen, Robert M.

Dold, George R.

Drevets, Wayne C

Eiden, Maribeth V.

Furey, Maura L.

Ginns, Edward I.

Hu, Huaizhong

Kowalak, Jeffrey A.

(b) (3) (A), (b)
(4), (b) (6)

\$26,257.99

(b) (3) (A), (b) (4),
(b) (6)

\$61,136.97

(b) (3) (A), (b) (4),
(b) (6)

LaMarca, Mary
Liu, Yuan Yi
Ma, Shenglin
Mahan, Lawrence C.
Manji, Hussein K.
Markey, Sanford P.
Masuda, Junichi
Morgan, Newlin T.
Neville, David
Scharff, Joshua
Thompson, Jerry

(b) (4)

Unsworth, Edward J.
Wilson, Carolyn A.

(b) (4)

Woo, Jung-Hee
Ye, Daniel
Zarate, Carlos A.

NINDS

\$132,112.98

Bielekova, Bibiana B
Blackstone, Craig D.
Brady, (b) (6) Roscoe O
Dobersen, Michael J
Gainer, Harold
Hallett, Mark
Hammer, Jeffrey A.
Hou, Jean
Hsu, Yite
Humbert, Ianessa A
Jensen, Peter N
Lee, Myoung Hwa
Li, Wenxue
Lowell, Soren Y
Ludlow, Christy L.

(b) (3) (A), (b) (4),
(b) (6)

(b) (3) (A), (b) (4),
(b) (6)

Major, Eugene O
Martin, Roland
McFarland, Henry F.
McVittie, Loris D.
Messam, Conrad A
Miranda, Pedro
Monsma, Jr., Frederick J.
Murray, Gary J
Nath, Avindra
Noronha, Antonio B
Oldfield, (b) (6) Edward H.
Pluta, Ryszard M
Poletto, Christopher J.
Quarles, Richard H.
Roth, Yiftach
Sibley, David R.
Steiner, Joseph Perry
Wang, Chunxin
Warach, Steven J.
Ward, Michael Emmerson
Youle, Richard J.
Zhu, Peng-Peng
NINR
Barr, Taura L.

(b) (4)

NLM

Lu, Zhiyong
Pang, Yifan

(b) (3) (A), (b) (4),
(b) (6)

NIH Patent Licensing Activities
CC
October 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-160-18/0	CC		Advanced Imaging Projects, LLC (AIP)	8-Oct-19						(b) (3) (A), (b) (4), (b) (6)
<i>Note: L-160-18/0 split between CC; NCI</i>										
L-111-06/0	CC		ICAD Inc	9-Oct-19						
<i>Note: L-111-06/0 split between CC; CIT; NIDCD</i>										
L-010-18/0	Harrison, Adam Patrick	(b)(4);	Ping An Technology (Shenzhen) Company LTD	25-Oct-19						
L-010-18/0	Lu, Le	(b)(6)	Ping An Technology (Shenzhen) Company LTD	25-Oct-19						
L-010-18/0	Mollura, Daniel Joseph		Ping An Technology (Shenzhen) Company LTD	25-Oct-19						
L-010-18/0	Summers, Ronald		Ping An Technology (Shenzhen) Company LTD	25-Oct-19						
L-010-18/0	Wang, Xiaosong		Ping An Technology (Shenzhen) Company LTD	25-Oct-19						
L-010-18/0	Xu, Ziyue		Ping An Technology (Shenzhen) Company LTD	25-Oct-19						
<i>Note: L-010-18/0 split between CC; NLM</i>										
L-059-18/0	Baecher, Nicolai		Ping An Technology (Shenzhen) Company It	28-Oct-19						
L-059-18/0	Lay, Nathan Stephan		Ping An Technology (Shenzhen) Company It	28-Oct-19						
L-059-18/0	Liu, Jiamin		Ping An Technology (Shenzhen) Company It	28-Oct-19						
L-059-18/0	Summers, Ronald		Ping An Technology (Shenzhen) Company It	28-Oct-19						
L-059-18/0	Yao, Jianhua		Ping An Technology (Shenzhen) Company It	28-Oct-19						
L-249-19/0	CC		TeamedOn International, Inc.	30-Oct-19						

NIH Patent Licensing Activities
CC
November 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
L-160-18/0	CC		Advanced Imaging Projects, LLC (AIP)	26-Nov-19						(b) (3) (A), (b) (4)
<i>Note: L-160-18/0 split between CC; NCI</i>										

NIH Patent Licensing Activities
CC
December 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
CC
January 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
L-145-19/0	Gladwin, Mark T.	(b)(4):	Globin Solutions, Inc	1-Jan-20						(b) (3) (A), (b) (4), (b) (6)
<i>Note: L-145-19/0 split between CC; NHLBI; NIDDK; NINDS</i>										
L-028-18/1	Lay, Nathan Stephan	(b)(4):	Scanmed LLC	2-Jan-20						
L-028-18/1	Reinhard Roth, Holger	(b)(6)	Scanmed LLC	2-Jan-20						
L-028-18/1	Summers, Ronald		Scanmed LLC	2-Jan-20						
L-028-18/1	Tsehay, Yohannes Kebede		Scanmed LLC	2-Jan-20						
<i>Note: L-028-18/1 split between CC; CIT; NCI</i>										
L-159-07/2	Gladwin, Mark T.		Hope Pharmaceuticals	7-Jan-20						
<i>Note: L-159-07/2 split between CC; NHLBI; NIDDK; NINDS</i>										
L-029-20/0	Lay, Nathan Stephan	(b)(4):	Translation Holdings, Inc	7-Jan-20						
L-029-20/0	Summers, Ronald	(b)(6)	Translation Holdings, Inc	7-Jan-20						
L-143-07/2	Gladwin, Mark T.		Hope Pharmaceuticals	7-Jan-20						
<i>Note: L-143-07/2 split between CC; NHLBI; NIDDK</i>										
L-143-18/1	CC		Geneius Biotechnology, Inc	8-Jan-20						
<i>Note: L-143-18/1 split between CC; NCI</i>										
L-160-18/0	CC		Advanced Imaging Projects, LLC (AIP)	22-Jan-20						
<i>Note: L-160-18/0 split between CC; NCI</i>										

NIH Patent Licensing Activities
CC
February 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
CC
March 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
L-122-17/0	Kwak, Jin Tae	(b)(4):	Koninklijke Philips N.V.	1-Mar-20						(b) (3) (A), (b) (4), (b) (6)
L-122-17/0	Summers, Ronald	(b)(6)	Koninklijke Philips N.V.	1-Mar-20						
L-122-17/0	Wood, Bradford J		Koninklijke Philips N.V.	1-Mar-20						
L-122-17/0	Xu, Sheng		Koninklijke Philips N.V.	1-Mar-20						
<i>Note: L-122-17/0 split between CC; NCI</i>										
					\$72,411.20	\$7,904.80	\$80,316.00		\$19,396.46	\$60,919.54

NIH Patent Licensing Activities
CIT

October 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-111-06/0	CIT		ICAD Inc	9-Oct-19						(b) (3) (A), (b) (4)

Note: L-111-06/0 split between CC; CIT; NIDCD

NIH Patent Licensing Activities
CIT
November 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
CIT
December 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
CIT
January 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
L-232-14/1	CIT		NanoString Technologies, Inc.	1-Jan-20						(b) (3) (A), (b) (4), (b) (6)
L-028-18/1	Cheng, Ruida	(b)(4);	Scanmed LLC	2-Jan-20						
L-028-18/1	McAuliffe, Matthew	(b)(6)	Scanmed LLC	2-Jan-20						
L-232-14/1	CIT		NanoString Technologies, Inc.	28-Jan-20						

Note: L-232-14/1 split between CIT; NCI

NIH Patent Licensing Activities
CIT
February 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
L-232-14/1	CIT		NanoString Technologies, Inc.	14-Feb-20						(b) (3) (A), (b) (4)

Note: L-232-14/1 split between CIT; NCI

NIH Patent Licensing Activities

CIT
March 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
										(b) (3) (A), (b) (4), (b) (6)

NIH Patent Licensing Activities
NCATS
October 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-224-19/0	Shen, Min	(b)(4);	Baobab-Pharm Co., Ltd.	19-Sep-19						(b) (3) (A), (b) (4), (b) (6)
L-224-19/0	Zhang, Ya-Qin	(b)(6)	Baobab-Pharm Co., Ltd.	19-Sep-19						
<i>Note: L-224-19/0 split between NCATS; NCI</i>										
L-105-16/1	Alimardanov, Asaf R.		Mycovia Pharmaceuticals Inc	24-Sep-19						
L-105-16/1	Behnke, Mark L.		Mycovia Pharmaceuticals Inc	24-Sep-19						

NIH Patent Licensing Activities
NCATS
November 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
L-204-19/0	Bantukallu, Ganesha	(b)(4);	Vanderbilt University	5-Nov-19						(b) (3) (A), (b) (4), (b) (6)
L-204-19/0	Brimacombe, Kyle R.	(b)(6)	Vanderbilt University	5-Nov-19						
L-204-19/0	Hall, Matthew D		Vanderbilt University	5-Nov-19						
L-204-19/0	Hu, Xin		Vanderbilt University	5-Nov-19						
L-204-19/0	Jadhav, Ajit P.		Vanderbilt University	5-Nov-19						
L-204-19/0	Kouznetsova, Jennifer		Vanderbilt University	5-Nov-19						
L-204-19/0	Maloney, David		Vanderbilt University	5-Nov-19						
L-204-19/0	Mott, Bryan		Vanderbilt University	5-Nov-19						
L-204-19/0	Simeonov, Anton		Vanderbilt University	5-Nov-19						
L-204-19/0	Urban, Daniel		Vanderbilt University	5-Nov-19						
L-204-19/0	Yang, Shyh Ming		Vanderbilt University	5-Nov-19						
<i>Note: L-204-19/0 split between NCATS; NCI</i>										

NIH Patent Licensing Activities
NCATS
December 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities

NCATS
January 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
L-196-19/0	Inglese, James	(b)(4);	Nuralis Pharmaceuticals, Inc	7-Jan-20						(b) (3) (A), (b) (4), (b) (6)
L-196-19/0		(b) (4)	Nuralis Pharmaceuticals, Inc	7-Jan-20						
L-196-19/0	Southall, Noel T.		Nuralis Pharmaceuticals, Inc	7-Jan-20						
L-196-19/0	Thomas, Craig J.		Nuralis Pharmaceuticals, Inc	7-Jan-20						
L-196-19/0	Titus, Steven		Nuralis Pharmaceuticals, Inc	7-Jan-20						
L-196-19/0	Zheng, Wei		Nuralis Pharmaceuticals, Inc	7-Jan-20						
<i>Note: L-196-19/0 split between NCATS; NIDDK</i>										
L-057-15/0	Austin, Christopher P.		Vtesse, Inc	8-Jan-20						
L-057-15/0	Liu, Ke		Vtesse, Inc	8-Jan-20						
L-057-15/0	Marugan, Juan J.		Vtesse, Inc	8-Jan-20						
L-057-15/0	McKew, John C.		Vtesse, Inc	8-Jan-20						
L-057-15/0	Southall, Noel T.		Vtesse, Inc	8-Jan-20						
L-057-15/0	Swaroop, Manju		Vtesse, Inc	8-Jan-20						
L-057-15/0	Xiao, Jingbo		Vtesse, Inc	8-Jan-20						
L-057-15/0	Xu, Miao		Vtesse, Inc	8-Jan-20						
L-057-15/0	Zheng, Wei		Vtesse, Inc	8-Jan-20						
<i>Note: L-057-15/0 split between NCATS; NHGRI</i>										
L-105-16/1	Alimardanov, Asaf R.		Mycovia Pharmaceuticals Inc	14-Jan-20						
L-105-16/1	Behnke, Mark L.		Mycovia Pharmaceuticals Inc	14-Jan-20						
L-055-15/1	NCATS		Lysosomal Therapeutics, Inc.	16-Jan-20						
<i>Note: L-055-15/1 split between NCATS; NHGRI</i>										
L-055-15/1	Marugan, Juan J.	(b)(4);	Lysosomal Therapeutics, Inc.	16-Jan-20						
L-055-15/1	Patnaik, Samarjit	(b)(6)	Lysosomal Therapeutics, Inc.	16-Jan-20						
L-055-15/1	Southall, Noel T.		Lysosomal Therapeutics, Inc.	16-Jan-20						
L-055-15/1	Zheng, Wei		Lysosomal Therapeutics, Inc.	16-Jan-20						
<i>Note: L-055-15/1 split between NCATS; NHGRI</i>										

NIH Patent Licensing Activities

NCATS
February 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
L-116-13/0	Auld, Douglas S.	(b)(4);	EMD Millipore Corp.	7-Feb-20						(b) (3) (A), (b) (4), (b) (6)
L-116-13/0	Boxer, Matthew	(b)(6)	EMD Millipore Corp.	7-Feb-20						
L-116-13/0	Inglese, James		EMD Millipore Corp.	7-Feb-20						
L-116-13/0	Jiang, Jian-kang		EMD Millipore Corp.	7-Feb-20						
L-116-13/0	Shen, Min		EMD Millipore Corp.	7-Feb-20						
L-116-13/0	Skoumbourdis, Amanda P.		EMD Millipore Corp.	7-Feb-20						
L-116-13/0	Thomas, Craig J.		EMD Millipore Corp.	7-Feb-20						
<i>Note: L-116-13/0 split between NCATS; NHGRI</i>										

NIH Patent Licensing Activities
NCATS
March 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
					\$161,319.12	\$90,964.40	\$252,283.52		\$42,050.95	\$210,232.57

NIH Patent Licensing Activities
NCI
October 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-246-02/0	Allegra, Carmen	(b)(4);	Dako Corp	28-Aug-19						(b) (3) (A), (b) (4), (b) (6)
L-246-02/0	Chabner, Bruce A	(b)(6)	Dako Corp	28-Aug-19						
L-246-02/0	Johnston, Patrick G.		Dako Corp	28-Aug-19						
L-246-02/0	Liang, Chi-Ming		Dako Corp	28-Aug-19						
L-002-04/1	Kawakami, Yutaka		Cell Marque	16-Sep-19						
L-002-04/1	Robbins, Paul F		Cell Marque	16-Sep-19						
L-002-04/1	Rosenberg, Steven A.		Cell Marque	16-Sep-19						
L-240-19/0	Bonomi, Carrie A.		Boehringer Ingelheim RCV GmbH & Co KG	17-Sep-19						
L-240-19/0	Dougherty, Kelly		Boehringer Ingelheim RCV GmbH & Co KG	17-Sep-19						
L-240-19/0	Hollingshead, Melinda G.		Boehringer Ingelheim RCV GmbH & Co KG	17-Sep-19						
L-097-19/0	Bonomi, Carrie A.		Janssen Research & Development, LLC	18-Sep-19						
L-097-19/0	Borgel, Suzanne D.		Janssen Research & Development, LLC	18-Sep-19						
L-097-19/0	Dougherty, Kelly		Janssen Research & Development, LLC	18-Sep-19						
L-097-19/0	Hollingshead, Melinda G.		Janssen Research & Development, LLC	18-Sep-19						
L-224-19/0	Kebebew, Electron		Baobab-Pharm Co., Ltd.	19-Sep-19						
L-224-19/0	Zhang, Lisa Juan		Baobab-Pharm Co., Ltd.	19-Sep-19						
<i>Note: L-224-19/0 split between NCATS; NCI</i>										
L-220-01/0	Erickson, John W.		Tibotec Pharm Ltd.	20-Sep-19						
L-220-01/0	Gulnik, Sergei V.		Tibotec Pharm Ltd.	20-Sep-19						
L-220-01/0	Mitsuya, Hiroaki		Tibotec Pharm Ltd.	20-Sep-19						
L-220-01/0	(b) (4)		Tibotec Pharm Ltd.	20-Sep-19						
L-092-11/0	Giardina, Steven		EMD Chemicals Inc.	20-Sep-19						
L-092-11/0	Longo, Dan L		EMD Chemicals Inc.	20-Sep-19						
L-092-11/0	Varesio, Luigi		EMD Chemicals Inc.	20-Sep-19						
L-288-19/0	Bonomi, Carrie A.		Merck Sharp & Dohme Corp.	23-Sep-19						
L-288-19/0	Dougherty, Kelly		Merck Sharp & Dohme Corp.	23-Sep-19						
L-288-19/0	Hollingshead, Melinda G.		Merck Sharp & Dohme Corp.	23-Sep-19						
L-272-19/0	Greiner, John W.		Aduro Biotech, Inc.	23-Sep-19						
L-272-19/0	Schlom, Jeffrey		Aduro Biotech, Inc.	23-Sep-19						

L-081-18/0	NCI		PathoVax LLV	24-Sep-19
L-255-19/0	Buck, Christopher	(b)(4);	BioE Holdings Inc.	24-Sep-19
L-255-19/0	Pastrana, Diana V	(b)(6)	BioE Holdings Inc.	24-Sep-19
L-255-19/0	RAY, UPASANA		BioE Holdings Inc.	24-Sep-19
L-039-11/0	Onda, Masanori		Rockland Immunochemicals, Inc.	25-Sep-19
L-039-11/0	Pastan, Ira H		Rockland Immunochemicals, Inc.	25-Sep-19
L-158-19/0	Bonomi, Carrie A.		Sumitomo Dainippon Parma Co., Ltd	25-Sep-19
L-158-19/0	Borgel, Suzanne D.		Sumitomo Dainippon Parma Co., Ltd	25-Sep-19
L-158-19/0	Dougherty, Kelly		Sumitomo Dainippon Parma Co., Ltd	25-Sep-19
L-158-19/0	Hollingshead, Melinda G.		Sumitomo Dainippon Parma Co., Ltd	25-Sep-19
L-255-19/0	NCI		BioE Holdings Inc.	26-Sep-19
L-255-19/0	NCI		BioE Holdings Inc.	26-Sep-19
L-221-17/1	Cao, Boliang (Brian)	(b)(4);	Cymeta Biopharmaceutical	26-Sep-19
L-221-17/1	Vande Woude, George	(b)(6)	Cymeta Biopharmaceutical	26-Sep-19
L-240-19/0	Bonomi, Carrie A.		Boehringer Ingelheim RCV GmbH & Co KG	26-Sep-19
L-240-19/0	Dougherty, Kelly		Boehringer Ingelheim RCV GmbH & Co KG	26-Sep-19
L-240-19/0	Hollingshead, Melinda G.		Boehringer Ingelheim RCV GmbH & Co KG	26-Sep-19
L-296-19/0	Bonomi, Carrie A.		Evelo Biosciences, Inc	30-Sep-19
L-296-19/0	Borgel, Suzanne D.		Evelo Biosciences, Inc	30-Sep-19
L-296-19/0	Dougherty, Kelly		Evelo Biosciences, Inc	30-Sep-19
L-296-19/0	Hollingshead, Melinda G.		Evelo Biosciences, Inc	30-Sep-19
L-080-93/3	Hathcock, Karen		BD Biosciences - BD PharMingen, Inc.	1-Oct-19
L-080-93/3	Hodes, Richard		BD Biosciences - BD PharMingen, Inc.	1-Oct-19
L-080-93/3	Laszlo, Gloria		BD Biosciences - BD PharMingen, Inc.	1-Oct-19
L-199-15/1	Hurwitz, Arthur A.		Agenus, Inc.	1-Oct-19
L-199-15/1	Ji, Qingyong		Agenus, Inc.	1-Oct-19
L-199-15/1	Singh, Vinod		Agenus, Inc.	1-Oct-19
L-199-15/1	Zhu, Ziqiang		Agenus, Inc.	1-Oct-19
L-273-14/0	Chang, Nancy T.		Grifols Worldwide Operations Ltd.	3-Oct-19
L-273-14/0	Crowl, Robert		Grifols Worldwide Operations Ltd.	3-Oct-19
L-273-14/0	Fisher, Amanda G.		Grifols Worldwide Operations Ltd.	3-Oct-19
L-273-14/0	Gallo, Robert C.		Grifols Worldwide Operations Ltd.	3-Oct-19
L-273-14/0	Hahn, Beatrice		Grifols Worldwide Operations Ltd.	3-Oct-19
L-273-14/0	Popovic, Mikulas		Grifols Worldwide Operations Ltd.	3-Oct-19
L-273-14/0	Reddy, E. Premkumar.		Grifols Worldwide Operations Ltd.	3-Oct-19
L-273-14/0	Sarngadharan, Mangalasseril		Grifols Worldwide Operations Ltd.	3-Oct-19
L-273-14/0	Shaw, George M		Grifols Worldwide Operations Ltd.	3-Oct-19
L-273-14/0	Wong-Staal, Flossie		Grifols Worldwide Operations Ltd.	3-Oct-19
L-049-18/1	Bonomi, Carrie A.		BrightPath Biotherapeutics Co., Ltd.	4-Oct-19
L-049-18/1	Borgel, Suzanne D.		BrightPath Biotherapeutics Co., Ltd.	4-Oct-19
L-049-18/1	Dougherty, Kelly		BrightPath Biotherapeutics Co., Ltd.	4-Oct-19
L-049-18/1	Hollingshead, Melinda G.		BrightPath Biotherapeutics Co., Ltd.	4-Oct-19

(b) (3) (A), (b) (4), (b) (6)

L-307-19/0	Bonomi, Carrie A.	(b)(4);	SyntheKine Inc	4-Oct-19
L-307-19/0	Borgel, Suzanne D.	(b)(6)	SyntheKine Inc	4-Oct-19
L-307-19/0	Dougherty, Kelly		SyntheKine Inc	4-Oct-19
L-307-19/0	Hollingshead, Melinda G.		SyntheKine Inc	4-Oct-19
L-214-19/0	Gallo, Robert C.		Cerus Corporation	8-Oct-19
L-214-19/0	Popovic, Mikulas		Cerus Corporation	8-Oct-19
L-269-19/0	Hamilton, Thomas C		Epizyme Inc.	8-Oct-19
L-269-19/0	Ozols, Robert F		Epizyme Inc.	8-Oct-19
L-160-18/0	NCI		Advanced Imaging Projects, LLC (AIP)	8-Oct-19
<i>Note: L-160-18/0 split between CC; NCI</i>				
L-284-19/0	Bonomi, Carrie A.	(b)(4);	Molecular Partners AG	10-Oct-19
L-284-19/0	Borgel, Suzanne D.	(b)(6)	Molecular Partners AG	10-Oct-19
L-284-19/0	Dougherty, Kelly		Molecular Partners AG	10-Oct-19
L-284-19/0	Hollingshead, Melinda G.		Molecular Partners AG	10-Oct-19
L-130-94/2	King, Charles R.		Santa Cruz Biotechnology	15-Oct-19
L-130-94/2	Liotta, Lance		Santa Cruz Biotechnology	15-Oct-19
L-130-94/2	Steeg, Patricia S.		Santa Cruz Biotechnology	15-Oct-19
L-073-12/1	Gazdar, Adi F.		JANSSEN BIOTECH INC	16-Oct-19
L-073-12/1	Johnson, Bruce E		JANSSEN BIOTECH INC	16-Oct-19
L-073-12/1	Kaye, Frederic J		JANSSEN BIOTECH INC	16-Oct-19
L-073-12/1	Khleif, Samir N.		JANSSEN BIOTECH INC	16-Oct-19
L-073-12/1	Minna, John D.		JANSSEN BIOTECH INC	16-Oct-19
L-073-12/1	Oie, Herbert K		JANSSEN BIOTECH INC	16-Oct-19
L-073-12/1	Pass, Harvey I.		JANSSEN BIOTECH INC	16-Oct-19
L-107-13/1	NCI		OPUS BIO INC	16-Oct-19
L-106-13/1	NCI		Opus Bio, Inc.	16-Oct-19
L-005-20/0	Bonomi, Carrie A.	(b)(4);	Khloris Biosciences, Inc.	21-Oct-19
L-005-20/0	Borgel, Suzanne D.	(b)(6)	Khloris Biosciences, Inc.	21-Oct-19
L-005-20/0	Dougherty, Kelly		Khloris Biosciences, Inc.	21-Oct-19
L-005-20/0	Hollingshead, Melinda G.		Khloris Biosciences, Inc.	21-Oct-19
L-235-19/0	Copeland, Neal		Vir Biotechnology, Inc.	22-Oct-19
L-235-19/0	Costantino, Nina		Vir Biotechnology, Inc.	22-Oct-19
L-235-19/0	Court, Donald		Vir Biotechnology, Inc.	22-Oct-19
L-235-19/0	Jenkins Copeland, Nancy A		Vir Biotechnology, Inc.	22-Oct-19
L-235-19/0	Warming, Soren		Vir Biotechnology, Inc.	22-Oct-19
L-237-19/0	Rosenberg, Steven A.		Sanofi-Aventis R&D	24-Oct-19
L-237-19/0	Spiese, Paul J		Sanofi-Aventis R&D	24-Oct-19
L-237-19/0	Yang, James C		Sanofi-Aventis R&D	24-Oct-19
L-006-20/0	Bonomi, Carrie A.		ABBA Therapeutics AG	24-Oct-19
L-006-20/0	Borgel, Suzanne D.		ABBA Therapeutics AG	24-Oct-19
L-006-20/0	Dougherty, Kelly		ABBA Therapeutics AG	24-Oct-19
L-006-20/0	Hollingshead, Melinda G.		ABBA Therapeutics AG	24-Oct-19

L-105-18/1	Bonomi, Carrie A.	(b)(4);	Chugai	25-Oct-19
L-105-18/1	Borgel, Suzanne D.	(b)(6)	Chugai	25-Oct-19
L-105-18/1	Dougherty, Kelly		Chugai	25-Oct-19
L-105-18/1	Hollingshead, Melinda G.		Chugai	25-Oct-19
L-224-15/0	Kochenderfer, James N		Bluebird Bio	30-Oct-19
L-311-19/0	Gazdar, Adi F.		Microgenics Corporation	30-Oct-19
L-311-19/0	Johnson, Bruce E		Microgenics Corporation	30-Oct-19
L-311-19/0	Kaye, Frederic J		Microgenics Corporation	30-Oct-19
L-311-19/0	Kheif, Samir N.		Microgenics Corporation	30-Oct-19
L-311-19/0	Minna, John D.		Microgenics Corporation	30-Oct-19
L-311-19/0	Oie, Herbert K		Microgenics Corporation	30-Oct-19
L-311-19/0	Pass, Harvey I.		Microgenics Corporation	30-Oct-19

(b) (3) (A), (b) (4), (b) (6)

NIH Patent Licensing Activities
NCI
November 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	November 2019			License Cumulative Income	Inventor Awards November	Net Remaining to IC
					% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income			
L-347-14/0	Muchmore, Brian P.	(b)(4);	Abcam, plc	1-Nov-19						(b) (3) (A), (b) (4), (b) (6)
L-347-14/0	O'Brien, Thomas R	(b)(6)	Abcam, plc	1-Nov-19						
L-347-14/0	Porter-Gill, Patricia A.		Abcam, plc	1-Nov-19						
L-347-14/0	Prokunina-Olsson, Ludmila		Abcam, plc	1-Nov-19						
<i>Note: L-347-14/0 split between FDA; NCI</i>										
L-064-11/0	Barry, Todd		Eptiomics Inc	1-Nov-19						
L-064-11/0	Rosenwald, Andreas		Eptiomics Inc	1-Nov-19						
L-064-11/0	Staudt, Louis M		Eptiomics Inc	1-Nov-19						
L-064-11/0	Wiestner, Adrian		Eptiomics Inc	1-Nov-19						
L-064-11/0	Wilson, Wyndham H.		Eptiomics Inc	1-Nov-19						
L-259-19/0	Bonomi, Carrie A.		Kintai Therapeutics	1-Nov-19						
L-259-19/0	Borgel, Suzanne D.		Kintai Therapeutics	1-Nov-19						
L-259-19/0	Dougherty, Kelly		Kintai Therapeutics	1-Nov-19						
L-259-19/0	Hollingshead, Melinda G.		Kintai Therapeutics	1-Nov-19						
L-225-19/0	Gallo, Robert C.		Biotest AG	1-Nov-19						
L-225-19/0	Popovic, Mikulas		Biotest AG	1-Nov-19						
L-204-19/0	Moore, William		Vanderbilt University	5-Nov-19						
L-204-19/0	Neckers, Leonard		Vanderbilt University	5-Nov-19						
<i>Note: L-204-19/0 split between NCATS; NCI</i>										
L-131-99/1	NCI		Purdue Research Foundation	5-Nov-19						
L-286-19/0	Michie, Megan Suzanne	(b)(4);	Quantum-Si	5-Nov-19						
L-286-19/0	Schermann, Martin	(b)(6)	Quantum-Si	5-Nov-19						
L-057-09/5	Aplan, Peter D.		Acceleron Pharma	6-Nov-19						
L-057-09/5	Lin, Ying-Wei		Acceleron Pharma	6-Nov-19						

L-057-09/5	Slape, Christopher I.	(b)(4);	Acceleron Pharma	6-Nov-19
L-057-09/5	Zhang, ZhenHua	(b)(6)	Acceleron Pharma	6-Nov-19
L-046-19/0	Bonomi, Carrie A.		Dragonfly Therapeutics	7-Nov-19
L-046-19/0	Borgel, Suzanne D.		Dragonfly Therapeutics	7-Nov-19
L-046-19/0	Dougherty, Kelly		Dragonfly Therapeutics	7-Nov-19
L-046-19/0	Hollingshead, Melinda G.		Dragonfly Therapeutics	7-Nov-19
L-046-19/0	Schlom, Jeffrey		Dragonfly Therapeutics	7-Nov-19
L-338-17/1	Hanada, Kenichi		Pact Pharma, Inc	13-Nov-19
L-338-17/1	Yang, James C		Pact Pharma, Inc	13-Nov-19
L-338-17/1	Yu, Zhiya		Pact Pharma, Inc	13-Nov-19
L-082-96/1	Chang, Nancy T.		ZeptoMetrix Corp.	13-Nov-19
L-082-96/1	Crowl, Robert		ZeptoMetrix Corp.	13-Nov-19
L-082-96/1	Fisher, Amanda G.		ZeptoMetrix Corp.	13-Nov-19
L-082-96/1	Gallo, Robert C.		ZeptoMetrix Corp.	13-Nov-19
L-082-96/1	Hahn, Beatrice		ZeptoMetrix Corp.	13-Nov-19
L-082-96/1	(b) (4)		ZeptoMetrix Corp.	13-Nov-19
L-082-96/1	Popovic, Mikulas		ZeptoMetrix Corp.	13-Nov-19
L-082-96/1	Reddy, E. Premkumar.		ZeptoMetrix Corp.	13-Nov-19
L-082-96/1	Sarrngadharan, Mangalasseril		ZeptoMetrix Corp.	13-Nov-19
L-082-96/1	Shaw, George M		ZeptoMetrix Corp.	13-Nov-19
L-082-96/1	Wong-Staal, Flossie		ZeptoMetrix Corp.	13-Nov-19
L-248-19/0	Hinrichs, Christian S.		Regeneron Pharmaceuticals, Inc.	13-Nov-19
L-248-19/0	Jin, Benjamin		Regeneron Pharmaceuticals, Inc.	13-Nov-19
L-018-20/0	Bonomi, Carrie A.		Recursion Pharmaceuticals, Inc.	13-Nov-19
L-018-20/0	Borgel, Suzanne D.		Recursion Pharmaceuticals, Inc.	13-Nov-19
L-018-20/0	Dougherty, Kelly		Recursion Pharmaceuticals, Inc.	13-Nov-19
L-018-20/0	Hollingshead, Melinda G.		Recursion Pharmaceuticals, Inc.	13-Nov-19
L-300-19/0	Bonomi, Carrie A.		Idorsia Pharmaceuticals Ltd	14-Nov-19
L-300-19/0	Dougherty, Kelly		Idorsia Pharmaceuticals Ltd	14-Nov-19
L-300-19/0	Hollingshead, Melinda G.		Idorsia Pharmaceuticals Ltd	14-Nov-19
L-238-19/0	Hanada, Kenichi		T-Cure Bioscience, Inc	14-Nov-19
L-238-19/0	Wang, Qiong		T-Cure Bioscience, Inc	14-Nov-19
L-238-19/0	Yang, James C		T-Cure Bioscience, Inc	14-Nov-19
L-239-19/0	NCI		Cartesian Therapeutics, Inc.	15-Nov-19
L-283-19/0	Bagni- Beyer, Rachel K.	(b)(4);	Nurix, Inc.	15-Nov-19
L-283-19/0	(b) (4)	(b)(6)	Nurix, Inc.	15-Nov-19
L-283-19/0	Holderfield, Matthew T.		Nurix, Inc.	15-Nov-19
L-283-19/0	Soppet, Dan		Nurix, Inc.	15-Nov-19
L-105-18/1	Bonomi, Carrie A.		Chugai	15-Nov-19
L-105-18/1	Borgel, Suzanne D.		Chugai	15-Nov-19
L-105-18/1	Dougherty, Kelly		Chugai	15-Nov-19
L-105-18/1	Hollingshead, Melinda G.		Chugai	15-Nov-19
L-123-19/0	NCI		Bull Run Capital Inc.	15-Nov-19

(b) (3) (A), (b) (4), (b) (6)

L-123-19/0	Blumberg, Peter M.	(b)(4);	Bull Run Capital Inc.	15-Nov-19
L-123-19/0	Pearce, Larry V	(b)(6)	Bull Run Capital Inc.	15-Nov-19
L-300-19/0	Bonomi, Carrie A.		Idorsia Pharmaceuticals Ltd	18-Nov-19
L-300-19/0	Dougherty, Kelly		Idorsia Pharmaceuticals Ltd	18-Nov-19
L-300-19/0	Hollingshead, Melinda G.		Idorsia Pharmaceuticals Ltd	18-Nov-19
L-242-17/0	Schlom, Jeffrey		Amal Therapeutics	19-Nov-19
L-200-15/0	Aaronson, Stuart A.		TILT Biotherapeutics, Ltd.	20-Nov-19
L-200-15/0	(b) (6) Donald J. Giard		TILT Biotherapeutics, Ltd.	20-Nov-19
L-200-15/0	Parks, Wade P		TILT Biotherapeutics, Ltd.	20-Nov-19
L-115-17/1	Aaronson, Stuart A.		VCN Biosciences, S.L.	20-Nov-19
L-115-17/1	Giard, Donald		VCN Biosciences, S.L.	20-Nov-19
L-115-17/1	Parks, Wade P		VCN Biosciences, S.L.	20-Nov-19
L-014-19/0	Bonomi, Carrie A.		ABL Bio Inc.	21-Nov-19
L-014-19/0	Borgel, Suzanne D.		ABL Bio Inc.	21-Nov-19
L-014-19/0	Dougherty, Kelly		ABL Bio Inc.	21-Nov-19
L-014-19/0	Hollingshead, Melinda G.		ABL Bio Inc.	21-Nov-19
L-018-20/0	Bonomi, Carrie A.		Recursion Pharmaceuticals, Inc.	21-Nov-19
L-018-20/0	Borgel, Suzanne D.		Recursion Pharmaceuticals, Inc.	21-Nov-19
L-018-20/0	Dougherty, Kelly		Recursion Pharmaceuticals, Inc.	21-Nov-19
L-018-20/0	Hollingshead, Melinda G.		Recursion Pharmaceuticals, Inc.	21-Nov-19
L-018-20/0	Bonomi, Carrie A.		Recursion Pharmaceuticals, Inc.	21-Nov-19
L-018-20/0	Borgel, Suzanne D.		Recursion Pharmaceuticals, Inc.	21-Nov-19
L-018-20/0	Dougherty, Kelly		Recursion Pharmaceuticals, Inc.	21-Nov-19
L-018-20/0	Hollingshead, Melinda G.		Recursion Pharmaceuticals, Inc.	21-Nov-19
L-274-18/0	Gros, Alena		Cellular Biomedicine Group, Inc.	21-Nov-19
L-274-18/0	Rosenberg, Steven A.		Cellular Biomedicine Group, Inc.	21-Nov-19
L-333-17/0	Bonomi, Carrie A.		Glenmark Pharmaceuticals, S A.	22-Nov-19
L-333-17/0	Borgel, Suzanne D.		Glenmark Pharmaceuticals, S A.	22-Nov-19
L-333-17/0	Dougherty, Kelly		Glenmark Pharmaceuticals, S A.	22-Nov-19
L-333-17/0	Hollingshead, Melinda G.		Glenmark Pharmaceuticals, S A.	22-Nov-19
L-333-17/0	Bonomi, Carrie A.		Glenmark Pharmaceuticals, S A.	22-Nov-19
L-333-17/0	Borgel, Suzanne D.		Glenmark Pharmaceuticals, S A.	22-Nov-19
L-333-17/0	Dougherty, Kelly		Glenmark Pharmaceuticals, S A.	22-Nov-19
L-333-17/0	Hollingshead, Melinda G.		Glenmark Pharmaceuticals, S A.	22-Nov-19
L-333-17/0	Bonomi, Carrie A.		Glenmark Pharmaceuticals, S A.	22-Nov-19
L-333-17/0	Borgel, Suzanne D.		Glenmark Pharmaceuticals, S A.	22-Nov-19
L-333-17/0	Dougherty, Kelly		Glenmark Pharmaceuticals, S A.	22-Nov-19
L-333-17/0	Hollingshead, Melinda G.		Glenmark Pharmaceuticals, S A.	22-Nov-19
L-039-11/0	Onda, Masanori		Rockland Immunochemicals, Inc.	22-Nov-19
L-039-11/0	Pastan, Ira H		Rockland Immunochemicals, Inc.	22-Nov-19
L-273-17/0	Bonomi, Carrie A.		Kyowa Hakko Kirin Co., Ltd	25-Nov-19
L-273-17/0	Borgel, Suzanne D.		Kyowa Hakko Kirin Co., Ltd	25-Nov-19

(b) (3) (A), (b) (4), (b) (6)

L-273-17/0	Dougherty, Kelly	(b)(4);	Kyowa Hakko Kirin Co., Ltd	25-Nov-19
L-273-17/0	Hollingshead, Melinda G.	(b)(6)	Kyowa Hakko Kirin Co., Ltd	25-Nov-19
L-109-15/0	Brinkmann, Ulrich		Chugai Pharmaceutical Co.	25-Nov-19
L-109-15/0	Jung, Sun-Hee		Chugai Pharmaceutical Co.	25-Nov-19
L-109-15/0	Lee, Byungkook		Chugai Pharmaceutical Co.	25-Nov-19
L-109-15/0	Pastan, Ira H		Chugai Pharmaceutical Co.	25-Nov-19
L-035-19/0	Greiner, John W.		EnGene Inc.	25-Nov-19
L-035-19/0	Schlom, Jeffrey		EnGene Inc.	25-Nov-19
L-064-18/0	Bonomi, Carrie A.		Alderley Park Limited	26-Nov-19
L-064-18/0	Borgel, Suzanne D.		Alderley Park Limited	26-Nov-19
L-064-18/0	Dougherty, Kelly		Alderley Park Limited	26-Nov-19
L-064-18/0	Hollingshead, Melinda G.		Alderley Park Limited	26-Nov-19
L-289-19/0	Bonomi, Carrie A.		Alkermes	26-Nov-19
L-289-19/0	Dougherty, Kelly		Alkermes	26-Nov-19
L-289-19/0	Hollingshead, Melinda G.		Alkermes	26-Nov-19
L-289-19/0	Bonomi, Carrie A.		Alkermes	26-Nov-19
L-289-19/0	Dougherty, Kelly		Alkermes	26-Nov-19
L-289-19/0	Hollingshead, Melinda G.		Alkermes	26-Nov-19
L-224-18/0	Bonomi, Carrie A.		Tolero Pharmaceuticals, Inc.	26-Nov-19
L-224-18/0	Borgel, Suzanne D.		Tolero Pharmaceuticals, Inc.	26-Nov-19
L-224-18/0	Dougherty, Kelly		Tolero Pharmaceuticals, Inc.	26-Nov-19
L-224-18/0	Hollingshead, Melinda G.		Tolero Pharmaceuticals, Inc.	26-Nov-19
L-160-18/0	NCI		Advanced Imaging Projects, LLC (AIP)	26-Nov-19
<i>Note: L-160-18/0 split between CC; NCI</i>				
L-083-11/0	Waldmann, Thomas A.	(b)(4);	Abbott Biotherapeutics Corp.	27-Nov-19
<i>Note: L-083-11/0 split between NCI; NINDS</i>				
L-259-17/0	NCI		CRISPR Therapeutics AG	27-Nov-19
L-146-19/0	Hinrichs, Christian S.	(b)(4);	Adicet Bio	27-Nov-19
L-146-19/0	Yongzu Jin, Benjamin	(b)(6)	Adicet Bio	27-Nov-19
L-072-19/0	Bagni- Beyer, Rachel K.		X-Chem, Inc.	29-Nov-19
L-072-19/0	(b) (4)		X-Chem, Inc.	29-Nov-19
L-072-19/0	Holderfield, Matthew T.		X-Chem, Inc.	29-Nov-19
L-072-19/0	Soppet, Dan		X-Chem, Inc.	29-Nov-19
L-304-19/0	Cafri, Gal		Intellia Therapeutics, Inc	29-Nov-19
L-304-19/0	Dudley, Mark		Intellia Therapeutics, Inc	29-Nov-19
L-304-19/0	Fitzgerald, Peter C.		Intellia Therapeutics, Inc	29-Nov-19
L-304-19/0	Gartner, Jared		Intellia Therapeutics, Inc	29-Nov-19
L-304-19/0	Gros, Alena		Intellia Therapeutics, Inc	29-Nov-19
L-304-19/0	Lu, Yong-Chen W.		Intellia Therapeutics, Inc	29-Nov-19
L-304-19/0	Robbins, Paul F		Intellia Therapeutics, Inc	29-Nov-19
L-304-19/0	Rosenberg, Steven A.		Intellia Therapeutics, Inc	29-Nov-19
L-304-19/0	Tran, Eric		Intellia Therapeutics, Inc	29-Nov-19
L-304-19/0	Wunderlich, John		Intellia Therapeutics, Inc	29-Nov-19

(b) (3) (A), (b) (4), (b) (6)

L-304-19/0	Zheng, Zhili	(b)(4);	Intellia Therapeutics, Inc	29-Nov-19
L-304-19/0	NCI		Intellia Therapeutics, Inc	29-Nov-19

NIH Patent Licensing Activities
NCI
December 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
L-162-17/0	Bonomi, Carrie A.	(b)(4);	Daiichi Sankyo Co., Ltd.	1-Dec-19						(b) (3) (A), (b) (4), (b) (6)
L-162-17/0	Dougherty, Kelly	(b)(6)	Daiichi Sankyo Co., Ltd.	1-Dec-19						
L-162-17/0	Hollingshead, Melinda G.		Daiichi Sankyo Co., Ltd.	1-Dec-19						
L-154-97/2	Mason, Llewellyn H.		BD Biosciences - BD PharMingen	2-Dec-19						
L-154-97/2	Ortaldo, John R.		BD Biosciences - BD PharMingen	2-Dec-19						
L-097-00/2	Austin, Faye C.		BD Biosciences, PharMingen	2-Dec-19						
L-097-00/2	Colcher, David		BD Biosciences, PharMingen	2-Dec-19						
L-097-00/2	Hand, Patricia H		BD Biosciences, PharMingen	2-Dec-19						
L-097-00/2	Nuti, Marianna		BD Biosciences, PharMingen	2-Dec-19						
L-097-00/2	Schlom, Jeffrey		BD Biosciences, PharMingen	2-Dec-19						
L-010-20/0	Bonomi, Carrie A.		Genentech, Inc.	2-Dec-19						
L-010-20/0	Dougherty, Kelly		Genentech, Inc.	2-Dec-19						
L-010-20/0	Hollingshead, Melinda G.		Genentech, Inc.	2-Dec-19						
L-194-19/0	Buck, Christopher		Etna Biotech Srl	2-Dec-19						
L-194-19/0	(b) (4)		Etna Biotech Srl	2-Dec-19						
L-194-19/0	Lowy, Douglas R.		Etna Biotech Srl	2-Dec-19						
L-194-19/0	Pastrana, Diana V		Etna Biotech Srl	2-Dec-19						
L-194-19/0	Roden, Richard B		Etna Biotech Srl	2-Dec-19						
L-194-19/0	Schiller, John T		Etna Biotech Srl	2-Dec-19						
L-030-18/0	Bonomi, Carrie A.		23andMe Therapeutics	2-Dec-19						
L-030-18/0	Borgel, Suzanne D.		23andMe Therapeutics	2-Dec-19						
L-030-18/0	Dougherty, Kelly		23andMe Therapeutics	2-Dec-19						
L-030-18/0	Hollingshead, Melinda G.		23andMe Therapeutics	2-Dec-19						
L-745-91/2	Chang, Nancy T.		BioMerieux, Inc.	2-Dec-19						
L-745-91/2	Crowl, Robert		BioMerieux, Inc.	2-Dec-19						
L-745-91/2	Fisher, Amanda G.		BioMerieux, Inc.	2-Dec-19						
L-745-91/2	Gallo, Robert C.		BioMerieux, Inc.	2-Dec-19						
L-745-91/2	Hahn, Beatrice		BioMerieux, Inc.	2-Dec-19						
L-745-91/2	(b) (4)		BioMerieux, Inc.	2-Dec-19						
L-745-91/2	Popovic, Mikulas		BioMerieux, Inc.	2-Dec-19						
L-745-91/2	Reddy, E. Premkumar.		BioMerieux, Inc.	2-Dec-19						
L-745-91/2	Sarrngadharan, Mangalasseril		BioMerieux, Inc.	2-Dec-19						
L-745-91/2	Shaw, George M		BioMerieux, Inc.	2-Dec-19						
L-745-91/2	Wong-Staal, Flossie		BioMerieux, Inc.	2-Dec-19						
L-253-18/1	Bonomi, Carrie A.		Yuhan R&D Institute	3-Dec-19						
L-253-18/1	Borgel, Suzanne D.		Yuhan R&D Institute	3-Dec-19						

L-253-18/1	Dougherty, Kelly	(b)(4);	Yuhan R&D Institute	3-Dec-19	(b) (3) (A), (b) (4), (b) (6)
L-253-18/1	Hollingshead, Melinda G.	(b)(6)	Yuhan R&D Institute	3-Dec-19	
L-086-15/0	Hanada, Kenichi		Compugen, Ltd.	3-Dec-19	
L-086-15/0	Rosenberg, Steven A.		Compugen, Ltd.	3-Dec-19	
L-086-15/0	Topalian, Suzanne L.		Compugen, Ltd.	3-Dec-19	
L-086-15/0	Yang, James C		Compugen, Ltd.	3-Dec-19	
L-086-15/0	Yu, Zhiya		Compugen, Ltd.	3-Dec-19	
L-130-16/0	Morgan, Richard A.		Five Prime Therapeutics, Inc	3-Dec-19	
L-130-16/0	Robbins, Paul F		Five Prime Therapeutics, Inc	3-Dec-19	
L-130-16/0	Rosenberg, Steven A.		Five Prime Therapeutics, Inc	3-Dec-19	
L-333-01/1	Gallo, Robert C.		ZeptoMetrix Corporation	3-Dec-19	
L-333-01/1	Lusso, Paolo		ZeptoMetrix Corporation	3-Dec-19	
L-205-18/0	Hodge, Deborah		Chugai Pharmaceutical	5-Dec-19	
L-205-18/0	Young, Howard A.		Chugai Pharmaceutical	5-Dec-19	

NIH Patent Licensing Activities
 NCI
 January 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	License			Inventor Awards January	Net Remaining to IC
					% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income		
L-200-14/0	Austin, Faye C.	(b)(4);	Becton, Dickinson and Company	1-Jan-20	(b) (3) (A), (b) (4), (b) (6)				
L-200-14/0	Colcher, David	(b)(6)	Becton, Dickinson and Company	1-Jan-20					
L-200-14/0	Hand, Patricia H		Becton, Dickinson and Company	1-Jan-20					
L-200-14/0	Nuti, Marianna		Becton, Dickinson and Company	1-Jan-20					
L-200-14/0	Schlom, Jeffrey		Becton, Dickinson and Company	1-Jan-20					
L-298-96/2	NCI		Merck & Co., Inc.	1-Jan-20					
L-182-18/0	Buck, Christopher	(b)(4);	Regeneron Pharmaceuticals, Inc.	1-Jan-20					
L-182-18/0	Pastrana, Diana V	(b)(6)	Regeneron Pharmaceuticals, Inc.	1-Jan-20					
L-182-18/0	Schiller, John T		Regeneron Pharmaceuticals, Inc.	1-Jan-20					
L-108-09/0	Conrads, Thomas P		AB Sciex, LLC	1-Jan-20					
L-108-09/0	Issaq, Haleem J.		AB Sciex, LLC	1-Jan-20					
L-108-09/0	Janini, George		AB Sciex, LLC	1-Jan-20					
L-108-09/0	Veenstra, Timothy D		AB Sciex, LLC	1-Jan-20					
L-108-09/0	Wilkens, Kenneth L.		AB Sciex, LLC	1-Jan-20					
L-089-07/0	Emmert-Buck, Michael R.		Theranostics Health	1-Jan-20					
L-089-07/0	Liotta, Lance		Theranostics Health	1-Jan-20					
L-089-07/0	Mehta, Arpita I		Theranostics Health	1-Jan-20					
L-089-07/0	Simone, Nicole L		Theranostics Health	1-Jan-20					
<i>Note: L-089-07/0 split between FDA; NCI</i>									
L-283-19/0	Bagni- Beyer, Rachel K.		Nurix, Inc.	1-Jan-20					
L-283-19/0	(b) (4)		Nurix, Inc.	1-Jan-20					
L-283-19/0	Holderfield, Matthew T.		Nurix, Inc.	1-Jan-20					
L-283-19/0	Soppet, Dan		Nurix, Inc.	1-Jan-20					

L-148-18/0	NCI		BravoVax Co., Ltd.	1-Jan-20
L-235-19/0	Copeland, Neal	(b)(4);	Vir Biotechnology, Inc.	1-Jan-20
L-235-19/0	Costantino, Nina	(b)(6)	Vir Biotechnology, Inc.	1-Jan-20
L-235-19/0	Court, Donald		Vir Biotechnology, Inc.	1-Jan-20
L-235-19/0	Jenkins Copeland, Nancy A		Vir Biotechnology, Inc.	1-Jan-20
L-235-19/0	Warming, Soren		Vir Biotechnology, Inc.	1-Jan-20
L-093-17/0	Gazdar, Adi F.		ADC Therapeutics SA	1-Jan-20
L-093-17/0	Minna, John D.		ADC Therapeutics SA	1-Jan-20
L-050-17/0	Bonomi, Carrie A.		Pfizer Global Research and Development	1-Jan-20
L-050-17/0	Dougherty, Kelly		Pfizer Global Research and Development	1-Jan-20
L-050-17/0	Hollingshead, Melinda G.		Pfizer Global Research and Development	1-Jan-20
L-031-16/0	Bonomi, Carrie A.		Shanghai ChemPartner Co., Ltd.	1-Jan-20
L-031-16/0	Borgel, Suzanne D.		Shanghai ChemPartner Co., Ltd.	1-Jan-20
L-031-16/0	Dougherty, Kelly		Shanghai ChemPartner Co., Ltd.	1-Jan-20
L-031-16/0	Hollingshead, Melinda G.		Shanghai ChemPartner Co., Ltd.	1-Jan-20
L-038-19/0	Bonomi, Carrie A.		Boehringer Ingelheim International GmbH	1-Jan-20
L-038-19/0	Borgel, Suzanne D.		Boehringer Ingelheim International GmbH	1-Jan-20
L-038-19/0	Dougherty, Kelly		Boehringer Ingelheim International GmbH	1-Jan-20
L-038-19/0	Hollingshead, Melinda G.		Boehringer Ingelheim International GmbH	1-Jan-20
L-012-16/1	Boyd, Michael R.		The Population Council, Inc.	1-Jan-20
L-012-16/1	McMahon, James		The Population Council, Inc.	1-Jan-20
L-012-16/1	O'Keefe, Barry		The Population Council, Inc.	1-Jan-20
L-012-16/1	Toshiyuki, Mori		The Population Council, Inc.	1-Jan-20
L-259-17/0	NCI		CRISPR Therapeutics AG	1-Jan-20
L-174-18/0	Bonomi, Carrie A.	(b)(4);	Scancell	1-Jan-20
L-174-18/0	Borgel, Suzanne D.	(b)(6)	Scancell	1-Jan-20
L-174-18/0	Dougherty, Kelly		Scancell	1-Jan-20
L-174-18/0	Hollingshead, Melinda G.		Scancell	1-Jan-20
L-076-10/1	(b)(4)		Scancell Ltd	1-Jan-20
L-076-10/1	Hwu, Patrick		Scancell Ltd	1-Jan-20
L-076-10/1	Kawakami, Yutaka		Scancell Ltd	1-Jan-20
L-076-10/1	Lapointe, Rejean		Scancell Ltd	1-Jan-20
L-076-10/1	Parkhurst, Maria		Scancell Ltd	1-Jan-20
L-076-10/1	Rosenberg, Steven A.		Scancell Ltd	1-Jan-20
L-076-10/1	(b)(4)		Scancell Ltd	1-Jan-20
L-076-10/1	Wang, Rong-fu		Scancell Ltd	1-Jan-20
L-241-19/0	Buck, Christopher		Pomona Ricerca SRL	1-Jan-20
L-241-19/0	Pastrana, Diana V		Pomona Ricerca SRL	1-Jan-20
L-241-19/0	Schiller, John T		Pomona Ricerca SRL	1-Jan-20
L-162-14/0	Gottesman, Michael M.		Pfizer	1-Jan-20
L-162-14/0	Pastan, Ira H		Pfizer	1-Jan-20
L-162-14/0	Ueda, Kazumitsu		Pfizer	1-Jan-20

(b) (3) (A), (b) (4), (b) (6)

L-066-15/0	Rosenberg, Steven A.	(b)(4); (b)(6)	Genentech., Inc.	1-Jan-20
L-011-06/0	Barry, Todd		Dako Denmark A/S	1-Jan-20
L-011-06/0	Rosenwald, Andreas		Dako Denmark A/S	1-Jan-20
L-011-06/0	Staudt, Louis M		Dako Denmark A/S	1-Jan-20
L-011-06/0	Wiestner, Adrian		Dako Denmark A/S	1-Jan-20
L-011-06/0	Wilson, Wyndham H.		Dako Denmark A/S	1-Jan-20
L-014-16/0	Hodge, James W.		Transgene SA	1-Jan-20
L-014-16/0	Schlom, Jeffrey		Transgene SA	1-Jan-20
L-064-18/0	Bonomi, Carrie A.		Alderley Park Limited	1-Jan-20
L-064-18/0	Borgel, Suzanne D.		Alderley Park Limited	1-Jan-20
L-064-18/0	Dougherty, Kelly		Alderley Park Limited	1-Jan-20
L-064-18/0	Hollingshead, Melinda G.		Alderley Park Limited	1-Jan-20
L-154-12/0	Gazdar, Adi F.		Ventana Medical Systems	1-Jan-20
L-154-12/0	Johnson, Bruce E		Ventana Medical Systems	1-Jan-20
L-154-12/0	Kaye, Frederic J		Ventana Medical Systems	1-Jan-20
L-154-12/0	Khleif, Samir N.		Ventana Medical Systems	1-Jan-20
L-154-12/0	Minna, John D.		Ventana Medical Systems	1-Jan-20
L-154-12/0	Oie, Herbert K		Ventana Medical Systems	1-Jan-20
L-154-12/0	Pass, Harvey I.		Ventana Medical Systems	1-Jan-20
L-099-12/0	Gazdar, Adi F.		Ventana Medical Systems Inc	1-Jan-20
L-099-12/0	Johnson, Bruce E		Ventana Medical Systems Inc	1-Jan-20
L-099-12/0	Kaye, Frederic J		Ventana Medical Systems Inc	1-Jan-20
L-099-12/0	Khleif, Samir N.		Ventana Medical Systems Inc	1-Jan-20
L-099-12/0	Minna, John D.		Ventana Medical Systems Inc	1-Jan-20
L-099-12/0	Oie, Herbert K		Ventana Medical Systems Inc	1-Jan-20
L-099-12/0	Pass, Harvey I.		Ventana Medical Systems Inc	1-Jan-20
L-056-17/0	Schlom, Jeffrey		F-star Biotechnology Ltd	1-Jan-20
L-165-18/0	Baskar, Sivasubramanian		Exbio Praha	1-Jan-20
L-165-18/0	Rader, Christoph		Exbio Praha	1-Jan-20
L-259-17/0	NCI		CRISPR Therapeutics AG	1-Jan-20
L-128-18/0	Bonomi, Carrie A.	(b)(4);	Xencor	1-Jan-20
L-128-18/0	Borgel, Suzanne D.	(b)(6)	Xencor	1-Jan-20
L-128-18/0	Dougherty, Kelly		Xencor	1-Jan-20
L-128-18/0	Hollingshead, Melinda G.		Xencor	1-Jan-20
L-317-17/0	Chen, Weizao		Lentigen Corporation Technology	1-Jan-20
L-317-17/0	Dimitrov, Dimiter S.		Lentigen Corporation Technology	1-Jan-20
L-317-17/0	Ponraj, Prabakaran		Lentigen Corporation Technology	1-Jan-20
L-015-20/0	Hamilton, Thomas C		Daiichi Sankyo Co., Ltd.	1-Jan-20
L-015-20/0	Ozols, Robert F		Daiichi Sankyo Co., Ltd.	1-Jan-20
L-007-20/0	Esposito, Dominic		Ceva Sante Animale S A.	1-Jan-20
L-007-20/0	Hopkins, Ralph F.		Ceva Sante Animale S A.	1-Jan-20
L-225-19/0	Gallo, Robert C.		Biotest AG	1-Jan-20

L-225-19/0	Popovic, Mikulas	(b)(4); (b)(6)	Biotest AG	1-Jan-20
L-221-19/0	Franchini, Genoveffa		Genosafe SAS	1-Jan-20
L-221-19/0	Gallo, Robert C.		Genosafe SAS	1-Jan-20
L-221-19/0	Kalyanaraman, Vaniambadi S.		Genosafe SAS	1-Jan-20
L-221-19/0	Markham, Phillip D.		Genosafe SAS	1-Jan-20
L-221-19/0	Salahuddin, Syed Z.		Genosafe SAS	1-Jan-20
L-221-19/0	Wong-Staal, Flossie		Genosafe SAS	1-Jan-20
L-049-18/1	Bonomi, Carrie A.		BrightPath Biotherapeutics Co., Ltd.	1-Jan-20
L-049-18/1	Borgel, Suzanne D.		BrightPath Biotherapeutics Co., Ltd.	1-Jan-20
L-049-18/1	Dougherty, Kelly		BrightPath Biotherapeutics Co., Ltd.	1-Jan-20
L-049-18/1	Hollingshead, Melinda G.		BrightPath Biotherapeutics Co., Ltd.	1-Jan-20
L-124-19/0	Gazdar, Adi F.		Nichirei Biosciences, Inc.	1-Jan-20
L-124-19/0	Johnson, Bruce E		Nichirei Biosciences, Inc.	1-Jan-20
L-124-19/0	Kaye, Frederic J		Nichirei Biosciences, Inc.	1-Jan-20
L-124-19/0	Kheif, Samir N.		Nichirei Biosciences, Inc.	1-Jan-20
L-124-19/0	Minna, John D.		Nichirei Biosciences, Inc.	1-Jan-20
L-124-19/0	Oie, Herbert K		Nichirei Biosciences, Inc.	1-Jan-20
L-124-19/0	Pass, Harvey I.		Nichirei Biosciences, Inc.	1-Jan-20
L-084-11/2	Gazdar, Adi F.		Nichirei Biosciences Inc	1-Jan-20
L-084-11/2	Johnson, Bruce E		Nichirei Biosciences Inc	1-Jan-20
L-084-11/2	Kaye, Frederic J		Nichirei Biosciences Inc	1-Jan-20
L-084-11/2	Khleif, Samir N.		Nichirei Biosciences Inc	1-Jan-20
L-084-11/2	Minna, John D.		Nichirei Biosciences Inc	1-Jan-20
L-084-11/2	Oie, Herbert K		Nichirei Biosciences Inc	1-Jan-20
L-084-11/2	Pass, Harvey I.		Nichirei Biosciences Inc	1-Jan-20
L-227-17/0	Bonomi, Carrie A.		Seres Therapeutics, Inc.	1-Jan-20
L-227-17/0	Borgel, Suzanne D.		Seres Therapeutics, Inc.	1-Jan-20
L-227-17/0	Dougherty, Kelly		Seres Therapeutics, Inc.	1-Jan-20
L-227-17/0	Hollingshead, Melinda G.		Seres Therapeutics, Inc.	1-Jan-20
L-121-19/0	Gottesman, Michael M.		Axcelead Drug Discovery Partners, Inc	1-Jan-20
L-121-19/0	Pastan, Ira H		Axcelead Drug Discovery Partners, Inc	1-Jan-20
L-121-19/0	Ueda, Kazumitsu		Axcelead Drug Discovery Partners, Inc	1-Jan-20
L-083-11/0	Waldmann, Thomas A.		Abbott Biotherapeutics Corp.	1-Jan-20
<i>Note: L-083-11/0 split between NCI; NINDS</i>				
L-091-10/0	Bonner, William M		Novus Biologicals, Inc.	1-Jan-20
L-091-10/0	Rogakou, Efthimia P		Novus Biologicals, Inc.	1-Jan-20
L-238-18/0	Bonomi, Carrie A.		Vividion Therapeutics, Inc.	1-Jan-20
L-238-18/0	Borgel, Suzanne D.		Vividion Therapeutics, Inc.	1-Jan-20
L-238-18/0	Dougherty, Kelly		Vividion Therapeutics, Inc.	1-Jan-20
L-238-18/0	Hollingshead, Melinda G.		Vividion Therapeutics, Inc.	1-Jan-20
L-190-19/0	Cafri, Gal		ZioPharm Oncology, Inc	1-Jan-20
L-190-19/0	Deniger, Drew		ZioPharm Oncology, Inc	1-Jan-20
L-190-19/0	Feldman, Steven A		ZioPharm Oncology, Inc	1-Jan-20
L-190-19/0	Fitzgerald, Peter C.		ZioPharm Oncology, Inc	1-Jan-20
L-190-19/0	Hanada, Kenichi		ZioPharm Oncology, Inc	1-Jan-20

(b) (3) (A), (b) (4), (b) (6)

L-190-19/0	Lo, Winifred Margaret	(b)(4);	ZioPharm Oncology, Inc	1-Jan-20
L-190-19/0	Lu, Yong-Chen W.	(b)(6)	ZioPharm Oncology, Inc	1-Jan-20
L-190-19/0	Malekzadeh, Parisa		ZioPharm Oncology, Inc	1-Jan-20
L-190-19/0	Parkhurst, Maria		ZioPharm Oncology, Inc	1-Jan-20
L-190-19/0	Pasetto, Anna		ZioPharm Oncology, Inc	1-Jan-20
L-190-19/0	Robbins, Paul F		ZioPharm Oncology, Inc	1-Jan-20
L-190-19/0	Rosenberg, Steven A.		ZioPharm Oncology, Inc	1-Jan-20
L-190-19/0	Tran, Eric		ZioPharm Oncology, Inc	1-Jan-20
L-190-19/0	Wang, Qiong		ZioPharm Oncology, Inc	1-Jan-20
L-190-19/0	Yang, James C		ZioPharm Oncology, Inc	1-Jan-20
L-190-19/0	Yoseph, Rami		ZioPharm Oncology, Inc	1-Jan-20
L-190-19/0	Yu, Zhiya		ZioPharm Oncology, Inc	1-Jan-20
L-190-19/0	Zhao, Chihao		ZioPharm Oncology, Inc	1-Jan-20
L-190-19/0	Zheng, Zhili		ZioPharm Oncology, Inc	1-Jan-20
L-259-18/0	Bonomi, Carrie A.		Oncoveda Cancer Research Center	1-Jan-20
L-259-18/0	Borgel, Suzanne D.		Oncoveda Cancer Research Center	1-Jan-20
L-259-18/0	Dougherty, Kelly		Oncoveda Cancer Research Center	1-Jan-20
L-259-18/0	Hollingshead, Melinda G.		Oncoveda Cancer Research Center	1-Jan-20
L-169-15/1	Gottesman, Michael M.		Enanta Pharmaceuticals, Inc.	1-Jan-20
L-169-15/1	Pastan, Ira H		Enanta Pharmaceuticals, Inc.	1-Jan-20
L-169-15/1	Ueda, Kazumitsu		Enanta Pharmaceuticals, Inc.	1-Jan-20
L-022-06/3	Gottesman, Michael M.		Abbott Laboratories	1-Jan-20
L-022-06/3	Pastan, Ira H		Abbott Laboratories	1-Jan-20
L-022-06/3	Ueda, Kazumitsu		Abbott Laboratories	1-Jan-20
L-297-19/0	Bonomi, Carrie A.		Incyte Corporation	1-Jan-20
L-297-19/0	Borgel, Suzanne D.		Incyte Corporation	1-Jan-20
L-297-19/0	Dougherty, Kelly		Incyte Corporation	1-Jan-20
L-297-19/0	Hodge, James W.		Incyte Corporation	1-Jan-20
L-297-19/0	Hollingshead, Melinda G.		Incyte Corporation	1-Jan-20
L-297-19/0	Schlom, Jeffrey		Incyte Corporation	1-Jan-20
L-232-14/1	NCI		NanoString Technologies, Inc.	1-Jan-20
<i>Note: L-232-14/1 split between CIT; NCI</i>				
L-224-15/0	Kochenderfer, James N	(b)(4);	Bluebird Bio	1-Jan-20
L-054-10/2	NCI		Research Corp Techn. Inc.	1-Jan-20
L-153-10/0	Greiner, John W.	(b)(4);	Arko Laboratories LTD	1-Jan-20
L-153-10/0	Schlom, Jeffrey	(b)(6)	Arko Laboratories LTD	1-Jan-20
L-153-10/0	Zaharoff, David		Arko Laboratories LTD	1-Jan-20
L-206-19/0	Gazdar, Adi F.		Crown Bioscience Inc.	1-Jan-20
L-206-19/0	Johnson, Bruce E		Crown Bioscience Inc.	1-Jan-20
L-206-19/0	Kaye, Frederic J		Crown Bioscience Inc.	1-Jan-20
L-206-19/0	Kheif, Samir N.		Crown Bioscience Inc.	1-Jan-20
L-206-19/0	Minna, John D.		Crown Bioscience Inc.	1-Jan-20
L-206-19/0	Oie, Herbert K		Crown Bioscience Inc.	1-Jan-20
L-206-19/0	Pass, Harvey I.		Crown Bioscience Inc.	1-Jan-20
L-208-13/0	Bernardo, Marcelino L.		Aspyrian THERapeutics, Inc.	1-Jan-20

L-208-13/0	Choyke, Peter L	(b)(4);	Aspyrian THerapeutics, Inc.	1-Jan-20
L-208-13/0	Kobayashi, Hisataka	(b)(6)	Aspyrian THerapeutics, Inc.	1-Jan-20
L-208-13/0	Mitsunaga, Makoto		Aspyrian THerapeutics, Inc.	1-Jan-20
L-208-13/0	NCI		Aspyrian THerapeutics, Inc.	1-Jan-20
L-208-13/0	NCI		Aspyrian THerapeutics, Inc.	1-Jan-20
L-054-10/2	Dimitrov, Dimiter S.	(b)(4); (b)(6)	Research Corp Techn. Inc.	1-Jan-20
L-191-18/0	Bonomi, Carrie A.		Palleon Pharmaceuticals	1-Jan-20
L-191-18/0	Borgel, Suzanne D.		Palleon Pharmaceuticals	1-Jan-20
L-191-18/0	Dougherty, Kelly		Palleon Pharmaceuticals	1-Jan-20
L-191-18/0	Hollingshead, Melinda G.		Palleon Pharmaceuticals	1-Jan-20
L-188-19/0	Schlom, Jeffrey		Good Therapeutics, Inc	1-Jan-20
L-048-15/1	Schlom, Jeffrey		PDS Biotechnology Corp	1-Jan-20
L-048-15/1	Tsang, Kwong-Yok		PDS Biotechnology Corp	1-Jan-20
L-048-15/1	NCI		PDS Biotechnology Corp	1-Jan-20
L-308-19/0	Bonomi, Carrie A.	(b)(4);	Microbiotica Ltd.	1-Jan-20
L-308-19/0	Borgel, Suzanne D.	(b)(6)	Microbiotica Ltd.	1-Jan-20
L-308-19/0	Dougherty, Kelly		Microbiotica Ltd.	1-Jan-20
L-308-19/0	Hollingshead, Melinda G.		Microbiotica Ltd.	1-Jan-20
L-061-20/0	LUCIANO, MICHAEL		Columbia Biosciences Corporation	1-Jan-20
L-061-20/0	Nani, Roger R.		Columbia Biosciences Corporation	1-Jan-20
L-061-20/0	Nourian, Saghar		Columbia Biosciences Corporation	1-Jan-20
L-061-20/0	Schnermann, Martin		Columbia Biosciences Corporation	1-Jan-20
L-009-18/0	Copeland, Neal		Spybiotech Limited	1-Jan-20
L-009-18/0	Costantino, Nina		Spybiotech Limited	1-Jan-20
L-009-18/0	Court, Donald		Spybiotech Limited	1-Jan-20
L-009-18/0	Ellis, Hilary Moyed		Spybiotech Limited	1-Jan-20
L-009-18/0	Jenkins Copeland, Nancy A		Spybiotech Limited	1-Jan-20
L-009-18/0	Lee, E-Chiang		Spybiotech Limited	1-Jan-20
L-009-18/0	Sharan, Shyam K.		Spybiotech Limited	1-Jan-20
L-009-18/0	Swaminathan, Srividya		Spybiotech Limited	1-Jan-20
L-009-18/0	Warming, Soren		Spybiotech Limited	1-Jan-20
L-009-18/0	Yu, Daiguan		Spybiotech Limited	1-Jan-20
L-085-19/0	Aaronson, Stuart A.		ImmunoActiva	1-Jan-20
L-085-19/0	Gazdar, Adi F.		ImmunoActiva	1-Jan-20
L-085-19/0	Giard, Donald		ImmunoActiva	1-Jan-20
L-085-19/0	Johnson, Bruce E		ImmunoActiva	1-Jan-20
L-085-19/0	Kaye, Frederic J		ImmunoActiva	1-Jan-20
L-085-19/0	Kheif, Samir N.		ImmunoActiva	1-Jan-20
L-085-19/0	Minna, John D.		ImmunoActiva	1-Jan-20
L-085-19/0	Oie, Herbert K		ImmunoActiva	1-Jan-20
L-085-19/0	Parks, Wade P		ImmunoActiva	1-Jan-20
L-085-19/0	Pass, Harvey I.		ImmunoActiva	1-Jan-20
L-161-18/0	Gazdar, Adi F.		ImmunoActiva	1-Jan-20

(b) (3) (A), (b) (4), (b) (6)

L-161-18/0	Johnson, Bruce E	(b)(4);	ImmunoActiva	1-Jan-20
L-161-18/0	Kaye, Frederic J	(b)(6)	ImmunoActiva	1-Jan-20
L-161-18/0	Kheif, Samir N.		ImmunoActiva	1-Jan-20
L-161-18/0	Minna, John D.		ImmunoActiva	1-Jan-20
L-161-18/0	Oie, Herbert K		ImmunoActiva	1-Jan-20
L-161-18/0	Pass, Harvey I.		ImmunoActiva	1-Jan-20
L-117-95/2	Hathcock, Karen		Southern Biotechnology Associates, Inc.	1-Jan-20
L-117-95/2	Hodes, Richard		Southern Biotechnology Associates, Inc.	1-Jan-20
L-117-95/2	Laszlo, Gloria		Southern Biotechnology Associates, Inc.	1-Jan-20
<i>Note: L-117-95/2 split between NCI; NIA</i>				
L-100-18/0	Bonomi, Carrie A.		Codiak Biosciences	1-Jan-20
L-100-18/0	Borgel, Suzanne D.		Codiak Biosciences	1-Jan-20
L-100-18/0	Dougherty, Kelly		Codiak Biosciences	1-Jan-20
L-100-18/0	Hollingshead, Melinda G.		Codiak Biosciences	1-Jan-20
L-216-14/0	Chang, Kai		Covance Research Product	1-Jan-20
L-216-14/0	Pastan, Ira H		Covance Research Product	1-Jan-20
L-216-14/0	Willingham, Mark C.		Covance Research Product	1-Jan-20
L-095-12/0	Baskar, Sivasubramanian		BioLegend	1-Jan-20
L-095-12/0	Rader, Christoph		BioLegend	1-Jan-20
L-070-12/0	Hathcock, Karen		BioLegend	1-Jan-20
L-070-12/0	Hodes, Richard		BioLegend	1-Jan-20
L-070-12/0	Laszlo, Gloria		BioLegend	1-Jan-20
L-162-08/1	Roberts, (b) (6) Anita		BioLegend	1-Jan-20
L-162-08/1	Sporn, Michael B.		BioLegend	1-Jan-20
<i>Note: L-162-08/1 split between NCI; NIAID</i>				
L-198-15/0	Ise, Tomoko		BioLegend	1-Jan-20
L-198-15/0	Nagata, Satoshi		BioLegend	1-Jan-20
L-198-15/0	Pastan, Ira H		BioLegend	1-Jan-20
L-073-09/0	Bonner, William M		BioLegend	1-Jan-20
L-073-09/0	Rogakou, Efthimia P		BioLegend	1-Jan-20
L-037-11/0	Jelinek, Ivett		BioLegend	1-Jan-20
L-037-11/0	Segal, David M.		BioLegend	1-Jan-20
L-037-11/0	Wang, Yan		BioLegend	1-Jan-20
L-042-08/1	Azimi, Nazli		Biolegend	1-Jan-20
L-042-08/1	Dubois, Sigrid		Biolegend	1-Jan-20
L-042-08/1	Goldman, Carolyn		Biolegend	1-Jan-20
L-042-08/1	Lantz, Valerie A		Biolegend	1-Jan-20
L-042-08/1	Mariner Kilbourne, Jennifer		Biolegend	1-Jan-20
L-042-08/1	Waldmann, Thomas A.		Biolegend	1-Jan-20
L-024-97/2	Kawakami, Yutaka		Signet Laboratories, Inc.	1-Jan-20
L-024-97/2	Rosenberg, Steven A.		Signet Laboratories, Inc.	1-Jan-20
L-007-11/1	Onda, Masanori		BioLegend	1-Jan-20
L-007-11/1	Pastan, Ira H		BioLegend	1-Jan-20

(b) (3) (A), (b) (4), (b) (6)

L-010-08/1	Hathcock, Karen	(b)(4);	BioLegend	1-Jan-20
L-010-08/1	Hodes, Richard	(b)(6)	BioLegend	1-Jan-20
L-010-08/1	Laszlo, Gloria		BioLegend	1-Jan-20
L-002-20/0	Bonomi, Carrie A.		Oncurious NV	1-Jan-20
L-002-20/0	Borgel, Suzanne D.		Oncurious NV	1-Jan-20
L-002-20/0	Dougherty, Kelly		Oncurious NV	1-Jan-20
L-002-20/0	Hollingshead, Melinda G.		Oncurious NV	1-Jan-20
L-002-20/0	Bonomi, Carrie A.		Oncurious NV	1-Jan-20
L-002-20/0	Borgel, Suzanne D.		Oncurious NV	1-Jan-20
L-002-20/0	Dougherty, Kelly		Oncurious NV	1-Jan-20
L-002-20/0	Hollingshead, Melinda G.		Oncurious NV	1-Jan-20
L-091-11/0	Chang, Nancy T.		Quest Diagnostics, Inc.	1-Jan-20
L-091-11/0	Fisher, Amanda G.		Quest Diagnostics, Inc.	1-Jan-20
L-091-11/0	Gallo, Robert C.		Quest Diagnostics, Inc.	1-Jan-20
L-091-11/0	Hahn, Beatrice		Quest Diagnostics, Inc.	1-Jan-20
L-091-11/0	(b) (4)		Quest Diagnostics, Inc.	1-Jan-20
L-091-11/0	Popovic, Mikulas		Quest Diagnostics, Inc.	1-Jan-20
L-091-11/0	Sarrngadharan, Mangalasseril		Quest Diagnostics, Inc.	1-Jan-20
L-091-11/0	Shaw, George M		Quest Diagnostics, Inc.	1-Jan-20
L-091-11/0	Wong-Staal, Flossie		Quest Diagnostics, Inc.	1-Jan-20
L-091-11/0	Chang, Nancy T.		Quest Diagnostics, Inc.	1-Jan-20
L-091-11/0	Fisher, Amanda G.		Quest Diagnostics, Inc.	1-Jan-20
L-091-11/0	Gallo, Robert C.		Quest Diagnostics, Inc.	1-Jan-20
L-091-11/0	Hahn, Beatrice		Quest Diagnostics, Inc.	1-Jan-20
L-091-11/0	(b) (4)		Quest Diagnostics, Inc.	1-Jan-20
L-091-11/0	Popovic, Mikulas		Quest Diagnostics, Inc.	1-Jan-20
L-091-11/0	Sarrngadharan, Mangalasseril		Quest Diagnostics, Inc.	1-Jan-20
L-091-11/0	Shaw, George M		Quest Diagnostics, Inc.	1-Jan-20
L-091-11/0	Wong-Staal, Flossie		Quest Diagnostics, Inc.	1-Jan-20
L-088-19/0	Bagni- Beyer, Rachel K.		Erasca, Inc.	1-Jan-20
L-088-19/0	(b) (4)		Erasca, Inc.	1-Jan-20
L-088-19/0	Holderfield, Matthew T.		Erasca, Inc.	1-Jan-20
L-088-19/0	Soppet, Dan		Erasca, Inc.	1-Jan-20
L-308-17/0	Fowler, Daniel		Rapa Therapeutics LLC	1-Jan-20
L-308-17/0	Gress, Ronald E.		Rapa Therapeutics LLC	1-Jan-20
L-308-17/0	Jung, Unsu		Rapa Therapeutics LLC	1-Jan-20
L-136-09/1	Mason, Llewellyn H.		BioLegend	1-Jan-20
L-136-09/1	Ortaldo, John R.		BioLegend	1-Jan-20
L-080-93/3	Hathcock, Karen		BD Biosciences - BD PharMingen, Inc.	2-Jan-20
L-080-93/3	Hodes, Richard		BD Biosciences - BD PharMingen, Inc.	2-Jan-20
L-080-93/3	Laszlo, Gloria		BD Biosciences - BD PharMingen, Inc.	2-Jan-20
L-239-19/0	NCI		Cartesian Therapeutics, Inc.	2-Jan-20
L-099-10/1	Gazdar, Adi F.	(b)(4);	Kao Corporation	2-Jan-20
L-099-10/1	Johnson, Bruce E	(b)(6)	Kao Corporation	2-Jan-20

L-099-10/1	Kaye, Frederic J	(b)(4);	Kao Corporation	2-Jan-20
L-099-10/1	Khleif, Samir N.	(b)(6)	Kao Corporation	2-Jan-20
L-099-10/1	Minna, John D.		Kao Corporation	2-Jan-20
L-099-10/1	Oie, Herbert K		Kao Corporation	2-Jan-20
L-099-10/1	Pass, Harvey I.		Kao Corporation	2-Jan-20
L-257-17/0	Buck, Christopher		Serum Institute of India PVT. LTD.	2-Jan-20
L-257-17/0	(b) (4)		Serum Institute of India PVT. LTD.	2-Jan-20
L-257-17/0	Lowy, Douglas R.		Serum Institute of India PVT. LTD.	2-Jan-20
L-257-17/0	Pastrana, Diana V		Serum Institute of India PVT. LTD.	2-Jan-20
L-257-17/0	Roden, Richard B		Serum Institute of India PVT. LTD.	2-Jan-20
L-257-17/0	Schiller, John T		Serum Institute of India PVT. LTD.	2-Jan-20
L-138-19/1	Bagni- Beyer, Rachel K.		Quanta Therapeutics, Inc., University of	2-Jan-20
L-138-19/1	(b) (4)		Quanta Therapeutics, Inc., University of	2-Jan-20
L-138-19/1	Holderfield, Matthew T.		Quanta Therapeutics, Inc., University of	2-Jan-20
L-138-19/1	Soppet, Dan		Quanta Therapeutics, Inc., University of	2-Jan-20
L-119-19/0	Esposito, Dominic		Quanta Therapeutics, Inc., University of	2-Jan-20
L-119-19/0	Gillette, William K.		Quanta Therapeutics, Inc., University of	2-Jan-20
L-119-19/0	Grose, Carissa L.		Quanta Therapeutics, Inc., University of	2-Jan-20
L-039-11/0	Onda, Masanori		Rockland Immunochemicals, Inc.	2-Jan-20
L-039-11/0	Pastan, Ira H		Rockland Immunochemicals, Inc.	2-Jan-20
L-028-18/1	Choyke, Peter L		Scanmed LLC	2-Jan-20
L-028-18/1	Greer, Matthew D.		Scanmed LLC	2-Jan-20
L-028-18/1	Mertan, Francesca		Scanmed LLC	2-Jan-20
L-028-18/1	Sonalee Gaur, Sonia		Scanmed LLC	2-Jan-20
L-028-18/1	Turkbey, Ismail B.		Scanmed LLC	2-Jan-20
<i>Note: L-028-18/1 split between CC; CIT; NCI</i>				
L-184-18/0	Bonomi, Carrie A.		Akrevia	2-Jan-20
L-184-18/0	Borgel, Suzanne D.		Akrevia	2-Jan-20
L-184-18/0	Dougherty, Kelly		Akrevia	2-Jan-20
L-184-18/0	Hollingshead, Melinda G.		Akrevia	2-Jan-20
L-294-19/0	NCI		Fannin Partners, LLC	2-Jan-20
L-086-06/0	Essand, Lars Magnus	(b)(4);	eBioscience	3-Jan-20
L-086-06/0	Lee, Byungkook	(b)(6)	eBioscience	3-Jan-20
L-086-06/0	Pastan, Ira H		eBioscience	3-Jan-20
L-086-06/0	Vasmatzis, George		eBioscience	3-Jan-20
L-086-06/0	Wolfgang, Curt		eBioscience	3-Jan-20
L-049-00/1	Hathcock, Karen		eBioscience, Inc..	3-Jan-20
L-049-00/1	Hodes, Richard		eBioscience, Inc..	3-Jan-20
L-049-00/1	Laszlo, Gloria		eBioscience, Inc..	3-Jan-20
<i>Note: L-049-00/1 split between NCI; NIAID</i>				
L-109-06/0	Mason, Llewellyn H.		eBioscience	3-Jan-20
L-109-06/0	Ortaldo, John R.		eBioscience	3-Jan-20
L-114-06/1	Azimi, Nazli		Affymetrix, Inc.	3-Jan-20
L-114-06/1	Dubois, Sigrid		Affymetrix, Inc.	3-Jan-20


L-114-06/1	Goldman, Carolyn	(b)(4);	Affymetrix, Inc.	3-Jan-20
L-114-06/1	Lantz, Valerie A	(b)(6)	Affymetrix, Inc.	3-Jan-20
L-114-06/1	Mariner Kilbourne, Jennifer		Affymetrix, Inc.	3-Jan-20
L-114-06/1	Waldmann, Thomas A.		Affymetrix, Inc.	3-Jan-20
L-152-18/0	Bonomi, Carrie A.		Cygnal Therapeutics	3-Jan-20
L-152-18/0	Dougherty, Kelly		Cygnal Therapeutics	3-Jan-20
L-152-18/0	Hollingshead, Melinda G.		Cygnal Therapeutics	3-Jan-20
L-084-19/0	Gelboin, (b) (6) Harry		Biopredic U.S., Inc.	6-Jan-20
L-084-19/0	Gonzalez, Frank J		Biopredic U.S., Inc.	6-Jan-20
L-084-19/0	Krausz, Kristopher W.		Biopredic U.S., Inc.	6-Jan-20
L-068-18/0	Bonomi, Carrie A.		Dicerna Pharmaceuticals	6-Jan-20
L-068-18/0	Dougherty, Kelly		Dicerna Pharmaceuticals	6-Jan-20
L-068-18/0	Hollingshead, Melinda G.		Dicerna Pharmaceuticals	6-Jan-20
L-063-19/2	NCI		Tailored Therapeutics, LLC	6-Jan-20
L-033-17/0	Bonomi, Carrie A.	(b)(4);	MD Biosciences, Inc.	6-Jan-20
L-033-17/0	Dougherty, Kelly	(b)(6)	MD Biosciences, Inc.	6-Jan-20
L-033-17/0	Hollingshead, Melinda G.		MD Biosciences, Inc.	6-Jan-20
L-097-00/2	Austin, Faye C.		BD Biosciences, PharMingen	7-Jan-20
L-097-00/2	Colcher, David		BD Biosciences, PharMingen	7-Jan-20
L-097-00/2	Hand, Patricia H		BD Biosciences, PharMingen	7-Jan-20
L-097-00/2	Nuti, Marianna		BD Biosciences, PharMingen	7-Jan-20
L-097-00/2	Schlom, Jeffrey		BD Biosciences, PharMingen	7-Jan-20
L-187-95/2	Yoshimura, Teizo		BD BIOSCIENCES	7-Jan-20
L-100-12/1	Ise, Tomoko		BD Biosciences	7-Jan-20
L-100-12/1	Nagata, Satoshi		BD Biosciences	7-Jan-20
L-100-12/1	Pastan, Ira H		BD Biosciences	7-Jan-20
L-076-16/0	Azimi, Nazli		BD Biosciences	7-Jan-20
L-076-16/0	Dubois, Sigrid		BD Biosciences	7-Jan-20
L-076-16/0	Goldman, Carolyn		BD Biosciences	7-Jan-20
L-076-16/0	Lantz, Valerie A		BD Biosciences	7-Jan-20
L-076-16/0	Mariner Kilbourne, Jennifer		BD Biosciences	7-Jan-20
L-076-16/0	Waldmann, Thomas A.		BD Biosciences	7-Jan-20
L-183-19/0	Esposito, Dominic		Plexxikon Inc.	7-Jan-20
L-183-19/0	Gillette, William K.		Plexxikon Inc.	7-Jan-20
L-183-19/0	Grose, Carissa L.		Plexxikon Inc.	7-Jan-20
L-165-99/1	Crowl, Robert		Trinity Biotech	7-Jan-20
L-165-99/1	Gallo, Robert C.		Trinity Biotech	7-Jan-20
L-165-99/1	(b) (4)		Trinity Biotech	7-Jan-20
L-165-99/1	Popovic, Mikulas		Trinity Biotech	7-Jan-20
L-165-99/1	Reddy, E. Premkumar.		Trinity Biotech	7-Jan-20
L-165-99/1	Sarngadharan, Mangalasseril		Trinity Biotech	7-Jan-20
L-165-99/1	Shaw, George M		Trinity Biotech	7-Jan-20
L-165-99/1	Wong-Staal, Flossie		Trinity Biotech	7-Jan-20

L-132-19/0	Bonomi, Carrie A.	(b)(4);	Shattuck Labs, Inc	7-Jan-20
L-132-19/0	Borgel, Suzanne D.	(b)(6)	Shattuck Labs, Inc	7-Jan-20
L-132-19/0	Dougherty, Kelly		Shattuck Labs, Inc	7-Jan-20
L-132-19/0	Hollingshead, Melinda G.		Shattuck Labs, Inc	7-Jan-20
L-045-19/0	Bonomi, Carrie A.		Alligator Bioscience AB	7-Jan-20
L-045-19/0	Borgel, Suzanne D.		Alligator Bioscience AB	7-Jan-20
L-045-19/0	Dougherty, Kelly		Alligator Bioscience AB	7-Jan-20
L-045-19/0	Hollingshead, Melinda G.		Alligator Bioscience AB	7-Jan-20
L-045-19/0	Schlom, Jeffrey		Alligator Bioscience AB	7-Jan-20
L-206-00/0	Aaronson, Stuart A.		LIFE TECHNOLOGIES	7-Jan-20
L-206-00/0	King, Charles R.		LIFE TECHNOLOGIES	7-Jan-20
L-206-00/0	Kraus (b) (6) Matthias		LIFE TECHNOLOGIES	7-Jan-20
L-071-93/0	Aaronson, Stuart A.		LIFE TECHNOLOGIES	7-Jan-20
L-071-93/0	Finch, Paul W.		LIFE TECHNOLOGIES	7-Jan-20
L-071-93/0	Rubin, Jeffrey S		LIFE TECHNOLOGIES	7-Jan-20
L-273-18/0	Bonomi, Carrie A.		PMI Biopharma Solutions, LLC.	7-Jan-20
L-273-18/0	Borgel, Suzanne D.		PMI Biopharma Solutions, LLC.	7-Jan-20
L-273-18/0	Dougherty, Kelly		PMI Biopharma Solutions, LLC.	7-Jan-20
L-273-18/0	Hollingshead, Melinda G.		PMI Biopharma Solutions, LLC.	7-Jan-20
L-158-17/0	Wang, Xiaohong		Mokobio Life Science Group, Inc.	7-Jan-20
L-158-17/0	Xu, Junfen		Mokobio Life Science Group, Inc.	7-Jan-20
L-158-17/0	Zheng, Zhi-Min g (Thomas)		Mokobio Life Science Group, Inc.	7-Jan-20
<i>Note: L-158-17/0 split between NCI; NHLBI</i>				
L-004-07/2	Qasba, Pradman		Life Technologies Corp.	7-Jan-20
L-004-07/2	Ramakrishnan, Boopathy		Life Technologies Corp.	7-Jan-20
L-331-17/1	(b) (4)		Istari Oncology Inc	7-Jan-20
L-331-17/1	Broadt, Trevor L.		Istari Oncology Inc	7-Jan-20
L-331-17/1	Mitra, Guatam (George)		Istari Oncology Inc	7-Jan-20
L-331-17/1	Shaban, Samir H.		Istari Oncology Inc	7-Jan-20
L-331-17/1	Xie, yuequing		Istari Oncology Inc	7-Jan-20
L-331-17/1	Zhu, Jianwei		Istari Oncology Inc	7-Jan-20
L-076-19/0	Gazdar, Adi F.		Salk Institute for Biological Studies	7-Jan-20
L-076-19/0	Johnson, Bruce E		Salk Institute for Biological Studies	7-Jan-20
L-076-19/0	Kaye, Frederic J		Salk Institute for Biological Studies	7-Jan-20
L-076-19/0	Kheif, Samir N.		Salk Institute for Biological Studies	7-Jan-20
L-076-19/0	Minna, John D.		Salk Institute for Biological Studies	7-Jan-20
L-076-19/0	Oie, Herbert K		Salk Institute for Biological Studies	7-Jan-20
L-076-19/0	Pass, Harvey I.		Salk Institute for Biological Studies	7-Jan-20
L-071-19/0	Dimitrov, Dimiter S.		Atara Biotherapeutics Inc.	8-Jan-20
L-071-19/0	Feng, Yang		Atara Biotherapeutics Inc.	8-Jan-20
L-071-19/0	Pastan, Ira H		Atara Biotherapeutics Inc.	8-Jan-20
L-004-07/2	NCI		Life Technologies Corp.	8-Jan-20
L-143-18/1	NCI		Geneius Biotechnology, Inc	8-Jan-20
<i>Note: (b) (4) split between CC; NCI</i>				

L-203-15/1	Gazdar, Adi F.	(b)(4):	SOTIO	9-Jan-20
L-203-15/1	Johnson, Bruce E	(b)(6)	SOTIO	9-Jan-20
L-203-15/1	Kaye, Frederic J		SOTIO	9-Jan-20
L-203-15/1	Khleif, Samir N.		SOTIO	9-Jan-20
L-203-15/1	Minna, John D.		SOTIO	9-Jan-20
L-203-15/1	Oie, Herbert K		SOTIO	9-Jan-20
L-203-15/1	Pass, Harvey I.		SOTIO	9-Jan-20
L-178-05/1	Chung, Jae Wook		BioGemex Ltd	9-Jan-20
L-201-19/0	Esposito, Dominic		LakePharma	9-Jan-20
L-201-19/0	Grose, Carissa L.		LakePharma	9-Jan-20
L-048-20/0	Esposito, Dominic		Arvinas Operations, Inc	9-Jan-20
L-048-20/0	Gillette, William K.		Arvinas Operations, Inc	9-Jan-20
L-048-20/0	Grose, Carissa L.		Arvinas Operations, Inc	9-Jan-20
L-063-20/0	Aplan, Peter D.		Keros Therapeutics, Inc.	9-Jan-20
L-063-20/0	Lin, Ying-Wei		Keros Therapeutics, Inc.	9-Jan-20
L-063-20/0	Slape, Christopher I.		Keros Therapeutics, Inc.	9-Jan-20
L-063-20/0	Zhang, ZhenHua		Keros Therapeutics, Inc.	9-Jan-20
L-304-19/0	Cafri, Gal		Intellia Therapeutics, Inc	10-Jan-20
L-304-19/0	Dudley, Mark		Intellia Therapeutics, Inc	10-Jan-20
L-304-19/0	Fitzgerald, Peter C.		Intellia Therapeutics, Inc	10-Jan-20
L-304-19/0	Gartner, Jared		Intellia Therapeutics, Inc	10-Jan-20
L-304-19/0	Gros, Alena		Intellia Therapeutics, Inc	10-Jan-20
L-304-19/0	Lu, Yong-Chen W.		Intellia Therapeutics, Inc	10-Jan-20
L-304-19/0	Robbins, Paul F		Intellia Therapeutics, Inc	10-Jan-20
L-304-19/0	Rosenberg, Steven A.		Intellia Therapeutics, Inc	10-Jan-20
L-304-19/0	Tran, Eric		Intellia Therapeutics, Inc	10-Jan-20
L-304-19/0	Wunderlich, John		Intellia Therapeutics, Inc	10-Jan-20
L-304-19/0	Zheng, Zhili		Intellia Therapeutics, Inc	10-Jan-20
L-281-17/0	Bonomi, Carrie A.		Intellia Therapeutics, Inc	10-Jan-20
L-281-17/0	Borgel, Suzanne D.		Intellia Therapeutics, Inc	10-Jan-20
L-281-17/0	Dougherty, Kelly		Intellia Therapeutics, Inc	10-Jan-20
L-281-17/0	Hollingshead, Melinda G.		Intellia Therapeutics, Inc	10-Jan-20
L-189-16/0	Kirnbauer, Reinhard		HIPRA Scientific	10-Jan-20
L-189-16/0	Lowy, Douglas R.		HIPRA Scientific	10-Jan-20
L-189-16/0	Roden, Richard B		HIPRA Scientific	10-Jan-20
L-189-16/0	Schiller, John T		HIPRA Scientific	10-Jan-20
L-066-07/0	Gupta, Shanker Lal		Childrens Hospital of Los Angeles	10-Jan-20
L-066-07/0	Vishnuvajjala, B. Rao		Childrens Hospital of Los Angeles	10-Jan-20
L-320-17/0	Bonomi, Carrie A.		Elstar Therapeutics	10-Jan-20
L-320-17/0	Borgel, Suzanne D.		Elstar Therapeutics	10-Jan-20
L-320-17/0	Dougherty, Kelly		Elstar Therapeutics	10-Jan-20
L-320-17/0	Hollingshead, Melinda G.		Elstar Therapeutics	10-Jan-20
L-095-19/0	Bonomi, Carrie A.		Elstar Therapeutics	10-Jan-20
L-095-19/0	Dougherty, Kelly		Elstar Therapeutics	10-Jan-20

L-095-19/0	Hollingshead, Melinda G.	(b)(4); (b)(6)	Elstar Therapeutics	10-Jan-20
L-082-15/0	Gazdar, Adi F.		Personal Genome Diagnostics	10-Jan-20
L-082-15/0	Johnson, Bruce E		Personal Genome Diagnostics	10-Jan-20
L-082-15/0	Kaye, Frederic J		Personal Genome Diagnostics	10-Jan-20
L-082-15/0	Khleif, Samir N.		Personal Genome Diagnostics	10-Jan-20
L-082-15/0	Minna, John D.		Personal Genome Diagnostics	10-Jan-20
L-082-15/0	Oie, Herbert K		Personal Genome Diagnostics	10-Jan-20
L-082-15/0	Pass, Harvey I.		Personal Genome Diagnostics	10-Jan-20
L-010-09/2	Felber, Barbara K.		Taimed Biologics USA	10-Jan-20
L-010-09/2	Pavlakakis, George N		Taimed Biologics USA	10-Jan-20
L-010-09/2	Felber, Barbara K.		Taimed Biologics USA	10-Jan-20
L-010-09/2	Pavlakakis, George N		Taimed Biologics USA	10-Jan-20
L-010-09/2	Felber, Barbara K.		Taimed Biologics USA	10-Jan-20
L-010-09/2	Pavlakakis, George N		Taimed Biologics USA	10-Jan-20
L-010-09/2	Felber, Barbara K.		Taimed Biologics USA	10-Jan-20
L-010-09/2	Pavlakakis, George N		Taimed Biologics USA	10-Jan-20
L-024-18/0	Gazdar, Adi F.		SeraCare Life	13-Jan-20
L-024-18/0	Johnson, Bruce E		SeraCare Life	13-Jan-20
L-024-18/0	Kaye, Frederic J		SeraCare Life	13-Jan-20
L-024-18/0	Kheif, Samir N.		SeraCare Life	13-Jan-20
L-024-18/0	Minna, John D.		SeraCare Life	13-Jan-20
L-024-18/0	Oie, Herbert K		SeraCare Life	13-Jan-20
L-024-18/0	Pass, Harvey I.		SeraCare Life	13-Jan-20
L-232-19/0	Palena, Claudia		Abcam plc	13-Jan-20
L-232-19/0	Schlom, Jeffrey		Abcam plc	13-Jan-20
L-011-20/0	Bonomi, Carrie A.		China Novartis Institutes for BioMedical	13-Jan-20
L-011-20/0	Borgel, Suzanne D.		China Novartis Institutes for BioMedical	13-Jan-20
L-011-20/0	Dougherty, Kelly		China Novartis Institutes for BioMedical	13-Jan-20
L-011-20/0	Hollingshead, Melinda G.		China Novartis Institutes for BioMedical	13-Jan-20
L-214-19/0	Gallo, Robert C.		Cerus Corporation	14-Jan-20
L-214-19/0	Popovic, Mikulas		Cerus Corporation	14-Jan-20
L-113-19/0	Gottesman, Michael M.		Pharmaron Beijing Co., LTD	14-Jan-20
L-113-19/0	Pastan, Ira H		Pharmaron Beijing Co., LTD	14-Jan-20
L-113-19/0	Ueda, Kazumitsu		Pharmaron Beijing Co., LTD	14-Jan-20
L-057-19/0	Bonomi, Carrie A.		Surface Oncology, Inc.	14-Jan-20
L-057-19/0	Borgel, Suzanne D.		Surface Oncology, Inc.	14-Jan-20
L-057-19/0	Dougherty, Kelly		Surface Oncology, Inc.	14-Jan-20
L-057-19/0	Hollingshead, Melinda G.		Surface Oncology, Inc.	14-Jan-20
L-108-15/0	NCI		Lion Biotechnologies	15-Jan-20
L-032-06/2	NCI		Morphotek, Inc.	15-Jan-20
L-129-16/0	Gazdar, Adi F.	(b)(4); (b)(6)	Galera Therapeutics, Inc.	15-Jan-20

L-129-16/0	Minna, John D.	(b)(4); (b)(6)	Galera Therapeutics, Inc.	15-Jan-20
L-220-19/1	Deniger, Drew		Myst Therapeutics, Inc.	15-Jan-20
L-220-19/1	Lalani, Almin		Myst Therapeutics, Inc.	15-Jan-20
L-220-19/1	Robbins, Paul F		Myst Therapeutics, Inc.	15-Jan-20
L-220-19/1	Rosenberg, Steven A.		Myst Therapeutics, Inc.	15-Jan-20
L-190-05/2	Gallo, Robert C.		GeoVax, Inc.	15-Jan-20
L-190-05/2	Popovic, Mikulas		GeoVax, Inc.	15-Jan-20
L-190-05/2	Sarngadharan, Mangalasseril		GeoVax, Inc.	15-Jan-20
<i>Note: L-190-05/2 split between NCI; NIAID</i>				
L-310-19/0	Bonomi, Carrie A.		Regeneron Pharmaceuticals, Inc.	15-Jan-20
L-310-19/0	Borgel, Suzanne D.		Regeneron Pharmaceuticals, Inc.	15-Jan-20
L-310-19/0	Dougherty, Kelly		Regeneron Pharmaceuticals, Inc.	15-Jan-20
L-310-19/0	Hollingshead, Melinda G.		Regeneron Pharmaceuticals, Inc.	15-Jan-20
*L-190-05/2	Gallo, Robert C.		GeoVax, Inc.	15-Jan-20
*L-190-05/2	Popovic, Mikulas		GeoVax, Inc.	15-Jan-20
*L-190-05/2	Sarngadharan, Mangalasseril		GeoVax, Inc.	15-Jan-20
<i>Note: L-190-05/2 split between NCI; NIAID</i>				
*L-190-05/2	Gallo, Robert C.		GeoVax, Inc.	15-Jan-20
L-190-05/2	(b) (4)		GeoVax, Inc.	15-Jan-20
*L-190-05/2	Popovic, Mikulas		GeoVax, Inc.	15-Jan-20
*L-190-05/2	Sarngadharan, Mangalasseril		GeoVax, Inc.	15-Jan-20
<i>Note: L-190-05/2 split between NCI; NIAID</i>				
L-247-17/0	Bagni- Beyer, Rachel K.		Revolution Medicines, Inc.	16-Jan-20
L-247-17/0	(b) (4)		Revolution Medicines, Inc.	16-Jan-20
L-247-17/0	Holderfield, Matthew T.		Revolution Medicines, Inc.	16-Jan-20
L-247-17/0	Soppet, Dan		Revolution Medicines, Inc.	16-Jan-20
L-100-17/0	Bonomi, Carrie A.		Genmab, B.V.	16-Jan-20
L-100-17/0	Borgel, Suzanne D.		Genmab, B.V.	16-Jan-20
L-100-17/0	Dougherty, Kelly		Genmab, B.V.	16-Jan-20
L-100-17/0	Hollingshead, Melinda G.		Genmab, B.V.	16-Jan-20
L-190-19/1	Cafri, Gal		ZioPharm Oncology, Inc	16-Jan-20
L-190-19/1	Deniger, Drew		ZioPharm Oncology, Inc	16-Jan-20
L-190-19/1	Feldman, Steven A		ZioPharm Oncology, Inc	16-Jan-20
L-190-19/1	Fitzgerald, Peter C.		ZioPharm Oncology, Inc	16-Jan-20
L-190-19/1	Hanada, Kenichi		ZioPharm Oncology, Inc	16-Jan-20
L-190-19/1	Lo, Winifred Margaret		ZioPharm Oncology, Inc	16-Jan-20
L-190-19/1	Lu, Yong-Chen W.		ZioPharm Oncology, Inc	16-Jan-20
L-190-19/1	Malekzadeh, Parisa		ZioPharm Oncology, Inc	16-Jan-20
L-190-19/1	Parkhurst, Maria		ZioPharm Oncology, Inc	16-Jan-20
L-190-19/1	Pasetto, Anna		ZioPharm Oncology, Inc	16-Jan-20
L-190-19/1	Robbins, Paul F		ZioPharm Oncology, Inc	16-Jan-20
L-190-19/1	Rosenberg, Steven A.		ZioPharm Oncology, Inc	16-Jan-20
L-190-19/1	Tran, Eric		ZioPharm Oncology, Inc	16-Jan-20
L-190-19/1	Wang, Qiong		ZioPharm Oncology, Inc	16-Jan-20
L-190-19/1	Yang, James C		ZioPharm Oncology, Inc	16-Jan-20
L-190-19/1	Yoseph, Rami		ZioPharm Oncology, Inc	16-Jan-20
L-190-19/1	Yu, Zhiya		ZioPharm Oncology, Inc	16-Jan-20



L-190-19/1	Zhao, Chihao	(b)(4);	ZioPharm Oncology, Inc	16-Jan-20
L-190-19/1	Zheng, Zhili	(b)(6)	ZioPharm Oncology, Inc	16-Jan-20
L-272-18/0	Aaronson, Stuart A.		CellSeed, Inc	22-Jan-20
L-272-18/0	Jainchill, John L.		CellSeed, Inc	22-Jan-20
L-272-18/0	Todaro, George J.		CellSeed, Inc	22-Jan-20
L-064-11/0	Barry, Todd		Eptiomics Inc	22-Jan-20
L-064-11/0	Rosenwald, Andreas		Eptiomics Inc	22-Jan-20
L-064-11/0	Staudt, Louis M		Eptiomics Inc	22-Jan-20
L-064-11/0	Wiestner, Adrian		Eptiomics Inc	22-Jan-20
L-064-11/0	Wilson, Wyndham H.		Eptiomics Inc	22-Jan-20
L-347-14/0	Muchmore, Brian P.		Abcam, plc	22-Jan-20
L-347-14/0	O'Brien, Thomas R		Abcam, plc	22-Jan-20
L-347-14/0	Porter-Gill, Patricia A.		Abcam, plc	22-Jan-20
L-347-14/0	Prokunina-Olsson, Ludmila		Abcam, plc	22-Jan-20
<i>Note: L-347-14/0 split between FDA; NCI</i>				
L-142-18/0	Gottesman, Michael M.		Takeda California	22-Jan-20
L-142-18/0	Pastan, Ira H		Takeda California	22-Jan-20
L-142-18/0	Ueda, Kazumitsu		Takeda California	22-Jan-20
L-025-04/0	Gaitanaris, George A.		Carolina Biological Supply Co., Inc.	22-Jan-20
L-025-04/0	Pavlakis, George N		Carolina Biological Supply Co., Inc.	22-Jan-20
L-025-04/0	Stauber, Roland H.		Carolina Biological Supply Co., Inc.	22-Jan-20
L-025-04/0	Vournakis, John M.		Carolina Biological Supply Co., Inc.	22-Jan-20
L-160-18/0	NCI		Advanced Imaging Projects, LLC (AIP)	22-Jan-20
<i>Note: L-160-18/0 split between CC; NCI</i>				
L-158-18/1	(b) (4)	(b)(4);	Merck Sharp & Dohme	23-Jan-20
L-158-18/1	Esposito, Dominic	(b)(6)	Merck Sharp & Dohme	23-Jan-20
L-158-18/1	Hopkins, Ralph F.		Merck Sharp & Dohme	23-Jan-20
L-158-18/1	Roberts, Veronica Ann		Merck Sharp & Dohme	23-Jan-20
L-288-19/0	Bonomi, Carrie A.		Merck Sharp & Dohme Corp.	23-Jan-20
L-288-19/0	Dougherty, Kelly		Merck Sharp & Dohme Corp.	23-Jan-20
L-288-19/0	Hollingshead, Melinda G.		Merck Sharp & Dohme Corp.	23-Jan-20
L-091-11/0	Chang, Nancy T.		Quest Diagnostics, Inc.	23-Jan-20
L-091-11/0	Fisher, Amanda G.		Quest Diagnostics, Inc.	23-Jan-20
L-091-11/0	Gallo, Robert C.		Quest Diagnostics, Inc.	23-Jan-20
L-091-11/0	Hahn, Beatrice		Quest Diagnostics, Inc.	23-Jan-20
L-091-11/0	(b) (4)		Quest Diagnostics, Inc.	23-Jan-20
L-091-11/0	Popovic, Mikulas		Quest Diagnostics, Inc.	23-Jan-20
L-091-11/0	Sarngadharan, Mangalasseril		Quest Diagnostics, Inc.	23-Jan-20
L-091-11/0	Shaw, George M		Quest Diagnostics, Inc.	23-Jan-20
L-091-11/0	Wong-Staal, Flossie		Quest Diagnostics, Inc.	23-Jan-20
L-250-17/0	Bonomi, Carrie A.		Aragen Bioscience, Inc.	23-Jan-20
L-250-17/0	Borgel, Suzanne D.		Aragen Bioscience, Inc.	23-Jan-20
L-250-17/0	Dougherty, Kelly		Aragen Bioscience, Inc.	23-Jan-20
L-250-17/0	Hollingshead, Melinda G.		Aragen Bioscience, Inc.	23-Jan-20

L-256-17/0	Bonomi, Carrie A.	(b)(4);	AbbVie	23-Jan-20
L-256-17/0	Borgel, Suzanne D.	(b)(6)	AbbVie	23-Jan-20
L-256-17/0	Dougherty, Kelly		AbbVie	23-Jan-20
L-256-17/0	Hollingshead, Melinda G.		AbbVie	23-Jan-20
L-218-19/0	Gazdar, Adi F.		Kintai Therapeutics	23-Jan-20
L-218-19/0	Johnson, Bruce E		Kintai Therapeutics	23-Jan-20
L-218-19/0	Kaye, Frederic J		Kintai Therapeutics	23-Jan-20
L-218-19/0	Kheif, Samir N.		Kintai Therapeutics	23-Jan-20
L-218-19/0	Minna, John D.		Kintai Therapeutics	23-Jan-20
L-218-19/0	Oie, Herbert K		Kintai Therapeutics	23-Jan-20
L-218-19/0	Pass, Harvey I.		Kintai Therapeutics	23-Jan-20
L-201-17/0	Gazdar, Adi F.		Leica Biosystems Newcastle Ltd	24-Jan-20
L-201-17/0	Johnson, Bruce E		Leica Biosystems Newcastle Ltd	24-Jan-20
L-201-17/0	Kaye, Frederic J		Leica Biosystems Newcastle Ltd	24-Jan-20
L-201-17/0	Kheif, Samir N.		Leica Biosystems Newcastle Ltd	24-Jan-20
L-201-17/0	Minna, John D.		Leica Biosystems Newcastle Ltd	24-Jan-20
L-201-17/0	Oie, Herbert K		Leica Biosystems Newcastle Ltd	24-Jan-20
L-201-17/0	Pass, Harvey I.		Leica Biosystems Newcastle Ltd	24-Jan-20
L-126-12/0	Austin, Faye C.		Leica Microsystems	24-Jan-20
L-126-12/0	Colcher, David		Leica Microsystems	24-Jan-20
L-126-12/0	Hand, Patricia H		Leica Microsystems	24-Jan-20
L-126-12/0	Nuti, Marianna		Leica Microsystems	24-Jan-20
L-126-12/0	Schlom, Jeffrey		Leica Microsystems	24-Jan-20
L-203-15/1	Gazdar, Adi F.		SOTIO	24-Jan-20
L-203-15/1	Johnson, Bruce E		SOTIO	24-Jan-20
L-203-15/1	Kaye, Frederic J		SOTIO	24-Jan-20
L-203-15/1	Khleif, Samir N.		SOTIO	24-Jan-20
L-203-15/1	Minna, John D.		SOTIO	24-Jan-20
L-203-15/1	Oie, Herbert K		SOTIO	24-Jan-20
L-203-15/1	Pass, Harvey I.		SOTIO	24-Jan-20
L-273-18/0	Bonomi, Carrie A.		PMI Biopharma Solutions, LLC.	24-Jan-20
L-273-18/0	Borgel, Suzanne D.		PMI Biopharma Solutions, LLC.	24-Jan-20
L-273-18/0	Dougherty, Kelly		PMI Biopharma Solutions, LLC.	24-Jan-20
L-273-18/0	Hollingshead, Melinda G.		PMI Biopharma Solutions, LLC.	24-Jan-20
L-209-18/0	Bonomi, Carrie A.		H3 Biomedicine Inc.	24-Jan-20
L-209-18/0	Borgel, Suzanne D.		H3 Biomedicine Inc.	24-Jan-20
L-209-18/0	Dougherty, Kelly		H3 Biomedicine Inc.	24-Jan-20
L-209-18/0	Hollingshead, Melinda G.		H3 Biomedicine Inc.	24-Jan-20
L-106-19/0	Bonomi, Carrie A.		Dracen Pharmaceuticals, Inc.	24-Jan-20
L-106-19/0	Borgel, Suzanne D.		Dracen Pharmaceuticals, Inc.	24-Jan-20
L-106-19/0	Dougherty, Kelly		Dracen Pharmaceuticals, Inc.	24-Jan-20
L-106-19/0	Hollingshead, Melinda G.		Dracen Pharmaceuticals, Inc.	24-Jan-20
L-066-09/0	Chang, Nancy T.		Becton Dickinson	27-Jan-20
L-066-09/0	Fisher, Amanda G.		Becton Dickinson	27-Jan-20
L-066-09/0	Franchini, Genoveffa		Becton Dickinson	27-Jan-20
L-066-09/0	Gallo, Robert C.		Becton Dickinson	27-Jan-20
L-066-09/0	Gartner, Suzanne		Becton Dickinson	27-Jan-20

L-066-09/0	Hahn, Beatrice	(b)(4);	Becton Dickinson	27-Jan-20
L-066-09/0	(b) (4)	(b)(6)	Becton Dickinson	27-Jan-20
L-066-09/0	Lori, Franco C.		Becton Dickinson	27-Jan-20
L-066-09/0	Markham, Phillip D.		Becton Dickinson	27-Jan-20
L-066-09/0	Popovic, Mikulas		Becton Dickinson	27-Jan-20
L-066-09/0	Reitz, Jr., Marvin S.		Becton Dickinson	27-Jan-20
L-066-09/0	Sarngadharan, Mangalasseril		Becton Dickinson	27-Jan-20
L-066-09/0	Shaw, George M		Becton Dickinson	27-Jan-20
L-066-09/0	Wong-Staal, Flossie		Becton Dickinson	27-Jan-20
L-284-17/0	Bonomi, Carrie A.		Merck Sharp & Dohme Corp.	28-Jan-20
L-284-17/0	Borgel, Suzanne D.		Merck Sharp & Dohme Corp.	28-Jan-20
L-284-17/0	Dougherty, Kelly		Merck Sharp & Dohme Corp.	28-Jan-20
L-284-17/0	Hollingshead, Melinda G.		Merck Sharp & Dohme Corp.	28-Jan-20
L-130-94/2	King, Charles R.		Santa Cruz Biotechnology	28-Jan-20
L-130-94/2	Liotta, Lance		Santa Cruz Biotechnology	28-Jan-20
L-130-94/2	Steeg, Patricia S.		Santa Cruz Biotechnology	28-Jan-20
L-197-94/3	Cheng, Sheue-Yann		Santa Cruz Biotechnology, Inc.	28-Jan-20
L-008-05/2	Cheng, Sheue-Yann		Santa Cruz Biotech.	28-Jan-20
L-138-05/3	Chang, Kai		Santa Cruz Biotechnology Inc	28-Jan-20
L-138-05/3	Pastan, Ira H		Santa Cruz Biotechnology Inc	28-Jan-20
L-138-05/3	Willingham, Mark C.		Santa Cruz Biotechnology Inc	28-Jan-20
L-031-07/2	Aaronson, Stuart A.		Santa Cruz Biotechnology	28-Jan-20
L-031-07/2	Lacal, Juan C.		Santa Cruz Biotechnology	28-Jan-20
L-130-94/2	King, Charles R.		Santa Cruz Biotechnology	28-Jan-20
L-130-94/2	Liotta, Lance		Santa Cruz Biotechnology	28-Jan-20
L-130-94/2	Steeg, Patricia S.		Santa Cruz Biotechnology	28-Jan-20
L-232-14/1	NCI		NanoString Technologies, Inc.	28-Jan-20
<i>Note: L-232-14/1 split between CIT; NCI</i>				
L-040-20/0	Greiner, John W.	(b)(4);	Pfizer Inc.	28-Jan-20
L-040-20/0	Schlom, Jeffrey	(b)(6)	Pfizer Inc.	28-Jan-20
L-051-17/0	Rudloff, Udo		Riptide Bioscience, Inc	28-Jan-20
L-086-11/0	Baskar, Sivasubramanian		Miltenyi Biotec GMBH	29-Jan-20
L-086-11/0	Rader, Christoph		Miltenyi Biotec GMBH	29-Jan-20
L-149-18/1	Esposito, Dominic		Merck Sharp & Dohme	29-Jan-20
L-149-18/1	Gillette, William K.		Merck Sharp & Dohme	29-Jan-20
L-149-18/1	Grose, Carissa L.		Merck Sharp & Dohme	29-Jan-20
L-118-16/0	Antony, Paul A.		Merck Sharp	29-Jan-20
L-118-16/0	Irvine, Kari R.		Merck Sharp	29-Jan-20
L-118-16/0	Restifo, Nicholas P.		Merck Sharp	29-Jan-20

NIH Patent Licensing Activities

NCI
February 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
L-082-16/0	Franchini, Genoveffa	(b)(4);	Gilead Sciences	1-Feb-20						(b) (3) (A), (b) (4), (b) (6)
L-082-16/0	Gallo, Robert C.	(b)(6)	Gilead Sciences	1-Feb-20						
L-082-16/0	Gartner, Suzanne		Gilead Sciences	1-Feb-20						
L-082-16/0	(b) (4)		Gilead Sciences	1-Feb-20						
L-082-16/0	Lori, Franco C.		Gilead Sciences	1-Feb-20						
L-082-16/0	Markham, Phillip D.		Gilead Sciences	1-Feb-20						
L-082-16/0	Popovic, Mikulas		Gilead Sciences	1-Feb-20						
L-082-16/0	Reitz, Jr., Marvin S.		Gilead Sciences	1-Feb-20						
L-098-17/0	Buck, Christopher		SK Chemicals	1-Feb-20						
L-098-17/0	Schiller, John T		SK Chemicals	1-Feb-20						
L-006-19/0	Gazdar, Adi F.		Genentech, Inc	1-Feb-20						
L-006-19/0	Johnson, Bruce E		Genentech, Inc	1-Feb-20						
L-006-19/0	Kaye, Frederic J		Genentech, Inc	1-Feb-20						
L-006-19/0	Kheif, Samir N.		Genentech, Inc	1-Feb-20						
L-006-19/0	Minna, John D.		Genentech, Inc	1-Feb-20						
L-006-19/0	Oie, Herbert K		Genentech, Inc	1-Feb-20						
L-006-19/0	Pass, Harvey I.		Genentech, Inc	1-Feb-20						
L-133-09/0	Gazdar, Adi F.		Ventana Medical Systems, Inc.	1-Feb-20						
L-133-09/0	Johnson, Bruce E		Ventana Medical Systems, Inc.	1-Feb-20						
L-133-09/0	Kaye, Frederic J		Ventana Medical Systems, Inc.	1-Feb-20						
L-133-09/0	Khleif, Samir N.		Ventana Medical Systems, Inc.	1-Feb-20						
L-133-09/0	Minna, John D.		Ventana Medical Systems, Inc.	1-Feb-20						
L-133-09/0	Oie, Herbert K		Ventana Medical Systems, Inc.	1-Feb-20						
L-133-09/0	Pass, Harvey I.		Ventana Medical Systems, Inc.	1-Feb-20						
L-113-07/1	Aaronson, Stuart A.		Ventana Medical Systems	1-Feb-20						
L-113-07/1	King, Charles R.		Ventana Medical Systems	1-Feb-20						
L-113-07/1	Kraus (b) (6) Matthias		Ventana Medical Systems	1-Feb-20						
L-121-19/0	Gottesman, Michael M.		Axcelead Drug Discovery Partners, Inc	1-Feb-20						
L-121-19/0	Pastan, Ira H		Axcelead Drug Discovery Partners, Inc	1-Feb-20						
L-121-19/0	Ueda, Kazumitsu		Axcelead Drug Discovery Partners, Inc	1-Feb-20						
L-153-16/0	Gazdar, Adi F.		Bayer Pharma AG	1-Feb-20						
L-153-16/0	Johnson, Bruce E		Bayer Pharma AG	1-Feb-20						
L-153-16/0	Kaye, Frederic J		Bayer Pharma AG	1-Feb-20						
L-153-16/0	Khleif, Samir N.		Bayer Pharma AG	1-Feb-20						
L-153-16/0	Minna, John D.		Bayer Pharma AG	1-Feb-20						
L-153-16/0	Oie, Herbert K		Bayer Pharma AG	1-Feb-20						
L-153-16/0	Pass, Harvey I.		Bayer Pharma AG	1-Feb-20						
L-093-10/1	Chang, Nancy T.		BioLytical Labs	1-Feb-20						
L-093-10/1	Crowl, Robert		BioLytical Labs	1-Feb-20						
L-093-10/1	Gallo, Robert C.		BioLytical Labs	1-Feb-20						
L-093-10/1	(b) (4)		BioLytical Labs	1-Feb-20						
L-093-10/1	Reddy, E. Premkumar.		BioLytical Labs	1-Feb-20						

L-093-10/1	Shaw, George M	(b)(4);	BioLytical Labs	1-Feb-20
L-093-10/1	Wong-Staal, Flossie	(b)(6)	BioLytical Labs	1-Feb-20
L-089-19/0	Gazdar, Adi F.		Guardant Health, Inc.	1-Feb-20
L-089-19/0	Johnson, Bruce E		Guardant Health, Inc.	1-Feb-20
L-089-19/0	Kaye, Frederic J		Guardant Health, Inc.	1-Feb-20
L-089-19/0	Kheif, Samir N.		Guardant Health, Inc.	1-Feb-20
L-089-19/0	Minna, John D.		Guardant Health, Inc.	1-Feb-20
L-089-19/0	Oie, Herbert K		Guardant Health, Inc.	1-Feb-20
L-089-19/0	Pass, Harvey I.		Guardant Health, Inc.	1-Feb-20
L-108-18/1	Esposito, Dominic		StrideBio	1-Feb-20
L-108-18/1	Grose, Carissa L.		StrideBio	1-Feb-20
L-263-19/0	Hanada, Kenichi		Teralmmune LLC	1-Feb-20
L-263-19/0	Yang, James C		Teralmmune LLC	1-Feb-20
L-263-19/0	Yu, Zhiya		Teralmmune LLC	1-Feb-20
L-166-18/0	Bonomi, Carrie A.		genOway S.A.	1-Feb-20
L-166-18/0	Borgel, Suzanne D.		genOway S.A.	1-Feb-20
L-166-18/0	Dougherty, Kelly		genOway S.A.	1-Feb-20
L-166-18/0	Hollingshead, Melinda G.		genOway S.A.	1-Feb-20
L-108-09/0	Conrads, Thomas P		AB Sciex, LLC	3-Feb-20
L-108-09/0	Issaq, Haleem J.		AB Sciex, LLC	3-Feb-20
L-108-09/0	Janini, George		AB Sciex, LLC	3-Feb-20
L-108-09/0	Veenstra, Timothy D		AB Sciex, LLC	3-Feb-20
L-108-09/0	Wilkens, Kenneth L.		AB Sciex, LLC	3-Feb-20
L-015-84/8	Chang, Nancy T.		Abbott Laboratories	4-Feb-20
L-015-84/8	Crowl, Robert		Abbott Laboratories	4-Feb-20
L-015-84/8	Fisher, Amanda G.		Abbott Laboratories	4-Feb-20
L-015-84/8	Gallo, Robert C.		Abbott Laboratories	4-Feb-20
L-015-84/8	Hahn, Beatrice		Abbott Laboratories	4-Feb-20
L-015-84/8	(b) (4)		Abbott Laboratories	4-Feb-20
L-015-84/8	Popovic, Mikulas		Abbott Laboratories	4-Feb-20
L-015-84/8	Reddy, E. Premkumar.		Abbott Laboratories	4-Feb-20
L-015-84/8	Sarngadharan, Mangalasseril		Abbott Laboratories	4-Feb-20
L-015-84/8	Shaw, George M		Abbott Laboratories	4-Feb-20
L-015-84/8	Wong-Staal, Flossie		Abbott Laboratories	4-Feb-20
L-273-14/0	Chang, Nancy T.		Grifols Worldwide Operations Ltd.	4-Feb-20
L-273-14/0	Crowl, Robert		Grifols Worldwide Operations Ltd.	4-Feb-20
L-273-14/0	Fisher, Amanda G.		Grifols Worldwide Operations Ltd.	4-Feb-20
L-273-14/0	Gallo, Robert C.		Grifols Worldwide Operations Ltd.	4-Feb-20
L-273-14/0	Hahn, Beatrice		Grifols Worldwide Operations Ltd.	4-Feb-20
L-273-14/0	Popovic, Mikulas		Grifols Worldwide Operations Ltd.	4-Feb-20
L-273-14/0	Reddy, E. Premkumar.		Grifols Worldwide Operations Ltd.	4-Feb-20
L-273-14/0	Sarngadharan, Mangalasseril		Grifols Worldwide Operations Ltd.	4-Feb-20
L-273-14/0	Shaw, George M		Grifols Worldwide Operations Ltd.	4-Feb-20
L-273-14/0	Wong-Staal, Flossie		Grifols Worldwide Operations Ltd.	4-Feb-20
L-279-18/1	Bera, Tapan K		Beoro Therapeutics, GmbH	4-Feb-20
L-279-18/1	Fitzgerald, David J.		Beoro Therapeutics, GmbH	4-Feb-20
L-279-18/1	Pastan, Ira H		Beoro Therapeutics, GmbH	4-Feb-20

L-279-18/1	(b) (4)	(b)(4):	Beoro Therapeutics, GmbH	4-Feb-20
L-279-18/1	Weldon, John	(b)(6)	Beoro Therapeutics, GmbH	4-Feb-20
L-026-05/8	Bang, Sook-Hee		INNATE PHARMA	5-Feb-20
L-026-05/8	Beers, Richard		INNATE PHARMA	5-Feb-20
L-026-05/8	Brinkmann, Ulrich		INNATE PHARMA	5-Feb-20
L-026-05/8	Fitzgerald, David J.		INNATE PHARMA	5-Feb-20
L-026-05/8	Ho, Mitchell		INNATE PHARMA	5-Feb-20
L-026-05/8	Jung, Sun-Hee		INNATE PHARMA	5-Feb-20
L-026-05/8	Kreitman, Robert J		INNATE PHARMA	5-Feb-20
L-026-05/8	Kuan, Chien-Tsun		INNATE PHARMA	5-Feb-20
L-026-05/8	Lee, Byungkook		INNATE PHARMA	5-Feb-20
L-026-05/8	Mansfield, Elizabeth		INNATE PHARMA	5-Feb-20
L-026-05/8	Pastan, Ira H		INNATE PHARMA	5-Feb-20
L-026-05/8	Salvatore, Giuliana		INNATE PHARMA	5-Feb-20
L-046-18/0	Bonomi, Carrie A.		Northern Biologics Inc.	5-Feb-20
L-046-18/0	Borgel, Suzanne D.		Northern Biologics Inc.	5-Feb-20
L-046-18/0	Dougherty, Kelly		Northern Biologics Inc.	5-Feb-20
L-046-18/0	Hollingshead, Melinda G.		Northern Biologics Inc.	5-Feb-20
L-229-19/0	Bonomi, Carrie A.		Northern Biologics Inc.	5-Feb-20
L-229-19/0	Dougherty, Kelly		Northern Biologics Inc.	5-Feb-20
L-229-19/0	Hollingshead, Melinda G.		Northern Biologics Inc.	5-Feb-20
L-060-20/0	Gazdar, Adi F.		Chugai Pharmaceutical Co., Ltd.	5-Feb-20
L-060-20/0	Johnson, Bruce E		Chugai Pharmaceutical Co., Ltd.	5-Feb-20
L-060-20/0	Kaye, Frederic J		Chugai Pharmaceutical Co., Ltd.	5-Feb-20
L-060-20/0	Kheif, Samir N.		Chugai Pharmaceutical Co., Ltd.	5-Feb-20
L-060-20/0	Minna, John D.		Chugai Pharmaceutical Co., Ltd.	5-Feb-20
L-060-20/0	Oie, Herbert K		Chugai Pharmaceutical Co., Ltd.	5-Feb-20
L-060-20/0	Pass, Harvey I.		Chugai Pharmaceutical Co., Ltd.	5-Feb-20
L-001-08/1	Austin, Faye C.		Cell Marque Corp	6-Feb-20
L-001-08/1	Colcher, David		Cell Marque Corp	6-Feb-20
L-001-08/1	Hand, Patricia H		Cell Marque Corp	6-Feb-20
L-001-08/1	Nuti, Marianna		Cell Marque Corp	6-Feb-20
L-001-08/1	Schlom, Jeffrey		Cell Marque Corp	6-Feb-20
L-002-04/1	Kawakami, Yutaka		Cell Marque	6-Feb-20
L-002-04/1	Robbins, Paul F		Cell Marque	6-Feb-20
L-002-04/1	Rosenberg, Steven A.		Cell Marque	6-Feb-20
L-181-18/0	Bonomi, Carrie A.		ModernaTX, Inc.	6-Feb-20
L-181-18/0	Borgel, Suzanne D.		ModernaTX, Inc.	6-Feb-20
L-181-18/0	Dougherty, Kelly		ModernaTX, Inc.	6-Feb-20
L-181-18/0	Hollingshead, Melinda G.		ModernaTX, Inc.	6-Feb-20
L-050-20/0	Greiner, John W.		Neoleukin Corporation	6-Feb-20
L-050-20/0	Schlom, Jeffrey		Neoleukin Corporation	6-Feb-20
L-163-15/0	Copeland, Neal		Intact Genomics, Inc.	6-Feb-20
L-163-15/0	Costantino, Nina		Intact Genomics, Inc.	6-Feb-20
L-163-15/0	Court, Donald		Intact Genomics, Inc.	6-Feb-20
L-163-15/0	Ellis, Hilary Moyed		Intact Genomics, Inc.	6-Feb-20

L-163-15/0	Jenkins Copeland, Nancy A	(b)(4);	Intact Genomics, Inc.	6-Feb-20
L-163-15/0	Lee, E-Chiang	(b)(6)	Intact Genomics, Inc.	6-Feb-20
L-163-15/0	Sharan, Shyam K		Intact Genomics, Inc.	6-Feb-20
L-163-15/0	Swaminathan, Srividya		Intact Genomics, Inc.	6-Feb-20
L-163-15/0	Warming, Soren		Intact Genomics, Inc.	6-Feb-20
L-163-15/0	Yu, Daiguan		Intact Genomics, Inc.	6-Feb-20
L-092-11/0	Giardina, Steven		EMD Chemicals Inc.	7-Feb-20
L-092-11/0	Longo, Dan L		EMD Chemicals Inc.	7-Feb-20
L-092-11/0	Varesio, Luigi		EMD Chemicals Inc.	7-Feb-20
L-153-10/0	Greiner, John W.		Arko Laboratories LTD	7-Feb-20
L-153-10/0	Schlom, Jeffrey		Arko Laboratories LTD	7-Feb-20
L-153-10/0	Zaharoff, David		Arko Laboratories LTD	7-Feb-20
L-090-98/1	Allegra, Carmen		NeoMarkers, Inc.	11-Feb-20
L-090-98/1	Chabner, Bruce A		NeoMarkers, Inc.	11-Feb-20
L-090-98/1	(b) (4)		NeoMarkers, Inc.	11-Feb-20
L-090-98/1	Johnston, Patrick G.		NeoMarkers, Inc.	11-Feb-20
L-090-98/1	Kawakami, Yutaka		NeoMarkers, Inc.	11-Feb-20
L-090-98/1	Liang, Chi-Ming		NeoMarkers, Inc.	11-Feb-20
L-090-98/1	Rosenberg, Steven A.		NeoMarkers, Inc.	11-Feb-20
L-090-98/1	Schlom, Jeffrey		NeoMarkers, Inc.	11-Feb-20
L-090-98/1	(b) (4)		NeoMarkers, Inc.	11-Feb-20
L-160-10/0	Jelinek, Ivett		AbD Serotec	11-Feb-20
L-160-10/0	Segal, David M.		AbD Serotec	11-Feb-20
L-160-10/0	Wang, Yan		AbD Serotec	11-Feb-20
L-023-09/2	Waugh, David		Takeda Pharmaceutical	11-Feb-20
L-168-17/0	Bera, Tapan K		Amgen, Inc.	11-Feb-20
L-168-17/0	Pastan, Ira H		Amgen, Inc.	11-Feb-20
L-012-18/1	Bonomi, Carrie A.		Nurix	12-Feb-20
L-012-18/1	Borgel, Suzanne D.		Nurix	12-Feb-20
L-012-18/1	Dougherty, Kelly		Nurix	12-Feb-20
L-012-18/1	Hollingshead, Melinda G.		Nurix	12-Feb-20
L-237-18/0	Bonomi, Carrie A.		Inovio Pharmaceuticals, Inc.	12-Feb-20
L-237-18/0	Borgel, Suzanne D.		Inovio Pharmaceuticals, Inc.	12-Feb-20
L-237-18/0	Dougherty, Kelly		Inovio Pharmaceuticals, Inc.	12-Feb-20
L-237-18/0	Hollingshead, Melinda G.		Inovio Pharmaceuticals, Inc.	12-Feb-20
L-006-18/0	Austin, Faye C.		Diagnostic BioSystems	12-Feb-20
L-006-18/0	Colcher, David		Diagnostic BioSystems	12-Feb-20
L-006-18/0	Hand, Patricia H		Diagnostic BioSystems	12-Feb-20
L-006-18/0	Nuti, Marianna		Diagnostic BioSystems	12-Feb-20
L-006-18/0	Schlom, Jeffrey		Diagnostic BioSystems	12-Feb-20
L-011-19/0	Gottesman, Michael M.		Amgen, Inc.	13-Feb-20
L-011-19/0	Pastan, Ira H		Amgen, Inc.	13-Feb-20
L-011-19/0	Ueda, Kazumitsu		Amgen, Inc.	13-Feb-20
L-079-20/0	Gazdar, Adi F.		Turning Point Therapeutics	13-Feb-20

(b) (3) (A), (b) (4), (b) (6)

L-079-20/0	Johnson, Bruce E	(b)(4);	Turning Point Therapeutics	13-Feb-20
L-079-20/0	Kaye, Frederic J	(b)(6)	Turning Point Therapeutics	13-Feb-20
L-079-20/0	Kheif, Samir N.		Turning Point Therapeutics	13-Feb-20
L-079-20/0	Minna, John D.		Turning Point Therapeutics	13-Feb-20
L-079-20/0	Oie, Herbert K		Turning Point Therapeutics	13-Feb-20
L-079-20/0	Pass, Harvey I.		Turning Point Therapeutics	13-Feb-20
L-106-12/0	Jelinek, Ivett		Miltenyi Biotec GMBH	14-Feb-20
L-106-12/0	Segal, David M.		Miltenyi Biotec GMBH	14-Feb-20
L-106-12/0	Wang, Yan		Miltenyi Biotec GMBH	14-Feb-20
L-053-11/0	Mason, Llewellyn H.		Miltenyi Biotec Gmbh	14-Feb-20
L-053-11/0	Ortaldo, John R.		Miltenyi Biotec Gmbh	14-Feb-20
L-086-11/0	Baskar, Sivasubramanian		Miltenyi Biotec GMBH	14-Feb-20
L-086-11/0	Rader, Christoph		Miltenyi Biotec GMBH	14-Feb-20
L-026-12/0	Mason, Llewellyn H.		Miltenyi Biotec GMBH	14-Feb-20
L-026-12/0	Ortaldo, John R.		Miltenyi Biotec GMBH	14-Feb-20
L-254-17/0	Bonomi, Carrie A.		Neon Therapeutics	14-Feb-20
L-254-17/0	Borgel, Suzanne D.		Neon Therapeutics	14-Feb-20
L-254-17/0	Dougherty, Kelly		Neon Therapeutics	14-Feb-20
L-254-17/0	Hollingshead, Melinda G.		Neon Therapeutics	14-Feb-20
L-232-14/1	NCI		NanoString Technologies, Inc.	14-Feb-20
<i>Note: L-232-14/1 split between CIT; NCI</i>				
L-089-16/3	Dimitrov, Dimiter S.		H2Bio	14-Feb-20
L-089-16/3	Feng, Mingqian		H2Bio	14-Feb-20
L-089-16/3	Gao, Wei		H2Bio	14-Feb-20
L-089-16/3	Ho, Mitchell		H2Bio	14-Feb-20
L-089-16/3	Pastan, Ira H		H2Bio	14-Feb-20
L-089-16/3	Tang, Zhewei		H2Bio	14-Feb-20
L-317-17/0	Chen, Weizao		Lentigen Corporation Technology	18-Feb-20
L-317-17/0	Dimitrov, Dimiter S.		Lentigen Corporation Technology	18-Feb-20
L-317-17/0	Ponraj, Prabakaran		Lentigen Corporation Technology	18-Feb-20
L-013-19/0	Dimitrov, Dimiter S.		Lentigen Corporation	18-Feb-20
L-013-19/0	Zhu, Zhongyu		Lentigen Corporation	18-Feb-20
L-075-16/1	Fry, Terry		Lentigen Corporation	18-Feb-20
L-075-16/1	Qin, Haiying		Lentigen Corporation	18-Feb-20
L-116-16/0	Esposito, Dominic		Relay Therapeutics, Inc.	18-Feb-20
L-116-16/0	Gillette, William K.		Relay Therapeutics, Inc.	18-Feb-20
L-116-16/0	Grose, Carissa L.		Relay Therapeutics, Inc.	18-Feb-20
L-062-18/0	Bonomi, Carrie A.		Constellation Pharmaceuticals	18-Feb-20
L-062-18/0	Borgel, Suzanne D.		Constellation Pharmaceuticals	18-Feb-20
L-062-18/0	Dougherty, Kelly		Constellation Pharmaceuticals	18-Feb-20
L-062-18/0	Hollingshead, Melinda G.		Constellation Pharmaceuticals	18-Feb-20
L-085-20/0	Austin, Faye C.		EXBIO Praha	18-Feb-20

L-085-20/0	Colcher, David	(b)(4);	EXBIO Praha	18-Feb-20
L-085-20/0	Hand, Patricia H	(b)(6)	EXBIO Praha	18-Feb-20
L-085-20/0	Nuti, Marianna		EXBIO Praha	18-Feb-20
L-085-20/0	Schlom, Jeffrey		EXBIO Praha	18-Feb-20
L-084-20/0	Ise, Tomoko		EXBIO Praha	18-Feb-20
L-084-20/0	Nagata, Satoshi		EXBIO Praha	18-Feb-20
L-084-20/0	Pastan, Ira H		EXBIO Praha	18-Feb-20
L-084-20/0	Xiang, Liaman		EXBIO Praha	18-Feb-20
L-115-95/2	NCI		MedImmune, Inc.	19-Feb-20
L-133-19/0	Aaronson, Stuart A.		DNATRIX, Inc.	19-Feb-20
L-133-19/0	Giard, Donald		DNATRIX, Inc.	19-Feb-20
L-133-19/0	Parks, Wade P		DNATRIX, Inc.	19-Feb-20
L-100-05/0	Hollingshead, Melinda G.		InvivoGen., Inc.	19-Feb-20
L-100-05/0	Sausville, Edward		InvivoGen., Inc.	19-Feb-20
L-100-05/0	Snader, Kenneth M		InvivoGen., Inc.	19-Feb-20
L-100-05/0	Vishnuvajjala, B. Rao		InvivoGen., Inc.	19-Feb-20
L-111-19/0	Bonomi, Carrie A.		Innate Pharma Research Labs	20-Feb-20
L-111-19/0	Borgel, Suzanne D.		Innate Pharma Research Labs	20-Feb-20
L-111-19/0	Dougherty, Kelly		Innate Pharma Research Labs	20-Feb-20
L-111-19/0	Hollingshead, Melinda G.		Innate Pharma Research Labs	20-Feb-20
L-274-18/0	NCI		Cellular Biomedicine Group, Inc.	20-Feb-20
L-190-19/1	Cafri, Gal	(b)(4);	ZioPharm Oncology, Inc	20-Feb-20
L-190-19/1	Deniger, Drew	(b)(6)	ZioPharm Oncology, Inc	20-Feb-20
L-190-19/1	Feldman, Steven A		ZioPharm Oncology, Inc	20-Feb-20
L-190-19/1	Fitzgerald, Peter C.		ZioPharm Oncology, Inc	20-Feb-20
L-190-19/1	Hanada, Kenichi		ZioPharm Oncology, Inc	20-Feb-20
L-190-19/1	Lo, Winifred Margaret		ZioPharm Oncology, Inc	20-Feb-20
L-190-19/1	Lu, Yong-Chen W.		ZioPharm Oncology, Inc	20-Feb-20
L-190-19/1	Malekzadeh, Parisa		ZioPharm Oncology, Inc	20-Feb-20
L-190-19/1	Parkhurst, Maria		ZioPharm Oncology, Inc	20-Feb-20
L-190-19/1	Pasetto, Anna		ZioPharm Oncology, Inc	20-Feb-20
L-190-19/1	Robbins, Paul F		ZioPharm Oncology, Inc	20-Feb-20
L-190-19/1	Rosenberg, Steven A.		ZioPharm Oncology, Inc	20-Feb-20
L-190-19/1	Tran, Eric		ZioPharm Oncology, Inc	20-Feb-20
L-190-19/1	Wang, Qiong		ZioPharm Oncology, Inc	20-Feb-20
L-190-19/1	Yang, James C		ZioPharm Oncology, Inc	20-Feb-20
L-190-19/1	Yoseph, Rami		ZioPharm Oncology, Inc	20-Feb-20
L-190-19/1	Yu, Zhiya		ZioPharm Oncology, Inc	20-Feb-20
L-190-19/1	Zhao, Chihao		ZioPharm Oncology, Inc	20-Feb-20
L-190-19/1	Zheng, Zhili		ZioPharm Oncology, Inc	20-Feb-20
L-001-08/1	Austin, Faye C.		Cell Marque Corp	21-Feb-20
L-001-08/1	Colcher, David		Cell Marque Corp	21-Feb-20
L-001-08/1	Hand, Patricia H		Cell Marque Corp	21-Feb-20
L-001-08/1	Nuti, Marianna		Cell Marque Corp	21-Feb-20
L-001-08/1	Schlom, Jeffrey		Cell Marque Corp	21-Feb-20
L-068-04/2	Bartlett, David L		Jennerex, LLC	21-Feb-20

L-068-04/2	McCart, Judith Andrea	(b)(4); (b)(6)	Jennerex, LLC	21-Feb-20
<i>Note: L-068-04/2 split between NCI; NIAID</i>				
L-069-20/0	(b) (4)		Arvinas Operations, Inc.	24-Feb-20
L-069-20/0	Esposito, Dominic		Arvinas Operations, Inc.	24-Feb-20
L-069-20/0	Hopkins, Ralph F.		Arvinas Operations, Inc.	24-Feb-20
L-069-20/0	Roberts, Veronica Ann		Arvinas Operations, Inc.	24-Feb-20
L-026-05/8	Bang, Sook-Hee		INNATE PHARMA	25-Feb-20
L-026-05/8	Beers, Richard		INNATE PHARMA	25-Feb-20
L-026-05/8	Brinkmann, Ulrich		INNATE PHARMA	25-Feb-20
L-026-05/8	Fitzgerald, David J.		INNATE PHARMA	25-Feb-20
L-026-05/8	Ho, Mitchell		INNATE PHARMA	25-Feb-20
L-026-05/8	Jung, Sun-Hee		INNATE PHARMA	25-Feb-20
L-026-05/8	Kreitman, Robert J		INNATE PHARMA	25-Feb-20
L-026-05/8	Kuan, Chien-Tsun		INNATE PHARMA	25-Feb-20
L-026-05/8	Lee, Byungkook		INNATE PHARMA	25-Feb-20
L-026-05/8	Mansfield, Elizabeth		INNATE PHARMA	25-Feb-20
L-026-05/8	Pastan, Ira H		INNATE PHARMA	25-Feb-20
L-026-05/8	Salvatore, Giuliana		INNATE PHARMA	25-Feb-20
L-248-17/1	(b) (4)		Vernalis	25-Feb-20
L-248-17/1	Esposito, Dominic		Vernalis	25-Feb-20
L-248-17/1	Hopkins, Ralph F.		Vernalis	25-Feb-20
L-248-17/1	Roberts, Veronica Ann		Vernalis	25-Feb-20
L-249-17/1	Esposito, Dominic		Vernalis	25-Feb-20
L-249-17/1	Gillette, William K.		Vernalis	25-Feb-20
L-249-17/1	Grose, Carissa L.		Vernalis	25-Feb-20
L-249-17/1	Stephens, Robert M.		Vernalis	25-Feb-20
L-045-08/1	Bonner, William M		Active Motif	25-Feb-20
L-045-08/1	Rogakou, Efthimia P		Active Motif	25-Feb-20
L-091-04/1	Makrigiannis, Andrew P.		Ebioscience	25-Feb-20
L-114-06/1	Azimi, Nazli		Affymetrix, Inc.	25-Feb-20
L-114-06/1	Dubois, Sigrid		Affymetrix, Inc.	25-Feb-20
L-114-06/1	Goldman, Carolyn		Affymetrix, Inc.	25-Feb-20
L-114-06/1	Lantz, Valerie A		Affymetrix, Inc.	25-Feb-20
L-114-06/1	Mariner Kilbourne, Jennifer		Affymetrix, Inc.	25-Feb-20
L-114-06/1	Waldmann, Thomas A.		Affymetrix, Inc.	25-Feb-20
L-049-00/1	Hathcock, Karen		eBioscience, Inc..	25-Feb-20
L-049-00/1	Hodes, Richard		eBioscience, Inc..	25-Feb-20
L-049-00/1	Laszlo, Gloria		eBioscience, Inc..	25-Feb-20
<i>Note: L-049-00/1 split between NCI; NIAID</i>				
L-200-97/2	Gelboin, (b) (6) Harry		Life Technologies	25-Feb-20
L-200-97/2	Gonzalez, Frank J		Life Technologies	25-Feb-20
L-049-94/2	Cheng, Sheue-Yann		Affinity BioReagents	25-Feb-20
L-234-00/5	Gelboin, (b) (6) Harry		Xeno Tech, LLC	25-Feb-20
L-234-00/5	Gonzalez, Frank J		Xeno Tech, LLC	25-Feb-20

(b) (3) (A), (b) (4), (b) (6)

L-234-00/5	Krausz, Kristopher W.	(b)(4):	Xeno Tech, LLC	25-Feb-20
L-234-00/5	Yang, Tian J.	(b)(6)	Xeno Tech, LLC	25-Feb-20
L-242-02/2	Kawakami, Yutaka		Biocare Medical, LLC	25-Feb-20
L-242-02/2	Rosenberg, Steven A.		Biocare Medical, LLC	25-Feb-20
L-047-06/2	Chang, Nancy T.		Chembio Diagnostic	25-Feb-20
L-047-06/2	Crowl, Robert		Chembio Diagnostic	25-Feb-20
L-047-06/2	Gallo, Robert C.		Chembio Diagnostic	25-Feb-20
L-047-06/2	(b) (4)		Chembio Diagnostic	25-Feb-20
L-047-06/2	Reddy, E. Premkumar.		Chembio Diagnostic	25-Feb-20
L-047-06/2	Shaw, George M		Chembio Diagnostic	25-Feb-20
L-047-06/2	Wong-Staal, Flossie		Chembio Diagnostic	25-Feb-20
L-004-07/2	Qasba, Pradman		Life Technologies Corp.	25-Feb-20
L-004-07/2	Ramakrishnan, Boopathy		Life Technologies Corp.	25-Feb-20

(b) (3) (A), (b) (4), (b) (6)

NIH Patent Licensing Activities
NCI
March 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License	Inventor Awards March	Net Remaining to IC
								Cumulative Income		
L-084-11/2	Gazdar, Adi F.	(b)(4):	Nichirei Biosciences Inc	1-Mar-20						(b) (3) (A), (b) (4), (b) (6)
L-084-11/2	Johnson, Bruce E	(b)(6)	Nichirei Biosciences Inc	1-Mar-20						
L-084-11/2	Kaye, Frederic J		Nichirei Biosciences Inc	1-Mar-20						
L-084-11/2	Khleif, Samir N.		Nichirei Biosciences Inc	1-Mar-20						
L-084-11/2	Minna, John D.		Nichirei Biosciences Inc	1-Mar-20						
L-084-11/2	Oie, Herbert K		Nichirei Biosciences Inc	1-Mar-20						
L-084-11/2	Pass, Harvey I.		Nichirei Biosciences Inc	1-Mar-20						
L-154-18/0	Caplen, Natasha		ERYtech Pharma	1-Mar-20						
L-154-18/0	Lorenzi, Philipp		ERYtech Pharma	1-Mar-20						
L-154-18/0	Weinstein, John N.		ERYtech Pharma	1-Mar-20						
L-200-15/1	Aaronson, Stuart A.		TILT Biotherapeutics, Ltd.	1-Mar-20						
L-200-15/1	(b) (6) Donald J. Giard		TILT Biotherapeutics, Ltd.	1-Mar-20						
L-200-15/1	Parks, Wade P		TILT Biotherapeutics, Ltd.	1-Mar-20						
L-122-17/0	Choyke, Peter L		Koninklijke Philips N.V.	1-Mar-20						
L-122-17/0	Pinto, Peter A		Koninklijke Philips N.V.	1-Mar-20						
L-122-17/0	Turkbey, Ismail B.		Koninklijke Philips N.V.	1-Mar-20						
<i>Note: L-122-17/0 split between CC; NCI</i>										
L-083-11/0	Waldmann, Thomas A.		Abbott Biotherapeutics Corp.	1-Mar-20						
<i>Note: L-083-11/0 split between NCI; NINDS</i>										
L-166-02/2	Schlom, Jeffrey		Biocare Medical LLC	1-Mar-20						
L-319-17/0	Bonomi, Carrie A.		BioTech AG	1-Mar-20						
L-319-17/0	Borgel, Suzanne D.		BioTech AG	1-Mar-20						
L-319-17/0	Dougherty, Kelly		BioTech AG	1-Mar-20						
L-319-17/0	Hollingshead, Melinda G.		BioTech AG	1-Mar-20						

L-263-17/1	(b) (4)	(b)(4);	KeraFAST	1-Mar-20
L-263-17/1	Esposito, Dominic	(b)(6)	KeraFAST	1-Mar-20
L-263-17/1	Hopkins, Ralph F.		KeraFAST	1-Mar-20
L-263-17/1	Roberts, Veronica Ann		KeraFAST	1-Mar-20
L-226-15/2	Hodge, James W.		KeraFAST	1-Mar-20
L-226-15/2	Schlom, Jeffrey		KeraFAST	1-Mar-20
L-261-17/0	Esposito, Dominic		KeraFAST	1-Mar-20
L-261-17/0	Gillette, William K.		KeraFAST	1-Mar-20
L-261-17/0	Grose, Carissa L.		KeraFAST	1-Mar-20
L-192-15/1	Burgess, Rebecca C.		KeraFAST	1-Mar-20
L-192-15/1	Misteli, Thomas		KeraFAST	1-Mar-20
L-192-15/1	Roukos, Vasileios		KeraFAST	1-Mar-20
L-192-15/1	Soutoglou, Evi		KeraFAST	1-Mar-20
L-086-17/0	Rader, Christoph		KeraFAST	1-Mar-20
L-054-17/0	Barrett, J Carl		KeraFAST	1-Mar-20
L-054-17/0	Custer, Mary		KeraFAST	1-Mar-20
L-054-17/0	Risinger, John		KeraFAST	1-Mar-20
L-037-17/2	Esposito, Dominic		KeraFAST	1-Mar-20
L-037-17/2	Hopkins, Ralph F.		KeraFAST	1-Mar-20
L-208-13/0	NCI		Aspyrian THERapeutics, Inc.	1-Mar-20
L-252-14/1	Copeland, Neal	(b)(4);	Warp Drive Bio, LLC	1-Mar-20
L-252-14/1	Costantino, Nina	(b)(6)	Warp Drive Bio, LLC	1-Mar-20
L-252-14/1	Court, Donald		Warp Drive Bio, LLC	1-Mar-20
L-252-14/1	Datta, Simanti		Warp Drive Bio, LLC	1-Mar-20
L-252-14/1	Ellis, Hilary Moyed		Warp Drive Bio, LLC	1-Mar-20
L-252-14/1	Jenkins Copeland, Nancy A		Warp Drive Bio, LLC	1-Mar-20
L-252-14/1	Lee, E-Chiang		Warp Drive Bio, LLC	1-Mar-20
L-252-14/1	Liu, Pentao		Warp Drive Bio, LLC	1-Mar-20
L-252-14/1	Sawitzke, James		Warp Drive Bio, LLC	1-Mar-20
L-252-14/1	Sharan, Shyam K		Warp Drive Bio, LLC	1-Mar-20
L-252-14/1	Swaminathan, Srividya		Warp Drive Bio, LLC	1-Mar-20
L-252-14/1	Warming, Soren		Warp Drive Bio, LLC	1-Mar-20
L-252-14/1	Yu, Daiguan		Warp Drive Bio, LLC	1-Mar-20
L-078-20/0	Bonomi, Carrie A.		Unity Biotechnology, Inc.	2-Mar-20
L-078-20/0	Borgel, Suzanne D.		Unity Biotechnology, Inc.	2-Mar-20
L-078-20/0	Dougherty, Kelly		Unity Biotechnology, Inc.	2-Mar-20
L-078-20/0	Hollingshead, Melinda G.		Unity Biotechnology, Inc.	2-Mar-20
L-037-11/0	Jelinek, Ivett		BioLegend	2-Mar-20
L-037-11/0	Segal, David M.		BioLegend	2-Mar-20
L-037-11/0	Wang, Yan		BioLegend	2-Mar-20
L-070-12/0	Hathcock, Karen		BioLegend	2-Mar-20
L-070-12/0	Hodes, Richard		BioLegend	2-Mar-20
L-070-12/0	Laszlo, Gloria		BioLegend	2-Mar-20

(b) (3) (A), (b) (4), (b) (6)

L-198-15/0	Ise, Tomoko	(b)(4);	BioLegend	2-Mar-20
L-198-15/0	Nagata, Satoshi	(b)(6)	BioLegend	2-Mar-20
L-198-15/0	Pastan, Ira H		BioLegend	2-Mar-20
L-162-08/1	Roberts, (b) (6) Anita		BioLegend	2-Mar-20
L-162-08/1	Sporn, Michael B.		BioLegend	2-Mar-20
<i>Note: L-162-08/1 split between NCI; NIAID</i>				
L-073-09/0	Bonner, William M		BioLegend	2-Mar-20
L-073-09/0	Rogakou, Efthimia P		BioLegend	2-Mar-20
L-095-12/0	Baskar, Sivasubramanian		BioLegend	2-Mar-20
L-095-12/0	Rader, Christoph		BioLegend	2-Mar-20
L-020-08/2	Roop, Dennis R.		BioLegend	2-Mar-20
L-020-08/2	Steinert (b) (6) Peter M.		BioLegend	2-Mar-20
L-020-08/2	Yuspa, Stuart H.		BioLegend	2-Mar-20
L-010-08/1	Hathcock, Karen		BioLegend	2-Mar-20
L-010-08/1	Hodes, Richard		BioLegend	2-Mar-20
L-010-08/1	Laszlo, Gloria		BioLegend	2-Mar-20
L-042-08/1	Azimi, Nazli		BioLegend	2-Mar-20
L-042-08/1	Dubois, Sigrid		BioLegend	2-Mar-20
L-042-08/1	Goldman, Carolyn		BioLegend	2-Mar-20
L-042-08/1	Lantz, Valerie A		BioLegend	2-Mar-20
L-042-08/1	Mariner Kilbourne, Jennifer		BioLegend	2-Mar-20
L-042-08/1	Waldmann, Thomas A.		BioLegend	2-Mar-20
L-007-11/1	Onda, Masanori		BioLegend	2-Mar-20
L-007-11/1	Pastan, Ira H		BioLegend	2-Mar-20
L-136-09/1	Mason, Llewellyn H.		BioLegend	2-Mar-20
L-136-09/1	Ortaldo, John R.		BioLegend	2-Mar-20
L-229-17/0	Bonomi, Carrie A.		Molecular Imaging, Inc.	3-Mar-20
L-229-17/0	Borgel, Suzanne D.		Molecular Imaging, Inc.	3-Mar-20
L-229-17/0	Dougherty, Kelly		Molecular Imaging, Inc.	3-Mar-20
L-229-17/0	Hollingshead, Melinda G.		Molecular Imaging, Inc.	3-Mar-20
L-039-11/0	Onda, Masanori		Rockland Immunochemicals, Inc.	3-Mar-20
L-039-11/0	Pastan, Ira H		Rockland Immunochemicals, Inc.	3-Mar-20
L-091-11/0	Chang, Nancy T.		Quest Diagnostics, Inc.	4-Mar-20
L-091-11/0	Fisher, Amanda G.		Quest Diagnostics, Inc.	4-Mar-20
L-091-11/0	Gallo, Robert C.		Quest Diagnostics, Inc.	4-Mar-20
L-091-11/0	Hahn, Beatrice		Quest Diagnostics, Inc.	4-Mar-20
L-091-11/0	(b) (4)		Quest Diagnostics, Inc.	4-Mar-20
L-091-11/0	Popovic, Mikulas		Quest Diagnostics, Inc.	4-Mar-20
L-091-11/0	Sarngadharan, Mangalasseril		Quest Diagnostics, Inc.	4-Mar-20
L-091-11/0	Shaw, George M		Quest Diagnostics, Inc.	4-Mar-20
L-091-11/0	Wong-Staal, Flossie		Quest Diagnostics, Inc.	4-Mar-20
L-271-01/8	Gupta, Shanker Lal		Millennium Pharmaceuticals, Inc.	4-Mar-20

L-271-01/8	(b) (4)	(b)(4); (b)(6)	Millennium Pharmaceuticals, Inc.	4-Mar-20
L-091-10/0	Bonner, William M		Novus Biologicals, Inc.	4-Mar-20
L-091-10/0	Rogakou, Efthimia P		Novus Biologicals, Inc.	4-Mar-20
L-093-10/1	Chang, Nancy T.		BioLytical Labs	5-Mar-20
L-093-10/1	Crowl, Robert		BioLytical Labs	5-Mar-20
L-093-10/1	Gallo, Robert C.		BioLytical Labs	5-Mar-20
L-093-10/1	(b) (4)		BioLytical Labs	5-Mar-20
L-093-10/1	Reddy, E. Premkumar.		BioLytical Labs	5-Mar-20
L-093-10/1	Shaw, George M		BioLytical Labs	5-Mar-20
L-093-10/1	Wong-Staal, Flossie		BioLytical Labs	5-Mar-20
L-135-19/0	NCI		Sixfold Bioscience Inc.	5-Mar-20
L-076-20/0	Gazdar, Adi F.	(b)(4);	Agilent Technologies Singapore Pte. Ltd.	5-Mar-20
L-076-20/0	Johnson, Bruce E	(b)(6)	Agilent Technologies Singapore Pte. Ltd.	5-Mar-20
L-076-20/0	Kaye, Frederic J		Agilent Technologies Singapore Pte. Ltd.	5-Mar-20
L-076-20/0	Kheif, Samir N.		Agilent Technologies Singapore Pte. Ltd.	5-Mar-20
L-076-20/0	Minna, John D.		Agilent Technologies Singapore Pte. Ltd.	5-Mar-20
L-076-20/0	Oie, Herbert K		Agilent Technologies Singapore Pte. Ltd.	5-Mar-20
L-076-20/0	Pass, Harvey I.		Agilent Technologies Singapore Pte. Ltd.	5-Mar-20
L-245-94/1	Gallo, Robert C.		SearCare Life Sciences	6-Mar-20
L-245-94/1	(b) (4)		SearCare Life Sciences	6-Mar-20
L-245-94/1	Popovic, Mikulas		SearCare Life Sciences	6-Mar-20
L-245-94/1	Sarngadharan, Mangalasseril		SearCare Life Sciences	6-Mar-20
<i>Note: L-245-94/1 split between NCI; NIAID</i>				
L-092-12/2	Bergamaschi, Cristina		Admune Therapeutics LLC	6-Mar-20
L-092-12/2	Felber, Barbara K.		Admune Therapeutics LLC	6-Mar-20
L-092-12/2	Pavlakis, George N		Admune Therapeutics LLC	6-Mar-20
L-092-12/2	Valentin, Antonio		Admune Therapeutics LLC	6-Mar-20
L-166-02/2	Schlom, Jeffrey		Biocare Medical LLC	6-Mar-20
L-245-94/1	Gallo, Robert C.		SearCare Life Sciences	6-Mar-20
L-245-94/1	(b) (4)		SearCare Life Sciences	6-Mar-20
L-245-94/1	Popovic, Mikulas		SearCare Life Sciences	6-Mar-20
L-245-94/1	Sarngadharan, Mangalasseril		SearCare Life Sciences	6-Mar-20
<i>Note: L-245-94/1 split between NCI; NIAID</i>				
L-024-18/0	Gazdar, Adi F.		SeraCare Life	6-Mar-20
L-024-18/0	Johnson, Bruce E		SeraCare Life	6-Mar-20
L-024-18/0	Kaye, Frederic J		SeraCare Life	6-Mar-20
L-024-18/0	Kheif, Samir N.		SeraCare Life	6-Mar-20
L-024-18/0	Minna, John D.		SeraCare Life	6-Mar-20
L-024-18/0	Oie, Herbert K		SeraCare Life	6-Mar-20
L-024-18/0	Pass, Harvey I.		SeraCare Life	6-Mar-20
L-161-04/1	Gallo, Robert C.		SeraCare Life Sciences, Inc.	6-Mar-20
L-161-04/1	(b) (4)		SeraCare Life Sciences, Inc.	6-Mar-20
L-161-04/1	Popovic, Mikulas		SeraCare Life Sciences, Inc.	6-Mar-20
L-161-04/1	Sarngadharan, Mangalasseril		SeraCare Life Sciences, Inc.	6-Mar-20

(b) (3) (A), (b) (4), (b) (6)

L-161-19/0	Gazdar, Adi F.	(b)(4);	SearCare Life Sciences	6-Mar-20
L-161-19/0	Johnson, Bruce E	(b)(6)	SearCare Life Sciences	6-Mar-20
L-161-19/0	Kaye, Frederic J		SearCare Life Sciences	6-Mar-20
L-161-19/0	Kheif, Samir N.		SearCare Life Sciences	6-Mar-20
L-161-19/0	Minna, John D.		SearCare Life Sciences	6-Mar-20
L-161-19/0	Oie, Herbert K		SearCare Life Sciences	6-Mar-20
L-161-19/0	Pass, Harvey I.		SearCare Life Sciences	6-Mar-20
L-082-20/0	Abrams, Scott I		Compass Therapeutics LLC	6-Mar-20
L-082-20/0	Schlom, Jeffrey		Compass Therapeutics LLC	6-Mar-20
L-035-20/0	Bonomi, Carrie A.		Celgene Corp	6-Mar-20
L-035-20/0	Dougherty, Kelly		Celgene Corp	6-Mar-20
L-035-20/0	Hollingshead, Melinda G.		Celgene Corp	6-Mar-20
L-015-11/0	Landry, Joseph W.		Millipore Sigma	6-Mar-20
L-015-11/0	Wu, Carl		Millipore Sigma	6-Mar-20
L-111-13/0	Muchmore, Brian P.		Millipore Sigma	6-Mar-20
L-111-13/0	O'Brien, Thomas R		Millipore Sigma	6-Mar-20
L-111-13/0	Porter-Gill, Patricia A.		Millipore Sigma	6-Mar-20
L-111-13/0	Prokunina-Olsson, Ludmila		Millipore Sigma	6-Mar-20
<i>Note: L-111-13/0 split between FDA; NCI</i>				
L-152-13/0	Doroshov, James H.		Millipore Sigma	6-Mar-20
L-152-13/0	Jiang, Guojian		Millipore Sigma	6-Mar-20
L-152-13/0	Roy, Krishnendu K.		Millipore Sigma	6-Mar-20
L-152-13/0	Wu, Yongzhong		Millipore Sigma	6-Mar-20
L-097-15/0	Rubin, Jeffrey S		Millipore Sigma	6-Mar-20
L-097-15/0	Uren, Aykut		Millipore Sigma	6-Mar-20
L-057-16/1	Hollingshead, Melinda G.		Millipore Sigma	6-Mar-20
L-057-16/1	Sausville, Edward		Millipore Sigma	6-Mar-20
L-057-16/1	Snader, Kenneth M		Millipore Sigma	6-Mar-20
L-057-16/1	Vishnuvajjala, B. Rao		Millipore Sigma	6-Mar-20
L-280-17/0	Ise, Tomoko		Millipore Sigma	6-Mar-20
L-280-17/0	Nagata, Satoshi		Millipore Sigma	6-Mar-20
L-280-17/0	Pastan, Ira H		Millipore Sigma	6-Mar-20
L-280-17/0	Xiang, Liaman		Millipore Sigma	6-Mar-20
L-019-18/0	Rosenberg, Steven A.		Millipore Sigma	6-Mar-20
L-019-18/0	Spiese, Paul J		Millipore Sigma	6-Mar-20
L-019-18/0	Yang, James C		Millipore Sigma	6-Mar-20
L-031-18/0	Abrams, Scott I		Millipore Sigma	6-Mar-20
L-031-18/0	Schlom, Jeffrey		Millipore Sigma	6-Mar-20
L-049-01/3	Bustin, Michael		Millipore Sigma	6-Mar-20
L-041-98/2	Alimandi, Maurizio		Millipore Sigma	6-Mar-20
L-041-98/2	Pierce, Jacalyn		Millipore Sigma	6-Mar-20
L-041-98/2	Wang, Ling-Mei		Millipore Sigma	6-Mar-20

L-012-19/0	Buck, Christopher	(b)(4); (b)(6)	EMD Millipore Corporation	6-Mar-20
L-154-97/2	Mason, Llewellyn H.		BD Biosciences - BD PharMingen	10-Mar-20
L-154-97/2	Ortaldo, John R.		BD Biosciences - BD PharMingen	10-Mar-20
L-097-00/2	Austin, Faye C.		BD Biosciences, PharMingen	10-Mar-20
L-097-00/2	Colcher, David		BD Biosciences, PharMingen	10-Mar-20
L-097-00/2	Hand, Patricia H		BD Biosciences, PharMingen	10-Mar-20
L-097-00/2	Nuti, Marianna		BD Biosciences, PharMingen	10-Mar-20
L-097-00/2	Schlom, Jeffrey		BD Biosciences, PharMingen	10-Mar-20
L-201-16/0	Chang, Nancy T.		F. Hoffmann-La Roche Ltd	10-Mar-20
L-201-16/0	Crowl, Robert		F. Hoffmann-La Roche Ltd	10-Mar-20
L-201-16/0	Fisher, Amanda G.		F. Hoffmann-La Roche Ltd	10-Mar-20
L-201-16/0	Hahn, Beatrice		F. Hoffmann-La Roche Ltd	10-Mar-20
L-201-16/0	Popovic, Mikulas		F. Hoffmann-La Roche Ltd	10-Mar-20
L-201-16/0	Reddy, E. Premkumar.		F. Hoffmann-La Roche Ltd	10-Mar-20
L-201-16/0	Sarrngadharan, Mangalasseril		F. Hoffmann-La Roche Ltd	10-Mar-20
L-201-16/0	Shaw, George M		F. Hoffmann-La Roche Ltd	10-Mar-20
L-046-20/0	Bluestone, Jeffrey A		Proteintech Group, Inc.	11-Mar-20
L-046-20/0	Leo, Oberdan		Proteintech Group, Inc.	11-Mar-20
L-046-20/0	Vos, Michele		Proteintech Group, Inc.	11-Mar-20
L-100-20/0	Benter, Thomas		Mikrogen GmbH	11-Mar-20
L-100-20/0	Felber, Barbara K.		Mikrogen GmbH	11-Mar-20
L-100-20/0	Sadaie, Mohammad Reza		Mikrogen GmbH	11-Mar-20
L-095-20/0	Burgess, Rebecca C.		Dewpoint Therapeutics	11-Mar-20
L-095-20/0	Misteli, Thomas		Dewpoint Therapeutics	11-Mar-20
L-107-18/0	Bonomi, Carrie A.		Codiak Biosciences	11-Mar-20
L-107-18/0	Dougherty, Kelly		Codiak Biosciences	11-Mar-20
L-107-18/0	Hollingshead, Melinda G.		Codiak Biosciences	11-Mar-20
L-148-17/0	NCI		Chimeron Bio Corporation	11-Mar-20
L-100-12/1	Ise, Tomoko	(b)(4);	BD Biosciences	12-Mar-20
L-100-12/1	Nagata, Satoshi	(b)(6)	BD Biosciences	12-Mar-20
L-100-12/1	Pastan, Ira H		BD Biosciences	12-Mar-20
L-076-16/0	Azimi, Nazli		BD Biosciences	12-Mar-20
L-076-16/0	Dubois, Sigrid		BD Biosciences	12-Mar-20
L-076-16/0	Goldman, Carolyn		BD Biosciences	12-Mar-20
L-076-16/0	Lantz, Valerie A		BD Biosciences	12-Mar-20
L-076-16/0	Mariner Kilbourne, Jennifer		BD Biosciences	12-Mar-20
L-076-16/0	Waldmann, Thomas A.		BD Biosciences	12-Mar-20
L-277-17/0	Aaronson, Stuart A.		Valo Therapeutics Oy	12-Mar-20
L-277-17/0	Giard, Donald		Valo Therapeutics Oy	12-Mar-20
L-277-17/0	Parks, Wade P		Valo Therapeutics Oy	12-Mar-20
L-088-20/0	Helman, Lee		OncoMyx Therapeutics, Inc	12-Mar-20
L-088-20/0	Khanna, Chand		OncoMyx Therapeutics, Inc	12-Mar-20

L-039-18/0	Gazdar, Adi F.	(b)(4);	Eurofins Cerep	16-Mar-20
L-039-18/0	Johnson, Bruce E	(b)(6)	Eurofins Cerep	16-Mar-20
L-039-18/0	Kaye, Frederic J		Eurofins Cerep	16-Mar-20
L-039-18/0	Kheif, Samir N.		Eurofins Cerep	16-Mar-20
L-039-18/0	Minna, John D.		Eurofins Cerep	16-Mar-20
L-039-18/0	Oie, Herbert K		Eurofins Cerep	16-Mar-20
L-039-18/0	Pass, Harvey I.		Eurofins Cerep	16-Mar-20
L-272-16/0	Bonomi, Carrie A.		KeraFAST	16-Mar-20
L-272-16/0	Borgel, Suzanne D.		KeraFAST	16-Mar-20
L-272-16/0	Dougherty, Kelly		KeraFAST	16-Mar-20
L-272-16/0	Hollingshead, Melinda G.		KeraFAST	16-Mar-20
L-019-08/0	Ahlers, Jeffrey D		Institut Pasteur	16-Mar-20
L-019-08/0	Berzofsky, Jay A.		Institut Pasteur	16-Mar-20
L-019-08/0	Chang, Nancy T.		Institut Pasteur	16-Mar-20
L-019-08/0	Crowl, Robert		Institut Pasteur	16-Mar-20
L-019-08/0	Fisher, Amanda G.		Institut Pasteur	16-Mar-20
L-019-08/0	Gallo, Robert C.		Institut Pasteur	16-Mar-20
L-019-08/0	Hahn, Beatrice		Institut Pasteur	16-Mar-20
L-019-08/0	Nara, Peter L		Institut Pasteur	16-Mar-20
L-019-08/0	Pendleton, Charles D.		Institut Pasteur	16-Mar-20
L-019-08/0	Popovic, Mikulas		Institut Pasteur	16-Mar-20
L-019-08/0	Reddy, E. Premkumar.		Institut Pasteur	16-Mar-20
L-019-08/0	Sarangadharan, Mangalasseril		Institut Pasteur	16-Mar-20
L-019-08/0	Shaw, George M		Institut Pasteur	16-Mar-20
L-019-08/0	Shirai, Mutsunori		Institut Pasteur	16-Mar-20
L-019-08/0	Wong-Staal, Flossie		Institut Pasteur	16-Mar-20
<i>Note: L-019-08/0 split between FDA; NCI; NIAID; NIBIB; NIDDK</i>				
L-361-98/2	Hamilton, Thomas C	(b)(4);	BioProcessing, Inc.	17-Mar-20
L-361-98/2	Ozols, Robert F	(b)(6)	BioProcessing, Inc.	17-Mar-20
L-125-13/0	Gazdar, Adi F.		BioRad	17-Mar-20
L-125-13/0	Johnson, Bruce E		BioRad	17-Mar-20
L-125-13/0	Kaye, Frederic J		BioRad	17-Mar-20
L-125-13/0	Khleif, Samir N.		BioRad	17-Mar-20
L-125-13/0	Minna, John D.		BioRad	17-Mar-20
L-125-13/0	Oie, Herbert K		BioRad	17-Mar-20
L-125-13/0	Pass, Harvey I.		BioRad	17-Mar-20
L-125-13/0	Gazdar, Adi F.		BioRad	17-Mar-20
L-125-13/0	Johnson, Bruce E		BioRad	17-Mar-20
L-125-13/0	Kaye, Frederic J		BioRad	17-Mar-20
L-125-13/0	Khleif, Samir N.		BioRad	17-Mar-20
L-125-13/0	Minna, John D.		BioRad	17-Mar-20
L-125-13/0	Oie, Herbert K		BioRad	17-Mar-20
L-125-13/0	Pass, Harvey I.		BioRad	17-Mar-20
*L-229-17/0	Bonomi, Carrie A.		Molecular Imaging, Inc.	17-Mar-20
*L-229-17/0	Borgel, Suzanne D.		Molecular Imaging, Inc.	17-Mar-20
*L-229-17/0	Dougherty, Kelly		Molecular Imaging, Inc.	17-Mar-20
*L-229-17/0	Hollingshead, Melinda G.		Molecular Imaging, Inc.	17-Mar-20
*L-055-12/1	Gazdar, Adi F.		Molecular Imaging	17-Mar-20

*L-055-12/1	Johnson, Bruce E	(b)(4);	Molecular Imaging	17-Mar-20
*L-055-12/1	Kaye, Frederic J	(b)(6)	Molecular Imaging	17-Mar-20
*L-055-12/1	Kheif, Samir N.		Molecular Imaging	17-Mar-20
*L-055-12/1	Minna, John D.		Molecular Imaging	17-Mar-20
*L-055-12/1	Oie, Herbert K		Molecular Imaging	17-Mar-20
*L-055-12/1	Pass, Harvey I.		Molecular Imaging	17-Mar-20
L-174-16/0	Costantino, Nina		BP Technology Ventures Inc.	17-Mar-20
L-174-16/0	Court, Donald		BP Technology Ventures Inc.	17-Mar-20
L-174-16/0	Datta, Simanti		BP Technology Ventures Inc.	17-Mar-20
*L-075-20/0	Acquavella, Nicolas		Lyell Immunopharma, Inc.	18-Mar-20
*L-075-20/0	Hanada, Kenichi		Lyell Immunopharma, Inc.	18-Mar-20
*L-075-20/0	Islam, S M Rafiqul		Lyell Immunopharma, Inc.	18-Mar-20
*L-075-20/0	Restifo, Nicholas P.		Lyell Immunopharma, Inc.	18-Mar-20
*L-075-20/0	Rosenberg, Steven A.		Lyell Immunopharma, Inc.	18-Mar-20
*L-075-20/0	Tamaoki, Naritaka		Lyell Immunopharma, Inc.	18-Mar-20
*L-075-20/0	Topalian, Suzanne L.		Lyell Immunopharma, Inc.	18-Mar-20
*L-075-20/0	Vizcardo Sakoda, Raul Eduardo		Lyell Immunopharma, Inc.	18-Mar-20
*L-075-20/0	Yang, James C		Lyell Immunopharma, Inc.	18-Mar-20
*L-075-20/0	Yu, Zhiya		Lyell Immunopharma, Inc.	18-Mar-20
*L-091-11/0	Chang, Nancy T.		Quest Diagnostics, Inc.	24-Mar-20
*L-091-11/0	Fisher, Amanda G.		Quest Diagnostics, Inc.	24-Mar-20
*L-091-11/0	Gallo, Robert C.		Quest Diagnostics, Inc.	24-Mar-20
*L-091-11/0	Hahn, Beatrice		Quest Diagnostics, Inc.	24-Mar-20
L-091-11/0	(b) (4)		Quest Diagnostics, Inc.	24-Mar-20
*L-091-11/0	Popovic, Mikulas		Quest Diagnostics, Inc.	24-Mar-20
*L-091-11/0	Sarngadharan, Mangalasseril		Quest Diagnostics, Inc.	24-Mar-20
*L-091-11/0	Shaw, George M		Quest Diagnostics, Inc.	24-Mar-20
*L-091-11/0	Wong-Staal, Flossie		Quest Diagnostics, Inc.	24-Mar-20
*L-102-13/0	Hathcock, Karen		EXBIO Praha	24-Mar-20
*L-102-13/0	Hodes, Richard		EXBIO Praha	24-Mar-20
*L-102-13/0	Laszlo, Gloria		EXBIO Praha	24-Mar-20
<i>Note: L-102-13/0 split between NCI; NIA</i>				
*L-092-13/0	Potter, (b) (6) Michael		EXBIO Praha	24-Mar-20
*L-137-10/1	Potter, (b) (6) Michael		Exbio	24-Mar-20
*L-003-12/1	Potter (b) (6) Michael		Exbio Praha AS	24-Mar-20
*L-141-05/0	Gallo, Robert C.		PerkinElmer	24-Mar-20
L-141-05/0	(b) (4)		PerkinElmer	24-Mar-20
*L-141-05/0	Popovic, Mikulas		PerkinElmer	24-Mar-20
*L-141-05/0	Sarngadharan, Mangalasseril		PerkinElmer	24-Mar-20
*L-294-19/0	NCI		Fannin Partners, LLC	24-Mar-20
*L-318-17/0	Onda, Masanori	(b)(4);	Millipore Sigma	25-Mar-20
*L-318-17/0	Pastan, Ira H	(b)(6)	Millipore Sigma	25-Mar-20
*L-101-20/0	Bonomi, Carrie A.		Carisma Therapeutics Inc.	26-Mar-20
*L-101-20/0	Borgel, Suzanne D.		Carisma Therapeutics Inc.	26-Mar-20

(b) (3) (A), (b) (4), (b) (6)

*L-101-20/0	Dougherty, Kelly	(b)(4);	Carisma Therapeutics Inc.	26-Mar-20
*L-101-20/0	Hollingshead, Melinda G.	(b)(6)	Carisma Therapeutics Inc.	26-Mar-20
*L-056-20/0	Gazdar, Adi F.		Amplify Medicines	26-Mar-20
*L-056-20/0	Johnson, Bruce E		Amplify Medicines	26-Mar-20
*L-056-20/0	Kaye, Frederic J		Amplify Medicines	26-Mar-20
*L-056-20/0	Kheif, Samir N.		Amplify Medicines	26-Mar-20
*L-056-20/0	Minna, John D.		Amplify Medicines	26-Mar-20
*L-056-20/0	Oie, Herbert K		Amplify Medicines	26-Mar-20
*L-056-20/0	Pass, Harvey I.		Amplify Medicines	26-Mar-20
*L-056-20/0	Gazdar, Adi F.		Amplify Medicines	26-Mar-20
*L-056-20/0	Johnson, Bruce E		Amplify Medicines	26-Mar-20
*L-056-20/0	Kaye, Frederic J		Amplify Medicines	26-Mar-20
*L-056-20/0	Kheif, Samir N.		Amplify Medicines	26-Mar-20
*L-056-20/0	Minna, John D.		Amplify Medicines	26-Mar-20
*L-056-20/0	Oie, Herbert K		Amplify Medicines	26-Mar-20
*L-056-20/0	Pass, Harvey I.		Amplify Medicines	26-Mar-20
*L-056-20/0	Gazdar, Adi F.		Amplify Medicines	26-Mar-20
*L-056-20/0	Johnson, Bruce E		Amplify Medicines	26-Mar-20
*L-056-20/0	Kaye, Frederic J		Amplify Medicines	26-Mar-20
*L-056-20/0	Kheif, Samir N.		Amplify Medicines	26-Mar-20
*L-056-20/0	Minna, John D.		Amplify Medicines	26-Mar-20
*L-056-20/0	Oie, Herbert K		Amplify Medicines	26-Mar-20
*L-056-20/0	Pass, Harvey I.		Amplify Medicines	26-Mar-20
*L-091-09/0	Bonner, William M		Research & Diagnostic Systems, Inc.	27-Mar-20
*L-091-09/0	Rogakou, Efthimia P		Research & Diagnostic Systems, Inc.	27-Mar-20

\$24,627,374.97	\$676,749.52	\$25,304,124.49	\$9,054,356.69	\$16,249,767.80
-----------------	--------------	-----------------	----------------	-----------------

* denotes an adjustment to fix a problem from a previous month

NIH Patent Licensing Activities
NEI
October 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-230-02/1	Bunce, George E.	(b)(4);	Bausch & Lomb	20-Sep-19						(b) (3) (A), (b) (4), (b) (6)
L-230-02/1	Ferris III, Frederick L.	(b)(6)	Bausch & Lomb	20-Sep-19						
L-230-02/1	Kinoshita, (b) (6) Jin H		Bausch & Lomb	20-Sep-19						
L-230-02/1	Smith, James Cecil		Bausch & Lomb	20-Sep-19						

NIH Patent Licensing Activities
NEI
November 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
NEI
December 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
NEI
January 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	----------------------	---------------------------	-------------------------	---------------------

NIH Patent Licensing Activities
NEI
February 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
NEI
March 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
L-230-02/1	NEI		Bausch & Lomb	1-Mar-20						(b) (3) (A), (b) (4), (b) (6)
L-168-15/0	Li, Tiansen	(b)(4);	EMD Millipore Corp.	6-Mar-20						
L-168-15/0	Swaroop, Anand	(b)(6)	EMD Millipore Corp.	6-Mar-20						
					\$6,759,902.78	\$0.00	\$6,759,902.78		\$600,572.20	\$6,159,330.58

NIH Patent Licensing Activities
NHGRI
October 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-216-17/0	NHGRI		Select a Biosciences, Inc.	2-Oct-19						(b) (3) (A), (b) (4)
L-216-17/0	NHGRI		Select a Biosciences, Inc.	17-Oct-19						

NIH Patent Licensing Activities
NHGRI

November 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
NHGRI
December 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
NHGRI
January 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC	
L-183-14/0	Gispert-Sanchez, Suzana	(b)(4);	UCSF	1-Jan-20						(b) (3) (A), (b) (4), (b) (6)	
L-183-14/0	Nussbaum, Robert L.	(b)(6)	UCSF	1-Jan-20							
L-186-16/0	Chandler, Randy J.		Galyatech LLC	1-Jan-20							
L-186-16/0	Pavan, William J		Galyatech LLC	1-Jan-20							
L-186-16/0	Venditti, Charles P.		Galyatech LLC	1-Jan-20							
L-057-15/0	NHGRI		Vtesse, Inc	8-Jan-20							
<i>Note: L-057-15/0 split between NCATS; NHGRI</i>											
L-207-19/0	Chandler, Randy J.	(b)(4);	LifeMax Laboratories Inc	8-Jan-20							
L-207-19/0	Manoli, Eirini	(b)(6)	LifeMax Laboratories Inc	8-Jan-20							
L-207-19/0	Venditti, Charles P.		LifeMax Laboratories Inc	8-Jan-20							
L-207-19/0	Chandler, Randy J.		LifeMax Laboratories Inc	8-Jan-20							
L-207-19/0	Manoli, Eirini		LifeMax Laboratories Inc	8-Jan-20							
L-207-19/0	Venditti, Charles P.		LifeMax Laboratories Inc	8-Jan-20							
L-055-15/1	NHGRI		Lysosomal Therapeutics, Inc.	16-Jan-20							
<i>Note: L-055-15/1 split between NCATS; NHGRI</i>											
L-055-15/1	Goldin, Ehud M.	(b)(4);	Lysosomal Therapeutics, Inc.	16-Jan-20							
L-055-15/1	Motabar, Omid	(b)(6)	Lysosomal Therapeutics, Inc.	16-Jan-20							
L-055-15/1	Sidransky, Ellen		Lysosomal Therapeutics, Inc.	16-Jan-20							
L-055-15/1	Westbroek, Wendy		Lysosomal Therapeutics, Inc.	16-Jan-20							
<i>Note: L-055-15/1 split between NCATS; NHGRI</i>											

NIH Patent Licensing Activities
NHGRI
February 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC	
L-204-18/0	Chandler, Randy J.	(b)(4);	Chameleon Biosciences Inc.	1-Feb-20						(b) (3) (A), (b) (4), (b) (6)	
L-204-18/0	Pavan, William J	(b)(6)	Chameleon Biosciences Inc.	1-Feb-20							
L-204-18/0	Venditti, Charles P.		Chameleon Biosciences Inc.	1-Feb-20							
L-116-13/0	NHGRI		EMD Millipore Corp.	7-Feb-20							
<i>Note: L-116-13/0 split between NCATS; NHGRI</i>											
L-227-18/0	Chandler, Randy J.	(b)(4);	LogicBio Therapeutics	12-Feb-20							
L-227-18/0	Smith, Stephanie N.	(b)(6)	LogicBio Therapeutics	12-Feb-20							
L-227-18/0	Venditti, Charles P.		LogicBio Therapeutics	12-Feb-20							
L-244-17/0	Chandler, Randy J.		Logic Bio Therapeutics, Inc.	12-Feb-20							
L-244-17/0	Venditti, Charles P.		Logic Bio Therapeutics, Inc.	12-Feb-20							
L-069-19/0	Chandler, Randy J.		LogicBio Therapeutics, Inc.	12-Feb-20							
L-069-19/0	Venditti, Charles P.		LogicBio Therapeutics, Inc.	12-Feb-20							
L-128-19/0	Chandler, Randy J.		HemoShear Therapeutics, LLC	14-Feb-20							
L-128-19/0	Manoli, Eirini		HemoShear Therapeutics, LLC	14-Feb-20							
L-128-19/0	Venditti, Charles P.		HemoShear Therapeutics, LLC	14-Feb-20							

NIH Patent Licensing Activities

NHGRI

March 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
L-228-18/0	Chandler, Randy J.	(b)(4);	Translate Bio	5-Mar-20						(b) (3) (A), (b) (4), (b) (6)
L-228-18/0	Manoli, Eirini	(b)(6)	Translate Bio	5-Mar-20						
L-228-18/0	Venditti, Charles P.		Translate Bio	5-Mar-20						
L-229-18/0	Chandler, Randy J.		Translate Bio	5-Mar-20						
L-229-18/0	Venditti, Charles P.		Translate Bio	5-Mar-20						
L-246-18/0	Chandler, Randy J.		Translate Bio, Inc	5-Mar-20						
L-246-18/0	Manoli, Eirini		Translate Bio, Inc	5-Mar-20						
L-246-18/0	Venditti, Charles P.		Translate Bio, Inc	5-Mar-20						
L-216-18/0	Chandler, Randy J.		StrideBio	16-Mar-20						
L-216-18/0	Pavan, William J		StrideBio	16-Mar-20						
L-216-18/0	Venditti, Charles P.		StrideBio	16-Mar-20						
*L-067-20/0	Chandler, Randy J.		Asklepios Biopharmaceuticals, Inc.	18-Mar-20						
*L-067-20/0	Manoli, Eirini		Asklepios Biopharmaceuticals, Inc.	18-Mar-20						
*L-067-20/0	Venditti, Charles P.		Asklepios Biopharmaceuticals, Inc.	18-Mar-20						
					\$193,103.47	\$62,329.35	\$255,432.82		\$48,630.39	

* denotes an adjustment to fix a problem from a previous month

NIH Patent Licensing Activities
 NHLBI
 October 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-097-08/4	Knepper, Mark A	(b)(4); (b)(6)	Novus	16-Sep-19						(b) (3) (A), (b) (4), (b) (6)
*L-258-18/0	Derbyshire, John Andrew		: Siemens Healthcare GmbH	16-Sep-19						
L-258-18/0	(b) (4)		: Siemens Healthcare GmbH	16-Sep-19						
*L-258-18/0	McVeigh, Elliott R		: Siemens Healthcare GmbH	16-Sep-19						
*L-258-18/0	Nezafat, Reza		: Siemens Healthcare GmbH	16-Sep-19						
L-015-12/2	Berra, Lorenzo		EndOclear LLC	18-Sep-19						
L-015-12/2	Kolobow, Theodor		EndOclear LLC	18-Sep-19						
L-088-12/0	NHLBI		Sangamo BioSciences Inc	20-Sep-19						
<i>Note: L-088-12/0 split between NHLBI; NIDCR</i>										
L-024-07/3	Al-Shami, Amin	(b)(4);	Schering-Plough Biopharma	23-Sep-19						
L-024-07/3	Keane-Myers, Andrea M.	(b)(6)	Schering-Plough Biopharma	23-Sep-19						
L-024-07/3	Leonard, Warren J.		Schering-Plough Biopharma	23-Sep-19						
L-024-07/3	Spolski, Rosanna J		Schering-Plough Biopharma	23-Sep-19						
L-299-19/0	Chen, Guokai		Avery Therapeutics, Inc.	4-Oct-19						
L-299-19/0	Lin, Yongshun		Avery Therapeutics, Inc.	4-Oct-19						
L-177-02/0	Kang, Dae-kyung		Loma Linda University	9-Oct-19						
L-177-02/0	Levine, Rodney L		Loma Linda University	9-Oct-19						
<i>Note: L-177-02/0 split between NHLBI; NICHD</i>										
L-002-14/0	NHLBI		Intelligent Imaging Innovations, Inc.	18-Oct-19						
<i>Note: L-002-14/0 split between NHLBI; NIBIB</i>										
L-002-14/0	NHLBI		Intelligent Imaging Innovations, Inc.	18-Oct-19						
<i>Note: L-002-14/0 split between NHLBI; NIBIB</i>										
L-002-14/0	Combs, Christian A.	(b)(4);	Intelligent Imaging Innovations, Inc.	18-Oct-19						
<i>Note: L-002-14/0 split between NHLBI; NIBIB</i>										
L-002-14/0	Combs, Christian A.	(b)(6)	Intelligent Imaging Innovations, Inc.	18-Oct-19						
<i>Note: L-002-14/0 split between NHLBI; NIBIB</i>										
L-327-14/0	NHLBI		Voyager Therapeutics	22-Oct-19						

NIH Patent Licensing Activities
 NHLBI
 November 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

L-098-18/2	NHLBI		T-Cure Bioscience	13-Nov-19	(b) (3) (A), (b) (4), (b) (6)
L-120-12/2	Ding, Chuantian	(b)(4);	Sangamo Biosciences	26-Nov-19	
L-120-12/2	Kotin, Robert M.	(b)(6)	Sangamo Biosciences	26-Nov-19	
L-120-12/2	Urabe, Masashi		Sangamo Biosciences	26-Nov-19	

NIH Patent Licensing Activities
NHLBI
December 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
L-058-14/0	NHLBI		Spark Therapeutics Ireland Ltd	1-Dec-19						(b) (3) (A), (b) (4), (b) (6)
L-088-12/0	Chiorini, John A.	(b)(4);	Sangamo BioSciences Inc	4-Dec-19						
L-088-12/0	Kotin, Robert M.	(b)(6)	Sangamo BioSciences Inc	4-Dec-19						
L-088-12/0	(b) (4)		Sangamo BioSciences Inc	4-Dec-19						

Note: L-088-12/0 split between NHLBI; NIDCR

NIH Patent Licensing Activities
NHLBI
January 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
L-096-16/0	Finkel, Toren	(b)(4); (b)(6)	Genentech, Inc.	1-Jan-20						(b) (3) (A), (b) (4), (b) (6)
L-243-16/0	Boehm, Manfred		StemCell Technologies Inc.	1-Jan-20						
L-243-16/0	Chen, Guibin		StemCell Technologies Inc.	1-Jan-20						
L-243-16/0	Larochelle, Andre		StemCell Technologies Inc.	1-Jan-20						
Note: L-243-16/0 split between NHLBI; NIAMS										
L-107-07/3	Ding, Chuantian		UniQure B.V.	1-Jan-20						
L-107-07/3	Kotin, Robert M.		UniQure B.V.	1-Jan-20						
L-107-07/3	Urabe, Masashi		UniQure B.V.	1-Jan-20						
L-116-11/3	Chiorini, John A.		uniQure B.V.	1-Jan-20						
L-116-11/3	Kotin, Robert M.		uniQure B.V.	1-Jan-20						
L-116-11/3	(b) (4)		uniQure B.V.	1-Jan-20						
Note: L-116-11/3 split between NHLBI; NIDCR										
L-327-14/0	Ding, Chuantian		Voyager Therapeutics	1-Jan-20						
L-327-14/0	Kotin, Robert M.		Voyager Therapeutics	1-Jan-20						
L-327-14/0	Smith, Richard H.		Voyager Therapeutics	1-Jan-20						
L-327-14/0	Urabe, Masashi		Voyager Therapeutics	1-Jan-20						
L-042-06/2	Aletras, Anthony Homer		Siemens AG, Med. Solutions	1-Jan-20						
L-042-06/2	Kellman, Peter		Siemens AG, Med. Solutions	1-Jan-20						
L-042-06/2	McVeigh, Elliott R		Siemens AG, Med. Solutions	1-Jan-20						
L-042-06/2	Wen, Han		Siemens AG, Med. Solutions	1-Jan-20						

L-042-06/2	NHLBI		Siemens AG, Med. Solutions	1-Jan-20
L-353-14/0	Chiorini, John A.	(b)(4);	Takara Bio. Inc.	1-Jan-20
L-353-14/0	Kotin, Robert M.	(b)(6)	Takara Bio. Inc.	1-Jan-20
L-097-08/4	Knepper, Mark A		Novus	1-Jan-20
L-072-18/0	Remaley, Alan T.		Corvidia Therapeutics	1-Jan-20
L-072-18/0	Sviridov, Denis O.		Corvidia Therapeutics	1-Jan-20
L-072-18/0	Wolska, Anna		Corvidia Therapeutics	1-Jan-20
L-199-18/1	(b) (4)		Solid Biosciences	1-Jan-20
L-199-18/1	Kotin, Robert M.		Solid Biosciences	1-Jan-20
L-199-18/1	Li, Lina		Solid Biosciences	1-Jan-20
L-145-19/0	Cannon, Richard O.		Globin Solutions, Inc	1-Jan-20
L-145-19/0	Gladwin, Mark T.		Globin Solutions, Inc	1-Jan-20
L-145-19/0	Hunter, Christian J		Globin Solutions, Inc	1-Jan-20
L-145-19/0	(b) (4)		Globin Solutions, Inc	1-Jan-20
L-145-19/0	(b) (4)		Globin Solutions, Inc	1-Jan-20
L-145-19/0	(b) (4)		Globin Solutions, Inc	1-Jan-20
L-145-19/0	(b) (4)		Globin Solutions, Inc	1-Jan-20
<i>Note: L-145-19/0 split between CC; NHLBI; NIDDK; NINDS</i>				
L-014-18/0	Chiorini, John A.	(b)(4);	Lacerta Therapeutics, Inc.	1-Jan-20
L-014-18/0	Kotin, Robert M.	(b)(6)	Lacerta Therapeutics, Inc.	1-Jan-20
L-246-14/1	Nirenberg, (b) (6) Marshall		BIOLEGEND	1-Jan-20
L-246-14/1	Walsh, Frank		BIOLEGEND	1-Jan-20
<i>Note: L-246-14/1 split between NHLBI; NIAID</i>				
L-105-12/0	Ding, Chuantian		Genethon	2-Jan-20
L-105-12/0	Kotin, Robert M.		Genethon	2-Jan-20
L-105-12/0	Urabe, Masashi		Genethon	2-Jan-20
L-125-12/0	Nirenberg, (b) (6) Marshall		BD Biosciences	7-Jan-20
L-125-12/0	Walsh, Frank		BD Biosciences	7-Jan-20
<i>Note: L-125-12/0 split between NHLBI; NIAID</i>				
L-209-17/0	Derbyshire, John Andrew		General Electric Co.	7-Jan-20
L-209-17/0	(b) (4)		General Electric Co.	7-Jan-20
L-209-17/0	McVeigh, Elliott R		General Electric Co.	7-Jan-20
L-209-17/0	Nezafat, Reza		General Electric Co.	7-Jan-20
L-010-14/0	Cecchini, Sylvain		Life Technology Corp. (BAC BV)	7-Jan-20
L-010-14/0	Kotin, Robert M.		Life Technology Corp. (BAC BV)	7-Jan-20
L-010-14/0	Smith, Richard H.		Life Technology Corp. (BAC BV)	7-Jan-20
L-159-07/2	Cannon, Richard O.		Hope Pharmaceuticals	7-Jan-20
L-159-07/2	Gladwin, Mark T.		Hope Pharmaceuticals	7-Jan-20
L-159-07/2	Hunter, Christian J		Hope Pharmaceuticals	7-Jan-20
L-159-07/2	(b) (4)		Hope Pharmaceuticals	7-Jan-20
L-159-07/2	(b) (4)		Hope Pharmaceuticals	7-Jan-20
L-159-07/2	(b) (4)		Hope Pharmaceuticals	7-Jan-20
L-159-07/2	(b) (4)		Hope Pharmaceuticals	7-Jan-20

Note: L-159-07/2 split between CC; NHLBI; NIDDK; NINDS


L-234-18/0	Kotin, Robert M.	(b)(4);	Generation Bio	7-Jan-20
L-234-18/0	Li, Lina	(b)(6)	Generation Bio	7-Jan-20
L-158-17/0	Yang, Yanqin		Mokobio Life Science Group, Inc.	7-Jan-20
L-158-17/0	Zhu, Jun		Mokobio Life Science Group, Inc.	7-Jan-20
Note: L-158-17/0 split between NCI; NHLBI				
L-143-07/2	Cannon, Richard O.		Hope Pharmaceuticals	7-Jan-20
Note: L-143-07/2 split between CC; NHLBI; NIDDK				
L-104-18/0	Ding, Chuan-Tian		LakePharma	9-Jan-20
L-104-18/0	Kotin, Robert M.		LakePharma	9-Jan-20
L-104-18/0	Urabe, Masashi		LakePharma	9-Jan-20
L-181-17/0	Ding, Chuan-Tian		Esteve Pharmaceuticals	14-Jan-20
L-181-17/0	Kotin, Robert M.		Esteve Pharmaceuticals	14-Jan-20
L-181-17/0	Urabe, Masashi		Esteve Pharmaceuticals	14-Jan-20



(b) (3) (A), (b) (4), (b) (6)

**NIH Patent Licensing Activities
NHLBI
February 2020**

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
L-170-15/0	Chiorini, John A.	(b)(4);	BioMarin Pharmaceuticals, Inc.	1-Feb-20						
L-170-15/0	Kotin, Robert M.	(b)(6)	BioMarin Pharmaceuticals, Inc.	1-Feb-20						
L-170-15/0	NHLBI		BioMarin Pharmaceuticals, Inc.	1-Feb-20						
L-214-18/0	NHLBI		Yokogawa Electric Corporation	1-Feb-20						
Note: L-214-18/0 split between NHLBI; NIBIB										
L-181-17/0	NHLBI		Esteve Pharmaceuticals	1-Feb-20						
L-063-15/0	Ding, Chuantian	(b)(4);	BioMarin Pharma.	6-Feb-20						
L-063-15/0	Kotin, Robert M.	(b)(6)	BioMarin Pharma.	6-Feb-20						
L-063-15/0	Urabe, Masashi		BioMarin Pharma.	6-Feb-20						
L-258-18/0	Derbyshire, John Andrew		Siemens Healthcare GmbH	10-Feb-20						
L-258-18/0	(b)(4)		Siemens Healthcare GmbH	10-Feb-20						
L-258-18/0	McVeigh, Elliott R		Siemens Healthcare GmbH	10-Feb-20						
L-258-18/0	Nezafat, Reza		Siemens Healthcare GmbH	10-Feb-20						
L-116-11/3	NHLBI		uniQure B.V.	12-Feb-20						
Note: L-116-11/3 split between NHLBI; NIDCR										
L-058-14/0	Chiorini, John A.	(b)(4);	Spark Therapeutics Ireland Ltd	13-Feb-20						
L-058-14/0	Kotin, Robert M.	(b)(6)	Spark Therapeutics Ireland Ltd	13-Feb-20						
L-044-08/1	Nirenberg, (b)(6) Marshall		Miltenyi Biotec GMBH	14-Feb-20						
L-044-08/1	Walsh, Frank		Miltenyi Biotec GMBH	14-Feb-20						



(b) (3) (A), (b) (4), (b) (6)

Note: L-044-08/1 split between NHLBI; NIAID

L-104-18/0	Ding, Chuan-Tian	(b)(4);	LakePharma	17-Feb-20
L-104-18/0	Kotin, Robert M.	(b)(6)	LakePharma	17-Feb-20
L-104-18/0	Urabe, Masashi		LakePharma	17-Feb-20
L-243-16/0	Boehm, Manfred		StemCell Technologies Inc.	21-Feb-20
L-243-16/0	Chen, Guibin		StemCell Technologies Inc.	21-Feb-20
L-243-16/0	Larochelle, Andre		StemCell Technologies Inc.	21-Feb-20
Note: L-243-16/0 split between NHLBI; NIAIMS				
L-102-07/1	Nirenberg, (b)(6) Marshall		Life Technologies Corporation	25-Feb-20
L-102-07/1	Walsh, Frank		Life Technologies Corporation	25-Feb-20
Note: (b)(4) split between NHLBI; NIAID				
L-010-14/0	Cecchini, Sylvain		Life Technology Corp. (BAC BV)	25-Feb-20
L-010-14/0	Kotin, Robert M.		Life Technology Corp. (BAC BV)	25-Feb-20
L-010-14/0	Smith, Richard H.		Life Technology Corp. (BAC BV)	25-Feb-20

(b) (3) (A), (b) (4), (b) (6)

NIH Patent Licensing Activities
NHLBI
March 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
L-111-18/0	Knepper, Mark A	(b)(4); (b)(6)	KeraFAST	1-Mar-20						(b) (3) (A), (b) (4), (b) (6)
L-228-96/3	Adelstein, Robert		Covance Research Products, Inc.	2-Mar-20						
L-228-96/3	Kelley, Christine A		Covance Research Products, Inc.	2-Mar-20						
L-138-10/0	Adelstein, Robert		Millipore Corp	6-Mar-20						
L-138-10/0	Kawamoto, Sachiyo		Millipore Corp	6-Mar-20						
L-138-10/0	Kim, Kee Kwang		Millipore Corp	6-Mar-20						
L-140-18/0	Haque, Nazmul		Millipore Sigma	6-Mar-20						
L-140-18/0	Hogg, John Robert		Millipore Sigma	6-Mar-20						
L-052-96/3	Leonard, Warren J.		Upstate	6-Mar-20						
L-052-96/3	Lin, Jian-Xin		Upstate	6-Mar-20						
L-042-06/2	Aletras, Anthony Homer		Siemens AG, Med. Solutions	9-Mar-20						
L-042-06/2	Kellman, Peter		Siemens AG, Med. Solutions	9-Mar-20						
L-042-06/2	McVeigh, Elliott R		Siemens AG, Med. Solutions	9-Mar-20						
L-042-06/2	Wen, Han		Siemens AG, Med. Solutions	9-Mar-20						
L-258-18/0	Derbyshire, John Andrew		: Siemens Healthcare GmbH	9-Mar-20						
L-258-18/0	(b)(4)		: Siemens Healthcare GmbH	9-Mar-20						
L-258-18/0	McVeigh, Elliott R		: Siemens Healthcare GmbH	9-Mar-20						
L-258-18/0	Nezafat, Reza		: Siemens Healthcare GmbH	9-Mar-20						
L-275-18/0	Amar, Marcelo A.		Hartis-Pharma Sarl	11-Mar-20						
L-275-18/0	Brewer, H. Bryan		Hartis-Pharma Sarl	11-Mar-20						
L-275-18/0	Demosky, Stephen J.		Hartis-Pharma Sarl	11-Mar-20						

L-275-18/0	Neufeld, Edward B.	(b)(4);	Hartis-Pharma Sarl	11-Mar-20	(b) (3) (A), (b) (4), (b) (6)
L-275-18/0	Remaley, Alan T.	(b)(6)	Hartis-Pharma Sarl	11-Mar-20	
L-275-18/0	Stonik, John A.		Hartis-Pharma Sarl	11-Mar-20	
L-275-18/0	Thomas, Fairwell		Hartis-Pharma Sarl	11-Mar-20	
L-243-16/0	NHLBI		StemCell Technologies Inc.	11-Mar-20	
<i>Note: L-243-16/0 split between NHLBI; NIAMS</i>					
L-186-18/0	Ding, Chuan-Tian	(b)(4);	Casebia Therapeutics	16-Mar-20	
L-186-18/0	Kotin, Robert M.	(b)(6)	Casebia Therapeutics	16-Mar-20	
L-186-18/0	Urabe, Masashi		Casebia Therapeutics	16-Mar-20	
*L-097-08/4	Knepper, Mark A		Novus	25-Mar-20	
*L-259-02/0	Nirenberg, (b) (6) Marshall		R & D Systems, Inc.	27-Mar-20	
*L-259-02/0	Walsh, Frank		R & D Systems, Inc.	27-Mar-20	
<i>Note: L-259-02/0 split between NHLBI; NIAID</i>					
*L-214-18/0	Combs, Christian A.		Yokogawa Electric Corporation	30-Mar-20	
<i>Note: L-214-18/0 split between NHLBI; NIBIB</i>					

\$606,749.26	\$54,798.84	\$661,548.10	\$256,572.25	\$404,975.85
--------------	-------------	--------------	--------------	--------------

* denotes an adjustment to fix a problem from a previous month

NIH Patent Licensing Activities

NIA

October 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-122-18/1	NIA		Peptron	25-Sep-19						(b) (3) (A), (b) (4)

NIH Patent Licensing Activities

NIA

November 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC

NIH Patent Licensing Activities

NIA

December 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC

NIH Patent Licensing Activities

NIA

January 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC	
L-122-18/1	Greig, Nigel H	(b)(4);	Peptron	1-Jan-20						(b) (3) (A), (b) (4), (b) (6)	
L-122-18/1	Kim, Dong Seok	(b)(6)	Peptron	1-Jan-20							
L-122-18/1	Li, Yazhou		Peptron	1-Jan-20							
L-281-14/1	Doyle, Maire E		Peptron	1-Jan-20							
L-281-14/1	Egan, Josephine M		Peptron	1-Jan-20							
L-281-14/1	Greig, Nigel H		Peptron	1-Jan-20							
L-281-14/1	Holloway, Harold		Peptron	1-Jan-20							
L-281-14/1	Perry, Tracy Ann		Peptron	1-Jan-20							
L-166-16/0	Falco, Geppino		Elixirgen, LLC	1-Jan-20							
L-166-16/0	Ko, Minoru S.		Elixirgen, LLC	1-Jan-20							
L-166-16/0	Lee, Sung-Lim		Elixirgen, LLC	1-Jan-20							
L-166-16/0	Monti, Manuela		Elixirgen, LLC	1-Jan-20							
L-166-16/0	Sharova, Lioudmila V.		Elixirgen, LLC	1-Jan-20							
L-166-16/0	Stanghellini, Ilaria		Elixirgen, LLC	1-Jan-20							
L-166-16/0	Zalzman, Michal		Elixirgen, LLC	1-Jan-20							
L-117-95/2	Hodes, Richard		Southern Biotechnology Associates, Inc.	1-Jan-20							
<i>Note: L-117-95/2 split between NCI; NIA</i>											
L-079-17/0	Matarin Jimenez, Maria Del Ma		VuEssence, Inc.	16-Jan-20							
L-079-17/0	Singleton, Andrew B.		VuEssence, Inc.	16-Jan-20							
<i>Note: L-079-17/0 split between NIA; NINDS; NINR</i>											
L-131-18/0	Bagrov, Alexei		CTS Biopharma	23-Jan-20							
L-131-18/0	Fedorova, Olga V.		CTS Biopharma	23-Jan-20							
L-131-18/0	Lakatta, Edward G.		CTS Biopharma	23-Jan-20							
L-131-18/0	NIA		CTS Biopharma	23-Jan-20							

NIH Patent Licensing Activities

NIA

February 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
L-160-07/0	Shin, Soojung	(b)(4); (b)	Life Technologies	25-Feb-20						(b) (3) (A), (b) (4), (b) (6)

NIH Patent Licensing Activities

NIA

March 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
*L-102-13/0	Hodes, Richard J	(b)(4); (b)	EXBIO Praha	24-Mar-20						(b) (3) (A), (b) (4), (b) (6)

Note: L-102-13/0 split between NCI; NIA

\$49,987.76	\$22,029.50	\$72,017.26	\$16,999.77	\$55,017.49
-------------	-------------	-------------	-------------	-------------

* denotes an adjustment to fix a problem from a previous month

NIH Patent Licensing Activities
NIAAA
October 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	----------------------	---------------------------	-------------------------	---------------------

NIH Patent Licensing Activities
NIAAA
November 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
NIAAA
December 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
NIAAA
January 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	----------------------	---------------------------	-------------------------	---------------------

NIH Patent Licensing Activities
NIAAA
February 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
L-257-19/0	Cinar, Resat	(b)(4):	Inversago Pharma Inc	3-Feb-20						(b) (3) (A), (b) (4), (b) (6)
L-257-19/0	Iyer, Malliga R.	(b)(6)	Inversago Pharma Inc	3-Feb-20						
L-257-19/0	Kunos, George I		Inversago Pharma Inc	3-Feb-20						
<i>Note: L-257-19/0 split between NIAAA; NIDA</i>										
L-257-19/0	NIAAA		Inversago Pharma Inc	7-Feb-20						
<i>Note: L-257-19/0 split between NIAAA; NIDA</i>										

NIH Patent Licensing Activities
NIAAA
March 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
L-276-17/0	NIAAA		Vital Spark Inc.	1-Mar-20						(b) (3) (A), (b) (4), (b) (6)
<i>Note: L-276-17/0 split between NIAAA; NIDA</i>										
L-162-16/3	Cinar, Resat	(b)(4);	Inversago	6-Mar-20						
L-162-16/3	Iyer, Malliga R.	(b)(6)	Inversago	6-Mar-20						
L-162-16/3	Kunos, George I		Inversago	6-Mar-20						
<i>Note: L-162-16/3 split between NIAAA; NIDA</i>										
					\$22,470.00	\$49,047.52	\$71,517.52		\$5,920.50	\$65,597.02

NIH Patent Licensing Activities
NIAID
October 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-079-93/2	Ohara, Junichi	(b)(4);	BD Biosciences - BD PharMingen	1-Oct-19						(b) (3) (A), (b) (4), (b) (6)
L-079-93/2	Paul, (b) (6) William E.	(b)(6)	BD Biosciences - BD PharMingen	1-Oct-19						
L-074-91/3	Harriman, Gregory R.		Becton Dickinson & Subsidiary PharMingen	1-Oct-19						
L-074-91/3	Kunimoto, Dennis Y.		Becton Dickinson & Subsidiary PharMingen	1-Oct-19						
L-074-91/3	Paul, (b) (6) William E.		Becton Dickinson & Subsidiary PharMingen	1-Oct-19						
L-074-91/3	Strober, Warren		Becton Dickinson & Subsidiary PharMingen	1-Oct-19						
L-101-85/0	Mackett, Michael		ZOETIS	2-Oct-19						
L-101-85/0	Moss, Bernard		ZOETIS	2-Oct-19						
L-101-85/0	Smith, Geoffrey L		ZOETIS	2-Oct-19						
L-097-18/1	Akin, Cem		Evotec International GmbH	4-Oct-19						
L-097-18/1	Kirshenbaum, Arnold		Evotec International GmbH	4-Oct-19						
L-097-18/1	Metcalfe, Dean D		Evotec International GmbH	4-Oct-19						
L-069-10/1	NIAID		Beijing Zhongyuan Ltd	9-Oct-19						
L-303-19/0	Chuang, Gwo-Yu	(b)(4);	TaiMed Biologics USA, Inc	9-Oct-19						
L-303-19/0	Connors, Mark	(b)(6)	TaiMed Biologics USA, Inc	9-Oct-19						
L-303-19/0	Georgiev, Ivelin S.		TaiMed Biologics USA, Inc	9-Oct-19						
L-303-19/0	Kwon, Young Do		TaiMed Biologics USA, Inc	9-Oct-19						
L-303-19/0	Kwong, Peter D.		TaiMed Biologics USA, Inc	9-Oct-19						
L-303-19/0	Mascola, John R		TaiMed Biologics USA, Inc	9-Oct-19						
L-303-19/0	Nabel, Gary J		TaiMed Biologics USA, Inc	9-Oct-19						
L-303-19/0	Rudicell, Rebecca S.		TaiMed Biologics USA, Inc	9-Oct-19						
L-303-19/0	Shi, Wei		TaiMed Biologics USA, Inc	9-Oct-19						
L-303-19/0	Wu, Xueling		TaiMed Biologics USA, Inc	9-Oct-19						
L-303-19/0	YANG, YONGPING		TaiMed Biologics USA, Inc	9-Oct-19						

L-303-19/0	Yang, Zhi-Yong	(b)(4);	TaiMed Biologics USA, Inc	9-Oct-19
L-303-19/0	Zhang, Baoshan	(b)(6)	TaiMed Biologics USA, Inc	9-Oct-19
L-303-19/0	Zhou, Tongqing		TaiMed Biologics USA, Inc	9-Oct-19
L-303-19/0	Zhu, Jiang		TaiMed Biologics USA, Inc	9-Oct-19
L-261-19/0	Coligan, John		Bristol-Myers Squibb Company	24-Oct-19
L-261-19/0	Krzewski, Konrad		Bristol-Myers Squibb Company	24-Oct-19
L-261-19/0	Lee, Ha Na		Bristol-Myers Squibb Company	24-Oct-19
L-261-19/0	Tian, Lirjie		Bristol-Myers Squibb Company	24-Oct-19
L-261-19/0	Voss, Oliver		Bristol-Myers Squibb Company	24-Oct-19
L-144-14/1	Baxa, Ulrich		Novartis	25-Oct-19
L-144-14/1	Boyington, Jeffrey C.		Novartis	25-Oct-19
L-144-14/1	Chen, Lei		Novartis	25-Oct-19
L-144-14/1	Chen, Man		Novartis	25-Oct-19
L-144-14/1	Chuang, Gwo-Yu		Novartis	25-Oct-19
L-144-14/1	Druz, Aliaksandr A.		Novartis	25-Oct-19
L-144-14/1	Galen, Joseph Van		Novartis	25-Oct-19
L-144-14/1	Georgiev, Ivelin S.		Novartis	25-Oct-19
L-144-14/1	Gorman, Jason		Novartis	25-Oct-19
L-144-14/1	Graham, Barney S.		Novartis	25-Oct-19
L-144-14/1	Joyce, Michael G.		Novartis	25-Oct-19
L-144-14/1	Kanekiyo, Masaru		Novartis	25-Oct-19
L-144-14/1	Kong, Wing-pui		Novartis	25-Oct-19
L-144-14/1	Kwong, Peter D.		Novartis	25-Oct-19
L-144-14/1	Mascola, John R.		Novartis	25-Oct-19
L-144-14/1	McLellan, Jason Scott		Novartis	25-Oct-19
L-144-14/1	OFEK, GILAD A		Novartis	25-Oct-19
L-144-14/1	Ou, Li		Novartis	25-Oct-19
L-144-14/1	Pancera, Marie L.		Novartis	25-Oct-19
L-144-14/1	Rundlet, Emily		Novartis	25-Oct-19
L-144-14/1	Sastry, Mallika		Novartis	25-Oct-19
L-144-14/1	Soto, Cinque		Novartis	25-Oct-19
L-144-14/1	Srivatsan, Sanjay R.		Novartis	25-Oct-19
L-144-14/1	Stewart-Jones, Guillaume BE		Novartis	25-Oct-19
L-144-14/1	Thomas, Paul V.		Novartis	25-Oct-19
L-144-14/1	Tsybovsky, Yaroslav		Novartis	25-Oct-19
L-144-14/1	YANG, YONGPING		Novartis	25-Oct-19
L-144-14/1	Zhang, Baoshan		Novartis	25-Oct-19
L-144-14/1	Zhou, Tongqing		Novartis	25-Oct-19

(b) (3) (A), (b) (4), (b) (6)

NIH Patent Licensing Activities

NIAID

November 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. M	Patent	Total November	License Cumulative	Inventor Awards	Net Remaining to
L-124-18/0	Garboczi, David	(b)(4); (b)	Abcam plc	1-Nov-19						(b) (3) (A), (b) (4), (b) (6)
L-124-18/0	Lantz, Larry	(6)	Abcam plc	1-Nov-19						
L-124-18/0	Leppla, Stephen H.		Abcam plc	1-Nov-19						
L-124-18/0	Leysath, Clinton E.		Abcam plc	1-Nov-19						
L-124-18/0	Phillips, Damilola D.		Abcam plc	1-Nov-19						

L-012-07/2	Eisenbarth, (b) (6) George	(b)(4);	Santa Cruz Biotechnology Inc	5-Nov-19
L-012-07/2	Fauci, Anthony	(b)(6)	Santa Cruz Biotechnology Inc	5-Nov-19
L-012-07/2	Haynes, Barton F.		Santa Cruz Biotechnology Inc	5-Nov-19
L-063-06/3	Barry, Clifton E		Sequella, Inc.	12-Nov-19
L-063-06/3	Lee, Richard E.		Sequella, Inc.	12-Nov-19
L-063-06/3	Slayden, Richard A		Sequella, Inc.	12-Nov-19
L-211-14/2	Biacchesi, Stephanie		ViraTree, LLC	13-Nov-19
L-211-14/2	Buchholz, Ursula		ViraTree, LLC	13-Nov-19
L-211-14/2	Bukreyev, Alexander		ViraTree, LLC	13-Nov-19
L-211-14/2	Collins, Peter L.		ViraTree, LLC	13-Nov-19
L-211-14/2	Luongo, Cindy L.		ViraTree, LLC	13-Nov-19
L-211-14/2	Murphy, Brian R.		ViraTree, LLC	13-Nov-19
L-211-14/2	Nutt, Anne S.		ViraTree, LLC	13-Nov-19
L-211-14/2	(b) (4)		ViraTree, LLC	13-Nov-19
L-211-14/2	Skidopoulos, Mario		ViraTree, LLC	13-Nov-19
L-211-14/2	(b) (4)		ViraTree, LLC	13-Nov-19
L-202-15/0	Akin, Cem		Genentech Inc.	18-Nov-19
L-202-15/0	Kirshenbaum, Arnold		Genentech Inc.	18-Nov-19
L-202-15/0	Metcalfe, Dean D		Genentech Inc.	18-Nov-19
L-018-18/1	Datta, Sandip Kumar		Forte Biosciences Inc	18-Nov-19
L-018-18/1	Myles, Ian		Forte Biosciences Inc	18-Nov-19
L-268-01/0	Collins, Peter L.		Washington University	20-Nov-19
L-266-16/0	Akin, Cem		Glenmark Pharmaceuticals, S A.	22-Nov-19
L-266-16/0	Kirshenbaum, Arnold		Glenmark Pharmaceuticals, S A.	22-Nov-19
L-266-16/0	Metcalfe, Dean D		Glenmark Pharmaceuticals, S A.	22-Nov-19
L-266-16/0	Akin, Cem		Glenmark Pharmaceuticals, S A.	22-Nov-19
L-266-16/0	Kirshenbaum, Arnold		Glenmark Pharmaceuticals, S A.	22-Nov-19
L-266-16/0	Metcalfe, Dean D		Glenmark Pharmaceuticals, S A.	22-Nov-19
L-266-16/1	Akin, Cem		Glenmark Pharmaceuticals, S A.	22-Nov-19
L-266-16/1	Kirshenbaum, Arnold		Glenmark Pharmaceuticals, S A.	22-Nov-19
L-266-16/1	Metcalfe, Dean D		Glenmark Pharmaceuticals, S A.	22-Nov-19
L-266-16/1	Akin, Cem		Glenmark Pharmaceuticals, S A.	22-Nov-19
L-266-16/1	Kirshenbaum, Arnold		Glenmark Pharmaceuticals, S A.	22-Nov-19
L-266-16/1	Metcalfe, Dean D		Glenmark Pharmaceuticals, S A.	22-Nov-19
L-200-18/0	Chanock, (b) (6) Robert		Shandong Yidu Biotechnology Co., Ltd.	22-Nov-19
L-200-18/0	Hoshino, Yasutaka		Shandong Yidu Biotechnology Co., Ltd.	22-Nov-19
L-200-18/0	Kapikian, (b) (6) Albert Z		Shandong Yidu Biotechnology Co., Ltd.	22-Nov-19
L-258-19/0	Ishizuka, Andrew S		Avidea Technologies	22-Nov-19
L-258-19/0	Seder, Robert		Avidea Technologies	22-Nov-19
L-258-19/0	Zhu, Yaling		Avidea Technologies	22-Nov-19
L-258-19/0	Ishizuka, Andrew S		Avidea Technologies	22-Nov-19
L-258-19/0	Seder, Robert		Avidea Technologies	22-Nov-19
L-258-19/0	Zhu, Yaling		Avidea Technologies	22-Nov-19

(b) (3) (A), (b) (4), (b) (6)

L-126-11/0	Cheung, Yiu Chong Gordon	(b)(4); (b)(6)	Emergent Biodefense	26-Nov-19
L-126-11/0	Gupta, Pradeep K.	(b)(6)	Emergent Biodefense	26-Nov-19
L-126-11/0	Hu, Haijing	(b)(6)	Emergent Biodefense	26-Nov-19
L-126-11/0	Leppla, Stephen H.	(b)(6)	Emergent Biodefense	26-Nov-19
L-126-11/0	Moayeri, Mahtab	(b)(6)	Emergent Biodefense	26-Nov-19
L-126-11/0	Pomerantsev, Andrei P	(b)(6)	Emergent Biodefense	26-Nov-19
L-028-19/0	NIAID	(b)(6)	Ridgeback Biotherapeutics	26-Nov-19

(b) (3) (A), (b) (4), (b) (6)

NIH Patent Licensing Activities
NIAID
December 2019

License	Inventor	Inventor Share %	Inventor Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
L-303-19/0	NIAID	(b)(6)	TaiMed Biologics USA, Inc	2-Dec-19	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b) (3) (A), (b) (4), (b) (6)
L-253-15/0	Chanock, (b) (6) Robert	(b)(4); (b)(6)	Sun Biotech Pte., Ltd.	2-Dec-19	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b) (3) (A), (b) (4), (b) (6)
L-253-15/0	Hoshino, Yasutaka	(b)(6)	Sun Biotech Pte., Ltd.	2-Dec-19	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b) (3) (A), (b) (4), (b) (6)
L-253-15/0	Kapikian, (b) (6) Albert Z	(b)(6)	Sun Biotech Pte., Ltd.	2-Dec-19	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b) (3) (A), (b) (4), (b) (6)
L-044-18/1	Boyington, Jeffrey C.	(b)(6)	ModernaTX, Inc.	3-Dec-19	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b) (3) (A), (b) (4), (b) (6)
L-044-18/1	Buchholz, Ursula	(b)(6)	ModernaTX, Inc.	3-Dec-19	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b) (3) (A), (b) (4), (b) (6)
L-044-18/1	Chen, Lei	(b)(6)	ModernaTX, Inc.	3-Dec-19	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b) (3) (A), (b) (4), (b) (6)
L-044-18/1	Chen, Man	(b)(6)	ModernaTX, Inc.	3-Dec-19	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b) (3) (A), (b) (4), (b) (6)
L-044-18/1	Chuang, Gwo-Yu	(b)(6)	ModernaTX, Inc.	3-Dec-19	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b) (3) (A), (b) (4), (b) (6)
L-044-18/1	Collins, Peter L.	(b)(6)	ModernaTX, Inc.	3-Dec-19	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b) (3) (A), (b) (4), (b) (6)
L-044-18/1	Druz, Aliaksandr A.	(b)(6)	ModernaTX, Inc.	3-Dec-19	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b) (3) (A), (b) (4), (b) (6)
L-044-18/1	Georgiev, Ivelin S.	(b)(6)	ModernaTX, Inc.	3-Dec-19	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b) (3) (A), (b) (4), (b) (6)
L-044-18/1	Gorman, Jason	(b)(6)	ModernaTX, Inc.	3-Dec-19	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b) (3) (A), (b) (4), (b) (6)
L-044-18/1	Graham, Barney S.	(b)(6)	ModernaTX, Inc.	3-Dec-19	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b) (3) (A), (b) (4), (b) (6)
L-044-18/1	Joyce, Michael G.	(b)(6)	ModernaTX, Inc.	3-Dec-19	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b) (3) (A), (b) (4), (b) (6)
L-044-18/1	Kanekiyo, Masaru	(b)(6)	ModernaTX, Inc.	3-Dec-19	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b) (3) (A), (b) (4), (b) (6)
L-044-18/1	Kong, Wing-pui	(b)(6)	ModernaTX, Inc.	3-Dec-19	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b) (3) (A), (b) (4), (b) (6)
L-044-18/1	Kwong, Peter D.	(b)(6)	ModernaTX, Inc.	3-Dec-19	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b) (3) (A), (b) (4), (b) (6)
L-044-18/1	Mascola, John R.	(b)(6)	ModernaTX, Inc.	3-Dec-19	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b) (3) (A), (b) (4), (b) (6)
L-044-18/1	McLellan, Jason Scott	(b)(6)	ModernaTX, Inc.	3-Dec-19	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b) (3) (A), (b) (4), (b) (6)
L-044-18/1	OFEK, GILAD A	(b)(6)	ModernaTX, Inc.	3-Dec-19	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b) (3) (A), (b) (4), (b) (6)
L-044-18/1	Ou, Li	(b)(6)	ModernaTX, Inc.	3-Dec-19	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b) (3) (A), (b) (4), (b) (6)
L-044-18/1	Pancera, Marie L.	(b)(6)	ModernaTX, Inc.	3-Dec-19	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b) (3) (A), (b) (4), (b) (6)
L-044-18/1	Sastry, Mallika	(b)(6)	ModernaTX, Inc.	3-Dec-19	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b) (3) (A), (b) (4), (b) (6)
L-044-18/1	Soto, Cinque	(b)(6)	ModernaTX, Inc.	3-Dec-19	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b) (3) (A), (b) (4), (b) (6)
L-044-18/1	Srivatsan, Sanjay R.	(b)(6)	ModernaTX, Inc.	3-Dec-19	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b) (3) (A), (b) (4), (b) (6)
L-044-18/1	Stewart-Jones, Guillaume BE	(b)(6)	ModernaTX, Inc.	3-Dec-19	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b) (3) (A), (b) (4), (b) (6)
L-044-18/1	Thomas, Paul V.	(b)(6)	ModernaTX, Inc.	3-Dec-19	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b) (3) (A), (b) (4), (b) (6)
L-044-18/1	Xu, Kai	(b)(6)	ModernaTX, Inc.	3-Dec-19	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b) (3) (A), (b) (4), (b) (6)
L-044-18/1	YANG, YONGPING	(b)(6)	ModernaTX, Inc.	3-Dec-19	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b) (3) (A), (b) (4), (b) (6)
L-044-18/1	Zhang, Baoshan	(b)(6)	ModernaTX, Inc.	3-Dec-19	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b) (3) (A), (b) (4), (b) (6)
L-044-18/1	Zhou, Tongqing	(b)(6)	ModernaTX, Inc.	3-Dec-19	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b)(6)	(b) (3) (A), (b) (4), (b) (6)

NIH Patent Licensing Activities

NIAID
January 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
L-118-11/1	Alexander, Robert M.	(b)(4);	Transwall	1-Jan-20						(b) (3) (A), (b) (4), (b) (6)
L-118-11/1	Jenkins, John P.	(b)(6)	Transwall	1-Jan-20						
L-118-11/1	Koh, Franklin		Transwall	1-Jan-20						
L-118-11/1	O'Brien, Daniel P.		Transwall	1-Jan-20						
L-118-11/1	Quasney, Judit A.		Transwall	1-Jan-20						
L-226-14/1	Nutman, Thomas B.		Quest Diagnostic, Inc	1-Jan-20						
L-226-14/1	Nutman, Thomas B.		Quest Diagnostic, Inc	1-Jan-20						
L-273-16/0	Akin, Cem		Heptares Therapeutics	1-Jan-20						
L-273-16/0	Kirshenbaum, Arnold		Heptares Therapeutics	1-Jan-20						
L-273-16/0	Metcalfe, Dean D		Heptares Therapeutics	1-Jan-20						
L-040-13/0	Emerson, Suzanne U.		Baxter Akiengesellschaft Industr	1-Jan-20						
L-040-13/0	Nguyen, Hanh T.		Baxter Akiengesellschaft Industr	1-Jan-20						
L-040-13/0	Purcell, Robert H		Baxter Akiengesellschaft Industr	1-Jan-20						
L-040-13/0	(b) (4)		Baxter Akiengesellschaft Industr	1-Jan-20						
L-040-13/0	Shukla Bajpai, Priyanka		Baxter Akiengesellschaft Industr	1-Jan-20						
L-142-07/2	Mackett, Michael		Transgene S A.	1-Jan-20						
L-142-07/2	Moss, Bernard		Transgene S A.	1-Jan-20						
L-142-07/2	Smith, Geoffrey L		Transgene S A.	1-Jan-20						
L-047-20/0	Morse III, Herbert		Genentech, Inc.	1-Jan-20						
L-261-19/0	Coligan, John		Bristol-Myers Squibb Company	1-Jan-20						
L-261-19/0	Krzewski, Konrad		Bristol-Myers Squibb Company	1-Jan-20						
L-261-19/0	Lee, Ha Na		Bristol-Myers Squibb Company	1-Jan-20						
L-261-19/0	Tian, Lirjie		Bristol-Myers Squibb Company	1-Jan-20						
L-261-19/0	Voss, Oliver		Bristol-Myers Squibb Company	1-Jan-20						
L-135-17/2	Boyington, Jeffrey C.		Emergent Product Development	1-Jan-20						
L-135-17/2	Corbett, Kizzmekia		Emergent Product Development	1-Jan-20						
L-135-17/2	Graham, Barney S.		Emergent Product Development	1-Jan-20						
L-135-17/2	Kanekiyo, Masaru		Emergent Product Development	1-Jan-20						
L-135-17/2	Kong, Wing-pui		Emergent Product Development	1-Jan-20						
L-135-17/2	Kwong, Peter D.		Emergent Product Development	1-Jan-20						
L-135-17/2	Mascola, John R.		Emergent Product Development	1-Jan-20						
L-135-17/2	McTamney, Patrick		Emergent Product Development	1-Jan-20						
L-135-17/2	Moin, Syed M.		Emergent Product Development	1-Jan-20						
L-135-17/2	Nabel, Gary J		Emergent Product Development	1-Jan-20						
L-135-17/2	Sullivan, Nancy J		Emergent Product Development	1-Jan-20						
L-135-17/2	Wang, Lingshu		Emergent Product Development	1-Jan-20						
L-135-17/2	Wei, Chih-Jen		Emergent Product Development	1-Jan-20						
L-135-17/2	Whittle, James R R		Emergent Product Development	1-Jan-20						
L-135-17/2	Yang, Zhi-Yong		Emergent Product Development	1-Jan-20						
L-135-17/2	Yassine, Hadi M.		Emergent Product Development	1-Jan-20						

Note: L-135-17/2 split between CDC; NIAID

L-031-09/1	Britt, William J.	(b)(4);	Tocagen Inc	1-Jan-20
L-031-09/1	Chesebro, Bruce	(b)(6)	Tocagen Inc	1-Jan-20
L-031-09/1	Evans, Leonard		Tocagen Inc	1-Jan-20
L-031-09/1	Miyazawa, Masaaki		Tocagen Inc	1-Jan-20
L-031-09/1	Robertson, Michael N.		Tocagen Inc	1-Jan-20
L-031-09/1	Wehrly, Kathryn		Tocagen Inc	1-Jan-20
L-221-16/1	Birmingham, Alison		Sanofi Pasteur	1-Jan-20
L-221-16/1	Buchholz, Ursula		Sanofi Pasteur	1-Jan-20
L-221-16/1	Collins, Peter L.		Sanofi Pasteur	1-Jan-20
L-221-16/1	Graham, Barney S.		Sanofi Pasteur	1-Jan-20
L-221-16/1	Kwong, Peter D.		Sanofi Pasteur	1-Jan-20
L-221-16/1	Liang, Bo		Sanofi Pasteur	1-Jan-20
L-221-16/1	Luongo, Cindy L.		Sanofi Pasteur	1-Jan-20
L-221-16/1	McCarty, Thomas Charles		Sanofi Pasteur	1-Jan-20
L-221-16/1	McLellan, Jason Scott		Sanofi Pasteur	1-Jan-20
L-221-16/1	Munir, Shirin		Sanofi Pasteur	1-Jan-20
L-221-16/1	Murphy, Brian R.		Sanofi Pasteur	1-Jan-20
L-221-16/1	Nutt, Anne S.		Sanofi Pasteur	1-Jan-20
L-024-19/1	Akin, Cem		Kyowa Kirin Pharmaceutical Research, Inc	1-Jan-20
L-024-19/1	Kirshenbaum, Arnold		Kyowa Kirin Pharmaceutical Research, Inc	1-Jan-20
L-024-19/1	Metcalfe, Dean D		Kyowa Kirin Pharmaceutical Research, Inc	1-Jan-20
L-309-19/0	Chesebro, Bruce		Allogene Therapeutics	1-Jan-20
L-309-19/0	Wehrly, Kathryn		Allogene Therapeutics	1-Jan-20
L-090-19/0	Akin, Cem		Numerate, Inc.	1-Jan-20
L-090-19/0	Kirshenbaum, Arnold		Numerate, Inc.	1-Jan-20
L-090-19/0	Metcalfe, Dean D		Numerate, Inc.	1-Jan-20
L-016-17/1	Fink, Doran		Drugs & Diagnostics for Tropical Disease	1-Jan-20
L-016-17/1	Kubofcik, Joseph		Drugs & Diagnostics for Tropical Disease	1-Jan-20
L-016-17/1	Nutman, Thomas B.		Drugs & Diagnostics for Tropical Disease	1-Jan-20
<i>Note: L-016-17/1 split between NIAID; NIDCR</i>				
L-258-19/0	Ishizuka, Andrew S		Avidea Technologies	1-Jan-20
L-258-19/0	Seder, Robert		Avidea Technologies	1-Jan-20
L-258-19/0	Zhu, Yaling		Avidea Technologies	1-Jan-20
L-034-20/0	(b) (4)		Helocyte, Inc	1-Jan-20
L-034-20/0	Mackett, Michael		Helocyte, Inc	1-Jan-20
L-034-20/0	Moss, Bernard		Helocyte, Inc	1-Jan-20
L-034-20/0	Smith, Geoffrey L		Helocyte, Inc	1-Jan-20
L-034-20/0	(b) (4)		Helocyte, Inc	1-Jan-20
L-034-20/0	Mackett, Michael		Helocyte, Inc	1-Jan-20
L-034-20/0	Moss, Bernard		Helocyte, Inc	1-Jan-20
L-034-20/0	Smith, Geoffrey L		Helocyte, Inc	1-Jan-20
L-056-18/1	Akin, Cem		ActivX Biosciences	1-Jan-20
L-056-18/1	Kirshenbaum, Arnold		ActivX Biosciences	1-Jan-20
L-056-18/1	Metcalfe, Dean D		ActivX Biosciences	1-Jan-20

(b) (3) (A), (b) (4), (b) (6)

L-155-18/1	Baxa, Ulrich	(b)(4);	Icosavax	1-Jan-20
L-155-18/1	Boyington, Jeffrey C.	(b)(6)	Icosavax	1-Jan-20
L-155-18/1	Chen, Lei		Icosavax	1-Jan-20
L-155-18/1	Chen, Man		Icosavax	1-Jan-20
L-155-18/1	Chuang, Gwo-Yu		Icosavax	1-Jan-20
L-155-18/1	Druz, Aliaksandr A.		Icosavax	1-Jan-20
L-155-18/1	Galen, Joseph Van		Icosavax	1-Jan-20
L-155-18/1	Georgiev, Ivelin S.		Icosavax	1-Jan-20
L-155-18/1	Gorman, Jason		Icosavax	1-Jan-20
L-155-18/1	Graham, Barney S.		Icosavax	1-Jan-20
L-155-18/1	Joyce, Michael G.		Icosavax	1-Jan-20
L-155-18/1	Kanekiyo, Masaru		Icosavax	1-Jan-20
L-155-18/1	Kong, Wing-pui		Icosavax	1-Jan-20
L-155-18/1	Kwong, Peter D.		Icosavax	1-Jan-20
L-155-18/1	Mascola, John R.		Icosavax	1-Jan-20
L-155-18/1	McLellan, Jason Scott		Icosavax	1-Jan-20
L-155-18/1	OFEK, GILAD A		Icosavax	1-Jan-20
L-155-18/1	Ou, Li		Icosavax	1-Jan-20
L-155-18/1	Pancera, Marie L.		Icosavax	1-Jan-20
L-155-18/1	Rundlet, Emily		Icosavax	1-Jan-20
L-155-18/1	Sastry, Mallika		Icosavax	1-Jan-20
L-155-18/1	Soto, Cinque		Icosavax	1-Jan-20
L-155-18/1	Srivatsan, Sanjay R.		Icosavax	1-Jan-20
L-155-18/1	Stewart-Jones, Guillaume		Icosavax	1-Jan-20
L-155-18/1	Thomas, Paul V.		Icosavax	1-Jan-20
L-155-18/1	Tsybovsky, Yaroslav		Icosavax	1-Jan-20
L-155-18/1	YANG, YONGPING		Icosavax	1-Jan-20
L-155-18/1	Zhang, Baoshan		Icosavax	1-Jan-20
L-155-18/1	Zhou, Tongqing		Icosavax	1-Jan-20
L-262-18/1	Baxa, Ulrich		Spybiotech Limited	1-Jan-20
L-262-18/1	Boyington, Jeffrey C.		Spybiotech Limited	1-Jan-20
L-262-18/1	Chen, Lei		Spybiotech Limited	1-Jan-20
L-262-18/1	Chen, Man		Spybiotech Limited	1-Jan-20
L-262-18/1	Chuang, Gwo-Yu		Spybiotech Limited	1-Jan-20
L-262-18/1	Druz, Aliaksandr A.		Spybiotech Limited	1-Jan-20
L-262-18/1	Galen, Joseph Van		Spybiotech Limited	1-Jan-20
L-262-18/1	Georgiev, Ivelin S.		Spybiotech Limited	1-Jan-20
L-262-18/1	Gorman, Jason		Spybiotech Limited	1-Jan-20
L-262-18/1	Graham, Barney S.		Spybiotech Limited	1-Jan-20
L-262-18/1	Joyce, Michael G.		Spybiotech Limited	1-Jan-20
L-262-18/1	Kanekiyo, Masaru		Spybiotech Limited	1-Jan-20
L-262-18/1	Kong, Wing-pui		Spybiotech Limited	1-Jan-20
L-262-18/1	Kwong, Peter D.		Spybiotech Limited	1-Jan-20
L-262-18/1	Mascola, John R.		Spybiotech Limited	1-Jan-20
L-262-18/1	McLellan, Jason Scott		Spybiotech Limited	1-Jan-20
L-262-18/1	OFEK, GILAD A		Spybiotech Limited	1-Jan-20
L-262-18/1	Ou, Li		Spybiotech Limited	1-Jan-20
L-262-18/1	Pancera, Marie L.		Spybiotech Limited	1-Jan-20
L-262-18/1	Rundlet, Emily		Spybiotech Limited	1-Jan-20
L-262-18/1	Sastry, Mallika		Spybiotech Limited	1-Jan-20
L-262-18/1	Soto, Cinque		Spybiotech Limited	1-Jan-20
L-262-18/1	Srivatsan, Sanjay R.		Spybiotech Limited	1-Jan-20
L-262-18/1	Stewart-Jones, Guillaume		Spybiotech Limited	1-Jan-20
L-262-18/1	Thomas, Paul V.		Spybiotech Limited	1-Jan-20

(b) (3) (A), (b) (4), (b) (6)

L-262-18/1	Tsybovsky, Yaroslav	(b)(4);	Spybiotech Limited	1-Jan-20
L-262-18/1	YANG, YONGPING	(b)(6)	Spybiotech Limited	1-Jan-20
L-262-18/1	Zhang, Baoshan		Spybiotech Limited	1-Jan-20
L-262-18/1	Zhou, Tongqing		Spybiotech Limited	1-Jan-20
L-036-06/0	Blaney, Jr., Joseph E		Hawaii Biotechnology Group, Inc.	1-Jan-20
L-036-06/0	Chanock, (b) (6) Robert		Hawaii Biotechnology Group, Inc.	1-Jan-20
L-036-06/0	Murphy, Brian R.		Hawaii Biotechnology Group, Inc.	1-Jan-20
L-036-06/0	Pletnev, Alexander G		Hawaii Biotechnology Group, Inc.	1-Jan-20
L-036-06/0	Putnak, J. Robert		Hawaii Biotechnology Group, Inc.	1-Jan-20
L-036-06/0	Whitehead, Stephen S.		Hawaii Biotechnology Group, Inc.	1-Jan-20
L-069-14/0	Mchugh, Rebecca S		BioLegend	1-Jan-20
L-069-14/0	Shevach, Ethan M		BioLegend	1-Jan-20
L-069-14/0	Stephens, Geoffrey L.		BioLegend	1-Jan-20
L-071-10/0	DeVico, Angela M.		BioLegend	1-Jan-20
L-071-10/0	Korty, Patricia E.		BioLegend	1-Jan-20
L-071-10/0	Shevach, Ethan M		BioLegend	1-Jan-20
L-072-09/1	Long, Eric O.		BioLegend	1-Jan-20
L-072-09/1	Rajagopalan, Sumati		BioLegend	1-Jan-20
L-110-17/0	Shevach, Ethan M		BioLegend Inc.	1-Jan-20
L-162-08/1	Sun, Peter D		BioLegend	1-Jan-20
L-162-08/1	Zou, Zhongcheng		BioLegend	1-Jan-20
<i>Note: L-162-08/1 split between NCI; NIAID</i>				
L-246-14/1	Eisenbarth, (b) (6) George		BIOLEGEND	1-Jan-20
<i>Note: L-246-14/1 split between NHLBI; NIAID</i>				
L-011-08/2	Shevach, Ethan M		BioLegend	1-Jan-20
L-003-11/0	Germain, Ronald N.		BioLegend	1-Jan-20
L-003-11/0	Porgador, Angel		BioLegend	1-Jan-20
L-005-03/1	Ohara, Junichi		BioLegend Inc	1-Jan-20
L-005-03/1	Paul, (b) (6) William E.		BioLegend Inc	1-Jan-20
L-142-07/2	NIAID		Transgene S A.	2-Jan-20
L-154-06/0	Mackett, Michael	(b)(4);	Merial Limited	2-Jan-20
L-154-06/0	Moss, Bernard	(b)(6)	Merial Limited	2-Jan-20
L-154-06/0	Smith, Geoffrey L		Merial Limited	2-Jan-20
L-149-15/1	Blaney, Jr., Joseph E		Serum Institute of India Ltd.	2-Jan-20
L-149-15/1	Hanley, Kathryn		Serum Institute of India Ltd.	2-Jan-20
L-149-15/1	Lai, Ching-Juh		Serum Institute of India Ltd.	2-Jan-20
L-149-15/1	Murphy, Brian R.		Serum Institute of India Ltd.	2-Jan-20
L-149-15/1	Whitehead, Stephen S.		Serum Institute of India Ltd.	2-Jan-20
<i>Note: L-149-15/1 split between FDA; NIAID</i>				
L-245-19/0	Akin, Cem		Escient Pharmaceuticals	2-Jan-20
L-245-19/0	Kirshenbaum, Arnold		Escient Pharmaceuticals	2-Jan-20

L-245-19/0	Metcalf, Dean D	(b)(4); (b)(6)	Escient Pharmaceuticals	2-Jan-20
L-197-05/5	Chanock, (b) (6) Robert		Serum Institute of India	3-Jan-20
L-197-05/5	Hoshino, Yasutaka		Serum Institute of India	3-Jan-20
L-197-05/5	Kapikian, (b) (6) Albert Z		Serum Institute of India	3-Jan-20
L-094-10/0	DeVico, Angela M.		eBioscience	3-Jan-20
L-094-10/0	Korty, Patricia E.		eBioscience	3-Jan-20
L-094-10/0	Shevach, Ethan M		eBioscience	3-Jan-20
L-049-00/1	Shevach, Ethan M		eBioscience, Inc..	3-Jan-20
<i>Note: L-049-00/1 split between NCI; NIAID</i>				
L-153-00/1	Ohara, Junichi		eBioscience	3-Jan-20
L-153-00/1	Paul, (b) (6) William E.		eBioscience	3-Jan-20
L-054-06/0	Germain, Ronald N.		eBioscience	3-Jan-20
L-054-06/0	Porgador, Angel		eBioscience	3-Jan-20
L-106-06/0	Shevach, Ethan M		eBioscience	3-Jan-20
L-292-19/0	Baxa, Ulrich		Beijing Advaccine Biotechnology Co., Ltd	3-Jan-20
L-292-19/0	Boyington, Jeffrey C.		Beijing Advaccine Biotechnology Co., Ltd	3-Jan-20
L-292-19/0	Chen, Lei		Beijing Advaccine Biotechnology Co., Ltd	3-Jan-20
L-292-19/0	Chen, Man		Beijing Advaccine Biotechnology Co., Ltd	3-Jan-20
L-292-19/0	Chuang, Gwo-Yu		Beijing Advaccine Biotechnology Co., Ltd	3-Jan-20
L-292-19/0	Druz, Aliaksandr A.		Beijing Advaccine Biotechnology Co., Ltd	3-Jan-20
L-292-19/0	Galen, Joseph Van		Beijing Advaccine Biotechnology Co., Ltd	3-Jan-20
L-292-19/0	Georgiev, Ivelin S.		Beijing Advaccine Biotechnology Co., Ltd	3-Jan-20
L-292-19/0	Gorman, Jason		Beijing Advaccine Biotechnology Co., Ltd	3-Jan-20
L-292-19/0	Graham, Barney S.		Beijing Advaccine Biotechnology Co., Ltd	3-Jan-20
L-292-19/0	Joyce, Michael G.		Beijing Advaccine Biotechnology Co., Ltd	3-Jan-20
L-292-19/0	Kanekiyo, Masaru		Beijing Advaccine Biotechnology Co., Ltd	3-Jan-20
L-292-19/0	Kong, Wing-pui		Beijing Advaccine Biotechnology Co., Ltd	3-Jan-20
L-292-19/0	Kwong, Peter D.		Beijing Advaccine Biotechnology Co., Ltd	3-Jan-20
L-292-19/0	Mascola, John R.		Beijing Advaccine Biotechnology Co., Ltd	3-Jan-20
L-292-19/0	McLellan, Jason Scott		Beijing Advaccine Biotechnology Co., Ltd	3-Jan-20
L-292-19/0	OFEK, GILAD A		Beijing Advaccine Biotechnology Co., Ltd	3-Jan-20
L-292-19/0	Ou, Li		Beijing Advaccine Biotechnology Co., Ltd	3-Jan-20
L-292-19/0	Pancera, Marie L.		Beijing Advaccine Biotechnology Co., Ltd	3-Jan-20
L-292-19/0	Rundlet, Emily		Beijing Advaccine Biotechnology Co., Ltd	3-Jan-20
L-292-19/0	Sastry, Mallika		Beijing Advaccine Biotechnology Co., Ltd	3-Jan-20
L-292-19/0	Soto, Cinque		Beijing Advaccine Biotechnology Co., Ltd	3-Jan-20
L-292-19/0	Srivatsan, Sanjay R.		Beijing Advaccine Biotechnology Co., Ltd	3-Jan-20
L-292-19/0	Stewart-Jones, Guillaume		Beijing Advaccine Biotechnology Co., Ltd	3-Jan-20
L-292-19/0	Thomas, Paul V.		Beijing Advaccine Biotechnology Co., Ltd	3-Jan-20
L-292-19/0	Tsybovsky, Yaroslav		Beijing Advaccine Biotechnology Co., Ltd	3-Jan-20
L-292-19/0	YANG, YONGPING		Beijing Advaccine Biotechnology Co., Ltd	3-Jan-20
L-292-19/0	Zhang, Baoshan		Beijing Advaccine Biotechnology Co., Ltd	3-Jan-20
L-292-19/0	Zhou, Tongqing		Beijing Advaccine Biotechnology Co., Ltd	3-Jan-20
L-197-05/5	Chanock, (b) (6) Robert		Serum Institute of India	6-Jan-20
L-197-05/5	Hoshino, Yasutaka		Serum Institute of India	6-Jan-20
L-197-05/5	Kapikian, (b) (6) Albert Z		Serum Institute of India	6-Jan-20

L-079-93/2	Ohara, Junichi	(b)(4);	BD Biosciences - BD PharMingen	7-Jan-20
L-079-93/2	Paul, (b) (6) William E.	(b)(6)	BD Biosciences - BD PharMingen	7-Jan-20
L-074-91/3	Harriman, Gregory R.		Becton Dickinson & Subsidiary PharMingen	7-Jan-20
L-074-91/3	Kunimoto, Dennis Y.		Becton Dickinson & Subsidiary PharMingen	7-Jan-20
L-074-91/3	Paul (b) (6) William E.		Becton Dickinson & Subsidiary PharMingen	7-Jan-20
L-074-91/3	Strober, Warren		Becton Dickinson & Subsidiary PharMingen	7-Jan-20
L-125-12/0	Eisenbarth, (b) (6) George		BD Biosciences	7-Jan-20
<i>Note: L-125-12/0 split between NHLBI; NIAID</i>				
L-268-01/0	Collins, Peter L.		Washington University	7-Jan-20
L-217-16/0	Blaney, Jr., Joseph E		Indian Immunologicals Ltd	8-Jan-20
L-217-16/0	Hanley, Kathryn		Indian Immunologicals Ltd	8-Jan-20
L-217-16/0	Lai, Ching-Juh		Indian Immunologicals Ltd	8-Jan-20
L-217-16/0	Murphy, Brian R.		Indian Immunologicals Ltd	8-Jan-20
L-217-16/0	Whitehead, Stephen S.		Indian Immunologicals Ltd	8-Jan-20
<i>Note: L-217-16/0 split between FDA; NIAID</i>				
L-188-18/0	Cohen, Jeffrey		Indian Immunologicals Limited	8-Jan-20
L-188-18/0	Pesnicak, Lesley M		Indian Immunologicals Limited	8-Jan-20
L-120-95/3	Shevach, Ethan M		Southern Biotechnology Associates, Inc.	8-Jan-20
L-120-95/3	Shevach, Ethan M		Southern Biotechnology Associates, Inc.	8-Jan-20
L-120-95/3	Shevach, Ethan M		Southern Biotechnology Associates, Inc.	8-Jan-20
L-031-20/0	Angermann, Bastian R		Kleo Pharmaceuticals, Inc.	8-Jan-20
L-031-20/0	Meier-Schellersheim, Martin		Kleo Pharmaceuticals, Inc.	8-Jan-20
L-080-04/1	Green, Kim Y.		R-Biopharm AG	10-Jan-20
L-080-04/1	Sosnovtsev, Stanislav V		R-Biopharm AG	10-Jan-20
L-170-98/2	Conrad, John T.		R-Biopharm GmbH	10-Jan-20
L-170-98/2	Lujan, Hugo D		R-Biopharm GmbH	10-Jan-20
L-170-98/2	Mowatt, Michael		R-Biopharm GmbH	10-Jan-20
L-170-98/2	Nash, Theodore		R-Biopharm GmbH	10-Jan-20
L-155-18/1	Baxa, Ulrich		Icosavax	10-Jan-20
L-155-18/1	Boyington, Jeffrey C.		Icosavax	10-Jan-20
L-155-18/1	Chen, Lei		Icosavax	10-Jan-20
L-155-18/1	Chen, Man		Icosavax	10-Jan-20
L-155-18/1	Chuang, Gwo-Yu		Icosavax	10-Jan-20
L-155-18/1	Druz, Aliaksandr A.		Icosavax	10-Jan-20
L-155-18/1	Galen, Joseph Van		Icosavax	10-Jan-20
L-155-18/1	Georgiev, Ivelin S.		Icosavax	10-Jan-20
L-155-18/1	Gorman, Jason		Icosavax	10-Jan-20
L-155-18/1	Graham, Barney S.		Icosavax	10-Jan-20
L-155-18/1	Joyce, Michael G.		Icosavax	10-Jan-20
L-155-18/1	Kanekiyo, Masaru		Icosavax	10-Jan-20
L-155-18/1	Kong, Wing-pui		Icosavax	10-Jan-20
L-155-18/1	Kwong, Peter D.		Icosavax	10-Jan-20
L-155-18/1	Mascola, John R.		Icosavax	10-Jan-20

L-155-18/1	McLellan, Jason Scott	(b)(4);	Icosavax	10-Jan-20
L-155-18/1	OFEK, GILAD A	(b)(6)	Icosavax	10-Jan-20
L-155-18/1	Ou, Li		Icosavax	10-Jan-20
L-155-18/1	Pancera, Marie L.		Icosavax	10-Jan-20
L-155-18/1	Rundlet, Emily		Icosavax	10-Jan-20
L-155-18/1	Sastry, Mallika		Icosavax	10-Jan-20
L-155-18/1	Soto, Cinque		Icosavax	10-Jan-20
L-155-18/1	Srivatsan, Sanjay R.		Icosavax	10-Jan-20
L-155-18/1	Stewart-Jones, Guillaume		Icosavax	10-Jan-20
L-155-18/1	Thomas, Paul V.		Icosavax	10-Jan-20
L-155-18/1	Tsybovsky, Yaroslav		Icosavax	10-Jan-20
L-155-18/1	YANG, YONGPING		Icosavax	10-Jan-20
L-155-18/1	Zhang, Baoshan		Icosavax	10-Jan-20
L-155-18/1	Zhou, Tongqing		Icosavax	10-Jan-20
L-046-17/1	Blaney, Jr., Joseph E		Medigen Vaccine Biologics Corp	10-Jan-20
L-046-17/1	Hanley, Kathryn		Medigen Vaccine Biologics Corp	10-Jan-20
L-046-17/1	Lai, Ching-Juh		Medigen Vaccine Biologics Corp	10-Jan-20
L-046-17/1	Murphy, Brian R.		Medigen Vaccine Biologics Corp	10-Jan-20
L-046-17/1	Whitehead, Stephen S.		Medigen Vaccine Biologics Corp	10-Jan-20
<i>Note: L-046-17/1 split between FDA; NIAID</i>				
L-207-13/2	Cheng, Cheng		Hookipa Biotech AG	13-Jan-20
L-207-13/2	Mangalampalli, Venkata R.		Hookipa Biotech AG	13-Jan-20
L-207-13/2	Merritt, Joshua S.		Hookipa Biotech AG	13-Jan-20
L-207-13/2	Schwartz, Richard M.		Hookipa Biotech AG	13-Jan-20
L-207-13/2	Wycuff, Diane L.		Hookipa Biotech AG	13-Jan-20
L-174-19/0	Boyd, Lisa		Maze Therapeutics, Inc	13-Jan-20
L-174-19/0	Margulies, David H		Maze Therapeutics, Inc	13-Jan-20
L-174-19/0	Natarajan, Kannan		Maze Therapeutics, Inc	13-Jan-20
L-174-19/0	Tilahun, Muluaelem		Maze Therapeutics, Inc	13-Jan-20
<i>Note: L-174-19/0 split between FDA; NIAID</i>				
L-068-16/1	Cheng, Cheng		Emergent Biosolutions	15-Jan-20
L-068-16/1	Merritt, Joshua S.		Emergent Biosolutions	15-Jan-20
L-068-16/1	Schwartz, Richard M.		Emergent Biosolutions	15-Jan-20
L-190-05/2	Bennink, Jack R.		GeoVax, Inc.	15-Jan-20
L-190-05/2	Broder, Christopher		GeoVax, Inc.	15-Jan-20
L-190-05/2	Chesebro, Bruce		GeoVax, Inc.	15-Jan-20
L-190-05/2	Cox, Josephine H		GeoVax, Inc.	15-Jan-20
L-190-05/2	Doms, Robert W.		GeoVax, Inc.	15-Jan-20
L-190-05/2	Earl, Patricia L.		GeoVax, Inc.	15-Jan-20
L-190-05/2	Moss, Bernard		GeoVax, Inc.	15-Jan-20
L-190-05/2	Wehrly, Kathryn		GeoVax, Inc.	15-Jan-20
L-190-05/2	Yewdell, Jonathan W.		GeoVax, Inc.	15-Jan-20
<i>Note: L-190-05/2 split between NCI; NIAID</i>				
*L-190-05/2	Bennink, Jack R.		GeoVax, Inc.	15-Jan-20
*L-190-05/2	Broder, Christopher		GeoVax, Inc.	15-Jan-20
*L-190-05/2	Chesebro, Bruce		GeoVax, Inc.	15-Jan-20
*L-190-05/2	Cox, Josephine H		GeoVax, Inc.	15-Jan-20
*L-190-05/2	Doms, Robert W.		GeoVax, Inc.	15-Jan-20
*L-190-05/2	Earl, Patricia L.		GeoVax, Inc.	15-Jan-20

*L-190-05/2	Moss, Bernard	(b)(4);	GeoVax, Inc.	15-Jan-20
*L-190-05/2	Wehrly, Kathryn	(b)(6)	GeoVax, Inc.	15-Jan-20
*L-190-05/2	Yewdell, Jonathan W.		GeoVax, Inc.	15-Jan-20
<i>Note: L-190-05/2 split between NCI; NIAID</i>				
*L-190-05/2	Bennink, Jack R.		GeoVax, Inc.	15-Jan-20
*L-190-05/2	Broder, Christopher		GeoVax, Inc.	15-Jan-20
*L-190-05/2	Chesebro, Bruce		GeoVax, Inc.	15-Jan-20
*L-190-05/2	Cox, Josephine H		GeoVax, Inc.	15-Jan-20
*L-190-05/2	Doms, Robert W.		GeoVax, Inc.	15-Jan-20
*L-190-05/2	Earl, Patricia L.		GeoVax, Inc.	15-Jan-20
*L-190-05/2	Moss, Bernard		GeoVax, Inc.	15-Jan-20
*L-190-05/2	Wehrly, Kathryn		GeoVax, Inc.	15-Jan-20
*L-190-05/2	Yewdell, Jonathan W.		GeoVax, Inc.	15-Jan-20
<i>Note: L-190-05/2 split between NCI; NIAID</i>				
L-065-18/0	Akin, Cem		Sanofi-Aventis	16-Jan-20
L-065-18/0	Kirshenbaum, Arnold		Sanofi-Aventis	16-Jan-20
L-065-18/0	Metcalfe, Dean D		Sanofi-Aventis	16-Jan-20
L-200-05/6	Chanock, (b) (6) Robert		Wuhan Institute of Bio. Prod.	16-Jan-20
L-200-05/6	Hoshino, Yasutaka		Wuhan Institute of Bio. Prod.	16-Jan-20
L-200-05/6	Kapikian, (b) (6) Albert Z		Wuhan Institute of Bio. Prod.	16-Jan-20
L-200-05/6	NIAID		Wuhan Institute of Bio. Prod.	16-Jan-20
L-200-05/6	NIAID		Wuhan Institute of Bio. Prod.	16-Jan-20
L-200-05/5	Chanock, (b) (6) Robert		Wuhan Institute of Bio. Prod.	16-Jan-20
L-200-05/5	Hoshino, Yasutaka		Wuhan Institute of Bio. Prod.	16-Jan-20
L-200-05/5	Kapikian, (b) (6) Albert Z		Wuhan Institute of Bio. Prod.	16-Jan-20
L-070-16/1	Akahata, Wataru		PaxVax, Inc.	16-Jan-20
L-070-16/1	Nabel, Gary J		PaxVax, Inc.	16-Jan-20
L-070-16/1	Rao, Srinivas		PaxVax, Inc.	16-Jan-20
L-070-16/1	Sullivan, Nancy J		PaxVax, Inc.	16-Jan-20
L-070-16/1	Yang, Zhi-Yong		PaxVax, Inc.	16-Jan-20
<i>Note: L-070-16/1 split between CDC; NIAID</i>				
L-268-18/1	Boyington, Jeffrey		ADMA Biologics, Inc	21-Jan-20
L-268-18/1	Chen, Lei		ADMA Biologics, Inc	21-Jan-20
L-268-18/1	Chen, Man		ADMA Biologics, Inc	21-Jan-20
L-268-18/1	Chuang, Gwo-Yu		ADMA Biologics, Inc	21-Jan-20
L-268-18/1	Georgiev, Ivelin S.		ADMA Biologics, Inc	21-Jan-20
L-268-18/1	Gorman, Jason		ADMA Biologics, Inc	21-Jan-20
L-268-18/1	Graham, Barney		ADMA Biologics, Inc	21-Jan-20
L-268-18/1	Joyce, Michael G.		ADMA Biologics, Inc	21-Jan-20
L-268-18/1	Kanekiyo, Masaru		ADMA Biologics, Inc	21-Jan-20
L-268-18/1	Kwong, Peter D.		ADMA Biologics, Inc	21-Jan-20
L-268-18/1	McLellan, Jason Scott		ADMA Biologics, Inc	21-Jan-20
L-268-18/1	OFEK, GILAD A		ADMA Biologics, Inc	21-Jan-20
L-268-18/1	Pancera, Marie L.		ADMA Biologics, Inc	21-Jan-20
L-268-18/1	Sastry, Mallika		ADMA Biologics, Inc	21-Jan-20
L-268-18/1	Soto, Cinque		ADMA Biologics, Inc	21-Jan-20
L-268-18/1	Srivatsan, Sanjay R.		ADMA Biologics, Inc	21-Jan-20

L-268-18/1	Stewart-Jones, Guillaume	(b)(4);	ADMA Biologics, Inc	21-Jan-20
L-268-18/1	YANG, YONGPING	(b)(6)	ADMA Biologics, Inc	21-Jan-20
L-268-18/1	Zhang, Baoshan		ADMA Biologics, Inc	21-Jan-20
L-268-18/1	Zhou, Tongqing		ADMA Biologics, Inc	21-Jan-20
L-046-17/1	Blaney, Jr., Joseph E		Medigen Vaccine Biologics Corp	22-Jan-20
L-046-17/1	Hanley, Kathryn		Medigen Vaccine Biologics Corp	22-Jan-20
L-046-17/1	Lai, Ching-Juh		Medigen Vaccine Biologics Corp	22-Jan-20
L-046-17/1	Murphy, Brian R.		Medigen Vaccine Biologics Corp	22-Jan-20
L-046-17/1	Whitehead, Stephen S.		Medigen Vaccine Biologics Corp	22-Jan-20
<i>Note: L-046-17/1 split between FDA; NIAID</i>				
L-005-19/0	Brock, Linda G.		Medigen Vaccine Biologics Corp	22-Jan-20
L-005-19/0	Buchholz, Ursula		Medigen Vaccine Biologics Corp	22-Jan-20
L-005-19/0	Collins, Peter L.		Medigen Vaccine Biologics Corp	22-Jan-20
L-005-19/0	Munir, Shirin		Medigen Vaccine Biologics Corp	22-Jan-20
L-271-18/0	NIAID		Medigen Vaccine Biologics Corp	22-Jan-20
L-115-00/2	Cheung, Yiu Chong Gordon		List Biological Laboratories, Inc.	23-Jan-20
L-115-00/2	Gupta, Pradeep K.		List Biological Laboratories, Inc.	23-Jan-20
L-115-00/2	Hsu, Su-Cheng Dana		List Biological Laboratories, Inc.	23-Jan-20
L-115-00/2	Hu, Haijing		List Biological Laboratories, Inc.	23-Jan-20
L-115-00/2	Leppla, Stephen H.		List Biological Laboratories, Inc.	23-Jan-20
L-115-00/2	Leysath, Clinton E.		List Biological Laboratories, Inc.	23-Jan-20
L-115-00/2	Moayeri, Mahtab		List Biological Laboratories, Inc.	23-Jan-20
L-115-00/2	Pomerantsev, Andrei P		List Biological Laboratories, Inc.	23-Jan-20
<i>Note: L-115-00/2 split between NIAID; NIDCR</i>				
L-001-15/2	NIAID		Merck Sharp & Dohme, Corp.	23-Jan-20
<i>Note: L-001-15/2 split between FDA; NIAID</i>				
L-028-11/1	Akin, Cem	(b)(4);	Amgen	23-Jan-20
L-028-11/1	Kirshenbaum, Arnold	(b)(6)	Amgen	23-Jan-20
L-028-11/1	Metcalfe, Dean D		Amgen	23-Jan-20
L-275-14/0	Emerson, Suzanne U.		CSL Behring (Australia)	24-Jan-20
L-275-14/0	Nguyen, Hanh T.		CSL Behring (Australia)	24-Jan-20
L-275-14/0	Purcell, Robert H		CSL Behring (Australia)	24-Jan-20
L-275-14/0	(b) (4)		CSL Behring (Australia)	24-Jan-20
L-275-14/0	Shukla Bajpai, Priyanka		CSL Behring (Australia)	24-Jan-20
L-136-04/2	Ohara, Junichi		Santa Cruz	28-Jan-20
L-136-04/2	Paul, (b) (6) William E.		Santa Cruz	28-Jan-20
L-012-07/2	Eisenbarth, (b) (6) George		Santa Cruz Biotechnology Inc	28-Jan-20
L-012-07/2	Fauci, Anthony		Santa Cruz Biotechnology Inc	28-Jan-20
L-012-07/2	Haynes, Barton F.		Santa Cruz Biotechnology Inc	28-Jan-20
L-108-07/1	Caldwell, Harlan D		Santa Cruz Biot., Inc.	28-Jan-20
L-108-07/1	Morrison, Richard P.		Santa Cruz Biot., Inc.	28-Jan-20
L-084-02/1	Shevach, Ethan M		Miltenyi Biotec GMBH	29-Jan-20

NIH Patent Licensing Activities
NIAID
February 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
L-169-07/2	Folks, Thomas M	(b)(4);	Gilead Sciences, Inc.	1-Feb-20						(b) (3) (A), (b) (4), (b) (6)
L-169-07/2	Justement, Jesse S	(b)(6)	Gilead Sciences, Inc.	1-Feb-20						
L-169-07/2	Kinter, Audrey L		Gilead Sciences, Inc.	1-Feb-20						
L-073-18/0	Guatam, Rejeev		Gilead Sciences, Inc.	1-Feb-20						
L-073-18/0	Martin, Malcolm A		Gilead Sciences, Inc.	1-Feb-20						
L-073-18/0	Nishimura, Michael		Gilead Sciences, Inc.	1-Feb-20						
L-073-18/0	Sadjadpour, Reza		Gilead Sciences, Inc.	1-Feb-20						
L-073-18/0	Shingai, Masashi		Gilead Sciences, Inc.	1-Feb-20						
L-266-16/1	Akin, Cem		Glenmark Pharmaceuticals, S A.	1-Feb-20						
L-266-16/1	Kirshenbaum, Arnold		Glenmark Pharmaceuticals, S A.	1-Feb-20						
L-266-16/1	Metcalfe, Dean D		Glenmark Pharmaceuticals, S A.	1-Feb-20						
L-273-16/1	Akin, Cem		Heptares Therapeutics	1-Feb-20						
L-273-16/1	Kirshenbaum, Arnold		Heptares Therapeutics	1-Feb-20						
L-273-16/1	Metcalfe, Dean D		Heptares Therapeutics	1-Feb-20						
L-155-18/1	NIAID		Icosavax	4-Feb-20						
L-034-20/0	(b) (4)		Helocyte, Inc	4-Feb-20						
L-034-20/0	Mackett, Michael		Helocyte, Inc	4-Feb-20						
L-034-20/0	Moss, Bernard		Helocyte, Inc	4-Feb-20						
L-034-20/0	Smith, Geoffrey L		Helocyte, Inc	4-Feb-20						
L-115-00/2	Cheung, Yiu Chong Gordon		List Biological Laboratories, Inc.	5-Feb-20						
L-115-00/2	Gupta, Pradeep K.		List Biological Laboratories, Inc.	5-Feb-20						
L-115-00/2	Hsu, Su-Cheng Dana		List Biological Laboratories, Inc.	5-Feb-20						
L-115-00/2	Hu, Haijing		List Biological Laboratories, Inc.	5-Feb-20						
L-115-00/2	Leppla, Stephen H.		List Biological Laboratories, Inc.	5-Feb-20						
L-115-00/2	Leysath, Clinton E.		List Biological Laboratories, Inc.	5-Feb-20						
L-115-00/2	Moayeri, Mahtab		List Biological Laboratories, Inc.	5-Feb-20						
L-115-00/2	Pomerantsev, Andrei P		List Biological Laboratories, Inc.	5-Feb-20						
<i>Note: L-115-00/2 split between NIAID; NIDCR</i>										
L-170-98/2	Conrad, John T.		R-Biopharm GmbH	5-Feb-20						
L-170-98/2	Lujan, Hugo D		R-Biopharm GmbH	5-Feb-20						
L-170-98/2	Mowatt, Michael		R-Biopharm GmbH	5-Feb-20						
L-170-98/2	Nash, Theodore		R-Biopharm GmbH	5-Feb-20						
L-225-94/4	Siebenlist, Ulrich		Millipore	7-Feb-20						
L-063-18/0	Shevach, Ethan M		Millipore Sigma	7-Feb-20						
L-236-16/1	Akin, Cem		IRBM	10-Feb-20						
L-236-16/1	Kirshenbaum, Arnold		IRBM	10-Feb-20						
L-236-16/1	Metcalfe, Dean D		IRBM	10-Feb-20						

L-094-13/1	Ohta, Akio	(b)(4);	Redoxtherapies Inc	11-Feb-20
L-094-13/1	Sitkovsky, Michail V.	(b)(6)	Redoxtherapies Inc	11-Feb-20
L-203-19/0	Akin, Cem		AstraZeneca AB	11-Feb-20
L-203-19/0	Kirshenbaum, Arnold		AstraZeneca AB	11-Feb-20
L-203-19/0	Metcalfe, Dean D		AstraZeneca AB	11-Feb-20
L-149-15/1	Blaney, Jr., Joseph E		Serum Institute of India Ltd.	13-Feb-20
L-149-15/1	Hanley, Kathryn		Serum Institute of India Ltd.	13-Feb-20
L-149-15/1	Lai, Ching-Juh		Serum Institute of India Ltd.	13-Feb-20
L-149-15/1	Murphy, Brian R.		Serum Institute of India Ltd.	13-Feb-20
L-149-15/1	Whitehead, Stephen S.		Serum Institute of India Ltd.	13-Feb-20
<i>Note: L-149-15/1 split between FDA; NIAID</i>				
L-149-15/1	NIAID		Serum Institute of India Ltd.	13-Feb-20
<i>Note: L-149-15/1 split between FDA; NIAID</i>				
L-098-10/0	Germain, Ronald N.		Miltenyi Biotec GmbH	14-Feb-20
L-098-10/0	Porgador, Angel		Miltenyi Biotec GmbH	14-Feb-20
L-084-02/1	Shevach, Ethan M		Miltenyi Biotec GMBH	14-Feb-20
L-051-11/0	DeVico, Angela M.		Miltenyi Biotec GmbH	14-Feb-20
L-051-11/0	Korty, Patricia E.		Miltenyi Biotec GmbH	14-Feb-20
L-051-11/0	Shevach, Ethan M		Miltenyi Biotec GmbH	14-Feb-20
L-044-08/1	Eisenbarth (b) (6) George		Miltenyi Biotec GMBH	14-Feb-20
<i>Note: L-044-08/1 split between NHLBI; NIAID</i>				
L-089-12/0	Shevach, Ethan M		Miltenyi Biotec GMBH	14-Feb-20
L-034-15/0	Mackett, Michael		Imanis Life Sciences, LLC	14-Feb-20
L-034-15/0	Moss, Bernard		Imanis Life Sciences, LLC	14-Feb-20
L-034-15/0	Smith, Geoffrey L		Imanis Life Sciences, LLC	14-Feb-20
L-113-04/1	Jeang, (b) (6) Kuan-Teh		Cell Signaling Technology, Inc.	14-Feb-20
L-068-16/1	Cheng, Cheng		Emergent Biosolutions	18-Feb-20
L-068-16/1	Merritt, Joshua S.		Emergent Biosolutions	18-Feb-20
L-068-16/1	Schwartz, Richard M.		Emergent Biosolutions	18-Feb-20
L-070-16/1	NIAID		PaxVax, Inc.	18-Feb-20
<i>Note: L-070-16/1 split between CDC; NIAID</i>				
L-091-20/0	Abisola Abiona, Olubukola Marj	(b)(4);	Medigen Vaccine Biologics Corp	18-Feb-20
L-091-20/0	Corbett, Kizzmekia	(b)(6)	Medigen Vaccine Biologics Corp	18-Feb-20
L-091-20/0	Graham, Barney S.		Medigen Vaccine Biologics Corp	18-Feb-20
L-091-20/0	Hutchinson, Geoffrey Bain		Medigen Vaccine Biologics Corp	18-Feb-20
L-091-20/0	Joyce, Michael G.		Medigen Vaccine Biologics Corp	18-Feb-20
L-091-20/0	Kanekiyo, Masaru		Medigen Vaccine Biologics Corp	18-Feb-20
L-091-20/0	Yassine, Hadi M.		Medigen Vaccine Biologics Corp	18-Feb-20
L-065-20/0	Blaney, Jr., Joseph E		AbViro LLC	18-Feb-20
L-065-20/0	Hanley, Kathryn		AbViro LLC	18-Feb-20
L-065-20/0	Lai, Ching-Juh		AbViro LLC	18-Feb-20

L-065-20/0	Murphy, Brian R.	(b)(4):	AbViro LLC	18-Feb-20
L-065-20/0	Whitehead, Stephen S.	(b)(6)	AbViro LLC	18-Feb-20
<i>Note: L-065-20/0 split between FDA; NIAID</i>				
L-126-15/1	NIAID		GlaxoSmithKline Biologicals, S A.	19-Feb-20
<i>Note: L-126-15/1 split between CDC; NIAID</i>				
L-035-13/0	NIAID		GlaxoSmithKline	19-Feb-20
<i>Note: L-035-13/0 split between FDA; NIAID</i>				
L-144-14/1	NIAID		Novartis	19-Feb-20
L-101-19/0	Blaney, Jr., Joseph E		GlaxoSmithKline Biologicals	19-Feb-20
L-101-19/0	Hanley, Kathryn		GlaxoSmithKline Biologicals	19-Feb-20
L-101-19/0	Lai, Ching-Juh		GlaxoSmithKline Biologicals	19-Feb-20
L-101-19/0	Murphy, Brian R.		GlaxoSmithKline Biologicals	19-Feb-20
L-101-19/0	Whitehead, Stephen S.		GlaxoSmithKline Biologicals	19-Feb-20
<i>Note: L-101-19/0 split between FDA; NIAID</i>				
L-093-05/4	Chakrabarti, Bimal K		Crucell Holland BV	20-Feb-20
L-093-05/4	Cheng, Cheng		Crucell Holland BV	20-Feb-20
L-093-05/4	(b)(6) Clement K. Asiedu		Crucell Holland BV	20-Feb-20
L-093-05/4	Huang, (b)(6) Yue		Crucell Holland BV	20-Feb-20
L-093-05/4	Mackett, Michael		Crucell Holland BV	20-Feb-20
L-093-05/4	Moss, Bernard		Crucell Holland BV	20-Feb-20
L-093-05/4	Nabel, Gary J		Crucell Holland BV	20-Feb-20
L-093-05/4	Smith, Geoffrey L		Crucell Holland BV	20-Feb-20
L-093-05/4	Sullivan, Nancy J		Crucell Holland BV	20-Feb-20
L-093-05/4	Ward, Lucy A.		Crucell Holland BV	20-Feb-20
L-093-05/4	Yang, Zhi-Yong		Crucell Holland BV	20-Feb-20
<i>Note: L-093-05/4 split between CDC; NIAID</i>				
L-147-19/0	NIAID		Mapp Biopharmaceutical, Inc.	20-Feb-20
L-068-04/2	Moss, Bernard	(b)(4):	Jennerex, LLC	21-Feb-20
<i>Note: L-068-04/2 split between NCI; NIAID</i>				
L-200-19/0	Emerson, Suzanne U.		Octapharma Biopharmaceuticals GmbH	24-Feb-20
L-200-19/0	Nguyen, Hanh T.		Octapharma Biopharmaceuticals GmbH	24-Feb-20
L-200-19/0	Purcell, Robert H		Octapharma Biopharmaceuticals GmbH	24-Feb-20
L-200-19/0	(b)(4)		Octapharma Biopharmaceuticals GmbH	24-Feb-20
L-200-19/0	Shukla Bajpai, Priyanka		Octapharma Biopharmaceuticals GmbH	24-Feb-20
L-200-18/0	NIAID		Shandong Yidu Biotechnology Co., Ltd.	24-Feb-20
L-034-20/0	(b)(4)	(b)(4):	Helocyte, Inc	24-Feb-20
L-034-20/0	Mackett, Michael	(b)(6)	Helocyte, Inc	24-Feb-20
L-034-20/0	Moss, Bernard		Helocyte, Inc	24-Feb-20
L-034-20/0	Smith, Geoffrey L		Helocyte, Inc	24-Feb-20
L-341-17/0	Garboczi, David		Active Motif, Inc.	25-Feb-20
L-341-17/0	Lantz, Larry		Active Motif, Inc.	25-Feb-20
L-341-17/0	Leppla, Stephen H.		Active Motif, Inc.	25-Feb-20
L-341-17/0	Leysath, Clinton E.		Active Motif, Inc.	25-Feb-20
L-341-17/0	Phillips, Damilola D.		Active Motif, Inc.	25-Feb-20

(b) (3) (A), (b) (4), (b) (6)

L-102-07/1	Eisenbarth, (b) (6) George	(b)(4); (b)(6)	Life Technologies Corporation	25-Feb-20	(b) (3) (A), (b) (4), (b) (6)
<i>Note: L-102-07/1 split between NHLBI; NIAID</i>					
L-054-06/0	Germain, Ronald N.		eBioscience	25-Feb-20	
L-054-06/0	Porgador, Angel		eBioscience	25-Feb-20	
L-153-00/1	Ohara, Junichi		eBioscience	25-Feb-20	
L-153-00/1	Paul, (b) (6) William E.		eBioscience	25-Feb-20	
L-049-00/1	Shevach, Ethan M		eBioscience, Inc..	25-Feb-20	
<i>Note: L-049-00/1 split between NCI; NIAID</i>					
L-094-10/0	DeVico, Angela M.		eBioscience	25-Feb-20	
L-094-10/0	Korty, Patricia E.		eBioscience	25-Feb-20	
L-094-10/0	Shevach, Ethan M		eBioscience	25-Feb-20	

NIH Patent Licensing Activities
NIAID
March 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. M	Patent	Total March	License Cumulative	Inventor Awards	Net Remaining to
L-154-06/0	Mackett, Michael	(b)(4);	Merial Limited	1-Mar-20						(b) (3) (A), (b) (4), (b) (6)
L-154-06/0	Moss, Bernard	(b)(6)	Merial Limited	1-Mar-20						
L-154-06/0	Smith, Geoffrey L		Merial Limited	1-Mar-20						
L-248-15/1	Marques, Adriana		InBios International, Inc.	1-Mar-20						
<i>Note: L-248-15/1 split between NIAID; NIDCR</i>										
L-181-14/0	Fink, Doran		InBios International Inc	1-Mar-20						
L-181-14/0	Kubofcik, Joseph		InBios International Inc	1-Mar-20						
L-181-14/0	Nutman, Thomas B.		InBios International Inc	1-Mar-20						
<i>Note: L-181-14/0 split between NIAID; NIDCR</i>										
L-197-05/5	Chanock, (b) (6) Robert		Serum Institute of India	2-Mar-20						
L-197-05/5	Hoshino, Yasutaka		Serum Institute of India	2-Mar-20						
L-197-05/5	Kapikian, (b) (6) Albert Z		Serum Institute of India	2-Mar-20						
L-071-10/0	DeVico, Angela M.		BioLegend	2-Mar-20						
L-071-10/0	Korty, Patricia E.		BioLegend	2-Mar-20						
L-071-10/0	Shevach, Ethan M		BioLegend	2-Mar-20						
L-072-09/1	Long, Eric O.		BioLegend	2-Mar-20						
L-072-09/1	Rajagopalan, Sumati		BioLegend	2-Mar-20						
L-162-08/1	Sun, Peter D		BioLegend	2-Mar-20						
L-162-08/1	Zou, Zhongcheng		BioLegend	2-Mar-20						
<i>Note: L-162-08/1 split between NCI; NIAID</i>										
L-005-03/1	Ohara, Junichi		Biolegend Inc	2-Mar-20						
L-005-03/1	Paul, (b) (6) William E.		Biolegend Inc	2-Mar-20						

L-011-08/2	Shevach, Ethan M	(b)(4); (b)(6)	BioLegend	2-Mar-20
L-003-11/0	Germain, Ronald N.		Biolegend	2-Mar-20
L-003-11/0	Porgador, Angel		Biolegend	2-Mar-20
L-080-06/3	Blaney, Jr., Joseph E		Panacea Biotech Ltd.	3-Mar-20
L-080-06/3	Hanley, Kathryn		Panacea Biotech Ltd.	3-Mar-20
L-080-06/3	Lai, Ching-Juh		Panacea Biotech Ltd.	3-Mar-20
L-080-06/3	Murphy, Brian R.		Panacea Biotech Ltd.	3-Mar-20
L-080-06/3	Whitehead, Stephen S.		Panacea Biotech Ltd.	3-Mar-20
<i>Note: L-080-06/3 split between FDA; NIAID</i>				
L-226-14/1	Nutman, Thomas B.		Quest Diagnostic, Inc	4-Mar-20
L-245-94/1	Folks, Thomas M		SearCare Life Sciences	6-Mar-20
L-245-94/1	Martin, Malcolm A		SearCare Life Sciences	6-Mar-20
L-245-94/1	Powell, Douglas M		SearCare Life Sciences	6-Mar-20
<i>Note: L-245-94/1 split between NCI; NIAID</i>				
L-245-94/1	Folks, Thomas M		SearCare Life Sciences	6-Mar-20
L-245-94/1	Martin, Malcolm A		SearCare Life Sciences	6-Mar-20
L-245-94/1	Powell, Douglas M		SearCare Life Sciences	6-Mar-20
<i>Note: L-245-94/1 split between NCI; NIAID</i>				
L-119-13/0	Jeang, (b) (6) Kuan-Teh		Millipore Sigma	6-Mar-20
L-011-15/0	Garboczi, David		Millipore Sigma	6-Mar-20
L-011-15/0	Lantz, Larry		Millipore Sigma	6-Mar-20
L-011-15/0	Leppla, Stephen H.		Millipore Sigma	6-Mar-20
L-011-15/0	Leysath, Clinton E.		Millipore Sigma	6-Mar-20
L-011-15/0	Phillips, Damilola D.		Millipore Sigma	6-Mar-20
L-050-18/0	Caldwell, Harlan D		Millipore Sigma	6-Mar-20
L-225-94/4	Siebenlist, Ulrich		Milipore	6-Mar-20
L-165-15/0	Davey, Richard T.		Millipore Sigma	6-Mar-20
L-165-15/0	Nutman, Thomas B.		Millipore Sigma	6-Mar-20
L-067-15/0	Milner, Joshua		Baylor College of Medicine	10-Mar-20
L-003-20/1	Boyington, Jeffrey C.		Calder Biosciences Inc	10-Mar-20
L-003-20/1	Chen, Lei		Calder Biosciences Inc	10-Mar-20
L-003-20/1	Chen, Man		Calder Biosciences Inc	10-Mar-20
L-003-20/1	Chuang, Gwo-Yu		Calder Biosciences Inc	10-Mar-20
L-003-20/1	Georgiev, Ivelin S.		Calder Biosciences Inc	10-Mar-20
L-003-20/1	Gorman, Jason		Calder Biosciences Inc	10-Mar-20
L-003-20/1	Graham, Barney S.		Calder Biosciences Inc	10-Mar-20
L-003-20/1	Joyce, Michael G.		Calder Biosciences Inc	10-Mar-20
L-003-20/1	Kanekiyo, Masaru		Calder Biosciences Inc	10-Mar-20
L-003-20/1	Kwong, Peter D.		Calder Biosciences Inc	10-Mar-20
L-003-20/1	McLellan, Jason Scott		Calder Biosciences Inc	10-Mar-20
L-003-20/1	OFEK, GILAD A		Calder Biosciences Inc	10-Mar-20
L-003-20/1	Pancera, Marie L.		Calder Biosciences Inc	10-Mar-20
L-003-20/1	Sastry, Mallika		Calder Biosciences Inc	10-Mar-20

L-003-20/1	Soto, Cinque	(b)(4);	Calder Biosciences Inc	10-Mar-20
L-003-20/1	Srivatsan, Sanjay R.	(b)(6)	Calder Biosciences Inc	10-Mar-20
L-003-20/1	Stewart-Jones, Guillaume		Calder Biosciences Inc	10-Mar-20
L-003-20/1	YANG, YONGPING		Calder Biosciences Inc	10-Mar-20
L-003-20/1	Zhang, Baoshan		Calder Biosciences Inc	10-Mar-20
L-003-20/1	Zhou, Tongqing		Calder Biosciences Inc	10-Mar-20
L-001-98/2	Shevach, Ethan M		BD Biosciences	12-Mar-20
L-056-12/0	DeVico, Angela M.		BD Biosciences	12-Mar-20
L-056-12/0	Korty, Patricia E.		BD Biosciences	12-Mar-20
L-056-12/0	Shevach, Ethan M		BD Biosciences	12-Mar-20
L-135-17/2	NIAID		Emergent Product Development	13-Mar-20
<i>Note: L-135-17/2 split between CDC; NIAID</i>				
L-116-20/0	Abisola Abiona, Olubukola Marjorie	(b)(4);	OncoSec Medical Incorporated	13-Mar-20
L-116-20/0	Corbett, Kizzmekia	(b)(6)	OncoSec Medical Incorporated	13-Mar-20
L-116-20/0	Graham, Barney S.		OncoSec Medical Incorporated	13-Mar-20
L-116-20/0	Hutchinson, Geoffrey Bain		OncoSec Medical Incorporated	13-Mar-20
L-116-20/0	Joyce, Michael G.		OncoSec Medical Incorporated	13-Mar-20
L-116-20/0	Kanekiyo, Masaru		OncoSec Medical Incorporated	13-Mar-20
L-116-20/0	Yassine, Hadi M.		OncoSec Medical Incorporated	13-Mar-20
L-114-09/0	Blaney, Jr., Joseph E		Co for Vaccine and Bio Productin	13-Mar-20
L-114-09/0	Hanley, Kathryn		Co for Vaccine and Bio Productin	13-Mar-20
L-114-09/0	Lai, Ching-Juh		Co for Vaccine and Bio Productin	13-Mar-20
L-114-09/0	Murphy, Brian R.		Co for Vaccine and Bio Productin	13-Mar-20
L-114-09/0	Whitehead, Stephen S.		Co for Vaccine and Bio Productin	13-Mar-20
<i>Note: L-114-09/0 split between FDA; NIAID</i>				
L-078-11/0	Mackett, Michael		CEVA Biomune	13-Mar-20
L-078-11/0	Moss, Bernard		CEVA Biomune	13-Mar-20
L-078-11/0	Smith, Geoffrey L		CEVA Biomune	13-Mar-20
L-061-13/0	Chen, Zhao Chun		BioFactura, Inc.	16-Mar-20
L-061-13/0	Emerson, Suzanne U.		BioFactura, Inc.	16-Mar-20
L-061-13/0	Moss, Bernard		BioFactura, Inc.	16-Mar-20
L-061-13/0	Purcell, Robert H		BioFactura, Inc.	16-Mar-20
L-019-08/0	Schubert, Ulrich K		Institut Pasteur	16-Mar-20
L-019-08/0	Yewdell, Jonathan W.		Institut Pasteur	16-Mar-20
<i>Note: L-019-08/0 split between FDA; NCI; NIAID; NIBIB; NIDDK</i>				
*L-059-20/0	Akin, Cem	(b)(4);	Merck Sharp & Dohme Corp.	17-Mar-20
*L-059-20/0	Kirshenbaum, Arnold	(b)(6)	Merck Sharp & Dohme Corp.	17-Mar-20
*L-059-20/0	Metcalfe, Dean D		Merck Sharp & Dohme Corp.	17-Mar-20
*L-066-20/0	Akahata, Wataru		The Native Antigen Company	19-Mar-20
*L-066-20/0	Nabel, Gary J		The Native Antigen Company	19-Mar-20
*L-066-20/0	Rao, Srinivas		The Native Antigen Company	19-Mar-20
*L-096-20/0	Akin, Cem		Ardelyx, Inc.	19-Mar-20
*L-096-20/0	Kirshenbaum, Arnold		Ardelyx, Inc.	19-Mar-20
*L-096-20/0	Metcalfe, Dean D		Ardelyx, Inc.	19-Mar-20

(b) (3) (A), (b) (4), (b) (6)

*L-066-20/0	Akahata, Wataru	(b)(4);	The Native Antigen Company	20-Mar-20
*L-066-20/0	Nabel, Gary J	(b)(6)	The Native Antigen Company	20-Mar-20
*L-066-20/0	Rao, Srinivas		The Native Antigen Company	20-Mar-20
*L-066-20/0	NIAID		The Native Antigen Company	20-Mar-20
*L-101-14/0	DeVico, Angela M.	(b)(4);	EXBIO Praha	24-Mar-20
*L-101-14/0	Korty, Patricia E.	(b)(6)	EXBIO Praha	24-Mar-20
*L-101-14/0	Shevach, Ethan M		EXBIO Praha	24-Mar-20
*L-021-10/1	Long, Eric O.		EXBIO Praha	24-Mar-20
*L-021-10/1	Rajagopalan, Sumati		EXBIO Praha	24-Mar-20
*L-014-07/4	Kalinina, Olga V.		Life Technologies Corp.	26-Mar-20
*L-014-07/4	Silver, Jonathan E.		Life Technologies Corp.	26-Mar-20
*L-259-02/0	Eisenbarth, (b) (6) George		R & D Systems, Inc.	27-Mar-20
<i>Note: L-259-02/0 split between NHLBI; NIAID</i>				
L-019-20/0	Connors, Mark		ViiV Healthcare UK (No.6) Ltd	30-Mar-20
L-019-20/0	Huang, Jinghe		ViiV Healthcare UK (No.6) Ltd	30-Mar-20
L-019-20/0	Ishida, Eliise H.		ViiV Healthcare UK (No.6) Ltd	30-Mar-20
L-019-20/0	Kang, Byong Ha		ViiV Healthcare UK (No.6) Ltd	30-Mar-20
L-019-20/0	Kong, Wing-pui		ViiV Healthcare UK (No.6) Ltd	30-Mar-20
L-019-20/0	Kwong, Peter D.		ViiV Healthcare UK (No.6) Ltd	30-Mar-20
L-019-20/0	Mascola, John R.		ViiV Healthcare UK (No.6) Ltd	30-Mar-20
L-019-20/0	Shi, Wei		ViiV Healthcare UK (No.6) Ltd	30-Mar-20
L-019-20/0	Zheng, Anqi		ViiV Healthcare UK (No.6) Ltd	30-Mar-20
L-019-20/0	Zhou, Tongqing		ViiV Healthcare UK (No.6) Ltd	30-Mar-20



\$4,988,435.43	\$606,339.02	\$5,594,774.45	\$1,254,579.93	\$4,340,194.52
----------------	--------------	----------------	----------------	----------------

* denotes an adjustment to fix a problem from a previous month

NIH Patent Licensing Activities
NIAMS
October 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	----------------------	---------------------------	-------------------------	---------------------

NIH Patent Licensing Activities
NIAMS
November 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

L-066-05/1	Kinet, Jean-Pierre	(b)(4);	President and Fellows of Harvard College	29-Nov-19						
------------	--------------------	---------	--	-----------	--	--	--	--	--	--

Note: L-066-05/1 split between NIAMS; NIDCR

(b) (3) (A), (b) (4), (b) (6)

NIH Patent Licensing Activities
NIAMS
December 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
NIAMS
January 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
L-243-16/0	Rao, Mahendra S	(b)(4);	StemCell Technologies Inc.	1-Jan-20						(b) (3) (A), (b) (4), (b) (6)

Note: L-243-16/0 split between NHLBI; NIAMS

NIH Patent Licensing Activities
NIAMS
February 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
L-087-18/0	Plotz, Paul H.	(b)(4);	Actus Therapeutics	6-Feb-20						(b) (3) (A), (b) (4), (b) (6)
L-087-18/0	Raben, Nina	(b)(6)	Actus Therapeutics	6-Feb-20						
L-243-16/0	Rao, Mahendra S		StemCell Technologies Inc.	21-Feb-20						

Note: L-243-16/0 split between NHLBI; NIAMS

NIH Patent Licensing Activities
NIAMS
March 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
L-243-16/0	NIAMS		StemCell Technologies Inc.	11-Mar-20						(b) (3) (A), (b) (4), (b) (6)
*L-171-19/0	Meylan, Francoise	(b)(4);	Bio X Cell	19-Mar-20						
*L-171-19/0	Siegel, Richard	(b)(6)	Bio X Cell	19-Mar-20						
*L-171-19/0	Song, Yun-Jeong		Bio X Cell	19-Mar-20						
*L-171-19/0	Meylan, Francoise		Bio X Cell	19-Mar-20						
*L-171-19/0	Siegel, Richard		Bio X Cell	19-Mar-20						
*L-171-19/0	Song, Yun-Jeong		Bio X Cell	19-Mar-20						
					\$37,562.67	\$0.00	\$37,562.67		\$10,309.40	\$27,253.27

* denotes an adjustment to fix a problem from a previous month

NIH Patent Licensing Activities
NIBIB
October 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-002-14/0	NIBIB		Intelligent Imaging Innovations, Inc.	18-Oct-19						(b) (3) (A), (b) (4), (b) (6)
<i>Note: L-002-14/0 split between NHLBI; NIBIB</i>										
L-002-14/0	NIBIB		Intelligent Imaging Innovations, Inc.	18-Oct-19						
<i>Note: L-002-14/0 split between NHLBI; NIBIB</i>										
L-002-14/0	Parekh, Sapun	(b)(4);	Intelligent Imaging Innovations, Inc.	18-Oct-19						
L-002-14/0	Shroff, Hari	(b)(6)	Intelligent Imaging Innovations, Inc.	18-Oct-19						
L-002-14/0	York, Andrew G.		Intelligent Imaging Innovations, Inc.	18-Oct-19						
<i>Note: L-002-14/0 split between NHLBI; NIBIB</i>										
L-002-14/0	Parekh, Sapun		Intelligent Imaging Innovations, Inc.	18-Oct-19						
L-002-14/0	Shroff, Hari		Intelligent Imaging Innovations, Inc.	18-Oct-19						
L-002-14/0	York, Andrew G.		Intelligent Imaging Innovations, Inc.	18-Oct-19						
<i>Note: L-002-14/0 split between NHLBI; NIBIB</i>										

NIH Patent Licensing Activities
NIBIB
November 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
NIBIB
December 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
NIBIB
January 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
L-315-19/0	Chen, Xiaoyuan	(b)(4);	Molecular Targeting Technologies, Inc	22-Jan-20						(b) (3) (A), (b) (4), (b) (6)
L-315-19/0	Weiss, Orit Jacobson	(b)(6)	Molecular Targeting Technologies, Inc	22-Jan-20						

NIH Patent Licensing Activities
NIBIB
February 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
L-214-18/0	NIBIB		Yokogawa Electric Corporation	1-Feb-20						(b) (3) (A), (b) (4)

Note: L-214-18/0 split between NHLBI; NIBIB

NIH Patent Licensing Activities
NIBIB
March 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
L-004-19/0	NIBIB		Sinotau Pharmaceutical Group	11-Mar-20						(b) (3) (A), (b) (4), (b) (6)
L-004-19/0	Chen, Xiaoyuan	(b)(4);	Sinotau Pharmaceutical Group	13-Mar-20						
L-004-19/0	Weiss, Orit Jacobson	(b)(6)	Sinotau Pharmaceutical Group	13-Mar-20						
L-019-08/0	Phillips, Terence M		Institut Pasteur	16-Mar-20						

Note: L-019-08/0 split between FDA; NCI; NIAID; NIBIB; NIDDK

*L-214-18/0 Parekh, Sapun (b)(4); Yokogawa Electric Corporation 30-Mar-20

*L-214-18/0 Shroff, Hari (b)(6) Yokogawa Electric Corporation 30-Mar-20

*L-214-18/0 York, Andrew G. Yokogawa Electric Corporation 30-Mar-20

Note: L-214-18/0 split between NHLBI; NIBIB

\$294,991.11 \$34,141.91 \$329,133.02 \$70,889.02 \$258,244.00

* denotes an adjustment to fix a problem from a previous month

NIH Patent Licensing Activities
NICHD
October 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-177-02/0	Rouault, Tracy	(b)(4);	Loma Linda University	9-Oct-19						(b) (3) (A), (b) (4), (b) (6)

Note: L-177-02/0 split between NHLBI; NICHD

NIH Patent Licensing Activities
NICHD
November 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
L-026-13/1	Bliethe, Diana L.	(b)(4);	Preglem SA	18-Nov-19						(b) (3) (A), (b) (4), (b) (6)
L-026-13/1	Nieman, Lynnette K.	(b)(6)	Preglem SA	18-Nov-19						
L-076-08/0	Robbins, John B.		Emergent Product Development Gaithersbur	26-Nov-19						
L-076-08/0	Schneerson, Rachel		Emergent Product Development Gaithersbur	26-Nov-19						

Note: L-076-08/0 split between NICHD; NIDCR; NIDDK

L-322-17/0 Chou, Janice Y.

(b)(4); (b) CRISPR Therapeutics AG

27-Nov-19

(b) (3) (A), (b) (4), (b) (6)

NIH Patent Licensing Activities
 NICHD
 December 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
 NICHD
 January 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
L-261-14/1	Bliithe, Diana L.	(b)(4);	Laboratorie HRA Pharma Corporation	1-Jan-20						(b) (3) (A), (b) (4), (b) (6)
L-261-14/1	Nieman, Lynnette K.	(b)(6)	Laboratorie HRA Pharma Corporation	1-Jan-20						
L-313-19/0	NICHD		Circumvent Pharmaceuticals, Inc.	6-Jan-20						
L-002-09/1	Dressler, Gregory R.	(b)(4); (b)(6)	Life Tech	7-Jan-20						
L-313-19/0	Mukherjee, Anil B.		Circumvent Pharmaceuticals, Inc.	7-Jan-20						
L-313-19/0	Sarkar, Chinmoy		Circumvent Pharmaceuticals, Inc.	7-Jan-20						
L-313-19/0	Zhang, Gary Zhongjian		Circumvent Pharmaceuticals, Inc.	7-Jan-20						
L-096-17/0	Chou, Janice Y.		Dimension Therapeutics	10-Jan-20						
L-061-19/0	Chou, Janice Y.		Dimension Therapeutics	10-Jan-20						
L-172-19/0	Romero, Roberto		Genesis Theranostix Ltd.,	15-Jan-20						
L-132-04/2	Klein, David C.		Santa Cruz Biotechnology Inc	28-Jan-20						
L-132-04/2	Moffett, John R		Santa Cruz Biotechnology Inc	28-Jan-20						
L-132-04/2	Namboodiri, Aryan M		Santa Cruz Biotechnology Inc	28-Jan-20						
L-132-04/2	Roseboom, Patrick		Santa Cruz Biotechnology Inc	28-Jan-20						
L-132-04/2	Weller, Joan		Santa Cruz Biotechnology Inc	28-Jan-20						

NIH Patent Licensing Activities
 NICHD
 February 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
L-255-02/2	Huang, Freesia	(b)(4);	Millipore	7-Feb-20						(b) (3) (A), (b) (4), (b) (6)
L-255-02/2	Huang, Kuo-Ping	(b)(6)	Millipore	7-Feb-20						
L-138-93/2	Crouch, Robert J.		Stratagene	10-Feb-20						

L-002-09/1 Dressler, Gregory R. (b)(4); (b) Life Tech

25-Feb-20

(b) (3) (A), (b) (4), (b) (6)

**NIH Patent Licensing Activities
 NICHD
 March 2020**

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
L-033-97/1	Dressler, Gregory R.	(b)(4); (b)(6)	Biogen	2-Mar-20						(b) (3) (A), (b) (4), (b) (6)
L-240-02/2	Deligiannidis, Kristina M Galarn		Novus Biologicals Inc	4-Mar-20						
L-240-02/2	Klein, David C.		Novus Biologicals Inc	4-Mar-20						
L-240-02/2	(b) (4)		Novus Biologicals Inc	4-Mar-20						
L-240-02/2	Weller, Joan		Novus Biologicals Inc	4-Mar-20						
L-204-02/2	Chumakov, Ekaterina		Novus Biologicals, LLC	4-Mar-20						
L-204-02/2	McDonald, John		Novus Biologicals, LLC	4-Mar-20						
L-204-02/2	Woodgate, Roger		Novus Biologicals, LLC	4-Mar-20						
L-018-99/1	Dawid, Igor		Millipore Sigma	6-Mar-20						
L-018-99/1	Karavanov, Alex A. or Irina		Millipore Sigma	6-Mar-20						
L-075-14/0	Huang, Freesia		Millipore Sigma	6-Mar-20						
L-075-14/0	Huang, Kuo-Ping		Millipore Sigma	6-Mar-20						
L-180-14/0	Dey, Anup K		Millipore Sigma	6-Mar-20						
L-180-14/0	Ozato Dawid, Keiko		Millipore Sigma	6-Mar-20						
L-242-15/0	Buonanno, Andres		Millipore Sigma	6-Mar-20						
L-242-15/0	Karavanov, Alex A. or Irina		Millipore Sigma	6-Mar-20						
L-242-15/0	Vullhorst, Detlef		Millipore Sigma	6-Mar-20						
L-079-18/0	Buonanno, Andres		Millipore Sigma	6-Mar-20						
L-079-18/0	Vullhorst, Detlef		Millipore Sigma	6-Mar-20						
L-080-20/0	Basser, Peter J		Computerized Imaging Reference Systems,	9-Mar-20						
L-080-20/0	Horkay, Ferenc		Computerized Imaging Reference Systems,	9-Mar-20						
L-080-20/0	Pierpaoli, Carlo		Computerized Imaging Reference Systems,	9-Mar-20						
L-026-13/1	Blithe, Diana L.		Preglem SA	12-Mar-20						
L-026-13/1	Nieman, Lynnette K.		Preglem SA	12-Mar-20						
L-026-13/1	Blithe, Diana L.		Preglem SA	12-Mar-20						
L-026-13/1	Nieman, Lynnette K.		Preglem SA	12-Mar-20						
*L-215-14/0	Bridson, William E.		Quest Diagnostics, Inc.	24-Mar-20						
*L-215-14/0	Hertz, Roy		Quest Diagnostics, Inc.	24-Mar-20						
*L-215-14/0	Kingfield, Joyce G.		Quest Diagnostics, Inc.	24-Mar-20						
*L-215-14/0	Kohler, Peter O		Quest Diagnostics, Inc.	24-Mar-20						
					\$449,275.77	\$10,000.00	\$459,275.77		\$116,406.90	\$342,868.87

* denotes an adjustment to fix a problem from a previous month

NIH Patent Licensing Activities
NIDA
October 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-070-03/2	NIDA		Brainsway, Inc.	18-Sep-19						(b) (3) (A), (b) (4), (b) (6)
<i>Note: L-070-03/2 split between NIDA; NINDS</i>										
L-070-03/2	Wise, Roy A	(b)(4);	Brainsway, Inc.	7-Oct-19						
L-070-03/2	Zangen, Abraham	(b)(6)	Brainsway, Inc.	7-Oct-19						
<i>Note: L-070-03/2 split between NIDA; NINDS</i>										
L-070-03/2	Wise, Roy A	(b)(4);	Brainsway, Inc.	7-Oct-19						
L-070-03/2	Zangen, Abraham	(b)(6)	Brainsway, Inc.	7-Oct-19						
<i>Note: L-070-03/2 split between NIDA; NINDS</i>										
L-070-03/2	NIDA		Brainsway, Inc.	7-Oct-19						
<i>Note: L-070-03/2 split between NIDA; NINDS</i>										
L-070-03/2	NIDA		Brainsway, Inc.	7-Oct-19						
<i>Note: L-070-03/2 split between NIDA; NINDS</i>										
L-070-03/2	Wise, Roy A	(b)(4);	Brainsway, Inc.	7-Oct-19						
L-070-03/2	Zangen, Abraham	(b)(6)	Brainsway, Inc.	7-Oct-19						
<i>Note: L-070-03/2 split between NIDA; NINDS</i>										
L-226-17/0	NIDA		EncepHeal Therapeutics, Inc	16-Oct-19						

NIH Patent Licensing Activities
NIDA
November 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
NIDA
December 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
NIDA
January 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
L-250-18/1	NIDA		Hello Bio Ltd.	3-Jan-20						
<i>Note: L-250-18/1 split between NIDA; NINDS</i>										
L-245-17/1	Cao, Jianjing	(b)(4);	Braeburn Pharmaceuticals Inc.	6-Jan-20						
L-245-17/1	Cyriac, George C.	(b)(6)	Braeburn Pharmaceuticals Inc.	6-Jan-20						
L-245-17/1	Grundt, Peter		Braeburn Pharmaceuticals Inc.	6-Jan-20						
L-245-17/1	Newman, Amy H.		Braeburn Pharmaceuticals Inc.	6-Jan-20						
L-245-17/1	(b) (4)		Braeburn Pharmaceuticals Inc.	6-Jan-20						
L-220-17/1	Kumar, Vivek		Braeburn Pharmaceuticals Inc.	6-Jan-20						
L-220-17/1	Newman, Amy H.		Braeburn Pharmaceuticals Inc.	6-Jan-20						
L-220-17/1	Shaik, Anerbasha		Braeburn Pharmaceuticals Inc.	6-Jan-20						

NIH Patent Licensing Activities

NIDA

February 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
<i>Note: L-257-19/0 split between NIAAA; NIDA</i>										
L-220-17/1	NIDA		Braeburn Pharmaceuticals Inc.	4-Feb-20						
L-257-19/0	NIDA		Inversago Pharma Inc	7-Feb-20						
<i>Note: L-257-19/0 split between NIAAA; NIDA</i>										
L-055-20/0	Backman, Christina M	(b)(4);	Kallyope, Inc	7-Feb-20						
L-055-20/0	Tomac, Andreas C	(b)(6)	Kallyope, Inc	7-Feb-20						
L-055-20/0	Backman, Christina M		Kallyope, Inc	10-Feb-20						
L-055-20/0	Tomac, Andreas C		Kallyope, Inc	10-Feb-20						
L-055-20/0	Backman, Christina M		Kallyope, Inc	11-Feb-20						
L-055-20/0	Tomac, Andreas C		Kallyope, Inc	11-Feb-20						

NIH Patent Licensing Activities

NIDA

March 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
<i>Note: L-276-17/0 split between NIAAA; NIDA</i>										
L-162-16/3	Rice, Kenner C.	(b)(4); (b)	Inversago	6-Mar-20						

Note: L-162-16/3 split between NIAAA; NIDA

\$137,808.24	\$37,138.93	\$174,947.17	\$33,816.42	\$141,130.75
--------------	-------------	--------------	-------------	--------------

NIH Patent Licensing Activities
NIDCD
October 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-111-06/0	NIDCD		ICAD Inc	9-Oct-19						(b) (3) (A), (b) (4)

Note: L-111-06/0 split between CC; CIT; NIDCD

NIH Patent Licensing Activities
NIDCD
November 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
L-211-19/0	Canseco De Kalinec, Gilda Mabe	(b)(4);	Applied Biological Materials Inc.	26-Nov-19						(b) (3) (A), (b) (4), (b) (6)
L-211-19/0	Kalinec, Federico	(b)(6)	Applied Biological Materials Inc.	26-Nov-19						

NIH Patent Licensing Activities
NIDCD
December 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
NIDCD
January 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
L-016-20/0	Canseco De Kalinec, Gilda Mabe	(b)(4);	Regeneron Pharmaceuticals, Inc	1-Jan-20						(b) (3) (A), (b) (4), (b) (6)
L-016-20/0	Kalinec, Federico	(b)(6)	Regeneron Pharmaceuticals, Inc	1-Jan-20						
L-078-18/0	NIDCD		miRecule	10-Jan-20						
L-078-18/0	Chen, Zhong	(b)(4);	miRecule	10-Jan-20						
L-078-18/0	Cheng, Hui	(b)(6)	miRecule	10-Jan-20						
L-078-18/0	Saleh, Anthony		miRecule	10-Jan-20						
L-078-18/0	Van Waes, Carter		miRecule	10-Jan-20						

NIH Patent Licensing Activities

NIDCD
February 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
L-036-20/0	De Kalinec, Gilda Mabel Cansec	(b)(4);	Regeneron Pharmaceuticals, Inc	1-Feb-20						(b) (3) (A), (b) (4), (b) (6)
L-036-20/0	Kalinec, Federico	(b)(6)	Regeneron Pharmaceuticals, Inc	1-Feb-20						

NIH Patent Licensing Activities
NIDCD
March 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
L-179-14/0	Montcouquiol, Mireille	(b)(4); (b)(6)	Millipore Sigma	6-Mar-20						(b) (3) (A), (b) (4), (b) (6)
L-154-16/0	Griffith, Andrew J.		Millipore Sigma	6-Mar-20						
L-154-16/0	Labay, Valentia		Millipore Sigma	6-Mar-20						
L-154-16/0	Makishima, Tomoko		Millipore Sigma	6-Mar-20						
L-214-92/8	RJ Wenthold, (b)(6)		EMD Chemicals	6-Mar-20						
					\$37,629.38	\$38,539.21	\$76,168.59		\$13,601.55	\$62,567.04

NIH Patent Licensing Activities
NIDCR
October 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-072-10/0	NIDCR		Mesoblast Inc.	17-Sep-19						(b) (3) (A), (b) (4)
L-088-12/0	NIDCR		Sangamo BioSciences Inc	20-Sep-19						
<i>Note: L-088-12/0 split between NHLBI; NIDCR</i>										

NIH Patent Licensing Activities
NIDCR
November 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
L-152-17/0	Akiyama, Steven	(b)(4);	Millipore Sigma	4-Nov-19						(b) (3) (A), (b) (4), (b) (6)
L-152-17/0	Yamada, Kenneth	(b)(6)	Millipore Sigma	4-Nov-19						
L-152-17/0	Yamada, Susan Sleeper		Millipore Sigma	4-Nov-19						
L-008-10/0	Erlenbach, Isolde		Regents Univ California	5-Nov-19						
L-008-10/0	Hoon, Mark		Regents Univ California	5-Nov-19						

L-008-10/0	Ryba, Nicholas	(b)(4); (b)(6)	Regents Univ California	5-Nov-19
L-113-00/0	Adler, Jon Elliot	(b)(4); (b)(6)	University of California	5-Nov-19
L-113-00/0	Hoon, Mark		University of California	5-Nov-19
L-113-00/0	Ryba, Nicholas		University of California	5-Nov-19
L-076-08/0	Hsu, Su-Cheng Dana	(b)(4); (b)(6)	Emergent Product Development Gaithersbur	26-Nov-19
L-076-08/0	Leppla, Stephen H.		Emergent Product Development Gaithersbur	26-Nov-19
L-076-08/0	Rosovitz, Mary Jo		Emergent Product Development Gaithersbur	26-Nov-19
<i>Note: L-076-08/0 split between NICHD; NIDCR; NIDDK</i>				
L-066-05/1	Siraganian, Reuben	(b)(4);	President and Fellows of Harvard College	29-Nov-19
<i>Note: L-066-05/1 split between NIAMS; NIDCR</i>				



(b) (3) (A), (b) (4), (b) (6)

**NIH Patent Licensing Activities
NIDCR
December 2019**

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
L-088-12/0	Chiorini, John A.	(b)(4);	Sangamo BioSciences Inc	4-Dec-19						(b) (3) (A), (b) (4), (b) (6)

Note: L-088-12/0 split between NHLBI; NIDCR

**NIH Patent Licensing Activities
NIDCR
January 2020**

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
L-116-11/3	Chiorini, John A.	(b)(4); (b)(6)	uniQure B.V.	1-Jan-20						(b) (3) (A), (b) (4), (b) (6)
<i>Note: L-116-11/3 split between NHLBI; NIDCR</i>										
L-182-17/0	Kulkarni, Ashok	(b)(4); (b)(6)	Freeline Therapeutics Limited	1-Jan-20						
L-182-17/0	Ohshima, Toshio		Freeline Therapeutics Limited	1-Jan-20						
<i>Note: L-182-17/0 split between NIDCR; NINDS</i>										
L-032-11/1	NIDCR		Sorrento Therapeutics, Inc	1-Jan-20						
L-016-17/1	Burbelo, Peter D.	(b)(4); (b)(6)	Drugs & Diagnostics for Tropical Disease	1-Jan-20						
<i>Note: L-016-17/1 split between NIAID; NIDCR</i>										
L-111-17/0	Akiyama, Steven	(b)(4); (b)(6)	BD Biosciences	3-Jan-20						
L-111-17/0	Yamada, Kenneth		BD Biosciences	3-Jan-20						
L-171-08/1	Siraganian, Reuben		BD Biosciences	7-Jan-20						
L-179-19/0	Kulkarni, Ashok	(b)(4); (b)(6)	Codexis, Inc.	14-Jan-20						
L-179-19/0	Ohshima, Toshio		Codexis, Inc.	14-Jan-20						
<i>Note: L-179-19/0 split between NIDCR; NINDS</i>										
L-115-00/2	Leppla, Stephen H.		List Biological Laboratories, Inc.	23-Jan-20						

Note: L-115-00/2 split between NIAID; NIDCR

L-153-07/2	Fisher, Larry	(b)(4); (b)(6)	Santa Cruz Biotech., Inc.	28-Jan-20	(b) (3) (A), (b) (4), (b) (6)				
L-153-07/2	Fisher, Larry		Santa Cruz Biotech., Inc.	28-Jan-20					

**NIH Patent Licensing Activities
NIDCR
February 2020**

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
L-102-09/0	Siraganian, Reuben	(b)(4); (b)(6)	Bio-Rad AbD	1-Feb-20	(b) (3) (A), (b) (4), (b) (6)					
L-115-00/2	Leppla, Stephen H.		List Biological Laboratories, Inc.	5-Feb-20						
<i>Note: L-115-00/2 split between NIAID; NIDCR</i>										
L-343-01/0	Keith, Jerry M		List Biological Laboratories, Inc.	5-Feb-20						
L-343-01/0	Merkel, Todd J.		List Biological Laboratories, Inc.	5-Feb-20						
L-343-01/0	Yang, Xiaoming		List Biological Laboratories, Inc.	5-Feb-20						
L-048-03/1	Elkin, Michael		Lees Pharmaceutical (HK) LTD	11-Feb-20						
L-048-03/1	Kleinman, Hynda		Lees Pharmaceutical (HK) LTD	11-Feb-20						
L-048-03/1	Philp, Deborah		Lees Pharmaceutical (HK) LTD	11-Feb-20						
L-048-03/1	NIDCR		Lees Pharmaceutical (HK) LTD	11-Feb-20						
L-072-10/0	Gronthos, Stan		Mesoblast Inc.	11-Feb-20						
L-072-10/0	Miura, Masako		Mesoblast Inc.	11-Feb-20						
L-072-10/0	Robey, Pamela G.		Mesoblast Inc.	11-Feb-20						
L-072-10/0	Seo, Byoung-Moo		Mesoblast Inc.	11-Feb-20						
L-072-10/0	Shi, Songtao		Mesoblast Inc.	11-Feb-20						
L-027-20/0	Chiorini, John A.		Beam Therapeutics, Inc.	11-Feb-20						
L-027-20/0	Pasquale, Giovanni Di		Beam Therapeutics, Inc.	11-Feb-20						
L-116-11/3	NIDCR		uniQure B.V.	12-Feb-20						
<i>Note: L-116-11/3 split between NHLBI; NIDCR</i>										
L-078-15/0	Chiorini, John A.	(b)(4); (b)(6)	Spark Therapeutics, Inc.	26-Feb-20						
L-078-15/0	Kaludov, Nikola		Spark Therapeutics, Inc.	26-Feb-20						

**NIH Patent Licensing Activities
NIDCR
March 2020**

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
L-248-15/1	Burbelo, Peter D.	(b)(4); (b)(6)	InBios International, Inc.	1-Mar-20	(b) (3) (A), (b) (4), (b) (6)					
L-248-15/1	Iadarola, Michael J.		InBios International, Inc.	1-Mar-20						
<i>Note: L-248-15/1 split between NIAID; NIDCR</i>										

L-181-14/0	Burbelo, Peter D.	(b)(4); (b)(6)	InBios International Inc	1-Mar-20	(b) (3) (A), (b) (4), (b) (6)
<i>Note: L-181-14/0 split between NIAID; NIDCR</i>					
L-024-17/1	Fisher, Larry		KeraFAST	1-Mar-20	
L-078-15/0	Chiorini, John A.		Spark Therapeutics, Inc.	4-Mar-20	
L-078-15/0	Kaludov, Nikola		Spark Therapeutics, Inc.	4-Mar-20	
L-233-14/0	Fisher, Larry		Millipore Sigma	6-Mar-20	
L-152-17/0	Akiyama, Steven		Millipore Sigma	6-Mar-20	
L-152-17/0	Yamada, Kenneth		Millipore Sigma	6-Mar-20	
L-152-17/0	Yamada, Susan Sleeper		Millipore Sigma	6-Mar-20	

\$561,913.83	\$43,200.00	\$605,113.83	\$141,203.66	\$463,910.17
--------------	-------------	--------------	--------------	--------------

NIH Patent Licensing Activities

NIDDK

October 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-155-07/1	Daly, (b) (6) John W	(b)(4); (b)(6)	Latoxan S A.S.	16-Sep-19						(b) (3) (A), (b) (4), (b) (6)
L-149-17/0	Oral, Elif A.		Aegerion Pharmaceuticals, Inc.	24-Sep-19						
L-149-17/0	Taylor, Simeon		Aegerion Pharmaceuticals, Inc.	24-Sep-19						

NIH Patent Licensing Activities

NIDDK

November 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
L-204-99/1	Jacobson, Kenneth A	(b)(4); (b)(6)	University of Virginia Patent Found.	5-Nov-19						(b) (3) (A), (b) (4), (b) (6)
L-076-08/0	Ramirez, Delia		Emergent Product Development Gaithersbur	26-Nov-19						
L-076-08/0	Shiloach, Joseph		Emergent Product Development Gaithersbur	26-Nov-19						
<i>Note: L-076-08/0 split between NICHD; NIDCR; NIDDK</i>										
*L-120-18/0	Rehermann, Barbara	(b)(4); (b)(6)	Taconic Biosciences, Inc.	26-Nov-19						
*L-120-18/0	Rosshart, Stephan Patrick	(b)(6)	Taconic Biosciences, Inc.	26-Nov-19						

NIH Patent Licensing Activities

NIDDK

December 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
L-339-17/0	Appella, Daniel H	(b)(4):	Altra Tech Ltd	2-Dec-19						(b) (3) (A), (b) (4), (b) (6)
L-339-17/0	Englund, Ethan A.	(b)(6)	Altra Tech Ltd	2-Dec-19						
L-339-17/0	Micklitsch, Christopher		Altra Tech Ltd	2-Dec-19						
L-339-17/0	Oquare, Bereket		Altra Tech Ltd	2-Dec-19						
L-339-17/0	Wang, Deyun		Altra Tech Ltd	2-Dec-19						
L-339-17/0	Zhang, Ning		Altra Tech Ltd	2-Dec-19						
L-339-17/0	Zhao, Chao		Altra Tech Ltd	2-Dec-19						
L-129-15/2	Proia, Richard L		Genzyme Corporation	3-Dec-19						

NIH Patent Licensing Activities
NIDDK
January 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
L-283-17/0	Jacobson, Kenneth A	(b)(4):	Tocris Cookson Ltd.	1-Jan-20						(b) (3) (A), (b) (4), (b) (6)
L-283-17/0	Tosh, Dilip K.	(b)(6)	Tocris Cookson Ltd.	1-Jan-20						
L-008-20/0	Gavrilova, Oksana Fedorovna		Bio-Techne Ltd	1-Jan-20						
L-008-20/0	Jacobson, Kenneth A		Bio-Techne Ltd	1-Jan-20						
L-008-20/0	Reitman, Marc Lionel		Bio-Techne Ltd	1-Jan-20						
L-008-20/0	Tosh, Dilip K.		Bio-Techne Ltd	1-Jan-20						
L-075-17/1	NIDDK		BioIntervene Inc.	1-Jan-20						
L-145-19/0	Schechter, Alan N.	(b)(4):	Globin Solutions, Inc	1-Jan-20						
<i>Note: L-145-19/0 split between CC; NHLBI; NIDDK; NINDS</i>										
L-159-07/2	Schechter, Alan N.	(b)(4):	Hope Pharmaceuticals	7-Jan-20						
<i>Note: L-159-07/2 split between CC; NHLBI; NIDDK; NINDS</i>										
L-196-19/0	Gershengorn, Marvin	(b)(4):	Nuralis Pharmaceuticals, Inc	7-Jan-20						
L-196-19/0	Huang, Wei	(b)(6)	Nuralis Pharmaceuticals, Inc	7-Jan-20						
L-196-19/0	Neumann, Susanne		Nuralis Pharmaceuticals, Inc	7-Jan-20						
L-196-19/0	Raaka, Bruce		Nuralis Pharmaceuticals, Inc	7-Jan-20						
<i>Note: L-196-19/0 split between NCATS; NIDDK</i>										
L-143-07/2	Schechter, Alan N.		Hope Pharmaceuticals	7-Jan-20						
<i>Note: L-143-07/2 split between CC; NHLBI; NIDDK</i>										
L-132-12/2	Chandramohan, Dhruva		Metalogics Corp	9-Jan-20						
L-132-12/2	Chou, Carson C.		Metalogics Corp	9-Jan-20						
L-132-12/2	Hall, Kevin		Metalogics Corp	9-Jan-20						

NIH Patent Licensing Activities
NIDDK
February 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann.	Patent	Total February	License	Inventor Awards	Net Remaining to
					Min./Exec. Fee	Prosecution Costs	Income	Cumulative		
L-033-19/0	Goldsmith, Paul K	(b)(4);	Bio-Techne Corporation	11-Feb-20						(b) (3) (A), (b) (4), (b) (6)
L-033-19/0	Spiegel, Allen M.	(b)(6)	Bio-Techne Corporation	11-Feb-20						
L-149-17/0	Oral, Elif A.		Aegerion Pharmaceuticals, Inc.	12-Feb-20						
L-149-17/0	Taylor, Simeon		Aegerion Pharmaceuticals, Inc.	12-Feb-20						
L-047-03/0	Goldsmith, Paul K		Pierce Biotechnology	25-Feb-20						
L-047-03/0	Spiegel, Allen M.		Pierce Biotechnology	25-Feb-20						

NIH Patent Licensing Activities
NIDDK
March 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann.	Patent	Total March	License	Inventor Awards	Net Remaining to
					Min./Exec. Fee	Prosecution Costs	Income	Cumulative		
L-242-13/0	Proia, Richard L	(b)(4);	Millipore Sigma	6-Mar-20						(b) (3) (A), (b) (4), (b) (6)
		(b)(6)								
L-001-14/1	Proia, Richard L		Millipore Sigma	6-Mar-20						
L-214-14/0	Simonds, William F.		Millipore Sigma	6-Mar-20						
L-214-14/0	Zhang, Jianhua		Millipore Sigma	6-Mar-20						
L-173-15/3	Ge, Kai		Millipore Sigma	6-Mar-20						
L-173-15/3	Lee, Ji-Eun		Millipore Sigma	6-Mar-20						
L-097-20/0	Jacobson, Kenneth A		Astrocyte Pharmaceuticals, Inc	9-Mar-20						
L-075-17/1	NIDDK		BiIntervene Inc.	10-Mar-20						
L-019-08/0	Kopp, Jeffrey B	(b)(4);	Institut Pasteur	16-Mar-20						
<i>Note: L-019-08/0 split between FDA; NCI; NIAID; NIBIB; NIDDK</i>										
					\$162,199.27	\$181,553.98	\$343,753.25		\$49,102.14	\$294,651.11

* denotes an adjustment to fix a problem from a previous month

NIH Patent Licensing Activities
NIEHS
October 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann.	Patent	Total October	License	Inventor Awards	Net Remaining to
					Min./Exec. Fee	Prosecution Costs	Income	Cumulative		
L-063-93/2	Eddy, Edward	(b)(4);	ThermoFisher	17-Sep-19						(b) (3) (A), (b) (4), (b) (6)

NIH Patent Licensing Activities
NIEHS
November 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann.	Patent	Total November	License	Inventor Awards	Net Remaining to
					Min./Exec. Fee	Prosecution Costs	Income	Cumulative		

NIH Patent Licensing Activities
NIEHS
December 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann.	Patent	Total December	License	Inventor Awards	Net Remaining to
					Min./Exec. Fee	Prosecution Costs	Income	Cumulative		

NIH Patent Licensing Activities
NIEHS
January 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann.	Patent	Total January	License	Inventor Awards	Net Remaining to
					Min./Exec. Fee	Prosecution Costs	Income	Cumulative		
L-244-16/0	(b) (4)	(b)(4); (b)(6)	Sumitomo Pharmaceuticals	1-Jan-20						(b) (3) (A), (b) (4), (b) (6)
L-244-16/0	Moore, Rickie	(6)	Sumitomo Pharmaceuticals	1-Jan-20						
L-244-16/0	Negishi, Masahiko		Sumitomo Pharmaceuticals	1-Jan-20						
L-080-94/3	(b) (4)		Oxford Biomedical Research, Inc.	28-Jan-20						
L-080-94/3	Wetsel, William		Oxford Biomedical Research, Inc.	28-Jan-20						

NIH Patent Licensing Activities
NIEHS
February 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann.	Patent	Total February	License	Inventor Awards	Net Remaining to
					Min./Exec. Fee	Prosecution Costs	Income	Cumulative		
L-119-10/0	Ehrenshaft, Marilyn I	(b)(4);	StressMarq Biosci.	1-Feb-20						(b) (3) (A), (b) (4), (b) (6)
L-119-10/0	Mason, Ronald P.	(b)(6)	StressMarq Biosci.	1-Feb-20						
L-119-10/0	Summers, Fiona A.		StressMarq Biosci.	1-Feb-20						
L-134-13/1	Mishina, Yuji		Clementia Pharmaceuticals Inc	3-Feb-20						
L-134-13/1	Ray, Manas K.		Clementia Pharmaceuticals Inc	3-Feb-20						
L-134-13/1	Scott, Gregory J.		Clementia Pharmaceuticals Inc	3-Feb-20						
L-144-04/3	Ehrenshaft, Marilyn I		Cayman Chemical Company	18-Feb-20						
L-144-04/3	Mason, Ronald P.		Cayman Chemical Company	18-Feb-20						
L-042-01/3	Beckley, Amy J.		Pierce Biotechnology	25-Feb-20						
L-042-01/3	Cidlowski, John A.		Pierce Biotechnology	25-Feb-20						

NIH Patent Licensing Activities
NIEHS
March 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
L-011-18/0	Bradbury, Jennifer Alyce	(b)(4);	KeraFAST	1-Mar-20						(b) (3) (A), (b) (4), (b) (6)
L-011-18/0	Graves, Joan P.	(b)(6)	KeraFAST	1-Mar-20						
L-011-18/0	Zeldin, Darryl C		KeraFAST	1-Mar-20						
L-244-16/1	(b)		Sumitomo Pharmaceuticals	1-Mar-20						
L-244-16/1	Moore, Rickie		Sumitomo Pharmaceuticals	1-Mar-20						
L-244-16/1	Negishi, Masahiko		Sumitomo Pharmaceuticals	1-Mar-20						
L-090-12/0	Blackshear, Perry J		Millipore Corp	6-Mar-20						
L-090-12/0	Kennington, Elizabeth A.		Millipore Corp	6-Mar-20						
L-013-15/0	Cidlowski, John A.		Millipore Sigma	6-Mar-20						
L-013-15/0	Oakley, Robert		Millipore Sigma	6-Mar-20						
L-010-05/4	DiAugustine, Richard P		Millipore Sigma	6-Mar-20						
L-010-05/4	Teng, Christina T.		Millipore Sigma	6-Mar-20						
*L-063-93/2	Eddy, Edward		ThermoFisher	25-Mar-20						
					\$49,828.49	\$0.00	\$49,828.49		\$26,257.99	\$23,570.50

* denotes an adjustment to fix a problem from a previous month

NIH Patent Licensing Activities

NIMH

October 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-091-18/0	NIMH		Defender Pharmaceuticals	20-Sep-19						(b) (3) (A), (b) (4), (b) (6)
L-261-16/0	Eiden, Maribeth V.	(b)(4);	Fred Hutchinson Cancer Research Center	22-Oct-19						
L-261-16/0	Wilson, Carolyn A.	(b)(6)	Fred Hutchinson Cancer Research Center	22-Oct-19						

NIH Patent Licensing Activities

NIMH

November 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
L-018-10/0	Manji, Hussein K.	(b)(4);	Mount Sinai Med Cntr	12-Nov-19						(b) (3) (A), (b) (4), (b) (6)
L-018-10/0	Zarate, Carlos A.	(b)(6)	Mount Sinai Med Cntr	12-Nov-19						

NIH Patent Licensing Activities

NIMH

December 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
NIMH
January 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
L-050-11/2	Dold, George R.	(b)(4);	Passy-Muir	1-Jan-20						(b) (3) (A), (b) (4), (b) (6)
L-050-11/2	Morgan, Newlin T.	(b)(6)	Passy-Muir	1-Jan-20						
<i>Note: L-050-11/2 split between NIMH; NINDS</i>										
L-050-11/2	Dold, George R.		Passy-Muir	1-Jan-20						
L-050-11/2	Morgan, Newlin T.		Passy-Muir	1-Jan-20						
<i>Note: L-050-11/2 split between NIMH; NINDS</i>										
L-091-18/0	Drevets, Wayne C		Defender Pharmaceuticals	1-Jan-20						
L-091-18/0	Furey, Maura L.		Defender Pharmaceuticals	1-Jan-20						
L-064-10/1	Hu, Huaizhong		Angimmune LLC	1-Jan-20						
L-064-10/1	Liu, Yuan Yi		Angimmune LLC	1-Jan-20						
L-064-10/1	Ma, Shenglin		Angimmune LLC	1-Jan-20						
L-064-10/1	Neville, David		Angimmune LLC	1-Jan-20						
L-064-10/1	Scharff, Joshua		Angimmune LLC	1-Jan-20						
L-064-10/1	Thompson, Jerry		Angimmune LLC	1-Jan-20						
L-064-10/1	(b) (4)		Angimmune LLC	1-Jan-20						
L-064-10/1	(b) (4)		Angimmune LLC	1-Jan-20						
L-064-10/1	Woo, Jung-Hee		Angimmune LLC	1-Jan-20						
L-313-14/0	Hu, Huaizhong		Angimmune LLC	1-Jan-20						
L-313-14/0	Ma, Shenglin		Angimmune LLC	1-Jan-20						
L-313-14/0	Neville, David		Angimmune LLC	1-Jan-20						
L-313-14/0	Scharff, Joshua		Angimmune LLC	1-Jan-20						
L-313-14/0	Thompson, Jerry		Angimmune LLC	1-Jan-20						
L-313-14/0	(b) (4)		Angimmune LLC	1-Jan-20						
L-313-14/0	(b) (4)		Angimmune LLC	1-Jan-20						
L-313-14/0	Woo, Jung-Hee		Angimmune LLC	1-Jan-20						
L-018-10/0	Manji, Husseini K.		Mount Sinai Med Cntr	3-Jan-20						
L-018-10/0	Zarate, Carlos A.		Mount Sinai Med Cntr	3-Jan-20						
L-236-18/0	Ginns, Edward I.		Idorsia Pharmaceuticals	8-Jan-20						
L-236-18/0	LaMarca, Mary		Idorsia Pharmaceuticals	8-Jan-20						
L-261-16/0	Eiden, Maribeth V.		Fred Hutchinson Cancer Research Center	28-Jan-20						
L-261-16/0	Wilson, Carolyn A.		Fred Hutchinson Cancer Research Center	28-Jan-20						

NIH Patent Licensing Activities
NIMH
February 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann.	Patent	Total February	License	Inventor Awards	Net Remaining to
					Min./Exec. Fee	Prosecution Costs	Income	Cumulative Income		
L-213-94/1	Mahan, Lawrence C.	(b)(4);	Eurofins Panlabs	1-Feb-20						(b) (3) (A), (b) (4), (b) (6)
<i>Note: L-213-94/1 split between NIMH; NINDS</i>										
L-328-17/0	Cohen, Robert M.	(b)(6)	PsychoGenics Inc.	3-Feb-20						
L-328-17/0	Ye, Daniel		PsychoGenics Inc.	3-Feb-20						
L-327-02/0	Kowalak, Jeffrey A.		Shimadzu Corp.	21-Feb-20						
L-327-02/0	Markey, Sanford P.		Shimadzu Corp.	21-Feb-20						
L-327-02/0	Masuda, Junichi		Shimadzu Corp.	21-Feb-20						
L-327-02/0	Unsworth, Edward J.		Shimadzu Corp.	21-Feb-20						

NIH Patent Licensing Activities

NIMH

March 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
					\$224,196.00	\$2,648.80	\$226,844.80		\$61,136.97	\$165,707.83

NIH Patent Licensing Activities

NINDS

October 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-070-03/2	NINDS		Brainsway, Inc.	18-Sep-19						(b) (3) (A), (b) (4), (b) (6)
<i>Note: L-070-03/2 split between NIDA; NINDS</i>										
L-070-03/2	Hallett, Mark	(b)(4);	Brainsway, Inc.	7-Oct-19						
L-070-03/2	Miranda, Pedro	(b)(6)	Brainsway, Inc.	7-Oct-19						
L-070-03/2	Roth, Yiftach		Brainsway, Inc.	7-Oct-19						
<i>Note: L-070-03/2 split between NIDA; NINDS</i>										
L-070-03/2	Hallett, Mark		Brainsway, Inc.	7-Oct-19						
L-070-03/2	Miranda, Pedro		Brainsway, Inc.	7-Oct-19						
L-070-03/2	Roth, Yiftach		Brainsway, Inc.	7-Oct-19						
<i>Note: L-070-03/2 split between NIDA; NINDS</i>										
L-070-03/2	NINDS		Brainsway, Inc.	7-Oct-19						
<i>Note: L-070-03/2 split between NIDA; NINDS</i>										
L-070-03/2	NINDS		Brainsway, Inc.	7-Oct-19						
<i>Note: L-070-03/2 split between NIDA; NINDS</i>										
L-070-03/2	Hallett, Mark	(b)(4);	Brainsway, Inc.	7-Oct-19						
L-070-03/2	Miranda, Pedro	(b)(6)	Brainsway, Inc.	7-Oct-19						
L-070-03/2	Roth, Yiftach		Brainsway, Inc.	7-Oct-19						

Note: L-070-03/2 split between NIDA; NINDS

L-257-18/0 Ward, Michael Emmerson (b)(4); (b)(6) The Regents of the University of Califor 25-Oct-19 (b) (3) (A), (b) (4), (b) (6)

**NIH Patent Licensing Activities
NINDS
November 2019**

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
L-304-17/2	Youle, Richard J.	(b)(4); (b)(6)	Genentech. Inc.	1-Nov-19						(b) (3) (A), (b) (4), (b) (6)
L-083-11/0	Bielekova, Bibiana B		Abbott Biotherapeutics Corp.	27-Nov-19						
L-083-11/0	Martin, Roland		Abbott Biotherapeutics Corp.	27-Nov-19						
L-083-11/0	McFarland, Henry F.		Abbott Biotherapeutics Corp.	27-Nov-19						

Note: L-083-11/0 split between NCI; NINDS

**NIH Patent Licensing Activities
NINDS
December 2019**

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

**NIH Patent Licensing Activities
NINDS
January 2020**

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
L-050-11/2	Humbert, Ianessa A	(b)(4); (b)(6)	Passy-Muir	1-Jan-20						(b) (3) (A), (b) (4), (b) (6)
L-050-11/2	Lowell, Soren Y		Passy-Muir	1-Jan-20						
L-050-11/2	Ludlow, Christy L.		Passy-Muir	1-Jan-20						
L-050-11/2	Poletto, Christopher J.		Passy-Muir	1-Jan-20						
Note: L-050-11/2 split between NIMH; NINDS										
L-050-11/2	Humbert, Ianessa A		Passy-Muir	1-Jan-20						
L-050-11/2	Lowell, Soren Y		Passy-Muir	1-Jan-20						
L-050-11/2	Ludlow, Christy L.		Passy-Muir	1-Jan-20						
L-050-11/2	Poletto, Christopher J.		Passy-Muir	1-Jan-20						
Note: L-050-11/2 split between NIMH; NINDS										
L-182-17/0	Brady, (b) (6) Roscoe O		Freeline Therapeutics Limited	1-Jan-20						
L-182-17/0	Murray, Gary J		Freeline Therapeutics Limited	1-Jan-20						
Note: L-182-17/0 split between NIDCR; NINDS										
L-083-11/0	Bielekova, Bibiana B		Abbott Biotherapeutics Corp.	1-Jan-20						
L-083-11/0	Martin, Roland		Abbott Biotherapeutics Corp.	1-Jan-20						
L-083-11/0	McFarland, Henry F.		Abbott Biotherapeutics Corp.	1-Jan-20						
Note: L-083-11/0 split between NCI; NINDS										

L-141-06/2	Jensen, Peter N	(b)(4);	ViraCor Laboratories	1-Jan-20
L-141-06/2	Major, Eugene O	(b)(6)	ViraCor Laboratories	1-Jan-20
L-145-19/0	Oldfield, (b)(6) f Edward H.		Globin Solutions, Inc	1-Jan-20
L-145-19/0	Pluta, Ryszard M		Globin Solutions, Inc	1-Jan-20
<i>Note: L-145-19/0 split between CC; NHLBI; NIDDK; NINDS</i>				
L-125-04/1	Hou, Jean	(b)(4);	BIOLEGEND INC	1-Jan-20
L-125-04/1	Major, Eugene O	(b)(6)	BIOLEGEND INC	1-Jan-20
L-125-04/1	Messam, Conrad A		BIOLEGEND INC	1-Jan-20
L-058-13/1	Hou, Jean		BioLegend	1-Jan-20
L-058-13/1	Major, Eugene O		BioLegend	1-Jan-20
L-058-13/1	Messam, Conrad A		BioLegend	1-Jan-20
L-198-17/0	Dobersen, Michael J		BioLegend	1-Jan-20
L-198-17/0	Hammer, Jeffrey A.		BioLegend	1-Jan-20
L-198-17/0	Noronha, Antonio B		BioLegend	1-Jan-20
L-198-17/0	Quarles, Richard H.		BioLegend	1-Jan-20
L-008-08/1	Hsu, Yite		Biolegend	1-Jan-20
L-008-08/1	Youle, Richard J.		Biolegend	1-Jan-20
L-002-19/0	Lee, Myoung Hwa		Geneuro SA	3-Jan-20
L-002-19/0	Li, Wenxue		Geneuro SA	3-Jan-20
L-002-19/0	Nath, Avindra		Geneuro SA	3-Jan-20
L-002-19/0	Steiner, Joseph Perry		Geneuro SA	3-Jan-20
L-053-00/1	Hsu, Yite		eBioscience	3-Jan-20
L-053-00/1	Youle, Richard J.		eBioscience	3-Jan-20
L-144-08/1	Hou, Jean		eBioscience	3-Jan-20
L-144-08/1	Major, Eugene O		eBioscience	3-Jan-20
L-144-08/1	Messam, Conrad A		eBioscience	3-Jan-20
L-250-18/1	NINDS		Hello Bio Ltd.	3-Jan-20
<i>Note: L-250-18/1 split between NIDA; NINDS</i>				
L-084-97/4	Hsu, Yite	(b)(4);	BD Biosciences	7-Jan-20
L-084-97/4	Youle, Richard J.	(b)(6)	BD Biosciences	7-Jan-20
L-159-07/2	Oldfield, (b)(6) Edward H.		Hope Pharmaceuticals	7-Jan-20
L-159-07/2	Pluta, Ryszard M		Hope Pharmaceuticals	7-Jan-20
<i>Note: L-159-07/2 split between CC; NHLBI; NIDDK; NINDS</i>				
L-182-04/2	Hou, Jean	(b)(4);	Novus Biologicals Inc	14-Jan-20
L-182-04/2	Major, Eugene O	(b)(6)	Novus Biologicals Inc	14-Jan-20
L-182-04/2	Messam, Conrad A		Novus Biologicals Inc	14-Jan-20
L-179-19/0	Brady, (b)(6) Roscoe O		Codexis, Inc.	14-Jan-20
L-179-19/0	Murray, Gary J		Codexis, Inc.	14-Jan-20
<i>Note: L-179-19/0 split between NIDCR; NINDS</i>				
L-079-17/0	Warach, Steven J.		VuEssence, Inc.	16-Jan-20

(b) (3) (A), (b) (4), (b) (6)

Note: L-079-17/0 split between NIA; NINDS; NINR

L-130-02/1	Hsu, Yite	(b)(4);	Santa Cruz Biotechnology Inc	28-Jan-20
L-130-02/1	Youle, Richard J.	(b)(6)	Santa Cruz Biotechnology Inc	28-Jan-20
L-130-02/1	Hsu, Yite		Santa Cruz Biotechnology Inc	28-Jan-20
L-130-02/1	Youle, Richard J.		Santa Cruz Biotechnology Inc	28-Jan-20
L-031-04/1	Hou, Jean		Santa Cruz Biotechnology	28-Jan-20
L-031-04/1	Major, Eugene O		Santa Cruz Biotechnology	28-Jan-20
L-031-04/1	Messam, Conrad A		Santa Cruz Biotechnology	28-Jan-20
L-031-04/1	Hou, Jean		Santa Cruz Biotechnology	28-Jan-20
L-031-04/1	Major, Eugene O		Santa Cruz Biotechnology	28-Jan-20
L-031-04/1	Messam, Conrad A		Santa Cruz Biotechnology	28-Jan-20
L-123-04/2	Hsu, Yite		Santa Cruz Biotechnology Inc	28-Jan-20
L-123-04/2	Youle, Richard J.		Santa Cruz Biotechnology Inc	28-Jan-20
L-123-04/2	Hsu, Yite		Santa Cruz Biotechnology Inc	28-Jan-20
L-123-04/2	Youle, Richard J.		Santa Cruz Biotechnology Inc	28-Jan-20

(b) (3) (A), (b) (4), (b) (6)

NIH Patent Licensing Activities
NINDS
February 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
L-213-94/1	McVittie, Loris D.	(b)(4);	Eurofins Panlabs	1-Feb-20						(b) (3) (A), (b) (4), (b) (6)
L-213-94/1	Monsma, Jr., Frederick J.	(b)(6)	Eurofins Panlabs	1-Feb-20						
L-213-94/1	Sibley, David R.		Eurofins Panlabs	1-Feb-20						
<i>Note: L-213-94/1 split between NIMH; NINDS</i>										
L-208-01/3	Hou, Jean		Millipore Sigma	7-Feb-20						
L-208-01/3	Major, Eugene O		Millipore Sigma	7-Feb-20						
L-208-01/3	Messam, Conrad A		Millipore Sigma	7-Feb-20						
L-208-01/3	Hou, Jean		Millipore Sigma	11-Feb-20						
L-208-01/3	Major, Eugene O		Millipore Sigma	11-Feb-20						
L-208-01/3	Messam, Conrad A		Millipore Sigma	11-Feb-20						
L-012-01/1	Hsu, Yite		NeoMarkers, Inc.	11-Feb-20						
L-012-01/1	Youle, Richard J.		NeoMarkers, Inc.	11-Feb-20						
L-091-98/3	Hsu, Yite		NeoMarkers, Inc.	11-Feb-20						
L-091-98/3	Youle, Richard J.		NeoMarkers, Inc.	11-Feb-20						
L-144-08/1	Hou, Jean		eBioscience	25-Feb-20						
L-144-08/1	Major, Eugene O		eBioscience	25-Feb-20						
L-144-08/1	Messam, Conrad A		eBioscience	25-Feb-20						

NIH Patent Licensing Activities

NINDS
March 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
L-083-11/0	Bielekova, Bibiana B	(b)(4);	Abbott Biotherapeutics Corp.	1-Mar-20						(b) (3) (A), (b) (4), (b) (6)
L-083-11/0	Martin, Roland	(b)(6)	Abbott Biotherapeutics Corp.	1-Mar-20						
L-083-11/0	McFarland, Henry F.		Abbott Biotherapeutics Corp.	1-Mar-20						
<i>Note: L-083-11/0 split between NCI; NINDS</i>										
L-065-03/2	Hsu, Yite		Biolegend	2-Mar-20						
L-065-03/2	Youle, Richard J.		Biolegend	2-Mar-20						
L-058-13/1	Hou, Jean		BioLegend	2-Mar-20						
L-058-13/1	Major, Eugene O		BioLegend	2-Mar-20						
L-058-13/1	Messam, Conrad A		BioLegend	2-Mar-20						
L-125-04/1	Hou, Jean		BIOLEGEND INC	2-Mar-20						
L-125-04/1	Major, Eugene O		BIOLEGEND INC	2-Mar-20						
L-125-04/1	Messam, Conrad A		BIOLEGEND INC	2-Mar-20						
L-008-08/1	Hsu, Yite		Biolegend	2-Mar-20						
L-008-08/1	Youle, Richard J.		Biolegend	2-Mar-20						
L-182-04/2	Hou, Jean		Novus Biologicals Inc	4-Mar-20						
L-182-04/2	Major, Eugene O		Novus Biologicals Inc	4-Mar-20						
L-182-04/2	Messam, Conrad A		Novus Biologicals Inc	4-Mar-20						
L-106-02/1	Hsu, Yite		BioCare Medical, LLC	6-Mar-20						
L-106-02/1	Youle, Richard J.		BioCare Medical, LLC	6-Mar-20						
L-208-01/3	Hou, Jean		Millipore Sigma	6-Mar-20						
L-208-01/3	Major, Eugene O		Millipore Sigma	6-Mar-20						
L-208-01/3	Messam, Conrad A		Millipore Sigma	6-Mar-20						
L-309-02/2	Hou, Jean		Millipore Sigma	6-Mar-20						
L-309-02/2	Major, Eugene O		Millipore Sigma	6-Mar-20						
L-309-02/2	Messam, Conrad A		Millipore Sigma	6-Mar-20						
L-264-14/0	Gainer, Harold		Millipore Sigma	6-Mar-20						
L-091-15/0	Hsu, Yite		Millipore Sigma	6-Mar-20						
L-091-15/0	Youle, Richard J.		Millipore Sigma	6-Mar-20						
L-167-15/0	Blackstone, Craig D.		Millipore Sigma	6-Mar-20						
L-167-15/0	Zhu, Peng-Peng		Millipore Sigma	6-Mar-20						
*L-096-18/1	Wang, Chunxin		Mitokinin	27-Mar-20						
*L-096-18/1	Youle, Richard J.		Mitokinin	27-Mar-20						
					\$454,230.35	\$0.00	\$454,230.35		\$132,112.98	\$322,117.37

* denotes an adjustment to fix a problem from a previous month

NIH Patent Licensing Activities
NINR
October 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	----------------------	---------------------------	-------------------------	---------------------

NIH Patent Licensing Activities
NINR
November 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
NINR
December 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
NINR
January 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
L-079-17/0	Barr, Taura L.	(b)(4);	VuEssence, Inc.	16-Jan-20						(b) (3) (A), (b) (4), (b) (6)
L-079-17/0	(b) (4)	(b)(6)	VuEssence, Inc.	16-Jan-20						

Note: L-079-17/0 split between NIA; NINDS; NINR

NIH Patent Licensing Activities
NINR
February 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
NINR
March 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	--------------------	---------------------------	-----------------------	---------------------

(b) (3) (A), (b) (4), (b) (6)

NIH Patent Licensing Activities
 NLM
 October 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-010-18/0	Lu, Zhiyong	(b)(4);	Ping An Technology (Shenzen) Company LTD	25-Oct-19						(b) (3) (A), (b) (4), (b) (6)
L-010-18/0	Pang, Yifan	(b)(6)	Ping An Technology (Shenzen) Company LTD	25-Oct-19						

Note: L-010-18/0 split between CC; NLM

NIH Patent Licensing Activities
 NLM
 November 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
 NLM
 December 2019

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
 NLM
 January 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	----------------------	---------------------------	-------------------------	---------------------

NIH Patent Licensing Activities
 NLM
 February 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
 NLM
 March 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	--------------------	---------------------------	-----------------------	---------------------

(b) (3) (A), (b) (4), (b) (6)

National Institutes of Health

Office of Financial Management

Royalties Semiannual Report -- Payments due to Inventors by IC -- Period ending: September 2020

CC

\$5,042.73

Franaszek, Marek

(b) (3) (A), (b) (4), (b) (6)

Huang, Hui-Yang

Iordanescu, Gheorghe

Jerebko, Anna K

Jin, Jianjian

Kwak, Jin Tae

(b) (4)

Roy, David

Sabatino, Marianna V.

Stroncek, David F.

Summers, Ronald

Wood, Bradford J

Xu, Sheng

Yao, Jianhua

CDC

\$267,159.83

Aloisio, Carol H.

(b) (3) (A), (b) (4), (b) (6)

Amador, Manuel

Anderson, Larry J.

Barclay, Leslie

Barrera, Roberto

Beck, Eric T.

Berman, LaShondra

Bishop, Henry

Black, Charlotte M.

CDC

Chang, Gwong-Jen J.


Chhabra, Preeti

Cox, Nancy J.

Crill, Wayne D.

Davis, Brent S.
Devos, Joshua R.
Dietrich, EB Gabrielle
Dolan, Marc C.
Dong, Renguang
Donis, Ruben O.
Emery, Shannon L.
Fields, Patricia
Folks, Thomas M
Freeman, Charlotte
Frey, Garrett S.
Galland, Gale G.
Garcia-Lerma, J. Geraldo
Gentsch, Jon R.
Glass, Roger I.
Granade, Timothy C.
Gregoricus, Nicole
Gubler, Duane J.
Guo, Zhu
Harmon, Maurice
Heneine, Walid M.
Hierholzer, John C.
Hill, Vincent R.
Hughes, Holly R
Janssen, Robert
Jiang, Baoming
Jothikumar, Prithiviraj
Katz, Jacqueline M.
Kendal, Alan P.
Kent, Rebekah J.
King, Grant W.
Kinney, Claire Huang
Kinney, Richard M.
Klimov, Alexander I.

(b) (3) (A), (b) (4), (b)
(6)

Komar, Nicholas
Kulkarni, Pramod
Leaumont, Collette F.
Lewis, Daniel M.
Lindstrom, Stephen
Loftin, Lamorris
Mackay, Andrew J.
Maher, Kaija
 (b) (4)
Maupin, Gary O.
McDougal, Steve
McDowell, Thomas
McQuiston, John R.
Miller, Arthur L.
Moore, Deborah D.
Munoz-Jordan, Jorge
Munoz-Jordon, Jorge L
Murphy, William J.
Narayanan, Jothikumar
Otten, Ronald
Pallansch, Mark A.
Panella, Nicholas A.
Parekh, Bharat S.
Pau, Chou-Pong
Phillips, Donald
Pohl, Jan
Qi, Chaolong
Rains, Richard
Raudabaugh, William M.
Reimer, Charles B.
Robertson, Shirley
Roehrig, John T.
Saluzzo, Jean-francious
Sammons, Deborah L.

(b) (3) (A), (b) (4), (b)

(6)

Sanchez, Anthony
Santiago, Gilberto
Schmechel, Detlef
Shu, Bo
Smith, Jerome P.
Snyder, Jay L.

(b) (4)

Stephenson, Mark R.
Stevens, James
Stockdale, Carol
Sunderman, Carl B.
Switzer, William
Thibodeaux, Brett A.
Tsou, Cecelia
Vergne, Edgardo
Vinje, Jan
Wagar, Nicholas
Walls, Harriet
Wang, Yuhuan
Warren, Christopher
Wei, Xierong
Welcome, Daniel
Wells, Thomas
Wilson, Jason Ray
Winner, Bryan
Wood, Gerry O.
Yang, Chunfu (Dustin)
York, Ian Arthur
Youngpairoj, Ae Saekhou
Zheng, HaoQiang
Zhou, Zhiyong

CIT

Malley, James
Pohida, Thomas J.

(b) (3) (A), (b) (4), (b)
(6)

\$888.55
(b) (3) (A), (b) (4), (b)
(6)

Wagner, Lynne M

(b) (3) (A), (b) (4), (b) (6)

FDA

\$20,075.23

Donnelly, Raymond P.

(b) (3) (A), (b) (4), (b) (6)

Falgout, Barry

Markoff, Lewis

NCATS

\$13,726.51

Cheng, Chih-Chien (Ken)

(b) (3) (A), (b) (4), (b) (6)

Hasson, Samuel A.

Inglese, James

Jang, Sung-Wook

Marugan, Juan J.

Morris, Patrick

Patnaik, Samarjit

Southall, Noel T.

Svaren, John

Thomas, Craig J.

Zheng, Wei

NCI

\$1,375,196.03

Aaronson, Stuart A.

(b) (3) (A), (b) (4), (b) (6)

Allegra, Carmen

Austin, Faye C.

Bagni- Beyer, Rachel K.

Barry, Todd

Baskar, Sivasubramanian

Bishop, Michael R

Bonner, William M

Bonomi, Carrie A.

Borgel, Suzanne D.

(b) (4)

Boyd, Michael R.

Brechbiel, Martin W.

Bustin, Michael

Cafri, Gal

(b) (4)

Chabner, Bruce A
Chackerian, Bryce
Chang, Kai
Chang, Nancy T.
Cherukuri, Murali K
Chien, Christopher
Chowdhury, Partha S
Choyke, Peter L
Chuaqui, Rodrigo
Colcher, David
Cook, J A
Copeland, Neal
Costantino, Nina
Court, Donald
Crowl, Robert

(b) (4)

Datta, Simanti
Deniger, Drew
Devasahayam, Nallathamby
Dimitrov, Dimiter S.
Doroshov, James H.
Dougherty, Kelly
Dudley, Mark
Ellis, Hilary Moyed
Emmert-Buck, Michael R.
Esposito, Dominic
Felber, Barbara K.
Feldman, Steven A
Finch, Paul W.
Fisher, Amanda G.
Fitzgerald, Peter C.
Fry, Terry
Gao, Wei
Garmestani, Kayhan

(b) (3) (A), (b) (4),
(b) (6)

Gartner, Suzanne
Gazdar, Adi F.
Gelboin, (b) (6) Harry
Giard, Donald
Gillette, William K.
Gonzalez, Frank J
Gottesman, Michael M.
Greiner, John W.
Gritz, Linda R.
Gros, Alena
Grose, Carissa L.
Hahn, Beatrice
Hanada, Kenichi
Hand, Patricia H
Hassan, Raffit
Hathcock, Karen
Hinrichs, Christian S.
Ho, Mitchell
Hodes, Richard
Hodge, James W.
Holderfield, Matthew T.
Hollingshead, Melinda G.
Hopkins, Ralph F.
(b) (4)
Jelinek, Ivett
Jenkins Copeland, Nancy A
Jensen, Roy A.
(b) (4)
Johnson, Bruce E
Johnston, Patrick G.
Kahn, Richard A
Kantor, Judith A.
Kaye, Frederic J
Keseling, Beverly G

(b) (3) (A), (b) (4), (b) (6)

Kheif, Samir N.
Khleif, Samir N.
Kim, Heungnam
Kinders, Robert
King, Charles R.
Kozlov, Andrei P.
Kraus, (b) (6) Matthias
Krausz, Kristopher W.
Lam, Norris
LaRochelle, William
Laszlo, Gloria
Lee, Choonsik
Lee, E-Chiang
Levin, Noam
Liang, Chi-Ming
Liu, Pentao
Lo, Winifred Margaret
Lowery, Fank
Lowy, Douglas R.
Lu, Yong-Chen W.
Malekzadeh, Parisa
Marquez, Victor E
Marrero, Allison M.
Mason, Llewellyn H.
Matsui, Toshimitsu
Matsumoto, Shingo
Mazzara, Gail P.
McMahon, James
Minna, John D.
Mitchell, James
Morgan, Richard A.
Mori, Toshiyuki
Muchmore, Brian P.
Nuti, Marianna

(b) (3) (A), (b) (4), (b)
(6)

O'Brien, Thomas R
O'Keefe, Barry
Oie, Herbert K
Onda, Masanori
Ortaldo, John R.
Palena, Claudia
Palmer, Douglas
Panicali, Dennis L.
Parchment, Ralph E.
Paria, Biman
Parkhurst, Maria
Parks, Wade P
Pasetto, Anna
Pass, Harvey I.
Pastan, Ira H
Pastrana, Diana V
Pavlakis, George N
Pfister, Thomas D.
Phung, Yen T.
Pierce, Jacalyn
Pinto, Peter A
Porter-Gill, Patricia A.
Prokunina-Olsson, Ludmila
Radar, Christoph
Rader, Christoph
Reddy, E. Premkumar.
Restifo, Nicholas P.
Robbins, Keith
Robbins, Paul F
Roberts, (b) (6) Anita
Roberts, Veronica Ann
Rogakou, Efthimia P
Rosenberg, Steven A.
Rosenwald, Andreas


(b) (3) (A), (b) (4), (b) (6)

Rubin, Jeffrey S
Salazar, Elena Barzaga
Samija, Ivan
Sarngadharan, Mangalasseril
Sausville, Edward
Schiller, John T
Schlom, Jeffrey
Segal, David M.
Sharan, Shyam K
Snader, Kenneth M
Somerville, Robert P.
Soppet, Dan
Spiese, Paul J
Sporn, Michael B.
Staudt, Louis M
Stephens, Robert M.
Stevanovic, Sanja
Subramanian, Sankaran
Suschak, Jessica M
Swaminathan, Srividya
Tangrea, Michael
Topalian, Suzanne L.
Tran, Eric
Tsang, Kwong-Yok
Turkbey, Ismail B.
Ueda, Kazumitsu
Vishnuvajjala, B. Rao
Waldmann, Thomas A.
Wang, Qiong
Wang, Yan
Warfield, Paul
Warming, Soren
Wiestner, Adrian
Willingham, Mark C.

(b) (3) (A), (b) (4), (b)
(6)

Wilson, Wyndham H.
Wunderlich, John
Yang, James C
Yang, Jiahui
Yoseph, Rami
Yoshimura, Teizo
Yu, Daiguan
Yu, Zhiya
Zaremba, Sam
Zhang, Ling
Zhang, Yifan
Zhao, Chihao
Zheng, Zhili
Zhu, Zhongyu

(b) (3) (A), (b) (4), (b)
(6)




NEI

\$12,484.97

Bharti, Kapil
Chen, Yu Holly
English, Milton A
Ruchi, Fnu
Shimada-Ishill, Hiroko
Swaroop, Anand

(b) (3) (A), (b)
(4), (b) (6)



NHGRI

\$21,496.06

Chandler, Randy J.
Gahl, William A.
Goldin, Ehud M.
Huizing, Marjan
Klootwijk, Riko
Manoli, Eirini
Motabar, Omid
Sidransky, Ellen
Stubblefield, Barbara K.
Venditti, Charles P.
Westbroek, Wendy

(b) (3) (A), (b) (4),
(b) (6)



NHLBI

\$229,771.84

Amar, Marcelo A.
(b) (4)

Boehm, Manfred
Brewer, H. Bryan
Chen, Guibin
Chiorini, John A.
Combs, Christian A.
Demosky, Stephen J.
Derbyshire, John Andrew
Ding, Chuantian
Finkel, Toren
(b) (4)

Kotin, Robert M.
Larochelle, Andre
Li, Lina
McVeigh, Elliott R
Neufeld, Edward B.
Nezafat, Reza
Remaley, Alan T.
Smith, Richard H.
Stonik, John A.
Thomas, Fairwell
Urabe, Masashi

NIA

Matarin Jimenez, Maria Del Mar
Moaddel, Ruin
Singleton, Andrew B.

NIAAA

Cinar, Resat
Iyer, Malliga R.
Kunos, George I

NIAID

Abisola Abiona, Olubukola Mary
Adachi, Akio

(b) (3) (A), (b) (4),
(b) (6)

\$1,379.50

(b) (3) (A), (b)
(4), (b) (6)

\$4,991.00

(b) (3) (A), (b)
(4), (b) (6)

\$1,164,872.29

(b) (3) (A), (b) (4),
(b) (6)

Akahata, Wataru
Akin, Cem
Barry, Clifton E
Baxa, Ulrich
Beeler, Judy A.
Biacchesi, Stephanie
Blaney, Jr., Joseph E
Boyington, Jeffrey
Boyington, Jeffrey C.
Bray, Michael
Buchholz, Ursula
(b) (4)
Chakrabarti, Bimal K
Chanock, (b) (6) Robert
Chen, Lei
Chen, Man
Chen, Man
Chen, Xi
Chen, Zhao Chun
Cheng, Cheng
Cheung, Yiu Chong Gordon
Chuang, Gwo-Yu
Chuang, Gwo-Yu
Coelingh, Kathleen L.
Collins, Peter L.
Connors, Mark
Corbett, Kizzmekia
(b) (4)
Datta, Sandip Kumar
De Wit, Emmie
DeBuysscher, Blair Lynn
DeVico, Angela M.
Druz, Aliaksandr A.
Eckels, Kenneth H

(b) (3) (A), (b) (4), (b)
(6)

Emerson, Suzanne U.
(b) (6) Clement K. Asiedu
fFldmann, Heinrich Ulrich
Fink, Doran
Folks, Thomas M
Galen, Joseph Van
Garboczi, David
Georgiev, Ivelin S.
Germain, Ronald N.
Gerner, Michael Y
Gorman, Jason
Graham, Barney
Graham, Barney S.
Green, Kim Y.
Guatam, Rejeev
Gupta, Pradeep K.
Hanley, Kathryn
Harriman, Gregory R.
Hoshino, Yasutaka
Hsu, Su-Cheng Dana
Hu, Haijing
Huang, (b) (6) Yue
Huang, Jinghe
Hutchinson, Geoffrey Bain
Ishida, Elilse H.
Joyce, Michael G.
Kanekiyo, Masaru
Kang, Byong Ha
Kapikian, (b) (6) Albert Z
Kim, Yong Chan
Kirshenbaum, Arnold
Kong, Wing-pui
Korty, Patricia E.
Kubofcik, Joseph

(b) (3) (A), (b) (4),
(b) (6)

Kunimoto, Dennis Y.
Kwon, Young Do
Kwong, Peter D.
Lai, Ching-Juh
Lantz, Larry
Ledgerwood, Julie
Lee, Richard E.
Leonard, John M.
Leppla, Stephen H.
Leysath, Clinton E.
Li, Weizhe
Lobos Lazzeri, M Edgard S
Long, Eric O.
Mackett, Michael
Martin, Malcolm A
Marzi, Andrea Maria
Mascola, John R
Mascola, John R.
McLellan, Jason Scott
McTamney, Patrick
Men, Ruhe
Merritt, Joshua S.
Metcalf, Dean D
Moayeri, Mahtab
Moin, Syed M.
Moss, Bernard
Murphy, Brian R.
Myles, Ian
Nabel, Gary J
Nguyen, Hanh T.
Nishimura, Michael
Nutman, Thomas B.
OFEK, GILAD A
Ohara, Junichi

(b) (3) (A), (b) (4), (b) (6)

Ou, Li
Pancera, Marie L.
Paul, (b) (6) William E.
Phillips, Damilola D.
Pletnev, Alexander G
Pomerantsev, Andrei P
Powell, Douglas M
Prescott, Joseph
Purcell, Robert H
Rabson, Arnold B.
Rajagopalan, Sumati
Rao, Srinivas
(b) (4)
Rudicell, Rebecca S.
Rundlet, Emily
(b) (4)
Rutledge, Rosamond A.
Sadjadpour, Reza
Sastry, Mallika
Schwartz, Richard M.
(b) (4)
Shevach, Ethan M
Shi, Wei
Shingai, Masashi
Shukla Bajpai, Priyanka
Slayden, Richard A
Smith, Geoffrey L
Sosnovtsev, Stanislav V
Soto, Cinque
Srivatsan, Sanjay R.
Stewart-Jones, Guillaume
Stewart-Jones, Guillaume BE
Strober, Warren
Sullivan, Nancy J

(b) (3) (A), (b) (4),
(b) (6)

Sun, Peter D
Theodore, (b) (6) Theodore S
Thomas, Paul V.
Torian, Udana M
Tsybovsky, Yaroslav

(b) (4)

Wang, Lingshu
Ward, Lucy A.
Wei, Chih--Jen
Whitehead, Stephen S.
Whittle, James R R
Willey, Ronald L.
Wu, Xueling
Xu, Kai
YANG, YONGPING
Yang, Zhi-Yong
Yassine, Hadi M.
Zhang, Baoshan
Zhang, Yi-Ming
Zheng, Anqi
Zhou, Tongqing
Zhou, Tongqing
Zhu, Jiang
Zou, Zhongcheng

NIAMS

Plotz, Paul H.
Raben, Nina
Rao, Mahendra S
Zou, Jizhong

NIBIB

Chen, Xiaoyuan
Parekh, Sapun
Shroff, Hari
Weiss, Orit Jacobson

(b) (3) (A), (b) (4), (b) (6)

\$7,636.66

(b) (3) (A), (b) (4), (b) (6)

\$4,437.50

(b) (3) (A), (b) (4), (b) (6)

York, Andrew G.

NICHD

Bonner, Robert F

Chou, Janice Y.

Dai, Lily Zhongdong

Kubler-Kielb, Joanna

Nelson, Lawrence M.

Schneerson, Rachel

Tong, Zhi-bin

NIDA

Backman, Christina M

Rice, Kenner C.

Tomac, Andreas C

NIDCD

RJ Wenthold, (b) (6)

Selbie, W. Scott

NIDCR

Akiyama, Steven

Burbelo, Peter D.

Chiorini, John A.

Kaludov, Nikola

Keith, Jerry M

Leppla, Stephen H.

Maeda, Azusa

Merkel, Todd J.

Moayeri, Mahtab

Ono, Mitsuki

Park, Sukjoon

Pasquale, Giovanni Di

Quinn, Conrad P.

Singh, Yogendra

Siraganian, Reuben

Yamada, Kenneth

Yamada, Susan Sleeper

(b) (3) (A), (b)
(4), (b) (6)

\$6,808.10

(b) (3) (A), (b)
(4), (b) (6)

\$5,898.42

(b) (3) (A), (b) (4),
(b) (6)

\$34,372.94

(b) (3) (A), (b) (4),
(b) (6)

Yang, Xiaoming
Young, Marian F.

NIDDK

Daly, (b) (6) John W
Jacobson, Kenneth A
Oral, Elif A.
Proia, Richard L
Sauer, Brian
Taylor, Simeon

NIEHS

Ehrenshaft, Marilyn I
Mason, Ronald P.
Summers, Fiona A.

NIMH

Drevets, Wayne C
Eiden, Maribeth V.
Furey, Maura L.
Jacobowitz, David
Wilson, Carolyn A.
Winsky, Lois
Zarate, Carlos A.

NINDS

Bankiewicz, Krystof S.
Bielekova, Bibiana B
Hou, Jean
Hsu, Yite
Jin, Seok-Min
Lonser, Russell R
Major, Eugene O
Martin, Roland
McFarland, Henry F.
Messam, Conrad A
Oldfield, (b) (6) Edward H.
Sliter, Danielle Angela

(b) (3) (A), (b)
(4), (b) (6)

\$9,353.07

(b) (3) (A), (b)
(4), (b) (6)

\$865.95

(b) (3) (A), (b)
(4), (b) (6)

\$24,993.25

(b) (3) (A), (b)
(4), (b) (6)

\$10,453.21

(b) (3) (A), (b)
(4), (b) (6)

Wang, Chunxin
Warach, Steven J.
Youle, Richard J.
NINR
Barr, Taura L.

(b) (4)

(b) (3) (A), (b)
(4), (b) (6)

NIH Patent Licensing Activities

CC

April 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
L-122-17/0	Kwak, Jin Tae	(b)(4);	Koninklijke Philips N.V.	1-Apr-20						(b) (3) (A), (b) (4), (b) (6)
L-122-17/0	Summers, Ronald	(b)(6)	Koninklijke Philips N.V.	1-Apr-20						
L-122-17/0	Wood, Bradford J		Koninklijke Philips N.V.	1-Apr-20						
L-122-17/0	Xu, Sheng		Koninklijke Philips N.V.	1-Apr-20						
<i>Note: L-122-17/0 split between CC; NCI</i>										
L-159-07/2	CC		Hope Pharmaceuticals	7-Apr-20						
<i>Note: L-159-07/2 split between CC; NHLBI; NIDDK; NINDS</i>										
L-107-15/1	Jin, Jianjian	(b)(4);	lovance Biotherapeutics Inc	28-Apr-20						
L-107-15/1	Sabatino, Marianna V.	(b)(6)	lovance Biotherapeutics Inc	28-Apr-20						
L-107-15/1	Stroncek, David F.		lovance Biotherapeutics Inc	28-Apr-20						
<i>Note: L-107-15/1 split between CC; NCI</i>										

NIH Patent Licensing Activities

CC

May 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
L-107-15/1	CC		lovance Biotherapeutics Inc	8-May-20						(b) (3) (A), (b) (4)
<i>Note: L-107-15/1 split between CC; NCI</i>										

NIH Patent Licensing Activities

CC

June 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
L-122-17/0	CC		Koninklijke Philips N.V.	9-Jun-20						(b) (3) (A), (b) (4)
<i>Note: L-122-17/0 split between CC; NCI</i>										

NIH Patent Licensing Activities

CC

July 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
L-111-06/0	Franaszek, Marek	(b)(4);	ICAD Inc	20-Jul-20						(b) (3) (A), (b) (4), (b) (6)
L-111-06/0	Huang, Hui-Yang	(b)(6)	ICAD Inc	20-Jul-20						

L-111-06/0	Iordanescu, Gheorghe	(b)(4);	ICAD Inc	20-Jul-20	
L-111-06/0	Jerebko, Anna K	(b)(6)	ICAD Inc	20-Jul-20	
L-111-06/0	(b) (4)		ICAD Inc	20-Jul-20	
L-111-06/0	Roy, David		ICAD Inc	20-Jul-20	
L-111-06/0	Summers, Ronald		ICAD Inc	20-Jul-20	
L-111-06/0	Yao, Jianhua		ICAD Inc	20-Jul-20	

Note: L-111-06/0 split between CC; CIT; NIDCD

(b) (3) (A), (b) (4), (b) (6)

NIH Patent Licensing Activities

CC

August 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
L-160-18/0	CC		Advanced Imaging Projects, LLC (AIP)	18-Aug-20						(b) (3) (A), (b) (4)

Note: L-160-18/0 split between CC; NCI

NIH Patent Licensing Activities

CC

September 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
					\$16,836.87	\$5,838.00	\$22,674.87		\$5,042.73	\$17,632.14

NIH Patent Licensing Activities

CIT

April 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
L-008-15/1	Pohida, Thomas J.	(b)(4);	xMD Diagnostics, LLC	1-Apr-20						(b) (3) (A), (b) (4), (b) (6)

Note: L-008-15/1 split between CIT; NCI; NICHD

NIH Patent Licensing Activities

CIT

May 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC

NIH Patent Licensing Activities

CIT

June 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
L-232-14/1	CIT		NanoString Technologies, Inc.	16-Jun-20						(b) (3) (A), (b) (4)
<i>Note: L-232-14/1 split between CIT; NCI</i>										
L-008-15/1	CIT		xMD Diagnostics, LLC	18-Jun-20						
<i>Note: L-008-15/1 split between CIT; NCI; NICHD</i>										

NIH Patent Licensing Activities
CIT
July 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
L-111-06/0	Malley, James	(b)(4);	ICAD Inc	20-Jul-20						(b) (3) (A), (b) (4), (b) (6)
L-111-06/0	Wagner, Lynne M	(b)(6)	ICAD Inc	20-Jul-20						
<i>Note: L-111-06/0 split between CC; CIT; NIDCD</i>										

NIH Patent Licensing Activities
CIT
August 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
NIH Patent Licensing Activities CIT September 2020										
					\$2,296.98	\$0.00	\$2,296.98		\$888 55	\$1,408.43

NIH Patent Licensing Activities
NCATS
April 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
L-076-18/0	Inglese, James	(b)(4);	Lead Discovery Center	1-Apr-20						(b) (3) (A), (b) (4), (b) (6)
L-076-18/0	Jang, Sung-Wook	(b)(6)	Lead Discovery Center	1-Apr-20						
L-076-18/0	Svaren, John		Lead Discovery Center	1-Apr-20						
L-080-15/0	Cheng, Chih-Chien (Ken)		Promega Corporation	28-Apr-20						

L-080-15/0 Hasson, Samuel A. (b)(4); Promega Corporation 28-Apr-20
 L-080-15/0 Inglese, James (b)(6) Promega Corporation 28-Apr-20

(b) (3) (A), (b) (4), (b) (6)

NIH Patent Licensing Activities
 NCATS
 May 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
L-169-16/2	NCATS		TeamedOn International, LLC	7-May-20						(b) (3) (A), (b) (4), (b) (6)
L-016-16/0	Marugan, Juan J.	(b)(4); (b)(6)	The General Hospital Corporation	19-May-20						
*L-016-16/0	Marugan, Juan J.		The General Hospital Corporation	26-May-20						

NIH Patent Licensing Activities
 NCATS
 June 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
L-025-17/1	Morris, Patrick	(b)(4);	Tocris Bioscience	9-Jun-20						(b) (3) (A), (b) (4), (b) (6)
L-025-17/1	Thomas, Craig J.	(b)(6)	Tocris Bioscience	9-Jun-20						
<i>Note: L-025-17/1 split between NCATS; NIA; NIMH</i>										
L-169-16/2	NCATS		TeamedOn International, LLC	27-Jun-20						

NIH Patent Licensing Activities
 NCATS
 July 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-------------------	---------------------------	----------------------	---------------------

NIH Patent Licensing Activities
 NCATS
 August 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
L-055-15/1	Marugan, Juan J.	(b)(4);	Lysosomal Therapeutics, Inc.	4-Aug-20						(b) (3) (A), (b) (4), (b) (6)
L-055-15/1	Patnaik, Samarjit	(b)(6)	Lysosomal Therapeutics, Inc.	4-Aug-20						
L-055-15/1	Southall, Noel T.		Lysosomal Therapeutics, Inc.	4-Aug-20						
L-055-15/1	Zheng, Wei		Lysosomal Therapeutics, Inc.	4-Aug-20						

Note: L-055-15/1 split between NCATS; NHGRI

NIH Patent Licensing Activities
NCATS
September 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
L-032-12/0	NCATS		Agios Pharmaceuticals Inc	2-Sep-20						(b) (3) (A), (b) (4)
<i>Note: L-032-12/0 split between NCATS; NHGRI</i>										
L-219-20/0	NCATS		FUJIFILM Cellular Dynamics, Inc.	11-Sep-20						
L-219-20/0	NCATS		FUJIFILM Cellular Dynamics, Inc.	11-Sep-20						
					\$67,074.01	\$79,707.56	\$146,781.57		\$13,726.51	\$132,055.06

* denotes an adjustment to fix a problem from a previous month

NIH Patent Licensing Activities
NCI
April 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
L-319-14/0	Gottesman, Michael M.	(b)(4);	WuXi AppTech, Co., Ltd.	1-Apr-20						(b) (3) (A), (b) (4), (b) (6)
L-319-14/0	Pastan, Ira H	(b)(6)	WuXi AppTech, Co., Ltd.	1-Apr-20						
L-319-14/0	Ueda, Kazumitsu		WuXi AppTech, Co., Ltd.	1-Apr-20						
L-122-17/0	Choyke, Peter L		Koninklijke Philips N.V.	1-Apr-20						
L-122-17/0	Pinto, Peter A		Koninklijke Philips N.V.	1-Apr-20						
L-122-17/0	Turkbey, Ismail B.		Koninklijke Philips N.V.	1-Apr-20						
<i>Note: L-122-17/0 split between CC; NCI</i>										
L-261-18/0	Bonomi, Carrie A.		CureVac AG	1-Apr-20						
L-261-18/0	Borgel, Suzanne D.		CureVac AG	1-Apr-20						
L-261-18/0	Dougherty, Kelly		CureVac AG	1-Apr-20						
L-261-18/0	Hollingshead, Melinda G.		CureVac AG	1-Apr-20						
L-017-89/0	Aaronson, Stuart A.		Bayer AG	1-Apr-20						
L-017-89/0	King, Charles R.		Bayer AG	1-Apr-20						
L-017-89/0	Kraus, (b) (6) Matthias		Bayer AG	1-Apr-20						
L-277-19/0	Bagni- Beyer, Rachel K.		Ribometrix Inc	1-Apr-20						
L-277-19/0	(b) (4)		Ribometrix Inc	1-Apr-20						
L-277-19/0	Holderfield, Matthew T.		Ribometrix Inc	1-Apr-20						
L-277-19/0	Soppet, Dan		Ribometrix Inc	1-Apr-20						
L-277-19/0	Bagni- Beyer, Rachel K.		Ribometrix Inc	1-Apr-20						
L-277-19/0	(b) (4)		Ribometrix Inc	1-Apr-20						

L-277-19/0	Holderfield, Matthew T.	(b)(4);	Ribometrix Inc	1-Apr-20
L-277-19/0	Soppet, Dan	(b)(6)	Ribometrix Inc	1-Apr-20
L-008-15/1	Chuaqui, Rodrigo		xMD Diagnostics, LLC	1-Apr-20
L-008-15/1	Emmert-Buck, Michael R.		xMD Diagnostics, LLC	1-Apr-20
L-008-15/1	Tangrea, Michael		xMD Diagnostics, LLC	1-Apr-20
<i>Note: L-008-15/1 split between CIT; NCI; NICHD</i>				
L-108-20/0	Chien, Christopher	(b)(4);	ElevateBio	1-Apr-20
L-108-20/0	Fry, Terry	(b)(6)	ElevateBio	1-Apr-20
L-187-95/2	Yoshimura, Teizo		BD BIOSCIENCES	2-Apr-20
L-249-18/2	NCI		Morphiex Biotherapeutics	3-Apr-20
L-072-20/0	Ho, Mitchell	(b)(4);	Janssen Pharmaceutica, N.V.	3-Apr-20
L-072-20/0	Kim, Heungnam	(b)(6)	Janssen Pharmaceutica, N.V.	3-Apr-20
L-072-20/0	Pastan, Ira H		Janssen Pharmaceutica, N.V.	3-Apr-20
L-080-93/3	Hathcock, Karen		BD Biosciences - BD PharMingen, Inc.	6-Apr-20
L-080-93/3	Hodes, Richard		BD Biosciences - BD PharMingen, Inc.	6-Apr-20
L-080-93/3	Laszlo, Gloria		BD Biosciences - BD PharMingen, Inc.	6-Apr-20
L-179-16/1	Gazdar, Adi F.		Janssen Research Foundation	6-Apr-20
L-179-16/1	Johnson, Bruce E		Janssen Research Foundation	6-Apr-20
L-179-16/1	Kaye, Frederic J		Janssen Research Foundation	6-Apr-20
L-179-16/1	Khleif, Samir N.		Janssen Research Foundation	6-Apr-20
L-179-16/1	Minna, John D.		Janssen Research Foundation	6-Apr-20
L-179-16/1	Oie, Herbert K		Janssen Research Foundation	6-Apr-20
L-179-16/1	Pass, Harvey I.		Janssen Research Foundation	6-Apr-20
L-259-16/4	NCI		Kite Pharma	6-Apr-20
L-099-20/0	Rosenberg, Steven A.	(b)(4);	Kite Pharma	6-Apr-20
		(b)(6)		
L-083-20/0	Gottesman, Michael M.		Q2 Solutions BioSciences LLC	6-Apr-20
L-083-20/0	Pastan, Ira H		Q2 Solutions BioSciences LLC	6-Apr-20
L-083-20/0	Ueda, Kazumitsu		Q2 Solutions BioSciences LLC	6-Apr-20
L-083-20/0	Gottesman, Michael M.		Q2 Solutions BioSciences LLC	6-Apr-20
L-083-20/0	Pastan, Ira H		Q2 Solutions BioSciences LLC	6-Apr-20
L-083-20/0	Ueda, Kazumitsu		Q2 Solutions BioSciences LLC	6-Apr-20
L-100-08/0	Pastan, Ira H		Duke University	7-Apr-20
L-083-20/0	Gottesman, Michael M.		Q2 Solutions BioSciences LLC	7-Apr-20
L-083-20/0	Pastan, Ira H		Q2 Solutions BioSciences LLC	7-Apr-20
L-083-20/0	Ueda, Kazumitsu		Q2 Solutions BioSciences LLC	7-Apr-20
L-083-18/1	Bonomi, Carrie A.		Evotec SAS	8-Apr-20
L-083-18/1	Borgel, Suzanne D.		Evotec SAS	8-Apr-20
L-083-18/1	Dougherty, Kelly		Evotec SAS	8-Apr-20
L-083-18/1	Hollingshead, Melinda G.		Evotec SAS	8-Apr-20

L-246-02/1	Allegra, Carmen	(b)(4);	Dako Denmark A/S	9-Apr-20
L-246-02/1	Chabner, Bruce A	(b)(6)	Dako Denmark A/S	9-Apr-20
L-246-02/1	Johnston, Patrick G.		Dako Denmark A/S	9-Apr-20
L-246-02/1	Liang, Chi-Ming		Dako Denmark A/S	9-Apr-20
L-091-09/0	Bonner, William M		Research & Diagnostic Systems, Inc.	9-Apr-20
L-091-09/0	Rogakou, Efthimia P		Research & Diagnostic Systems, Inc.	9-Apr-20
L-136-20/0	Dudley, Mark		Intima Bioscience Inc.	13-Apr-20
L-136-20/0	Fitzgerald, Peter C.		Intima Bioscience Inc.	13-Apr-20
L-136-20/0	Gros, Alena		Intima Bioscience Inc.	13-Apr-20
L-136-20/0	Lu, Yong-Chen W.		Intima Bioscience Inc.	13-Apr-20
L-136-20/0	Palmer, Douglas		Intima Bioscience Inc.	13-Apr-20
L-136-20/0	Restifo, Nicholas P.		Intima Bioscience Inc.	13-Apr-20
L-136-20/0	Robbins, Paul F		Intima Bioscience Inc.	13-Apr-20
L-136-20/0	Rosenberg, Steven A.		Intima Bioscience Inc.	13-Apr-20
L-136-20/0	Tran, Eric		Intima Bioscience Inc.	13-Apr-20
L-136-20/0	Wunderlich, John		Intima Bioscience Inc.	13-Apr-20
L-136-20/0	Zheng, Zhili		Intima Bioscience Inc.	13-Apr-20
L-026-05/8	NCI		INNATE PHARMA	14-Apr-20
L-272-19/0	Greiner, John W.	(b)(4);	Aduro Biotech, Inc.	17-Apr-20
L-272-19/0	Schlom, Jeffrey	(b)(6)	Aduro Biotech, Inc.	17-Apr-20
L-325-17/0	Gao, Wei		Diagnostic BioSystems	17-Apr-20
L-325-17/0	Ho, Mitchell		Diagnostic BioSystems	17-Apr-20
L-325-17/0	Phung, Yen T.		Diagnostic BioSystems	17-Apr-20
L-325-17/0	Zhang, Yifan		Diagnostic BioSystems	17-Apr-20
L-327-17/0	Gao, Wei		Diagnostic BioSystems	17-Apr-20
L-327-17/0	Hassan, Raffit		Diagnostic BioSystems	17-Apr-20
L-327-17/0	Ho, Mitchell		Diagnostic BioSystems	17-Apr-20
L-327-17/0	Pastan, Ira H		Diagnostic BioSystems	17-Apr-20
L-327-17/0	Phung, Yen T.		Diagnostic BioSystems	17-Apr-20
L-327-17/0	Zhang, Yifan		Diagnostic BioSystems	17-Apr-20
L-325-17/0	NCI		Diagnostic BioSystems	17-Apr-20
L-327-17/0	NCI		Diagnostic BioSystems	17-Apr-20
L-026-05/8	NCI		INNATE PHARMA	20-Apr-20
L-060-18/0	Bonomi, Carrie A.	(b)(4);	Kineta, Inc	20-Apr-20
L-060-18/0	Borgel, Suzanne D.	(b)(6)	Kineta, Inc	20-Apr-20
L-060-18/0	Dougherty, Kelly		Kineta, Inc	20-Apr-20
L-060-18/0	Hollingshead, Melinda G.		Kineta, Inc	20-Apr-20
L-094-20/1	Morgan, Richard A.		Innovative Cellular Therapeutics	20-Apr-20
L-094-20/1	Restifo, Nicholas P.		Innovative Cellular Therapeutics	20-Apr-20
L-094-20/1	Rosenberg, Steven A.		Innovative Cellular Therapeutics	20-Apr-20
L-094-20/1	Zhang, Ling		Innovative Cellular Therapeutics	20-Apr-20

(b) (3) (A), (b) (4), (b) (6)

L-089-20/0	Bonomi, Carrie A.	(b)(4);	genOway SA	21-Apr-20
L-089-20/0	Dougherty, Kelly	(b)(6)	genOway SA	21-Apr-20
L-089-20/0	Hollingshead, Melinda G.		genOway SA	21-Apr-20
L-068-19/0	Gazdar, Adi F.		Merck Sharp & Dohme Corp	22-Apr-20
L-068-19/0	Johnson, Bruce E		Merck Sharp & Dohme Corp	22-Apr-20
L-068-19/0	Kaye, Frederic J		Merck Sharp & Dohme Corp	22-Apr-20
L-068-19/0	Kheif, Samir N.		Merck Sharp & Dohme Corp	22-Apr-20
L-068-19/0	Minna, John D.		Merck Sharp & Dohme Corp	22-Apr-20
L-068-19/0	Oie, Herbert K		Merck Sharp & Dohme Corp	22-Apr-20
L-068-19/0	Pass, Harvey I.		Merck Sharp & Dohme Corp	22-Apr-20
L-118-20/0	Bonomi, Carrie A.		Nitto BioPharma, Inc.	22-Apr-20
L-118-20/0	Dougherty, Kelly		Nitto BioPharma, Inc.	22-Apr-20
L-118-20/0	Hollingshead, Melinda G.		Nitto BioPharma, Inc.	22-Apr-20
L-347-14/0	Muchmore, Brian P.		Abcam, plc	23-Apr-20
L-347-14/0	O'Brien, Thomas R		Abcam, plc	23-Apr-20
L-347-14/0	Porter-Gill, Patricia A.		Abcam, plc	23-Apr-20
L-347-14/0	Prokunina-Olsson, Ludmila		Abcam, plc	23-Apr-20
<i>Note: L-347-14/0 split between FDA; NCI</i>				
L-064-11/0	Barry, Todd		Eptiomics Inc	23-Apr-20
L-064-11/0	Rosenwald, Andreas		Eptiomics Inc	23-Apr-20
L-064-11/0	Staudt, Louis M		Eptiomics Inc	23-Apr-20
L-064-11/0	Wiestner, Adrian		Eptiomics Inc	23-Apr-20
L-064-11/0	Wilson, Wyndham H.		Eptiomics Inc	23-Apr-20
L-148-18/0	(b) (4)		BravoVax Co., Ltd.	24-Apr-20
L-148-18/0	Lowy, Douglas R.		BravoVax Co., Ltd.	24-Apr-20
L-148-18/0	Pastrana, Diana V		BravoVax Co., Ltd.	24-Apr-20
L-148-18/0	Schiller, John T		BravoVax Co., Ltd.	24-Apr-20
L-104-20/0	Hinrichs, Christian S.		T-Cure Bioscience, Inc.	24-Apr-20
L-104-20/0	Stevanovic, Sanja		T-Cure Bioscience, Inc.	24-Apr-20
L-104-20/0	Hinrichs, Christian S.		T-Cure Bioscience, Inc.	24-Apr-20
L-104-20/0	Stevanovic, Sanja		T-Cure Bioscience, Inc.	24-Apr-20
L-104-20/0	NCI		T-Cure Bioscience, Inc.	24-Apr-20
L-108-15/0	Gros, Alena		Iovance Biotherapeutics Inc	28-Apr-20
L-108-15/0	Rosenberg, Steven A.		Iovance Biotherapeutics Inc	28-Apr-20
L-149-08/2	NCI		Bavarian Nordic	28-Apr-20
L-079-08/0	NCI		Avant Diagnostics, Inc	28-Apr-20
<i>Note: L-079-08/0 split between FDA; NCI</i>				
L-107-15/1	Dudley, Mark	(b)(4);	Iovance Biotherapeutics Inc	28-Apr-20
L-107-15/1	Hinrichs, Christian S.	(b)(6)	Iovance Biotherapeutics Inc	28-Apr-20
L-107-15/1	Rosenberg, Steven A.		Iovance Biotherapeutics Inc	28-Apr-20

L-107-15/1	Somerville, Robert P.	(b)(4);	Iovance Biotherapeutics Inc	28-Apr-20
L-107-15/1	Wunderlich, John	(b)(6)	Iovance Biotherapeutics Inc	28-Apr-20
<i>Note: L-107-15/1 split between CC; NCI</i>				
L-042-18/3	Rosenberg, Steven A.		Sapience Therapeutics	29-Apr-20
L-042-18/3	Topalian, Suzanne L.		Sapience Therapeutics	29-Apr-20
L-042-18/3	Rosenberg, Steven A.		Sapience Therapeutics	29-Apr-20
L-042-18/3	Topalian, Suzanne L.		Sapience Therapeutics	29-Apr-20
L-042-18/3	Rosenberg, Steven A.		Sapience Therapeutics	29-Apr-20
L-042-18/3	Topalian, Suzanne L.		Sapience Therapeutics	29-Apr-20

(b) (3) (A), (b) (4), (b) (6)

NIH Patent Licensing Activities

NCI

May 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
L-006-20/0	Bonomi, Carrie A.	(b)(4);	ABBA Therapeutics AG	1-May-20						(b) (3) (A), (b) (4), (b) (6)
L-006-20/0	Borgel, Suzanne D.	(b)(6)	ABBA Therapeutics AG	1-May-20						
L-006-20/0	Dougherty, Kelly		ABBA Therapeutics AG	1-May-20						
L-006-20/0	Hollingshead, Melinda G.		ABBA Therapeutics AG	1-May-20						
L-228-01/0	Chackerian, Bryce		Kuros Biosciences AG	1-May-20						
L-228-01/0	Lowy, Douglas R.		Kuros Biosciences AG	1-May-20						
L-228-01/0	Schiller, John T		Kuros Biosciences AG	1-May-20						
L-228-01/0	NCI		Kuros Biosciences AG	1-May-20						
L-035-19/1	Greiner, John W.	(b)(4);	EnGene Inc.	1-May-20						
L-035-19/1	Schlom, Jeffrey	(b)(6)	EnGene Inc.	1-May-20						
L-126-20/0	Lam, Norris		Kite Pharma, Inc.	1-May-20						
L-127-20/0	Lam, Norris		Kite Pharma, Inc	1-May-20						
L-127-20/0	NCI		Kite Pharma, Inc	1-May-20						
L-133-20/0	Gartner, Suzanne	(b)(4);	LumiraDx	1-May-20						
L-231-15/0	NCI		Cartesian Therapeutics, Inc	4-May-20						
L-231-15/0	NCI		Cartesian Therapeutics, Inc	4-May-20						
L-216-14/1	Chang, Kai	(b)(4);	Biolegend Inc	6-May-20						
L-216-14/1	Pastan, Ira H	(b)(6)	Biolegend Inc	6-May-20						
L-216-14/1	Willingham, Mark C.		Biolegend Inc	6-May-20						
L-119-17/0	Esposito, Dominic		Boehringer Ingelheim International Gml	6-May-20						
L-119-17/0	Gillette, William K.		Boehringer Ingelheim International Gml	6-May-20						

L-119-17/0	Grose, Carissa L.	(b)(4);	Boehringer Ingelheim International Gml	6-May-20	(b) (3) (A), (b) (4), (b) (6)	
L-119-17/0	Stephens, Robert M.	(b)(6)	Boehringer Ingelheim International Gml	6-May-20		
L-147-18/0	Bonomi, Carrie A.		Genentech	7-May-20		
L-147-18/0	Borgel, Suzanne D.		Genentech	7-May-20		
L-147-18/0	Dougherty, Kelly		Genentech	7-May-20		
L-147-18/0	Hollingshead, Melinda G.		Genentech	7-May-20		
L-045-19/1	Bonomi, Carrie A.		Alligator Bioscience AB	7-May-20		
L-045-19/1	Borgel, Suzanne D.		Alligator Bioscience AB	7-May-20		
L-045-19/1	Dougherty, Kelly		Alligator Bioscience AB	7-May-20		
L-045-19/1	Hollingshead, Melinda G.		Alligator Bioscience AB	7-May-20		
L-045-19/1	Schlom, Jeffrey		Alligator Bioscience AB	7-May-20		
L-040-19/0	Bonomi, Carrie A.		Blueprint Medicines Corporation	7-May-20		
L-040-19/0	Borgel, Suzanne D.		Blueprint Medicines Corporation	7-May-20		
L-040-19/0	Dougherty, Kelly		Blueprint Medicines Corporation	7-May-20		
L-040-19/0	Hollingshead, Melinda G.		Blueprint Medicines Corporation	7-May-20		
L-108-20/0	NCI		ElevateBio	7-May-20		
L-164-13/3	NCI		Aura Biosciences, Inc.	8-May-20		
L-107-15/1	NCI		lovance Biotherapeutics Inc	8-May-20		
<i>Note: L-107-15/1 split between CC; NCI</i>						
L-063-16/1	Gazdar, Adi F.	(b)(4);	GlaxoSmithKline	14-May-20		
L-063-16/1	Johnson, Bruce E	(b)(6)	GlaxoSmithKline	14-May-20		
L-063-16/1	Kaye, Frederic J		GlaxoSmithKline	14-May-20		
L-063-16/1	Kheif, Samir N.		GlaxoSmithKline	14-May-20		
L-063-16/1	Minna, John D.		GlaxoSmithKline	14-May-20		
L-063-16/1	Oie, Herbert K		GlaxoSmithKline	14-May-20		
L-063-16/1	Pass, Harvey I.		GlaxoSmithKline	14-May-20		
L-077-15/2	NCI		Kite Pharma, Inc.	14-May-20		
L-218-16/1	NCI		Kite Pharma, Inc	14-May-20		
L-122-20/0	Baskar, Sivasubramanian	(b)(4);	T-CURX GmbH	15-May-20		
L-122-20/0	Bishop, Michael R	(b)(6)	T-CURX GmbH	15-May-20		
L-122-20/0	Rader, Christoph		T-CURX GmbH	15-May-20		
L-122-20/0	Samija, Ivan		T-CURX GmbH	15-May-20		
L-122-20/0	Suschak, Jessica M		T-CURX GmbH	15-May-20		
L-049-91/5	Aaronson, Stuart A.		Biovitium AB (publ)	15-May-20		
L-049-91/5	Finch, Paul W.		Biovitium AB (publ)	15-May-20		
L-049-91/5	Rubin, Jeffrey S		Biovitium AB (publ)	15-May-20		
L-333-17/0	Bonomi, Carrie A.		Glenmark Pharmaceuticals, S.A.	15-May-20		
L-333-17/0	Borgel, Suzanne D.		Glenmark Pharmaceuticals, S.A.	15-May-20		
L-333-17/0	Dougherty, Kelly		Glenmark Pharmaceuticals, S.A.	15-May-20		
L-333-17/0	Hollingshead, Melinda G.		Glenmark Pharmaceuticals, S.A.	15-May-20		

L-277-17/0	Aaronson, Stuart A.	(b)(4);	Valo Therapeutics Oy	18-May-20
L-277-17/0	Giard, Donald	(b)(6)	Valo Therapeutics Oy	18-May-20
L-277-17/0	Parks, Wade P		Valo Therapeutics Oy	18-May-20
L-032-16/0	NCI		Novartis International Pharmaceuticals	19-May-20
L-068-13/2	NCI		Kite Pharma, Inc.	19-May-20
L-289-19/0	Bonomi, Carrie A.	(b)(4);	Alkermes	19-May-20
L-289-19/0	Dougherty, Kelly	(b)(6)	Alkermes	19-May-20
L-289-19/0	Hollingshead, Melinda G.		Alkermes	19-May-20
L-134-16/1	NCI		Ardeagen Corporation	21-May-20
L-134-16/1	Baskar, Sivasubramanian	(b)(4);	Ardeagen Corporation	21-May-20
L-134-16/1	Radar, Christoph	(b)(6)	Ardeagen Corporation	21-May-20
L-134-16/1	Yang, Jiahui		Ardeagen Corporation	21-May-20
L-297-14/1	Gelboin, (b) (6) Harry		CYP450-GP	22-May-20
L-297-14/1	Gonzalez, Frank J		CYP450-GP	22-May-20
L-297-14/1	Krausz, Kristopher W.		CYP450-GP	22-May-20
*L-273-14/0	Chang, Nancy T.		Grifols Worldwide Operations Ltd.	22-May-20
*L-273-14/0	Crowl, Robert		Grifols Worldwide Operations Ltd.	22-May-20
*L-273-14/0	Fisher, Amanda G.		Grifols Worldwide Operations Ltd.	22-May-20
*L-273-14/0	Hahn, Beatrice		Grifols Worldwide Operations Ltd.	22-May-20
*L-273-14/0	Reddy, E. Premkumar.		Grifols Worldwide Operations Ltd.	22-May-20
*L-273-14/0	Sarngadharan, Mangalasse		Grifols Worldwide Operations Ltd.	22-May-20
*L-095-17/0	Bonomi, Carrie A.		Millennium Pharmaceuticals, Inc.	22-May-20
*L-095-17/0	Borgel, Suzanne D.		Millennium Pharmaceuticals, Inc.	22-May-20
*L-095-17/0	Dougherty, Kelly		Millennium Pharmaceuticals, Inc.	22-May-20
*L-095-17/0	Hollingshead, Melinda G.		Millennium Pharmaceuticals, Inc.	22-May-20
L-052-18/1	Gros, Alena		MedGene Therapeutics, Inc.	22-May-20
*L-032-06/2	Chang, Kai		Eisai Inc	27-May-20
*L-032-06/2	Chowdhury, Partha S		Eisai Inc	27-May-20
*L-032-06/2	Pastan, Ira H		Eisai Inc	27-May-20
*L-032-06/2	Willingham, Mark C.		Eisai Inc	27-May-20
*L-168-07/2	Chowdhury, Partha S		Eisai Inc	27-May-20
*L-168-07/2	Pastan, Ira H		Eisai Inc	27-May-20
*L-317-17/0	NCI		Lentigen Technology Inc	27-May-20
*L-137-19/0	Bonomi, Carrie A.	(b)(4);	Good Therapeutics, Inc.	27-May-20
*L-137-19/0	Borgel, Suzanne D.	(b)(6)	Good Therapeutics, Inc.	27-May-20
*L-137-19/0	Dougherty, Kelly		Good Therapeutics, Inc.	27-May-20
*L-137-19/0	Hollingshead, Melinda G.		Good Therapeutics, Inc.	27-May-20
*L-253-18/2	Bonomi, Carrie A.		Yuhan R&D Institute	28-May-20
*L-253-18/2	Borgel, Suzanne D.		Yuhan R&D Institute	28-May-20

(b) (3) (A), (b) (4), (b) (6)

*L-253-18/2	Dougherty, Kelly	(b)(4);	Yuhan R&D Institute	28-May-20
*L-253-18/2	Hollingshead, Melinda G.	(b)(6)	Yuhan R&D Institute	28-May-20
*L-086-16/0	Bonomi, Carrie A.		Compass Therapeutics, LLC	28-May-20
*L-086-16/0	Dougherty, Kelly		Compass Therapeutics, LLC	28-May-20
*L-086-16/0	Hollingshead, Melinda G.		Compass Therapeutics, LLC	28-May-20
*L-308-17/0	NCI		Rapa Therapeutics LLC	28-May-20
*L-254-16/1	Lee, Choonsik	(b)(4);	PHS Technologies Group, LLC	28-May-20
L-109-18/1	(b) (4)	(b)(6)	StrideBio	29-May-20
*L-109-18/1	Esposito, Dominic		StrideBio	29-May-20
*L-109-18/1	Hopkins, Ralph F.		StrideBio	29-May-20
*L-109-18/1	Roberts, Veronica Ann		StrideBio	29-May-20
*L-254-16/1	Lee, Choonsik		PHS Technologies Group, LLC	29-May-20
*L-151-19/0	Bonomi, Carrie A.		Pliant Therapeutics, Inc	29-May-20
*L-151-19/0	Borgel, Suzanne D.		Pliant Therapeutics, Inc	29-May-20
*L-151-19/0	Dougherty, Kelly		Pliant Therapeutics, Inc	29-May-20
*L-151-19/0	Hollingshead, Melinda G.		Pliant Therapeutics, Inc	29-May-20

NIH Patent Licensing Activities

NCI

June 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
L-083-11/0	Waldmann, Thomas A.	(b)(4);	AbbVie Biotherapeutics, Inc.	1-Jun-20						(b) (3) (A), (b) (4), (b) (6)
<i>Note: L-083-11/0 split between NCI; NINDS</i>										
L-252-17/0	Bonomi, Carrie A.	(b)(6)	Champions Oncology, Inc.	1-Jun-20						
L-252-17/0	Borgel, Suzanne D.		Champions Oncology, Inc.	1-Jun-20						
L-252-17/0	Dougherty, Kelly		Champions Oncology, Inc.	1-Jun-20						
L-252-17/0	Hollingshead, Melinda G.		Champions Oncology, Inc.	1-Jun-20						
L-231-19/0	Copeland, Neal		Redbiotec AG	2-Jun-20						
L-231-19/0	Costantino, Nina		Redbiotec AG	2-Jun-20						
L-231-19/0	Court, Donald		Redbiotec AG	2-Jun-20						
L-231-19/0	Ellis, Hilary Moyed		Redbiotec AG	2-Jun-20						
L-231-19/0	Jenkins Copeland, Nancy A		Redbiotec AG	2-Jun-20						
L-231-19/0	Lee, E-Chiang		Redbiotec AG	2-Jun-20						
L-231-19/0	Sharan, Shyam K		Redbiotec AG	2-Jun-20						
L-231-19/0	Swaminathan, Srividya		Redbiotec AG	2-Jun-20						
L-231-19/0	Warming, Soren		Redbiotec AG	2-Jun-20						
L-231-19/0	Yu, Daiguan		Redbiotec AG	2-Jun-20						
L-024-18/0	Gazdar, Adi F.		SeraCare Life	2-Jun-20						
L-024-18/0	Johnson, Bruce E		SeraCare Life	2-Jun-20						
L-024-18/0	Kaye, Frederic J		SeraCare Life	2-Jun-20						

L-024-18/0	Kheif, Samir N.	(b)(4);	SeraCare Life	2-Jun-20
L-024-18/0	Minna, John D.	(b)(6)	SeraCare Life	2-Jun-20
L-024-18/0	Oie, Herbert K		SeraCare Life	2-Jun-20
L-024-18/0	Pass, Harvey I.		SeraCare Life	2-Jun-20
L-161-04/1	(b) (4)		SeraCare Life Sciences, Inc.	2-Jun-20
L-161-04/1	Sarngadharan, Mangalasse		SeraCare Life Sciences, Inc.	2-Jun-20
L-161-19/0	Gazdar, Adi F.		SearCare Life Sciences	2-Jun-20
L-161-19/0	Johnson, Bruce E		SearCare Life Sciences	2-Jun-20
L-161-19/0	Kaye, Frederic J		SearCare Life Sciences	2-Jun-20
L-161-19/0	Kheif, Samir N.		SearCare Life Sciences	2-Jun-20
L-161-19/0	Minna, John D.		SearCare Life Sciences	2-Jun-20
L-161-19/0	Oie, Herbert K		SearCare Life Sciences	2-Jun-20
L-161-19/0	Pass, Harvey I.		SearCare Life Sciences	2-Jun-20
L-245-94/1	(b) (4)		SearCare Life Sciences	2-Jun-20
L-245-94/1	Sarngadharan, Mangalasse		SearCare Life Sciences	2-Jun-20
<i>Note: L-245-94/1 split between NCI; NIAID</i>				
L-331-17/1	NCI		Istari Oncology Inc	2-Jun-20
L-062-20/0	Bonomi, Carrie A.	(b)(4);	H3 Biomedicine Inc.	2-Jun-20
L-062-20/0	Borgel, Suzanne D.	(b)(6)	H3 Biomedicine Inc.	2-Jun-20
L-062-20/0	Dougherty, Kelly		H3 Biomedicine Inc.	2-Jun-20
L-062-20/0	Hollingshead, Melinda G.		H3 Biomedicine Inc.	2-Jun-20
L-197-17/0	Bonomi, Carrie A.		Seattle Genetics, Inc.	4-Jun-20
L-197-17/0	Borgel, Suzanne D.		Seattle Genetics, Inc.	4-Jun-20
L-197-17/0	Dougherty, Kelly		Seattle Genetics, Inc.	4-Jun-20
L-197-17/0	Hollingshead, Melinda G.		Seattle Genetics, Inc.	4-Jun-20
L-142-20/0	Gazdar, Adi F.		Chugai Pharmaceutical Co., Ltd	5-Jun-20
L-142-20/0	Johnson, Bruce E		Chugai Pharmaceutical Co., Ltd	5-Jun-20
L-142-20/0	Kaye, Frederic J		Chugai Pharmaceutical Co., Ltd	5-Jun-20
L-142-20/0	Kheif, Samir N.		Chugai Pharmaceutical Co., Ltd	5-Jun-20
L-142-20/0	Minna, John D.		Chugai Pharmaceutical Co., Ltd	5-Jun-20
L-142-20/0	Oie, Herbert K		Chugai Pharmaceutical Co., Ltd	5-Jun-20
L-142-20/0	Pass, Harvey I.		Chugai Pharmaceutical Co., Ltd	5-Jun-20
L-086-19/0	Bonomi, Carrie A.		Pionyr Immunotherapeutics, Inc.	8-Jun-20
L-086-19/0	Dougherty, Kelly		Pionyr Immunotherapeutics, Inc.	8-Jun-20
L-086-19/0	Hollingshead, Melinda G.		Pionyr Immunotherapeutics, Inc.	8-Jun-20
L-025-07/0	Hollingshead, Melinda G.		Tocris Bioscience	9-Jun-20
L-025-07/0	Sausville, Edward		Tocris Bioscience	9-Jun-20
L-025-07/0	Snader, Kenneth M		Tocris Bioscience	9-Jun-20
L-025-07/0	Vishnuvajjala, B. Rao		Tocris Bioscience	9-Jun-20
L-265-02/0	Marquez, Victor E		Tocris Cookson, Ltd.	9-Jun-20
<i>Note: L-265-02/0 split between NCI; NIDDK</i>				
L-002-20/0	Bonomi, Carrie A.		Oncurious NV	9-Jun-20

L-002-20/0	Borgel, Suzanne D.	(b)(4);	Oncurious NV	9-Jun-20
L-002-20/0	Dougherty, Kelly	(b)(6)	Oncurious NV	9-Jun-20
L-002-20/0	Hollingshead, Melinda G.		Oncurious NV	9-Jun-20
L-122-17/0	NCI		Koninklijke Philips N.V.	9-Jun-20
<i>Note: L-122-17/0 split between CC; NCI</i>				
L-209-15/0	Gazdar, Adi F.	(b)(4);	HistoCyte Laboratories	9-Jun-20
L-209-15/0	Johnson, Bruce E	(b)(6)	HistoCyte Laboratories	9-Jun-20
L-209-15/0	Kaye, Frederic J		HistoCyte Laboratories	9-Jun-20
L-209-15/0	Khleif, Samir N.		HistoCyte Laboratories	9-Jun-20
L-209-15/0	Minna, John D.		HistoCyte Laboratories	9-Jun-20
L-209-15/0	Oie, Herbert K		HistoCyte Laboratories	9-Jun-20
L-209-15/0	Pass, Harvey I.		HistoCyte Laboratories	9-Jun-20
L-154-97/2	Mason, Llewellyn H.		BD Biosciences - BD PharMingen	10-Jun-20
L-154-97/2	Ortaldo, John R.		BD Biosciences - BD PharMingen	10-Jun-20
L-097-00/2	Austin, Faye C.		BD Biosciences, PharMingen	10-Jun-20
L-097-00/2	Colcher, David		BD Biosciences, PharMingen	10-Jun-20
L-097-00/2	Hand, Patricia H		BD Biosciences, PharMingen	10-Jun-20
L-097-00/2	Nuti, Marianna		BD Biosciences, PharMingen	10-Jun-20
L-097-00/2	Schlom, Jeffrey		BD Biosciences, PharMingen	10-Jun-20
L-154-17/0	Bonomi, Carrie A.		Agios Pharmaceuticals	10-Jun-20
L-154-17/0	Borgel, Suzanne D.		Agios Pharmaceuticals	10-Jun-20
L-154-17/0	Dougherty, Kelly		Agios Pharmaceuticals	10-Jun-20
L-154-17/0	Hollingshead, Melinda G.		Agios Pharmaceuticals	10-Jun-20
L-153-19/0	Bagni- Beyer, Rachel K.		Novartis Institutes for BioMedical Resea	10-Jun-20
L-153-19/0	(b) (4)		Novartis Institutes for BioMedical Resea	10-Jun-20
L-153-19/0	Holderfield, Matthew T.		Novartis Institutes for BioMedical Resea	10-Jun-20
L-153-19/0	Soppet, Dan		Novartis Institutes for BioMedical Resea	10-Jun-20
L-209-15/0	Gazdar, Adi F.		HistoCyte Laboratories	10-Jun-20
L-209-15/0	Johnson, Bruce E		HistoCyte Laboratories	10-Jun-20
L-209-15/0	Kaye, Frederic J		HistoCyte Laboratories	10-Jun-20
L-209-15/0	Khleif, Samir N.		HistoCyte Laboratories	10-Jun-20
L-209-15/0	Minna, John D.		HistoCyte Laboratories	10-Jun-20
L-209-15/0	Oie, Herbert K		HistoCyte Laboratories	10-Jun-20
L-209-15/0	Pass, Harvey I.		HistoCyte Laboratories	10-Jun-20
L-216-19/0	Bonomi, Carrie A.		Revolution Medicines, Inc	12-Jun-20
L-216-19/0	Dougherty, Kelly		Revolution Medicines, Inc	12-Jun-20
L-216-19/0	Hollingshead, Melinda G.		Revolution Medicines, Inc	12-Jun-20
L-184-19/0	Bonomi, Carrie A.		Kowa Company LTD	15-Jun-20
L-184-19/0	Borgel, Suzanne D.		Kowa Company LTD	15-Jun-20
L-184-19/0	Dougherty, Kelly		Kowa Company LTD	15-Jun-20
L-184-19/0	Hollingshead, Melinda G.		Kowa Company LTD	15-Jun-20
L-191-20/0	Bonomi, Carrie A.		Actym Therapeutics, Inc	15-Jun-20
L-191-20/0	Borgel, Suzanne D.		Actym Therapeutics, Inc	15-Jun-20

(b) (3) (A), (b) (4), (b) (6)

L-191-20/0	Dougherty, Kelly	(b)(4);	Actym Therapeutics, Inc	15-Jun-20
L-191-20/0	Hollingshead, Melinda G.	(b)(6)	Actym Therapeutics, Inc	15-Jun-20
L-232-14/1	NCI		NanoString Technologies, Inc.	16-Jun-20
<i>Note: L-232-14/1 split between CIT; NCI</i>				
L-151-20/0	Gazdar, Adi F.	(b)(4);	Harpoon Therapeutics	16-Jun-20
L-151-20/0	Johnson, Bruce E	(b)(6)	Harpoon Therapeutics	16-Jun-20
L-151-20/0	Kaye, Frederic J		Harpoon Therapeutics	16-Jun-20
L-151-20/0	Kheif, Samir N.		Harpoon Therapeutics	16-Jun-20
L-151-20/0	Minna, John D.		Harpoon Therapeutics	16-Jun-20
L-151-20/0	Oie, Herbert K		Harpoon Therapeutics	16-Jun-20
L-151-20/0	Pass, Harvey I.		Harpoon Therapeutics	16-Jun-20
L-196-20/0	Boyd, Michael R.		Jiashu (HealthTree) Medical (Shenzhen)	17-Jun-20
L-196-20/0	McMahon, James		Jiashu (HealthTree) Medical (Shenzhen)	17-Jun-20
L-196-20/0	Mori, Toshiyuki		Jiashu (HealthTree) Medical (Shenzhen)	17-Jun-20
L-196-20/0	O'Keefe, Barry		Jiashu (HealthTree) Medical (Shenzhen)	17-Jun-20
L-239-15/0	Gazdar, Adi F.		Dako North America	18-Jun-20
L-239-15/0	Johnson, Bruce E		Dako North America	18-Jun-20
L-239-15/0	Kaye, Frederic J		Dako North America	18-Jun-20
L-239-15/0	Khleif, Samir N.		Dako North America	18-Jun-20
L-239-15/0	Minna, John D.		Dako North America	18-Jun-20
L-239-15/0	Oie, Herbert K		Dako North America	18-Jun-20
L-239-15/0	Pass, Harvey I.		Dako North America	18-Jun-20
L-011-06/0	NCI		Dako Denmark A/S	18-Jun-20
L-239-15/0	Gazdar, Adi F.	(b)(4);	Dako North America	18-Jun-20
L-239-15/0	Johnson, Bruce E	(b)(6)	Dako North America	18-Jun-20
L-239-15/0	Kaye, Frederic J		Dako North America	18-Jun-20
L-239-15/0	Khleif, Samir N.		Dako North America	18-Jun-20
L-239-15/0	Minna, John D.		Dako North America	18-Jun-20
L-239-15/0	Oie, Herbert K		Dako North America	18-Jun-20
L-239-15/0	Pass, Harvey I.		Dako North America	18-Jun-20
L-008-15/1	NCI		xMD Diagnostics, LLC	18-Jun-20
<i>Note: L-008-15/1 split between CIT; NCI; NICHD</i>				
L-117-18/0	Bonomi, Carrie A.	(b)(4);	Morphic Therapeutic	19-Jun-20
L-117-18/0	Borgel, Suzanne D.	(b)(6)	Morphic Therapeutic	19-Jun-20
L-117-18/0	Dougherty, Kelly		Morphic Therapeutic	19-Jun-20
L-117-18/0	Hollingshead, Melinda G.		Morphic Therapeutic	19-Jun-20
L-092-19/1	Bonomi, Carrie A.		Glympse Bio, Inc., c/o Advanced Technic	19-Jun-20
L-092-19/1	Borgel, Suzanne D.		Glympse Bio, Inc., c/o Advanced Technic	19-Jun-20
L-092-19/1	Dougherty, Kelly		Glympse Bio, Inc., c/o Advanced Technic	19-Jun-20
L-092-19/1	Hollingshead, Melinda G.		Glympse Bio, Inc., c/o Advanced Technic	19-Jun-20
L-297-14/1	Gelboin (b)(6) Harry		CYP450-GP	19-Jun-20
L-297-14/1	Gonzalez, Frank J		CYP450-GP	19-Jun-20
L-297-14/1	Krausz, Kristopher W.		CYP450-GP	19-Jun-20

(b) (3) (A), (b) (4), (b) (6)

L-159-20/0	Bonomi, Carrie A.	(b)(4);	Ascendis Pharma A/S	19-Jun-20
L-159-20/0	Borgel, Suzanne D.	(b)(6)	Ascendis Pharma A/S	19-Jun-20
L-159-20/0	Dougherty, Kelly		Ascendis Pharma A/S	19-Jun-20
L-159-20/0	Hollingshead, Melinda G.		Ascendis Pharma A/S	19-Jun-20
L-224-15/0	NCI		Bluebird Bio	22-Jun-20
L-073-03/3	Gottesman, Michael M.	(b)(4);	Genentech	23-Jun-20
L-073-03/3	Pastan, Ira H	(b)(6)	Genentech	23-Jun-20
L-073-03/3	Ueda, Kazumitsu		Genentech	23-Jun-20
L-192-18/0	Bonomi, Carrie A.		iOmx	23-Jun-20
L-192-18/0	Borgel, Suzanne D.		iOmx	23-Jun-20
L-192-18/0	Dougherty, Kelly		iOmx	23-Jun-20
L-192-18/0	Hollingshead, Melinda G.		iOmx	23-Jun-20
L-272-16/0	Bonomi, Carrie A.		KeraFAST	24-Jun-20
L-272-16/0	Borgel, Suzanne D.		KeraFAST	24-Jun-20
L-272-16/0	Dougherty, Kelly		KeraFAST	24-Jun-20
L-272-16/0	Hollingshead, Melinda G.		KeraFAST	24-Jun-20
L-160-20/0	Bonomi, Carrie A.		Hanmi Pharmaceutical Co., Ltd	24-Jun-20
L-160-20/0	Borgel, Suzanne D.		Hanmi Pharmaceutical Co., Ltd	24-Jun-20
L-160-20/0	Dougherty, Kelly		Hanmi Pharmaceutical Co., Ltd	24-Jun-20
L-160-20/0	Hollingshead, Melinda G.		Hanmi Pharmaceutical Co., Ltd	24-Jun-20
L-055-18/1	Keseling, Beverly G		PTC Therapeutics Inc	25-Jun-20
L-055-18/1	Warfield, Paul		PTC Therapeutics Inc	25-Jun-20
L-170-07/0	Dimitrov, Dimiter S.		Indian Immunologicals Ltd.	26-Jun-20
L-170-07/0	Zhu, Zhongyu		Indian Immunologicals Ltd.	26-Jun-20
L-052-18/1	NCI		MedGene Therapeutics, Inc.	26-Jun-20
L-239-16/1	Bonomi, Carrie A.	(b)(4);	Alkermes, Inc.	29-Jun-20
L-239-16/1	Borgel, Suzanne D.	(b)(6)	Alkermes, Inc.	29-Jun-20
L-239-16/1	Dougherty, Kelly		Alkermes, Inc.	29-Jun-20
L-239-16/1	Hollingshead, Melinda G.		Alkermes, Inc.	29-Jun-20
L-180-20/0	Schlom, Jeffrey		Merck Sharp & Dohme Corp	29-Jun-20
L-155-19/0	Bonomi, Carrie A.		HJB (Hangzhou) Co., Ltd.	30-Jun-20
L-155-19/0	Borgel, Suzanne D.		HJB (Hangzhou) Co., Ltd.	30-Jun-20
L-155-19/0	Dougherty, Kelly		HJB (Hangzhou) Co., Ltd.	30-Jun-20
L-155-19/0	Hollingshead, Melinda G.		HJB (Hangzhou) Co., Ltd.	30-Jun-20

NIH Patent Licensing Activities
 NCI
 July 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
L-097-19/0	Bonomi, Carrie A.	(b)(4);	Janssen Research & Development, LLC	1-Jul-20						(b) (3) (A), (b) (4), (b) (6)
L-097-19/0	Borgel, Suzanne D.	(b)(6)	Janssen Research & Development, LLC	1-Jul-20						
L-097-19/0	Dougherty, Kelly		Janssen Research & Development, LLC	1-Jul-20						
L-097-19/0	Hollingshead, Melinda G.		Janssen Research & Development, LLC	1-Jul-20						
L-163-18/0	Bonomi, Carrie A.		Japan Tobacco	1-Jul-20						
L-163-18/0	Borgel, Suzanne D.		Japan Tobacco	1-Jul-20						
L-163-18/0	Dougherty, Kelly		Japan Tobacco	1-Jul-20						
L-163-18/0	Hollingshead, Melinda G.		Japan Tobacco	1-Jul-20						
L-203-94/0	Aaronson, Stuart A.		BD Biosciences - BD PharMingen, Inc.	1-Jul-20						
L-203-94/0	Jensen, Roy A.		BD Biosciences - BD PharMingen, Inc.	1-Jul-20						
L-203-94/0	LaRochelle, William		BD Biosciences - BD PharMingen, Inc.	1-Jul-20						
L-203-94/0	Matsui, Toshimitsu		BD Biosciences - BD PharMingen, Inc.	1-Jul-20						
L-203-94/0	Pierce, Jacalyn		BD Biosciences - BD PharMingen, Inc.	1-Jul-20						
L-203-94/0	Robbins, Keith		BD Biosciences - BD PharMingen, Inc.	1-Jul-20						
L-080-93/3	Hathcock, Karen		BD Biosciences - BD PharMingen, Inc.	1-Jul-20						
L-080-93/3	Hodes, Richard		BD Biosciences - BD PharMingen, Inc.	1-Jul-20						
L-080-93/3	Laszlo, Gloria		BD Biosciences - BD PharMingen, Inc.	1-Jul-20						
L-190-19/1	Cafri, Gal		ZioPharm Oncology, Inc	1-Jul-20						
L-190-19/1	Deniger, Drew		ZioPharm Oncology, Inc	1-Jul-20						
L-190-19/1	Feldman, Steven A		ZioPharm Oncology, Inc	1-Jul-20						
L-190-19/1	Fitzgerald, Peter C.		ZioPharm Oncology, Inc	1-Jul-20						
L-190-19/1	Hanada, Kenichi		ZioPharm Oncology, Inc	1-Jul-20						
L-190-19/1	Lo, Winifred Margaret		ZioPharm Oncology, Inc	1-Jul-20						
L-190-19/1	Lu, Yong-Chen W.		ZioPharm Oncology, Inc	1-Jul-20						
L-190-19/1	Malekzadeh, Parisa		ZioPharm Oncology, Inc	1-Jul-20						
L-190-19/1	Parkhurst, Maria		ZioPharm Oncology, Inc	1-Jul-20						
L-190-19/1	Pasetto, Anna		ZioPharm Oncology, Inc	1-Jul-20						
L-190-19/1	Robbins, Paul F		ZioPharm Oncology, Inc	1-Jul-20						
L-190-19/1	Tran, Eric		ZioPharm Oncology, Inc	1-Jul-20						
L-190-19/1	Wang, Qiong		ZioPharm Oncology, Inc	1-Jul-20						
L-190-19/1	Yang, James C		ZioPharm Oncology, Inc	1-Jul-20						
L-190-19/1	Yoseph, Rami		ZioPharm Oncology, Inc	1-Jul-20						
L-190-19/1	Yu, Zhiya		ZioPharm Oncology, Inc	1-Jul-20						
L-190-19/1	Zhao, Chihao		ZioPharm Oncology, Inc	1-Jul-20						
L-190-19/1	Zheng, Zhili		ZioPharm Oncology, Inc	1-Jul-20						
L-126-10/0	Bonner, William M		Enzo Life Sciences, Inc.	1-Jul-20						
L-126-10/0	Rogakou, Efthimia P		Enzo Life Sciences, Inc.	1-Jul-20						
L-224-15/0	NCI		Bluebird Bio	1-Jul-20						
L-211-17/0	Kahn, Richard A		Emory University	1-Jul-20						
L-159-20/0	Bonomi, Carrie A.		Ascendis Pharma A/S	1-Jul-20						
L-159-20/0	Borgel, Suzanne D.		Ascendis Pharma A/S	1-Jul-20						
L-159-20/0	Dougherty, Kelly		Ascendis Pharma A/S	1-Jul-20						

L-159-20/0	Hollingshead, Melinda G.	(b)(4); (b)(6)	Ascendis Pharma A/S	1-Jul-20
L-159-20/0	Bonomi, Carrie A.		Ascendis Pharma A/S	1-Jul-20
L-159-20/0	Borgel, Suzanne D.		Ascendis Pharma A/S	1-Jul-20
L-159-20/0	Dougherty, Kelly		Ascendis Pharma A/S	1-Jul-20
L-159-20/0	Hollingshead, Melinda G.		Ascendis Pharma A/S	1-Jul-20
L-165-20/0	Gazdar, Adi F.		Light Chain Bioscience-Novimmune SA	1-Jul-20
L-165-20/0	Johnson, Bruce E		Light Chain Bioscience-Novimmune SA	1-Jul-20
L-165-20/0	Kaye, Frederic J		Light Chain Bioscience-Novimmune SA	1-Jul-20
L-165-20/0	Kheif, Samir N.		Light Chain Bioscience-Novimmune SA	1-Jul-20
L-165-20/0	Minna, John D.		Light Chain Bioscience-Novimmune SA	1-Jul-20
L-165-20/0	Oie, Herbert K		Light Chain Bioscience-Novimmune SA	1-Jul-20
L-165-20/0	Pass, Harvey I.		Light Chain Bioscience-Novimmune SA	1-Jul-20
L-092-20/0	Cherukuri, Murali K		O2M Technologies, LLC	2-Jul-20
L-092-20/0	Cook, J A		O2M Technologies, LLC	2-Jul-20
L-092-20/0	Devasahayam, Nallathamb		O2M Technologies, LLC	2-Jul-20
L-092-20/0	Matsumoto, Shingo		O2M Technologies, LLC	2-Jul-20
L-092-20/0	Mitchell, James		O2M Technologies, LLC	2-Jul-20
L-092-20/0	Subramanian, Sankaran		O2M Technologies, LLC	2-Jul-20
L-264-17/0	Bonomi, Carrie A.		AstraZeneca	3-Jul-20
L-264-17/0	Borgel, Suzanne D.		AstraZeneca	3-Jul-20
L-264-17/0	Dougherty, Kelly		AstraZeneca	3-Jul-20
L-264-17/0	Hollingshead, Melinda G.		AstraZeneca	3-Jul-20
L-064-19/0	Bonomi, Carrie A.		Torque Therapeutics, Inc.	8-Jul-20
L-064-19/0	Borgel, Suzanne D.		Torque Therapeutics, Inc.	8-Jul-20
L-064-19/0	Dougherty, Kelly		Torque Therapeutics, Inc.	8-Jul-20
L-064-19/0	Hollingshead, Melinda G.		Torque Therapeutics, Inc.	8-Jul-20
L-329-17/1	NCI		Abpro	8-Jul-20
L-002-16/1	NCI		Kite Pharma, Inc.	9-Jul-20
L-108-19/0	Bonomi, Carrie A.	(b)(4); (b)(6)	GB006 (Gossamer Bio, Inc.)	10-Jul-20
L-108-19/0	Borgel, Suzanne D.		GB006 (Gossamer Bio, Inc.)	10-Jul-20
L-108-19/0	Dougherty, Kelly		GB006 (Gossamer Bio, Inc.)	10-Jul-20
L-108-19/0	Hollingshead, Melinda G.		GB006 (Gossamer Bio, Inc.)	10-Jul-20
L-201-20/0	Gao, Wei		Navrogen Inc	13-Jul-20
L-201-20/0	Hassan, Raffit		Navrogen Inc	13-Jul-20
L-201-20/0	Ho, Mitchell		Navrogen Inc	13-Jul-20
L-201-20/0	Pastan, Ira H		Navrogen Inc	13-Jul-20
L-201-20/0	Phung, Yen T.		Navrogen Inc	13-Jul-20
L-201-20/0	Zhang, Yifan		Navrogen Inc	13-Jul-20
L-176-19/0	Bonomi, Carrie A.		Pionyr Immunotherapeutics, Inc	14-Jul-20
L-176-19/0	Borgel, Suzanne D.		Pionyr Immunotherapeutics, Inc	14-Jul-20
L-176-19/0	Dougherty, Kelly		Pionyr Immunotherapeutics, Inc	14-Jul-20
L-176-19/0	Hollingshead, Melinda G.		Pionyr Immunotherapeutics, Inc	14-Jul-20

(b) (3) (A), (b) (4), (b) (6)

L-120-20/0	Gazdar, Adi F.	(b)(4);	Daiichi Sankyo Co., Ltd	15-Jul-20
L-120-20/0	Johnson, Bruce E	(b)(6)	Daiichi Sankyo Co., Ltd	15-Jul-20
L-120-20/0	Kaye, Frederic J		Daiichi Sankyo Co., Ltd	15-Jul-20
L-120-20/0	Kheif, Samir N.		Daiichi Sankyo Co., Ltd	15-Jul-20
L-120-20/0	Minna, John D.		Daiichi Sankyo Co., Ltd	15-Jul-20
L-120-20/0	Oie, Herbert K		Daiichi Sankyo Co., Ltd	15-Jul-20
L-120-20/0	Pass, Harvey I.		Daiichi Sankyo Co., Ltd	15-Jul-20
L-183-20/0	Felber, Barbara K.		Frontier Biotechnologies Inc.	15-Jul-20
L-183-20/0	Pavlakis, George N		Frontier Biotechnologies Inc.	15-Jul-20
L-037-11/1	Jelinek, Ivett		BioLegend	16-Jul-20
L-037-11/1	Segal, David M.		BioLegend	16-Jul-20
L-037-11/1	Wang, Yan		BioLegend	16-Jul-20
L-007-11/2	Onda, Masanori		BioLegend	16-Jul-20
L-007-11/2	Pastan, Ira H		BioLegend	16-Jul-20
L-073-09/1	Bonner, William M		BioLegend	16-Jul-20
L-073-09/1	Rogakou, Efthimia P		BioLegend	16-Jul-20
L-070-12/1	Hathcock, Karen		BioLegend	16-Jul-20
L-070-12/1	Hodes, Richard		BioLegend	16-Jul-20
L-070-12/1	Laszlo, Gloria		BioLegend	16-Jul-20
L-127-11/2	NCI		Bavarian Nordic Inc	17-Jul-20
L-121-08/0	NCI		Medtronic Inc	20-Jul-20
<i>Note: L-121-08/0 split between NCI; NINDS</i>				
L-121-08/0	Brechbiel, Martin W.	(b)(4);	Medtronic Inc	20-Jul-20
L-121-08/0	Garmestani, Kayhan	(b)(6)	Medtronic Inc	20-Jul-20
<i>Note: L-121-08/0 split between NCI; NINDS</i>				
L-192-19/0	Bonomi, Carrie A.		Hookipa Biotech GmbH	21-Jul-20
L-192-19/0	Borgel, Suzanne D.		Hookipa Biotech GmbH	21-Jul-20
L-192-19/0	Dougherty, Kelly		Hookipa Biotech GmbH	21-Jul-20
L-192-19/0	Hollingshead, Melinda G.		Hookipa Biotech GmbH	21-Jul-20
L-259-16/5	Cafri, Gal		Kite Pharma	21-Jul-20
L-259-16/5	Hanada, Kenichi		Kite Pharma	21-Jul-20
L-259-16/5	Levin, Noam		Kite Pharma	21-Jul-20
L-259-16/5	Lowery, Fank		Kite Pharma	21-Jul-20
L-259-16/5	Lu, Yong-Chen W.		Kite Pharma	21-Jul-20
L-259-16/5	Paria, Biman		Kite Pharma	21-Jul-20
L-259-16/5	Parkhurst, Maria		Kite Pharma	21-Jul-20
L-259-16/5	Pasetto, Anna		Kite Pharma	21-Jul-20
L-259-16/5	Robbins, Paul F		Kite Pharma	21-Jul-20
L-259-16/5	Tran, Eric		Kite Pharma	21-Jul-20
L-259-16/5	Wang, Qiong		Kite Pharma	21-Jul-20
L-259-16/5	Yang, James C		Kite Pharma	21-Jul-20
L-259-16/5	Yoseph, Rami		Kite Pharma	21-Jul-20
L-259-16/5	Yu, Zhiya		Kite Pharma	21-Jul-20

(b) (3) (A), (b) (4), (b) (6)

L-259-16/5	Zheng, Zhili	(b)(4); (b)(6)	Kite Pharma	21-Jul-20	(b) (3) (A), (b) (4), (b) (6)
L-252-17/0	Bonomi, Carrie A.	(b)(4); (b)(6)	Champions Oncology, Inc.	22-Jul-20	
L-252-17/0	Borgel, Suzanne D.		Champions Oncology, Inc.	22-Jul-20	
L-252-17/0	Dougherty, Kelly		Champions Oncology, Inc.	22-Jul-20	
L-252-17/0	Hollingshead, Melinda G.		Champions Oncology, Inc.	22-Jul-20	
L-117-17/0	NCI		Aspyrian Therapeutics, Inc.	23-Jul-20	
L-256-18/0	Bonomi, Carrie A.	(b)(4); (b)(6)	Genentech, Inc.	28-Jul-20	
L-256-18/0	Dougherty, Kelly		Genentech, Inc.	28-Jul-20	
L-256-18/0	Hollingshead, Melinda G.		Genentech, Inc.	28-Jul-20	
L-308-19/0	Bonomi, Carrie A.		Microbiotica Ltd.	28-Jul-20	
L-308-19/0	Borgel, Suzanne D.		Microbiotica Ltd.	28-Jul-20	
L-308-19/0	Dougherty, Kelly		Microbiotica Ltd.	28-Jul-20	
L-308-19/0	Hollingshead, Melinda G.		Microbiotica Ltd.	28-Jul-20	
L-308-19/0	Bonomi, Carrie A.		Microbiotica Ltd.	28-Jul-20	
L-308-19/0	Borgel, Suzanne D.		Microbiotica Ltd.	28-Jul-20	
L-308-19/0	Dougherty, Kelly		Microbiotica Ltd.	28-Jul-20	
L-308-19/0	Hollingshead, Melinda G.		Microbiotica Ltd.	28-Jul-20	
L-064-11/0	Barry, Todd		Eptiomics Inc	29-Jul-20	
L-064-11/0	Rosenwald, Andreas		Eptiomics Inc	29-Jul-20	
L-064-11/0	Staudt, Louis M		Eptiomics Inc	29-Jul-20	
L-064-11/0	Wiestner, Adrian		Eptiomics Inc	29-Jul-20	
L-064-11/0	Wilson, Wyndham H.		Eptiomics Inc	29-Jul-20	
L-215-20/0	Rader, Christoph		Lyell Immunopharma, Inc.	31-Jul-20	
L-215-20/0	Yang, Jiahui		Lyell Immunopharma, Inc.	31-Jul-20	

NIH Patent Licensing Activities

NCI

August 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
L-010-20/0	Bonomi, Carrie A.	(b)(4);	Genentech, Inc.	1-Aug-20	(b) (3) (A), (b) (4), (b) (6)					
L-010-20/0	Dougherty, Kelly	(b)(6)	Genentech, Inc.	1-Aug-20						
L-010-20/0	Hollingshead, Melinda G.		Genentech, Inc.	1-Aug-20						
L-114-19/0	Bonomi, Carrie A.		GigaGen Inc	1-Aug-20						
L-114-19/0	Borgel, Suzanne D.		GigaGen Inc	1-Aug-20						
L-114-19/0	Dougherty, Kelly		GigaGen Inc	1-Aug-20						
L-114-19/0	Hollingshead, Melinda G.		GigaGen Inc	1-Aug-20						
L-284-19/0	Bonomi, Carrie A.		Molecular Partners AG	3-Aug-20						
L-284-19/0	Borgel, Suzanne D.		Molecular Partners AG	3-Aug-20						
L-284-19/0	Dougherty, Kelly		Molecular Partners AG	3-Aug-20						
L-284-19/0	Hollingshead, Melinda G.		Molecular Partners AG	3-Aug-20						

L-206-20/0	Spiese, Paul J	(b)(4);	Oncodesign Biotechnology	3-Aug-20
L-206-20/0	Yang, James C	(b)(6)	Oncodesign Biotechnology	3-Aug-20
L-249-14/0	Copeland, Neal		Merck Sharp & Dohme Corp.	4-Aug-20
L-249-14/0	Costantino, Nina		Merck Sharp & Dohme Corp.	4-Aug-20
L-249-14/0	Court, Donald		Merck Sharp & Dohme Corp.	4-Aug-20
L-249-14/0	Ellis, Hilary Moyed		Merck Sharp & Dohme Corp.	4-Aug-20
L-249-14/0	Jenkins Copeland, Nancy A		Merck Sharp & Dohme Corp.	4-Aug-20
L-249-14/0	Lee, E-Chiang		Merck Sharp & Dohme Corp.	4-Aug-20
L-249-14/0	Liu, Pentao		Merck Sharp & Dohme Corp.	4-Aug-20
L-249-14/0	Sharan, Shyam K		Merck Sharp & Dohme Corp.	4-Aug-20
L-249-14/0	Swaminathan, Srividya		Merck Sharp & Dohme Corp.	4-Aug-20
L-249-14/0	Warming, Soren		Merck Sharp & Dohme Corp.	4-Aug-20
L-249-14/0	Yu, Daiguan		Merck Sharp & Dohme Corp.	4-Aug-20
L-201-20/0	NCI		Navrogen Inc	4-Aug-20
L-273-14/0	Chang, Nancy T.	(b)(4);	Grifols Worldwide Operations Ltd.	7-Aug-20
L-273-14/0	Crowl, Robert	(b)(6)	Grifols Worldwide Operations Ltd.	7-Aug-20
L-273-14/0	Fisher, Amanda G.		Grifols Worldwide Operations Ltd.	7-Aug-20
L-273-14/0	Hahn, Beatrice		Grifols Worldwide Operations Ltd.	7-Aug-20
L-273-14/0	Reddy, E. Premkumar.		Grifols Worldwide Operations Ltd.	7-Aug-20
L-273-14/0	Sargadharan, Mangalasse		Grifols Worldwide Operations Ltd.	7-Aug-20
L-213-20/0	Bagni- Beyer, Rachel K.		Bristol Myers Squibb Company	7-Aug-20
L-213-20/0	(b) (4)		Bristol Myers Squibb Company	7-Aug-20
L-213-20/0	Holderfield, Matthew T.		Bristol Myers Squibb Company	7-Aug-20
L-213-20/0	Soppet, Dan		Bristol Myers Squibb Company	7-Aug-20
L-149-19/0	NCI		Kite Pharma	11-Aug-20
L-225-18/0	Schlom, Jeffrey	(b)(4);	Incyte Corporation	11-Aug-20
L-151-19/0	Bonomi, Carrie A.	(b)(6)	Pliant Therapeutics, Inc	11-Aug-20
L-151-19/0	Borgel, Suzanne D.		Pliant Therapeutics, Inc	11-Aug-20
L-151-19/0	Dougherty, Kelly		Pliant Therapeutics, Inc	11-Aug-20
L-151-19/0	Hollingshead, Melinda G.		Pliant Therapeutics, Inc	11-Aug-20
L-073-20/0	Bonomi, Carrie A.		Glenmark Research Center	11-Aug-20
L-073-20/0	Borgel, Suzanne D.		Glenmark Research Center	11-Aug-20
L-073-20/0	Dougherty, Kelly		Glenmark Research Center	11-Aug-20
L-073-20/0	Hollingshead, Melinda G.		Glenmark Research Center	11-Aug-20
L-140-20/0	Bonomi, Carrie A.		Zymeworks Inc.	11-Aug-20
L-140-20/0	Borgel, Suzanne D.		Zymeworks Inc.	11-Aug-20
L-140-20/0	Dougherty, Kelly		Zymeworks Inc.	11-Aug-20
L-140-20/0	Hollingshead, Melinda G.		Zymeworks Inc.	11-Aug-20
L-224-17/0	Costantino, Nina		Delve Therapeutics	12-Aug-20
L-224-17/0	Court, Donald		Delve Therapeutics	12-Aug-20
L-224-17/0	Datta, Simanti		Delve Therapeutics	12-Aug-20

L-329-17/1	Gao, Wei	(b)(4);	Abpro	13-Aug-20
L-329-17/1	Ho, Mitchell	(b)(6)	Abpro	13-Aug-20
L-329-17/1	Phung, Yen T.		Abpro	13-Aug-20
L-329-17/1	Zhang, Yifan		Abpro	13-Aug-20
L-329-17/1	NCI		Abpro	13-Aug-20
L-165-99/1	Crowl, Robert	(b)(4);	Trinity Biotech	18-Aug-20
L-165-99/1	(b)(4)	(b)(6)	Trinity Biotech	18-Aug-20
L-165-99/1	Reddy, E. Premkumar.		Trinity Biotech	18-Aug-20
L-148-18/1	NCI		BravoVax Co., Ltd.	18-Aug-20
L-160-18/0	NCI		Advanced Imaging Projects, LLC (AIP)	18-Aug-20
<i>Note: L-160-18/0 split between CC; NCI</i>				
L-008-19/0	Doroshov, James H.	(b)(4);	AstraZeneca	19-Aug-20
L-008-19/0	Kinders, Robert	(b)(6)	AstraZeneca	19-Aug-20
L-008-19/0	Marrero, Allison M.		AstraZeneca	19-Aug-20
L-008-19/0	Parchment, Ralph E.		AstraZeneca	19-Aug-20
L-008-19/0	Pfister, Thomas D.		AstraZeneca	19-Aug-20
L-159-18/1	Bonomi, Carrie A.		Bicycle Therapeutics	19-Aug-20
L-159-18/1	Borgel, Suzanne D.		Bicycle Therapeutics	19-Aug-20
L-159-18/1	Dougherty, Kelly		Bicycle Therapeutics	19-Aug-20
L-159-18/1	Hollingshead, Melinda G.		Bicycle Therapeutics	19-Aug-20
L-049-91/5	Aaronson, Stuart A.		Biovitium AB (publ)	21-Aug-20
L-049-91/5	Finch, Paul W.		Biovitium AB (publ)	21-Aug-20
L-049-91/5	Rubin, Jeffrey S		Biovitium AB (publ)	21-Aug-20
L-049-01/3	Bustin, Michael		Millipore Sigma	21-Aug-20
L-277-14/2	NCI		Kite Pharma, Inc.	25-Aug-20
L-136-20/0	Dudley, Mark	(b)(4);	Intima Bioscience Inc.	25-Aug-20
L-136-20/0	Fitzgerald, Peter C.	(b)(6)	Intima Bioscience Inc.	25-Aug-20
L-136-20/0	Gros, Alena		Intima Bioscience Inc.	25-Aug-20
L-136-20/0	Lu, Yong-Chen W.		Intima Bioscience Inc.	25-Aug-20
L-136-20/0	Palmer, Douglas		Intima Bioscience Inc.	25-Aug-20
L-136-20/0	Restifo, Nicholas P.		Intima Bioscience Inc.	25-Aug-20
L-136-20/0	Robbins, Paul F		Intima Bioscience Inc.	25-Aug-20
L-136-20/0	Tran, Eric		Intima Bioscience Inc.	25-Aug-20
L-136-20/0	Wunderlich, John		Intima Bioscience Inc.	25-Aug-20
L-136-20/0	Zheng, Zhili		Intima Bioscience Inc.	25-Aug-20
L-162-08/1	Roberts (b)(6) Anita		BioLegend	26-Aug-20
L-162-08/1	Sporn, Michael B.		BioLegend	26-Aug-20
<i>Note: L-162-08/1 split between NCI; NIAID</i>				
L-095-12/0	Baskar, Sivasubramanian		BioLegend	26-Aug-20
L-095-12/0	Rader, Christoph		BioLegend	26-Aug-20

(b) (3) (A), (b) (4), (b) (6)

L-106-18/0	Bonomi, Carrie A.	(b)(4);	KSQ Therapeutics	27-Aug-20
L-106-18/0	Dougherty, Kelly	(b)(6)	KSQ Therapeutics	27-Aug-20
L-106-18/0	Hollingshead, Melinda G.		KSQ Therapeutics	27-Aug-20
L-133-19/1	Aaronson, Stuart A.		DNatrix, Inc.	27-Aug-20
L-133-19/1	Giard, Donald		DNatrix, Inc.	27-Aug-20
L-133-19/1	Parks, Wade P		DNatrix, Inc.	27-Aug-20
L-137-20/0	NCI		AbbVie	27-Aug-20
L-135-20/0	Gartner, Suzanne	(b)(4);	AbbVie	27-Aug-20
L-022-17/0	NCI		Etubics Corporation	28-Aug-20
L-022-17/0	(b)(4)	(b)(4);	Etubics Corporation	28-Aug-20
L-022-17/0	Gritz, Linda R.	(b)(6)	Etubics Corporation	28-Aug-20
L-022-17/0	Hodge, James W.		Etubics Corporation	28-Aug-20
L-022-17/0	Kantor, Judith A.		Etubics Corporation	28-Aug-20
L-022-17/0	Kozlov, Andrei P.		Etubics Corporation	28-Aug-20
L-022-17/0	Mazzara, Gail P.		Etubics Corporation	28-Aug-20
L-022-17/0	Palena, Claudia		Etubics Corporation	28-Aug-20
L-022-17/0	Panicali, Dennis L.		Etubics Corporation	28-Aug-20
L-022-17/0	Salazar, Elena Barzaga		Etubics Corporation	28-Aug-20
L-022-17/0	Schlom, Jeffrey		Etubics Corporation	28-Aug-20
L-022-17/0	Tsang, Kwong-Yok		Etubics Corporation	28-Aug-20
L-022-17/0	Zaremba, Sam		Etubics Corporation	28-Aug-20
L-083-11/0	NCI		AbbVie Biotherapeutics, Inc.	28-Aug-20
<i>Note: L-083-11/0 split between NCI; NINDS</i>				
L-113-19/1	Gottesman, Michael M.	(b)(4);	Pharmaron Beijing Co., LTD	28-Aug-20
L-113-19/1	Pastan, Ira H	(b)(6)	Pharmaron Beijing Co., LTD	28-Aug-20
L-113-19/1	Ueda, Kazumitsu		Pharmaron Beijing Co., LTD	28-Aug-20

(b) (3) (A), (b) (4), (b) (6)

NIH Patent Licensing Activities
NCI
September 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. M	Patent	Total September	License Cumulative	Inventor Awards	Net Remaining to
L-166-20/0	Bonomi, Carrie A.	(b)(4);	Evotec SAS	1-Sep-20						(b) (3) (A), (b) (4), (b) (6)
L-166-20/0	Dougherty, Kelly	(b)(6)	Evotec SAS	1-Sep-20						
L-166-20/0	Hollingshead, Melinda G.		Evotec SAS	1-Sep-20						
L-146-20/0	Bonomi, Carrie A.		Harpoon Therapeutics	1-Sep-20						
L-146-20/0	Borgel, Suzanne D.		Harpoon Therapeutics	1-Sep-20						
L-146-20/0	Dougherty, Kelly		Harpoon Therapeutics	1-Sep-20						
L-146-20/0	Hollingshead, Melinda G.		Harpoon Therapeutics	1-Sep-20						
L-281-19/1	Gazdar, Adi F.		Lengo Therapeutics, Inc	1-Sep-20						
L-281-19/1	Johnson, Bruce E		Lengo Therapeutics, Inc	1-Sep-20						

L-281-19/1	Kaye, Frederic J	(b)(4);	Lengo Therapeutics, Inc	1-Sep-20
L-281-19/1	Kheif, Samir N.	(b)(6)	Lengo Therapeutics, Inc	1-Sep-20
L-281-19/1	Minna, John D.		Lengo Therapeutics, Inc	1-Sep-20
L-281-19/1	Oie, Herbert K		Lengo Therapeutics, Inc	1-Sep-20
L-281-19/1	Pass, Harvey I.		Lengo Therapeutics, Inc	1-Sep-20
L-085-19/1	Aaronson, Stuart A.		NEUVOGEN, Inc	1-Sep-20
L-085-19/1	Gazdar, Adi F.		NEUVOGEN, Inc	1-Sep-20
L-085-19/1	Giard, Donald		NEUVOGEN, Inc	1-Sep-20
L-085-19/1	Johnson, Bruce E		NEUVOGEN, Inc	1-Sep-20
L-085-19/1	Kaye, Frederic J		NEUVOGEN, Inc	1-Sep-20
L-085-19/1	Kheif, Samir N.		NEUVOGEN, Inc	1-Sep-20
L-085-19/1	Minna, John D.		NEUVOGEN, Inc	1-Sep-20
L-085-19/1	Oie, Herbert K		NEUVOGEN, Inc	1-Sep-20
L-085-19/1	Parks, Wade P		NEUVOGEN, Inc	1-Sep-20
L-085-19/1	Pass, Harvey I.		NEUVOGEN, Inc	1-Sep-20
L-091-11/0	Fisher, Amanda G.		Quest Diagnostics, Inc.	2-Sep-20
L-091-11/0	Hahn, Beatrice		Quest Diagnostics, Inc.	2-Sep-20
L-091-11/0	(b) (4)		Quest Diagnostics, Inc.	2-Sep-20
L-099-18/0	NCI		Kite Pharma, Inc	2-Sep-20
L-089-16/3	NCI		H2Bio	3-Sep-20
L-026-05/8	NCI		INNATE PHARMA	4-Sep-20
L-167-20/0	Bonomi, Carrie A.	(b)(4);	GlaxoSmithKline LLC	4-Sep-20
L-167-20/0	Borgel, Suzanne D.	(b)(6)	GlaxoSmithKline LLC	4-Sep-20
L-167-20/0	Dougherty, Kelly		GlaxoSmithKline LLC	4-Sep-20
L-167-20/0	Hollingshead, Melinda G.		GlaxoSmithKline LLC	4-Sep-20
L-241-20/0	Bonomi, Carrie A.		Light Chain Bioscience-Novimmune SA	8-Sep-20
L-241-20/0	Borgel, Suzanne D.		Light Chain Bioscience-Novimmune SA	8-Sep-20
L-241-20/0	Dougherty, Kelly		Light Chain Bioscience-Novimmune SA	8-Sep-20
L-241-20/0	Hollingshead, Melinda G.		Light Chain Bioscience-Novimmune SA	8-Sep-20
L-241-20/0	Bonomi, Carrie A.		Light Chain Bioscience-Novimmune SA	8-Sep-20
L-241-20/0	Borgel, Suzanne D.		Light Chain Bioscience-Novimmune SA	8-Sep-20
L-241-20/0	Dougherty, Kelly		Light Chain Bioscience-Novimmune SA	8-Sep-20
L-241-20/0	Hollingshead, Melinda G.		Light Chain Bioscience-Novimmune SA	8-Sep-20
L-097-00/2	Austin, Faye C.		BD Biosciences, PharMingen	9-Sep-20
L-097-00/2	Colcher, David		BD Biosciences, PharMingen	9-Sep-20
L-097-00/2	Hand, Patricia H		BD Biosciences, PharMingen	9-Sep-20
L-097-00/2	Nuti, Marianna		BD Biosciences, PharMingen	9-Sep-20
L-097-00/2	Schlom, Jeffrey		BD Biosciences, PharMingen	9-Sep-20
L-091-10/0	Bonner, William M		Novus Biologicals, Inc.	9-Sep-20
L-091-10/0	Rogakou, Efthimia P		Novus Biologicals, Inc.	9-Sep-20
L-154-97/2	Mason, Llewellyn H.		BD Biosciences - BD PharMingen	9-Sep-20
L-154-97/2	Ortaldo, John R.		BD Biosciences - BD PharMingen	9-Sep-20

L-220-20/0	Bonomi, Carrie A.	(b)(4);	Inzen Therapeutics, Inc.	9-Sep-20
L-220-20/0	Borgel, Suzanne D.	(b)(6)	Inzen Therapeutics, Inc.	9-Sep-20
L-220-20/0	Dougherty, Kelly		Inzen Therapeutics, Inc.	9-Sep-20
L-220-20/0	Hollingshead, Melinda G.		Inzen Therapeutics, Inc.	9-Sep-20
L-220-20/0	Bonomi, Carrie A.		Inzen Therapeutics, Inc.	9-Sep-20
L-220-20/0	Borgel, Suzanne D.		Inzen Therapeutics, Inc.	9-Sep-20
L-220-20/0	Dougherty, Kelly		Inzen Therapeutics, Inc.	9-Sep-20
L-220-20/0	Hollingshead, Melinda G.		Inzen Therapeutics, Inc.	9-Sep-20
L-270-19/0	Bonomi, Carrie A.		Bluefin Biomedicine, Inc.	10-Sep-20
L-270-19/0	Borgel, Suzanne D.		Bluefin Biomedicine, Inc.	10-Sep-20
L-270-19/0	Dougherty, Kelly		Bluefin Biomedicine, Inc.	10-Sep-20
L-270-19/0	Hollingshead, Melinda G.		Bluefin Biomedicine, Inc.	10-Sep-20
L-037-19/0	Hodge, James W.		Merck KGaA	10-Sep-20
L-037-19/0	Schlom, Jeffrey		Merck KGaA	10-Sep-20
L-296-19/0	Bonomi, Carrie A.		Evelo Biosciences, Inc	10-Sep-20
L-296-19/0	Borgel, Suzanne D.		Evelo Biosciences, Inc	10-Sep-20
L-296-19/0	Dougherty, Kelly		Evelo Biosciences, Inc	10-Sep-20
L-296-19/0	Hollingshead, Melinda G.		Evelo Biosciences, Inc	10-Sep-20
L-083-11/0	Waldmann, Thomas A.		AbbVie Biotherapeutics, Inc.	10-Sep-20
<i>Note: L-083-11/0 split between NCI; NINDS</i>				
L-238-20/0	Bonomi, Carrie A.		Turnstone Biologics Inc.	11-Sep-20
L-238-20/0	Borgel, Suzanne D.		Turnstone Biologics Inc.	11-Sep-20
L-238-20/0	Dougherty, Kelly		Turnstone Biologics Inc.	11-Sep-20
L-238-20/0	Hollingshead, Melinda G.		Turnstone Biologics Inc.	11-Sep-20
L-238-20/0	Bonomi, Carrie A.		Turnstone Biologics Inc.	11-Sep-20
L-238-20/0	Borgel, Suzanne D.		Turnstone Biologics Inc.	11-Sep-20
L-238-20/0	Dougherty, Kelly		Turnstone Biologics Inc.	11-Sep-20
L-238-20/0	Hollingshead, Melinda G.		Turnstone Biologics Inc.	11-Sep-20
L-237-20/0	Bonomi, Carrie A.		Phenomic AI	11-Sep-20
L-237-20/0	Borgel, Suzanne D.		Phenomic AI	11-Sep-20
L-237-20/0	Dougherty, Kelly		Phenomic AI	11-Sep-20
L-237-20/0	Hollingshead, Melinda G.		Phenomic AI	11-Sep-20
L-237-20/0	Bonomi, Carrie A.		Phenomic AI	11-Sep-20
L-237-20/0	Borgel, Suzanne D.		Phenomic AI	11-Sep-20
L-237-20/0	Dougherty, Kelly		Phenomic AI	11-Sep-20
L-237-20/0	Hollingshead, Melinda G.		Phenomic AI	11-Sep-20

\$6,588,198.49	\$1,399,206.96	\$7,987,405.45	\$1,375,196.03	\$6,612,209.42
----------------	----------------	----------------	----------------	----------------

* denotes an adjustment to fix a problem from a previous month

NIH Patent Licensing Activities
NEI
April 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	--------------------	---------------------------	-----------------------	---------------------

NIH Patent Licensing Activities
NEI
May 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
L-139-20/0	Chen, Yu Holly	(b)(4);	EditForce, Inc.	21-May-20						(b) (3) (A), (b) (4), (b) (6)
L-139-20/0	English, Milton A	(b)(6)	EditForce, Inc.	21-May-20						
L-139-20/0	Shimada-Ishill, Hiroko		EditForce, Inc.	21-May-20						
L-139-20/0	Swaroop, Anand		EditForce, Inc.	21-May-20						
L-139-20/0	Chen, Yu Holly		EditForce, Inc.	24-May-20						
L-139-20/0	English, Milton A		EditForce, Inc.	24-May-20						
L-139-20/0	Shimada-Ishill, Hiroko		EditForce, Inc.	24-May-20						
L-139-20/0	Swaroop, Anand		EditForce, Inc.	24-May-20						
L-139-20/0	Chen, Yu Holly		EditForce, Inc.	24-May-20						
L-139-20/0	English, Milton A		EditForce, Inc.	24-May-20						
L-139-20/0	Shimada-Ishill, Hiroko		EditForce, Inc.	24-May-20						
L-139-20/0	Swaroop, Anand		EditForce, Inc.	24-May-20						

NIH Patent Licensing Activities
NEI
June 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-------------------	---------------------------	----------------------	---------------------

NIH Patent Licensing Activities
NEI
July 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
L-187-20/0	Bharti, Kapil	(b)(4);	Regeneron Pharmaceuticals, Inc.	28-Jul-20						(b) (3) (A), (b) (4), (b) (6)
L-187-20/0	Ruchi, Fnu	(b)(6)	Regeneron Pharmaceuticals, Inc.	28-Jul-20						

NIH Patent Licensing Activities
NEI
August 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
L-230-02/1	NEI		Bausch & Lomb	28-Aug-20						(b) (3) (A), (b) (4)

NIH Patent Licensing Activities
NEI
September 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
					\$3,503,761.80	\$0.00	\$3,503,761.80		\$12,484 97	\$3,491,276.83

NIH Patent Licensing Activities
NHGRI
April 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
L-068-20/0	Chandler, Randy J.	(b)(4);	Asklepios Biopharmaceuticals, Inc.	7-Apr-20						(b) (3) (A), (b) (4), (b) (6)
L-068-20/0	Manoli, Eirini	(b)(6)	Asklepios Biopharmaceuticals, Inc.	7-Apr-20						
L-068-20/0	Venditti, Charles P.		Asklepios Biopharmaceuticals, Inc.	7-Apr-20						
L-260-17/0	Sidransky, Ellen		Shire Human Genetic Therapies, Inc.	29-Apr-20						
L-260-17/0	Stubblefield, Barbara K.		Shire Human Genetic Therapies, Inc.	29-Apr-20						

NIH Patent Licensing Activities
NHGRI
May 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	------------------	---------------------------	---------------------	---------------------

NIH Patent Licensing Activities
NHGRI
June 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-------------------	---------------------------	----------------------	---------------------

NIH Patent Licensing Activities
NHGRI
July 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
L-146-18/0	Gahl, William A.	(b)(4);	Leadiant Biosciences	1-Jul-20						(b) (3) (A), (b) (4), (b) (6)
L-146-18/0	Huizing, Marjan	(b)(6)	Leadiant Biosciences	1-Jul-20						
L-146-18/0	Klootwijk, Riko		Leadiant Biosciences	1-Jul-20						
L-146-18/0	Manoli, Eirini		Leadiant Biosciences	1-Jul-20						

NIH Patent Licensing Activities
NHGRI
August 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
L-055-15/1	Goldin, Ehud M.	(b)(4);	Lysosomal Therapeutics, Inc.	4-Aug-20						(b) (3) (A), (b) (4), (b) (6)
L-055-15/1	Motabar, Omid	(b)(6)	Lysosomal Therapeutics, Inc.	4-Aug-20						
L-055-15/1	Sidransky, Ellen		Lysosomal Therapeutics, Inc.	4-Aug-20						
L-055-15/1	Westbroek, Wendy		Lysosomal Therapeutics, Inc.	4-Aug-20						

Note: L-055-15/1 split between NCATS; NHGRI

NIH Patent Licensing Activities
NHGRI
September 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
L-069-19/0	NHGRI		LogicBio Therapeutics, Inc.	1-Sep-20						(b) (3) (A), (b) (4)
L-032-12/0	NHGRI		Agios Pharmaceuticals Inc	2-Sep-20						

Note: L-032-12/0 split between NCATS; NHGRI

\$90,065.40 \$17,925.56 \$107,990.96 \$21,496.06 \$86,494.90

NIH Patent Licensing Activities
NHLBI
April 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
L-029-12/0	Derbyshire, John Andrew	(b)(4);	Koninklijke Philips Electronics NV	1-Apr-20						(b) (3) (A), (b) (4), (b) (6)
L-029-12/0	(b) (4)	(b)(6)	Koninklijke Philips Electronics NV	1-Apr-20						
L-029-12/0	McVeigh, Elliott R		Koninklijke Philips Electronics NV	1-Apr-20						
L-029-12/0	Nezafat, Reza		Koninklijke Philips Electronics NV	1-Apr-20						
L-106-20/0	Finkel, Toren		H. Lundbeck A/S	1-Apr-20						
L-159-07/2	NHLBI		Hope Pharmaceuticals	7-Apr-20						

Note: L-159-07/2 split between CC; NHLBI; NIDDK; NINDS

L-248-14/0	Chiorini, John A.	(b)(4);	Applied Genetic Technologies Corp	15-Apr-20	(b) (3) (A), (b) (4), (b) (6)	
L-248-14/0	Kotin, Robert M.	(b)(6)	Applied Genetic Technologies Corp	15-Apr-20		
L-248-14/0	NHLBI		Applied Genetic Technologies Corp	15-Apr-20		
L-124-17/1	(b) (4)		Generation Bio Co	15-Apr-20		
L-124-17/1	Kotin, Robert M.		Generation Bio Co	15-Apr-20		
L-124-17/1	Li, Lina		Generation Bio Co	15-Apr-20		
L-256-14/0	Combs, Christian A.		VisiTech International	21-Apr-20		
Note: L-256-14/0 split between NHLBI; NIBIB						
L-098-18/3	NHLBI		T-Cure Bioscience	24-Apr-20		

NIH Patent Licensing Activities
NHLBI
May 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
L-275-18/0	Amar, Marcelo A.	(b)(4);	Hartis-Pharma Sarl	11-May-20	(b) (3) (A), (b) (4), (b) (6)					
L-275-18/0	Brewer, H. Bryan	(b)(6)	Hartis-Pharma Sarl	11-May-20						
L-275-18/0	Demosky, Stephen J.		Hartis-Pharma Sarl	11-May-20						
L-275-18/0	Neufeld, Edward B.		Hartis-Pharma Sarl	11-May-20						
L-275-18/0	Remaley, Alan T.		Hartis-Pharma Sarl	11-May-20						
L-275-18/0	Stonik, John A.		Hartis-Pharma Sarl	11-May-20						
L-275-18/0	Thomas, Fairwell		Hartis-Pharma Sarl	11-May-20						
L-063-15/0	Ding, Chuantian		BioMarin Pharma.	15-May-20						
L-063-15/0	Kotin, Robert M.		BioMarin Pharma.	15-May-20						
L-063-15/0	Urabe, Masashi		BioMarin Pharma.	15-May-20						
L-063-15/0	Ding, Chuantian		BioMarin Pharma.	15-May-20						
L-063-15/0	Kotin, Robert M.		BioMarin Pharma.	15-May-20						
L-063-15/0	Urabe, Masashi		BioMarin Pharma.	15-May-20						
L-170-15/0	Chiorini, John A.		BioMarin Pharmaceuticals, Inc.	15-May-20						
L-170-15/0	Kotin, Robert M.		BioMarin Pharmaceuticals, Inc.	15-May-20						
L-186-18/0	NHLBI		Casebia Therapeutics	26-May-20						
*L-077-04/5	Ding, Chuantian	(b)(4);	Boeringer Ingelheim Pharma	28-May-20						
*L-077-04/5	Kotin, Robert M.	(b)(6)	Boeringer Ingelheim Pharma	28-May-20						
*L-077-04/5	Smith, Richard H.		Boeringer Ingelheim Pharma	28-May-20						
*L-077-04/5	Urabe, Masashi		Boeringer Ingelheim Pharma	28-May-20						
*L-074-12/0	Chiorini, John A.		Vector BioLabs-TGDC	28-May-20						
*L-074-12/0	Kotin, Robert M.		Vector BioLabs-TGDC	28-May-20						

NIH Patent Licensing Activities
NHLBI
June 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
*L-058-14/0	NHLBI		Spark Therapeutics Ireland Ltd	8-Jun-20						(b) (3) (A), (b) (4), (b) (6)
L-209-17/0	Derbyshire, John Andrew	(b)(4);	General Electric Co.	15-Jun-20						
L-209-17/0	(b) (4)	(b)(6)	General Electric Co.	15-Jun-20						
L-209-17/0	McVeigh, Elliott R		General Electric Co.	15-Jun-20						
L-209-17/0	Nezafat, Reza		General Electric Co.	15-Jun-20						
L-187-14/0	NHLBI		Andor Technology PLC	25-Jun-20						

Note: L-187-14/0 split between NHLBI; NIBIB

NIH Patent Licensing Activities
NHLBI
July 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
L-248-14/0	NHLBI		Applied Genetic Technologies Corp	8-Jul-20						(b) (3) (A), (b) (4)
L-069-09/0	NHLBI		MRI Interventions Inc	10-Jul-20						

NIH Patent Licensing Activities
NHLBI
August 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
L-096-16/1	Finkel, Toren	(b)(4);	Genentech, Inc.	20-Aug-20						(b) (3) (A), (b) (4), (b) (6)
L-243-16/0	Boehm, Manfred	(b)(6)	StemCell Technologies Inc.	21-Aug-20						
L-243-16/0	Chen, Guibin		StemCell Technologies Inc.	21-Aug-20						
L-243-16/0	Larochelle, Andre		StemCell Technologies Inc.	21-Aug-20						
Note: L-243-16/0 split between NHLBI; NIAMS										
L-209-17/0	Derbyshire, John Andrew		General Electric Co.	26-Aug-20						
L-209-17/0	(b) (4)		General Electric Co.	26-Aug-20						
L-209-17/0	McVeigh, Elliott R		General Electric Co.	26-Aug-20						
L-209-17/0	Nezafat, Reza		General Electric Co.	26-Aug-20						
L-181-17/0	NHLBI		Esteve Pharmaceuticals	28-Aug-20						
L-223-20/0	Chiorini, John A.	(b)(4);	Cellular Biomedicine Group, Inc	28-Aug-20						

L-223-20/0	Kotin, Robert M.	(b)(4); (b)(6)	Cellular Biomedicine Group, Inc	28-Aug-20	(b) (3) (A), (b) (4), (b) (6)				
L-223-20/0	Chiorini, John A.		Cellular Biomedicine Group, Inc	28-Aug-20					
L-223-20/0	Kotin, Robert M.		Cellular Biomedicine Group, Inc	28-Aug-20					

NIH Patent Licensing Activities

NHLBI

September 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
L-258-18/0	Derbyshire, John Andrew	(b)(4);	: Siemens Healthcare GmbH	8-Sep-20						(b) (3) (A), (b) (4), (b) (6)
L-258-18/0	(b) (4)	(b)(6)	: Siemens Healthcare GmbH	8-Sep-20						
L-258-18/0	McVeigh, Elliott R		: Siemens Healthcare GmbH	8-Sep-20						
L-258-18/0	Nezafat, Reza		: Siemens Healthcare GmbH	8-Sep-20						
					\$563,828.58	\$40,406.69	\$604,235.27		\$229,771.84	\$374,463.43

* denotes an adjustment to fix a problem from a previous month

NIH Patent Licensing Activities

NIA

April 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	--------------------	---------------------------	-----------------------	---------------------

NIH Patent Licensing Activities

NIA

May 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
L-328-14/0	NIA		Novo Nordisk A/S	18-May-20						(b) (3) (A), (b) (4)

NIH Patent Licensing Activities

NIA

June 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
L-025-17/1	Moaddel, Ruin	(b)(4);	Tocris Bioscience	9-Jun-20						(b) (3) (A), (b) (4), (b) (6)
<i>Note: L-025-17/1 split between NCATS; NIA; NIMH</i>										
L-132-17/0	Matarin Jimenez, Maria De	(b)(4);	CereDx Inc.	10-Jun-20						
L-132-17/0	Singleton, Andrew B.	(b)(6)	CereDx Inc.	10-Jun-20						

Note: L-132-17/0 split between NIA; NINDS; NINR

L-079-17/0 NIA VuEssence, Inc.
 Note: L-079-17/0 split between NIA; NINDS; NINR

22-Jun-20

(b) (3) (A), (b) (4)

NIH Patent Licensing Activities
 NIA
 July 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-------------------	---------------------------	----------------------	---------------------

NIH Patent Licensing Activities
 NIA
 August 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
L-281-14/1	NIA		Peptron	10-Aug-20						(b) (3) (A), (b) (4)
L-281-14/1	NIA		Peptron	25-Aug-20						

NIH Patent Licensing Activities
 NIA
 September 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
					\$2,399.50	\$16,434.62	\$18,834.12		\$1,379.50	\$17,454.62

NIH Patent Licensing Activities
 NIAAAA
 April 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
L-276-17/0	Cinar, Resat	(b)(4);	Vital Spark Inc.	1-Apr-20						(b) (3) (A), (b) (4), (b) (6)
L-276-17/0	Iyer, Malliga R.	(b)(6)	Vital Spark Inc.	1-Apr-20						
L-276-17/0	Kunos, George I		Vital Spark Inc.	1-Apr-20						

Note: L-276-17/0 split between NIAAAA; NIDA

NIH Patent Licensing Activities
 NIAAAA
 May 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	------------------	---------------------------	---------------------	---------------------

NIH Patent Licensing Activities
NIAAA
June 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
L-194-05/1	Kunos, George I	(b)(4);	Tocris Bioscience	9-Jun-20						(b) (3) (A), (b) (4), (b) (6)

NIH Patent Licensing Activities
NIAAA
July 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-------------------	---------------------------	----------------------	---------------------

NIH Patent Licensing Activities
NIAAA
August 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	---------------------	---------------------------	------------------------	---------------------

NIH Patent Licensing Activities
NIAAA
September 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	------------------------	---------------------------	---------------------------	---------------------

					\$19,653.50	\$0.00	\$19,653.50		\$4,991.00	\$14,662.50
--	--	--	--	--	-------------	--------	-------------	--	------------	-------------

NIH Patent Licensing Activities
NIAID
April 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
L-128-20/0	Abisola Abiona, Olubukola	(b)(4);	Dynavax Technologies, Inc.	1-Apr-20						(b) (3) (A), (b) (4), (b) (6)
L-128-20/0	Cheng, Cheng	(b)(6)	Dynavax Technologies, Inc.	1-Apr-20						
L-128-20/0	Corbett, Kizzmekia		Dynavax Technologies, Inc.	1-Apr-20						
L-128-20/0	Graham, Barney S.		Dynavax Technologies, Inc.	1-Apr-20						

L-128-20/0	Hutchinson, Geoffrey Bain	(b)(4):	Dynavax Technologies, Inc.	1-Apr-20
L-128-20/0	Joyce, Michael G.	(b)(6)	Dynavax Technologies, Inc.	1-Apr-20
L-128-20/0	Kanekiyo, Masaru		Dynavax Technologies, Inc.	1-Apr-20
L-128-20/0	Merritt, Joshua S.		Dynavax Technologies, Inc.	1-Apr-20
L-128-20/0	Schwartz, Richard M.		Dynavax Technologies, Inc.	1-Apr-20
L-128-20/0	Yassine, Hadi M.		Dynavax Technologies, Inc.	1-Apr-20
L-079-93/2	Ohara, Junichi		BD Biosciences - BD PharMingen	2-Apr-20
L-079-93/2	Paul, (b) (6) William E.		BD Biosciences - BD PharMingen	2-Apr-20
L-074-91/3	Harriman, Gregory R.		Becton, Dickson and Company	2-Apr-20
L-074-91/3	Kunimoto, Dennis Y.		Becton, Dickson and Company	2-Apr-20
L-074-91/3	Paul (b) (6) William E.		Becton, Dickson and Company	2-Apr-20
L-074-91/3	Strober, Warren		Becton, Dickson and Company	2-Apr-20
L-001-15/2	Blaney, Jr., Joseph E		Merck Sharp & Dohme, Corp.	2-Apr-20
L-001-15/2	Bray, Michael		Merck Sharp & Dohme, Corp.	2-Apr-20
L-001-15/2	Chanock, (b) (6) Robert		Merck Sharp & Dohme, Corp.	2-Apr-20
L-001-15/2	Eckels, Kenneth H		Merck Sharp & Dohme, Corp.	2-Apr-20
L-001-15/2	Hanley, Kathryn		Merck Sharp & Dohme, Corp.	2-Apr-20
L-001-15/2	Lai, Ching-Juh		Merck Sharp & Dohme, Corp.	2-Apr-20
L-001-15/2	Men, Ruhe		Merck Sharp & Dohme, Corp.	2-Apr-20
L-001-15/2	Murphy, Brian R.		Merck Sharp & Dohme, Corp.	2-Apr-20
L-001-15/2	Pletnev, Alexander G		Merck Sharp & Dohme, Corp.	2-Apr-20
L-001-15/2	Whitehead, Stephen S.		Merck Sharp & Dohme, Corp.	2-Apr-20
L-001-15/2	Zhang, Yi-Ming		Merck Sharp & Dohme, Corp.	2-Apr-20
<i>Note: L-001-15/2 split between FDA; NIAID</i>				
L-129-20/0	Abisola Abiona, Olubukola		N4 Pharma UK Limited	2-Apr-20
L-129-20/0	Corbett, Kizzmekia		N4 Pharma UK Limited	2-Apr-20
L-129-20/0	Graham, Barney S.		N4 Pharma UK Limited	2-Apr-20
L-129-20/0	Hutchinson, Geoffrey Bain		N4 Pharma UK Limited	2-Apr-20
L-129-20/0	Joyce, Michael G.		N4 Pharma UK Limited	2-Apr-20
L-129-20/0	Kanekiyo, Masaru		N4 Pharma UK Limited	2-Apr-20
L-129-20/0	Yassine, Hadi M.		N4 Pharma UK Limited	2-Apr-20
L-138-16/1	Biacchesi, Stephanie		Merck Sharp & Dohme Corp.	3-Apr-20
L-138-16/1	Buchholz, Ursula		Merck Sharp & Dohme Corp.	3-Apr-20
L-138-16/1	Collins, Peter L.		Merck Sharp & Dohme Corp.	3-Apr-20
L-144-14/1	Baxa, Ulrich		GlaxoSmithKline Biologicals SA	3-Apr-20
L-144-14/1	Boyington, Jeffrey C.		GlaxoSmithKline Biologicals SA	3-Apr-20
L-144-14/1	Chen, Lei		GlaxoSmithKline Biologicals SA	3-Apr-20
L-144-14/1	Chen, Man		GlaxoSmithKline Biologicals SA	3-Apr-20
L-144-14/1	Chuang, Gwo-Yu		GlaxoSmithKline Biologicals SA	3-Apr-20
L-144-14/1	Druz, Aliaksandr A.		GlaxoSmithKline Biologicals SA	3-Apr-20
L-144-14/1	Galen, Joseph Van		GlaxoSmithKline Biologicals SA	3-Apr-20
L-144-14/1	Georgiev, Ivelin S.		GlaxoSmithKline Biologicals SA	3-Apr-20
L-144-14/1	Gorman, Jason		GlaxoSmithKline Biologicals SA	3-Apr-20
L-144-14/1	Graham, Barney S.		GlaxoSmithKline Biologicals SA	3-Apr-20
L-144-14/1	Joyce, Michael G.		GlaxoSmithKline Biologicals SA	3-Apr-20
L-144-14/1	Kanekiyo, Masaru		GlaxoSmithKline Biologicals SA	3-Apr-20
L-144-14/1	Kong, Wing-pui		GlaxoSmithKline Biologicals SA	3-Apr-20

L-144-14/1	Kwong, Peter D.	(b)(4);	GlaxoSmithKline Biologicals SA	3-Apr-20
L-144-14/1	Mascola, John R.	(b)(6)	GlaxoSmithKline Biologicals SA	3-Apr-20
L-144-14/1	McLellan, Jason Scott		GlaxoSmithKline Biologicals SA	3-Apr-20
L-144-14/1	OFEK, GILAD A		GlaxoSmithKline Biologicals SA	3-Apr-20
L-144-14/1	Ou, Li		GlaxoSmithKline Biologicals SA	3-Apr-20
L-144-14/1	Pancera, Marie L.		GlaxoSmithKline Biologicals SA	3-Apr-20
L-144-14/1	Rundlet, Emily		GlaxoSmithKline Biologicals SA	3-Apr-20
L-144-14/1	Sastry, Mallika		GlaxoSmithKline Biologicals SA	3-Apr-20
L-144-14/1	Soto, Cinque		GlaxoSmithKline Biologicals SA	3-Apr-20
L-144-14/1	Srivatsan, Sanjay R.		GlaxoSmithKline Biologicals SA	3-Apr-20
L-144-14/1	Stewart-Jones, Guillaume B		GlaxoSmithKline Biologicals SA	3-Apr-20
L-144-14/1	Thomas, Paul V.		GlaxoSmithKline Biologicals SA	3-Apr-20
L-144-14/1	Tsybovsky, Yaroslav		GlaxoSmithKline Biologicals SA	3-Apr-20
L-144-14/1	YANG, YONGPING		GlaxoSmithKline Biologicals SA	3-Apr-20
L-144-14/1	Zhang, Baoshan		GlaxoSmithKline Biologicals SA	3-Apr-20
L-144-14/1	Zhou, Tongqing		GlaxoSmithKline Biologicals SA	3-Apr-20
L-140-98/1	Beeler, Judy A.		SmithKline Beecham	3-Apr-20
L-140-98/1	Chanock, (b) (6) Robert		SmithKline Beecham	3-Apr-20
L-140-98/1	Coelingh, Kathleen L.		SmithKline Beecham	3-Apr-20
L-140-98/1	Collins, Peter L.		SmithKline Beecham	3-Apr-20
L-140-98/1	Murphy, Brian R.		SmithKline Beecham	3-Apr-20
L-028-19/0	NIAID		Ridgeback Biotherapeutics	6-Apr-20
L-162-15/2	NIAID		Merck Sharp and dohme	15-Apr-20
L-141-20/0	Abisola Abiona, Olubukola	(b)(4);	RNAceuticals, Inc.	17-Apr-20
L-141-20/0	Corbett, Kizzmekia	(b)(6)	RNAceuticals, Inc.	17-Apr-20
L-141-20/0	Graham, Barney S.		RNAceuticals, Inc.	17-Apr-20
L-141-20/0	Hutchinson, Geoffrey Bain		RNAceuticals, Inc.	17-Apr-20
L-141-20/0	Joyce, Michael G.		RNAceuticals, Inc.	17-Apr-20
L-141-20/0	Kanekiyo, Masaru		RNAceuticals, Inc.	17-Apr-20
L-141-20/0	Yassine, Hadi M.		RNAceuticals, Inc.	17-Apr-20
L-162-15/2	Baxa, Ulrich		Merck Sharp and dohme	20-Apr-20
L-162-15/2	Boyington, Jeffrey C.		Merck Sharp and dohme	20-Apr-20
L-162-15/2	Chen, Lei		Merck Sharp and dohme	20-Apr-20
L-162-15/2	Chen, Man		Merck Sharp and dohme	20-Apr-20
L-162-15/2	Chuang, Gwo-Yu		Merck Sharp and dohme	20-Apr-20
L-162-15/2	Druz, Aliaksandr A.		Merck Sharp and dohme	20-Apr-20
L-162-15/2	Galen, Joseph Van		Merck Sharp and dohme	20-Apr-20
L-162-15/2	Georgiev, Ivelin S.		Merck Sharp and dohme	20-Apr-20
L-162-15/2	Gorman, Jason		Merck Sharp and dohme	20-Apr-20
L-162-15/2	Graham, Barney S.		Merck Sharp and dohme	20-Apr-20
L-162-15/2	Joyce, Michael G.		Merck Sharp and dohme	20-Apr-20
L-162-15/2	Kanekiyo, Masaru		Merck Sharp and dohme	20-Apr-20
L-162-15/2	Kong, Wing-pui		Merck Sharp and dohme	20-Apr-20
L-162-15/2	Kwong, Peter D.		Merck Sharp and dohme	20-Apr-20
L-162-15/2	Mascola, John R.		Merck Sharp and dohme	20-Apr-20
L-162-15/2	McLellan, Jason Scott		Merck Sharp and dohme	20-Apr-20
L-162-15/2	OFEK, GILAD A		Merck Sharp and dohme	20-Apr-20
L-162-15/2	Ou, Li		Merck Sharp and dohme	20-Apr-20

L-162-15/2	Pancera, Marie L.	(b)	Merck Sharp and dohme	20-Apr-20
L-162-15/2	Rundlet, Emily	(4):	Merck Sharp and dohme	20-Apr-20
L-162-15/2	Sastry, Mallika	(b)(6)	Merck Sharp and dohme	20-Apr-20
L-162-15/2	Soto, Cinque		Merck Sharp and dohme	20-Apr-20
L-162-15/2	Srivatsan, Sanjay R.		Merck Sharp and dohme	20-Apr-20
L-162-15/2	Stewart-Jones, Guillaume B		Merck Sharp and dohme	20-Apr-20
L-162-15/2	Thomas, Paul V.		Merck Sharp and dohme	20-Apr-20
L-162-15/2	Tsybovsky, Yaroslav		Merck Sharp and dohme	20-Apr-20
L-162-15/2	YANG, YONGPING		Merck Sharp and dohme	20-Apr-20
L-162-15/2	Zhang, Baoshan		Merck Sharp and dohme	20-Apr-20
L-162-15/2	Zhou, Tongqing		Merck Sharp and dohme	20-Apr-20
L-037-06/0	NIAID		Apath, LLC	20-Apr-20
L-253-15/0	NIAID		Sun Biotech Pte., Ltd.	21-Apr-20
L-078-11/0	Mackett, Michael	(b)(4);	CEVA Biomune	21-Apr-20
L-078-11/0	Moss, Bernard	(b)(6)	CEVA Biomune	21-Apr-20
L-078-11/0	Smith, Geoffrey L		CEVA Biomune	21-Apr-20
L-044-18/1	Boyington, Jeffrey C.		ModernaTX, Inc.	21-Apr-20
L-044-18/1	Buchholz, Ursula		ModernaTX, Inc.	21-Apr-20
L-044-18/1	Chen, Lei		ModernaTX, Inc.	21-Apr-20
L-044-18/1	Chen, Man		ModernaTX, Inc.	21-Apr-20
L-044-18/1	Chuang, Gwo-Yu		ModernaTX, Inc.	21-Apr-20
L-044-18/1	Collins, Peter L.		ModernaTX, Inc.	21-Apr-20
L-044-18/1	Druz, Aliaksandr A.		ModernaTX, Inc.	21-Apr-20
L-044-18/1	Georgiev, Ivelin S.		ModernaTX, Inc.	21-Apr-20
L-044-18/1	Gorman, Jason		ModernaTX, Inc.	21-Apr-20
L-044-18/1	Graham, Barney S.		ModernaTX, Inc.	21-Apr-20
L-044-18/1	Joyce, Michael G.		ModernaTX, Inc.	21-Apr-20
L-044-18/1	Kanekiyo, Masaru		ModernaTX, Inc.	21-Apr-20
L-044-18/1	Kong, Wing-pui		ModernaTX, Inc.	21-Apr-20
L-044-18/1	Kwong, Peter D.		ModernaTX, Inc.	21-Apr-20
L-044-18/1	Mascola, John R.		ModernaTX, Inc.	21-Apr-20
L-044-18/1	McLellan, Jason Scott		ModernaTX, Inc.	21-Apr-20
L-044-18/1	OFEK, GILAD A		ModernaTX, Inc.	21-Apr-20
L-044-18/1	Ou, Li		ModernaTX, Inc.	21-Apr-20
L-044-18/1	Pancera, Marie L.		ModernaTX, Inc.	21-Apr-20
L-044-18/1	Sastry, Mallika		ModernaTX, Inc.	21-Apr-20
L-044-18/1	Soto, Cinque		ModernaTX, Inc.	21-Apr-20
L-044-18/1	Srivatsan, Sanjay R.		ModernaTX, Inc.	21-Apr-20
L-044-18/1	Stewart-Jones, Guillaume B		ModernaTX, Inc.	21-Apr-20
L-044-18/1	Thomas, Paul V.		ModernaTX, Inc.	21-Apr-20
L-044-18/1	Xu, Kai		ModernaTX, Inc.	21-Apr-20
L-044-18/1	YANG, YONGPING		ModernaTX, Inc.	21-Apr-20
L-044-18/1	Zhang, Baoshan		ModernaTX, Inc.	21-Apr-20
L-044-18/1	Zhou, Tongqing		ModernaTX, Inc.	21-Apr-20
L-057-18/0	Akin, Cem		Opsidio, LLC	21-Apr-20
L-057-18/0	Kirshenbaum, Arnold		Opsidio, LLC	21-Apr-20
L-057-18/0	Metcalfe, Dean D		Opsidio, LLC	21-Apr-20

(b) (3) (A), (b) (4), (b) (6)

L-057-18/0	Akin, Cem	(b)(4);	Opsidio, LLC	21-Apr-20
L-057-18/0	Kirshenbaum, Arnold	(b)(6)	Opsidio, LLC	21-Apr-20
L-057-18/0	Metcalfe, Dean D		Opsidio, LLC	21-Apr-20
L-057-20/0	NIAID		Drugs & Diagnostics for Tropical Disease	21-Apr-20
L-057-20/0	NIAID		Drugs & Diagnostics for Tropical Disease	21-Apr-20
L-144-14/1	Baxa, Ulrich	(b)(4);	GlaxoSmithKline Biologicals SA	22-Apr-20
L-144-14/1	Boyington, Jeffrey C.	(b)(6)	GlaxoSmithKline Biologicals SA	22-Apr-20
L-144-14/1	Chen, Lei		GlaxoSmithKline Biologicals SA	22-Apr-20
L-144-14/1	Chen, Man		GlaxoSmithKline Biologicals SA	22-Apr-20
L-144-14/1	Chuang, Gwo-Yu		GlaxoSmithKline Biologicals SA	22-Apr-20
L-144-14/1	Druz, Aliaksandr A.		GlaxoSmithKline Biologicals SA	22-Apr-20
L-144-14/1	Galen, Joseph Van		GlaxoSmithKline Biologicals SA	22-Apr-20
L-144-14/1	Georgiev, Ivelin S.		GlaxoSmithKline Biologicals SA	22-Apr-20
L-144-14/1	Gorman, Jason		GlaxoSmithKline Biologicals SA	22-Apr-20
L-144-14/1	Graham, Barney S.		GlaxoSmithKline Biologicals SA	22-Apr-20
L-144-14/1	Joyce, Michael G.		GlaxoSmithKline Biologicals SA	22-Apr-20
L-144-14/1	Kanekiyo, Masaru		GlaxoSmithKline Biologicals SA	22-Apr-20
L-144-14/1	Kong, Wing-pui		GlaxoSmithKline Biologicals SA	22-Apr-20
L-144-14/1	Kwong, Peter D.		GlaxoSmithKline Biologicals SA	22-Apr-20
L-144-14/1	Mascola, John R.		GlaxoSmithKline Biologicals SA	22-Apr-20
L-144-14/1	McLellan, Jason Scott		GlaxoSmithKline Biologicals SA	22-Apr-20
L-144-14/1	OFEK, GILAD A		GlaxoSmithKline Biologicals SA	22-Apr-20
L-144-14/1	Ou, Li		GlaxoSmithKline Biologicals SA	22-Apr-20
L-144-14/1	Pancera, Marie L.		GlaxoSmithKline Biologicals SA	22-Apr-20
L-144-14/1	Rundlet, Emily		GlaxoSmithKline Biologicals SA	22-Apr-20
L-144-14/1	Sastry, Mallika		GlaxoSmithKline Biologicals SA	22-Apr-20
L-144-14/1	Soto, Cinque		GlaxoSmithKline Biologicals SA	22-Apr-20
L-144-14/1	Srivatsan, Sanjay R.		GlaxoSmithKline Biologicals SA	22-Apr-20
L-144-14/1	Stewart-Jones, Guillaume B		GlaxoSmithKline Biologicals SA	22-Apr-20
L-144-14/1	Thomas, Paul V.		GlaxoSmithKline Biologicals SA	22-Apr-20
L-144-14/1	Tsybovsky, Yaroslav		GlaxoSmithKline Biologicals SA	22-Apr-20
L-144-14/1	YANG, YONGPING		GlaxoSmithKline Biologicals SA	22-Apr-20
L-144-14/1	Zhang, Baoshan		GlaxoSmithKline Biologicals SA	22-Apr-20
L-144-14/1	Zhou, Tongqing		GlaxoSmithKline Biologicals SA	22-Apr-20
L-093-05/4	Chakrabarti, Bimal K		Janssen Vaccines & Prevention BV	23-Apr-20
L-093-05/4	Cheng, Cheng		Janssen Vaccines & Prevention BV	23-Apr-20
L-093-05/4	(b)(6) Clement K. Asiedu		Janssen Vaccines & Prevention BV	23-Apr-20
L-093-05/4	Huang, (b)(6) Yue		Janssen Vaccines & Prevention BV	23-Apr-20
L-093-05/4	Mackett, Michael		Janssen Vaccines & Prevention BV	23-Apr-20
L-093-05/4	Moss, Bernard		Janssen Vaccines & Prevention BV	23-Apr-20
L-093-05/4	Nabel, Gary J		Janssen Vaccines & Prevention BV	23-Apr-20
L-093-05/4	Smith, Geoffrey L		Janssen Vaccines & Prevention BV	23-Apr-20
L-093-05/4	Sullivan, Nancy J		Janssen Vaccines & Prevention BV	23-Apr-20
L-093-05/4	Ward, Lucy A.		Janssen Vaccines & Prevention BV	23-Apr-20
L-093-05/4	Yang, Zhi-Yong		Janssen Vaccines & Prevention BV	23-Apr-20
<i>Note: L-093-05/4 split between CDC; NIAID</i>				
L-124-18/0	Garboczi, David		Abcam plc	23-Apr-20
L-124-18/0	Lantz, Larry		Abcam plc	23-Apr-20

(b) (3) (A), (b) (4), (b) (6)

L-124-18/0	Leppla, Stephen H.	(b)(4);	Abcam plc	23-Apr-20
L-124-18/0	Leysath, Clinton E.	(b)(6)	Abcam plc	23-Apr-20
L-124-18/0	Phillips, Damilola D.		Abcam plc	23-Apr-20
L-035-18/0	DeVico, Angela M.		Celgene Corporation	23-Apr-20
L-035-18/0	Shevach, Ethan M		Celgene Corporation	23-Apr-20
L-191-16/2	Akin, Cem		GlaxoSmithKline LLC	24-Apr-20
L-191-16/2	Kirshenbaum, Arnold		GlaxoSmithKline LLC	24-Apr-20
L-191-16/2	Metcalfe, Dean D		GlaxoSmithKline LLC	24-Apr-20
L-019-20/0	Connors, Mark		ViiV Healthcare UK (No.6) Ltd	24-Apr-20
L-019-20/0	Huang, Jinghe		ViiV Healthcare UK (No.6) Ltd	24-Apr-20
L-019-20/0	Ishida, Elilse H.		ViiV Healthcare UK (No.6) Ltd	24-Apr-20
L-019-20/0	Kang, Byong Ha		ViiV Healthcare UK (No.6) Ltd	24-Apr-20
L-019-20/0	Kong, Wing-pui		ViiV Healthcare UK (No.6) Ltd	24-Apr-20
L-019-20/0	Kwong, Peter D.		ViiV Healthcare UK (No.6) Ltd	24-Apr-20
L-019-20/0	Mascola, John R.		ViiV Healthcare UK (No.6) Ltd	24-Apr-20
L-019-20/0	Shi, Wei		ViiV Healthcare UK (No.6) Ltd	24-Apr-20
L-019-20/0	Zheng, Anqi		ViiV Healthcare UK (No.6) Ltd	24-Apr-20
L-019-20/0	Zhou, Tongqing		ViiV Healthcare UK (No.6) Ltd	24-Apr-20
L-046-17/1	Blaney, Jr., Joseph E		Medigen Vaccine Biologics Corp	24-Apr-20
L-046-17/1	Hanley, Kathryn		Medigen Vaccine Biologics Corp	24-Apr-20
L-046-17/1	Lai, Ching-Juh		Medigen Vaccine Biologics Corp	24-Apr-20
L-046-17/1	Murphy, Brian R.		Medigen Vaccine Biologics Corp	24-Apr-20
L-046-17/1	Whitehead, Stephen S.		Medigen Vaccine Biologics Corp	24-Apr-20
<i>Note: L-046-17/1 split between FDA; NIAID</i>				
L-039-20/0	Chen, Xi		Novartis Pharma AG	28-Apr-20
L-039-20/0	Paul (b) (6) William E.		Novartis Pharma AG	28-Apr-20

(b) (3) (A), (b) (4), (b) (6)

NIH Patent Licensing Activities

NIAID

May 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
L-121-20/0	NIAID		Noachis Terra Inc	1-May-20						(b) (3) (A), (b) (4), (b) (6)
L-117-20/0	Emerson, Suzanne U.	(b)(4);	Southern Research Institute	4-May-20						
L-117-20/0	Nguyen, Hanh T.	(b)(6)	Southern Research Institute	4-May-20						
L-117-20/0	Purcell, Robert H		Southern Research Institute	4-May-20						
L-117-20/0	Shukla Bajpai, Priyanka		Southern Research Institute	4-May-20						
L-117-20/0	Torian, Udana M		Southern Research Institute	4-May-20						
L-203-19/1	Akin, Cem		AstraZeneca AB	5-May-20						
L-203-19/1	Kirshenbaum, Arnold		AstraZeneca AB	5-May-20						
L-203-19/1	Metcalfe, Dean D		AstraZeneca AB	5-May-20						
L-203-19/1	Akin, Cem		AstraZeneca AB	5-May-20						

L-203-19/1	Kirshenbaum, Arnold	(b)(4);	AstraZeneca AB	5-May-20
L-203-19/1	Metcalfe, Dean D	(b)(6)	AstraZeneca AB	5-May-20
L-119-09/2	Blaney, Jr., Joseph E		Fundacao Butantan	5-May-20
L-119-09/2	Hanley, Kathryn		Fundacao Butantan	5-May-20
L-119-09/2	Lai, Ching-Juh		Fundacao Butantan	5-May-20
L-119-09/2	Murphy, Brian R.		Fundacao Butantan	5-May-20
L-119-09/2	Whitehead, Stephen S.		Fundacao Butantan	5-May-20
<i>Note: L-119-09/2 split between FDA; NIAID</i>				
L-298-19/0	Connors, Mark		GlaxoSmithKline Intellectual Property Li	5-May-20
L-298-19/0	Huang, Jinghe		GlaxoSmithKline Intellectual Property Li	5-May-20
L-298-19/0	Ishida, Eilise H.		GlaxoSmithKline Intellectual Property Li	5-May-20
L-298-19/0	Kang, Byong Ha		GlaxoSmithKline Intellectual Property Li	5-May-20
L-298-19/0	Kwong, Peter D.		GlaxoSmithKline Intellectual Property Li	5-May-20
L-298-19/0	Mascola, John R.		GlaxoSmithKline Intellectual Property Li	5-May-20
L-298-19/0	Zheng, Anqi		GlaxoSmithKline Intellectual Property Li	5-May-20
L-298-19/0	Zhou, Tongqing		GlaxoSmithKline Intellectual Property Li	5-May-20
L-298-19/0	NIAID		GlaxoSmithKline Intellectual Property Li	5-May-20
L-071-10/1	DeVico, Angela M.	(b)(4);	BioLegend	6-May-20
L-071-10/1	Korty, Patricia E.	(b)(6)	BioLegend	6-May-20
L-071-10/1	Shevach, Ethan M		BioLegend	6-May-20
L-121-20/0	Abisola Abiona, Olubukola		Noachis Terra Inc	6-May-20
L-121-20/0	Corbett, Kizzmekia		Noachis Terra Inc	6-May-20
L-121-20/0	Graham, Barney S.		Noachis Terra Inc	6-May-20
L-121-20/0	Hutchinson, Geoffrey Bain		Noachis Terra Inc	6-May-20
L-121-20/0	Joyce, Michael G.		Noachis Terra Inc	6-May-20
L-121-20/0	Kanekiyo, Masaru		Noachis Terra Inc	6-May-20
L-121-20/0	Yassine, Hadi M.		Noachis Terra Inc	6-May-20
L-068-05/2	NIAID		Fundacao	12-May-20
L-162-20/0	Abisola Abiona, Olubukola	(b)(4);	Adimmune Corporation	14-May-20
L-162-20/0	Corbett, Kizzmekia	(b)(6)	Adimmune Corporation	14-May-20
L-162-20/0	(b) (4)		Adimmune Corporation	14-May-20
L-162-20/0	Graham, Barney S.		Adimmune Corporation	14-May-20
L-162-20/0	Hutchinson, Geoffrey Bain		Adimmune Corporation	14-May-20
L-162-20/0	Joyce, Michael G.		Adimmune Corporation	14-May-20
L-162-20/0	Kanekiyo, Masaru		Adimmune Corporation	14-May-20
L-162-20/0	(b) (4)		Adimmune Corporation	14-May-20
L-162-20/0	(b) (4)		Adimmune Corporation	14-May-20
L-162-20/0	Yassine, Hadi M.		Adimmune Corporation	14-May-20
L-163-20/0	Abisola Abiona, Olubukola		Vaxess Technologies	18-May-20
L-163-20/0	Corbett, Kizzmekia		Vaxess Technologies	18-May-20
L-163-20/0	(b) (4)		Vaxess Technologies	18-May-20
L-163-20/0	Graham, Barney S.		Vaxess Technologies	18-May-20
L-163-20/0	Hutchinson, Geoffrey Bain		Vaxess Technologies	18-May-20
L-163-20/0	Joyce, Michael G.		Vaxess Technologies	18-May-20
L-163-20/0	Kanekiyo, Masaru		Vaxess Technologies	18-May-20

(b) (3) (A), (b) (4), (b) (6)

L-163-20/0	Kong, Wing-pui	(b)(4);	Vaxess Technologies	18-May-20
L-163-20/0	Mascola, John R.	(b)(6)	Vaxess Technologies	18-May-20
L-163-20/0	(b) (4)		Vaxess Technologies	18-May-20
L-163-20/0	(b) (4)		Vaxess Technologies	18-May-20
L-163-20/0	Wang, Lingshu		Vaxess Technologies	18-May-20
L-163-20/0	Yassine, Hadi M.		Vaxess Technologies	18-May-20
*L-164-15/0	Emerson, Suzanne U.		Texcell	19-May-20
*L-164-15/0	Nguyen, Hanh T.		Texcell	19-May-20
*L-164-15/0	Purcell, Robert H		Texcell	19-May-20
L-164-15/0	(b) (4)		Texcell	19-May-20
*L-164-15/0	Shukla Bajpai, Priyanka		Texcell	19-May-20
*L-061-13/0	NIAID		BioFactura, Inc.	20-May-20
L-244-19/0	De Wit, Emmie	(b)(4);	Public Health Vaccines, LLC.	21-May-20
L-244-19/0	DeBuysscher, Blair Lynn	(b)(6)	Public Health Vaccines, LLC.	21-May-20
L-244-19/0	fFldmann, Heinrich Ulrich		Public Health Vaccines, LLC.	21-May-20
L-244-19/0	Marzi, Andrea Maria		Public Health Vaccines, LLC.	21-May-20
L-244-19/0	Prescott, Joseph		Public Health Vaccines, LLC.	21-May-20
L-147-20/0	Abisola Abiona, Olubukola		Sanofi Pasteur	28-May-20
L-147-20/0	Corbett, Kizzmekia		Sanofi Pasteur	28-May-20
L-147-20/0	Graham, Barney S.		Sanofi Pasteur	28-May-20
L-147-20/0	Hutchinson, Geoffrey Bain		Sanofi Pasteur	28-May-20
L-147-20/0	Joyce, Michael G.		Sanofi Pasteur	28-May-20
L-147-20/0	Kanekiyo, Masaru		Sanofi Pasteur	28-May-20
L-147-20/0	Kong, Wing-pui		Sanofi Pasteur	28-May-20
L-147-20/0	Mascola, John R.		Sanofi Pasteur	28-May-20
L-147-20/0	Wang, Lingshu		Sanofi Pasteur	28-May-20
L-147-20/0	Yassine, Hadi M.		Sanofi Pasteur	28-May-20
L-158-20/0	Abisola Abiona, Olubukola		AbCellera Biologics Inc.	28-May-20
L-158-20/0	Corbett, Kizzmekia		AbCellera Biologics Inc.	28-May-20
L-158-20/0	Graham, Barney S.		AbCellera Biologics Inc.	28-May-20
L-158-20/0	Kong, Wing-pui		AbCellera Biologics Inc.	28-May-20
L-158-20/0	Ledgerwood, Julie		AbCellera Biologics Inc.	28-May-20
L-158-20/0	Mascola, John R.		AbCellera Biologics Inc.	28-May-20
L-158-20/0	Shi, Wei		AbCellera Biologics Inc.	28-May-20
L-158-20/0	Wang, Lingshu		AbCellera Biologics Inc.	28-May-20
L-158-20/0	Zhang, Yi-Ming		AbCellera Biologics Inc.	28-May-20
L-158-20/0	Abisola Abiona, Olubukola		AbCellera Biologics Inc.	28-May-20
L-158-20/0	Corbett, Kizzmekia		AbCellera Biologics Inc.	28-May-20
L-158-20/0	Graham, Barney S.		AbCellera Biologics Inc.	28-May-20
L-158-20/0	Kong, Wing-pui		AbCellera Biologics Inc.	28-May-20
L-158-20/0	Ledgerwood, Julie		AbCellera Biologics Inc.	28-May-20
L-158-20/0	Mascola, John R.		AbCellera Biologics Inc.	28-May-20
L-158-20/0	Shi, Wei		AbCellera Biologics Inc.	28-May-20
L-158-20/0	Wang, Lingshu		AbCellera Biologics Inc.	28-May-20
L-158-20/0	Zhang, Yi-Ming		AbCellera Biologics Inc.	28-May-20

NIH Patent Licensing Activities
NIAID
June 2020

License	Inventor	Inventor Share %	Licensor	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
L-118-09/2	NIAID		Sinovac Biotech, Ltd.	1-Jun-20						(b) (3) (A), (b) (4), (b) (6)
L-245-94/1	Folks, Thomas M	(b)(4);	SearCare Life Sciences	2-Jun-20						
L-245-94/1	Martin, Malcolm A	(b)(6)	SearCare Life Sciences	2-Jun-20						
L-245-94/1	Powell, Douglas M		SearCare Life Sciences	2-Jun-20						
<i>Note: L-245-94/1 split between NCI; NIAID</i>										
L-165-13/1	Mackett, Michael		Sillajen Biotherapeutics, Inc	2-Jun-20						
L-165-13/1	Moss, Bernard		Sillajen Biotherapeutics, Inc	2-Jun-20						
L-165-13/1	Smith, Geoffrey L		Sillajen Biotherapeutics, Inc	2-Jun-20						
L-080-04/1	Green, Kim Y.		R-Biopharm AG	3-Jun-20						
L-080-04/1	Sosnovtsev, Stanislav V		R-Biopharm AG	3-Jun-20						
L-013-20/0	Chanock, (b) (6) Robert		Excell BIO, Inc	3-Jun-20						
L-013-20/0	Hoshino, Yasutaka		Excell BIO, Inc	3-Jun-20						
L-013-20/0	Kapikian (b) (6) Albert Z		Excell BIO, Inc	3-Jun-20						
L-119-09/2	NIAID		Fundacao Butantan	4-Jun-20						
<i>Note: L-119-09/2 split between FDA; NIAID</i>										
L-074-13/0	Sun, Peter D	(b)(4);	Therapyx Inc	11-Jun-20						
L-074-13/0	Zou, Zhongcheng	(b)(6)	Therapyx Inc	11-Jun-20						
L-063-06/3	Barry, Clifton E		Sequella, Inc.	12-Jun-20						
L-063-06/3	Lee, Richard E.		Sequella, Inc.	12-Jun-20						
L-063-06/3	Slayden, Richard A		Sequella, Inc.	12-Jun-20						
L-018-18/2	Datta, Sandip Kumar		Forte Biosciences Inc	12-Jun-20						
L-018-18/2	Myles, Ian		Forte Biosciences Inc	12-Jun-20						
L-138-16/1	Biacchesi, Stephanie		Merck Sharp & Dohme Corp.	16-Jun-20						
L-138-16/1	Buchholz, Ursula		Merck Sharp & Dohme Corp.	16-Jun-20						
L-138-16/1	Collins, Peter L.		Merck Sharp & Dohme Corp.	16-Jun-20						
L-074-20/0	NIAID		China National Biotec Group Company I	18-Jun-20						
L-074-20/0	Baxa, Ulrich	(b)(4);	China National Biotec Group Company I	18-Jun-20						
L-074-20/0	Boyington, Jeffrey C.	(b)(6)	China National Biotec Group Company I	18-Jun-20						
L-074-20/0	Chen, Lei		China National Biotec Group Company I	18-Jun-20						
L-074-20/0	Chen, Man		China National Biotec Group Company I	18-Jun-20						
L-074-20/0	Chuang, Gwo-Yu		China National Biotec Group Company I	18-Jun-20						
L-074-20/0	Druz, Aliaksandr A.		China National Biotec Group Company I	18-Jun-20						
L-074-20/0	Galen, Joseph Van		China National Biotec Group Company I	18-Jun-20						
L-074-20/0	Georgiev, Ivelin S.		China National Biotec Group Company I	18-Jun-20						
L-074-20/0	Gorman, Jason		China National Biotec Group Company I	18-Jun-20						

L-074-20/0	Graham, Barney S.	(b)(4);	China National Biotec Group Company I	18-Jun-20
L-074-20/0	Joyce, Michael G.	(b)(6)	China National Biotec Group Company I	18-Jun-20
L-074-20/0	Kanekiyo, Masaru		China National Biotec Group Company I	18-Jun-20
L-074-20/0	Kong, Wing-pui		China National Biotec Group Company I	18-Jun-20
L-074-20/0	Kwong, Peter D.		China National Biotec Group Company I	18-Jun-20
L-074-20/0	Mascola, John R.		China National Biotec Group Company I	18-Jun-20
L-074-20/0	McLellan, Jason Scott		China National Biotec Group Company I	18-Jun-20
L-074-20/0	OFEK, GILAD A		China National Biotec Group Company I	18-Jun-20
L-074-20/0	Ou, Li		China National Biotec Group Company I	18-Jun-20
L-074-20/0	Pancera, Marie L.		China National Biotec Group Company I	18-Jun-20
L-074-20/0	Rundlet, Emily		China National Biotec Group Company I	18-Jun-20
L-074-20/0	Sastry, Mallika		China National Biotec Group Company I	18-Jun-20
L-074-20/0	Soto, Cinque		China National Biotec Group Company I	18-Jun-20
L-074-20/0	Srivatsan, Sanjay R.		China National Biotec Group Company I	18-Jun-20
L-074-20/0	Stewart-Jones, Guillaume		China National Biotec Group Company I	18-Jun-20
L-074-20/0	Thomas, Paul V.		China National Biotec Group Company I	18-Jun-20
L-074-20/0	Tsybovsky, Yaroslav		China National Biotec Group Company I	18-Jun-20
L-074-20/0	YANG, YONGPING		China National Biotec Group Company I	18-Jun-20
L-074-20/0	Zhang, Baoshan		China National Biotec Group Company I	18-Jun-20
L-074-20/0	Zhou, Tongqing		China National Biotec Group Company I	18-Jun-20
L-200-05/6	NIAID		Wuhan Institute of Bio. Prod.	19-Jun-20
L-197-05/5	NIAID		Serum Institute of India	22-Jun-20
L-152-02/3	Hsu, Su-Cheng Dana	(b)(4);	Emergent BioDefense	24-Jun-20
L-152-02/3	Leppla, Stephen H.	(b)(6)	Emergent BioDefense	24-Jun-20
L-152-02/3	Pomerantsev, Andrei P		Emergent BioDefense	24-Jun-20
<i>Note: L-152-02/3 split between NIAID; NIDCR</i>				
L-130-05/2	NIAID		Biological E Limited	24-Jun-20
L-181-14/0	Fink, Doran	(b)(4);	InBios International Inc	24-Jun-20
L-181-14/0	Kubofcik, Joseph	(b)(6)	InBios International Inc	24-Jun-20
L-181-14/0	Nutman, Thomas B.		InBios International Inc	24-Jun-20
<i>Note: L-181-14/0 split between NIAID; NIDCR</i>				
L-298-19/0	Connors, Mark		GlaxoSmithKline Intellectual Property Li	25-Jun-20
L-298-19/0	Huang, Jinghe		GlaxoSmithKline Intellectual Property Li	25-Jun-20
L-298-19/0	Ishida, Elilse H.		GlaxoSmithKline Intellectual Property Li	25-Jun-20
L-298-19/0	Kang, Byong Ha		GlaxoSmithKline Intellectual Property Li	25-Jun-20
L-298-19/0	Kwong, Peter D.		GlaxoSmithKline Intellectual Property Li	25-Jun-20
L-298-19/0	Mascola, John R.		GlaxoSmithKline Intellectual Property Li	25-Jun-20
L-298-19/0	Zheng, Anqi		GlaxoSmithKline Intellectual Property Li	25-Jun-20
L-298-19/0	Zhou, Tongqing		GlaxoSmithKline Intellectual Property Li	25-Jun-20

(b) (3) (A), (b) (4), (b) (6)

NIH Patent Licensing Activities
NIAID
July 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
L-074-91/3	Harriman, Gregory R.	(b)(4);	Becton, Dickson and Company	1-Jul-20						(b) (3) (A), (b) (4), (b) (6)
L-074-91/3	Kunimoto, Dennis Y.	(b)(6)	Becton, Dickson and Company	1-Jul-20						
L-074-91/3	Paul, (b) (6) William E.		Becton, Dickson and Company	1-Jul-20						
L-074-91/3	Strober, Warren		Becton, Dickson and Company	1-Jul-20						
L-079-93/2	Ohara, Junichi		BD Biosciences - BD PharMingen	1-Jul-20						
L-079-93/2	Paul, (b) (6) William E.		BD Biosciences - BD PharMingen	1-Jul-20						
L-157-20/0	Germain, Ronald N.		Biolegend, Inc.	1-Jul-20						
L-157-20/0	Gerner, Michael Y		Biolegend, Inc.	1-Jul-20						
L-157-20/0	Li, Weizhe		Biolegend, Inc.	1-Jul-20						
L-199-17/0	Akahata, Wataru		Infectious Disease Research Institute	2-Jul-20						
L-199-17/0	Nabel, Gary J		Infectious Disease Research Institute	2-Jul-20						
L-199-17/0	Rao, Srinivas		Infectious Disease Research Institute	2-Jul-20						
L-199-17/0	Yang, Zhi-Yong		Infectious Disease Research Institute	2-Jul-20						
L-199-17/0	NIAID		Infectious Disease Research Institute	2-Jul-20						
L-155-20/0	Akahata, Wataru	(b)(4);	Emergent Product Development Gaithe	2-Jul-20						
L-155-20/0	Nabel, Gary J	(b)(6)	Emergent Product Development Gaithe	2-Jul-20						
L-155-20/0	Rao, Srinivas		Emergent Product Development Gaithe	2-Jul-20						
L-155-20/0	Yang, Zhi-Yong		Emergent Product Development Gaithe	2-Jul-20						
L-155-20/0	NIAID		Emergent Product Development Gaithe	2-Jul-20						
L-135-17/3	NIAID		Emergent Product Development	2-Jul-20						
L-135-17/3	NIAID		Emergent Product Development	2-Jul-20						
L-135-17/3	NIAID		Emergent Product Development	2-Jul-20						
L-135-17/3	NIAID		Emergent Product Development	2-Jul-20						
*L-135-17/3	Boyington, Jeffrey C.	(b)(4);	Emergent Product Development	2-Jul-20						
*L-135-17/3	Corbett, Kizzmekia	(b)(6)	Emergent Product Development	2-Jul-20						
*L-135-17/3	Graham, Barney S.		Emergent Product Development	2-Jul-20						
*L-135-17/3	Kanekiyo, Masaru		Emergent Product Development	2-Jul-20						
*L-135-17/3	Kong, Wing-pui		Emergent Product Development	2-Jul-20						
*L-135-17/3	Kwong, Peter D.		Emergent Product Development	2-Jul-20						
*L-135-17/3	Mascola, John R.		Emergent Product Development	2-Jul-20						
*L-135-17/3	McTamney, Patrick		Emergent Product Development	2-Jul-20						
*L-135-17/3	Moin, Syed M.		Emergent Product Development	2-Jul-20						
*L-135-17/3	Nabel, Gary J		Emergent Product Development	2-Jul-20						
*L-135-17/3	Wang, Lingshu		Emergent Product Development	2-Jul-20						
*L-135-17/3	Wei, Chih--Jen		Emergent Product Development	2-Jul-20						
*L-135-17/3	Whittle, James R R		Emergent Product Development	2-Jul-20						
*L-135-17/3	Yang, Zhi-Yong		Emergent Product Development	2-Jul-20						
*L-135-17/3	Yassine, Hadi M.		Emergent Product Development	2-Jul-20						
L-069-10/1	Chanock, (b) (6) Robert		Beijing Minhai Biotechnology Co Ltd	6-Jul-20						
L-069-10/1	Hoshino, Yasutaka		Beijing Minhai Biotechnology Co Ltd	6-Jul-20						

L-069-10/1	Kapikian, (b) (6) Albert Z	(b)(4); (b)(6)	Beijing Minhai Biotechnology Co Ltd	6-Jul-20
L-158-20/0	Abisola Abiona, Olubukola		AbCellera Biologics Inc.	8-Jul-20
L-158-20/0	Corbett, Kizzmekia		AbCellera Biologics Inc.	8-Jul-20
L-158-20/0	Graham, Barney S.		AbCellera Biologics Inc.	8-Jul-20
L-158-20/0	Kong, Wing-pui		AbCellera Biologics Inc.	8-Jul-20
L-158-20/0	Ledgerwood, Julie		AbCellera Biologics Inc.	8-Jul-20
L-158-20/0	Mascola, John R.		AbCellera Biologics Inc.	8-Jul-20
L-158-20/0	Shi, Wei		AbCellera Biologics Inc.	8-Jul-20
L-158-20/0	Wang, Lingshu		AbCellera Biologics Inc.	8-Jul-20
L-158-20/0	Zhang, Yi-Ming		AbCellera Biologics Inc.	8-Jul-20
L-158-20/0	Abisola Abiona, Olubukola		AbCellera Biologics Inc.	8-Jul-20
L-158-20/0	Corbett, Kizzmekia		AbCellera Biologics Inc.	8-Jul-20
L-158-20/0	Graham, Barney S.		AbCellera Biologics Inc.	8-Jul-20
L-158-20/0	Kong, Wing-pui		AbCellera Biologics Inc.	8-Jul-20
L-158-20/0	Ledgerwood, Julie		AbCellera Biologics Inc.	8-Jul-20
L-158-20/0	Mascola, John R.		AbCellera Biologics Inc.	8-Jul-20
L-158-20/0	Shi, Wei		AbCellera Biologics Inc.	8-Jul-20
L-158-20/0	Wang, Lingshu		AbCellera Biologics Inc.	8-Jul-20
L-158-20/0	Zhang, Yi-Ming		AbCellera Biologics Inc.	8-Jul-20
L-191-16/2	Akin, Cem		GlaxoSmithKline LLC	9-Jul-20
L-191-16/2	Kirshenbaum, Arnold		GlaxoSmithKline LLC	9-Jul-20
L-191-16/2	Metcalfe, Dean D		GlaxoSmithKline LLC	9-Jul-20
L-016-11/1	Adachi, Akio		Merck Sharp & Dohme, Corp.	9-Jul-20
L-016-11/1	Folks, Thomas M		Merck Sharp & Dohme, Corp.	9-Jul-20
L-016-11/1	Leonard, John M.		Merck Sharp & Dohme, Corp.	9-Jul-20
L-016-11/1	Martin, Malcolm A		Merck Sharp & Dohme, Corp.	9-Jul-20
L-016-11/1	Rabson, Arnold B.		Merck Sharp & Dohme, Corp.	9-Jul-20
L-016-11/1	Rutledge, Rosamond A.		Merck Sharp & Dohme, Corp.	9-Jul-20
L-016-11/1	Theodore, (b) (6) Theodor		Merck Sharp & Dohme, Corp.	9-Jul-20
L-016-11/1	Willey, Ronald L.		Merck Sharp & Dohme, Corp.	9-Jul-20
L-116-18/0	Emerson, Suzanne U.		Katholieke	10-Jul-20
L-116-18/0	Nguyen, Hanh T.		Katholieke	10-Jul-20
L-116-18/0	Purcell, Robert H		Katholieke	10-Jul-20
L-116-18/0	(b) (4)		Katholieke	10-Jul-20
L-116-18/0	Shukla Bajpai, Priyanka		Katholieke	10-Jul-20
L-126-15/1	Chakrabarti, Bimal K		GlaxoSmithKline Biologicals, S.A.	15-Jul-20
L-126-15/1	Cheng, Cheng		GlaxoSmithKline Biologicals, S.A.	15-Jul-20
L-126-15/1	(b) (6) Clement K. Asiedu		GlaxoSmithKline Biologicals, S.A.	15-Jul-20
L-126-15/1	Huang, (b) (6) Yue		GlaxoSmithKline Biologicals, S.A.	15-Jul-20
L-126-15/1	Mackett, Michael		GlaxoSmithKline Biologicals, S.A.	15-Jul-20
L-126-15/1	Moss, Bernard		GlaxoSmithKline Biologicals, S.A.	15-Jul-20
L-126-15/1	Nabel, Gary J		GlaxoSmithKline Biologicals, S.A.	15-Jul-20
L-126-15/1	Smith, Geoffrey L		GlaxoSmithKline Biologicals, S.A.	15-Jul-20
L-126-15/1	Sullivan, Nancy J		GlaxoSmithKline Biologicals, S.A.	15-Jul-20
L-126-15/1	Yang, Zhi-Yong		GlaxoSmithKline Biologicals, S.A.	15-Jul-20

Note (b) (4) split between CDC; NIAID

L-126-15/1	NIAID	GlaxoSmithKline Biologicals, S.A.	15-Jul-20
<i>Note: L-126-15/1 split between CDC; NIAID</i>			
L-101-85/0	Mackett, Michael	(b)(4); ZOETIS	15-Jul-20
L-101-85/0	Moss, Bernard	(b)(6) ZOETIS	15-Jul-20
L-101-85/0	Smith, Geoffrey L	ZOETIS	15-Jul-20
L-126-15/0	Cheng, Cheng	GlaxoSmithKline Biologicals, S.A.	15-Jul-20
L-126-15/0	(b) (6) Clement K. Asiedu	GlaxoSmithKline Biologicals, S.A.	15-Jul-20
L-126-15/0	Huang, (b) (6) Yue	GlaxoSmithKline Biologicals, S.A.	15-Jul-20
L-126-15/0	Mackett, Michael	GlaxoSmithKline Biologicals, S.A.	15-Jul-20
L-126-15/0	Moss, Bernard	GlaxoSmithKline Biologicals, S.A.	15-Jul-20
L-126-15/0	Nabel, Gary J	GlaxoSmithKline Biologicals, S.A.	15-Jul-20
L-126-15/0	Smith, Geoffrey L	GlaxoSmithKline Biologicals, S.A.	15-Jul-20
L-126-15/0	Sullivan, Nancy J	GlaxoSmithKline Biologicals, S.A.	15-Jul-20
L-126-15/0	Yang, Zhi-Yong	GlaxoSmithKline Biologicals, S.A.	15-Jul-20
<i>Note: L-126-15/0 split between CDC; NIAID</i>			
L-141-18/0	Graham, Barney S.	Universiteit Ghent VIB vzw	16-Jul-20
L-188-20/0	Kim, Yong Chan	Terimmune Inc.	20-Jul-20
L-188-20/0	Shevach, Ethan M	Terimmune Inc.	20-Jul-20
L-057-18/0	Akin, Cem	Opsidio, LLC	22-Jul-20
L-057-18/0	Kirshenbaum, Arnold	Opsidio, LLC	22-Jul-20
L-057-18/0	Metcalfe, Dean D	Opsidio, LLC	22-Jul-20
L-132-20/0	Chen, Zhao Chun	Absolute Antibody Ltd.	22-Jul-20
L-132-20/0	Emerson, Suzanne U.	Absolute Antibody Ltd.	22-Jul-20
L-132-20/0	Leppla, Stephen H.	Absolute Antibody Ltd.	22-Jul-20
L-132-20/0	Purcell, Robert H	Absolute Antibody Ltd.	22-Jul-20
<i>Note: L-132-20/0 split between NIAID; NICHD; NIDCR</i>			
L-333-14/0	Fink, Doran	(b)(4); PATH Vaccine Solutions	27-Jul-20
L-333-14/0	Kubofcik, Joseph	(b)(6) PATH Vaccine Solutions	27-Jul-20
L-333-14/0	Nutman, Thomas B.	PATH Vaccine Solutions	27-Jul-20
<i>Note: L-333-14/0 split between NIAID; NIDCR</i>			
L-079-13/0	Lobos Lazzeri, M Edgard S	PATH Vaccine Solutions	27-Jul-20
L-079-13/0	Nutman, Thomas B.	PATH Vaccine Solutions	27-Jul-20
L-126-15/1	Chakrabarti, Bimal K	GlaxoSmithKline Biologicals, S.A.	29-Jul-20
L-126-15/1	Cheng, Cheng	GlaxoSmithKline Biologicals, S.A.	29-Jul-20
L-126-15/1	(b) (6) Clement K. Asiedu	GlaxoSmithKline Biologicals, S.A.	29-Jul-20
L-126-15/1	Huang, (b) (6) Yue	GlaxoSmithKline Biologicals, S.A.	29-Jul-20
L-126-15/1	Mackett, Michael	GlaxoSmithKline Biologicals, S.A.	29-Jul-20
L-126-15/1	Moss, Bernard	GlaxoSmithKline Biologicals, S.A.	29-Jul-20
L-126-15/1	Nabel, Gary J	GlaxoSmithKline Biologicals, S.A.	29-Jul-20
L-126-15/1	Smith, Geoffrey L	GlaxoSmithKline Biologicals, S.A.	29-Jul-20
L-126-15/1	Sullivan, Nancy J	GlaxoSmithKline Biologicals, S.A.	29-Jul-20
L-126-15/1	Yang, Zhi-Yong	GlaxoSmithKline Biologicals, S.A.	29-Jul-20
<i>Note: L-126-15/1 split between CDC; NIAID</i>			

(b) (3) (A), (b) (4), (b) (6)

L-124-18/0	Garboczi, David	(b)(4);	Abcam plc	29-Jul-20
L-124-18/0	Lantz, Larry	(b)(6)	Abcam plc	29-Jul-20
L-124-18/0	Leppla, Stephen H.		Abcam plc	29-Jul-20
L-124-18/0	Leysath, Clinton E.		Abcam plc	29-Jul-20
L-124-18/0	Phillips, Damilola D.		Abcam plc	29-Jul-20
L-124-18/0	Garboczi, David		Abcam plc	29-Jul-20
L-124-18/0	Lantz, Larry		Abcam plc	29-Jul-20
L-124-18/0	Leppla, Stephen H.		Abcam plc	29-Jul-20
L-124-18/0	Leysath, Clinton E.		Abcam plc	29-Jul-20
L-124-18/0	Phillips, Damilola D.		Abcam plc	29-Jul-20

NIH Patent Licensing Activities

NIAID

August 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
L-188-20/0	Kim, Yong Chan	(b)(4);	Teraimmune Inc.	1-Aug-20						(b) (3) (A), (b) (4), (b) (6)
L-188-20/0	Shevach, Ethan M	(b)(6)	Teraimmune Inc.	1-Aug-20						
L-188-20/0	NIAID		Teraimmune Inc.	1-Aug-20						
*L-205-20/0	Collins, Peter L.	(b)(4);	Vir Biotechnology, Inc	4-Aug-20						
L-205-20/0	(b) (4)	(b)(6)	Vir Biotechnology, Inc	4-Aug-20						
L-179-20/0	NIAID		BioNTech AG	13-Aug-20						
L-197-05/5	Chanock (b) (6) Robert	(b)(4);	Serum Institute of India	14-Aug-20						
L-197-05/5	Hoshino, Yasutaka	(b)(6)	Serum Institute of India	14-Aug-20						
L-197-05/5	Kapikian, (b) (6) Albert Z		Serum Institute of India	14-Aug-20						
L-190-20/0	Abisola Abiona, Olubukola		Meso Scale Diagnostics, LLC	17-Aug-20						
L-190-20/0	Boyington, Jeffrey C.		Meso Scale Diagnostics, LLC	17-Aug-20						
L-190-20/0	Chen, Lei		Meso Scale Diagnostics, LLC	17-Aug-20						
L-190-20/0	Chen, Man		Meso Scale Diagnostics, LLC	17-Aug-20						
L-190-20/0	Chuang, Gwo-Yu		Meso Scale Diagnostics, LLC	17-Aug-20						
L-190-20/0	Corbett, Kizzmekia		Meso Scale Diagnostics, LLC	17-Aug-20						
L-190-20/0	(b) (4)		Meso Scale Diagnostics, LLC	17-Aug-20						
L-190-20/0	Georgiev, Ivelin S.		Meso Scale Diagnostics, LLC	17-Aug-20						
L-190-20/0	Gorman, Jason		Meso Scale Diagnostics, LLC	17-Aug-20						
L-190-20/0	Graham, Barney S.		Meso Scale Diagnostics, LLC	17-Aug-20						
L-190-20/0	Hutchinson, Geoffrey Bain		Meso Scale Diagnostics, LLC	17-Aug-20						
L-190-20/0	Joyce, Michael G.		Meso Scale Diagnostics, LLC	17-Aug-20						
L-190-20/0	Kanekiyo, Masaru		Meso Scale Diagnostics, LLC	17-Aug-20						
L-190-20/0	Kwong, Peter D.		Meso Scale Diagnostics, LLC	17-Aug-20						
L-190-20/0	McLellan, Jason Scott		Meso Scale Diagnostics, LLC	17-Aug-20						
L-190-20/0	OFEK, GILAD A		Meso Scale Diagnostics, LLC	17-Aug-20						
L-190-20/0	Pancera, Marie L.		Meso Scale Diagnostics, LLC	17-Aug-20						
L-190-20/0	Sastry, Mallika		Meso Scale Diagnostics, LLC	17-Aug-20						
L-190-20/0	(b) (4)		Meso Scale Diagnostics, LLC	17-Aug-20						

L-190-20/0	Soto, Cinque	(b)(4);	Meso Scale Diagnostics, LLC	17-Aug-20
L-190-20/0	Srivatsan, Sanjay R.	(b)(6)	Meso Scale Diagnostics, LLC	17-Aug-20
L-190-20/0	Stewart-Jones, Guillaume B		Meso Scale Diagnostics, LLC	17-Aug-20
L-190-20/0	(b) (4)		Meso Scale Diagnostics, LLC	17-Aug-20
L-190-20/0	YANG, YONGPING		Meso Scale Diagnostics, LLC	17-Aug-20
L-190-20/0	Yassine, Hadi M.		Meso Scale Diagnostics, LLC	17-Aug-20
L-190-20/0	Zhang, Baoshan		Meso Scale Diagnostics, LLC	17-Aug-20
L-190-20/0	Zhou, Tongqing		Meso Scale Diagnostics, LLC	17-Aug-20
L-009-06/0	Collins, Peter L.		Apath, LLC	18-Aug-20
L-208-20/0	Guatam, Rejeev		Gilead Sciences, Inc.	18-Aug-20
L-208-20/0	Martin, Malcolm A		Gilead Sciences, Inc.	18-Aug-20
L-208-20/0	Nishimura, Michael		Gilead Sciences, Inc.	18-Aug-20
L-208-20/0	Sadjadpour, Reza		Gilead Sciences, Inc.	18-Aug-20
L-208-20/0	Shingai, Masashi		Gilead Sciences, Inc.	18-Aug-20
*L-190-20/0	Abisola Abiona, Olubukola		Meso Scale Diagnostics, LLC	18-Aug-20
*L-190-20/0	Boyington, Jeffrey C.		Meso Scale Diagnostics, LLC	18-Aug-20
*L-190-20/0	Chen, Lei		Meso Scale Diagnostics, LLC	18-Aug-20
*L-190-20/0	Chen, Man		Meso Scale Diagnostics, LLC	18-Aug-20
*L-190-20/0	Chuang, Gwo-Yu		Meso Scale Diagnostics, LLC	18-Aug-20
*L-190-20/0	Corbett, Kizzmekia		Meso Scale Diagnostics, LLC	18-Aug-20
L-190-20/0	(b) (4)		Meso Scale Diagnostics, LLC	18-Aug-20
*L-190-20/0	Georgiev, Ivelin S.		Meso Scale Diagnostics, LLC	18-Aug-20
*L-190-20/0	Gorman, Jason		Meso Scale Diagnostics, LLC	18-Aug-20
*L-190-20/0	Graham, Barney S.		Meso Scale Diagnostics, LLC	18-Aug-20
*L-190-20/0	Hutchinson, Geoffrey Bain		Meso Scale Diagnostics, LLC	18-Aug-20
*L-190-20/0	Joyce, Michael G.		Meso Scale Diagnostics, LLC	18-Aug-20
*L-190-20/0	Kanekiyo, Masaru		Meso Scale Diagnostics, LLC	18-Aug-20
*L-190-20/0	Kwong, Peter D.		Meso Scale Diagnostics, LLC	18-Aug-20
*L-190-20/0	McLellan, Jason Scott		Meso Scale Diagnostics, LLC	18-Aug-20
*L-190-20/0	OFEK, GILAD A		Meso Scale Diagnostics, LLC	18-Aug-20
*L-190-20/0	Pancera, Marie L.		Meso Scale Diagnostics, LLC	18-Aug-20
*L-190-20/0	Sastry, Mallika		Meso Scale Diagnostics, LLC	18-Aug-20
L-190-20/0	(b) (4)		Meso Scale Diagnostics, LLC	18-Aug-20
*L-190-20/0	Soto, Cinque		Meso Scale Diagnostics, LLC	18-Aug-20
*L-190-20/0	Srivatsan, Sanjay R.		Meso Scale Diagnostics, LLC	18-Aug-20
*L-190-20/0	Stewart-Jones, Guillaume B		Meso Scale Diagnostics, LLC	18-Aug-20
L-190-20/0	(b) (4)		Meso Scale Diagnostics, LLC	18-Aug-20
*L-190-20/0	YANG, YONGPING		Meso Scale Diagnostics, LLC	18-Aug-20
*L-190-20/0	Yassine, Hadi M.		Meso Scale Diagnostics, LLC	18-Aug-20
*L-190-20/0	Zhang, Baoshan		Meso Scale Diagnostics, LLC	18-Aug-20
*L-190-20/0	Zhou, Tongqing		Meso Scale Diagnostics, LLC	18-Aug-20
*L-179-20/0	Abisola Abiona, Olubukola		BioNTech AG	18-Aug-20
*L-179-20/0	Corbett, Kizzmekia		BioNTech AG	18-Aug-20
L-179-20/0	(b) (4)		BioNTech AG	18-Aug-20
*L-179-20/0	Graham, Barney S.		BioNTech AG	18-Aug-20
*L-179-20/0	Hutchinson, Geoffrey Bain		BioNTech AG	18-Aug-20
*L-179-20/0	Joyce, Michael G.		BioNTech AG	18-Aug-20
*L-179-20/0	Kanekiyo, Masaru		BioNTech AG	18-Aug-20
L-179-20/0	(b) (4)		BioNTech AG	18-Aug-20

(b) (3) (A), (b) (4), (b) (6)

L-179-20/0	(b) (4)	(b)(4);	BioNTech AG	18-Aug-20
*L-179-20/0	Yassine, Hadi M.	(b)(6)	BioNTech AG	18-Aug-20
L-115-00/2	Cheung, Yiu Chong Gordon		List Biological Laboratories, Inc.	21-Aug-20
L-115-00/2	Gupta, Pradeep K.		List Biological Laboratories, Inc.	21-Aug-20
L-115-00/2	Hsu, Su-Cheng Dana		List Biological Laboratories, Inc.	21-Aug-20
L-115-00/2	Hu, Haijing		List Biological Laboratories, Inc.	21-Aug-20
L-115-00/2	Leppla, Stephen H.		List Biological Laboratories, Inc.	21-Aug-20
L-115-00/2	Leysath, Clinton E.		List Biological Laboratories, Inc.	21-Aug-20
L-115-00/2	Moayeri, Mahtab		List Biological Laboratories, Inc.	21-Aug-20
L-115-00/2	Pomerantsev, Andrei P		List Biological Laboratories, Inc.	21-Aug-20
<i>Note: L-115-00/2 split between NIAID; NIDCR</i>				
L-268-18/2	Boyington, Jeffrey		ADMA Biologics, Inc	21-Aug-20
L-268-18/2	Chen, Lei		ADMA Biologics, Inc	21-Aug-20
L-268-18/2	Chen, Man		ADMA Biologics, Inc	21-Aug-20
L-268-18/2	Chuang, Gwo-Yu		ADMA Biologics, Inc	21-Aug-20
L-268-18/2	Georgiev, Ivelin S.		ADMA Biologics, Inc	21-Aug-20
L-268-18/2	Gorman, Jason		ADMA Biologics, Inc	21-Aug-20
L-268-18/2	Graham, Barney		ADMA Biologics, Inc	21-Aug-20
L-268-18/2	Joyce, Michael G.		ADMA Biologics, Inc	21-Aug-20
L-268-18/2	Kanekiyo, Masaru		ADMA Biologics, Inc	21-Aug-20
L-268-18/2	Kwong, Peter D.		ADMA Biologics, Inc	21-Aug-20
L-268-18/2	McLellan, Jason Scott		ADMA Biologics, Inc	21-Aug-20
L-268-18/2	OFEK, GILAD A		ADMA Biologics, Inc	21-Aug-20
L-268-18/2	Pancera, Marie L.		ADMA Biologics, Inc	21-Aug-20
L-268-18/2	Sastry, Mallika		ADMA Biologics, Inc	21-Aug-20
L-268-18/2	Soto, Cinque		ADMA Biologics, Inc	21-Aug-20
L-268-18/2	Srivatsan, Sanjay R.		ADMA Biologics, Inc	21-Aug-20
L-268-18/2	Stewart-Jones, Guillaume		ADMA Biologics, Inc	21-Aug-20
L-268-18/2	YANG, YONGPING		ADMA Biologics, Inc	21-Aug-20
L-268-18/2	Zhang, Baoshan		ADMA Biologics, Inc	21-Aug-20
L-268-18/2	Zhou, Tongqing		ADMA Biologics, Inc	21-Aug-20
*L-179-20/0	Abisola Abiona, Olubukola		BioNTech AG	21-Aug-20
*L-179-20/0	Corbett, Kizzmekia		BioNTech AG	21-Aug-20
L-179-20/0	(b) (4)		BioNTech AG	21-Aug-20
*L-179-20/0	Graham, Barney S.		BioNTech AG	21-Aug-20
*L-179-20/0	Hutchinson, Geoffrey Bain		BioNTech AG	21-Aug-20
*L-179-20/0	Joyce, Michael G.		BioNTech AG	21-Aug-20
*L-179-20/0	Kanekiyo, Masaru		BioNTech AG	21-Aug-20
L-179-20/0	(b) (4)		BioNTech AG	21-Aug-20
L-179-20/0	(b) (4)		BioNTech AG	21-Aug-20
*L-179-20/0	Yassine, Hadi M.		BioNTech AG	21-Aug-20
L-072-09/1	Long, Eric O.		BioLegend	26-Aug-20
L-072-09/1	Rajagopalan, Sumati		BioLegend	26-Aug-20
L-162-08/1	Sun, Peter D		BioLegend	26-Aug-20
L-162-08/1	Zou, Zhongcheng		BioLegend	26-Aug-20
<i>Note: L-162-08/1 split between NCI; NIAID</i>				
L-208-14/1	Emerson, Suzanne U.		Grifols Therapeutics, Inc.	27-Aug-20

L-208-14/1	Nguyen, Hanh T.	(b)(4);	Grifols Therapeutics, Inc.	27-Aug-20
L-208-14/1	Purcell, Robert H	(b)(6)	Grifols Therapeutics, Inc.	27-Aug-20
L-208-14/1	(b) (4)		Grifols Therapeutics, Inc.	27-Aug-20
L-208-14/1	Shukla Bajpai, Priyanka		Grifols Therapeutics, Inc.	27-Aug-20
L-154-06/0	Mackett, Michael		Boehringer Ingelheim Animal Health US	28-Aug-20
L-154-06/0	Moss, Bernard		Boehringer Ingelheim Animal Health US	28-Aug-20
L-154-06/0	Smith, Geoffrey L		Boehringer Ingelheim Animal Health US	28-Aug-20
*L-296-14/3	Collins, Peter L.		Janssen R&D Ireland	28-Aug-20
L-296-14/3	(b) (4)		Janssen R&D Ireland	28-Aug-20
L-034-20/0	(b) (4)		Helocyte, Inc	31-Aug-20
L-150-20/0	NIAID		Medigen Vaccine Biologics Corp	31-Aug-20
L-150-20/0	Abisola Abiona, Olubukola	(b)(4);	Medigen Vaccine Biologics Corp	31-Aug-20
L-150-20/0	Corbett, Kizzmekia	(b)(6)	Medigen Vaccine Biologics Corp	31-Aug-20
L-150-20/0	(b) (4)		Medigen Vaccine Biologics Corp	31-Aug-20
L-150-20/0	Graham, Barney S.		Medigen Vaccine Biologics Corp	31-Aug-20
L-150-20/0	Hutchinson, Geoffrey Bain		Medigen Vaccine Biologics Corp	31-Aug-20
L-150-20/0	Joyce, Michael G.		Medigen Vaccine Biologics Corp	31-Aug-20
L-150-20/0	Kanekiyo, Masaru		Medigen Vaccine Biologics Corp	31-Aug-20
L-150-20/0	Kong, Wing-pui		Medigen Vaccine Biologics Corp	31-Aug-20
L-150-20/0	Mascola, John R.		Medigen Vaccine Biologics Corp	31-Aug-20
L-150-20/0	(b) (4)		Medigen Vaccine Biologics Corp	31-Aug-20
L-150-20/0	(b) (4)		Medigen Vaccine Biologics Corp	31-Aug-20
L-150-20/0	Wang, Lingshu		Medigen Vaccine Biologics Corp	31-Aug-20
L-150-20/0	Yassine, Hadi M.		Medigen Vaccine Biologics Corp	31-Aug-20
L-181-20/0	Abisola Abiona, Olubukola		Medigen Vaccine Biologics Corp	31-Aug-20
L-181-20/0	Corbett, Kizzmekia		Medigen Vaccine Biologics Corp	31-Aug-20
L-181-20/0	(b) (4)		Medigen Vaccine Biologics Corp	31-Aug-20
L-181-20/0	Graham, Barney S.		Medigen Vaccine Biologics Corp	31-Aug-20
L-181-20/0	Hutchinson, Geoffrey Bain		Medigen Vaccine Biologics Corp	31-Aug-20
L-181-20/0	Joyce, Michael G.		Medigen Vaccine Biologics Corp	31-Aug-20
L-181-20/0	Kanekiyo, Masaru		Medigen Vaccine Biologics Corp	31-Aug-20
L-181-20/0	Kong, Wing-pui		Medigen Vaccine Biologics Corp	31-Aug-20
L-181-20/0	Mascola, John R.		Medigen Vaccine Biologics Corp	31-Aug-20
L-181-20/0	(b) (4)		Medigen Vaccine Biologics Corp	31-Aug-20
L-181-20/0	(b) (4)		Medigen Vaccine Biologics Corp	31-Aug-20
L-181-20/0	Wang, Lingshu		Medigen Vaccine Biologics Corp	31-Aug-20
L-181-20/0	Yassine, Hadi M.		Medigen Vaccine Biologics Corp	31-Aug-20

(b) (3) (A), (b) (4), (b) (6)

NIH Patent Licensing Activities
NIAID
September 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
L-226-14/1	Nutman, Thomas B.	(b)(4);	Quest Diagnostic, Inc	2-Sep-20						(b) (3) (A), (b) (4), (b) (6)

L-152-19/1	Akin, Cem	(b)(4);	Celltrion, Inc.	2-Sep-20
L-152-19/1	Kirshenbaum, Arnold	(b)(6)	Celltrion, Inc.	2-Sep-20
L-152-19/1	Metcalfe, Dean D		Celltrion, Inc.	2-Sep-20
L-303-19/1	Chuang, Gwo-Yu		TaiMed Biologics USA, Inc	9-Sep-20
L-303-19/1	Connors, Mark		TaiMed Biologics USA, Inc	9-Sep-20
L-303-19/1	Georgiev, Ivelin S.		TaiMed Biologics USA, Inc	9-Sep-20
L-303-19/1	Kwon, Young Do		TaiMed Biologics USA, Inc	9-Sep-20
L-303-19/1	Kwong, Peter D.		TaiMed Biologics USA, Inc	9-Sep-20
L-303-19/1	Mascola, John R		TaiMed Biologics USA, Inc	9-Sep-20
L-303-19/1	Nabel, Gary J		TaiMed Biologics USA, Inc	9-Sep-20
L-303-19/1	Rudicell, Rebecca S.		TaiMed Biologics USA, Inc	9-Sep-20
L-303-19/1	Shi, Wei		TaiMed Biologics USA, Inc	9-Sep-20
L-303-19/1	Wu, Xueling		TaiMed Biologics USA, Inc	9-Sep-20
L-303-19/1	YANG, YONGPING		TaiMed Biologics USA, Inc	9-Sep-20
L-303-19/1	Yang, Zhi-Yong		TaiMed Biologics USA, Inc	9-Sep-20
L-303-19/1	Zhang, Baoshan		TaiMed Biologics USA, Inc	9-Sep-20
L-303-19/1	Zhou, Tongqing		TaiMed Biologics USA, Inc	9-Sep-20
L-303-19/1	Zhu, Jiang		TaiMed Biologics USA, Inc	9-Sep-20
L-043-18/0	Boyington, Jeffrey C.		MedImmune	10-Sep-20
L-043-18/0	Chen, Lei		MedImmune	10-Sep-20
L-043-18/0	Chen, Man		MedImmune	10-Sep-20
L-043-18/0	Chuang, Gwo-Yu		MedImmune	10-Sep-20
L-043-18/0	Georgiev, Ivelin S.		MedImmune	10-Sep-20
L-043-18/0	Gorman, Jason		MedImmune	10-Sep-20
L-043-18/0	Graham, Barney S.		MedImmune	10-Sep-20
L-043-18/0	Joyce, Michael G.		MedImmune	10-Sep-20
L-043-18/0	Kanekiyo, Masaru		MedImmune	10-Sep-20
L-043-18/0	Kwong, Peter D.		MedImmune	10-Sep-20
L-043-18/0	McLellan, Jason Scott		MedImmune	10-Sep-20
L-043-18/0	OFEK, GILAD A		MedImmune	10-Sep-20
L-043-18/0	Pancera, Marie L.		MedImmune	10-Sep-20
L-043-18/0	Sastry, Mallika		MedImmune	10-Sep-20
L-043-18/0	Soto, Cinque		MedImmune	10-Sep-20
L-043-18/0	Srivatsan, Sanjay R.		MedImmune	10-Sep-20
L-043-18/0	Stewart-Jones, Guillaume B		MedImmune	10-Sep-20
L-043-18/0	YANG, YONGPING		MedImmune	10-Sep-20
L-043-18/0	Zhang, Baoshan		MedImmune	10-Sep-20
L-043-18/0	Zhou, Tongqing		MedImmune	10-Sep-20



\$5,056,247.55	\$302,028.29	\$5,358,275.84	\$1,164,872.29	\$4,193,403.55
----------------	--------------	----------------	----------------	----------------

* denotes an adjustment to fix a problem from a previous month

NIH Patent Licensing Activities
NIAMS
April 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
L-054-18/0	Plotz, Paul H.	(b)(4);	AVROBIO, Inc	1-Apr-20						(b) (3) (A), (b) (4), (b) (6)
L-054-18/0	Raben, Nina	(b)(6)	AVROBIO, Inc	1-Apr-20						

NIH Patent Licensing Activities
NIAMS
May 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
L-102-20/0	Rao, Mahendra S	(b)(4);	Lyell Immunopharma, Inc.	6-May-20						(b) (3) (A), (b) (4), (b) (6)
L-102-20/0	Zou, Jizhong	(b)(6)	Lyell Immunopharma, Inc.	6-May-20						

NIH Patent Licensing Activities
NIAMS
June 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-------------------	---------------------------	----------------------	---------------------

NIH Patent Licensing Activities
NIAMS
July 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-------------------	---------------------------	----------------------	---------------------

NIH Patent Licensing Activities
NIAMS
August 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
L-243-16/0	Rao, Mahendra S	(b)(4);	StemCell Technologies Inc.	21-Aug-20						(b) (3) (A), (b) (4), (b) (6)

Note: L-243-16/0 split between NHLBI; NIAMS

NIH Patent Licensing Activities
NIAMS
September 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	------------------------	---------------------------	---------------------------	---------------------

\$28,244.45	\$0.00	\$28,244.45	\$7,636.66	\$20,607.79
-------------	--------	-------------	------------	-------------

NIH Patent Licensing Activities
NIBIB
April 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
L-256-14/0	Parekh, Sapun	(b)(4);	VisiTech International	21-Apr-20						(b) (3) (A), (b) (4), (b) (6)
L-256-14/0	Shroff, Hari	(b)(6)	VisiTech International	21-Apr-20						
L-256-14/0	York, Andrew G.		VisiTech International	21-Apr-20						

Note: L-256-14/0 split between NHLBI; NIBIB

NIH Patent Licensing Activities
NIBIB
May 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
L-276-18/0	Chen, Xiaoyuan	(b)(4);	Molecular Targeting Technologies, Inc	11-May-20						(b) (3) (A), (b) (4), (b) (6)
L-276-18/0	Weiss, Orit Jacobson	(b)(6)	Molecular Targeting Technologies, Inc	11-May-20						

NIH Patent Licensing Activities
NIBIB
June 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
L-187-14/0	NIBIB		Andor Technology PLC	25-Jun-20						(b) (3) (A), (b) (4)

Note: L-187-14/0 split between NHLBI; NIBIB

NIH Patent Licensing Activities
NIBIB
July 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-------------------	---------------------------	----------------------	---------------------

NIH Patent Licensing Activities
NIBIB
August 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	---------------------	---------------------------	------------------------	---------------------

NIH Patent Licensing Activities
NIBIB
September 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
					\$9,750.00	\$13,625.86	\$23,375.86		\$4,437.50	\$18,938.36

NIH Patent Licensing Activities
NICHD
April 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
L-008-15/1	Bonner, Robert F	(b)(4);	xMD Diagnostics, LLC	1-Apr-20						(b) (3) (A), (b) (4), (b) (6)
<i>Note: L-008-15/1 split between CIT; NCI; NICHD</i>										
L-207-18/0	Chou, Janice Y.	(b)(4);	Generation Bio	16-Apr-20						

NIH Patent Licensing Activities
NICHD
May 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	------------------	---------------------------	---------------------	---------------------

NIH Patent Licensing Activities
NICHD
June 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
L-069-18/0	Chou, Janice Y.	(b)(4);	Dimension Therapeutics	5-Jun-20						(b) (3) (A), (b) (4), (b) (6)
L-076-08/0	NICHD		Emergent Product Development Gaithe	17-Jun-20						
<i>Note: L-076-08/0 split between NICHD; NIDCR; NIDDK</i>										
L-008-15/1	NICHD		xMD Diagnostics, LLC	18-Jun-20						
<i>Note: L-008-15/1 split between CIT; NCI; NICHD</i>										
L-080-09/0	Nelson, Lawrence M.	(b)(4);	Origene Technologies Inc	26-Jun-20						
L-080-09/0	Tong, Zhi-bin	(b)(6)	Origene Technologies Inc	26-Jun-20						

NIH Patent Licensing Activities

NICHD
July 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total Julv Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
L-167-17/0	NICHD		Cyprium Therapeutics Inc.	7-Jul-20						(b) (3) (A), (b) (4), (b) (6)
L-132-20/0	Dai, Lily Zhongdong	(b)(4)	Absolute Antibody Ltd.	22-Jul-20						
L-132-20/0	Kubler-Kielb, Joanna	(b)(6)	Absolute Antibody Ltd.	22-Jul-20						
L-132-20/0	Schneerson, Rachel		Absolute Antibody Ltd.	22-Jul-20						

Note: L-132-20/0 split between NIAID; NICHD; NIDCR

NIH Patent Licensing Activities
NICHD
August 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
L-061-19/0	NICHD		Ultragenyx Pharmaceutical Inc	14-Aug-20						(b) (3) (A), (b) (4)

NIH Patent Licensing Activities
NICHD
September 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
					\$17,916.92	\$49,153.19	\$67,070.11		\$6,808.10	\$60,262.01

NIH Patent Licensing Activities
NIDA
April 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
L-276-17/0	Rice, Kenner C.	(b)(4); (b)	Vital Spark Inc.	1-Apr-20						(b) (3) (A), (b) (4), (b) (6)
L-250-18/1	NIDA		Hello Bio Ltd.	15-Apr-20						

Note: L-276-17/0 split between NIAAAA; NIDA
Note: L-250-18/1 split between NIDA; NINDS

NIH Patent Licensing Activities
NIDA
May 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	------------------	---------------------------	---------------------	---------------------

NIH Patent Licensing Activities
NIDA
June 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
L-186-20/0	Backman, Christina M	(b)(4);	Maplight Therapeutics	18-Jun-20						(b) (3) (A), (b) (4), (b) (6)
L-186-20/0	Tomac, Andreas C	(b)(6)	Maplight Therapeutics	18-Jun-20						
L-186-20/0	Backman, Christina M		Maplight Therapeutics	18-Jun-20						
L-186-20/0	Tomac, Andreas C		Maplight Therapeutics	18-Jun-20						

NIH Patent Licensing Activities
NIDA
July 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-------------------	---------------------------	----------------------	---------------------

NIH Patent Licensing Activities
NIDA
August 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
L-245-17/1	NIDA		Braeburn Pharmaceuticals Inc.	28-Aug-20						(b) (3) (A), (b) (4)
L-220-17/1	NIDA		Braeburn Pharmaceuticals Inc.	28-Aug-20						

NIH Patent Licensing Activities
NIDA
September 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	------------------------	---------------------------	---------------------------	---------------------

\$29,788.66	\$9,939.75	\$39,728.41	\$5,898.42	\$33,829.99
-------------	------------	-------------	------------	-------------

NIH Patent Licensing Activities
NIDCD
April 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	--------------------	---------------------------	-----------------------	---------------------

NIH Patent Licensing Activities
NIDCD
May 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	------------------	---------------------------	---------------------	---------------------

NIH Patent Licensing Activities
NIDCD
June 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-------------------	---------------------------	----------------------	---------------------

NIH Patent Licensing Activities
NIDCD
July 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-------------------	---------------------------	----------------------	---------------------

L-111-06/0 Selbie, W. Scott (b)(4); ICAD Inc 20-Jul-20 (b) (3) (A), (b) (4), (b) (6)

Note: L-111-06/0 split between CC; CIT; NIDCD

NIH Patent Licensing Activities
NIDCD
August 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	---------------------	---------------------------	------------------------	---------------------

L-078-18/0 NIDCD miRecule 5-Aug-20 (b) (3) (A), (b) (4), (b) (6)

L-214-92/8 RJ Wenthold, (b) (6) (b)(4); EMD Chemicals 21-Aug-20

NIH Patent Licensing Activities
NIDCD
September 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	------------------------	---------------------------	---------------------------	---------------------

(b) (3) (A), (b) (4), (b) (6)

NIH Patent Licensing Activities
NIDCR
April 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	--------------------	---------------------------	-----------------------	---------------------

NIH Patent Licensing Activities
NIDCR
May 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
L-233-15/1	Maeda, Azusa	(b)(4);	Nestle Inst. of Health Sciences	6-May-20						(b) (3) (A), (b) (4), (b) (6)
L-233-15/1	Ono, Mitsuaki	(b)(6)	Nestle Inst. of Health Sciences	6-May-20						
L-233-15/1	Young, Marian F.		Nestle Inst. of Health Sciences	6-May-20						
L-152-17/0	Akiyama, Steven		Millipore Sigma	14-May-20						
L-152-17/0	Yamada, Kenneth		Millipore Sigma	14-May-20						
L-152-17/0	Yamada, Susan Sleeper		Millipore Sigma	14-May-20						
L-102-09/1	Siraganian, Reuben		Bio-Rad AbD	15-May-20						
L-263-18/0	NIDCR		MeiraGTx	22-May-20						
L-115-20/0	Chiorini, John A.	(b)(4);	Kriya Therapeutics, Inc.	28-May-20						
L-115-20/0	Pasquale, Giovanni Di	(b)(6)	Kriya Therapeutics, Inc.	28-May-20						
L-115-20/0	Chiorini, John A.		Kriya Therapeutics, Inc.	28-May-20						
L-115-20/0	Pasquale, Giovanni Di		Kriya Therapeutics, Inc.	28-May-20						
L-115-20/0	NIDCR		Kriya Therapeutics, Inc.	28-May-20						

NIH Patent Licensing Activities
NIDCR
June 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
L-102-17/0	Keith, Jerry M	(b)(4);	Inventprise LLC	10-Jun-20						(b) (3) (A), (b) (4), (b) (6)
L-102-17/0	Merkel, Todd J.	(b)(6)	Inventprise LLC	10-Jun-20						
L-102-17/0	Yang, Xiaoming		Inventprise LLC	10-Jun-20						
L-076-08/0	NIDCR		Emergent Product Development Gaithe	17-Jun-20						
<i>Note: L-076-08/0 split between NICHD; NIDCR; NIDDK</i>										
L-152-02/3	Leppla, Stephen H.	(b)(4);	Emergent BioDefense	24-Jun-20						
L-152-02/3	Park, Sukjoon	(b)(6)	Emergent BioDefense	24-Jun-20						

L-152-02/3 Quinn, Conrad P. (b)(4); Emergent BioDefense 24-Jun-20
 L-152-02/3 Singh, Yogendra (b)(6) Emergent BioDefense 24-Jun-20
 Note: L-152-02/3 split between NIAID; NIDCR

L-181-14/0 Burbelo, Peter D. (b)(4); InBios International Inc 24-Jun-20
 Note: L-181-14/0 split between NIAID; NIDCR

(b) (3) (A), (b) (4), (b) (6)

NIH Patent Licensing Activities
NIDCR
July 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
L-132-20/0	Moayeri, Mahtab	(b)(4);	Absolute Antibody Ltd.	22-Jul-20						(b) (3) (A), (b) (4), (b) (6)
Note: L-132-20/0 split between NIAID; NICHD; NIDCR										
L-333-14/0	Burbelo, Peter D.	(b)(4);	PATH Vaccine Solutions	27-Jul-20						
Note: L-333-14/0 split between NIAID; NIDCR										

NIH Patent Licensing Activities
NIDCR
August 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
L-078-15/0	Chiorini, John A.	(b)(4);	Spark Therapeutics, Inc.	13-Aug-20						(b) (3) (A), (b) (4), (b) (6)
L-078-15/0	Kaludov, Nikola	(b)(6)	Spark Therapeutics, Inc.	13-Aug-20						
L-115-00/2	Leppla, Stephen H.		List Biological Laboratories, Inc.	21-Aug-20						
Note: L-115-00/2 split between NIAID; NIDCR										
L-343-01/0	Keith, Jerry M		List Biological Laboratories, Inc.	21-Aug-20						
L-343-01/0	Merkel, Todd J.		List Biological Laboratories, Inc.	21-Aug-20						
L-343-01/0	Yang, Xiaoming		List Biological Laboratories, Inc.	21-Aug-20						
L-152-17/0	Akiyama, Steven		Millipore Sigma	21-Aug-20						
L-152-17/0	Yamada, Kenneth		Millipore Sigma	21-Aug-20						
L-152-17/0	Yamada, Susan Sleeper		Millipore Sigma	21-Aug-20						

NIH Patent Licensing Activities
NIDCR
September 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
					\$139,167.63	\$128,150.31	\$267,317.94		\$34,372.94	\$232,945.00

NIH Patent Licensing Activities
NIDDK
April 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
L-159-07/2	NIDDK		Hope Pharmaceuticals	7-Apr-20						(b) (3) (A), (b) (4), (b) (6)
<i>Note: L-159-07/2 split between CC; NHLBI; NIDDK; NINDS</i>										
L-155-07/1	Daly, (b) (6) John W	(b)(4); (b)(6)	Latoxan S.A.S.	21-Apr-20						
L-010-02/1	Sauer, Brian		Sigma-Aldrich Israel Ltd	27-Apr-20						
L-001-14/1	Proia, Richard L		Millipore Sigma	28-Apr-20						

NIH Patent Licensing Activities
NIDDK
May 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
*L-047-18/1	Proia, Richard L	(b)(4);	Recursion	29-May-20						(b) (3) (A), (b) (4), (b) (6)

NIH Patent Licensing Activities
NIDDK
June 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
L-265-02/0	Jacobson, Kenneth A	(b)(4);	Tocris Cookson, Ltd.	9-Jun-20						(b) (3) (A), (b) (4), (b) (6)
<i>Note: L-265-02/0 split between NCI; NIDDK</i>										
L-075-17/1	NIDDK		Biolntervene Inc.	17-Jun-20						
L-076-08/0	NIDDK		Emergent Product Development Gaithe	17-Jun-20						
<i>Note: L-076-08/0 split between NICHD; NIDCR; NIDDK</i>										

NIH Patent Licensing Activities
NIDDK
July 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
L-204-99/1	Jacobson, Kenneth A	(b)(4);	University of Virginia Patent Found.	2-Jul-20						(b) (3) (A), (b) (4), (b) (6)

NIH Patent Licensing Activities
NIDDK
August 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
L-149-17/0	Oral, Elif A.	(b)(4);	Aegerion Pharmaceuticals, Inc.	27-Aug-20						(b) (3) (A), (b) (4), (b) (6)
L-149-17/0	Taylor, Simeon	(b)(6)	Aegerion Pharmaceuticals, Inc.	27-Aug-20						

NIH Patent Licensing Activities
NIDDK
September 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
					\$29,465.45	\$46,244.93	\$75,710.38		\$9,353.07	\$66,357.31

* denotes an adjustment to fix a problem from a previous month

NIH Patent Licensing Activities
NIEHS
April 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	--------------------	---------------------------	-----------------------	---------------------

NIH Patent Licensing Activities
NIEHS
May 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	------------------	---------------------------	---------------------	---------------------

NIH Patent Licensing Activities
NIEHS
June 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-------------------	---------------------------	----------------------	---------------------

NIH Patent Licensing Activities
NIEHS
July 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
L-031-10/0	Ehrenshaft, Marilyn I	(b)(4);	Enzo Life Sciences AG	1-Jul-20						(b) (3) (A), (b) (4), (b) (6)
L-031-10/0	Mason, Ronald P.	(b)(6)	Enzo Life Sciences AG	1-Jul-20						
L-031-10/0	Summers, Fiona A.		Enzo Life Sciences AG	1-Jul-20						

NIH Patent Licensing Activities
NIEHS
August 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	---------------------	---------------------------	------------------------	---------------------

NIH Patent Licensing Activities
NIEHS
September 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
					\$865.95	\$0.00	\$865.95		\$865.95	\$0.00

NIH Patent Licensing Activities
NIMH
April 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	--------------------	---------------------------	-----------------------	---------------------

NIH Patent Licensing Activities
NIMH
May 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
L-091-18/0	Drevets, Wayne C	(b)(4);	Defender Pharmaceuticals	5-May-20						(b) (3) (A), (b) (4), (b) (6)
L-091-18/0	Furey, Maura L.	(b)(6)	Defender Pharmaceuticals	5-May-20						

NIH Patent Licensing Activities
NIMH
June 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
L-261-16/0	Eiden, Maribeth V.	(b)(4);	Fred Hutchinson Cancer Research Cente	1-Jun-20						(b) (3) (A), (b) (4), (b) (6)
L-261-16/0	Wilson, Carolyn A.	(b)(6)	Fred Hutchinson Cancer Research Cente	1-Jun-20						
L-025-17/1	Zarate, Carlos A.		Tocris Bioscience	9-Jun-20						
<i>Note: L-025-17/1 split between NCATS; NIA; NIMH</i>										
L-165-97/2	Jacobowitz, David	(b)(4);	Millipore Sigma	25-Jun-20						
L-165-97/2	Winsky, Lois	(b)(6)	Millipore Sigma	25-Jun-20						

NIH Patent Licensing Activities
NIMH
July 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
L-185-20/0	Drevets, Wayne C	(b)(4);	Defender Pharmaceuticals, Inc	29-Jul-20						(b) (3) (A), (b) (4), (b) (6)
L-185-20/0	Furey, Maura L.	(b)(6)	Defender Pharmaceuticals, Inc	29-Jul-20						
L-185-20/0	NIMH		Defender Pharmaceuticals, Inc	29-Jul-20						

NIH Patent Licensing Activities
NIMH
August 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
L-261-16/0	Eiden, Maribeth V.	(b)(4);	Fred Hutchinson Cancer Research Cente	1-Aug-20						(b) (3) (A), (b) (4), (b) (6)
L-261-16/0	Wilson, Carolyn A.	(b)(6)	Fred Hutchinson Cancer Research Cente	1-Aug-20						
L-064-10/1	NIMH		Angimmune LLC	3-Aug-20						

NIH Patent Licensing Activities
NIMH
September 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
							\$124,324.50		\$24,993.25	\$197,446.19

NIH Patent Licensing Activities
NINDS
April 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
L-159-07/2	NINDS		Hope Pharmaceuticals	7-Apr-20						(b) (3) (A), (b) (4), (b) (6)
<i>Note: L-159-07/2 split between CC; NHLBI; NIDDK; NINDS</i>										
L-250-18/1	NINDS		Hello Bio Ltd.	15-Apr-20						
<i>Note: L-250-18/1 split between NIDA; NINDS</i>										
L-087-99/1	Hsu, Yite	(b)(4);	Sigma-Aldrich Israel, Ltd.	27-Apr-20						
L-087-99/1	Youle, Richard J.	(b)(6)	Sigma-Aldrich Israel, Ltd.	27-Apr-20						

NIH Patent Licensing Activities

NINDS
May 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
L-144-20/0	Sliter, Danielle Angela	(b)(4);	Vincere Biosciences, Inc	11-May-20						(b) (3) (A), (b) (4), (b) (6)
L-144-20/0	Wang, Chunxin	(b)(6)	Vincere Biosciences, Inc	11-May-20						
L-144-20/0	Youle, Richard J.		Vincere Biosciences, Inc	11-May-20						

NIH Patent Licensing Activities

NINDS
June 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
L-083-11/0	Bielekova, Bibiana B	(b)(4);	AbbVie Biotherapeutics, Inc.	1-Jun-20						(b) (3) (A), (b) (4), (b) (6)
L-083-11/0	Martin, Roland	(b)(6)	AbbVie Biotherapeutics, Inc.	1-Jun-20						
L-083-11/0	McFarland, Henry F.		AbbVie Biotherapeutics, Inc.	1-Jun-20						
<i>Note: L-083-11/0 split between NCI; NINDS</i>										
L-181-04/2	Hou, Jean	(b)(4);	Immuquest Ltd	1-Jun-20						
L-181-04/2	Major, Eugene O	(b)(6)	Immuquest Ltd	1-Jun-20						
L-181-04/2	Messam, Conrad A		Immuquest Ltd	1-Jun-20						
L-132-17/0	Warach, Steven J.		CereDx Inc.	10-Jun-20						
<i>Note: L-132-17/0 split between NIA; NINDS; NINR</i>										
L-079-17/0	NINDS		VuEssence, Inc.	22-Jun-20						
<i>Note: L-079-17/0 split between NIA; NINDS; NINR</i>										

NIH Patent Licensing Activities

NINDS
July 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
L-058-13/2	Hou, Jean	(b)(4);	BioLegend	16-Jul-20						(b) (3) (A), (b) (4), (b) (6)
L-058-13/2	Major, Eugene O	(b)(6)	BioLegend	16-Jul-20						
L-058-13/2	Messam, Conrad A		BioLegend	16-Jul-20						
L-121-08/0	NINDS		Medtronic Inc	20-Jul-20						
<i>Note: L-121-08/0 split between NCI; NINDS</i>										
L-121-08/0	Bankiewicz, Krystof S.	(b)(4);	Medtronic Inc	20-Jul-20						
L-121-08/0	Lonser, Russell R	(b)(6)	Medtronic Inc	20-Jul-20						
L-121-08/0	Oldfield (b) (6) Edward I		Medtronic Inc	20-Jul-20						
<i>Note: L-121-08/0 split between NCI; NINDS</i>										

NIH Patent Licensing Activities
NINDS
August 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
L-032-19/1	Jin, Seok-Min	(b)(4);	Mitokinin	1-Aug-20						(b) (3) (A), (b) (4), (b) (6)
L-032-19/1	Youle, Richard J.	(b)(6)	Mitokinin	1-Aug-20						
L-083-11/0	Bielekova, Bibiana B		AbbVie Biotherapeutics, Inc.	28-Aug-20						
L-083-11/0	Martin, Roland		AbbVie Biotherapeutics, Inc.	28-Aug-20						
L-083-11/0	McFarland, Henry F.		AbbVie Biotherapeutics, Inc.	28-Aug-20						
<i>Note: L-083-11/0 split between NCI; NINDS</i>										

NIH Patent Licensing Activities
NINDS
September 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
L-083-11/0	Bielekova, Bibiana B	(b)(4);	AbbVie Biotherapeutics, Inc.	10-Sep-20						(b) (3) (A), (b) (4), (b) (6)
L-083-11/0	Martin, Roland	(b)(6)	AbbVie Biotherapeutics, Inc.	10-Sep-20						
L-083-11/0	McFarland, Henry F.		AbbVie Biotherapeutics, Inc.	10-Sep-20						
<i>Note: L-083-11/0 split between NCI; NINDS</i>										
					\$21,792.53	\$7,489.60	\$29,282.13		\$10,453.21	\$18,828.92

NIH Patent Licensing Activities
NINR
April 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	--------------------	---------------------------	-----------------------	---------------------

NIH Patent Licensing Activities
NINR
May 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	------------------	---------------------------	---------------------	---------------------

NIH Patent Licensing Activities
NINR
June 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
L-132-17/0	Barr, Taura L.	(b)(4);	CereDx Inc.	10-Jun-20						
L-132-17/0	(b)(4)	(b)(6)	CereDx Inc.	10-Jun-20						
L-079-17/0	NINR		VuEssence, Inc.	22-Jun-20						

Note: L-132-17/0 split between NIA; NINDS; NINR

Note: L-079-17/0 split between NIA; NINDS; NINR

(b) (3) (A), (b) (4), (b) (6)

NIH Patent Licensing Activities
NINR
July 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-------------------	---------------------------	----------------------	---------------------

NIH Patent Licensing Activities
NINR
August 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	---------------------	---------------------------	------------------------	---------------------

NIH Patent Licensing Activities
NINR
September 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	------------------------	---------------------------	---------------------------	---------------------

(b) (3) (A), (b) (4), (b) (6)

National Institutes of Health

Office of Financial Management

Royalties Semiannual Report -- Payments due to Inventors by IC -- Period ending: March 2021

CC	\$25,345.38
Baecher, Nicolai	(b) (4), (b) (3)
Danis, Marion	(A), (b) (6)
Franaszek, Marek	
Gladwin, Mark T.	
Harrison, Adam Patrick	
Huang, Hui-Yang	
Iordanescu, Gheorghe	
Jerebko, Anna K	
Jin, Jianjian	
Kwak, Jin Tae	
Lay, Nathan Stephan	
Liu, Jiamin	
Lu, Le	
(b) (4)	
Mollura, Daniel Joseph	
Reinhard Roth, Holger	
Roy, David	
Sabatino, Marianna V.	
Stroncek, David F.	
Summers, Ronald	
Tsehay, Yohannes Kebede	
Turkbey, Evrim	
Wang, Xiaosong	
Wood, Bradford J	
Xu, Sheng	
Xu, Ziyue	
Yao, Jianhua	
CDC	\$318,971.81
Ades, Edwin W.	(b) (4), (b) (3) (A), (b) (6)

Albarino, Cesar G.
Alisio, Carol H.
Aloisio, Carol H.
Amador, Manuel
Anderson, Larry J.
Anderson, Raydel
Bagarozzi, Dennis Anthony
Barclay, Leslie
Barrera, Roberto
Beall, David S.
Beck, Eric T.
Bellini, William J.
Benitez, Alvaro J.
Berman, LaShondra
Bird, Brian H.
Birkness, Kristin A.
Bishop, Henry
Black, Charlotte M.
Black, Jodi B.
Bobick, Thomas G.
Boyer, Anne E.
Burns, Cara C.
Butera, Salvatore T.
Campagnoli, Raymond
Candal, Francisco (Paco) J.
Cantis, Douglas M.
Carlone, George M.
Carvalho, Maria Da Gloria
Castro, Arnold R.
CDC
Chang, Gwong-Jen J.
Chhabra, Preeti
Cox, Nancy J.
Crill, Wayne D.

(b) (4), (b) (3) (A),
(b) (6)

Cromeans, Theresa
Damon, Inger K.
Davis, Brent S.
Deslauries, Manon
Devos, Joshua R.
Diaz, Maureen
Dietrich, EB Gabrielle
Dolan, Marc C.
Donis, Ruben O.
Donlan, Rodney M.
Edgell, Herbert D.
Emery, Shannon L.
Erdman, Dean D.
Esposito, Joseph J.
Esswein, Eric J.
Fields, Howard A.
Fields, Patricia
Folks, Thomas M
Freeman, Charlotte
Galland, Gale G.
Garcia Lerma, Jose Gerardo
Garcia-Lerma, J. Geraldo
Gasebom, Shane Dallas
Gentsch, Jon R.
George, Robert W.
Glass, Roger I.
Goldstein, Jason Marc
Granade, Timothy C.
Gregoricus, Nicole
Gubler, Duane J.
Guo, Zhu
Hanlon, Cathleen
Harmon, Maurice
Hart, John C.

(b) (4), (b) (3) (A),
(b) (6)

Hatcher, Cynthia P.
Heneine, Walid M.
Hill, Vincent R.
Hughes, Holly R
Hummer, Jon
Janssen, Robert
Jiang, Baoming
Jothikumar, Prithiviraj
Katz, Jacqueline M.
Kendal, Alan P.
Kennedy, Eugene R.
Kew, Olen M.
King, Peter
Kinney, Claire Huang
Kinney, Richard M.
Kirby, Wayne
Klimov, Alexander I.
Ksiazek, Thomas G.
Kulkarni, Pramod
Leaumont, Collette F.
Lindstrom, Stephen
Loftin, Lamorris
Lopez, Carlos
Lu, Xiaoyan
Mackay, Andrew J.
Maher, Kaija
[REDACTED] (b) (4)
Mark W. Reimer, (b) (6)
Maupin, Gary O.
Mayer, Leonard W.
McDougal, Steve
McGee, Lesley
McKenzie, Eugene A.
McQuiston, John R.

(b) (4), (b) (3)
(A), (b) (6)

Moore, Deborah D.
Morrill, William E.
Munoz-Jordan, Jorge
Munoz-Jordon, Jorge L
Murga, Ricardo
Murphy, William J.
Narayanan, Jothikumar
Nichol, Stuart T.
O'Connor, Steven
Olson, Victoria Ann
Otten, Ronald
Pallansch, Mark A.
Panella, Nicholas A.
Parekh, Bharat S.
Pau, Chou-Pong
Pellett, Philip E.
Peret, Teresa C.
Perez, Victor L.
Phillips, Donald
Pope, Victoria
Qi, Chaolong
Quay, Jacqueline
Quinn, Conrad P.
Quinn, Frederick D.
Raudabaugh, William M.
Reimer, Charles B.
Robertson, Shirley
Roehrig, John T.
Rupprecht, Charles E.
Russell, Harold
Saluzzo, Jean-francious
Sammons, Deborah L.
Sampson, Jacquelyn S.
Sanchez, Anthony

(b) (4), (b) (3) (A),
(b) (6)

Santiago, Gilberto

Shaw, Jing

Shu, Bo

Smith, Jean S.

Smith, Jerome P.

Snawder, John E.

Snyder, Jay L.

Sparks, Kansas

(b) (4)

Stephenson, Mark R.

Stevens, James

Stockdale, Carol

Striley, Cynthia A.

Summer, John

Tamin, Azibi

Tatti, Kathleen M.

Tharpe, Jean A.

Theodore, Mary J.

Thibodeaux, Brett A.

Thomas, Jennifer D.

Tondella, Maria-Lucia

Tong, Suxiang

Tsou, Cecelia

Tuchman, Donald P.

Vergne, Edgardo

Vinje, Jan

Volkwein, Jon C.

Wagar, Nicholas

Walls, Harriet

Wang, Xin

Wang, Yuhuan

Wang, Zhongde

Wei, Xierong

Wells, Thomas

(b) (4), (b) (3) (A),
(b) (6)

Wilson, Jason Ray	(b) (4), (b) (3) (A), (b) (6)
Winchell, Jonas M.	
Wolff, Bernard	
Wood, Gerry O.	
Wu, Xianfu	
Yager, Pamela	
Yamamoto, Masahiro	
Yang, Chunfu (Dustin)	
Yang, Yong	
York, Ian Arthur	
Zhou, Zhiyong	
CIT	\$1,137.56
Cheng, Ruida	(b) (4), (b) (3) (A), (b) (6)
Malley, James	
McAuliffe, Matthew	
Wagner, Lynne M	
FDA	\$71,438.89
Donnelly, Raymond P.	(b) (4), (b) (3) (A), (b) (6)
Falgout, Barry	
Golding, Hana	
Khurana, Surrender	
Markoff, Lewis	
Petricoin, Emanuel	
NCATS	\$26,938.96
Auld, Douglas S.	(b) (4), (b) (3) (A), (b) (6)
Austin, Christopher P.	
Boxer, Matthew	
Chen, Yu	
Cheng, Chih-Chien (Ken)	
Deng, Tao	
Hasson, Samuel A.	
Inglese, James	
Jang, Sung-Wook	
Jiang, Jian-kang	

Liu, Ke
Marugan, Juan J.
McKew, John C.
Morris, Patrick
Shen, Min
Simeonov, Anton
Singec, Ilyas
Skoumbourdis, Amanda P.
Southall, Noel T.
Svaren, John
Swaroop, Manju
Thomas, Craig J.
Titus, Steven
Xiao, Jingbo
Xu, Miao
Zheng, Wei

(b) (4), (b) (3) (A),
(b) (6)

NCI

\$4,013,213.23

Aaronson, Stuart A.
Abrams, Scott I
Acquavella, Nicolas
Ahlers, Jeffrey D
Alewine, Christine
Allegra, Carmen
Aplan, Peter D.
Austin, Faye C.
Azimi, Nazli
Bagni-Beyer, Rachel K.
Barrett, J Carl
Barry, Todd
Baskar, Sivasubramanian
Bera, Tapan K
Bernardo, Marcelino L (b) (6)
Berzofsky, Jay A.
Bogdan, Christian

(b) (4), (b) (3) (A),
(b) (6)

Bonner, William M

Bonomi, Carrie A.

Borgel, Suzanne D.

(b) (4)

Brinkmann, Ulrich

Buck, Christopher

Burgess, Rebecca C.

Bustin, Michael

Cafri, Gal

(b) (4)

Chabner, Bruce A

Chang, Kai

Chang, Nancy T.

Chatterjee, Deb K

Chen, Weizao

Chen, Xin

Cheng, Sheue-Yann

Chien, Christopher

Choyke, Peter L

Chung, Jae Wook

Chung-Yin Yang, James

Colcher, David

Cole, Katharine H.

Collins, Norman Keith

Conrads, Thomas P

Copeland, Neal

Costantino, Nina

Court, Donald

Crowl, Robert

(b) (4)

Custer, Mary

Datta, Simanti

Day, Chi-Ping

Deniger, Drew

(b) (4), (b) (3) (A),
(b) (6)


Dimitrov, Dimiter S.
Doroshov, James H.
Dougherty, Kelly
Dougherty, Kelly
Dubois, Sigrid
Dudley, Mark
Eil, Robert Languard
Ellis, Hilary Moyed
Ellmore, Nelson
Emmert-Buck, Michael R.
Esposito, Dominic
(b) (6) Donald J. Giard
Felber, Barbara K.
Feldman, Steven A
Feng, Yang
Figg, William D
Finch, Paul W.
Fisher, Amanda G.
Fitzgerald, David J.
Fitzgerald, Peter C.
Fowler, Daniel
Franchini, Genoveffa
Fry, Terry
Gallo, Robert C.
Gao, Wei
Gartner, Jared
Gartner, Suzanne
Gattinoni, Luca
Gazdar, Adi
Gelboin, (b) (6) Harry
(b) (4)
Giard, Donald
Giardina, Steven
Gillette, William K.

(b) (4), (b) (3) (A),
(b) (6)

Goldman, Carolyn
Gonzalez, Frank J
Good, Meghan
Gottesman, Michael M.
Greer, Matthew D.
Greiner, John W.
Gress, Ronald E.
Gros, Alena
Grose, Carissa L.
Guerin, Theresa
Gupta, Shanker Lal
Hahn, Beatrice
Hamilton, Thomas C
Hanada, Kenichi
Hand, Patricia H
Harmon, Stephanie Anne
Harris, Curtis C.
[REDACTED]
Hassan, Raffit
Hathcock, Karen
Helman, Lee
Hinrichs, Christian S.
Ho, Mitchell
Hodes, Richard J
Hodes, Richard J
Hodge, Deborah
Hodge, James W.
Holderfield, Matthew T.
Hollingshead, Melinda G.
Hopkins, Ralph F.
Horie, Kyoji
Hurwitz, Arthur A.
Hwu, Patrick

[REDACTED]

(b) (4), (b) (3) (A), (b)
(6)



Ise, Tomoko
Islam, S M Rafiqul
Issaq, Haleem J.
Jainchill, John L.
Janini, George
Jelinek, Ivett
Jenkins Copeland, Nancy A
Jensen, Roy A.
Ji, Qingyong
Ji, Xinhua
Jiang, Guojian
Jin, Benjamin

Johnson, Bruce E
Johnston, Patrick G.
Jung, Sun-Hee
Jung, Unsu
Kaczmarczyk, Stanislaw
Kahn, Richard A
Kalyanaraman, Vaniambadi S.
Kawakami, Yutaka
Kawamura, Masaru
Kaye, Frederic J
Keefer, Larry K
Keseling, Beverly G
Khanna, Chand
Khleif, Samir N.
Khleif, Samir N.
King, Charles R.
Kishton, Rigel Joseph
Klemen, Nicholas Donald
Kobayashi, Hisataka
Kochenderfer, James N
Kozlov, Serguei

(b) (4), (b) (3) (A),
(b) (6)

(b) (4)

Kraus, (b) (6) Matthias
Krausz, Kristopher W.
Lalani, Almin
Lam, Norris
Landry, Joseph W.
Lantz, Valerie A
Lapointe, Rejean
LaRochelle, William
Laszlo, Gloria
Lechner, John F.
Lee, Byungkook
Lee, Choonsik
Lee, E-Chiang
Levin, Noam
Li, Dan
Li, Nan
Liang, Chi-Ming
Lin, Ying-Wei
Linehan, Marston
Liotta, Lance
Liu, Pentao
Lo, Winifred Margaret
Longo, Dan L
Lori, Franco C.
Lowery, Fank
Lowy, Douglas R.
Lu, Yong-Chen
Luciano, Michael
Makrigiannis, Andrew P.
Malekzadeh, Parisa
Mariner Kilbourne, Jennifer
Markham, Phillip D.
Marquez, Victor E
Mason, Llewellyn H.

(b) (4), (b) (3) (A), (b) (6)

Matsui, Toshimitsu
McVicar, Daniel W
Mehta, Arpita I
Merlino, Glenn T.
Mertan, Francesca
Michie, Megan Suzanne
Minna, John D.
Misteli, Thomas
Mitsunaga, Makoto
Morgan, Richard A.
Muchmore, Brian P.
Nagata, Satoshi
Nani, Roger R.
Nara, Peter L
Nutti, Marianna
O'Brien, Thomas R
O'Shea, John J.
O'Sullivan, Theresa
Oberdoerffer, Phillip
Oie, Herbert K
Onda, Masanori
Oppenheim, Joost J
Ortaldo, John R.
Ozols, Robert F
Palmer, Douglas
Paria, Biman
Parkhurst, Maria
Parks, Wade P
Pasetto, Anna
Pass, Harvey I
Pastan, Ira H
Pastrana, Diana V
Patel, Shashankkumar
Pavlakis, George N

(b) (4), (b) (3) (A), (b)
(6)

Pendleton, Charles D.
Phung, Yen T.
Pierce, Jacalyn
Pinto, Peter A
Ponraj, Prabakaran
Popovic, Mikulas
Porter-Gill, Patricia A.
Prokunina-Olsson, Ludmila
Qasba, Pradman
Qin, Haiying
Rader, Christoph
Ramakrishnan, Boopathy
RAY, UPASANA
Reddel, Roger R.
Reddy, E. Premkumar.
Reitz, Jr., Marvin S.
Restifo, Nicholas P.
Reynolds, Della Anne
Rice, William G
Risinger, John
Robbins, Keith
Robbins, Paul F
Roberts, Veronica Ann
Roden, Richard B
Rogakou, Efthimia P
Roop, Dennis R.
Rosenberg, Steven A.
Rosenwald, Andreas
Roukos, Vasileios
Roy, Krishnendu K.
Rubin, Jeffrey S
Rudloff, Udo
Saavedra, Joseph E
Salahuddin, Syed Z.

(b) (4), (b) (3) (A), (b)
(6)

Sarngadharan, Mangalasseril
Sato, Kazuhide
Sato, Noriko
Sausville, Edward
Schiller, John T
Schlom, Jeffrey
Schlomer, Jerome J
Schnermann, Martin
Segal, David M.
Sharan, Shyam K
Shaw, George M
Shirai, Mutsunori
Simone, Nicole L
Singh, Vinod
Slape, Christopher I.
Snader, Kenneth M
Somerville, Robert P.
Sonalee Gaur, Sonia
Soppet, Dan
Soutoglou, Evi
Spiese, Paul J
Srinivasan, Aloka
Staudt, Louis M
Steinert, (b) (6) Peter M.
Stevanovic, Sanja
Swaminathan, Srividya
Swaminathan, Srividya
Tamaoki, Naritaka
Todaro, George J.
Topalian, Suzanne L.
Tran, Eric
Tsang, Kwong-Yok
Turkbey, Ismail B.
Ueda, Kazumitsu

(b) (4), (b) (3) (A), (b)
(6)

(b) (4)

(b) (4), (b) (3) (A), (b) (6)

Uren, Aykut

Varesio, Luigi

Veenstra, Timothy D

Vishnuvajjala, B. Rao

Vizcardo Sakoda, Raul Eduardo

Vodnala, Suman Kumar

Waldmann, Thomas A.

Wang, Qiong

Wang, Rong-fu

Wang, Xiaohong

Wang, Yan

Warfield, Paul

Warming, Soren

Waugh, David

Wiestner, Adrian

Wilkens, Kenneth L.

Willingham, Mark C.

Wilson, Wyndham H.

Wong-Staal (b) (6)

Wu, Carl

Wu, Yongzhong

Wunderlich, John

Xiang, Liaman

Xu, Junfen

Yang, De

Yang, James C

Yang, Tian J.

Yang, Youfeng

Yongzu Jin, Benjamin

Yoseph, Rami

Yoshimura, Teizo

Young, Howard A.

Yu, Daiguan
Yu, Zhiya
Yuspa, Stuart H.
Zaharoff, David
Zhang, Ling
Zhang, Xianyu
Zhang, Yifan
Zhang, ZhenHua
Zhao, Chihao
Zheng, Zhi-Min g (Thomas)
Zheng, Zhili
Zhu, Zhongyu
Zhu, Ziqiang

(b) (4), (b) (3) (A), (b) (6)

NEI **\$612,714.26**

Amaral, Juan A
Bharti, Kapil
Bunce, George E.
Charles, Steven Thomas
Chen, Yu Holly
Clore-Gronenborn, Katharina
Davis, Janine A
English, Milton A
Ferris III, Frederick L.
Hotaling, Nathan
Khristov, Vladimir R.
Kinoshita, (b) (6) Jin H
Li, Tiansen
Maminishkis, Arvydas
Miyagishima, Kiyoharu
NIST
Shimada-Ishill, Hiroko
Smith, James Cecil
Swaroop, Anand

(b) (4), (b) (3) (A), (b) (6)

NHGRI **\$801,712.66**

Capell, Brian C
Chandler, Randy J.
Collins, Francis S
Gahl, William A.
Gispert-Sanchez, Suzana
Huizing, Marjan
Klootwijk, Enriko D
Manoli, Eirini
Manoli, Eirini
Mijares, Lilia A.
Nicoli, Elena-Raluca
Nussbaum, Robert L.
Pavan, William J

(b) (4), (b) (3) (A), (b)
(6)

(b) (4)

Segre, Julia A
Smith, Stephanie N.
Tifft, Cynthia J.

(b) (4)

Venditti, Charles P.

NHLBI

\$471,077.28

Adelstein, Robert
Aletras, Anthony Homer
Amar, Marcelo A.
Arai, Andrew Ernest

(b) (4), (b) (3) (A),
(b) (6)

(b) (4)

Boehm, Manfred
Brewer, H. Bryan
Cannon, Richard O.
Carlsten, Mattias CV
Cecchini, Sylvain
Chen, Guibin
Cherkasova, Elena A.
Childs, Richard W.
Chiorini, John A.

Combs, Christian A.
Demosky, Stephen J.
Derbyshire, John Andrew
Ding, Chuan-Tian
Ding, Chuan-Tian
Finkel, Toren
Gladwin, Mark T.
Haque, Nazmul
Hogg, John Robert
Hsu, Li - Yueh
Hunter, Christian J
Jacobs, Matthew James

(b) (4)

Kawamoto, Sachiyo
Kelley, Christine A
Kellman, Peter
Kim, Kee Kwang
Knepper, Mark A
Kotin, Robert M.
Larochelle, Andre
Leonard, Warren J.
Li, Lina
Lin, Jian-Xin

(b) (4)

McVeigh, Elliott R
Mitra, Suman
Neufeld, Edward B.
Nezafat, Reza
Nirenberg, (b) (6) Marshall
Remaley, Alan T.
Russell, Sarah M
Smith, Richard H.

(b) (4), (b) (3) (A), (b)
(6)

Stonik, John A.
Thomas, Fairwell

(b) (4)

Urabe, Masashi

(b) (4)

Walsh, Frank

Wen, Han

Yang, Yanqin

Zhu, Jun

NIA

\$42,094.27

Bagrov, Alexei

Doyle, Maire E

Egan, Josephine M

Falco, Geppino

Fedorova, Olga V.

Ferrucci, Luigi

Goetzl, Edward

Greig, Nigel H

Hodes, Richard J

Holloway, Harold

Ingram, Donald

Kim, Dong Seok

Ko, Minoru S.

Lakatta, Edward G.

Lee, Sung-Lim

Li, Yazhou

Luo, Weiming

Matarin Jimenez, Maria Del Mar

Moaddel, Ruin

Monti, Manuela

Perry, Tracy Ann

Sharova, Lioudmila V.

(b) (4), (b) (3) (A), (b) (6)

(b) (4), (b) (3) (A), (b) (6)

Shaw, Karen
Shin, Soojung
Singleton, Andrew B.
Stanghellini, Ilaria
Tweedie, David

(b) (4)

Yu, Qian-sheng
Zalzman, Michal

NIAAA

Cinar, Resat
Iyer, Malliga R.
Kunos, George I

\$17,658.75

(b) (4), (b) (3)
(A), (b) (6)

NIAID

\$3,372,739.01

Abisola Abiona, Olubukola Mary
Adachi, Akio
Akahata, Wataru
Akin, Cem
Alexander, Robert M.
Angermann, Bastian R
Barry, Clifton E
Baxa, Ulrich
Beeler, Judy A.
Bennink, Jack R.
Birmingham, Alison
Best, Sonja M.
Biacchesi, Stephanie
Blaney, Jr., Joseph E
Boyington, Jeffrey C.
Brock, Linda G.
Broder, Christopher
Buchholz, Ursula
Bukreyev, Alexander
Caldwell, Harlan D
Carey, Elizabeth

(b) (4), (b) (3) (A), (b)
(6)

(b) (4)

Chakrabarti, Bimal K

Chakrabarti, Sekhar

Chanock, (b) (6) Robert

Chen, Lei

Chen, Man

Chen, Mingzong

Chen, Peifeng

Chen, Zhao Chun

Cheng, Cheng

Chesebro, Bruce

Cheung, Yiu Chong Gordon

Chuang, Gwo-Yu

Chuang, Gwo-Yu

Clouse, Thomas

Coelingh, Kathleen L.

Cohen, Jeffrey

Coligan, John

Collins, Peter L.

Connors, Mark

Conrad, John T.

Corbett, Kizzmekia

Cox, Josephine H

(b) (4)

Datta, Sandip Kumar

Davey, Richard T.

David, Alexandre

De Wit, Emmie

DeBuysscher, Blair Lynn

DeVico, Angela M.

Doms, Robert W.

Druz, Aliaksandr A.

Earl, Patricia L.

Eisenbarth, (b) (6) George

(b) (4), (b) (3) (A), (b) (6)

Emerson, Suzanne U.

(b) (6) Clement K. Asiedu

Feldmann, Heinrich Ulrich

Fink, Doran

Folks, Thomas M

Galen, Joseph Van

Garboczi, David

Georgiev, Ivelin S.

Germain, Ronald N.

Ghosh, Mridul K.

Gorman, Jason

Graham, Barney

Green, Kim Y.

Guatam, Rejeev

Gupta, Pradeep K.

Hanley, Kathryn

Harriman, Gregory R.

Horwitz, Joseph

Hoshino, Yasutaka

Hsu, Su-Cheng Dana

Hu, Haijing

Huang, (b) (6) Yue

Huang, Jinghe

(b) (4)

Hutchinson, Geoffrey Bain

(b) (4)

Ishida, Elise H.

Ishizuka, Andrew S

Jahrling, Peter B.

Jeang, (b) (6) Kuan-Teh

Jenkins, John P.

Johnson, Reed F.

Joyce, Michael G.

Justement, Jesse S

(b) (4), (b) (3) (A), (b) (6)

Kanekiyo, Masaru
Kang, Byong Ha
Kapikian, (b) (6) Albert Z
Kim, Yong Chan
Kinter, Audrey L
Kirshenbaum, Arnold
Koh, Franklin
Kong, Wing-pui
Korty, Patricia E.
Krzewski, Konrad
Kubofcik, Joseph
Kunimoto, Dennis Y.
Kwon, Young Do
Kwong, Peter D.
Lai, Ching-Juh
Lantz, Larry
Ledgerwood, Julie
Lee, Ha Na
Lee, Richard E.
Leonard, John M.
Leppla, Stephen H.
Leung, Kwanyee
Leysath, Clinton E.
Liang, Bo
Liu, Shi-Hui
Long, Eric O.
Lubick, Kirk
Lujan, Hugo D
Luongo, Cindy L.
Mackett, Michael
Mangalampalli, Venkata R.
Marques, Adriana
Martin, Malcolm A
Marzi, Andrea Maria

(b) (4), (b) (3) (A), (b)
(6)

Mascola, John R.
McCarty, Thomas Charles
Mchugh, Rebecca S
McLellan, Jason Scott
McTamney, Patrick
Meier-Schellersheim, Martin
Merritt, Joshua S.
Metcalf, Dean D
Moayeri, Mahtab
Moin, Syed M.
Morse III, Herbert
Moss, Bernard
Mowatt, Michael
Mulangu, Sabue
Munir, Shirin
Murphy, Brian R.
Muyembe-Tamfun, Jean-Jacques
Myles, Ian
Nabel, Gary J
Nagy, Attila
Nash, Theodore
Nguyen, Hanh T.
Nishimura, Michael
Nutman, Thomas B.
Nutt, Anne S.
O'Brien, Daniel P.
OFEK, GILAD A
Ohara, Junichi
Ohta, Akio
Ou, Li
Pancera, Marie L.
Paragas, Jason J.
Paul, (b) (6) William E.
Pesnicak, Lesley M

(b) (4), (b) (3) (A), (b) (6)

Phillips, Damilola D.
Pomerantsev, Andrei P
Porgador, Angel
Powell, Douglas M
Prescott, Joseph
Purcell, Robert H
Quasney, Judit A.
Rabson, Arnold B.
Rajagopalan, Sumati
Rao, Srinivas
Robertson, Shelly J.
Rudicell, Rebecca S.
Rundlet, Emily J
Rutledge, Rosamond A.
Sadjadpour, Reza
Sastry, Mallika
Schubert, Ulrich K
Schwartz, Richard M.
Seder, Robert
Shevach, Ethan M
Shi, Wei
Shingai, Masashi
Shukla Bajpai, Priyanka
Siebenlist, Ulrich
Sitkovsky, Michail V.
Skiadopoulos, Mario
Slayden, Richard A
Smith, Geoffrey L
Sosnovtsev, Stanislav V
Soto, Cinque
Srivatsan, Sanjay R.

(b) (4), (b) (3) (A), (b) (6)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

Stanley, Daphne Amanda
Stephens, Geoffrey L.
Stewart-Jones, Guillaume
Stewart-Jones, Guillaume BE
Strober, Warren
Sullivan, Nancy J
Sun, Peter D

(b) (4)

Theodore, (b) (6) Theodore S

(b) (4)

Thomas, Paul V.
Tian, Lirjie
Torian, Udana M
Tsybovsky, Yaroslav
United States Army

(b) (4)

(b) (4)

Voss, Oliver
Wang, Lingshu
Ward, Lucy A.
Wehrly, Kathryn
Wei, Chih-Jen
Whitehead, Stephen S.
Whittle, James R R
Willey, Ronald L.
Wu, Xueling
Wyatt, Linda S.
Wycuff, Diane L.

(b) (4)

Yang, Eun Sung
YANG, YONGPING
Yang, Zhi-Yong
Yassine, Hadi M.

(b) (4), (b) (3) (A), (b) (6)

[Redacted]

Yewdell, Jonathan W.

Zhang, Baoshan

Zhang, Yi

Zhang, Yi-Ming

Zheng, Anqi

Zhou, Tongqing

Zhou, Tongqing

Zhu, Jiang

Zhu, Yaling

Zou, Zhongcheng

NIAMS

(b) (4), (b) (3) (A), (b) (6)

\$17,652.87

Brydges, Susannah Diane

Chu, Emily Yin

Foster, Brian Lee

Johnston, James A.

Kastner, Daniel L

Kinet, Jean-Pierre

Kong, Heidi H.

Nociti, Francisco

Rao, Mahendra S

Somerman, Martha J

Thumbigere-Math, Vivek

(b) (4)

(b) (4), (b) (3) (A), (b) (6)

\$60,405.23

NIBIB

Chen, Xiaoyuan

Parekh, Sapun

Phillips, Terence M

Shroff, Hari

Weiss, Orit Jacobson

York, Andrew G.

(b) (4), (b) (3) (A), (b) (6)

\$41,381.68

NICHD

Chou, Janice Yang

Crouch, Robert J.

Dai, Lily Zhongdong

(b) (4), (b) (3) (A), (b) (6)

Dawid, Igor
Deligiannidis, Kristina M Galarneau
Dey, Anup K
Dressler, Gregory R.
Gandjbakhche, Amir H

(b) (4), (b) (3) (A),
(b) (6)

(b) (4)

Huang, Freesia
Huang, Kuo-Ping
Karavanov, Alex A. or Irina
Klein, David C.

(b) (4)

Kubler-Kielb, Joanna
Ozato Dawid, Keiko
Riley, Jason D.
Robbins, John B.
Romero, Roberto
Schneerson, Rachel
Szu, Shousun C
Weller, Joan

NIDA

\$45,553.25

Backman, Christina M
Cao, Jianjing
Cyriac, George C.
Grundt, Peter
Kumar, Vivek
Newman, Amy H.
Okunola-Bakare, Oluyomi M.
Rice, Kenner C.
Shaik, Anerbasha
Tomac, Andreas C

(b) (4), (b) (3) (A),
(b) (6)

(b) (4)

Wise, Roy A
Zangen, Abraham

NIDCD

\$12,375.63

Chen, Zhong

Cheng, Hui

Drayna, Dennis T.

Griffith, Andrew J.

Kim, Un-kyung

Labay, Valentia

Makishima, Tomoko

Montcouquiol, Mireille

RJ Wenthold, (b) (6)

Saleh, Anthony

Selbie, W. Scott

(b) (4)

Van Waes, Carter

NIDCR

Akiyama, Steven

Burbelo, Peter D.

Chiorini, John A.

Elkin, Michael

Fisher, Larry

Hsu, Su-Cheng Dana

Iadarola, Michael J.

Kaludov, Nikola

Keith, Jerry M

Kleinman, Hynda

Kulkarni, Ashok

Leppla, Stephen H.

Merkel, Todd J.

Moayeri, Mahtab

Ohshima, Toshio

Park, Sukjoon

Pasquale, Giovanni Di

Philp, Deborah

Quinn, Conrad P.

Rosovitz, Mary Jo

(b) (4), (b) (3) (A),
(b) (6)

\$70,269.34

(b) (4), (b) (3)
(A), (b) (6)

Singh, Yogendra
Siraganian, Reuben
Yamada, Kenneth
Yamada, Susan Sleeper
Yang, Xiaoming

NIDDK

(b) (4), (b) (3) (A),
(b) (6)

\$67,405.00

Appella, Daniel H
Daly, (b) (6) John W
Dean, Jurrien
East, Iain
Englund, Ethan A.
Gao, Zhan-Guo
Ge, Kai
Gershengorn, Marvin
Goldsmith, Paul K
Huang, Wei
Jacobson, Kenneth A
Jiang, Ji-Long
Karton, Yishai
Kim, Yong-Chul
Kopp, Jeffrey B
Lee, Ji-Eun

(b) (4), (b) (3) (A),
(b) (6)

(b) (4)

Micklitsch, Christopher
Neumann, Susanne
Oquare, Bereket
Oral, Elif A.
Proia, Richard L
Raaka, Bruce
Ramirez, Delia
Rehermann, Barbara
Rosshart, Stephan Patrick
Sakairi, Toru
Schechter, Alan N.

(b) (4)

Shiloach, Joseph
Simonds, William F.
Spiegel, Allen M.
Taylor, Simeon
Tosh, Dilip K.
Van Rhee, Albert M
Wang, Deyun
Zhang, Jianhua
Zhang, Ning
Zhao, Chao

(b) (4), (b) (3) (A),
(b) (6)

NIEHS

\$22,428.91

(b) (4)
Beckley, Amy J.
Bradbury, Jennifer Alyce
Cidlowski, John A.
Eddy, Edward
Ehrenshaft, Marilyn I
Graves, Joan P.
Jensen, Patricia
Jetten, Anton M.
Mason, Ronald P.
Mishina, Yuji
Moore, Rickie
Negishi, Masahiko
Plummer, Nicholas W.
Ray, Manas K.
Scott, Gregory J.

(b) (4), (b) (3)
(A), (b) (6)

(b) (4)

Zeldin, Darryl C

NIMH

\$114,268.62

Cohen, Robert M.
Dold, George R.
Drevets, Wayne C
Eiden, Maribeth V.

(b) (4), (b) (3) (A),
(b) (6)

Furey, Maura L.
Ginns, Edward I.
Kowalak, Jeffrey A.
LaMarca, Mary
Manji, Husseini K.
Markey, Sanford P.
Masuda, Junichi
Morgan, Newlin T.
Unsworth, Edward J.
Wilson, Carolyn A.
Ye, Daniel
Zarate, Carlos A.

(b) (4), (b) (3) (A),
(b) (6)

NINDS

\$122,836.99

Amyot, Franck
Bharti, Kapil
Bielekova, Bibiana B
Brady, (b) (6) Roscoe O
Dobersen, Michael J
Gainer, Harold
Hallett, Mark
Hammer, Jeffrey A.
Hou, Jean
Hsu, Yite
Humbert, Ianessa A
Lee, Myoung Hwa
Li, Wenxue
Lowell, Soren Y
Ludlow, Christy L.
Major, Eugene O
Martin, Roland
McFarland, Henry F.
Messam, Conrad A
Miranda, Pedro
Murray, Gary J

(b) (4), (b) (3) (A), (b)
(6)

Nath, Avindra

Noronha, Antonio B

Oldfield, (b) (6) Edward H.

Pluta, Ryszard M

Poletto, Christopher J.

Quarles, Richard H.

Roth, Yiftach

Steiner, Joseph Perry

Warach, Steven J.

Wasserman, Eric M.

Youle, Richard J.

NINR

Barr, Taura L.

(b) (4)

NLM

Lu, Zhiyong

Pang, Yifan

(b) (4), (b) (3) (A), (b) (6)

NIH Patent Licensing Activities
CC
October 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-059-18/0	Baecher, Nicolai	(b)(4);	Ping An Technology (Shenzhen) Company It	1-Oct-20						(b) (4), (b) (3) (A), (b) (6)
L-059-18/0	Lay, Nathan Stephan	(b)(6)	Ping An Technology (Shenzhen) Company It	1-Oct-20						
L-059-18/0	Liu, Jiamin		Ping An Technology (Shenzhen) Company It	1-Oct-20						
L-059-18/0	Summers, Ronald		Ping An Technology (Shenzhen) Company It	1-Oct-20						
L-059-18/0	Yao, Jianhua		Ping An Technology (Shenzhen) Company It	1-Oct-20						
L-010-18/0	Harrison, Adam Patrick		Ping An Technology (Shenzen) Company LTD	1-Oct-20						
L-010-18/0	Lu, Le		Ping An Technology (Shenzen) Company LTD	1-Oct-20						
L-010-18/0	Mollura, Daniel Joseph		Ping An Technology (Shenzen) Company LTD	1-Oct-20						
L-010-18/0	Summers, Ronald		Ping An Technology (Shenzen) Company LTD	1-Oct-20						
L-010-18/0	Wang, Xiaosong		Ping An Technology (Shenzen) Company LTD	1-Oct-20						
L-010-18/0	Xu, Ziyue		Ping An Technology (Shenzen) Company LTD	1-Oct-20						
<i>Note: L-010-18/0 split between CC; NLM</i>										
L-160-18/0	CC		Advanced Imaging Projects, LLC (AIP)	22-Oct-20						
<i>Note: L-160-18/0 split between CC; NCI</i>										

NIH Patent Licensing Activities
CC
November 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
L-160-18/0	CC		Advanced Imaging Projects, LLC (AIP)	14-Nov-20						(b) (4), (b) (3) (A), (b) (6)
<i>Note: L-160-18/0 split between CC; NCI</i>										
L-143-07/2	Gladwin, Mark T.	(b)(4);	Hope Pharmaceuticals	16-Nov-20						
<i>Note: L-143-07/2 split between CC; NHLBI; NIDDK</i>										
L-159-07/2	Gladwin, Mark T.	(b)(4);	Hope Pharmaceuticals	16-Nov-20						
<i>Note: L-159-07/2 split between CC; NHLBI; NIDDK; NINDS</i>										
L-029-20/0	Lay, Nathan Stephan	(b)(4);	Translation Holdings, Inc	23-Nov-20						
L-029-20/0	Summers, Ronald	(b)(6)	Translation Holdings, Inc	23-Nov-20						

NIH Patent Licensing Activities
CC
December 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
L-160-18/0	CC		Advanced Imaging Projects, LLC (AIP)	15-Dec-20						(b) (4), (b) (3) (A), (b) (6)
<i>Note: L-160-18/0 split between CC; NCI</i>										

L-107-15/1	Jin, Jianjian	(b)(4);	lovance Biotherapeutics Inc	16-Dec-20
L-107-15/1	Sabatino, Marianna V.	(b)(6)	lovance Biotherapeutics Inc	16-Dec-20
L-107-15/1	Stroncek, David F.		lovance Biotherapeutics Inc	16-Dec-20

Note: L-107-15/1 split between CC; NCI

L-059-18/0	Baecher, Nicolai		Ping An Technology (Shenzhen) Company It	22-Dec-20
L-059-18/0	Lay, Nathan Stephan		Ping An Technology (Shenzhen) Company It	22-Dec-20
L-059-18/0	Liu, Jiamin		Ping An Technology (Shenzhen) Company It	22-Dec-20
L-059-18/0	Summers, Ronald		Ping An Technology (Shenzhen) Company It	22-Dec-20
L-059-18/0	Yao, Jianhua		Ping An Technology (Shenzhen) Company It	22-Dec-20

L-111-06/0	CC		ICAD Inc	23-Dec-20
------------	----	--	----------	-----------

Note: L-111-06/0 split between CC; CIT; NIDCD

L-010-18/0	Harrison, Adam Patrick	(b)(4);	Ping An Technology (Shenzen) Company LTD	23-Dec-20
L-010-18/0	Lu, Le	(b)(6)	Ping An Technology (Shenzen) Company LTD	23-Dec-20
L-010-18/0	Mollura, Daniel Joseph		Ping An Technology (Shenzen) Company LTD	23-Dec-20
L-010-18/0	Summers, Ronald		Ping An Technology (Shenzen) Company LTD	23-Dec-20
L-010-18/0	Wang, Xiaosong		Ping An Technology (Shenzen) Company LTD	23-Dec-20
L-010-18/0	Xu, Ziyue		Ping An Technology (Shenzen) Company LTD	23-Dec-20

Note: L-010-18/0 split between CC; NLM

(b) (4), (b) (3) (A), (b) (6)

NIH Patent Licensing Activities

CC

January 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
L-231-01/2	Danis, Marion	(b)(4);	University of Michigan	22-Jan-21						(b) (4), (b) (3) (A), (b) (6)
L-160-18/0	CC		Advanced Imaging Projects, LLC (AIP)	27-Jan-21						

Note: L-160-18/0 split between CC; NCI

NIH Patent Licensing Activities

CC

February 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
L-145-19/0	Gladwin, Mark T.	(b)(4);	Globin Solutions, Inc	1-Feb-21						(b) (4), (b) (3) (A), (b) (6)
L-111-06/0	Franaszek, Marek	(b)(4);	ICAD Inc	12-Feb-21						
L-111-06/0	Huang, Hui-Yang	(b)(6)	ICAD Inc	12-Feb-21						
L-111-06/0	Iordanescu, Gheorghe		ICAD Inc	12-Feb-21						
L-111-06/0	Jerebko, Anna K		ICAD Inc	12-Feb-21						
L-111-06/0	(b) (4)		ICAD Inc	12-Feb-21						
L-111-06/0	Roy, David		ICAD Inc	12-Feb-21						
L-111-06/0	Summers, Ronald		ICAD Inc	12-Feb-21						
L-111-06/0	Yao, Jianhua		ICAD Inc	12-Feb-21						

Note: L-111-06/0 split between CC; CIT; NIDCD

NIH Patent Licensing Activities
CC
March 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
L-122-17/0	Kwak, Jin Tae	(b)(4);	Koninklijke Philips N.V.	1-Mar-21						(b) (4), (b) (3) (A), (b) (6)
L-122-17/0	Summers, Ronald	(b)(6)	Koninklijke Philips N.V.	1-Mar-21						
L-122-17/0	Wood, Bradford J		Koninklijke Philips N.V.	1-Mar-21						
L-122-17/0	Xu, Sheng		Koninklijke Philips N.V.	1-Mar-21						
<i>Note: L-122-17/0 split between CC; NCI</i>										
L-028-18/1	Lay, Nathan Stephan		Scanmed LLC	3-Mar-21						
L-028-18/1	Reinhard Roth, Holger		Scanmed LLC	3-Mar-21						
L-028-18/1	Summers, Ronald		Scanmed LLC	3-Mar-21						
L-028-18/1	Tsehay, Yohannes Kebede		Scanmed LLC	3-Mar-21						
<i>Note: L-028-18/1 split between CC; CIT; NCI</i>										
L-160-18/0	CC		Advanced Imaging Projects, LLC (AIP)	20-Mar-21						
<i>Note: L-160-18/0 split between CC; NCI</i>										
L-047-21/0	Turkbey, Evrim	(b)(4);	Canon Medical Systems USA, Inc.	25-Mar-21						
L-047-21/0	Wood, Bradford J	(b)(6)	Canon Medical Systems USA, Inc.	25-Mar-21						
L-047-21/0	Xu, Sheng		Canon Medical Systems USA, Inc.	25-Mar-21						
<i>Note: L-047-21/0 split between CC; NCI</i>										
					\$94,444.96	\$8,810.00	\$103,254.96		\$25,345.38	\$77,909.58

NIH Patent Licensing Activities
CIT
October 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	----------------------	---------------------------	-------------------------	---------------------

NIH Patent Licensing Activities
CIT
November 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
CIT
December 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

L-008-15/1	CIT	xMD Diagnostics, LLC	10-Dec-20	(b) (4), (b) (3) (A)
<i>Note: L-008-15/1 split between CIT; NCI; NICHHD</i>				
L-232-14/1	CIT	NanoString Technologies, Inc.	16-Dec-20	
<i>Note: L-232-14/1 split between CIT; NCI</i>				
L-111-06/0	CIT	ICAD Inc	23-Dec-20	
<i>Note: L-111-06/0 split between CC; CIT; NIDCD</i>				

NIH Patent Licensing Activities
CIT
January 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	----------------------	---------------------------	-------------------------	---------------------

NIH Patent Licensing Activities
CIT
February 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
L-232-14/1	CIT		NanoString Technologies, Inc.	4-Feb-21						(b) (4), (b) (3) (A), (b) (6)
<i>Note: L-232-14/1 split between CIT; NCI</i>										
L-111-06/0	Malley, James	(b)(4);	ICAD Inc	12-Feb-21						
L-111-06/0	Wagner, Lynne M	(b)(6)	ICAD Inc	12-Feb-21						
<i>Note: L-111-06/0 split between CC; CIT; NIDCD</i>										

NIH Patent Licensing Activities
CIT
March 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
L-028-18/1	Cheng, Ruida	(b)(4);	Scanmed LLC	3-Mar-21						(b) (4), (b) (3) (A), (b) (6)
L-028-18/1	McAuliffe, Matthew	(b)(6)	Scanmed LLC	3-Mar-21						
<i>Note: L-028-18/1 split between CC; CIT; NCI</i>										
					\$3,834.60	\$0.00	\$3,834.60		\$1,137.56	\$2,697.04

NIH Patent Licensing Activities
NCATS
October 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	----------------------	---------------------------	-------------------------	---------------------

L-025-17/1	Morris, Patrick	(b)(4);	ocris Bioscience	9-Oct-20	(b) (4), (b) (3) (A), (b) (6)
L-025-17/1	Thomas, Craig J.	(b)(6)	ocris Bioscience	9-Oct-20	
<i>Note: L-025-17/1 split between NCATS; NIA; NIMH</i>					
L-169-16/2	NCATS		TeamedOn International, LLC	15-Oct-20	(b) (4), (b) (3) (A), (b) (6)

NIH Patent Licensing Activities
NCATS
November 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
L-076-18/0	Inglese, James	(b)(4);	Lead Discovery Center	27-Nov-20						
L-076-18/0	Jang, Sung-Wook	(b)(6)	Lead Discovery Center	27-Nov-20						
L-076-18/0	Svaren, John		Lead Discovery Center	27-Nov-20						

NIH Patent Licensing Activities
NCATS
December 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
L-038-20/0	Deng, Tao	(b)(6)	STEMCELL Technologies, Inc.	1-Dec-20						
L-038-20/0	Simeonov, Anton		STEMCELL Technologies, Inc.	1-Dec-20						
L-038-20/0	Singec, Ilyas		STEMCELL Technologies, Inc.	1-Dec-20						
L-055-15/1	NCATS		Lysosomal Therapeutics, Inc.	23-Dec-20						

Note: L-055-15/1 split between NCATS; NHGRI

NIH Patent Licensing Activities
NCATS
January 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
L-057-15/0	Liu, Ke	(b)(6)	Vtesse, Inc	19-Jan-21						
L-057-15/0	Marugan, Juan J.		Vtesse, Inc	19-Jan-21						
L-057-15/0	McKew, John C.		Vtesse, Inc	19-Jan-21						
L-057-15/0	Southall, Noel T.		Vtesse, Inc	19-Jan-21						
L-057-15/0	Swaroop, Manju		Vtesse, Inc	19-Jan-21						
L-057-15/0	Xiao, Jingbo		Vtesse, Inc	19-Jan-21						
L-057-15/0	Xu, Miao		Vtesse, Inc	19-Jan-21						
L-057-15/0	Zheng, Wei		Vtesse, Inc	19-Jan-21						

Note: L-057-15/0 split between NCATS; NHGRI

L-196-19/1	Inglese, James	(b)(4);	Nuralis Pharmaceuticals, Inc	20-Jan-21	(b) (4), (b) (3) (A), (b) (6)
L-196-19/1	Southall, Noel T.	(b)(6)	Nuralis Pharmaceuticals, Inc	20-Jan-21	
L-196-19/1	Thomas, Craig J.		Nuralis Pharmaceuticals, Inc	20-Jan-21	
L-196-19/1	Titus, Steven		Nuralis Pharmaceuticals, Inc	20-Jan-21	
L-196-19/1	Zheng, Wei		Nuralis Pharmaceuticals, Inc	20-Jan-21	

Note: L-196-19/1 split between NCATS; NIDDK

NIH Patent Licensing Activities
NCATS
February 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
NCATS
March 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	--------------------	---------------------------	-----------------------	---------------------

L-116-13/0	Auld, Douglas S.	(b)(4);	EMD Millipore Corp.	10-Mar-21	(b) (4), (b) (3) (A), (b) (6)
L-116-13/0	Boxer, Matthew	(b)(6)	EMD Millipore Corp.	10-Mar-21	
L-116-13/0	Inglese, James		EMD Millipore Corp.	10-Mar-21	
L-116-13/0	Jiang, Jian-kang		EMD Millipore Corp.	10-Mar-21	
L-116-13/0	Shen, Min		EMD Millipore Corp.	10-Mar-21	
L-116-13/0	Skoumbourdis, Amanda P.		EMD Millipore Corp.	10-Mar-21	
L-116-13/0	Thomas, Craig J.		EMD Millipore Corp.	10-Mar-21	

Note: L-116-13/0 split between NCATS; NHGRI

L-080-15/0	Cheng, Chih-Chien (Ken)		Promega Corporation	12-Mar-21
L-080-15/0	Hasson, Samuel A.		Promega Corporation	12-Mar-21
L-080-15/0	Inglese, James		Promega Corporation	12-Mar-21
L-025-17/1	Morris, Patrick		Tocris Bioscience	18-Mar-21
L-025-17/1	Thomas, Craig J.		Tocris Bioscience	18-Mar-21

Note: L-025-17/1 split between NCATS; NIA; NIMH

L-049-14/1	NCATS		Rockefeller University	31-Mar-21
------------	-------	--	------------------------	-----------

\$81,824.44 \$85,744.78 \$167,569.22 \$26,938.96 \$140,630.26

NIH Patent Licensing Activities
NCI
October 2020


License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	----------------------	---------------------------	-------------------------	---------------------

L-029-19/1	Gazdar, Adi	(b)(4);	F. Hoffmann-La Roche AG	1-Oct-20	(b) (4), (b) (3) (A), (b) (6)
L-029-19/1	Johnson, Bruce E	(b)(6)	F. Hoffmann-La Roche AG	1-Oct-20	
L-029-19/1	Kaye, Frederic J		F. Hoffmann-La Roche AG	1-Oct-20	

L-029-19/1	Khleif, Samir N.	(b)(4);	F. Hoffmann-La Roche AG	1-Oct-20
L-029-19/1	Minna, John D.	(b)(6)	F. Hoffmann-La Roche AG	1-Oct-20
L-029-19/1	Oie, Herbert K		F. Hoffmann-La Roche AG	1-Oct-20
L-029-19/1	Pass, Harvey I		F. Hoffmann-La Roche AG	1-Oct-20
L-063-16/2	Gazdar, Adi		GlaxoSmithKline	1-Oct-20
L-063-16/2	Johnson, Bruce E		GlaxoSmithKline	1-Oct-20
L-063-16/2	Kaye, Frederic J		GlaxoSmithKline	1-Oct-20
L-063-16/2	Khleif, Samir N.		GlaxoSmithKline	1-Oct-20
L-063-16/2	Minna, John D.		GlaxoSmithKline	1-Oct-20
L-063-16/2	Oie, Herbert K		GlaxoSmithKline	1-Oct-20
L-063-16/2	Pass, Harvey I		GlaxoSmithKline	1-Oct-20
L-124-13/3	Bogdan, Christian		JSK Therapeutics, Inc.	1-Oct-20
L-124-13/3	Ji, Xinhua		JSK Therapeutics, Inc.	1-Oct-20
L-124-13/3	Keefer, Larry K		JSK Therapeutics, Inc.	1-Oct-20
L-124-13/3	Rice, William G		JSK Therapeutics, Inc.	1-Oct-20
L-124-13/3	Saavedra, Joseph E		JSK Therapeutics, Inc.	1-Oct-20
L-124-13/3	Srinivasan, Aloka		JSK Therapeutics, Inc.	1-Oct-20
L-152-20/0	Felber, Barbara K.		Cidara Therapeutics, Inc.	1-Oct-20
L-152-20/0	Pavlikis, George N		Cidara Therapeutics, Inc.	1-Oct-20
L-255-19/0	Buck, Christopher		BioE Holdings Inc.	1-Oct-20
L-255-19/0	Pastrana, Diana V		BioE Holdings Inc.	1-Oct-20
L-255-19/0	RAY, UPASANA		BioE Holdings Inc.	1-Oct-20
L-148-20/0	Bonomi, Carrie A.		Samyang Biopharma USA, Inc.	1-Oct-20
L-148-20/0	Borgel, Suzanne D.		Samyang Biopharma USA, Inc.	1-Oct-20
L-148-20/0	Dougherty, Kelly		Samyang Biopharma USA, Inc.	1-Oct-20
L-148-20/0	Hollingshead, Melinda G.		Samyang Biopharma USA, Inc.	1-Oct-20
L-259-20/0	Bonomi, Carrie A.		STipe Therapeutics ApS	1-Oct-20
L-259-20/0	Borgel, Suzanne D.		STipe Therapeutics ApS	1-Oct-20
L-259-20/0	Dougherty, Kelly		STipe Therapeutics ApS	1-Oct-20
L-259-20/0	Hollingshead, Melinda G.		STipe Therapeutics ApS	1-Oct-20
L-066-15/1	Rosenberg, Steven A.		Genentech., Inc.	1-Oct-20
L-190-19/1	NCI		ZioPharm Oncology, Inc	1-Oct-20
L-169-15/2	Gottesman, Michael M.		Enanta Pharmaceuticals, Inc.	1-Oct-20
L-169-15/2	Pastan, Ira H		Enanta Pharmaceuticals, Inc.	1-Oct-20
L-169-15/2	Ueda, Kazumitsu		Enanta Pharmaceuticals, Inc.	1-Oct-20
L-297-19/0	Bonomi, Carrie A.		Incyte Corporation	1-Oct-20
L-297-19/0	Borgel, Suzanne D.		Incyte Corporation	1-Oct-20
L-297-19/0	Dougherty, Kelly		Incyte Corporation	1-Oct-20
L-297-19/0	Hodge, James W.		Incyte Corporation	1-Oct-20
L-297-19/0	Hollingshead, Melinda G.		Incyte Corporation	1-Oct-20
L-297-19/0	Schlom, Jeffrey		Incyte Corporation	1-Oct-20
L-210-20/0	Gazdar, Adi		Signal Pharmaceuticals, LLC	1-Oct-20
L-210-20/0	Johnson, Bruce E		Signal Pharmaceuticals, LLC	1-Oct-20
L-210-20/0	Kaye, Frederic J		Signal Pharmaceuticals, LLC	1-Oct-20

L-210-20/0	Khleif, Samir N.	(b)(4);	Signal Pharmaceuticals, LLC	1-Oct-20
L-210-20/0	Minna, John D.	(b)(6)	Signal Pharmaceuticals, LLC	1-Oct-20
L-210-20/0	Oie, Herbert K		Signal Pharmaceuticals, LLC	1-Oct-20
L-210-20/0	Pass, Harvey I		Signal Pharmaceuticals, LLC	1-Oct-20
L-224-20/0	Chen, Xin		TheraVab Biomedics Pte. Ltd	1-Oct-20
L-224-20/0	Dimitrov, Dimiter S.		TheraVab Biomedics Pte. Ltd	1-Oct-20
L-224-20/0	Oppenheim, Joost J		TheraVab Biomedics Pte. Ltd	1-Oct-20
L-224-20/0	Yang, De		TheraVab Biomedics Pte. Ltd	1-Oct-20
L-224-20/0	Zhu, Zhongyu		TheraVab Biomedics Pte. Ltd	1-Oct-20
L-222-20/0	Chien, Christopher		Senti Biosciences, Inc.	1-Oct-20
L-222-20/0	Fry, Terry		Senti Biosciences, Inc.	1-Oct-20
L-222-20/0	Chien, Christopher		Senti Biosciences, Inc.	1-Oct-20
L-222-20/0	Fry, Terry		Senti Biosciences, Inc.	1-Oct-20
L-222-20/0	NCI		Senti Biosciences, Inc.	1-Oct-20
L-248-20/0	Hamilton, Thomas C		Ciscovery Bio Inc.	1-Oct-20
L-248-20/0	Ozols, Robert F		Ciscovery Bio Inc.	1-Oct-20
L-248-20/0	Hamilton, Thomas C		Ciscovery Bio Inc.	1-Oct-20
L-248-20/0	Ozols, Robert F		Ciscovery Bio Inc.	1-Oct-20
L-060-18/1	Bonomi, Carrie A.		Kineta, Inc	1-Oct-20
L-060-18/1	Borgel, Suzanne D.		Kineta, Inc	1-Oct-20
L-060-18/1	Dougherty, Kelly		Kineta, Inc	1-Oct-20
L-060-18/1	Hollingshead, Melinda G.		Kineta, Inc	1-Oct-20
L-010-09/2	Felber, Barbara K.		Taimed Biologics USA	1-Oct-20
L-010-09/2	Pavlakakis, George N		Taimed Biologics USA	1-Oct-20
L-136-19/0	NCI		Nano Red, LLC	1-Oct-20
L-224-15/0	Kochenderfer, James N	(b)(4);	Bluebird Bio	1-Oct-20
L-229-20/0	Bagni-Beyer, Rachel K.	(b)(6)	Frontier Medicines Corporation	1-Oct-20
L-229-20/0	(b) (4)		Frontier Medicines Corporation	1-Oct-20
L-229-20/0	Holderfield, Matthew T.		Frontier Medicines Corporation	1-Oct-20
L-229-20/0	Soppet, Dan		Frontier Medicines Corporation	1-Oct-20
L-239-20/0	Alewine, Christine		Merck Research Laboratories	1-Oct-20
L-239-20/0	Collins, Norman Keith		Merck Research Laboratories	1-Oct-20
L-239-20/0	Guerin, Theresa		Merck Research Laboratories	1-Oct-20
L-239-20/0	Kozlov, Serguei		Merck Research Laboratories	1-Oct-20
L-239-20/0	O'Sullivan, Theresa		Merck Research Laboratories	1-Oct-20
L-239-20/0	Schlomer, Jerome J		Merck Research Laboratories	1-Oct-20
L-239-20/0	Zhang, Xianyu		Merck Research Laboratories	1-Oct-20
L-244-20/0	Deniger, Drew		Kite Pharma, Inc.	6-Oct-20
L-244-20/0	Malekzadeh, Parisa		Kite Pharma, Inc.	6-Oct-20
L-244-20/0	Pasetto, Anna		Kite Pharma, Inc.	6-Oct-20
L-244-20/0	Rosenberg, Steven A.		Kite Pharma, Inc.	6-Oct-20

L-080-93/3	Hathcock, Karen	(b)(4);	BD Biosciences - BD PharMingen, Inc.	7-Oct-20
L-080-93/3	Hodes, Richard J	(b)(6)	BD Biosciences - BD PharMingen, Inc.	7-Oct-20
L-080-93/3	Laszlo, Gloria		BD Biosciences - BD PharMingen, Inc.	7-Oct-20
L-239-19/0	Kochenderfer, James N		Cartesian Therapeutics, Inc.	7-Oct-20
L-218-20/0	Franchini, Genoveffa		Charles River Laboratories, Inc.	7-Oct-20
L-218-20/0	Gallo, Robert C.		Charles River Laboratories, Inc.	7-Oct-20
L-218-20/0	Kalyanaraman, Vaniambadi S.		Charles River Laboratories, Inc.	7-Oct-20
L-218-20/0	Markham, Phillip D.		Charles River Laboratories, Inc.	7-Oct-20
L-218-20/0	Salahuddin, Syed Z.		Charles River Laboratories, Inc.	7-Oct-20
L-218-20/0	Wong-Staal (b) (6)		Charles River Laboratories, Inc.	7-Oct-20
L-255-19/0	NCI		BioE Holdings Inc.	13-Oct-20
L-218-20/0	Franchini, Genoveffa	(b)(4);	Charles River Laboratories, Inc.	13-Oct-20
L-218-20/0	Gallo, Robert C.	(b)(6)	Charles River Laboratories, Inc.	13-Oct-20
L-218-20/0	Kalyanaraman, Vaniambadi S.		Charles River Laboratories, Inc.	13-Oct-20
L-218-20/0	Markham, Phillip D.		Charles River Laboratories, Inc.	13-Oct-20
L-218-20/0	Salahuddin, Syed Z.		Charles River Laboratories, Inc.	13-Oct-20
L-218-20/0	Wong-Staal (b) (6)		Charles River Laboratories, Inc.	13-Oct-20
L-273-17/0	Bonomi, Carrie A.		Kyowa Hakko Kirin Co., Ltd	15-Oct-20
L-273-17/0	Borgel, Suzanne D.		Kyowa Hakko Kirin Co., Ltd	15-Oct-20
L-273-17/0	Dougherty, Kelly		Kyowa Hakko Kirin Co., Ltd	15-Oct-20
L-273-17/0	Hollingshead, Melinda G.		Kyowa Hakko Kirin Co., Ltd	15-Oct-20
L-215-19/0	Gottesman, Michael M.		Vertex Pharmaceuticals Inc	19-Oct-20
L-215-19/0	Pastan, Ira H		Vertex Pharmaceuticals Inc	19-Oct-20
L-215-19/0	Ueda, Kazumitsu		Vertex Pharmaceuticals Inc	19-Oct-20
L-199-15/1	Hurwitz, Arthur A.		AgenTus Therapeutics, Inc.	19-Oct-20
L-199-15/1	Ji, Qingyong		AgenTus Therapeutics, Inc.	19-Oct-20
L-199-15/1	Singh, Vinod		AgenTus Therapeutics, Inc.	19-Oct-20
L-199-15/1	Zhu, Ziqiang		AgenTus Therapeutics, Inc.	19-Oct-20
L-075-16/1	NCI		Lentigen Technology, Inc.	21-Oct-20
L-240-20/0	Bonomi, Carrie A.	(b)(4);	Medytox Inc.	21-Oct-20
L-240-20/0	Borgel, Suzanne D.	(b)(6)	Medytox Inc.	21-Oct-20
L-240-20/0	Dougherty, Kelly		Medytox Inc.	21-Oct-20
L-240-20/0	Hollingshead, Melinda G.		Medytox Inc.	21-Oct-20
L-068-04/2	NCI		Sillajen Biotherapeutics, Inc	22-Oct-20
<i>Note: L-068-04/2 split between NCI; NIAID</i>				
L-160-18/0	NCI		Advanced Imaging Projects, LLC (AIP)	22-Oct-20
<i>Note: L-160-18/0 split between CC; NCI</i>				
L-347-14/0	Muchmore, Brian P.	(b)(4);	Abcam, plc	26-Oct-20
L-347-14/0	O'Brien, Thomas R	(b)(6)	Abcam, plc	26-Oct-20
L-347-14/0	Porter-Gill, Patricia A.		Abcam, plc	26-Oct-20
L-347-14/0	Prokunina-Olsson, Ludmila		Abcam, plc	26-Oct-20
<i>Note: L-347-14/0 split between FDA; NCI</i>				



(b) (4), (b) (3) (A), (b) (6)

L-064-11/0	Barry, Todd	(b)(4);	Eptiomics Inc	26-Oct-20
L-064-11/0	Rosenwald, Andreas	(b)(6)	Eptiomics Inc	26-Oct-20
L-064-11/0	Staudt, Louis M		Eptiomics Inc	26-Oct-20
L-064-11/0	Wiestner, Adrian		Eptiomics Inc	26-Oct-20
L-064-11/0	Wilson, Wyndham H.		Eptiomics Inc	26-Oct-20
L-022-17/0	NCI		Etubics Corporation	26-Oct-20
L-075-13/0	Franchini, Genoveffa	(b)(4);	Wuxi Apptec Inc	29-Oct-20
L-075-13/0	Gallo, Robert C.	(b)(6)	Wuxi Apptec Inc	29-Oct-20
L-075-13/0	Kalyanaraman, Vaniambadi S.		Wuxi Apptec Inc	29-Oct-20
L-075-13/0	Markham, Phillip D.		Wuxi Apptec Inc	29-Oct-20
L-075-13/0	Salahuddin, Syed Z.		Wuxi Apptec Inc	29-Oct-20
L-075-13/0	Wong-Staal (b) (6)		Wuxi Apptec Inc	29-Oct-20
L-107-10/2	NCI		Vasculox, Inc.	29-Oct-20
L-245-20/0	Lee, Choonsik	(b)(4);	PHS Technologies Group, LLC	30-Oct-20



NIH Patent Licensing Activities
NCI
November 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
L-006-20/0	Bonomi, Carrie A.	(b)(4);	ABBA Therapeutics AG	1-Nov-20						(b) (4), (b) (3) (A), (b) (6)
L-006-20/0	Borgel, Suzanne D.	(b)(6)	ABBA Therapeutics AG	1-Nov-20						
L-006-20/0	Dougherty, Kelly		ABBA Therapeutics AG	1-Nov-20						
L-006-20/0	Hollingshead, Melinda G.		ABBA Therapeutics AG	1-Nov-20						
L-130-19/0	Bonomi, Carrie A.		Exelixis, Inc.	1-Nov-20						
L-130-19/0	Borgel, Suzanne D.		Exelixis, Inc.	1-Nov-20						
L-130-19/0	Dougherty, Kelly		Exelixis, Inc.	1-Nov-20						
L-130-19/0	Hollingshead, Melinda G.		Exelixis, Inc.	1-Nov-20						
L-255-19/0	NCI		BioE Holdings Inc.	2-Nov-20						
L-255-19/0	Buck, Christopher	(b)(4);	BioE Holdings Inc.	2-Nov-20						
L-255-19/0	Pastrana, Diana V	(b)(6)	BioE Holdings Inc.	2-Nov-20						
L-255-19/0	RAY, UPASANA		BioE Holdings Inc.	2-Nov-20						
L-108-09/0	Conrads, Thomas P		AB Sciex, LLC	3-Nov-20						
L-108-09/0	Issaq, Haleem J.		AB Sciex, LLC	3-Nov-20						
L-108-09/0	Janini, George		AB Sciex, LLC	3-Nov-20						
L-108-09/0	Veenstra, Timothy D		AB Sciex, LLC	3-Nov-20						
L-108-09/0	Wilkens, Kenneth L.		AB Sciex, LLC	3-Nov-20						
L-105-18/1	Bonomi, Carrie A.		Chugai	5-Nov-20						
L-105-18/1	Borgel, Suzanne D.		Chugai	5-Nov-20						
L-105-18/1	Dougherty, Kelly		Chugai	5-Nov-20						
L-105-18/1	Hollingshead, Melinda G.		Chugai	5-Nov-20						
L-165-99/1	Crowl, Robert		Trinity Biotech	6-Nov-20						

L-165-99/1	Gallo, Robert C.	(b)(4);	Trinity Biotech	6-Nov-20
L-165-99/1	(b) (4)	(b)(6)	Trinity Biotech	6-Nov-20
L-165-99/1	Popovic, Mikulas		Trinity Biotech	6-Nov-20
L-165-99/1	Reddy, E. Premkumar.		Trinity Biotech	6-Nov-20
L-165-99/1	Sarngadharan, Mangalasseril		Trinity Biotech	6-Nov-20
L-165-99/1	Shaw, George M		Trinity Biotech	6-Nov-20
L-165-99/1	Wong-Staa (b) (6)		Trinity Biotech	6-Nov-20
L-190-19/2	Cafri, Gal		ZioPharm Oncology, Inc	6-Nov-20
L-190-19/2	Deniger, Drew		ZioPharm Oncology, Inc	6-Nov-20
L-190-19/2	Feldman, Steven A		ZioPharm Oncology, Inc	6-Nov-20
L-190-19/2	Fitzgerald, Peter C.		ZioPharm Oncology, Inc	6-Nov-20
L-190-19/2	Hanada, Kenichi		ZioPharm Oncology, Inc	6-Nov-20
L-190-19/2	Levin, Noam		ZioPharm Oncology, Inc	6-Nov-20
L-190-19/2	Lo, Winifred Margaret		ZioPharm Oncology, Inc	6-Nov-20
L-190-19/2	Lowery, Fank		ZioPharm Oncology, Inc	6-Nov-20
L-190-19/2	Lu, Yong-Chen		ZioPharm Oncology, Inc	6-Nov-20
L-190-19/2	Malekzadeh, Parisa		ZioPharm Oncology, Inc	6-Nov-20
L-190-19/2	Paria, Biman		ZioPharm Oncology, Inc	6-Nov-20
L-190-19/2	Parkhurst, Maria		ZioPharm Oncology, Inc	6-Nov-20
L-190-19/2	Pasetto, Anna		ZioPharm Oncology, Inc	6-Nov-20
L-190-19/2	Robbins, Paul F		ZioPharm Oncology, Inc	6-Nov-20
L-190-19/2	Rosenberg, Steven A.		ZioPharm Oncology, Inc	6-Nov-20
L-190-19/2	Tran, Eric		ZioPharm Oncology, Inc	6-Nov-20
L-190-19/2	Wang, Qiong		ZioPharm Oncology, Inc	6-Nov-20
L-190-19/2	Yang, James C		ZioPharm Oncology, Inc	6-Nov-20
L-190-19/2	Yoseph, Rami		ZioPharm Oncology, Inc	6-Nov-20
L-190-19/2	Yu, Zhiya		ZioPharm Oncology, Inc	6-Nov-20
L-190-19/2	Zhao, Chihao		ZioPharm Oncology, Inc	6-Nov-20
L-190-19/2	Zheng, Zhili		ZioPharm Oncology, Inc	6-Nov-20
L-273-14/0	Chang, Nancy T.		Grifols Worldwide Operations Ltd.	9-Nov-20
L-273-14/0	Crowl, Robert		Grifols Worldwide Operations Ltd.	9-Nov-20
L-273-14/0	Fisher, Amanda G.		Grifols Worldwide Operations Ltd.	9-Nov-20
L-273-14/0	Gallo, Robert C.		Grifols Worldwide Operations Ltd.	9-Nov-20
L-273-14/0	Hahn, Beatrice		Grifols Worldwide Operations Ltd.	9-Nov-20
L-273-14/0	Popovic, Mikulas		Grifols Worldwide Operations Ltd.	9-Nov-20
L-273-14/0	Reddy, E. Premkumar.		Grifols Worldwide Operations Ltd.	9-Nov-20
L-273-14/0	Sarngadharan, Mangalasseril		Grifols Worldwide Operations Ltd.	9-Nov-20
L-273-14/0	Shaw, George M		Grifols Worldwide Operations Ltd.	9-Nov-20
L-273-14/0	Wong-Staal (b) (6)		Grifols Worldwide Operations Ltd.	9-Nov-20
L-026-05/8	NCI		INNATE PHARMA	9-Nov-20
L-213-18/1	NCI		University of North Carolina, Charlotte	10-Nov-20
L-258-20/0	Luciano, Michael	(b)(4);	Tocris Bioscience	12-Nov-20
L-258-20/0	Michie, Megan Suzanne	(b)(6)	Tocris Bioscience	12-Nov-20
L-258-20/0	Nani, Roger R.		Tocris Bioscience	12-Nov-20
L-258-20/0	Schnermann, Martin		Tocris Bioscience	12-Nov-20
L-056-20/0	Gazdar, Adi		Amplify Medicines	12-Nov-20
L-056-20/0	Johnson, Bruce E		Amplify Medicines	12-Nov-20
L-056-20/0	Kaye, Frederic J		Amplify Medicines	12-Nov-20
L-056-20/0	Khleif, Samir N.		Amplify Medicines	12-Nov-20

(b) (4), (b) (3) (A), (b) (6)

L-056-20/0	Minna, John D.	(b)(4);	Amplify Medicines	12-Nov-20
L-056-20/0	Oie, Herbert K	(b)(6)	Amplify Medicines	12-Nov-20
L-056-20/0	Pass, Harvey I		Amplify Medicines	12-Nov-20
L-004-07/2	NCI		Life Technologies Corp.	12-Nov-20
L-001-06/0	NCI		Henry Jackson Foundation	13-Nov-20
L-001-06/0	NCI		Henry Jackson Foundation	13-Nov-20
L-160-18/0	NCI		Advanced Imaging Projects, LLC (AIP)	14-Nov-20
<i>Note: L-160-18/0 split between CC; NCI</i>				
L-256-20/0	Hodge, Deborah	(b)(4);	Selecta Biosciences Inc	17-Nov-20
L-256-20/0	Young, Howard A.	(b)(6)	Selecta Biosciences Inc	17-Nov-20
L-130-20/0	Hamilton, Thomas C		Janssen Research and Development, LLC	17-Nov-20
L-130-20/0	Ozols, Robert F		Janssen Research and Development, LLC	17-Nov-20
L-002-04/1	Kawakami, Yutaka		Cell Marque	17-Nov-20
L-002-04/1	Robbins, Paul F		Cell Marque	17-Nov-20
L-002-04/1	Rosenberg, Steven A.		Cell Marque	17-Nov-20
L-026-20/0	Bonomi, Carrie A.		Imanis Life Sciences, LLC	17-Nov-20
L-026-20/0	Borgel, Suzanne D.		Imanis Life Sciences, LLC	17-Nov-20
L-026-20/0	Dougherty, Kelly		Imanis Life Sciences, LLC	17-Nov-20
L-026-20/0	Hollingshead, Melinda G.		Imanis Life Sciences, LLC	17-Nov-20
L-164-20/0	Hathcock, Karen		Proteintech Group, Inc.	17-Nov-20
L-164-20/0	Hodes, Richard J		Proteintech Group, Inc.	17-Nov-20
L-164-20/0	Laszlo, Gloria		Proteintech Group, Inc.	17-Nov-20
L-218-20/0	Franchini, Genoveffa		Charles River Laboratories, Inc.	17-Nov-20
L-218-20/0	Gallo, Robert C.		Charles River Laboratories, Inc.	17-Nov-20
L-218-20/0	Kalyanaraman, Vaniambadi S.		Charles River Laboratories, Inc.	17-Nov-20
L-218-20/0	Markham, Phillip D.		Charles River Laboratories, Inc.	17-Nov-20
L-218-20/0	Salahuddin, Syed Z.		Charles River Laboratories, Inc.	17-Nov-20
L-218-20/0	Wong-Staal (b) (6)		Charles River Laboratories, Inc.	17-Nov-20
L-167-20/0	Bonomi, Carrie A.		GlaxoSmithKline LLC	18-Nov-20
L-167-20/0	Borgel, Suzanne D.		GlaxoSmithKline LLC	18-Nov-20
L-167-20/0	Dougherty, Kelly		GlaxoSmithKline LLC	18-Nov-20
L-167-20/0	Hollingshead, Melinda G.		GlaxoSmithKline LLC	18-Nov-20
L-263-19/0	Hanada, Kenichi		Teralmmune LLC	18-Nov-20
L-263-19/0	Yang, James C		Teralmmune LLC	18-Nov-20
L-263-19/0	Yu, Zhiya		Teralmmune LLC	18-Nov-20
L-010-09/2	Felber, Barbara K.		Taimed Biologics USA	18-Nov-20
L-010-09/2	Pavliakis, George N		Taimed Biologics USA	18-Nov-20
L-174-16/0	Costantino, Nina		BP Technology Ventures Inc.	18-Nov-20
L-174-16/0	Court, Donald		BP Technology Ventures Inc.	18-Nov-20
L-174-16/0	Datta, Simanti		BP Technology Ventures Inc.	18-Nov-20

(b) (4), (b) (3) (A), (b) (6)

L-248-20/0	Hamilton, Thomas C	(b)(4);	Discovery Bio Inc.	18-Nov-20
L-248-20/0	Ozols, Robert F	(b)(6)	Discovery Bio Inc.	18-Nov-20
L-066-15/1	Rosenberg, Steven A.		Genentech., Inc.	19-Nov-20
L-227-20/0	Gazdar, Adi		Champions Oncology, Inc.	19-Nov-20
L-227-20/0	Johnson, Bruce E		Champions Oncology, Inc.	19-Nov-20
L-227-20/0	Kaye, Frederic J		Champions Oncology, Inc.	19-Nov-20
L-227-20/0	Khleif, Samir N.		Champions Oncology, Inc.	19-Nov-20
L-227-20/0	Minna, John D.		Champions Oncology, Inc.	19-Nov-20
L-227-20/0	Oie, Herbert K		Champions Oncology, Inc.	19-Nov-20
L-227-20/0	Pass, Harvey I		Champions Oncology, Inc.	19-Nov-20
L-745-91/2	Chang, Nancy T.		BioMerieux, Inc.	19-Nov-20
L-745-91/2	Crowl, Robert		BioMerieux, Inc.	19-Nov-20
L-745-91/2	Fisher, Amanda G.		BioMerieux, Inc.	19-Nov-20
L-745-91/2	Gallo, Robert C.		BioMerieux, Inc.	19-Nov-20
L-745-91/2	Hahn, Beatrice		BioMerieux, Inc.	19-Nov-20
L-745-91/2	(b) (4)		BioMerieux, Inc.	19-Nov-20
L-745-91/2	Popovic, Mikulas		BioMerieux, Inc.	19-Nov-20
L-745-91/2	Reddy, E. Premkumar.		BioMerieux, Inc.	19-Nov-20
L-745-91/2	Sarngadharan, Mangalasseril		BioMerieux, Inc.	19-Nov-20
L-745-91/2	Shaw, George M		BioMerieux, Inc.	19-Nov-20
L-745-91/2	Wong-Staal (b) (6)		BioMerieux, Inc.	19-Nov-20
L-115-17/1	Aaronson, Stuart A.		VCN Biosciences, S.L.	19-Nov-20
L-115-17/1	Giard, Donald		VCN Biosciences, S.L.	19-Nov-20
L-115-17/1	Parks, Wade P		VCN Biosciences, S.L.	19-Nov-20
L-308-17/0	Fowler, Daniel		Rapa Therapeutics LLC	19-Nov-20
L-308-17/0	Gress, Ronald E.		Rapa Therapeutics LLC	19-Nov-20
L-308-17/0	Jung, Unsu		Rapa Therapeutics LLC	19-Nov-20
L-089-07/0	Emmert-Buck, Michael R.		Theranostics Health	19-Nov-20
L-089-07/0	Liotta, Lance		Theranostics Health	19-Nov-20
L-089-07/0	Mehta, Arpita I		Theranostics Health	19-Nov-20
L-089-07/0	Simone, Nicole L		Theranostics Health	19-Nov-20
<i>Note: L-089-07/0 split between FDA; NCI</i>				
L-165-99/1	Crowl, Robert		Trinity Biotech	20-Nov-20
L-165-99/1	Gallo, Robert C.		Trinity Biotech	20-Nov-20
L-165-99/1	(b) (4)		Trinity Biotech	20-Nov-20
L-165-99/1	Popovic, Mikulas		Trinity Biotech	20-Nov-20
L-165-99/1	Reddy, E. Premkumar.		Trinity Biotech	20-Nov-20
L-165-99/1	Sarngadharan, Mangalasseril		Trinity Biotech	20-Nov-20
L-165-99/1	Shaw, George M		Trinity Biotech	20-Nov-20
L-165-99/1	Wong-Staal (b) (6)		Trinity Biotech	20-Nov-20
L-073-20/0	Bonomi, Carrie A.		Glenmark Research Center	20-Nov-20
L-073-20/0	Borgel, Suzanne D.		Glenmark Research Center	20-Nov-20
L-073-20/0	Dougherty, Kelly		Glenmark Research Center	20-Nov-20
L-073-20/0	Hollingshead, Melinda G.		Glenmark Research Center	20-Nov-20
L-039-11/0	Onda, Masanori		Rockland Immunochemicals, Inc.	20-Nov-20
L-039-11/0	Pastan, Ira H		Rockland Immunochemicals, Inc.	20-Nov-20

L-297-14/2	Gelboin, (b) (6) Harry	(b)(4);	CYP450-GP	20-Nov-20
L-297-14/2	Gonzalez, Frank J	(b)(6)	CYP450-GP	20-Nov-20
L-297-14/2	Krausz, Kristopher W.		CYP450-GP	20-Nov-20
L-015-20/0	Hamilton, Thomas C		Daichi Sankyo Co., Ltd.	23-Nov-20
L-015-20/0	Ozols, Robert F		Daichi Sankyo Co., Ltd.	23-Nov-20
L-191-18/0	Bonomi, Carrie A.		Palleon Pharmaceuticals	23-Nov-20
L-191-18/0	Borgel, Suzanne D.		Palleon Pharmaceuticals	23-Nov-20
L-191-18/0	Dougherty, Kelly		Palleon Pharmaceuticals	23-Nov-20
L-191-18/0	Hollingshead, Melinda G.		Palleon Pharmaceuticals	23-Nov-20
L-046-19/0	Bonomi, Carrie A.		Dragonfly Therapeutics	23-Nov-20
L-046-19/0	Borgel, Suzanne D.		Dragonfly Therapeutics	23-Nov-20
L-046-19/0	Dougherty, Kelly		Dragonfly Therapeutics	23-Nov-20
L-046-19/0	Hollingshead, Melinda G.		Dragonfly Therapeutics	23-Nov-20
L-046-19/0	Schlom, Jeffrey		Dragonfly Therapeutics	23-Nov-20
L-041-21/0	Kochenderfer, James N		Kyverna Therapeutics	23-Nov-20
L-218-20/0	Franchini, Genoveffa		Charles River Laboratories, Inc.	24-Nov-20
L-218-20/0	Gallo, Robert C.		Charles River Laboratories, Inc.	24-Nov-20
L-218-20/0	Kalyanaraman, Vaniambadi S.		Charles River Laboratories, Inc.	24-Nov-20
L-218-20/0	Markham, Phillip D.		Charles River Laboratories, Inc.	24-Nov-20
L-218-20/0	Salahuddin, Syed Z.		Charles River Laboratories, Inc.	24-Nov-20
L-218-20/0	Wong-Staal (b) (6)		Charles River Laboratories, Inc.	24-Nov-20
L-054-10/3	NCI		Research Corp Techn. Inc.	24-Nov-20
L-274-18/0	Gros, Alena	(b)(4);	Cellular Biomedicine Group, Inc.	24-Nov-20
L-274-18/0	Rosenberg, Steven A.	(b)(6)	Cellular Biomedicine Group, Inc.	24-Nov-20
L-242-17/0	Schlom, Jeffrey		Amal Therapeutics	24-Nov-20
L-006-19/0	Gazdar, Adi		Genentech, Inc	25-Nov-20
L-006-19/0	Johnson, Bruce E		Genentech, Inc	25-Nov-20
L-006-19/0	Kaye, Frederic J		Genentech, Inc	25-Nov-20
L-006-19/0	Khleif, Samir N.		Genentech, Inc	25-Nov-20
L-006-19/0	Minna, John D.		Genentech, Inc	25-Nov-20
L-006-19/0	Oie, Herbert K		Genentech, Inc	25-Nov-20
L-006-19/0	Pass, Harvey I		Genentech, Inc	25-Nov-20
L-259-17/0	NCI		CRISPR Therapeutics AG	25-Nov-20
L-206-20/0	Rosenberg, Steven A.	(b)(4);	Oncodesign Biotechnology	25-Nov-20
L-206-20/0	Spiese, Paul J	(b)(6)	Oncodesign Biotechnology	25-Nov-20
L-206-20/0	Yang, James C		Oncodesign Biotechnology	25-Nov-20
L-093-17/0	Gazdar, Adi		ADC Therapeutics SA	25-Nov-20
L-093-17/0	Minna, John D.		ADC Therapeutics SA	25-Nov-20
L-005-20/0	Bonomi, Carrie A.		Khloris Biosciences, Inc.	25-Nov-20
L-005-20/0	Borgel, Suzanne D.		Khloris Biosciences, Inc.	25-Nov-20
L-005-20/0	Dougherty, Kelly		Khloris Biosciences, Inc.	25-Nov-20

(b) (4), (b) (3) (A), (b) (6)

L-005-20/0	Hollingshead, Melinda G.	(b)(4); (b)(6)	Khloris Biosciences, Inc.	25-Nov-20	(b) (4), (b) (3) (A), (b) (6)
L-014-19/0	Bonomi, Carrie A.	(b)(6)	ABL Bio Inc.	27-Nov-20	
L-014-19/0	Borgel, Suzanne D.	(b)(6)	ABL Bio Inc.	27-Nov-20	
L-014-19/0	Dougherty, Kelly	(b)(6)	ABL Bio Inc.	27-Nov-20	
L-014-19/0	Hollingshead, Melinda G.	(b)(6)	ABL Bio Inc.	27-Nov-20	

**NIH Patent Licensing Activities
NCI
December 2020**

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
L-154-97/2	Mason, Llewellyn H.	(b)(4);	BD Biosciences - BD PharMingen	1-Dec-20	(b) (4), (b) (3) (A), (b) (6)					
L-154-97/2	Ortaldo, John R.	(b)(6)	BD Biosciences - BD PharMingen	1-Dec-20						
L-097-00/2	Austin, Faye C.	(b)(6)	BD Biosciences - BD PharMingen	1-Dec-20						
L-097-00/2	Colcher, David	(b)(6)	BD Biosciences - BD PharMingen	1-Dec-20						
L-097-00/2	Hand, Patricia H	(b)(6)	BD Biosciences - BD PharMingen	1-Dec-20						
L-097-00/2	Nuti, Marianna	(b)(6)	BD Biosciences - BD PharMingen	1-Dec-20						
L-097-00/2	Schlom, Jeffrey	(b)(6)	BD Biosciences - BD PharMingen	1-Dec-20						
L-269-19/1	Hamilton, Thomas C	(b)(6)	Epizyme Inc.	1-Dec-20						
L-269-19/1	Ozols, Robert F	(b)(6)	Epizyme Inc.	1-Dec-20						
L-323-17/1	Bonomi, Carrie A.	(b)(6)	SQZ Biotechnologies	1-Dec-20						
L-323-17/1	Borgel, Suzanne D.	(b)(6)	SQZ Biotechnologies	1-Dec-20						
L-323-17/1	Dougherty, Kelly	(b)(6)	SQZ Biotechnologies	1-Dec-20						
L-323-17/1	Hollingshead, Melinda G.	(b)(6)	SQZ Biotechnologies	1-Dec-20						
L-056-17/0	Schlom, Jeffrey	(b)(6)	F-star Biotechnology Ltd	1-Dec-20						
L-221-19/0	Franchini, Genoveffa	(b)(6)	Genosafe SAS	1-Dec-20						
L-221-19/0	Gallo, Robert C.	(b)(6)	Genosafe SAS	1-Dec-20						
L-221-19/0	Kalyanaraman, Vaniambadi S.	(b)(6)	Genosafe SAS	1-Dec-20						
L-221-19/0	Markham, Phillip D.	(b)(6)	Genosafe SAS	1-Dec-20						
L-221-19/0	Salahuddin, Syed Z.	(b)(6)	Genosafe SAS	1-Dec-20						
L-221-19/0	Wong-Staal (b) (6)	(b)(6)	Genosafe SAS	1-Dec-20						
L-100-17/0	Bonomi, Carrie A.	(b)(6)	Genmab, B.V.	1-Dec-20						
L-100-17/0	Borgel, Suzanne D.	(b)(6)	Genmab, B.V.	1-Dec-20						
L-100-17/0	Dougherty, Kelly	(b)(6)	Genmab, B.V.	1-Dec-20						
L-100-17/0	Hollingshead, Melinda G.	(b)(6)	Genmab, B.V.	1-Dec-20						
L-088-20/0	Helman, Lee	(b)(6)	OncoMyx Therapeutics, Inc	1-Dec-20						
L-088-20/0	Khanna, Chand	(b)(6)	OncoMyx Therapeutics, Inc	1-Dec-20						
L-229-20/0	Bagni-Beyer, Rachel K.	(b)(4)	Frontier Medicines Corporation	1-Dec-20						
L-229-20/0	(b) (4)	(b)(4)	Frontier Medicines Corporation	1-Dec-20						
L-229-20/0	Holderfield, Matthew T.	(b)(4)	Frontier Medicines Corporation	1-Dec-20						
L-229-20/0	Soppet, Dan	(b)(4)	Frontier Medicines Corporation	1-Dec-20						
L-129-16/0	Gazdar, Adi	(b)(6)	Galera Therapeutics, Inc.	1-Dec-20						

L-129-16/0	Minna, John D.	(b)(4);	Galera Therapeutics, Inc.	1-Dec-20
L-022-17/0	NCI		Etubics Corporation	1-Dec-20
L-014-21/0	Hinrichs, Christian S.	(b)(4);	SQZ Biotechnologies Company	1-Dec-20
L-014-21/0	Rosenberg, Steven A.	(b)(6)	SQZ Biotechnologies Company	1-Dec-20
L-323-17/1	Bonomi, Carrie A.		SQZ Biotechnologies	1-Dec-20
L-323-17/1	Borgel, Suzanne D.		SQZ Biotechnologies	1-Dec-20
L-323-17/1	Dougherty, Kelly		SQZ Biotechnologies	1-Dec-20
L-323-17/1	Hollingshead, Melinda G.		SQZ Biotechnologies	1-Dec-20
L-014-21/0	Hinrichs, Christian S.		SQZ Biotechnologies Company	1-Dec-20
L-014-21/0	Rosenberg, Steven A.		SQZ Biotechnologies Company	1-Dec-20
L-013-21/0	Lu, Yong-Chen		SQZ Biotechnologies Company	1-Dec-20
L-013-21/0	Pasetto, Anna		SQZ Biotechnologies Company	1-Dec-20
L-013-21/0	Robbins, Paul F		SQZ Biotechnologies Company	1-Dec-20
L-013-21/0	Rosenberg, Steven A.		SQZ Biotechnologies Company	1-Dec-20
L-013-21/0	Tran, Eric		SQZ Biotechnologies Company	1-Dec-20
L-013-21/0	Wang, Qiong		SQZ Biotechnologies Company	1-Dec-20
L-013-21/0	Yang, James C		SQZ Biotechnologies Company	1-Dec-20
L-013-21/0	Yu, Zhiya		SQZ Biotechnologies Company	1-Dec-20
L-013-21/0	Zheng, Zhili		SQZ Biotechnologies Company	1-Dec-20
L-013-21/0	Lu, Yong-Chen		SQZ Biotechnologies Company	1-Dec-20
L-013-21/0	Pasetto, Anna		SQZ Biotechnologies Company	1-Dec-20
L-013-21/0	Robbins, Paul F		SQZ Biotechnologies Company	1-Dec-20
L-013-21/0	Rosenberg, Steven A.		SQZ Biotechnologies Company	1-Dec-20
L-013-21/0	Tran, Eric		SQZ Biotechnologies Company	1-Dec-20
L-013-21/0	Wang, Qiong		SQZ Biotechnologies Company	1-Dec-20
L-013-21/0	Yang, James C		SQZ Biotechnologies Company	1-Dec-20
L-013-21/0	Yu, Zhiya		SQZ Biotechnologies Company	1-Dec-20
L-013-21/0	Zheng, Zhili		SQZ Biotechnologies Company	1-Dec-20
L-323-17/1	Bonomi, Carrie A.		SQZ Biotechnologies	1-Dec-20
L-323-17/1	Borgel, Suzanne D.		SQZ Biotechnologies	1-Dec-20
L-323-17/1	Dougherty, Kelly		SQZ Biotechnologies	1-Dec-20
L-323-17/1	Hollingshead, Melinda G.		SQZ Biotechnologies	1-Dec-20
L-012-21/0	Hinrichs, Christian S.		SQZ Biotechnologies Company	1-Dec-20
L-012-21/0	Rosenberg, Steven A.		SQZ Biotechnologies Company	1-Dec-20
L-012-21/0	Hinrichs, Christian S.		SQZ Biotechnologies Company	1-Dec-20
L-012-21/0	Rosenberg, Steven A.		SQZ Biotechnologies Company	1-Dec-20
L-012-21/0	Hinrichs, Christian S.		SQZ Biotechnologies Company	1-Dec-20
L-012-21/0	Rosenberg, Steven A.		SQZ Biotechnologies Company	1-Dec-20
L-014-21/0	Hinrichs, Christian S.		SQZ Biotechnologies Company	1-Dec-20
L-014-21/0	Rosenberg, Steven A.		SQZ Biotechnologies Company	1-Dec-20
L-201-19/0	Esposito, Dominic		LakePharma	1-Dec-20
L-201-19/0	Grose, Carissa L.		LakePharma	1-Dec-20

L-120-20/0	Gazdar, Adi	(b)(4);	Daiichi Sankyo Co., Ltd	1-Dec-20
L-120-20/0	Johnson, Bruce E	(b)(6)	Daiichi Sankyo Co., Ltd	1-Dec-20
L-120-20/0	Kaye, Frederic J		Daiichi Sankyo Co., Ltd	1-Dec-20
L-120-20/0	Khleif, Samir N.		Daiichi Sankyo Co., Ltd	1-Dec-20
L-120-20/0	Minna, John D.		Daiichi Sankyo Co., Ltd	1-Dec-20
L-120-20/0	Oie, Herbert K		Daiichi Sankyo Co., Ltd	1-Dec-20
L-120-20/0	Pass, Harvey I		Daiichi Sankyo Co., Ltd	1-Dec-20
L-086-15/0	Hanada, Kenichi		Compugen, Ltd.	3-Dec-20
L-086-15/0	Rosenberg, Steven A.		Compugen, Ltd.	3-Dec-20
L-086-15/0	Topalian, Suzanne L.		Compugen, Ltd.	3-Dec-20
L-086-15/0	Yang, James C		Compugen, Ltd.	3-Dec-20
L-086-15/0	Yu, Zhiya		Compugen, Ltd.	3-Dec-20
L-333-17/0	Bonomi, Carrie A.		Glenmark Pharmaceuticals, S A.	3-Dec-20
L-333-17/0	Borgel, Suzanne D.		Glenmark Pharmaceuticals, S A.	3-Dec-20
L-333-17/0	Dougherty, Kelly		Glenmark Pharmaceuticals, S A.	3-Dec-20
L-333-17/0	Hollingshead, Melinda G.		Glenmark Pharmaceuticals, S A.	3-Dec-20
L-123-17/0	Bonomi, Carrie A.		Lupin Ltd.	4-Dec-20
L-123-17/0	Dougherty, Kelly		Lupin Ltd.	4-Dec-20
L-123-17/0	Hollingshead, Melinda G.		Lupin Ltd.	4-Dec-20
L-254-16/1	Lee, Choonsik		PHS Technologies Group, LLC	4-Dec-20
L-274-18/0	NCI		Cellular Biomedicine Group, Inc.	4-Dec-20
L-205-18/0	Hodge, Deborah	(b)(4);	Chugai Pharmaceutical	7-Dec-20
L-205-18/0	Young, Howard A.	(b)(6)	Chugai Pharmaceutical	7-Dec-20
L-128-18/0	Bonomi, Carrie A.		Xencor	7-Dec-20
L-128-18/0	Borgel, Suzanne D.		Xencor	7-Dec-20
L-128-18/0	Dougherty, Kelly		Xencor	7-Dec-20
L-128-18/0	Hollingshead, Melinda G.		Xencor	7-Dec-20
L-238-18/0	Bonomi, Carrie A.		Vividion Therapeutics, Inc.	7-Dec-20
L-238-18/0	Borgel, Suzanne D.		Vividion Therapeutics, Inc.	7-Dec-20
L-238-18/0	Dougherty, Kelly		Vividion Therapeutics, Inc.	7-Dec-20
L-238-18/0	Hollingshead, Melinda G.		Vividion Therapeutics, Inc.	7-Dec-20
L-117-95/2	Hathcock, Karen		Southern Biotechnology Associates, Inc.	7-Dec-20
L-117-95/2	Hodes, Richard J		Southern Biotechnology Associates, Inc.	7-Dec-20
L-117-95/2	Laszlo, Gloria		Southern Biotechnology Associates, Inc.	7-Dec-20
<i>Note: L-117-95/2 split between NCI; NIA</i>				
L-133-09/0	Gazdar, Adi		Ventana Medical Systems, Inc.	8-Dec-20
L-133-09/0	Johnson, Bruce E		Ventana Medical Systems, Inc.	8-Dec-20
L-133-09/0	Kaye, Frederic J		Ventana Medical Systems, Inc.	8-Dec-20
L-133-09/0	Khleif, Samir N.		Ventana Medical Systems, Inc.	8-Dec-20
L-133-09/0	Minna, John D.		Ventana Medical Systems, Inc.	8-Dec-20
L-133-09/0	Oie, Herbert K		Ventana Medical Systems, Inc.	8-Dec-20
L-133-09/0	Pass, Harvey I		Ventana Medical Systems, Inc.	8-Dec-20
L-177-19/0	Bonomi, Carrie A.		Gilead Sciences, Inc	8-Dec-20
L-177-19/0	Borgel, Suzanne D.		Gilead Sciences, Inc	8-Dec-20

L-177-19/0	Dougherty, Kelly	(b)(4);	Gilead Sciences, Inc	8-Dec-20
L-177-19/0	Hollingshead, Melinda G.	(b)(6)	Gilead Sciences, Inc	8-Dec-20
L-154-12/0	Gazdar, Adi		Ventana Medical Systems	8-Dec-20
L-154-12/0	Johnson, Bruce E		Ventana Medical Systems	8-Dec-20
L-154-12/0	Kaye, Frederic J		Ventana Medical Systems	8-Dec-20
L-154-12/0	Khleif, Samir N.		Ventana Medical Systems	8-Dec-20
L-154-12/0	Minna, John D.		Ventana Medical Systems	8-Dec-20
L-154-12/0	Oie, Herbert K		Ventana Medical Systems	8-Dec-20
L-154-12/0	Pass, Harvey I		Ventana Medical Systems	8-Dec-20
L-099-12/0	Gazdar, Adi		Ventana Medical Systems Inc	8-Dec-20
L-099-12/0	Johnson, Bruce E		Ventana Medical Systems Inc	8-Dec-20
L-099-12/0	Kaye, Frederic J		Ventana Medical Systems Inc	8-Dec-20
L-099-12/0	Khleif, Samir N.		Ventana Medical Systems Inc	8-Dec-20
L-099-12/0	Minna, John D.		Ventana Medical Systems Inc	8-Dec-20
L-099-12/0	Oie, Herbert K		Ventana Medical Systems Inc	8-Dec-20
L-099-12/0	Pass, Harvey I		Ventana Medical Systems Inc	8-Dec-20
L-101-20/0	Bonomi, Carrie A.		Carisma Therapeutics Inc.	8-Dec-20
L-101-20/0	Borgel, Suzanne D.		Carisma Therapeutics Inc.	8-Dec-20
L-101-20/0	Dougherty, Kelly		Carisma Therapeutics Inc.	8-Dec-20
L-101-20/0	Hollingshead, Melinda G.		Carisma Therapeutics Inc.	8-Dec-20
L-101-20/0	Bonomi, Carrie A.		Carisma Therapeutics Inc.	8-Dec-20
L-101-20/0	Borgel, Suzanne D.		Carisma Therapeutics Inc.	8-Dec-20
L-101-20/0	Dougherty, Kelly		Carisma Therapeutics Inc.	8-Dec-20
L-101-20/0	Hollingshead, Melinda G.		Carisma Therapeutics Inc.	8-Dec-20
L-108-15/0	NCI		lovance Biotherapeutics Inc	8-Dec-20
L-136-20/0	Dudley, Mark	(b)(4);	Intima Bioscience Inc.	8-Dec-20
L-136-20/0	Fitzgerald, Peter C.	(b)(6)	Intima Bioscience Inc.	8-Dec-20
L-136-20/0	Gros, Alena		Intima Bioscience Inc.	8-Dec-20
L-136-20/0	Lu, Yong-Chen		Intima Bioscience Inc.	8-Dec-20
L-136-20/0	Palmer, Douglas		Intima Bioscience Inc.	8-Dec-20
L-136-20/0	Restifo, Nicholas P.		Intima Bioscience Inc.	8-Dec-20
L-136-20/0	Robbins, Paul F		Intima Bioscience Inc.	8-Dec-20
L-136-20/0	Rosenberg, Steven A.		Intima Bioscience Inc.	8-Dec-20
L-136-20/0	Tran, Eric		Intima Bioscience Inc.	8-Dec-20
L-136-20/0	Wunderlich, John		Intima Bioscience Inc.	8-Dec-20
L-136-20/0	Zheng, Zhili		Intima Bioscience Inc.	8-Dec-20
L-010-21/0	Bonomi, Carrie A.		Vir Biotechnology, Inc.	9-Dec-20
L-010-21/0	Borgel, Suzanne D.		Vir Biotechnology, Inc.	9-Dec-20
L-010-21/0	Dougherty, Kelly		Vir Biotechnology, Inc.	9-Dec-20
L-010-21/0	Hollingshead, Melinda G.		Vir Biotechnology, Inc.	9-Dec-20
L-010-21/0	Bonomi, Carrie A.		Vir Biotechnology, Inc.	9-Dec-20
L-010-21/0	Borgel, Suzanne D.		Vir Biotechnology, Inc.	9-Dec-20
L-010-21/0	Dougherty, Kelly		Vir Biotechnology, Inc.	9-Dec-20
L-010-21/0	Hollingshead, Melinda G.		Vir Biotechnology, Inc.	9-Dec-20
L-010-21/0	Bonomi, Carrie A.		Vir Biotechnology, Inc.	9-Dec-20
L-010-21/0	Borgel, Suzanne D.		Vir Biotechnology, Inc.	9-Dec-20

L-010-21/0	Dougherty, Kelly	(b)(4);	Vir Biotechnology, Inc.	9-Dec-20	(b) (4), (b) (3) (A), (b) (6)
L-010-21/0	Hollingshead, Melinda G.	(b)(6)	Vir Biotechnology, Inc.	9-Dec-20	
L-235-19/0	Copeland, Neal		Vir Biotechnology, Inc.	9-Dec-20	
L-235-19/0	Costantino, Nina		Vir Biotechnology, Inc.	9-Dec-20	
L-235-19/0	Court, Donald		Vir Biotechnology, Inc.	9-Dec-20	
L-235-19/0	Jenkins Copeland, Nancy A		Vir Biotechnology, Inc.	9-Dec-20	
L-235-19/0	Warming, Soren		Vir Biotechnology, Inc.	9-Dec-20	
L-241-20/0	Bonomi, Carrie A.		Light Chain Bioscience-Novimmune SA	9-Dec-20	
L-241-20/0	Borgel, Suzanne D.		Light Chain Bioscience-Novimmune SA	9-Dec-20	
L-241-20/0	Dougherty, Kelly		Light Chain Bioscience-Novimmune SA	9-Dec-20	
L-241-20/0	Hollingshead, Melinda G.		Light Chain Bioscience-Novimmune SA	9-Dec-20	
L-165-20/0	Gazdar, Adi		Light Chain Bioscience-Novimmune SA	9-Dec-20	
L-165-20/0	Johnson, Bruce E		Light Chain Bioscience-Novimmune SA	9-Dec-20	
L-165-20/0	Kaye, Frederic J		Light Chain Bioscience-Novimmune SA	9-Dec-20	
L-165-20/0	Khleif, Samir N.		Light Chain Bioscience-Novimmune SA	9-Dec-20	
L-165-20/0	Minna, John D.		Light Chain Bioscience-Novimmune SA	9-Dec-20	
L-165-20/0	Oie, Herbert K		Light Chain Bioscience-Novimmune SA	9-Dec-20	
L-165-20/0	Pass, Harvey I		Light Chain Bioscience-Novimmune SA	9-Dec-20	
L-048-15/1	Schlom, Jeffrey		PDS Biotechnology Corp	9-Dec-20	
L-048-15/1	Tsang, Kwong-Yok		PDS Biotechnology Corp	9-Dec-20	
L-104-20/0	Hinrichs, Christian S.		T-Cure Bioscience, Inc.	9-Dec-20	
L-104-20/0	Stevanovic, Sanja		T-Cure Bioscience, Inc.	9-Dec-20	
L-238-19/0	Hanada, Kenichi		T-Cure Bioscience, Inc	9-Dec-20	
L-238-19/0	Wang, Qiong		T-Cure Bioscience, Inc	9-Dec-20	
L-238-19/0	Yang, James C		T-Cure Bioscience, Inc	9-Dec-20	
L-190-05/2	Gallo, Robert C.		GeoVax, Inc.	9-Dec-20	
L-190-05/2	(b) (4)		GeoVax, Inc.	9-Dec-20	
L-190-05/2	Popovic, Mikulas		GeoVax, Inc.	9-Dec-20	
L-190-05/2	Sarngadharan, Mangalasseril		GeoVax, Inc.	9-Dec-20	
<i>Note: L-190-05/2 split between NCI; NIAID</i>					
L-100-18/0	Bonomi, Carrie A.		Codiak Biosciences	9-Dec-20	
L-100-18/0	Borgel, Suzanne D.		Codiak Biosciences	9-Dec-20	
L-100-18/0	Dougherty, Kelly		Codiak Biosciences	9-Dec-20	
L-100-18/0	Hollingshead, Melinda G.		Codiak Biosciences	9-Dec-20	
L-107-18/0	Bonomi, Carrie A.		Codiak Biosciences	9-Dec-20	
L-107-18/0	Dougherty, Kelly		Codiak Biosciences	9-Dec-20	
L-107-18/0	Hollingshead, Melinda G.		Codiak Biosciences	9-Dec-20	
L-097-09/0	Cole, Katharine H.		Bristol-Myers Squibb	10-Dec-20	
L-097-09/0	Gelboin, (b) (6) Harry		Bristol-Myers Squibb	10-Dec-20	
L-097-09/0	Gonzalez, Frank J		Bristol-Myers Squibb	10-Dec-20	
L-097-09/0	Harris, Curtis C.		Bristol-Myers Squibb	10-Dec-20	
L-097-09/0	Lechner, John F.		Bristol-Myers Squibb	10-Dec-20	
L-097-09/0	Reddel, Roger R.		Bristol-Myers Squibb	10-Dec-20	
L-008-15/1	NCI		xMD Diagnostics, LLC	10-Dec-20	

Note: L-008-15/1 split between CIT; NCI; NICHD

L-153-10/0	Greiner, John W.	(b)(4);	Arko Laboratories LTD	10-Dec-20
L-153-10/0	Schlom, Jeffrey	(b)(6)	Arko Laboratories LTD	10-Dec-20
L-153-10/0	Zaharoff, David		Arko Laboratories LTD	10-Dec-20
L-208-13/0	NCI		Aspyrian THERapeutics, Inc.	10-Dec-20
L-117-17/0	Choyke, Peter L	(b)(4);	Aspyrian Therapeutics, Inc.	10-Dec-20
L-117-17/0	Kobayashi, Hisataka	(b)(6)	Aspyrian Therapeutics, Inc.	10-Dec-20
L-117-17/0	Sato, Kazuhide		Aspyrian Therapeutics, Inc.	10-Dec-20
L-117-17/0	Sato, Noriko		Aspyrian Therapeutics, Inc.	10-Dec-20
L-075-20/0	Acquavella, Nicolas		Lyell Immunopharma, Inc.	11-Dec-20
L-075-20/0	Hanada, Kenichi		Lyell Immunopharma, Inc.	11-Dec-20
L-075-20/0	Islam, S M Rafiqul		Lyell Immunopharma, Inc.	11-Dec-20
L-075-20/0	Restifo, Nicholas P.		Lyell Immunopharma, Inc.	11-Dec-20
L-075-20/0	Rosenberg, Steven A.		Lyell Immunopharma, Inc.	11-Dec-20
L-075-20/0	Tamaoki, Naritaka		Lyell Immunopharma, Inc.	11-Dec-20
L-075-20/0	Topalian, Suzanne L.		Lyell Immunopharma, Inc.	11-Dec-20
L-075-20/0	Vizcardo Sakoda, Raul Eduardo		Lyell Immunopharma, Inc.	11-Dec-20
L-075-20/0	Yang, James C		Lyell Immunopharma, Inc.	11-Dec-20
L-075-20/0	Yu, Zhiya		Lyell Immunopharma, Inc.	11-Dec-20
L-180-20/0	Schlom, Jeffrey		Merck Sharp & Dohme Corp	11-Dec-20
L-183-20/0	Felber, Barbara K.		Frontier Biotechnologies Inc.	11-Dec-20
L-183-20/0	Pavlakakis, George N		Frontier Biotechnologies Inc.	11-Dec-20
L-225-19/0	Gallo, Robert C.		Biotest AG	11-Dec-20
L-225-19/0	Popovic, Mikulas		Biotest AG	11-Dec-20
L-277-19/0	Bagni-Beyer, Rachel K.		Ribometrix Inc	11-Dec-20
L-277-19/0	(b) (4)		Ribometrix Inc	11-Dec-20
L-277-19/0	Holderfield, Matthew T.		Ribometrix Inc	11-Dec-20
L-277-19/0	Soppet, Dan		Ribometrix Inc	11-Dec-20
L-009-21/0	NCI		Connectyx Technologies Holdings Group	11-Dec-20
L-025-07/0	Hollingshead, Melinda G.		Tocris Bioscience	14-Dec-20
L-025-07/0	Sausville, Edward		Tocris Bioscience	14-Dec-20
L-025-07/0	Snader, Kenneth M		Tocris Bioscience	14-Dec-20
L-025-07/0	Vishnuvajjala, B. Rao		Tocris Bioscience	14-Dec-20
L-014-16/0	Hodge, James W.		Transgene SA	14-Dec-20
L-014-16/0	Schlom, Jeffrey		Transgene SA	14-Dec-20
L-241-19/0	Buck, Christopher		Pomona Ricerca SRL	14-Dec-20
L-241-19/0	Pastrana, Diana V		Pomona Ricerca SRL	14-Dec-20
L-241-19/0	Schiller, John T		Pomona Ricerca SRL	14-Dec-20
L-209-16/0	Copeland, Neal		GlaxoSmithKline Biologicals, S A.	14-Dec-20
L-209-16/0	Costantino, Nina		GlaxoSmithKline Biologicals, S A.	14-Dec-20
L-209-16/0	Court, Donald		GlaxoSmithKline Biologicals, S A.	14-Dec-20
L-209-16/0	Ellis, Hilary Moyed		GlaxoSmithKline Biologicals, S A.	14-Dec-20

(b) (4), (b) (3) (A), (b) (6)

L-209-16/0	Jenkins Copeland, Nancy A	(b)(4);	GlaxoSmithKline Biologicals, S A.	14-Dec-20
L-209-16/0	Lee, E-Chiang	(b)(6)	GlaxoSmithKline Biologicals, S A.	14-Dec-20
L-209-16/0	Liu, Pentao		GlaxoSmithKline Biologicals, S A.	14-Dec-20
L-209-16/0	Sharan, Shyam K		GlaxoSmithKline Biologicals, S A.	14-Dec-20
L-209-16/0	Swaminathan, Srividya		GlaxoSmithKline Biologicals, S A.	14-Dec-20
L-209-16/0	Warming, Soren		GlaxoSmithKline Biologicals, S A.	14-Dec-20
L-209-16/0	Yu, Daiguan		GlaxoSmithKline Biologicals, S A.	14-Dec-20
L-152-20/0	Felber, Barbara K.		Cidara Therapeutics, Inc.	14-Dec-20
L-152-20/0	Pavlakis, George N		Cidara Therapeutics, Inc.	14-Dec-20
L-095-17/1	Bonomi, Carrie A.		Millennium Pharmaceuticals, Inc.	14-Dec-20
L-095-17/1	Borgel, Suzanne D.		Millennium Pharmaceuticals, Inc.	14-Dec-20
L-095-17/1	Dougherty, Kelly		Millennium Pharmaceuticals, Inc.	14-Dec-20
L-095-17/1	Hollingshead, Melinda G.		Millennium Pharmaceuticals, Inc.	14-Dec-20
L-238-20/0	Bonomi, Carrie A.		Turnstone Biologics Inc.	15-Dec-20
L-238-20/0	Borgel, Suzanne D.		Turnstone Biologics Inc.	15-Dec-20
L-238-20/0	Dougherty, Kelly		Turnstone Biologics Inc.	15-Dec-20
L-238-20/0	Hollingshead, Melinda G.		Turnstone Biologics Inc.	15-Dec-20
L-078-19/1	Bonomi, Carrie A.		OMEROS Corporation	15-Dec-20
L-078-19/1	Borgel, Suzanne D.		OMEROS Corporation	15-Dec-20
L-078-19/1	Dougherty, Kelly		OMEROS Corporation	15-Dec-20
L-078-19/1	Hollingshead, Melinda G.		OMEROS Corporation	15-Dec-20
L-078-19/1	Bonomi, Carrie A.		OMEROS Corporation	15-Dec-20
L-078-19/1	Borgel, Suzanne D.		OMEROS Corporation	15-Dec-20
L-078-19/1	Dougherty, Kelly		OMEROS Corporation	15-Dec-20
L-078-19/1	Hollingshead, Melinda G.		OMEROS Corporation	15-Dec-20
L-023-01/3	Horie, Kyoji		Omeros Corporation	15-Dec-20
L-023-01/3	Pavlakis, George N		Omeros Corporation	15-Dec-20
L-160-18/0	NCI		Advanced Imaging Projects, LLC (AIP)	15-Dec-20
<i>Note: L-160-18/0 split between CC; NCI</i>				
L-034-21/0	Hamilton, Thomas C	(b)(4);	Celmatix Inc.	15-Dec-20
L-034-21/0	Ozols, Robert F	(b)(6)	Celmatix Inc.	15-Dec-20
L-034-21/0	Hamilton, Thomas C		Celmatix Inc.	15-Dec-20
L-034-21/0	Ozols, Robert F		Celmatix Inc.	15-Dec-20
L-108-09/0	Conrads, Thomas P		AB Sciex, LLC	16-Dec-20
L-108-09/0	Issaq, Haleem J.		AB Sciex, LLC	16-Dec-20
L-108-09/0	Janini, George		AB Sciex, LLC	16-Dec-20
L-108-09/0	Veenstra, Timothy D		AB Sciex, LLC	16-Dec-20
L-108-09/0	Wilkins, Kenneth L.		AB Sciex, LLC	16-Dec-20
L-108-15/0	Gros, Alena		lovance Biotherapeutics Inc	16-Dec-20
L-108-15/0	Rosenberg, Steven A.		lovance Biotherapeutics Inc	16-Dec-20
L-107-15/1	Dudley, Mark		lovance Biotherapeutics Inc	16-Dec-20
L-107-15/1	Hinrichs, Christian S.		lovance Biotherapeutics Inc	16-Dec-20
L-107-15/1	Rosenberg, Steven A.		lovance Biotherapeutics Inc	16-Dec-20

L-107-15/1	Somerville, Robert P.	(b)(4);	lovance Biotherapeutics Inc	16-Dec-20
L-107-15/1	Wunderlich, John	(b)(6)	lovance Biotherapeutics Inc	16-Dec-20
<i>Note: L-107-15/1 split between CC; NCI</i>				
L-057-09/5	Aplan, Peter D.		Acceleron Pharma	16-Dec-20
L-057-09/5	Lin, Ying-Wei		Acceleron Pharma	16-Dec-20
L-057-09/5	Slape, Christopher I.		Acceleron Pharma	16-Dec-20
L-057-09/5	Zhang, ZhenHua		Acceleron Pharma	16-Dec-20
L-130-16/0	Morgan, Richard A.		Five Prime Therapeutics, Inc	16-Dec-20
L-130-16/0	Robbins, Paul F		Five Prime Therapeutics, Inc	16-Dec-20
L-130-16/0	Rosenberg, Steven A.		Five Prime Therapeutics, Inc	16-Dec-20
L-013-21/0	Lu, Yong-Chen		SQZ Biotechnologies Company	16-Dec-20
L-013-21/0	Pasetto, Anna		SQZ Biotechnologies Company	16-Dec-20
L-013-21/0	Robbins, Paul F		SQZ Biotechnologies Company	16-Dec-20
L-013-21/0	Rosenberg, Steven A.		SQZ Biotechnologies Company	16-Dec-20
L-013-21/0	Tran, Eric		SQZ Biotechnologies Company	16-Dec-20
L-013-21/0	Wang, Qiong		SQZ Biotechnologies Company	16-Dec-20
L-013-21/0	Yang, James C		SQZ Biotechnologies Company	16-Dec-20
L-013-21/0	Yu, Zhiya		SQZ Biotechnologies Company	16-Dec-20
L-013-21/0	Zheng, Zhili		SQZ Biotechnologies Company	16-Dec-20
L-232-14/1	NCI		NanoString Technologies, Inc.	16-Dec-20
<i>Note: L-232-14/1 split between CIT; NCI</i>				
L-042-21/0	Copeland, Neal	(b)(4);	Solid Biosciences Inc.	16-Dec-20
L-042-21/0	Costantino, Nina	(b)(6)	Solid Biosciences Inc.	16-Dec-20
L-042-21/0	Court, Donald		Solid Biosciences Inc.	16-Dec-20
L-042-21/0	Jenkins Copeland, Nancy A		Solid Biosciences Inc.	16-Dec-20
L-042-21/0	Warming, Soren		Solid Biosciences Inc.	16-Dec-20
L-256-20/0	Hodge, Deborah		Selecta Biosciences Inc	17-Dec-20
L-256-20/0	Young, Howard A.		Selecta Biosciences Inc	17-Dec-20
L-013-19/0	Dimitrov, Dimiter S.		Lentigen Corporation	17-Dec-20
L-013-19/0	Zhu, Zhongyu		Lentigen Corporation	17-Dec-20
L-075-16/1	Fry, Terry		Lentigen Technology, Inc.	17-Dec-20
L-075-16/1	Qin, Haiying		Lentigen Technology, Inc.	17-Dec-20
L-317-17/0	Chen, Weizao		Lentigen Technology Inc	17-Dec-20
L-317-17/0	Dimitrov, Dimiter S.		Lentigen Technology Inc	17-Dec-20
L-317-17/0	Ponraj, Prabakaran		Lentigen Technology Inc	17-Dec-20
L-304-19/0	Cafri, Gal		Intellia Therapeutics, Inc	17-Dec-20
L-304-19/0	Dudley, Mark		Intellia Therapeutics, Inc	17-Dec-20
L-304-19/0	Fitzgerald, Peter C.		Intellia Therapeutics, Inc	17-Dec-20
L-304-19/0	Gartner, Jared		Intellia Therapeutics, Inc	17-Dec-20
L-304-19/0	Gros, Alena		Intellia Therapeutics, Inc	17-Dec-20
L-304-19/0	Lu, Yong-Chen		Intellia Therapeutics, Inc	17-Dec-20
L-304-19/0	Robbins, Paul F		Intellia Therapeutics, Inc	17-Dec-20
L-304-19/0	Rosenberg, Steven A.		Intellia Therapeutics, Inc	17-Dec-20
L-304-19/0	Tran, Eric		Intellia Therapeutics, Inc	17-Dec-20
L-304-19/0	Wunderlich, John		Intellia Therapeutics, Inc	17-Dec-20

L-304-19/0	Zheng, Zhili	(b)(4); (b)(6)	Intellia Therapeutics, Inc	17-Dec-20
L-281-17/0	Bonomi, Carrie A.		Intellia Therapeutics, Inc	17-Dec-20
L-281-17/0	Borgel, Suzanne D.		Intellia Therapeutics, Inc	17-Dec-20
L-281-17/0	Dougherty, Kelly		Intellia Therapeutics, Inc	17-Dec-20
L-281-17/0	Hollingshead, Melinda G.		Intellia Therapeutics, Inc	17-Dec-20
L-197-17/0	Bonomi, Carrie A.		Seattle Genetics, Inc.	17-Dec-20
L-197-17/0	Borgel, Suzanne D.		Seattle Genetics, Inc.	17-Dec-20
L-197-17/0	Dougherty, Kelly		Seattle Genetics, Inc.	17-Dec-20
L-197-17/0	Hollingshead, Melinda G.		Seattle Genetics, Inc.	17-Dec-20
L-225-18/0	Schlom, Jeffrey		Incyte Corporation	17-Dec-20
L-046-21/0	(b) (4)		Genentech, Inc.	17-Dec-20
L-046-21/0	Oberdoerffer, Phillip		Genentech, Inc.	17-Dec-20
L-089-20/0	Bonomi, Carrie A.		genOway SA	18-Dec-20
L-089-20/0	Dougherty, Kelly		genOway SA	18-Dec-20
L-089-20/0	Hollingshead, Melinda G.		genOway SA	18-Dec-20
L-166-18/0	Bonomi, Carrie A.		genOway S.A.	18-Dec-20
L-166-18/0	Borgel, Suzanne D.		genOway S.A.	18-Dec-20
L-166-18/0	Dougherty, Kelly		genOway S.A.	18-Dec-20
L-166-18/0	Hollingshead, Melinda G.		genOway S.A.	18-Dec-20
L-084-20/0	Ise, Tomoko		EXBIO Praha	18-Dec-20
L-084-20/0	Nagata, Satoshi		EXBIO Praha	18-Dec-20
L-084-20/0	Pastan, Ira H		EXBIO Praha	18-Dec-20
L-084-20/0	Xiang, Liaman		EXBIO Praha	18-Dec-20
L-182-18/0	Buck, Christopher		Regeneron Pharmaceuticals, Inc.	21-Dec-20
L-182-18/0	Pastrana, Diana V		Regeneron Pharmaceuticals, Inc.	21-Dec-20
L-182-18/0	Schiller, John T		Regeneron Pharmaceuticals, Inc.	21-Dec-20
L-121-19/0	Gottesman, Michael M.		Axcelead Drug Discovery Partners, Inc	21-Dec-20
L-121-19/0	Pastan, Ira H		Axcelead Drug Discovery Partners, Inc	21-Dec-20
L-121-19/0	Ueda, Kazumitsu		Axcelead Drug Discovery Partners, Inc	21-Dec-20
L-011-21/0	Bonomi, Carrie A.		Pharma Mar, S.A.	21-Dec-20
L-011-21/0	Dougherty, Kelly		Pharma Mar, S.A.	21-Dec-20
L-011-21/0	Hollingshead, Melinda G.		Pharma Mar, S.A.	21-Dec-20
L-011-21/0	Bonomi, Carrie A.		Pharma Mar, S.A.	21-Dec-20
L-011-21/0	Dougherty, Kelly		Pharma Mar, S.A.	21-Dec-20
L-011-21/0	Hollingshead, Melinda G.		Pharma Mar, S.A.	21-Dec-20
L-011-21/0	Bonomi, Carrie A.		Pharma Mar, S.A.	21-Dec-20
L-011-21/0	Dougherty, Kelly		Pharma Mar, S.A.	21-Dec-20
L-011-21/0	Hollingshead, Melinda G.		Pharma Mar, S.A.	21-Dec-20
L-114-06/1	Azimi, Nazli		Affymetrix, Inc.	21-Dec-20
L-114-06/1	Dubois, Sigrid		Affymetrix, Inc.	21-Dec-20
L-114-06/1	Goldman, Carolyn		Affymetrix, Inc.	21-Dec-20
L-114-06/1	Lantz, Valerie A		Affymetrix, Inc.	21-Dec-20

L-114-06/1	Mariner Kilbourne, Jennifer	(b)(4);	Affymetrix, Inc.	21-Dec-20
L-114-06/1	Waldmann, Thomas A.	(b)(6)	Affymetrix, Inc.	21-Dec-20
L-109-06/0	Mason, Llewellyn H.		eBioscience	21-Dec-20
L-109-06/0	Ortaldo, John R.		eBioscience	21-Dec-20
L-049-00/1	Hathcock, Karen		eBioscience, Inc..	21-Dec-20
L-049-00/1	Hodes, Richard J		eBioscience, Inc..	21-Dec-20
L-049-00/1	Laszlo, Gloria		eBioscience, Inc..	21-Dec-20
<i>Note: L-049-00/1 split between NCI; NIAID</i>				
L-206-00/0	Aaronson, Stuart A.		LIFE TECHNOLOGIES	21-Dec-20
L-206-00/0	King, Charles R.		LIFE TECHNOLOGIES	21-Dec-20
L-206-00/0	Kraus, (b) (6) Matthias		LIFE TECHNOLOGIES	21-Dec-20
L-004-07/2	Qasba, Pradman		Life Technologies Corp.	21-Dec-20
L-004-07/2	Ramakrishnan, Boopathy		Life Technologies Corp.	21-Dec-20
L-071-93/0	Aaronson, Stuart A.		LIFE TECHNOLOGIES	21-Dec-20
L-071-93/0	Finch, Paul W.		LIFE TECHNOLOGIES	21-Dec-20
L-071-93/0	Rubin, Jeffrey S		LIFE TECHNOLOGIES	21-Dec-20
L-161-20/0	Aaronson, Stuart A.		Cancer Research Technology Limited (Ximb	21-Dec-20
L-161-20/0	Ellmore, Nelson		Cancer Research Technology Limited (Ximb	21-Dec-20
L-046-21/0	(b) (4)		Genentech, Inc.	21-Dec-20
L-046-21/0	Oberdoerffer, Phillip		Genentech, Inc.	21-Dec-20
L-046-21/0	(b) (4)		Genentech, Inc.	21-Dec-20
L-046-21/0	Oberdoerffer, Phillip		Genentech, Inc.	21-Dec-20
L-076-19/0	Gazdar, Adi		Salk Institute for Biological Studies	22-Dec-20
L-076-19/0	Johnson, Bruce E		Salk Institute for Biological Studies	22-Dec-20
L-076-19/0	Kaye, Frederic J		Salk Institute for Biological Studies	22-Dec-20
L-076-19/0	Khleif, Samir N.		Salk Institute for Biological Studies	22-Dec-20
L-076-19/0	Minna, John D.		Salk Institute for Biological Studies	22-Dec-20
L-076-19/0	Oie, Herbert K		Salk Institute for Biological Studies	22-Dec-20
L-076-19/0	Pass, Harvey I		Salk Institute for Biological Studies	22-Dec-20
L-240-20/0	Bonomi, Carrie A.		Medytox Inc.	22-Dec-20
L-240-20/0	Borgel, Suzanne D.		Medytox Inc.	22-Dec-20
L-240-20/0	Dougherty, Kelly		Medytox Inc.	22-Dec-20
L-240-20/0	Hollingshead, Melinda G.		Medytox Inc.	22-Dec-20
L-222-20/0	Chien, Christopher		Senti Biosciences, Inc.	22-Dec-20
L-222-20/0	Fry, Terry		Senti Biosciences, Inc.	22-Dec-20
L-052-21/0	Hinrichs, Christian S.		T-Cure Bioscience, Inc.	22-Dec-20
L-050-20/0	Greiner, John W.		Neoleukin Corporation	23-Dec-20
L-050-20/0	Schlom, Jeffrey		Neoleukin Corporation	23-Dec-20
L-098-17/0	Buck, Christopher		SK Chemicals	23-Dec-20
L-098-17/0	Schiller, John T		SK Chemicals	23-Dec-20

L-109-18/1	(b) (4)	(b)(4);	StrideBio	23-Dec-20
L-109-18/1	Esposito, Dominic	(b)(6)	StrideBio	23-Dec-20
L-109-18/1	Hopkins, Ralph F.		StrideBio	23-Dec-20
L-109-18/1	Roberts, Veronica Ann		StrideBio	23-Dec-20
L-108-18/1	Esposito, Dominic		StrideBio	23-Dec-20
L-108-18/1	Grose, Carissa L.		StrideBio	23-Dec-20
L-148-17/0	Chatterjee, Deb K		Chimeron Bio Corporation	23-Dec-20
L-148-17/0	Kaczmarczyk, Stanislaw		Chimeron Bio Corporation	23-Dec-20
L-048-20/0	Esposito, Dominic		Arvinas Operations, Inc	23-Dec-20
L-048-20/0	Gillette, William K.		Arvinas Operations, Inc	23-Dec-20
L-048-20/0	Grose, Carissa L.		Arvinas Operations, Inc	23-Dec-20
L-253-18/2	Bonomi, Carrie A.		Yuhan R&D Institute	23-Dec-20
L-253-18/2	Borgel, Suzanne D.		Yuhan R&D Institute	23-Dec-20
L-253-18/2	Dougherty, Kelly		Yuhan R&D Institute	23-Dec-20
L-253-18/2	Hollingshead, Melinda G.		Yuhan R&D Institute	23-Dec-20
L-272-18/0	Aaronson, Stuart A.		CellSeed, Inc	24-Dec-20
L-272-18/0	Jainchill, John L.		CellSeed, Inc	24-Dec-20
L-272-18/0	Todaro, George J.		CellSeed, Inc	24-Dec-20
L-148-20/0	Bonomi, Carrie A.		Samyang Biopharma USA, Inc.	24-Dec-20
L-148-20/0	Borgel, Suzanne D.		Samyang Biopharma USA, Inc.	24-Dec-20
L-148-20/0	Dougherty, Kelly		Samyang Biopharma USA, Inc.	24-Dec-20
L-148-20/0	Hollingshead, Melinda G.		Samyang Biopharma USA, Inc.	24-Dec-20
L-068-13/2	NCI		Kite Pharma, Inc.	24-Dec-20
L-077-15/2	NCI		Kite Pharma, Inc.	24-Dec-20
L-242-02/2	Kawakami, Yutaka	(b)(4);	Biocare Medical, LLC	24-Dec-20
L-242-02/2	Rosenberg, Steven A.	(b)(6)	Biocare Medical, LLC	24-Dec-20
L-242-02/2	Kawakami, Yutaka		Biocare Medical, LLC	24-Dec-20
L-242-02/2	Rosenberg, Steven A.		Biocare Medical, LLC	24-Dec-20
L-166-02/2	Schlom, Jeffrey		Biocare Medical LLC	24-Dec-20
L-035-21/0	Gazdar, Adi		Daiichi Sankyo Co., Ltd.	24-Dec-20
L-035-21/0	Johnson, Bruce E		Daiichi Sankyo Co., Ltd.	24-Dec-20
L-035-21/0	Kaye, Frederic J		Daiichi Sankyo Co., Ltd.	24-Dec-20
L-035-21/0	Khleif, Samir N.		Daiichi Sankyo Co., Ltd.	24-Dec-20
L-035-21/0	Minna, John D.		Daiichi Sankyo Co., Ltd.	24-Dec-20
L-035-21/0	Oie, Herbert K		Daiichi Sankyo Co., Ltd.	24-Dec-20
L-035-21/0	Pass, Harvey I		Daiichi Sankyo Co., Ltd.	24-Dec-20
L-035-21/0	Gazdar, Adi		Daiichi Sankyo Co., Ltd.	24-Dec-20
L-035-21/0	Johnson, Bruce E		Daiichi Sankyo Co., Ltd.	24-Dec-20
L-035-21/0	Kaye, Frederic J		Daiichi Sankyo Co., Ltd.	24-Dec-20
L-035-21/0	Khleif, Samir N.		Daiichi Sankyo Co., Ltd.	24-Dec-20
L-035-21/0	Minna, John D.		Daiichi Sankyo Co., Ltd.	24-Dec-20
L-035-21/0	Oie, Herbert K		Daiichi Sankyo Co., Ltd.	24-Dec-20

L-035-21/0	Pass, Harvey I	(b)(4); (b)(6)	Daiichi Sankyo Co., Ltd.	24-Dec-20
L-035-21/0	Gazdar, Adi		Daiichi Sankyo Co., Ltd.	24-Dec-20
L-035-21/0	Johnson, Bruce E		Daiichi Sankyo Co., Ltd.	24-Dec-20
L-035-21/0	Kaye, Frederic J		Daiichi Sankyo Co., Ltd.	24-Dec-20
L-035-21/0	Khleif, Samir N.		Daiichi Sankyo Co., Ltd.	24-Dec-20
L-035-21/0	Minna, John D.		Daiichi Sankyo Co., Ltd.	24-Dec-20
L-035-21/0	Oie, Herbert K		Daiichi Sankyo Co., Ltd.	24-Dec-20
L-035-21/0	Pass, Harvey I		Daiichi Sankyo Co., Ltd.	24-Dec-20
L-084-11/2	Gazdar, Adi		Nichirei Biosciences Inc	28-Dec-20
L-084-11/2	Johnson, Bruce E		Nichirei Biosciences Inc	28-Dec-20
L-084-11/2	Kaye, Frederic J		Nichirei Biosciences Inc	28-Dec-20
L-084-11/2	Khleif, Samir N.		Nichirei Biosciences Inc	28-Dec-20
L-084-11/2	Minna, John D.		Nichirei Biosciences Inc	28-Dec-20
L-084-11/2	Oie, Herbert K		Nichirei Biosciences Inc	28-Dec-20
L-084-11/2	Pass, Harvey I		Nichirei Biosciences Inc	28-Dec-20
L-160-20/0	Bonomi, Carrie A.		Hanmi Pharmaceutical Co., Ltd	28-Dec-20
L-160-20/0	Borgel, Suzanne D.		Hanmi Pharmaceutical Co., Ltd	28-Dec-20
L-160-20/0	Dougherty, Kelly		Hanmi Pharmaceutical Co., Ltd	28-Dec-20
L-160-20/0	Hollingshead, Melinda G.		Hanmi Pharmaceutical Co., Ltd	28-Dec-20
L-259-18/0	Bonomi, Carrie A.		Oncoveda Cancer Research Center	28-Dec-20
L-259-18/0	Borgel, Suzanne D.		Oncoveda Cancer Research Center	28-Dec-20
L-259-18/0	Dougherty, Kelly		Oncoveda Cancer Research Center	28-Dec-20
L-259-18/0	Hollingshead, Melinda G.		Oncoveda Cancer Research Center	28-Dec-20
L-082-20/0	Abrams, Scott I		Compass Therapeutics LLC	28-Dec-20
L-082-20/0	Schlom, Jeffrey		Compass Therapeutics LLC	28-Dec-20
L-033-17/0	Bonomi, Carrie A.		MD Biosciences, Inc.	28-Dec-20
L-033-17/0	Dougherty, Kelly		MD Biosciences, Inc.	28-Dec-20
L-033-17/0	Hollingshead, Melinda G.		MD Biosciences, Inc.	28-Dec-20
L-094-20/1	Morgan, Richard A.		Innovative Cellular Therapeutics	28-Dec-20
L-094-20/1	Restifo, Nicholas P.		Innovative Cellular Therapeutics	28-Dec-20
L-094-20/1	Rosenberg, Steven A.		Innovative Cellular Therapeutics	28-Dec-20
L-094-20/1	Zhang, Ling		Innovative Cellular Therapeutics	28-Dec-20
L-745-91/2	Chang, Nancy T.		BioMerieux, Inc.	28-Dec-20
L-745-91/2	Crowl, Robert		BioMerieux, Inc.	28-Dec-20
L-745-91/2	Fisher, Amanda G.		BioMerieux, Inc.	28-Dec-20
L-745-91/2	Gallo, Robert C.		BioMerieux, Inc.	28-Dec-20
L-745-91/2	Hahn, Beatrice		BioMerieux, Inc.	28-Dec-20
L-745-91/2	(b) (4)		BioMerieux, Inc.	28-Dec-20
L-745-91/2	Popovic, Mikulas		BioMerieux, Inc.	28-Dec-20
L-745-91/2	Reddy, E. Premkumar.		BioMerieux, Inc.	28-Dec-20
L-745-91/2	Sarangadharan, Mangalasseril		BioMerieux, Inc.	28-Dec-20
L-745-91/2	Shaw, George M		BioMerieux, Inc.	28-Dec-20
L-745-91/2	Wong-Staal (b) (6)		BioMerieux, Inc.	28-Dec-20
L-178-05/1	Chung, Jae Wook		BioGemex Ltd	29-Dec-20
L-022-06/3	Gottesman, Michael M.		Abbott Laboratories	29-Dec-20

(b) (4), (b) (3) (A), (b) (6)

L-022-06/3	Pastan, Ira H	(b)(4);	Abbott Laboratories	29-Dec-20
L-022-06/3	Ueda, Kazumitsu	(b)(6)	Abbott Laboratories	29-Dec-20
L-200-14/0	Austin, Faye C.		Becton, Dickinson and Company	30-Dec-20
L-200-14/0	Colcher, David		Becton, Dickinson and Company	30-Dec-20
L-200-14/0	Hand, Patricia H		Becton, Dickinson and Company	30-Dec-20
L-200-14/0	Nuti, Marianna		Becton, Dickinson and Company	30-Dec-20
L-200-14/0	Schlom, Jeffrey		Becton, Dickinson and Company	30-Dec-20
L-216-14/1	Chang, Kai		Biolegend Inc	30-Dec-20
L-216-14/1	Pastan, Ira H		Biolegend Inc	30-Dec-20
L-216-14/1	Willingham, Mark C.		Biolegend Inc	30-Dec-20
L-007-11/2	Onda, Masanori		BioLegend	30-Dec-20
L-007-11/2	Pastan, Ira H		BioLegend	30-Dec-20
L-010-08/1	Hathcock, Karen		BioLegend	30-Dec-20
L-010-08/1	Hodes, Richard J		BioLegend	30-Dec-20
L-010-08/1	Laszlo, Gloria		BioLegend	30-Dec-20
L-024-97/2	Kawakami, Yutaka		Signet Laboratories, Inc.	30-Dec-20
L-024-97/2	Rosenberg, Steven A.		Signet Laboratories, Inc.	30-Dec-20
L-037-11/1	Jelinek, Ivett		BioLegend	30-Dec-20
L-037-11/1	Segal, David M.		BioLegend	30-Dec-20
L-037-11/1	Wang, Yan		BioLegend	30-Dec-20
L-042-08/1	Azimi, Nazli		Biolegend	30-Dec-20
L-042-08/1	Dubois, Sigrid		Biolegend	30-Dec-20
L-042-08/1	Goldman, Carolyn		Biolegend	30-Dec-20
L-042-08/1	Lantz, Valerie A		Biolegend	30-Dec-20
L-042-08/1	Mariner Kilbourne, Jennifer		Biolegend	30-Dec-20
L-042-08/1	Waldmann, Thomas A.		Biolegend	30-Dec-20
L-070-12/1	Hathcock, Karen		BioLegend	30-Dec-20
L-070-12/1	Hodes, Richard J		BioLegend	30-Dec-20
L-070-12/1	Laszlo, Gloria		BioLegend	30-Dec-20
L-095-12/0	Baskar, Sivasubramanian		BioLegend	30-Dec-20
L-095-12/0	Rader, Christoph		BioLegend	30-Dec-20
L-136-09/1	Mason, Llewellyn H.		BioLegend	30-Dec-20
L-136-09/1	Ortaldo, John R.		BioLegend	30-Dec-20
L-198-15/0	Ise, Tomoko		BioLegend	30-Dec-20
L-198-15/0	Nagata, Satoshi		BioLegend	30-Dec-20
L-198-15/0	Pastan, Ira H		BioLegend	30-Dec-20
L-162-17/0	Bonomi, Carrie A.		Daiichi Sankyo Co., Ltd.	30-Dec-20
L-162-17/0	Dougherty, Kelly		Daiichi Sankyo Co., Ltd.	30-Dec-20
L-162-17/0	Hollingshead, Melinda G.		Daiichi Sankyo Co., Ltd.	30-Dec-20
L-083-11/0	Waldmann, Thomas A.		AbbVie Biotherapeutics, Inc.	30-Dec-20

Note: (b) (4) split between NCI; NINDS



(b) (4), (b) (3) (A), (b) (6)

L-220-20/0	Bonomi, Carrie A.	(b)(4);	Inzen Therapeutics, Inc.	30-Dec-20
L-220-20/0	Borgel, Suzanne D.	(b)(6)	Inzen Therapeutics, Inc.	30-Dec-20
L-220-20/0	Dougherty, Kelly		Inzen Therapeutics, Inc.	30-Dec-20
L-220-20/0	Hollingshead, Melinda G.		Inzen Therapeutics, Inc.	30-Dec-20
L-031-21/0	NCI		Caprico Biotechnologies, Inc	30-Dec-20
L-031-21/0	NCI		Caprico Biotechnologies, Inc	30-Dec-20
L-031-21/0	NCI		Caprico Biotechnologies, Inc	30-Dec-20

NIH Patent Licensing Activities
NCI
January 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min /Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
L-080-93/3	Hathcock, Karen	(b)(4);	BD Biosciences - BD PharMingen, Inc.	1-Jan-21						(b) (4), (b) (3) (A), (b) (6)
L-080-93/3	Hodes, Richard J	(b)(6)	BD Biosciences - BD PharMingen, Inc.	1-Jan-21						
L-080-93/3	Laszlo, Gloria		BD Biosciences - BD PharMingen, Inc.	1-Jan-21						
L-047-06/2	Chang, Nancy T.		Chembio Diagnostic	3-Jan-21						
L-047-06/2	Crowl, Robert		Chembio Diagnostic	3-Jan-21						
L-047-06/2	Gallo, Robert C.		Chembio Diagnostic	3-Jan-21						
L-047-06/2	(b) (4)		Chembio Diagnostic	3-Jan-21						
L-047-06/2	Reddy, E. Premkumar.		Chembio Diagnostic	3-Jan-21						
L-047-06/2	Shaw, George M		Chembio Diagnostic	3-Jan-21						
L-047-06/2	Wong-Staal (b) (6)		Chembio Diagnostic	3-Jan-21						
L-255-19/0	Buck, Christopher		BioE Holdings Inc.	4-Jan-21						
L-255-19/0	Pastrana, Diana V		BioE Holdings Inc.	4-Jan-21						
L-255-19/0	RAY, UPASANA		BioE Holdings Inc.	4-Jan-21						
L-117-09/2	Aaronson, Stuart A.		Targovax	4-Jan-21						
L-117-09/2	(b) (6) Donald J. Giard		Targovax	4-Jan-21						
L-117-09/2	Parks, Wade P		Targovax	4-Jan-21						
L-030-18/0	Bonomi, Carrie A.		23andMe Therapeutics	4-Jan-21						
L-030-18/0	Borgel, Suzanne D.		23andMe Therapeutics	4-Jan-21						
L-030-18/0	Dougherty, Kelly		23andMe Therapeutics	4-Jan-21						
L-030-18/0	Hollingshead, Melinda G.		23andMe Therapeutics	4-Jan-21						
L-119-19/0	Esposito, Dominic		Quanta Therapeutics, Inc., University of	4-Jan-21						
L-119-19/0	Gillette, William K.		Quanta Therapeutics, Inc., University of	4-Jan-21						
L-119-19/0	Grose, Carissa L.		Quanta Therapeutics, Inc., University of	4-Jan-21						
L-201-20/0	Gao, Wei		Navrogen Inc	4-Jan-21						
L-201-20/0	Hassan, Raffit		Navrogen Inc	4-Jan-21						
L-201-20/0	Ho, Mitchell		Navrogen Inc	4-Jan-21						
L-201-20/0	Pastan, Ira H		Navrogen Inc	4-Jan-21						
L-201-20/0	Phung, Yen T.		Navrogen Inc	4-Jan-21						
L-201-20/0	Zhang, Yifan		Navrogen Inc	4-Jan-21						

L-161-18/1	Gazdar, Adi	(b)(4):	NEUVOGEN, Inc	4-Jan-21
L-161-18/1	Johnson, Bruce E	(b)(6)	NEUVOGEN, Inc	4-Jan-21
L-161-18/1	Kaye, Frederic J		NEUVOGEN, Inc	4-Jan-21
L-161-18/1	Khleif, Samir N.		NEUVOGEN, Inc	4-Jan-21
L-161-18/1	Minna, John D.		NEUVOGEN, Inc	4-Jan-21
L-161-18/1	Oie, Herbert K		NEUVOGEN, Inc	4-Jan-21
L-161-18/1	Pass, Harvey I		NEUVOGEN, Inc	4-Jan-21
L-085-19/1	Aaronson, Stuart A.		NEUVOGEN, Inc	4-Jan-21
L-085-19/1	Gazdar, Adi		NEUVOGEN, Inc	4-Jan-21
L-085-19/1	Giard, Donald		NEUVOGEN, Inc	4-Jan-21
L-085-19/1	Johnson, Bruce E		NEUVOGEN, Inc	4-Jan-21
L-085-19/1	Kaye, Frederic J		NEUVOGEN, Inc	4-Jan-21
L-085-19/1	Khleif, Samir N.		NEUVOGEN, Inc	4-Jan-21
L-085-19/1	Minna, John D.		NEUVOGEN, Inc	4-Jan-21
L-085-19/1	Oie, Herbert K		NEUVOGEN, Inc	4-Jan-21
L-085-19/1	Parks, Wade P		NEUVOGEN, Inc	4-Jan-21
L-085-19/1	Pass, Harvey I		NEUVOGEN, Inc	4-Jan-21
L-152-18/0	Bonomi, Carrie A.		Cygnal Therapeutics	4-Jan-21
L-152-18/0	Dougherty, Kelly		Cygnal Therapeutics	4-Jan-21
L-152-18/0	Hollingshead, Melinda G.		Cygnal Therapeutics	4-Jan-21
L-327-17/0	Gao, Wei		Diagnostic BioSystems	4-Jan-21
L-327-17/0	Hassan, Raffit		Diagnostic BioSystems	4-Jan-21
L-327-17/0	Ho, Mitchell		Diagnostic BioSystems	4-Jan-21
L-327-17/0	Pastan, Ira H		Diagnostic BioSystems	4-Jan-21
L-327-17/0	Phung, Yen T.		Diagnostic BioSystems	4-Jan-21
L-327-17/0	Zhang, Yifan		Diagnostic BioSystems	4-Jan-21
L-325-17/0	Gao, Wei		Diagnostic BioSystems	4-Jan-21
L-325-17/0	Ho, Mitchell		Diagnostic BioSystems	4-Jan-21
L-325-17/0	Phung, Yen T.		Diagnostic BioSystems	4-Jan-21
L-325-17/0	Zhang, Yifan		Diagnostic BioSystems	4-Jan-21
L-138-19/1	Bagni-Beyer, Rachel K.		Quanta Therapeutics, Inc., University of	4-Jan-21
L-138-19/1	(b) (4)		Quanta Therapeutics, Inc., University of	4-Jan-21
L-138-19/1	Holderfield, Matthew T.		Quanta Therapeutics, Inc., University of	4-Jan-21
L-138-19/1	Soppet, Dan		Quanta Therapeutics, Inc., University of	4-Jan-21
L-072-21/0	Bonomi, Carrie A.		Bristol Myers Squibb	4-Jan-21
L-072-21/0	Borgel, Suzanne D.		Bristol Myers Squibb	4-Jan-21
L-072-21/0	Dougherty, Kelly		Bristol Myers Squibb	4-Jan-21
L-072-21/0	Hollingshead, Melinda G.		Bristol Myers Squibb	4-Jan-21
L-203-15/1	Gazdar, Adi		SOTIO	5-Jan-21
L-203-15/1	Johnson, Bruce E		SOTIO	5-Jan-21
L-203-15/1	Kaye, Frederic J		SOTIO	5-Jan-21
L-203-15/1	Khleif, Samir N.		SOTIO	5-Jan-21
L-203-15/1	Minna, John D.		SOTIO	5-Jan-21
L-203-15/1	Oie, Herbert K		SOTIO	5-Jan-21
L-203-15/1	Pass, Harvey I		SOTIO	5-Jan-21
L-083-20/0	Gottesman, Michael M.		Q2 Solutions BioSciences LLC	5-Jan-21
L-083-20/0	Pastan, Ira H		Q2 Solutions BioSciences LLC	5-Jan-21

L-083-20/0	Ueda, Kazumitsu	(b)(4); (b)(6)	Q2 Solutions BioSciences LLC	5-Jan-21
L-158-17/0	Wang, Xiaohong		Mokobio Life Science Group, Inc.	5-Jan-21
L-158-17/0	Xu, Junfen		Mokobio Life Science Group, Inc.	5-Jan-21
L-158-17/0	Zheng, Zhi-Min g (Thomas)		Mokobio Life Science Group, Inc.	5-Jan-21
<i>Note: L-158-17/0 split between NCI; NHLBI</i>				
L-126-12/0	Austin, Faye C.		Leica Microsystems	6-Jan-21
L-126-12/0	Colcher, David		Leica Microsystems	6-Jan-21
L-126-12/0	Hand, Patricia H		Leica Microsystems	6-Jan-21
L-126-12/0	Nuti, Marianna		Leica Microsystems	6-Jan-21
L-126-12/0	Schlom, Jeffrey		Leica Microsystems	6-Jan-21
L-201-17/0	Gazdar, Adi		Leica Biosystems Newcastle Ltd	6-Jan-21
L-201-17/0	Johnson, Bruce E		Leica Biosystems Newcastle Ltd	6-Jan-21
L-201-17/0	Kaye, Frederic J		Leica Biosystems Newcastle Ltd	6-Jan-21
L-201-17/0	Khleif, Samir N.		Leica Biosystems Newcastle Ltd	6-Jan-21
L-201-17/0	Minna, John D.		Leica Biosystems Newcastle Ltd	6-Jan-21
L-201-17/0	Oie, Herbert K		Leica Biosystems Newcastle Ltd	6-Jan-21
L-201-17/0	Pass, Harvey I		Leica Biosystems Newcastle Ltd	6-Jan-21
L-063-20/0	Aplan, Peter D.		Keros Therapeutics, Inc.	6-Jan-21
L-063-20/0	Lin, Ying-Wei		Keros Therapeutics, Inc.	6-Jan-21
L-063-20/0	Slape, Christopher I.		Keros Therapeutics, Inc.	6-Jan-21
L-063-20/0	Zhang, ZhenHua		Keros Therapeutics, Inc.	6-Jan-21
L-297-19/0	Bonomi, Carrie A.		Incyte Corporation	6-Jan-21
L-297-19/0	Borgel, Suzanne D.		Incyte Corporation	6-Jan-21
L-297-19/0	Dougherty, Kelly		Incyte Corporation	6-Jan-21
L-297-19/0	Hodge, James W.		Incyte Corporation	6-Jan-21
L-297-19/0	Hollingshead, Melinda G.		Incyte Corporation	6-Jan-21
L-297-19/0	Schlom, Jeffrey		Incyte Corporation	6-Jan-21
L-146-20/0	Bonomi, Carrie A.		Harpoon Therapeutics	6-Jan-21
L-146-20/0	Borgel, Suzanne D.		Harpoon Therapeutics	6-Jan-21
L-146-20/0	Dougherty, Kelly		Harpoon Therapeutics	6-Jan-21
L-146-20/0	Hollingshead, Melinda G.		Harpoon Therapeutics	6-Jan-21
L-239-19/0	Kochenderfer, James N		Cartesian Therapeutics, Inc.	6-Jan-21
L-063-21/0	Gazdar, Adi		Janssen Research & Development, LLC	7-Jan-21
L-063-21/0	Johnson, Bruce E		Janssen Research & Development, LLC	7-Jan-21
L-063-21/0	Kaye, Frederic J		Janssen Research & Development, LLC	7-Jan-21
L-063-21/0	Khleif, Samir N.		Janssen Research & Development, LLC	7-Jan-21
L-063-21/0	Minna, John D.		Janssen Research & Development, LLC	7-Jan-21
L-063-21/0	Oie, Herbert K		Janssen Research & Development, LLC	7-Jan-21
L-063-21/0	Pass, Harvey I		Janssen Research & Development, LLC	7-Jan-21
L-200-15/1	Aaronson, Stuart A.		TILT Biotherapeutics, Ltd.	7-Jan-21
L-200-15/1	(b) (6) Donald J. Giard		TILT Biotherapeutics, Ltd.	7-Jan-21
L-200-15/1	Parks, Wade P		TILT Biotherapeutics, Ltd.	7-Jan-21
L-126-20/0	Kochenderfer, James N		Kite Pharma, Inc.	7-Jan-21
L-126-20/0	Lam, Norris		Kite Pharma, Inc.	7-Jan-21

L-127-20/0	Kochenderfer, James N	(b)(4);	Kite Pharma, Inc	7-Jan-21
L-127-20/0	Lam, Norris	(b)(6)	Kite Pharma, Inc	7-Jan-21
L-127-20/0	Lam, Norris		Kite Pharma, Inc	7-Jan-21
L-218-16/1	NCI		Kite Pharma, Inc	7-Jan-21
L-126-20/0	Kochenderfer, James N		Kite Pharma, Inc.	7-Jan-21
L-126-20/0	Lam, Norris		Kite Pharma, Inc.	7-Jan-21
L-277-17/0	Aaronson, Stuart A.		Valo Therapeutics Oy	7-Jan-21
L-277-17/0	Giard, Donald		Valo Therapeutics Oy	7-Jan-21
L-277-17/0	Parks, Wade P		Valo Therapeutics Oy	7-Jan-21
L-108-20/0	Chien, Christopher		ElevateBio	7-Jan-21
L-108-20/0	Fry, Terry		ElevateBio	7-Jan-21
L-038-19/0	Bonomi, Carrie A.		Boehringer Ingelheim International GmbH	8-Jan-21
L-038-19/0	Borgel, Suzanne D.		Boehringer Ingelheim International GmbH	8-Jan-21
L-038-19/0	Dougherty, Kelly		Boehringer Ingelheim International GmbH	8-Jan-21
L-038-19/0	Hollingshead, Melinda G.		Boehringer Ingelheim International GmbH	8-Jan-21
L-097-00/2	Austin, Faye C.		BD Biosciences - BD PharMingen	11-Jan-21
L-097-00/2	Colcher, David		BD Biosciences - BD PharMingen	11-Jan-21
L-097-00/2	Hand, Patricia H		BD Biosciences - BD PharMingen	11-Jan-21
L-097-00/2	Nuti, Marianna		BD Biosciences - BD PharMingen	11-Jan-21
L-097-00/2	Schlom, Jeffrey		BD Biosciences - BD PharMingen	11-Jan-21
L-187-95/2	Yoshimura, Teizo		BD BIOSCIENCES	11-Jan-21
L-100-12/1	Ise, Tomoko		BD Biosciences	11-Jan-21
L-100-12/1	Nagata, Satoshi		BD Biosciences	11-Jan-21
L-100-12/1	Pastan, Ira H		BD Biosciences	11-Jan-21
L-267-20/0	Gazdar, Adi		Boehringer Ingelheim RCV GmbH & Co KG	11-Jan-21
L-267-20/0	Johnson, Bruce E		Boehringer Ingelheim RCV GmbH & Co KG	11-Jan-21
L-267-20/0	Kaye, Frederic J		Boehringer Ingelheim RCV GmbH & Co KG	11-Jan-21
L-267-20/0	Khleif, Samir N.		Boehringer Ingelheim RCV GmbH & Co KG	11-Jan-21
L-267-20/0	Minna, John D.		Boehringer Ingelheim RCV GmbH & Co KG	11-Jan-21
L-267-20/0	Oie, Herbert K		Boehringer Ingelheim RCV GmbH & Co KG	11-Jan-21
L-267-20/0	Pass, Harvey I		Boehringer Ingelheim RCV GmbH & Co KG	11-Jan-21
L-256-17/0	Bonomi, Carrie A.		AbbVie	11-Jan-21
L-256-17/0	Borgel, Suzanne D.		AbbVie	11-Jan-21
L-256-17/0	Dougherty, Kelly		AbbVie	11-Jan-21
L-256-17/0	Hollingshead, Melinda G.		AbbVie	11-Jan-21
L-039-11/0	Onda, Masanori		Rockland Immunochemicals, Inc.	11-Jan-21
L-039-11/0	Pastan, Ira H		Rockland Immunochemicals, Inc.	11-Jan-21
L-060-18/1	Bonomi, Carrie A.		Kineta, Inc	11-Jan-21
L-060-18/1	Borgel, Suzanne D.		Kineta, Inc	11-Jan-21
L-060-18/1	Dougherty, Kelly		Kineta, Inc	11-Jan-21
L-060-18/1	Hollingshead, Melinda G.		Kineta, Inc	11-Jan-21

L-076-16/0	Azimi, Nazli	(b)(4);	BD Biosciences	11-Jan-21
L-076-16/0	Dubois, Sigrid	(b)(6)	BD Biosciences	11-Jan-21
L-076-16/0	Goldman, Carolyn		BD Biosciences	11-Jan-21
L-076-16/0	Lantz, Valerie A		BD Biosciences	11-Jan-21
L-076-16/0	Mariner Kilbourne, Jennifer		BD Biosciences	11-Jan-21
L-076-16/0	Waldmann, Thomas A.		BD Biosciences	11-Jan-21
L-257-17/0	Buck, Christopher		Serum Institute of India PVT. LTD.	12-Jan-21
L-257-17/0	(b) (4)		Serum Institute of India PVT. LTD.	12-Jan-21
L-257-17/0	Lowy, Douglas R.		Serum Institute of India PVT. LTD.	12-Jan-21
L-257-17/0	Pastrana, Diana V		Serum Institute of India PVT. LTD.	12-Jan-21
L-257-17/0	Roden, Richard B		Serum Institute of India PVT. LTD.	12-Jan-21
L-257-17/0	Schiller, John T		Serum Institute of India PVT. LTD.	12-Jan-21
L-260-20/0	Gazdar, Adi		Circle Pharma	12-Jan-21
L-260-20/0	Johnson, Bruce E		Circle Pharma	12-Jan-21
L-260-20/0	Kaye, Frederic J		Circle Pharma	12-Jan-21
L-260-20/0	Khleif, Samir N.		Circle Pharma	12-Jan-21
L-260-20/0	Minna, John D.		Circle Pharma	12-Jan-21
L-260-20/0	Oie, Herbert K		Circle Pharma	12-Jan-21
L-260-20/0	Pass, Harvey I		Circle Pharma	12-Jan-21
L-061-21/0	Bonomi, Carrie A.		Amunix Pharmaceuticals, Inc.	12-Jan-21
L-061-21/0	Borgel, Suzanne D.		Amunix Pharmaceuticals, Inc.	12-Jan-21
L-061-21/0	Dougherty, Kelly		Amunix Pharmaceuticals, Inc.	12-Jan-21
L-061-21/0	Hollingshead, Melinda G.		Amunix Pharmaceuticals, Inc.	12-Jan-21
L-216-19/0	Bonomi, Carrie A.		Revolution Medicines, Inc	13-Jan-21
L-216-19/0	Dougherty, Kelly		Revolution Medicines, Inc	13-Jan-21
L-216-19/0	Hollingshead, Melinda G.		Revolution Medicines, Inc	13-Jan-21
L-247-17/0	Bagni-Beyer, Rachel K.		Revolution Medicines, Inc.	13-Jan-21
L-247-17/0	(b) (4)		Revolution Medicines, Inc.	13-Jan-21
L-247-17/0	Holderfield, Matthew T.		Revolution Medicines, Inc.	13-Jan-21
L-247-17/0	Soppet, Dan		Revolution Medicines, Inc.	13-Jan-21
L-091-11/0	Chang, Nancy T.		Quest Diagnostics, Inc.	13-Jan-21
L-091-11/0	Fisher, Amanda G.		Quest Diagnostics, Inc.	13-Jan-21
L-091-11/0	Gallo, Robert C.		Quest Diagnostics, Inc.	13-Jan-21
L-091-11/0	Hahn, Beatrice		Quest Diagnostics, Inc.	13-Jan-21
L-091-11/0	(b) (4)		Quest Diagnostics, Inc.	13-Jan-21
L-091-11/0	Popovic, Mikulas		Quest Diagnostics, Inc.	13-Jan-21
L-091-11/0	Sarngadharan, Mangalasseril		Quest Diagnostics, Inc.	13-Jan-21
L-091-11/0	Shaw, George M		Quest Diagnostics, Inc.	13-Jan-21
L-091-11/0	Wong-Staa (b) (6)		Quest Diagnostics, Inc.	13-Jan-21
L-267-20/0	Gazdar, Adi		Boehringer Ingelheim RCV GmbH & Co KG	13-Jan-21
L-267-20/0	Johnson, Bruce E		Boehringer Ingelheim RCV GmbH & Co KG	13-Jan-21
L-267-20/0	Kaye, Frederic J		Boehringer Ingelheim RCV GmbH & Co KG	13-Jan-21
L-267-20/0	Khleif, Samir N.		Boehringer Ingelheim RCV GmbH & Co KG	13-Jan-21
L-267-20/0	Minna, John D.		Boehringer Ingelheim RCV GmbH & Co KG	13-Jan-21
L-267-20/0	Oie, Herbert K		Boehringer Ingelheim RCV GmbH & Co KG	13-Jan-21
L-267-20/0	Pass, Harvey I		Boehringer Ingelheim RCV GmbH & Co KG	13-Jan-21
L-071-19/1	Dimitrov, Dimitar S.		Atara Biotherapeutics Inc.	13-Jan-21

L-071-19/1	Feng, Yang	(b)(4);	Atara Biotherapeutics Inc.	13-Jan-21
L-071-19/1	Pastan, Ira H	(b)(6)	Atara Biotherapeutics Inc.	13-Jan-21
L-113-07/1	Aaronson, Stuart A.		Ventana Medical Systems	13-Jan-21
L-113-07/1	King, Charles R.		Ventana Medical Systems	13-Jan-21
L-113-07/1	Kraus, (b) (6) Matthias		Ventana Medical Systems	13-Jan-21
L-307-19/0	Bonomi, Carrie A.		SyntheKine Inc	13-Jan-21
L-307-19/0	Borgel, Suzanne D.		SyntheKine Inc	13-Jan-21
L-307-19/0	Dougherty, Kelly		SyntheKine Inc	13-Jan-21
L-307-19/0	Hollingshead, Melinda G.		SyntheKine Inc	13-Jan-21
L-260-20/0	Gazdar, Adi		Circle Pharma	13-Jan-21
L-260-20/0	Johnson, Bruce E		Circle Pharma	13-Jan-21
L-260-20/0	Kaye, Frederic J		Circle Pharma	13-Jan-21
L-260-20/0	Khleif, Samir N.		Circle Pharma	13-Jan-21
L-260-20/0	Minna, John D.		Circle Pharma	13-Jan-21
L-260-20/0	Oie, Herbert K		Circle Pharma	13-Jan-21
L-260-20/0	Pass, Harvey I		Circle Pharma	13-Jan-21
L-092-19/1	Bonomi, Carrie A.		Glympse Bio, Inc., c/o Advanced Technolo	13-Jan-21
L-092-19/1	Borgel, Suzanne D.		Glympse Bio, Inc., c/o Advanced Technolo	13-Jan-21
L-092-19/1	Dougherty, Kelly		Glympse Bio, Inc., c/o Advanced Technolo	13-Jan-21
L-092-19/1	Hollingshead, Melinda G.		Glympse Bio, Inc., c/o Advanced Technolo	13-Jan-21
L-038-21/0	Bonomi, Carrie A.		HiberCell, Inc.	13-Jan-21
L-038-21/0	Borgel, Suzanne D.		HiberCell, Inc.	13-Jan-21
L-038-21/0	Dougherty, Kelly		HiberCell, Inc.	13-Jan-21
L-038-21/0	Hollingshead, Melinda G.		HiberCell, Inc.	13-Jan-21
L-192-18/0	Bonomi, Carrie A.		iOmx	14-Jan-21
L-192-18/0	Borgel, Suzanne D.		iOmx	14-Jan-21
L-192-18/0	Dougherty, Kelly		iOmx	14-Jan-21
L-192-18/0	Hollingshead, Melinda G.		iOmx	14-Jan-21
L-214-19/0	Gallo, Robert C.		Cerus Corporation	15-Jan-21
L-214-19/0	Popovic, Mikulas		Cerus Corporation	15-Jan-21
L-069-20/0	(b) (4)		Arvinas Operations, Inc.	15-Jan-21
L-069-20/0	Esposito, Dominic		Arvinas Operations, Inc.	15-Jan-21
L-069-20/0	Hopkins, Ralph F.		Arvinas Operations, Inc.	15-Jan-21
L-069-20/0	Roberts, Veronica Ann		Arvinas Operations, Inc.	15-Jan-21
L-133-20/0	Gallo, Robert C.		LumiraDx	15-Jan-21
L-133-20/0	Gartner, Suzanne		LumiraDx	15-Jan-21
L-133-20/0	Popovic, Mikulas		LumiraDx	15-Jan-21
L-109-15/0	Brinkmann, Ulrich		Chugai Pharmaceutical Co.	15-Jan-21
L-109-15/0	Jung, Sun-Hee		Chugai Pharmaceutical Co.	15-Jan-21
L-109-15/0	Lee, Byungkook		Chugai Pharmaceutical Co.	15-Jan-21
L-109-15/0	Pastan, Ira H		Chugai Pharmaceutical Co.	15-Jan-21
L-063-21/0	Gazdar, Adi		Janssen Research & Development, LLC	15-Jan-21
L-063-21/0	Johnson, Bruce E		Janssen Research & Development, LLC	15-Jan-21
L-063-21/0	Kaye, Frederic J		Janssen Research & Development, LLC	15-Jan-21

L-063-21/0	Khleif, Samir N.	(b)(4);	Janssen Research & Development, LLC	15-Jan-21
L-063-21/0	Minna, John D.	(b)(6)	Janssen Research & Development, LLC	15-Jan-21
L-063-21/0	Oie, Herbert K		Janssen Research & Development, LLC	15-Jan-21
L-063-21/0	Pass, Harvey I		Janssen Research & Development, LLC	15-Jan-21
L-148-18/1	(b) (4)		BravoVax Co., Ltd.	19-Jan-21
L-148-18/1	Lowy, Douglas R.		BravoVax Co., Ltd.	19-Jan-21
L-148-18/1	Pastrana, Diana V		BravoVax Co., Ltd.	19-Jan-21
L-148-18/1	Schiller, John T		BravoVax Co., Ltd.	19-Jan-21
L-136-20/0	Dudley, Mark		Intima Bioscience Inc.	20-Jan-21
L-136-20/0	Fitzgerald, Peter C.		Intima Bioscience Inc.	20-Jan-21
L-136-20/0	Gros, Alena		Intima Bioscience Inc.	20-Jan-21
L-136-20/0	Lu, Yong-Chen		Intima Bioscience Inc.	20-Jan-21
L-136-20/0	Palmer, Douglas		Intima Bioscience Inc.	20-Jan-21
L-136-20/0	Restifo, Nicholas P.		Intima Bioscience Inc.	20-Jan-21
L-136-20/0	Robbins, Paul F		Intima Bioscience Inc.	20-Jan-21
L-136-20/0	Rosenberg, Steven A.		Intima Bioscience Inc.	20-Jan-21
L-136-20/0	Tran, Eric		Intima Bioscience Inc.	20-Jan-21
L-136-20/0	Wunderlich, John		Intima Bioscience Inc.	20-Jan-21
L-136-20/0	Zheng, Zhili		Intima Bioscience Inc.	20-Jan-21
L-272-16/0	Bonomi, Carrie A.		KeraFAST	21-Jan-21
L-272-16/0	Borgel, Suzanne D.		KeraFAST	21-Jan-21
L-272-16/0	Dougherty, Kelly		KeraFAST	21-Jan-21
L-272-16/0	Hollingshead, Melinda G.		KeraFAST	21-Jan-21
L-192-15/2	Burgess, Rebecca C.		KeraFAST	21-Jan-21
L-192-15/2	Misteli, Thomas		KeraFAST	21-Jan-21
L-192-15/2	Roukos, Vasileios		KeraFAST	21-Jan-21
L-192-15/2	Soutoglou, Evi		KeraFAST	21-Jan-21
L-160-10/0	Jelinek, Ivett		Bio-Rad AbD Serotec Limited	22-Jan-21
L-160-10/0	Segal, David M.		Bio-Rad AbD Serotec Limited	22-Jan-21
L-160-10/0	Wang, Yan		Bio-Rad AbD Serotec Limited	22-Jan-21
L-227-17/0	Bonomi, Carrie A.		Seres Therapeutics, Inc.	22-Jan-21
L-227-17/0	Borgel, Suzanne D.		Seres Therapeutics, Inc.	22-Jan-21
L-227-17/0	Dougherty, Kelly		Seres Therapeutics, Inc.	22-Jan-21
L-227-17/0	Hollingshead, Melinda G.		Seres Therapeutics, Inc.	22-Jan-21
L-088-19/0	Bagni-Beyer, Rachel K.		Erasca, Inc.	22-Jan-21
L-088-19/0	(b) (4)		Erasca, Inc.	22-Jan-21
L-088-19/0	Holderfield, Matthew T.		Erasca, Inc.	22-Jan-21
L-088-19/0	Soppet, Dan		Erasca, Inc.	22-Jan-21
L-153-16/0	Gazdar, Adi		Bayer Pharma AG	25-Jan-21
L-153-16/0	Johnson, Bruce E		Bayer Pharma AG	25-Jan-21
L-153-16/0	Kaye, Frederic J		Bayer Pharma AG	25-Jan-21
L-153-16/0	Khleif, Samir N.		Bayer Pharma AG	25-Jan-21
L-153-16/0	Minna, John D.		Bayer Pharma AG	25-Jan-21
L-153-16/0	Oie, Herbert K		Bayer Pharma AG	25-Jan-21
L-153-16/0	Pass, Harvey I		Bayer Pharma AG	25-Jan-21
L-347-14/0	Muchmore, Brian P.		Abcam, plc	25-Jan-21

L-347-14/0	O'Brien, Thomas R	(b)(4);	Abcam, plc	25-Jan-21
L-347-14/0	Porter-Gill, Patricia A.	(b)(6)	Abcam, plc	25-Jan-21
L-347-14/0	Prokunina-Olsson, Ludmila		Abcam, plc	25-Jan-21
<i>Note: L-347-14/0 split between FDA; NCI</i>				
L-064-11/0	Barry, Todd		Eptiomics Inc	25-Jan-21
L-064-11/0	Rosenwald, Andreas		Eptiomics Inc	25-Jan-21
L-064-11/0	Staudt, Louis M		Eptiomics Inc	25-Jan-21
L-064-11/0	Wiestner, Adrian		Eptiomics Inc	25-Jan-21
L-064-11/0	Wilson, Wyndham H.		Eptiomics Inc	25-Jan-21
L-161-18/1	Gazdar, Adi		NEUVOGEN, Inc	25-Jan-21
L-161-18/1	Johnson, Bruce E		NEUVOGEN, Inc	25-Jan-21
L-161-18/1	Kaye, Frederic J		NEUVOGEN, Inc	25-Jan-21
L-161-18/1	Khleif, Samir N.		NEUVOGEN, Inc	25-Jan-21
L-161-18/1	Minna, John D.		NEUVOGEN, Inc	25-Jan-21
L-161-18/1	Oie, Herbert K		NEUVOGEN, Inc	25-Jan-21
L-161-18/1	Pass, Harvey I		NEUVOGEN, Inc	25-Jan-21
L-327-17/0	NCI		Diagnostic BioSystems	25-Jan-21
L-325-17/0	NCI		Diagnostic BioSystems	25-Jan-21
L-106-19/0	Bonomi, Carrie A.	(b)(4);	Dracen Pharmaceuticals, Inc.	25-Jan-21
L-106-19/0	Borgel, Suzanne D.	(b)(6)	Dracen Pharmaceuticals, Inc.	25-Jan-21
L-106-19/0	Dougherty, Kelly		Dracen Pharmaceuticals, Inc.	25-Jan-21
L-106-19/0	Hollingshead, Melinda G.		Dracen Pharmaceuticals, Inc.	25-Jan-21
L-070-21/0	Bonomi, Carrie A.		Eisai Co., Ltd.	25-Jan-21
L-070-21/0	Dougherty, Kelly		Eisai Co., Ltd.	25-Jan-21
L-070-21/0	Hollingshead, Melinda G.		Eisai Co., Ltd.	25-Jan-21
L-183-19/0	Esposito, Dominic		Plexxikon Inc.	26-Jan-21
L-183-19/0	Gillette, William K.		Plexxikon Inc.	26-Jan-21
L-183-19/0	Grose, Carissa L.		Plexxikon Inc.	26-Jan-21
L-057-19/0	Bonomi, Carrie A.		Surface Oncology, Inc.	26-Jan-21
L-057-19/0	Borgel, Suzanne D.		Surface Oncology, Inc.	26-Jan-21
L-057-19/0	Dougherty, Kelly		Surface Oncology, Inc.	26-Jan-21
L-057-19/0	Hollingshead, Melinda G.		Surface Oncology, Inc.	26-Jan-21
L-042-21/0	Copeland, Neal		Solid Biosciences Inc.	26-Jan-21
L-042-21/0	Costantino, Nina		Solid Biosciences Inc.	26-Jan-21
L-042-21/0	Court, Donald		Solid Biosciences Inc.	26-Jan-21
L-042-21/0	Jenkins Copeland, Nancy A		Solid Biosciences Inc.	26-Jan-21
L-042-21/0	Warming, Soren		Solid Biosciences Inc.	26-Jan-21
L-273-14/0	Chang, Nancy T.		Grifols Worldwide Operations Ltd.	27-Jan-21
L-273-14/0	Crowl, Robert		Grifols Worldwide Operations Ltd.	27-Jan-21
L-273-14/0	Fisher, Amanda G.		Grifols Worldwide Operations Ltd.	27-Jan-21
L-273-14/0	Gallo, Robert C.		Grifols Worldwide Operations Ltd.	27-Jan-21
L-273-14/0	Hahn, Beatrice		Grifols Worldwide Operations Ltd.	27-Jan-21
L-273-14/0	Popovic, Mikulas		Grifols Worldwide Operations Ltd.	27-Jan-21
L-273-14/0	Reddy, E. Premkumar.		Grifols Worldwide Operations Ltd.	27-Jan-21
L-273-14/0	Sarngadharan, Mangalasseril		Grifols Worldwide Operations Ltd.	27-Jan-21

L-273-14/0	Shaw, George M	(b)(4);	Grifols Worldwide Operations Ltd.	27-Jan-21
L-273-14/0	Wong-Staal (b) (6)	(b)(6)	Grifols Worldwide Operations Ltd.	27-Jan-21
L-160-18/0	NCI		Advanced Imaging Projects, LLC (AIP)	27-Jan-21
<i>Note: L-160-18/0 split between CC; NCI</i>				
L-239-15/0	Gazdar, Adi	(b)(4);	Dako North America	27-Jan-21
L-239-15/0	Johnson, Bruce E	(b)(6)	Dako North America	27-Jan-21
L-239-15/0	Kaye, Frederic J		Dako North America	27-Jan-21
L-239-15/0	Khleif, Samir N.		Dako North America	27-Jan-21
L-239-15/0	Minna, John D.		Dako North America	27-Jan-21
L-239-15/0	Oie, Herbert K		Dako North America	27-Jan-21
L-239-15/0	Pass, Harvey I		Dako North America	27-Jan-21
L-058-21/0	Gazdar, Adi		Erasca, Inc.	27-Jan-21
L-058-21/0	Johnson, Bruce E		Erasca, Inc.	27-Jan-21
L-058-21/0	Kaye, Frederic J		Erasca, Inc.	27-Jan-21
L-058-21/0	Khleif, Samir N.		Erasca, Inc.	27-Jan-21
L-058-21/0	Minna, John D.		Erasca, Inc.	27-Jan-21
L-058-21/0	Oie, Herbert K		Erasca, Inc.	27-Jan-21
L-058-21/0	Pass, Harvey I		Erasca, Inc.	27-Jan-21
L-319-17/0	Bonomi, Carrie A.		BioTech AG	28-Jan-21
L-319-17/0	Borgel, Suzanne D.		BioTech AG	28-Jan-21
L-319-17/0	Dougherty, Kelly		BioTech AG	28-Jan-21
L-319-17/0	Hollingshead, Melinda G.		BioTech AG	28-Jan-21
L-308-17/0	NCI		Rapa Therapeutics LLC	28-Jan-21
L-146-19/0	Hinrichs, Christian S.	(b)(4);	Adicet Bio	28-Jan-21
L-146-19/0	Yongzu Jin, Benjamin	(b)(6)	Adicet Bio	28-Jan-21



NIH Patent Licensing Activities
NCI
February 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
L-294-19/0	NCI		Fannin Partners, LLC	1-Feb-21						
L-108-09/0	Conrads, Thomas P	(b)(4);	AB Sciex, LLC	1-Feb-21						
L-108-09/0	Issaq, Haleem J.	(b)(6)	AB Sciex, LLC	1-Feb-21						
L-108-09/0	Janini, George		AB Sciex, LLC	1-Feb-21						
L-108-09/0	Veenstra, Timothy D		AB Sciex, LLC	1-Feb-21						
L-108-09/0	Wilkens, Kenneth L.		AB Sciex, LLC	1-Feb-21						
L-188-19/0	Schlom, Jeffrey		Good Therapeutics, Inc	1-Feb-21						
L-137-19/0	Bonomi, Carrie A.		Good Therapeutics, Inc.	1-Feb-21						
L-137-19/0	Borgel, Suzanne D.		Good Therapeutics, Inc.	1-Feb-21						
L-137-19/0	Dougherty, Kelly		Good Therapeutics, Inc.	1-Feb-21						

L-137-19/0	Hollingshead, Melinda G.	(b)(4); (b)(6)	Good Therapeutics, Inc.	1-Feb-21
L-234-00/5	Gelboin (b) (6) Harry		Xeno Tech, LLC	1-Feb-21
L-234-00/5	Gonzalez, Frank J		Xeno Tech, LLC	1-Feb-21
L-234-00/5	Krausz, Kristopher W.		Xeno Tech, LLC	1-Feb-21
L-234-00/5	Yang, Tian J.		Xeno Tech, LLC	1-Feb-21
L-051-21/0	Gazdar, Adi		DS Bio Limited	1-Feb-21
L-051-21/0	Johnson, Bruce E		DS Bio Limited	1-Feb-21
L-051-21/0	Kaye, Frederic J		DS Bio Limited	1-Feb-21
L-051-21/0	Khleif, Samir N.		DS Bio Limited	1-Feb-21
L-051-21/0	Minna, John D.		DS Bio Limited	1-Feb-21
L-051-21/0	Oie, Herbert K		DS Bio Limited	1-Feb-21
L-051-21/0	Pass, Harvey I		DS Bio Limited	1-Feb-21
L-051-21/0	Gazdar, Adi		DS Bio Limited	1-Feb-21
L-051-21/0	Johnson, Bruce E		DS Bio Limited	1-Feb-21
L-051-21/0	Kaye, Frederic J		DS Bio Limited	1-Feb-21
L-051-21/0	Khleif, Samir N.		DS Bio Limited	1-Feb-21
L-051-21/0	Minna, John D.		DS Bio Limited	1-Feb-21
L-051-21/0	Oie, Herbert K		DS Bio Limited	1-Feb-21
L-051-21/0	Pass, Harvey I		DS Bio Limited	1-Feb-21
L-208-13/0	Bernardo, Marcelino L (b) (6)		Aspyrian THERapeutics, Inc.	1-Feb-21
L-208-13/0	Choyke, Peter L		Aspyrian THERapeutics, Inc.	1-Feb-21
L-208-13/0	Kobayashi, Hisataka		Aspyrian THERapeutics, Inc.	1-Feb-21
L-208-13/0	Mitsunaga, Makoto		Aspyrian THERapeutics, Inc.	1-Feb-21
L-065-21/0	Eil, Robert Langland		Lyell Immunopharma, Inc.	1-Feb-21
L-065-21/0	Gattinoni, Luca		Lyell Immunopharma, Inc.	1-Feb-21
L-065-21/0	Good, Meghan		Lyell Immunopharma, Inc.	1-Feb-21
L-065-21/0	Islam, S M Rafiqul		Lyell Immunopharma, Inc.	1-Feb-21
L-065-21/0	Kishton, Rigel Joseph		Lyell Immunopharma, Inc.	1-Feb-21
L-065-21/0	Klemen, Nicholas Donald		Lyell Immunopharma, Inc.	1-Feb-21
L-065-21/0	Patel, Shashankumar		Lyell Immunopharma, Inc.	1-Feb-21
L-065-21/0	Restifo, Nicholas P.		Lyell Immunopharma, Inc.	1-Feb-21
L-065-21/0	Tamaoki, Naritaka		Lyell Immunopharma, Inc.	1-Feb-21
L-065-21/0	Vizcardo Sakoda, Raul Eduardo		Lyell Immunopharma, Inc.	1-Feb-21
L-065-21/0	Vodnala, Suman Kumar		Lyell Immunopharma, Inc.	1-Feb-21
L-154-17/0	Bonomi, Carrie A.		Agios Pharmaceuticals	1-Feb-21
L-154-17/0	Borgel, Suzanne D.		Agios Pharmaceuticals	1-Feb-21
L-154-17/0	Dougherty, Kelly		Agios Pharmaceuticals	1-Feb-21
L-154-17/0	Hollingshead, Melinda G.		Agios Pharmaceuticals	1-Feb-21
L-068-21/0	Linehan, Marston		ADRx, Inc.	1-Feb-21
L-068-21/0	Yang, Youfeng		ADRx, Inc.	1-Feb-21
L-111-19/0	Bonomi, Carrie A.		Innate Pharma Research Labs	2-Feb-21
L-111-19/0	Borgel, Suzanne D.		Innate Pharma Research Labs	2-Feb-21
L-111-19/0	Dougherty, Kelly		Innate Pharma Research Labs	2-Feb-21
L-111-19/0	Hollingshead, Melinda G.		Innate Pharma Research Labs	2-Feb-21
L-011-06/0	Barry, Todd		Dako Denmark A/S	2-Feb-21
L-011-06/0	Rosenwald, Andreas		Dako Denmark A/S	2-Feb-21

L-011-06/0	Staudt, Louis M	(b)(4);	Dako Denmark A/S	2-Feb-21
L-011-06/0	Wiestner, Adrian	(b)(6)	Dako Denmark A/S	2-Feb-21
L-011-06/0	Wilson, Wyndham H.		Dako Denmark A/S	2-Feb-21
L-239-15/0	Gazdar, Adi		Dako North America	2-Feb-21
L-239-15/0	Johnson, Bruce E		Dako North America	2-Feb-21
L-239-15/0	Kaye, Frederic J		Dako North America	2-Feb-21
L-239-15/0	Khleif, Samir N.		Dako North America	2-Feb-21
L-239-15/0	Minna, John D.		Dako North America	2-Feb-21
L-239-15/0	Oie, Herbert K		Dako North America	2-Feb-21
L-239-15/0	Pass, Harvey I		Dako North America	2-Feb-21
L-011-06/0	NCI		Dako Denmark A/S	2-Feb-21
L-246-02/1	Allegra, Carmen	(b)(4);	Dako Denmark A/S	2-Feb-21
L-246-02/1	Chabner, Bruce A	(b)(6)	Dako Denmark A/S	2-Feb-21
L-246-02/1	Johnston, Patrick G.		Dako Denmark A/S	2-Feb-21
L-246-02/1	Liang, Chi-Ming		Dako Denmark A/S	2-Feb-21
L-028-21/0	Gazdar, Adi		Rentschler Biopharma SE	2-Feb-21
L-028-21/0	Johnson, Bruce E		Rentschler Biopharma SE	2-Feb-21
L-028-21/0	Kaye, Frederic J		Rentschler Biopharma SE	2-Feb-21
L-028-21/0	Khleif, Samir N.		Rentschler Biopharma SE	2-Feb-21
L-028-21/0	Minna, John D.		Rentschler Biopharma SE	2-Feb-21
L-028-21/0	Oie, Herbert K		Rentschler Biopharma SE	2-Feb-21
L-028-21/0	Pass, Harvey I		Rentschler Biopharma SE	2-Feb-21
L-083-11/0	Waldmann, Thomas A.		AbbVie Biotherapeutics, Inc.	2-Feb-21
<i>Note: L-083-11/0 split between NCI; NINDS</i>				
L-031-16/0	Bonomi, Carrie A.		Shanghai ChemPartner Co., Ltd.	3-Feb-21
L-031-16/0	Borgel, Suzanne D.		Shanghai ChemPartner Co., Ltd.	3-Feb-21
L-031-16/0	Dougherty, Kelly		Shanghai ChemPartner Co., Ltd.	3-Feb-21
L-031-16/0	Hollingshead, Melinda G.		Shanghai ChemPartner Co., Ltd.	3-Feb-21
L-049-21/0	Franchini, Genoveffa		Genezen Laboratories, Inc.	3-Feb-21
L-049-21/0	Kalyanaraman, Vaniambadi S.		Genezen Laboratories, Inc.	3-Feb-21
L-049-21/0	Markham, Phillip D.		Genezen Laboratories, Inc.	3-Feb-21
L-049-21/0	Salahuddin, Syed Z.		Genezen Laboratories, Inc.	3-Feb-21
L-283-19/0	Bagni-Beyer, Rachel K.		Nurix, Inc.	4-Feb-21
L-283-19/0	(b) (4)		Nurix, Inc.	4-Feb-21
L-283-19/0	Holderfield, Matthew T.		Nurix, Inc.	4-Feb-21
L-283-19/0	Soppet, Dan		Nurix, Inc.	4-Feb-21
L-232-14/1	NCI		NanoString Technologies, Inc.	4-Feb-21
<i>Note: L-232-14/1 split between CIT; NCI</i>				
L-259-17/0	NCI		CRISPR Therapeutics AG	4-Feb-21
L-304-19/0	NCI		Intellia Therapeutics, Inc	4-Feb-21
L-071-19/0	Dimitrov, Dimiter S.	(b)(4);	Atara Biotherapeutics Inc.	4-Feb-21
L-071-19/0	Feng, Yang	(b)(6)	Atara Biotherapeutics Inc.	4-Feb-21
L-071-19/0	Pastan, Ira H		Atara Biotherapeutics Inc.	4-Feb-21

L-082-15/0	Gazdar, Adi	(b)(4);	Personal Genome Diagnostics	5-Feb-21	
L-082-15/0	Johnson, Bruce E	(b)(6)	Personal Genome Diagnostics	5-Feb-21	
L-082-15/0	Kaye, Frederic J		Personal Genome Diagnostics	5-Feb-21	
L-082-15/0	Khleif, Samir N.		Personal Genome Diagnostics	5-Feb-21	
L-082-15/0	Minna, John D.		Personal Genome Diagnostics	5-Feb-21	
L-082-15/0	Oie, Herbert K		Personal Genome Diagnostics	5-Feb-21	
L-082-15/0	Pass, Harvey I		Personal Genome Diagnostics	5-Feb-21	
L-093-10/1	Chang, Nancy T.		BioLytical Labs	5-Feb-21	
L-093-10/1	Crowl, Robert		BioLytical Labs	5-Feb-21	
L-093-10/1	Gallo, Robert C.		BioLytical Labs	5-Feb-21	
L-093-10/1	(b) (4)		BioLytical Labs	5-Feb-21	
L-093-10/1	Reddy, E. Premkumar.		BioLytical Labs	5-Feb-21	
L-093-10/1	Shaw, George M		BioLytical Labs	5-Feb-21	
L-093-10/1	Wong-Staal (b) (6)		BioLytical Labs	5-Feb-21	
L-066-09/0	Chang, Nancy T.		Becton Dickinson	8-Feb-21	
L-066-09/0	Fisher, Amanda G.		Becton Dickinson	8-Feb-21	
L-066-09/0	Franchini, Genoveffa		Becton Dickinson	8-Feb-21	
L-066-09/0	Gallo, Robert C.		Becton Dickinson	8-Feb-21	
L-066-09/0	Gartner, Suzanne		Becton Dickinson	8-Feb-21	
L-066-09/0	Hahn, Beatrice		Becton Dickinson	8-Feb-21	
L-066-09/0	(b) (4)		Becton Dickinson	8-Feb-21	
L-066-09/0	Lori, Franco C.		Becton Dickinson	8-Feb-21	
L-066-09/0	Markham, Phillip D.		Becton Dickinson	8-Feb-21	
L-066-09/0	Popovic, Mikulas		Becton Dickinson	8-Feb-21	
L-066-09/0	Reitz, Jr., Marvin S.		Becton Dickinson	8-Feb-21	
L-066-09/0	Sarngadharan, Mangalasseril		Becton Dickinson	8-Feb-21	
L-066-09/0	Shaw, George M		Becton Dickinson	8-Feb-21	
L-066-09/0	Wong-Staal (b) (6)		Becton Dickinson	8-Feb-21	
L-082-21/0	Bonomi, Carrie A.		Sensei Biotherapeutics Inc.,	8-Feb-21	
L-082-21/0	Borgel, Suzanne D.		Sensei Biotherapeutics Inc.,	8-Feb-21	
L-082-21/0	Dougherty, Kelly		Sensei Biotherapeutics Inc.,	8-Feb-21	
L-082-21/0	Hollingshead, Melinda G.		Sensei Biotherapeutics Inc.,	8-Feb-21	
L-062-21/0	Bonomi, Carrie A.		Kezar Life Sciences, Inc.	8-Feb-21	
L-062-21/0	Borgel, Suzanne D.		Kezar Life Sciences, Inc.	8-Feb-21	
L-062-21/0	Dougherty, Kelly		Kezar Life Sciences, Inc.	8-Feb-21	
L-062-21/0	Hollingshead, Melinda G.		Kezar Life Sciences, Inc.	8-Feb-21	
L-271-01/8	Gupta, Shanker Lal		Millennium Pharmaceuticals, Inc.	9-Feb-21	\$
L-271-01/8	(b) (4)		Millennium Pharmaceuticals, Inc.	9-Feb-21	
L-118-20/0	Bonomi, Carrie A.		Nitto BioPharma, Inc.	9-Feb-21	
L-118-20/0	Dougherty, Kelly		Nitto BioPharma, Inc.	9-Feb-21	
L-118-20/0	Hollingshead, Melinda G.		Nitto BioPharma, Inc.	9-Feb-21	
L-165-18/0	Baskar, Sivasubramanian		Exbio Praha	10-Feb-21	
L-165-18/0	Rader, Christoph		Exbio Praha	10-Feb-21	
L-002-20/0	Bonomi, Carrie A.		Oncurious NV	10-Feb-21	
L-002-20/0	Borgel, Suzanne D.		Oncurious NV	10-Feb-21	
L-002-20/0	Dougherty, Kelly		Oncurious NV	10-Feb-21	

L-002-20/0	Hollingshead, Melinda G.	(b)(4); (b)(6)	Oncurious NV	10-Feb-21
L-284-17/0	Bonomi, Carrie A.		Merck Sharp & Dohme Corp.	11-Feb-21
L-284-17/0	Borgel, Suzanne D.		Merck Sharp & Dohme Corp.	11-Feb-21
L-284-17/0	Dougherty, Kelly		Merck Sharp & Dohme Corp.	11-Feb-21
L-284-17/0	Hollingshead, Melinda G.		Merck Sharp & Dohme Corp.	11-Feb-21
L-062-18/0	Bonomi, Carrie A.		Constellation Pharmaceuticals	11-Feb-21
L-062-18/0	Borgel, Suzanne D.		Constellation Pharmaceuticals	11-Feb-21
L-062-18/0	Dougherty, Kelly		Constellation Pharmaceuticals	11-Feb-21
L-062-18/0	Hollingshead, Melinda G.		Constellation Pharmaceuticals	11-Feb-21
L-095-17/1	Bonomi, Carrie A.		Millennium Pharmaceuticals, Inc.	11-Feb-21
L-095-17/1	Borgel, Suzanne D.		Millennium Pharmaceuticals, Inc.	11-Feb-21
L-095-17/1	Dougherty, Kelly		Millennium Pharmaceuticals, Inc.	11-Feb-21
L-095-17/1	Hollingshead, Melinda G.		Millennium Pharmaceuticals, Inc.	11-Feb-21
L-220-19/1	Deniger, Drew		Myst Therapeutics, Inc.	11-Feb-21
L-220-19/1	Lalani, Almin		Myst Therapeutics, Inc.	11-Feb-21
L-220-19/1	Robbins, Paul F		Myst Therapeutics, Inc.	11-Feb-21
L-220-19/1	Rosenberg, Steven A.		Myst Therapeutics, Inc.	11-Feb-21
L-095-19/0	Bonomi, Carrie A.		Elstar Therapeutics	11-Feb-21
L-095-19/0	Dougherty, Kelly		Elstar Therapeutics	11-Feb-21
L-095-19/0	Hollingshead, Melinda G.		Elstar Therapeutics	11-Feb-21
L-043-21/0	Keseling, Beverly G		PTC Therapeutics GT, Inc.	11-Feb-21
L-043-21/0	Warfield, Paul		PTC Therapeutics GT, Inc.	11-Feb-21
L-011-19/0	Gottesman, Michael M.		Amgen, Inc.	11-Feb-21
L-011-19/0	Pastan, Ira H		Amgen, Inc.	11-Feb-21
L-011-19/0	Ueda, Kazumitsu		Amgen, Inc.	11-Feb-21
L-168-17/0	Bera, Tapan K		Amgen, Inc.	11-Feb-21
L-168-17/0	Pastan, Ira H		Amgen, Inc.	11-Feb-21
L-288-19/0	Bonomi, Carrie A.		Merck Sharp & Dohme Corp.	12-Feb-21
L-288-19/0	Dougherty, Kelly		Merck Sharp & Dohme Corp.	12-Feb-21
L-288-19/0	Hollingshead, Melinda G.		Merck Sharp & Dohme Corp.	12-Feb-21
L-239-20/0	Alewine, Christine		Merck Research Laboratories	12-Feb-21
L-239-20/0	Collins, Norman Keith		Merck Research Laboratories	12-Feb-21
L-239-20/0	Guerin, Theresa		Merck Research Laboratories	12-Feb-21
L-239-20/0	Kozlov, Serguei		Merck Research Laboratories	12-Feb-21
L-239-20/0	O'Sullivan, Theresa		Merck Research Laboratories	12-Feb-21
L-239-20/0	Schlomer, Jerome J		Merck Research Laboratories	12-Feb-21
L-239-20/0	Zhang, Xianyu		Merck Research Laboratories	12-Feb-21
L-255-19/0	NCI		BioE Holdings Inc.	12-Feb-21
L-034-21/0	Hamilton, Thomas C	(b)(4);	Celmatix Inc.	12-Feb-21
L-034-21/0	Ozols, Robert F	(b)(6)	Celmatix Inc.	12-Feb-21
L-158-18/2	(b) (4)		Merck Sharp & Dohme Corp.	12-Feb-21
L-158-18/2	Esposito, Dominic		Merck Sharp & Dohme Corp.	12-Feb-21

L-158-18/2	Hopkins, Ralph F.	(b)(4);	Merck Sharp & Dohme Corp.	12-Feb-21
L-158-18/2	Roberts, Veronica Ann	(b)(6)	Merck Sharp & Dohme Corp.	12-Feb-21
L-149-18/2	Esposito, Dominic		Merck Sharp & Dohme Corp.	12-Feb-21
L-149-18/2	Gillette, William K.		Merck Sharp & Dohme Corp.	12-Feb-21
L-149-18/2	Grose, Carissa L.		Merck Sharp & Dohme Corp.	12-Feb-21
L-174-18/0	Bonomi, Carrie A.		Scancell	16-Feb-21
L-174-18/0	Borgel, Suzanne D.		Scancell	16-Feb-21
L-174-18/0	Dougherty, Kelly		Scancell	16-Feb-21
L-174-18/0	Hollingshead, Melinda G.		Scancell	16-Feb-21
L-001-08/1	Austin, Faye C.		Cell Marque Corp	16-Feb-21
L-001-08/1	Colcher, David		Cell Marque Corp	16-Feb-21
L-001-08/1	Hand, Patricia H		Cell Marque Corp	16-Feb-21
L-001-08/1	Nuti, Marianna		Cell Marque Corp	16-Feb-21
L-001-08/1	Schlom, Jeffrey		Cell Marque Corp	16-Feb-21
L-277-19/1	Bagni-Beyer, Rachel K.		Ribometrix Inc	16-Feb-21
L-277-19/1	(b) (4)		Ribometrix Inc	16-Feb-21
L-277-19/1	Holderfield, Matthew T.		Ribometrix Inc	16-Feb-21
L-277-19/1	Soppet, Dan		Ribometrix Inc	16-Feb-21
L-076-10/1	(b) (4)		Scancell Ltd	16-Feb-21
L-076-10/1	Hwu, Patrick		Scancell Ltd	16-Feb-21
L-076-10/1	Kawakami, Yutaka		Scancell Ltd	16-Feb-21
L-076-10/1	Lapointe, Rejean		Scancell Ltd	16-Feb-21
L-076-10/1	Parkhurst, Maria		Scancell Ltd	16-Feb-21
L-076-10/1	Rosenberg, Steven A.		Scancell Ltd	16-Feb-21
L-076-10/1	(b) (4)		Scancell Ltd	16-Feb-21
L-076-10/1	Wang, Rong-fu		Scancell Ltd	16-Feb-21
L-083-11/0	Waldmann, Thomas A.		AbbVie Biotherapeutics, Inc.	17-Feb-21
<i>Note: L-083-11/0 split between NCI; NINDS</i>				
L-069-21/0	Gao, Wei		Cytovia Therapeutics	18-Feb-21
L-069-21/0	Ho, Mitchell		Cytovia Therapeutics	18-Feb-21
L-069-21/0	Li, Dan		Cytovia Therapeutics	18-Feb-21
L-069-21/0	Li, Nan		Cytovia Therapeutics	18-Feb-21
L-069-21/0	Phung, Yen T.		Cytovia Therapeutics	18-Feb-21
L-069-21/0	Zhang, Yifan		Cytovia Therapeutics	18-Feb-21
L-069-21/0	NCI		Cytovia Therapeutics	18-Feb-21
L-069-21/0	Gao, Wei	(b)(4);	Cytovia Therapeutics	18-Feb-21
L-069-21/0	Ho, Mitchell	(b)(6)	Cytovia Therapeutics	18-Feb-21
L-069-21/0	Li, Dan		Cytovia Therapeutics	18-Feb-21
L-069-21/0	Li, Nan		Cytovia Therapeutics	18-Feb-21
L-069-21/0	Phung, Yen T.		Cytovia Therapeutics	18-Feb-21
L-069-21/0	Zhang, Yifan		Cytovia Therapeutics	18-Feb-21
L-203-94/0	Aaronson, Stuart A.		BD Biosciences - BD PharMingen, Inc.	19-Feb-21
L-203-94/0	Jensen, Roy A.		BD Biosciences - BD PharMingen, Inc.	19-Feb-21
L-203-94/0	LaRochelle, William		BD Biosciences - BD PharMingen, Inc.	19-Feb-21
L-203-94/0	Matsui, Toshimitsu		BD Biosciences - BD PharMingen, Inc.	19-Feb-21

L-203-94/0	Pierce, Jacalyn	(b)(4);	BD Biosciences - BD PharMingen, Inc.	19-Feb-21
L-203-94/0	Robbins, Keith	(b)(6)	BD Biosciences - BD PharMingen, Inc.	19-Feb-21
L-009-05/1	Fitzgerald, David J.		Snaofi Pasteur	19-Feb-21
L-009-05/1	Pastan, Ira H		Snaofi Pasteur	19-Feb-21
<i>Note: L-009-05/1 split between NCI; NICHD; NIDDK</i>				
L-135-07/2	Copeland, Neal	(b)(4);	Genentech, Inc	19-Feb-21
L-135-07/2	Costantino, Nina	(b)(6)	Genentech, Inc	19-Feb-21
L-135-07/2	Court, Donald		Genentech, Inc	19-Feb-21
L-135-07/2	Datta, Simanti		Genentech, Inc	19-Feb-21
L-135-07/2	Ellis, Hilary Moyed		Genentech, Inc	19-Feb-21
L-135-07/2	Jenkins Copeland, Nancy A		Genentech, Inc	19-Feb-21
L-135-07/2	Lee, E-Chiang		Genentech, Inc	19-Feb-21
L-135-07/2	Liu, Pentao		Genentech, Inc	19-Feb-21
L-135-07/2	Sharan, Shyam K		Genentech, Inc	19-Feb-21
L-135-07/2	Swaminathan, Srividya		Genentech, Inc	19-Feb-21
L-135-07/2	Warming, Soren		Genentech, Inc	19-Feb-21
L-135-07/2	Yu, Daiguan		Genentech, Inc	19-Feb-21
L-153-10/0	Greiner, John W.		Arko Laboratories LTD	19-Feb-21
L-153-10/0	Schlom, Jeffrey		Arko Laboratories LTD	19-Feb-21
L-153-10/0	Zaharoff, David		Arko Laboratories LTD	19-Feb-21
L-015-84/8	Chang, Nancy T.		Abbott Laboratories	23-Feb-21
L-015-84/8	Crowl, Robert		Abbott Laboratories	23-Feb-21
L-015-84/8	Fisher, Amanda G.		Abbott Laboratories	23-Feb-21
L-015-84/8	Gallo, Robert C.		Abbott Laboratories	23-Feb-21
L-015-84/8	Hahn, Beatrice		Abbott Laboratories	23-Feb-21
L-015-84/8	(b) (4)		Abbott Laboratories	23-Feb-21
L-015-84/8	Popovic, Mikulas		Abbott Laboratories	23-Feb-21
L-015-84/8	Reddy, E. Premkumar.		Abbott Laboratories	23-Feb-21
L-015-84/8	Sarngadharan, Mangalasseril		Abbott Laboratories	23-Feb-21
L-015-84/8	Shaw, George M		Abbott Laboratories	23-Feb-21
L-015-84/8	Wong-Staal (b) (6)		Abbott Laboratories	23-Feb-21
L-264-17/0	Bonomi, Carrie A.		AstraZeneca	23-Feb-21
L-264-17/0	Borgel, Suzanne D.		AstraZeneca	23-Feb-21
L-264-17/0	Dougherty, Kelly		AstraZeneca	23-Feb-21
L-264-17/0	Hollingshead, Melinda G.		AstraZeneca	23-Feb-21
L-133-19/1	Aaronson, Stuart A.		DNAtrix, Inc.	23-Feb-21
L-133-19/1	Giard, Donald		DNAtrix, Inc.	23-Feb-21
L-133-19/1	Parks, Wade P		DNAtrix, Inc.	23-Feb-21
L-054-17/0	Barrett, J Carl		KeraFAST	23-Feb-21
L-054-17/0	Custer, Mary		KeraFAST	23-Feb-21
L-054-17/0	Risinger, John		KeraFAST	23-Feb-21
L-037-17/2	Esposito, Dominic		KeraFAST	23-Feb-21
L-037-17/2	Hopkins, Ralph F.		KeraFAST	23-Feb-21
L-086-17/0	Rader, Christoph		KeraFAST	23-Feb-21
L-039-17/0	Day, Chi-Ping		KeraFAST	23-Feb-21

L-039-17/0	Esposito, Dominic	(b)(4);	KeraFAST	23-Feb-21
L-039-17/0	Merlino, Glenn T.	(b)(6)	KeraFAST	23-Feb-21
L-192-15/2	Burgess, Rebecca C.		KeraFAST	23-Feb-21
L-192-15/2	Misteli, Thomas		KeraFAST	23-Feb-21
L-192-15/2	Roukos, Vasileios		KeraFAST	23-Feb-21
L-192-15/2	Soutoglou, Evi		KeraFAST	23-Feb-21
L-092-21/0	Schlom, Jeffrey		Light Chain Bioscience-Novimmune SA	23-Feb-21
L-092-21/0	Schlom, Jeffrey		Light Chain Bioscience-Novimmune SA	23-Feb-21
L-119-18/0	Reynolds, Della Anne		KeraFAST	23-Feb-21
L-119-18/0	Young, Howard A.		KeraFAST	23-Feb-21
L-226-15/2	Hodge, James W.		KeraFAST	23-Feb-21
L-226-15/2	Schlom, Jeffrey		KeraFAST	23-Feb-21
L-272-16/0	Bonomi, Carrie A.		KeraFAST	23-Feb-21
L-272-16/0	Borgel, Suzanne D.		KeraFAST	23-Feb-21
L-272-16/0	Dougherty, Kelly		KeraFAST	23-Feb-21
L-272-16/0	Hollingshead, Melinda G.		KeraFAST	23-Feb-21
L-201-16/0	Chang, Nancy T.		F. Hoffmann-La Roche Ltd	24-Feb-21
L-201-16/0	Crowl, Robert		F. Hoffmann-La Roche Ltd	24-Feb-21
L-201-16/0	Fisher, Amanda G.		F. Hoffmann-La Roche Ltd	24-Feb-21
L-201-16/0	Gallo, Robert C.		F. Hoffmann-La Roche Ltd	24-Feb-21
L-201-16/0	Hahn, Beatrice		F. Hoffmann-La Roche Ltd	24-Feb-21
L-201-16/0	Popovic, Mikulas		F. Hoffmann-La Roche Ltd	24-Feb-21
L-201-16/0	Reddy, E. Premkumar.		F. Hoffmann-La Roche Ltd	24-Feb-21
L-201-16/0	Sarngadharan, Mangalasseril		F. Hoffmann-La Roche Ltd	24-Feb-21
L-201-16/0	Shaw, George M		F. Hoffmann-La Roche Ltd	24-Feb-21
L-201-16/0	Wong-Staal (b) (6)		F. Hoffmann-La Roche Ltd	24-Feb-21
L-051-17/0	Rudloff, Udo		Riptide Bioscience, Inc	24-Feb-21
L-081-21/0	Hinrichs, Christian S.		Rubius Therapeutics, Inc.	25-Feb-21
L-081-21/0	Rosenberg, Steven A.		Rubius Therapeutics, Inc.	25-Feb-21
L-080-21/0	Hinrichs, Christian S.		Rubius Therapeutics, Inc	25-Feb-21
L-080-21/0	Rosenberg, Steven A.		Rubius Therapeutics, Inc	25-Feb-21
L-229-17/0	Bonomi, Carrie A.		Covance Laboratories Inc.	25-Feb-21
L-229-17/0	Borgel, Suzanne D.		Covance Laboratories Inc.	25-Feb-21
L-229-17/0	Dougherty, Kelly		Covance Laboratories Inc.	25-Feb-21
L-229-17/0	Hollingshead, Melinda G.		Covance Laboratories Inc.	25-Feb-21

NIH Patent Licensing Activities
 NCI
 March 2021

License	Inventor	Inventor Share %	Inventor Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
---------	----------	------------------	-------------------	-----------------	--------------------------------	--------------------------	--------------------	---------------------------	-----------------------	---------------------

L-073-21/0	Figg, William D	(b)(4);	AevisBio, Inc	1-Mar-21
<i>Note: L-073-21/0 split between NCI; NIA</i>				
L-084-11/2	Gazdar, Adi	(b)(6)	Nichirei Biosciences Inc	1-Mar-21
L-084-11/2	Johnson, Bruce E		Nichirei Biosciences Inc	1-Mar-21
L-084-11/2	Kaye, Frederic J		Nichirei Biosciences Inc	1-Mar-21
L-084-11/2	Khleif, Samir N.		Nichirei Biosciences Inc	1-Mar-21
L-084-11/2	Minna, John D.		Nichirei Biosciences Inc	1-Mar-21
L-084-11/2	Oie, Herbert K		Nichirei Biosciences Inc	1-Mar-21
L-084-11/2	Pass, Harvey I		Nichirei Biosciences Inc	1-Mar-21
L-121-19/0	Gottesman, Michael M.		Axcelead Drug Discovery Partners, Inc	1-Mar-21
L-121-19/0	Pastan, Ira H		Axcelead Drug Discovery Partners, Inc	1-Mar-21
L-121-19/0	Ueda, Kazumitsu		Axcelead Drug Discovery Partners, Inc	1-Mar-21
L-116-16/0	Esposito, Dominic		Relay Therapeutics, Inc.	1-Mar-21
L-116-16/0	Gillette, William K.		Relay Therapeutics, Inc.	1-Mar-21
L-116-16/0	Grose, Carissa L.		Relay Therapeutics, Inc.	1-Mar-21
L-122-17/0	Choyke, Peter L		Koninklijke Philips N.V.	1-Mar-21
L-122-17/0	Pinto, Peter A		Koninklijke Philips N.V.	1-Mar-21
L-122-17/0	Turkbey, Ismail B.		Koninklijke Philips N.V.	1-Mar-21
<i>Note: L-122-17/0 split between CC; NCI</i>				
L-093-10/1	Chang, Nancy T.		BioLytical Labs	1-Mar-21
L-093-10/1	Crowl, Robert		BioLytical Labs	1-Mar-21
L-093-10/1	(b) (4)		BioLytical Labs	1-Mar-21
L-093-10/1	Reddy, E. Premkumar.		BioLytical Labs	1-Mar-21
L-093-10/1	Shaw, George M		BioLytical Labs	1-Mar-21
L-026-12/0	Mason, Llewellyn H.		Miltenyi Biotec GMBH	2-Mar-21
L-026-12/0	Ortaldo, John R.		Miltenyi Biotec GMBH	2-Mar-21
L-106-12/0	Jelinek, Ivett		Miltenyi Biotec GMBH	2-Mar-21
L-106-12/0	Segal, David M.		Miltenyi Biotec GMBH	2-Mar-21
L-106-12/0	Wang, Yan		Miltenyi Biotec GMBH	2-Mar-21
L-159-20/0	Bonomi, Carrie A.		Ascendis Pharma A/S	2-Mar-21
L-159-20/0	Borgel, Suzanne D.		Ascendis Pharma A/S	2-Mar-21
L-159-20/0	Dougherty, Kelly		Ascendis Pharma A/S	2-Mar-21
L-159-20/0	Hollingshead, Melinda G.		Ascendis Pharma A/S	2-Mar-21
L-009-18/0	Copeland, Neal		Spybiotech Limited	2-Mar-21
L-009-18/0	Costantino, Nina		Spybiotech Limited	2-Mar-21
L-009-18/0	Court, Donald		Spybiotech Limited	2-Mar-21
L-009-18/0	Ellis, Hilary Moyed		Spybiotech Limited	2-Mar-21
L-009-18/0	Jenkins Copeland, Nancy A		Spybiotech Limited	2-Mar-21
L-009-18/0	Lee, E-Chiang		Spybiotech Limited	2-Mar-21
L-009-18/0	Sharan, Shyam K		Spybiotech Limited	2-Mar-21
L-009-18/0	Swaminathan, Srividya		Spybiotech Limited	2-Mar-21
L-009-18/0	Warming, Soren		Spybiotech Limited	2-Mar-21
L-009-18/0	Yu, Daiguan		Spybiotech Limited	2-Mar-21
L-113-19/1	Gottesman, Michael M.		Pharmaron Beijing Co., LTD	3-Mar-21
L-113-19/1	Pastan, Ira H		Pharmaron Beijing Co., LTD	3-Mar-21

L-113-19/1	Ueda, Kazumitsu	(b)(4); (b)(6)	Pharmaron Beijing Co., LTD	3-Mar-21
L-090-21/0	Bonomi, Carrie A.		Jounce Therapeutics, Inc.	3-Mar-21
L-090-21/0	Dougherty, Kelly		Jounce Therapeutics, Inc.	3-Mar-21
L-090-21/0	Hollingshead, Melinda G.		Jounce Therapeutics, Inc.	3-Mar-21
L-028-18/1	Choyke, Peter L		Scanmed LLC	3-Mar-21
L-028-18/1	Greer, Matthew D.		Scanmed LLC	3-Mar-21
L-028-18/1	Mertan, Francesca		Scanmed LLC	3-Mar-21
L-028-18/1	Sonalee Gaur, Sonia		Scanmed LLC	3-Mar-21
L-028-18/1	Turkbey, Ismail B.		Scanmed LLC	3-Mar-21
<i>Note: L-028-18/1 split between CC; CIT; NCI</i>				
L-024-21/0	Fry, Terry		Vor Biopharma, Inc.	4-Mar-21
L-024-21/0	Qin, Haiying		Vor Biopharma, Inc.	4-Mar-21
L-031-16/0	Bonomi, Carrie A.		Shanghai ChemPartner Co., Ltd.	4-Mar-21
L-031-16/0	Borgel, Suzanne D.		Shanghai ChemPartner Co., Ltd.	4-Mar-21
L-031-16/0	Dougherty, Kelly		Shanghai ChemPartner Co., Ltd.	4-Mar-21
L-031-16/0	Hollingshead, Melinda G.		Shanghai ChemPartner Co., Ltd.	4-Mar-21
L-090-98/1	Allegra, Carmen		NeoMarkers, Inc.	5-Mar-21
L-090-98/1	Chabner, Bruce A		NeoMarkers, Inc.	5-Mar-21
L-090-98/1	(b) (4)		NeoMarkers, Inc.	5-Mar-21
L-090-98/1	Johnston, Patrick G.		NeoMarkers, Inc.	5-Mar-21
L-090-98/1	Kawakami, Yutaka		NeoMarkers, Inc.	5-Mar-21
L-090-98/1	Liang, Chi-Ming		NeoMarkers, Inc.	5-Mar-21
L-090-98/1	Rosenberg, Steven A.		NeoMarkers, Inc.	5-Mar-21
L-090-98/1	Schlom, Jeffrey		NeoMarkers, Inc.	5-Mar-21
L-090-98/1	(b) (4)		NeoMarkers, Inc.	5-Mar-21
L-010-08/1	Hathcock, Karen		BioLegend	5-Mar-21
L-010-08/1	Hodes, Richard J		BioLegend	5-Mar-21
L-010-08/1	Laszlo, Gloria		BioLegend	5-Mar-21
L-020-08/2	Roop, Dennis R.		BioLegend	5-Mar-21
L-020-08/2	Steinert, (b) (6) Peter M.		BioLegend	5-Mar-21
L-020-08/2	Yuspa, Stuart H.		BioLegend	5-Mar-21
L-095-12/0	Baskar, Sivasubramanian		BioLegend	5-Mar-21
L-095-12/0	Rader, Christoph		BioLegend	5-Mar-21
L-198-15/0	Ise, Tomoko		BioLegend	5-Mar-21
L-198-15/0	Nagata, Satoshi		BioLegend	5-Mar-21
L-198-15/0	Pastan, Ira H		BioLegend	5-Mar-21
L-070-12/1	Hathcock, Karen		BioLegend	5-Mar-21
L-070-12/1	Hodes, Richard J		BioLegend	5-Mar-21
L-070-12/1	Laszlo, Gloria		BioLegend	5-Mar-21
L-037-11/1	Jelinek, Ivett		BioLegend	5-Mar-21
L-037-11/1	Segal, David M.		BioLegend	5-Mar-21
L-037-11/1	Wang, Yan		BioLegend	5-Mar-21
L-007-11/2	Onda, Masanori		BioLegend	5-Mar-21

L-007-11/2	Pastan, Ira H	(b)(4); (b)(6)	BioLegend	5-Mar-21
L-042-08/1	Azimi, Nazli		Biolegend	5-Mar-21
L-042-08/1	Dubois, Sigrid		Biolegend	5-Mar-21
L-042-08/1	Goldman, Carolyn		Biolegend	5-Mar-21
L-042-08/1	Lantz, Valerie A		Biolegend	5-Mar-21
L-042-08/1	Mariner Kilbourne, Jennifer		Biolegend	5-Mar-21
L-042-08/1	Waldmann, Thomas A.		Biolegend	5-Mar-21
L-136-09/1	Mason, Llewellyn H.		BioLegend	5-Mar-21
L-136-09/1	Ortaldo, John R.		BioLegend	5-Mar-21
L-073-09/1	Bonner, William M		BioLegend	5-Mar-21
L-073-09/1	Rogakou, Efthimia P		BioLegend	5-Mar-21
L-091-11/0	Chang, Nancy T.		Quest Diagnostics, Inc.	5-Mar-21
L-091-11/0	Fisher, Amanda G.		Quest Diagnostics, Inc.	5-Mar-21
L-091-11/0	Hahn, Beatrice		Quest Diagnostics, Inc.	5-Mar-21
L-091-11/0	(b) (4)		Quest Diagnostics, Inc.	5-Mar-21
L-091-11/0	Popovic, Mikulas		Quest Diagnostics, Inc.	5-Mar-21
L-091-11/0	Sarngadharan, Mangalasseril		Quest Diagnostics, Inc.	5-Mar-21
L-091-11/0	Shaw, George M		Quest Diagnostics, Inc.	5-Mar-21
L-017-89/0	Aaronson, Stuart A.		Bayer AG	5-Mar-21
L-017-89/0	King, Charles R.		Bayer AG	5-Mar-21
L-017-89/0	Kraus, (b) (4) Matthias		Bayer AG	5-Mar-21
L-056-21/0	Bonomi, Carrie A.		Merus N.V.	5-Mar-21
L-056-21/0	Borgel, Suzanne D.		Merus N.V.	5-Mar-21
L-056-21/0	Dougherty, Kelly		Merus N.V.	5-Mar-21
L-056-21/0	Hollingshead, Melinda G.		Merus N.V.	5-Mar-21
L-045-08/1	Bonner, William M		Active Motif	5-Mar-21
L-045-08/1	Rogakou, Efthimia P		Active Motif	5-Mar-21
L-125-13/0	Gazdar, Adi		BioRad	5-Mar-21
L-125-13/0	Johnson, Bruce E		BioRad	5-Mar-21
L-125-13/0	Kaye, Frederic J		BioRad	5-Mar-21
L-125-13/0	Khleif, Samir N.		BioRad	5-Mar-21
L-125-13/0	Minna, John D.		BioRad	5-Mar-21
L-125-13/0	Oie, Herbert K		BioRad	5-Mar-21
L-125-13/0	Pass, Harvey I		BioRad	5-Mar-21
L-004-07/2	Qasba, Pradman		Life Technologies Corp.	5-Mar-21
L-004-07/2	Ramakrishnan, Boopathy		Life Technologies Corp.	5-Mar-21
L-092-09/2	Makrigiannis, Andrew P.		BioLegend, Inc.	5-Mar-21
L-091-04/1	Makrigiannis, Andrew P.		Ebioscience	8-Mar-21
L-049-00/1	Hathcock, Karen		eBioscience, Inc..	8-Mar-21
L-049-00/1	Hodes, Richard J		eBioscience, Inc..	8-Mar-21
L-049-00/1	Laszlo, Gloria		eBioscience, Inc..	8-Mar-21

Note: L-049-00/1 split between NCI; NIAID

(b) (4), (b) (3) (A), (b) (6)

L-114-06/1	Azimi, Nazli	(b)(4);	Affymetrix, Inc.	8-Mar-21
L-114-06/1	Dubois, Sigrid	(b)(6)	Affymetrix, Inc.	8-Mar-21
L-114-06/1	Goldman, Carolyn		Affymetrix, Inc.	8-Mar-21
L-114-06/1	Lantz, Valerie A		Affymetrix, Inc.	8-Mar-21
L-114-06/1	Mariner Kilbourne, Jennifer		Affymetrix, Inc.	8-Mar-21
L-114-06/1	Waldmann, Thomas A.		Affymetrix, Inc.	8-Mar-21
L-049-21/0	Franchini, Genoveffa		Genezen Laboratories, Inc.	8-Mar-21
L-049-21/0	Kalyanaraman, Vaniambadi S.		Genezen Laboratories, Inc.	8-Mar-21
L-049-21/0	Markham, Phillip D.		Genezen Laboratories, Inc.	8-Mar-21
L-049-21/0	Salahuddin, Syed Z.		Genezen Laboratories, Inc.	8-Mar-21
L-097-19/0	Bonomi, Carrie A.		Janssen Research & Development, LLC	9-Mar-21
L-097-19/0	Borgel, Suzanne D.		Janssen Research & Development, LLC	9-Mar-21
L-097-19/0	Dougherty, Kelly		Janssen Research & Development, LLC	9-Mar-21
L-097-19/0	Hollingshead, Melinda G.		Janssen Research & Development, LLC	9-Mar-21
L-200-97/2	Gelboin, (b) (6) Harry		Life Technologies	9-Mar-21
L-200-97/2	Gonzalez, Frank J		Life Technologies	9-Mar-21
L-049-94/2	Cheng, Sheue-Yann		Pierce BioTechnology, Inc	9-Mar-21
L-039-11/0	Onda, Masanori		Rockland Immunochemicals, Inc.	9-Mar-21
L-039-11/0	Pastan, Ira H		Rockland Immunochemicals, Inc.	9-Mar-21
L-090-20/0	NCI		Lyell Immunopharma, Inc.	9-Mar-21
L-111-13/0	Muchmore, Brian P.	(b)(4);	Millipore Sigma	10-Mar-21
L-111-13/0	O'Brien, Thomas R	(b)(6)	Millipore Sigma	10-Mar-21
L-111-13/0	Porter-Gill, Patricia A.		Millipore Sigma	10-Mar-21
L-111-13/0	Prokunina-Olsson, Ludmila		Millipore Sigma	10-Mar-21
<i>Note: L-111-13/0 split between FDA; NCI</i>				
L-023-15/0	Gelboin, (b) (6) Harry		EMD Millipore Corp.	10-Mar-21
L-023-15/0	Krausz, Kristopher W.		EMD Millipore Corp.	10-Mar-21
<i>Note: L-023-15/0 split between NCI; NIEHS</i>				
L-097-15/0	Rubin, Jeffrey S		Millipore Sigma	10-Mar-21
L-097-15/0	Uren, Aykut		Millipore Sigma	10-Mar-21
L-057-16/1	Hollingshead, Melinda G.		Millipore Sigma	10-Mar-21
L-057-16/1	Sausville, Edward		Millipore Sigma	10-Mar-21
L-057-16/1	Snader, Kenneth M		Millipore Sigma	10-Mar-21
L-057-16/1	Vishnuvajjala, B. Rao		Millipore Sigma	10-Mar-21
L-152-13/0	Doroshov, James H.		Millipore Sigma	10-Mar-21
L-152-13/0	Jiang, Guojian		Millipore Sigma	10-Mar-21
L-152-13/0	Roy, Krishnendu K.		Millipore Sigma	10-Mar-21
L-152-13/0	Wu, Yongzhong		Millipore Sigma	10-Mar-21
L-280-17/0	Ise, Tomoko		Millipore Sigma	10-Mar-21
L-280-17/0	Nagata, Satoshi		Millipore Sigma	10-Mar-21
L-280-17/0	Pastan, Ira H		Millipore Sigma	10-Mar-21
L-280-17/0	Xiang, Liaman		Millipore Sigma	10-Mar-21

L-019-18/0	Rosenberg, Steven A.	(b)(4);	Millipore Sigma	10-Mar-21
L-019-18/0	Spiese, Paul J	(b)(6)	Millipore Sigma	10-Mar-21
L-019-18/0	Yang, James C		Millipore Sigma	10-Mar-21
L-031-18/0	Abrams, Scott I		Millipore Sigma	10-Mar-21
L-031-18/0	Schlom, Jeffrey		Millipore Sigma	10-Mar-21
L-012-19/0	Buck, Christopher		EMD Millipore Corporation	10-Mar-21
L-049-01/3	Bustin, Michael		Millipore Sigma	10-Mar-21
L-015-11/0	Landry, Joseph W.		Millipore Sigma	10-Mar-21
L-015-11/0	Wu, Carl		Millipore Sigma	10-Mar-21
L-092-11/0	Giardina, Steven		EMD Chemicals Inc.	10-Mar-21
L-092-11/0	Longo, Dan L		EMD Chemicals Inc.	10-Mar-21
L-092-11/0	Varesio, Luigi		EMD Chemicals Inc.	10-Mar-21
L-097-00/3	Austin, Faye C.		BD Biosciences, PharMingen	11-Mar-21
L-097-00/3	Colcher, David		BD Biosciences, PharMingen	11-Mar-21
L-097-00/3	Hand, Patricia H		BD Biosciences, PharMingen	11-Mar-21
L-097-00/3	Nuti, Marianna		BD Biosciences, PharMingen	11-Mar-21
L-097-00/3	Schlom, Jeffrey		BD Biosciences, PharMingen	11-Mar-21
L-310-19/0	Bonomi, Carrie A.		Regeneron Pharmaceuticals, Inc.	11-Mar-21
L-310-19/0	Borgel, Suzanne D.		Regeneron Pharmaceuticals, Inc.	11-Mar-21
L-310-19/0	Dougherty, Kelly		Regeneron Pharmaceuticals, Inc.	11-Mar-21
L-310-19/0	Hollingshead, Melinda G.		Regeneron Pharmaceuticals, Inc.	11-Mar-21
L-248-19/0	Hinrichs, Christian S.		Regeneron Pharmaceuticals, Inc.	11-Mar-21
L-248-19/0	Jin, Benjamin		Regeneron Pharmaceuticals, Inc.	11-Mar-21
L-059-19/0	Chung-Yin Yang, James		Regeneron Pharmaceuticals, Inc	11-Mar-21
L-059-19/0	Rosenberg, Steven A.		Regeneron Pharmaceuticals, Inc	11-Mar-21
L-059-19/0	Spiese, Paul J		Regeneron Pharmaceuticals, Inc	11-Mar-21
L-271-01/8	(b) (4)		Millennium Pharmaceuticals, Inc.	11-Mar-21
L-154-97/2	Mason, Llewellyn H.		BD Biosciences - BD PharMingen	12-Mar-21
L-154-97/2	Ortaldo, John R.		BD Biosciences - BD PharMingen	12-Mar-21
L-097-00/2	Austin, Faye C.		BD Biosciences - BD PharMingen	12-Mar-21
L-097-00/2	Colcher, David		BD Biosciences - BD PharMingen	12-Mar-21
L-097-00/2	Hand, Patricia H		BD Biosciences - BD PharMingen	12-Mar-21
L-097-00/2	Nuti, Marianna		BD Biosciences - BD PharMingen	12-Mar-21
L-097-00/2	Schlom, Jeffrey		BD Biosciences - BD PharMingen	12-Mar-21
L-100-12/1	Ise, Tomoko		BD Biosciences	12-Mar-21
L-100-12/1	Nagata, Satoshi		BD Biosciences	12-Mar-21
L-100-12/1	Pastan, Ira H		BD Biosciences	12-Mar-21
L-076-16/0	Azimi, Nazli		BD Biosciences	12-Mar-21
L-076-16/0	Dubois, Sigrid		BD Biosciences	12-Mar-21
L-076-16/0	Goldman, Carolyn		BD Biosciences	12-Mar-21
L-076-16/0	Lantz, Valerie A		BD Biosciences	12-Mar-21

L-076-16/0	Mariner Kilbourne, Jennifer	(b)(4);	BD Biosciences	12-Mar-21
L-076-16/0	Waldmann, Thomas A.	(b)(6)	BD Biosciences	12-Mar-21
L-203-94/0	Aaronson, Stuart A.		BD Biosciences - BD PharMingen, Inc.	12-Mar-21
L-203-94/0	Jensen, Roy A.		BD Biosciences - BD PharMingen, Inc.	12-Mar-21
L-203-94/0	LaRochelle, William		BD Biosciences - BD PharMingen, Inc.	12-Mar-21
L-203-94/0	Matsui, Toshimitsu		BD Biosciences - BD PharMingen, Inc.	12-Mar-21
L-203-94/0	Pierce, Jacalyn		BD Biosciences - BD PharMingen, Inc.	12-Mar-21
L-203-94/0	Robbins, Keith		BD Biosciences - BD PharMingen, Inc.	12-Mar-21
L-075-13/0	Franchini, Genoveffa		Wuxi Apptec Inc	12-Mar-21
L-075-13/0	Kalyanaraman, Vaniambadi S.		Wuxi Apptec Inc	12-Mar-21
L-075-13/0	Markham, Phillip D.		Wuxi Apptec Inc	12-Mar-21
L-075-13/0	Salahuddin, Syed Z.		Wuxi Apptec Inc	12-Mar-21
L-242-02/2	Kawakami, Yutaka		Biocare Medical, LLC	12-Mar-21
L-242-02/2	Rosenberg, Steven A.		Biocare Medical, LLC	12-Mar-21
L-166-02/2	Schlom, Jeffrey		Biocare Medical LLC	12-Mar-21
L-095-21/0	Aplan, Peter D.		Daiichi Sankyo Co., Ltd.	15-Mar-21
L-095-21/0	Lin, Ying-Wei		Daiichi Sankyo Co., Ltd.	15-Mar-21
L-095-21/0	Slape, Christopher I.		Daiichi Sankyo Co., Ltd.	15-Mar-21
L-095-21/0	Zhang, ZhenHua		Daiichi Sankyo Co., Ltd.	15-Mar-21
L-051-13/0	Kawamura, Masaru		Cell Signaling Technology Inc	15-Mar-21
L-051-13/0	McVicar, Daniel W		Cell Signaling Technology Inc	15-Mar-21
L-051-13/0	O'Shea, John J.		Cell Signaling Technology Inc	15-Mar-21
<i>Note: L-051-13/0 split between NCI; NHLBI; NIAMS</i>				
L-062-21/0	Bonomi, Carrie A.		Kezar Life Sciences, Inc.	15-Mar-21
L-062-21/0	Borgel, Suzanne D.		Kezar Life Sciences, Inc.	15-Mar-21
L-062-21/0	Dougherty, Kelly		Kezar Life Sciences, Inc.	15-Mar-21
L-062-21/0	Hollingshead, Melinda G.		Kezar Life Sciences, Inc.	15-Mar-21
L-237-20/0	Bonomi, Carrie A.		Phenomic AI	16-Mar-21
L-237-20/0	Borgel, Suzanne D.		Phenomic AI	16-Mar-21
L-237-20/0	Dougherty, Kelly		Phenomic AI	16-Mar-21
L-237-20/0	Hollingshead, Melinda G.		Phenomic AI	16-Mar-21
L-025-07/0	Hollingshead, Melinda G.		Tocris Bioscience	18-Mar-21
L-025-07/0	Sausville, Edward		Tocris Bioscience	18-Mar-21
L-025-07/0	Snader, Kenneth M		Tocris Bioscience	18-Mar-21
L-025-07/0	Vishnuvajjala, B. Rao		Tocris Bioscience	18-Mar-21
L-265-02/0	Marquez, Victor E		Tocris Cookson, Ltd.	18-Mar-21
<i>Note: L-265-02/0 split between NCI; NIDDK</i>				
L-049-91/5	Aaronson, Stuart A.		Biovitium AB (publ)	19-Mar-21
L-049-91/5	Finch, Paul W.		Biovitium AB (publ)	19-Mar-21
L-049-91/5	Rubin, Jeffrey S		Biovitium AB (publ)	19-Mar-21
L-191-20/0	Bonomi, Carrie A.		Actym Therapeutics, Inc	19-Mar-21
L-191-20/0	Borgel, Suzanne D.		Actym Therapeutics, Inc	19-Mar-21
L-191-20/0	Dougherty, Kelly		Actym Therapeutics, Inc	19-Mar-21

L-191-20/0	Hollingshead, Melinda G.	(b)(4); (b)(6)	Actym Therapeutics, Inc	19-Mar-21
L-006-18/0	Austin, Faye C.		Diagnostic BioSystems	19-Mar-21
L-006-18/0	Colcher, David		Diagnostic BioSystems	19-Mar-21
L-006-18/0	Hand, Patricia H		Diagnostic BioSystems	19-Mar-21
L-006-18/0	Nuti, Marianna		Diagnostic BioSystems	19-Mar-21
L-006-18/0	Schlom, Jeffrey		Diagnostic BioSystems	19-Mar-21
L-160-18/0	NCI		Advanced Imaging Projects, LLC (AIP)	20-Mar-21
<i>Note: L-160-18/0 split between CC; NCI</i>				
L-252-17/0	Bonomi, Carrie A.	(b)(4);	Champions Oncology, Inc.	23-Mar-21
L-252-17/0	Borgel, Suzanne D.	(b)(6)	Champions Oncology, Inc.	23-Mar-21
L-252-17/0	Dougherty, Kelly		Champions Oncology, Inc.	23-Mar-21
L-252-17/0	Hollingshead, Melinda G.		Champions Oncology, Inc.	23-Mar-21
L-227-20/0	Gazdar, Adi		Champions Oncology, Inc.	23-Mar-21
L-227-20/0	Johnson, Bruce E		Champions Oncology, Inc.	23-Mar-21
L-227-20/0	Kaye, Frederic J		Champions Oncology, Inc.	23-Mar-21
L-227-20/0	Khleif, Samir N.		Champions Oncology, Inc.	23-Mar-21
L-227-20/0	Minna, John D.		Champions Oncology, Inc.	23-Mar-21
L-227-20/0	Oie, Herbert K		Champions Oncology, Inc.	23-Mar-21
L-227-20/0	Pass, Harvey I		Champions Oncology, Inc.	23-Mar-21
L-206-19/0	Gazdar, Adi		Crown Bioscience Inc.	23-Mar-21
L-206-19/0	Johnson, Bruce E		Crown Bioscience Inc.	23-Mar-21
L-206-19/0	Kaye, Frederic J		Crown Bioscience Inc.	23-Mar-21
L-206-19/0	Khleif, Samir N.		Crown Bioscience Inc.	23-Mar-21
L-206-19/0	Minna, John D.		Crown Bioscience Inc.	23-Mar-21
L-206-19/0	Oie, Herbert K		Crown Bioscience Inc.	23-Mar-21
L-206-19/0	Pass, Harvey I		Crown Bioscience Inc.	23-Mar-21
L-122-20/0	NCI		T-CURX GmbH	24-Mar-21
L-071-21/0	Bonomi, Carrie A.	(b)	Takeda Pharmaceutical Company Ltd	25-Mar-21
L-071-21/0	Dougherty, Kelly	(4);	Takeda Pharmaceutical Company Ltd	25-Mar-21
L-071-21/0	Hollingshead, Melinda G.	(b)(6)	Takeda Pharmaceutical Company Ltd	25-Mar-21
L-071-21/0	Bonomi, Carrie A.		Takeda Pharmaceutical Company Ltd	25-Mar-21
L-071-21/0	Dougherty, Kelly		Takeda Pharmaceutical Company Ltd	25-Mar-21
L-071-21/0	Hollingshead, Melinda G.		Takeda Pharmaceutical Company Ltd	25-Mar-21
L-019-08/0	Ahlers, Jeffrey D		Institut Pasteur	25-Mar-21
L-019-08/0	Berzofsky, Jay A.		Institut Pasteur	25-Mar-21
L-019-08/0	Chang, Nancy T.		Institut Pasteur	25-Mar-21
L-019-08/0	Crowl, Robert		Institut Pasteur	25-Mar-21
L-019-08/0	Fisher, Amanda G.		Institut Pasteur	25-Mar-21
L-019-08/0	Hahn, Beatrice		Institut Pasteur	25-Mar-21
L-019-08/0	Nara, Peter L		Institut Pasteur	25-Mar-21
L-019-08/0	Pendleton, Charles D.		Institut Pasteur	25-Mar-21
L-019-08/0	Popovic, Mikulas		Institut Pasteur	25-Mar-21
L-019-08/0	Reddy, E. Premkumar.		Institut Pasteur	25-Mar-21
L-019-08/0	Sarngadharan, Mangalasseril		Institut Pasteur	25-Mar-21
L-019-08/0	Shaw, George M		Institut Pasteur	25-Mar-21
L-019-08/0	Shirai, Mutsunori		Institut Pasteur	25-Mar-21

Note: L-019-08/0 split between FDA; NCI; NIAID; NIBIB; NIDDK

L-047-21/0	Harmon, Stephanie Anne	(b)(4);	Canon Medical Systems USA, Inc.	25-Mar-21
L-047-21/0	Turkbey, Ismail B.	(b)(6)	Canon Medical Systems USA, Inc.	25-Mar-21
Note: L-047-21/0 split between CC; NCI				
L-029-19/1	Gazdar, Adi		F. Hoffmann-La Roche AG	26-Mar-21
L-029-19/1	Johnson, Bruce E		F. Hoffmann-La Roche AG	26-Mar-21
L-029-19/1	Kaye, Frederic J		F. Hoffmann-La Roche AG	26-Mar-21
L-029-19/1	Khleif, Samir N.		F. Hoffmann-La Roche AG	26-Mar-21
L-029-19/1	Minna, John D.		F. Hoffmann-La Roche AG	26-Mar-21
L-029-19/1	Oie, Herbert K		F. Hoffmann-La Roche AG	26-Mar-21
L-029-19/1	Pass, Harvey I		F. Hoffmann-La Roche AG	26-Mar-21
L-089-19/0	Gazdar, Adi		Guardant Health, Inc.	26-Mar-21
L-089-19/0	Johnson, Bruce E		Guardant Health, Inc.	26-Mar-21
L-089-19/0	Kaye, Frederic J		Guardant Health, Inc.	26-Mar-21
L-089-19/0	Khleif, Samir N.		Guardant Health, Inc.	26-Mar-21
L-089-19/0	Minna, John D.		Guardant Health, Inc.	26-Mar-21
L-089-19/0	Oie, Herbert K		Guardant Health, Inc.	26-Mar-21
L-089-19/0	Pass, Harvey I		Guardant Health, Inc.	26-Mar-21
L-101-20/0	Bonomi, Carrie A.		Carisma Therapeutics Inc.	26-Mar-21
L-101-20/0	Borgel, Suzanne D.		Carisma Therapeutics Inc.	26-Mar-21
L-101-20/0	Dougherty, Kelly		Carisma Therapeutics Inc.	26-Mar-21
L-101-20/0	Hollingshead, Melinda G.		Carisma Therapeutics Inc.	26-Mar-21
L-024-18/0	Gazdar, Adi		SeraCare Life	26-Mar-21
L-024-18/0	Johnson, Bruce E		SeraCare Life	26-Mar-21
L-024-18/0	Kaye, Frederic J		SeraCare Life	26-Mar-21
L-024-18/0	Khleif, Samir N.		SeraCare Life	26-Mar-21
L-024-18/0	Minna, John D.		SeraCare Life	26-Mar-21
L-024-18/0	Oie, Herbert K		SeraCare Life	26-Mar-21
L-024-18/0	Pass, Harvey I		SeraCare Life	26-Mar-21
L-161-19/0	Gazdar, Adi		SearCare Life Sciences	26-Mar-21
L-161-19/0	Johnson, Bruce E		SearCare Life Sciences	26-Mar-21
L-161-19/0	Kaye, Frederic J		SearCare Life Sciences	26-Mar-21
L-161-19/0	Khleif, Samir N.		SearCare Life Sciences	26-Mar-21
L-161-19/0	Minna, John D.		SearCare Life Sciences	26-Mar-21
L-161-19/0	Oie, Herbert K		SearCare Life Sciences	26-Mar-21
L-161-19/0	Pass, Harvey I		SearCare Life Sciences	26-Mar-21
L-161-04/1	(b) (4)		SeraCare Life Sciences, Inc.	26-Mar-21
L-161-04/1	Popovic, Mikulas		SeraCare Life Sciences, Inc.	26-Mar-21
L-161-04/1	Sarngadharan, Mangalasseril		SeraCare Life Sciences, Inc.	26-Mar-21
L-245-94/1	Popovic, Mikulas		SearCare Life Sciences	26-Mar-21
L-245-94/1	Sarngadharan, Mangalasseril		SearCare Life Sciences	26-Mar-21
Note: L-245-94/1 split between NCI; NIAID				
L-039-18/0	Gazdar, Adi		Eurofins Cerep	29-Mar-21
L-039-18/0	Johnson, Bruce E		Eurofins Cerep	29-Mar-21
L-039-18/0	Kaye, Frederic J		Eurofins Cerep	29-Mar-21
L-039-18/0	Khleif, Samir N.		Eurofins Cerep	29-Mar-21

(b) (4), (b) (3) (A), (b) (6)

L-039-18/0	Minna, John D.	(b)(4);	Eurofins Cerep	29-Mar-21
L-039-18/0	Oie, Herbert K	(b)(6)	Eurofins Cerep	29-Mar-21
L-039-18/0	Pass, Harvey I		Eurofins Cerep	29-Mar-21
L-080-93/3	Hathcock, Karen		BD Biosciences - BD PharMingen, Inc.	31-Mar-21
L-080-93/3	Hodes, Richard J		BD Biosciences - BD PharMingen, Inc.	31-Mar-21
L-080-93/3	Laszlo, Gloria		BD Biosciences - BD PharMingen, Inc.	31-Mar-21
L-211-17/0	Kahn, Richard A		Emory University	31-Mar-21
L-023-09/2	Waugh, David		Takeda Pharmaceutical	31-Mar-21
L-100-21/0	Bonomi, Carrie A.		Cellarity, Inc	31-Mar-21
L-100-21/0	Borgel, Suzanne D.		Cellarity, Inc	31-Mar-21
L-100-21/0	Dougherty, Kelly		Cellarity, Inc	31-Mar-21
L-100-21/0	Hollingshead, Melinda G.		Cellarity, Inc	31-Mar-21
L-104-21/0	Franchini, Genoveffa		The Discovery Labs	31-Mar-21
L-104-21/0	Kalyanaraman, Vaniambadi S.		The Discovery Labs	31-Mar-21
L-104-21/0	Markham, Phillip D.		The Discovery Labs	31-Mar-21
L-104-21/0	Salahuddin, Syed Z.		The Discovery Labs	31-Mar-21
L-104-21/0	Franchini, Genoveffa		The Discovery Labs	31-Mar-21
L-104-21/0	Kalyanaraman, Vaniambadi S.		The Discovery Labs	31-Mar-21
L-104-21/0	Markham, Phillip D.		The Discovery Labs	31-Mar-21
L-104-21/0	Salahuddin, Syed Z.		The Discovery Labs	31-Mar-21



\$16,344,754.62	\$1,211,839.87	\$17,556,594.49	\$4,013,213.23	\$13,543,381.26
-----------------	----------------	-----------------	----------------	-----------------

NIH Patent Licensing Activities
NEI
October 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	----------------------	---------------------------	-------------------------	---------------------

NIH Patent Licensing Activities
NEI
November 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
NEI
December 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities

NEI
January 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	----------------------	---------------------------	-------------------------	---------------------

NIH Patent Licensing Activities
NEI
February 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
L-088-21/0	Bharti, Kapil	(b)(4);	Connectyx Technologies Holdings Group	16-Feb-21						(b) (4), (b) (3) (A), (b) (6)
L-088-21/0	Clore-Gronenborn, Katharina	(b)(6)	Connectyx Technologies Holdings Group	16-Feb-21						
L-088-21/0	Miyagishima, Kiyoharu		Connectyx Technologies Holdings Group	16-Feb-21						
L-088-21/0	NEI		Connectyx Technologies Holdings Group	16-Feb-21						

NIH Patent Licensing Activities
NEI
March 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
L-230-02/1	Bunce, George E.	(b)(4);	Bausch & Lomb	1-Mar-21						(b) (4), (b) (3) (A), (b) (6)
L-230-02/1	Ferris III, Frederick L.	(b)(6)	Bausch & Lomb	1-Mar-21						
L-230-02/1	Kinoshita, (b) (6) Jin H		Bausch & Lomb	1-Mar-21						
L-230-02/1	Smith, James Cecil		Bausch & Lomb	1-Mar-21						
L-050-21/0	Amaral, Juan A		CellRay, LLC	4-Mar-21						
L-050-21/0	Bharti, Kapil		CellRay, LLC	4-Mar-21						
L-050-21/0	Charles, Steven Thomas		CellRay, LLC	4-Mar-21						
L-050-21/0	Davis, Janine A		CellRay, LLC	4-Mar-21						
L-050-21/0	Hotaling, Nathan		CellRay, LLC	4-Mar-21						
L-050-21/0	Khristov, Vladimir R.		CellRay, LLC	4-Mar-21						
L-050-21/0	Maminishkis, Arvydas		CellRay, LLC	4-Mar-21						
L-050-21/0	NIST		CellRay, LLC	4-Mar-21						
<i>Note: L-050-21/0 split between NEI; NINDS</i>										
L-168-15/0	Li, Tiansen		EMD Millipore Corp.	10-Mar-21						
L-168-15/0	Swaroop, Anand		EMD Millipore Corp.	10-Mar-21						
L-139-20/0	Chen, Yu Holly		EditForce, Inc.	15-Mar-21						
L-139-20/0	English, Milton A		EditForce, Inc.	15-Mar-21						
L-139-20/0	Shimada-Ishill, Hiroko		EditForce, Inc.	15-Mar-21						
L-139-20/0	Swaroop, Anand		EditForce, Inc.	15-Mar-21						

\$4,261,113.55 \$8,500.00 \$4,269,613.55 \$612,714.26 \$3,656,899.29

NIH Patent Licensing Activities

NHGRI
October 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-002-21/0	Nicoli, Elena-Raluca	(b)(4);	GT Gain Therapeutics	15-Oct-20						(b) (4), (b) (3) (A), (b) (6)
L-002-21/0	Tifft, Cynthia J.	(b)(6)	GT Gain Therapeutics	15-Oct-20						
L-002-21/0	Nicoli, Elena-Raluca		GT Gain Therapeutics	15-Oct-20						
L-002-21/0	Tifft, Cynthia J.		GT Gain Therapeutics	15-Oct-20						

NIH Patent Licensing Activities
NHGRI
November 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
L-006-21/0	Mijares, Lilia A.	(b)(4);	Federation Bio	9-Nov-20						(b) (4), (b) (3) (A), (b) (6)
L-006-21/0	Segre, Julia A	(b)(6)	Federation Bio	9-Nov-20						
<i>Note: L-006-21/0 split between NHGRI; NIAMS</i>										
L-006-21/0	Mijares, Lilia A.		Federation Bio	9-Nov-20						
L-006-21/0	Segre, Julia A		Federation Bio	9-Nov-20						
<i>Note: L-006-21/0 split between NHGRI; NIAMS</i>										
L-006-21/0	Mijares, Lilia A.		Federation Bio	9-Nov-20						
L-006-21/0	Segre, Julia A		Federation Bio	9-Nov-20						
<i>Note: L-006-21/0 split between NHGRI; NIAMS</i>										
L-183-14/0	Gispert-Sanchez, Suzana		UCSF	17-Nov-20						
L-183-14/0	Nussbaum, Robert L.		UCSF	17-Nov-20						

NIH Patent Licensing Activities
NHGRI
December 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
L-146-18/2	Gahl, William A.	(b)(4);	Leadiant Biosciences	10-Dec-20						(b) (4), (b) (3) (A), (b) (6)
L-146-18/2	Huizing, Marjan	(b)(6)	Leadiant Biosciences	10-Dec-20						
L-146-18/2	Klootwijk, Enriko D		Leadiant Biosciences	10-Dec-20						
L-146-18/2	Manoli, Eirini		Leadiant Biosciences	10-Dec-20						
L-017-21/0	Chandler, Randy J.		Genespire	17-Dec-20						
L-017-21/0	Manoli, Eirini		Genespire	17-Dec-20						
L-017-21/0	Venditti, Charles P.		Genespire	17-Dec-20						
L-017-21/0	Chandler, Randy J.		Genespire	17-Dec-20						
L-017-21/0	Manoli, Eirini		Genespire	17-Dec-20						
L-017-21/0	Venditti, Charles P.		Genespire	17-Dec-20						

(b) (4), (b) (3) (A), (b) (6)

L-017-21/0	Chandler, Randy J.	(b)(4);	Genespire	17-Dec-20
L-017-21/0	Manoli, Eirini	(b)(6)	Genespire	17-Dec-20
L-017-21/0	Venditti, Charles P.		Genespire	17-Dec-20
L-055-15/1	NHGRI		Lysosomal Therapeutics, Inc.	23-Dec-20
<i>Note: L-055-15/1 split between NCATS; NHGRI</i>				
L-216-18/0	Chandler, Randy J.	(b)(4);	StrideBio	23-Dec-20
L-216-18/0	Pavan, William J	(b)(6)	StrideBio	23-Dec-20
L-216-18/0	Venditti, Charles P.		StrideBio	23-Dec-20
L-186-16/0	Chandler, Randy J.		Galyatech LLC	29-Dec-20
L-186-16/0	Pavan, William J		Galyatech LLC	29-Dec-20
L-186-16/0	Venditti, Charles P.		Galyatech LLC	29-Dec-20

NIH Patent Licensing Activities
NHGRI
January 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
L-002-21/0	Tiftt, Cynthia J.	(b)(6)	GT Gain Therapeutics	7-Jan-21						
L-204-18/0	Chandler, Randy J.		Chameleon Biosciences Inc.	12-Jan-21						
L-204-18/0	Pavan, William J		Chameleon Biosciences Inc.	12-Jan-21						
L-204-18/0	Venditti, Charles P.		Chameleon Biosciences Inc.	12-Jan-21						
L-057-15/0	NHGRI		Vtesse, Inc	19-Jan-21						
<i>Note: L-057-15/0 split between NCATS; NHGRI</i>										

NIH Patent Licensing Activities
NHGRI
February 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
L-017-21/0	Manoli, Eirini	(b)(6)	Genespire	1-Feb-21						
L-017-21/0	Venditti, Charles P.		Genespire	1-Feb-21						
L-045-21/1	Chandler, Randy J.		Novartis Gene Therapies, Inc	1-Feb-21						
L-045-21/1	Pavan, William J		Novartis Gene Therapies, Inc	1-Feb-21						
L-045-21/1	Venditti, Charles P.		Novartis Gene Therapies, Inc	1-Feb-21						
L-244-17/0	Chandler, Randy J.		Logic Bio Therapeutics, Inc.	4-Feb-21						
L-244-17/0	Venditti, Charles P.		Logic Bio Therapeutics, Inc.	4-Feb-21						
L-069-19/0	Chandler, Randy J.		LogicBio Therapeutics, Inc.	4-Feb-21						
L-069-19/0	Venditti, Charles P.		LogicBio Therapeutics, Inc.	4-Feb-21						

(b) (4), (b) (3) (A), (b) (6)

L-175-20/0	Capell, Brian C	(b)(4);	Progeria Research Foundation	11-Feb-21
L-175-20/0	Collins, Francis S	(b)(6)	Progeria Research Foundation	11-Feb-21
L-175-20/0	(b) (4)		Progeria Research Foundation	11-Feb-21
L-175-20/0			Progeria Research Foundation	11-Feb-21

NIH Patent Licensing Activities
NHGRI
March 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
L-091-21/0	Chandler, Randy J.	(b)(4);	LogicBio Therapeutics, Inc	1-Mar-21						(b) (4), (b) (3) (A), (b) (6)
L-091-21/0	Smith, Stephanie N.	(b)(6)	LogicBio Therapeutics, Inc	1-Mar-21						
L-091-21/0	Venditti, Charles P.		LogicBio Therapeutics, Inc	1-Mar-21						
L-116-13/0	NHGRI		EMD Millipore Corp.	10-Mar-21						
<i>Note: L-116-13/0 split between NCATS; NHGRI</i>										
L-084-21/0	Chandler, Randy J.	(b)(4);	Selecta Biosciences, Inc.	11-Mar-21						
L-084-21/0	Manoli, Eirini	(b)(6)	Selecta Biosciences, Inc.	11-Mar-21						
L-084-21/0	Venditti, Charles P.		Selecta Biosciences, Inc.	11-Mar-21						
L-084-21/0	Chandler, Randy J.		Selecta Biosciences, Inc.	11-Mar-21						
L-084-21/0	Manoli, Eirini		Selecta Biosciences, Inc.	11-Mar-21						
L-084-21/0	Venditti, Charles P.		Selecta Biosciences, Inc.	11-Mar-21						
L-091-21/0	Chandler, Randy J.		LogicBio Therapeutics, Inc	22-Mar-21						
L-091-21/0	Smith, Stephanie N.		LogicBio Therapeutics, Inc	22-Mar-21						
L-091-21/0	Venditti, Charles P.		LogicBio Therapeutics, Inc	22-Mar-21						
L-167-19/0	Chandler, Randy J.		Agios Pharmaceuticals, Inc	25-Mar-21						
L-167-19/0	Manoli, Eirini		Agios Pharmaceuticals, Inc	25-Mar-21						
L-167-19/0	Venditti, Charles P.		Agios Pharmaceuticals, Inc	25-Mar-21						
					\$2,462,213.64	\$13,221.24	\$2,475,434.88		\$801,712.66	\$1,673,722.22

NIH Patent Licensing Activities
NHLBI
October 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-105-17/0	Chiorini, John A.	(b)(4);	Genzyme Corporation	1-Oct-20						(b) (4), (b) (3) (A), (b) (6)
L-105-17/0	Kotin, Robert M.	(b)(6)	Genzyme Corporation	1-Oct-20						
L-105-17/0	NHLBI		Genzyme Corporation	1-Oct-20						
L-063-15/0	NHLBI		BioMarin Pharma.	1-Oct-20						
L-105-17/0	Chiorini, John A.	(b)(4);	Genzyme Corporation	1-Oct-20						

L-105-17/0	Kotin, Robert M.	(b)(4); (b)(6)	Genzyme Corporation	1-Oct-20
L-097-08/4	Knepper, Mark A	(b)(6)	Novus Biologicals, LLC	1-Oct-20
L-327-14/0	NHLBI		Voyager Therapeutics	8-Oct-20
L-058-14/0	Chiorini, John A.	(b)(4);	Spark Therapeutics Ireland Ltd	14-Oct-20
L-058-14/0	Kotin, Robert M.	(b)(6)	Spark Therapeutics Ireland Ltd	14-Oct-20
L-246-14/2	Nirenberg, (b)(6) Marshall		BIOLEGEND	21-Oct-20
L-246-14/2	Walsh, Frank		BIOLEGEND	21-Oct-20
<i>Note: L-246-14/2 split between NHLBI; NIAID</i>				
L-116-11/3	Chiorini, John A.		uniQure B.V.	28-Oct-20
L-116-11/3	Kotin, Robert M.		uniQure B.V.	28-Oct-20
L-116-11/3	(b)(4)		uniQure B.V.	28-Oct-20
<i>Note: L-116-11/3 split between NHLBI; NIDCR</i>				
L-264-18/0	Arai, Andrew Ernest		Circle Cardiovascular Imaging Inc.	28-Oct-20
L-264-18/0	Hsu, Li - Yueh		Circle Cardiovascular Imaging Inc.	28-Oct-20
L-264-18/0	Jacobs, Matthew James		Circle Cardiovascular Imaging Inc.	28-Oct-20
L-098-18/3	NHLBI		T-Cure Bioscience	30-Oct-20



NIH Patent Licensing Activities
NHLBI
November 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
L-003-21/0	Ding, Chuan-Tian	(b)(4);	Frontera Therapeutics, Inc	12-Nov-20						(b) (4), (b) (3) (A), (b) (6)
L-003-21/0	Kotin, Robert M.	(b)(6)	Frontera Therapeutics, Inc	12-Nov-20						
L-003-21/0	Smith, Richard H.		Frontera Therapeutics, Inc	12-Nov-20						
L-003-21/0	Urabe, Masashi		Frontera Therapeutics, Inc	12-Nov-20						
L-143-07/2	Cannon, Richard O.		Hope Pharmaceuticals	16-Nov-20						
<i>Note: L-143-07/2 split between CC; NHLBI; NIDDK</i>										
L-159-07/2	Cannon, Richard O.	(b)(4);	Hope Pharmaceuticals	16-Nov-20						
L-159-07/2	Gladwin, Mark T.	(b)(6)	Hope Pharmaceuticals	16-Nov-20						
L-159-07/2	Hunter, Christian J		Hope Pharmaceuticals	16-Nov-20						
L-159-07/2	(b)(4)		Hope Pharmaceuticals	16-Nov-20						
L-159-07/2	(b)(4)		Hope Pharmaceuticals	16-Nov-20						
L-159-07/2	(b)(4)		Hope Pharmaceuticals	16-Nov-20						
L-159-07/2	(b)(4)		Hope Pharmaceuticals	16-Nov-20						
<i>Note: L-159-07/2 split between CC; NHLBI; NIDDK; NINDS</i>										
L-098-18/3	NHLBI		T-Cure Bioscience	18-Nov-20						
L-029-18/0	NHLBI		Abeona Therapeutics Inc.	18-Nov-20						
L-029-18/0	Ding, Chuan-Tian	(b)(4);	Abeona Therapeutics Inc.	18-Nov-20						
L-029-18/0	Kotin, Robert M.	(b)(6)	Abeona Therapeutics Inc.	18-Nov-20						

L-029-18/0	Urabe, Masashi	(b)(4); (b)(6)	Abeona Therapeutics Inc.	18-Nov-20
L-096-16/1	Finkel, Toren		Genentech, Inc.	20-Nov-20
L-106-20/0	Finkel, Toren		H. Lundbeck A/S	20-Nov-20
L-264-18/0	Arai, Andrew Ernest		Circle Cardiovascular Imaging Inc.	23-Nov-20
L-264-18/0	Hsu, Li - Yueh		Circle Cardiovascular Imaging Inc.	23-Nov-20
L-264-18/0	Jacobs, Matthew James		Circle Cardiovascular Imaging Inc.	23-Nov-20
L-107-07/3	Ding, Chuan-Tian		UniQure B.V.	25-Nov-20
L-107-07/3	Kotin, Robert M.		UniQure B.V.	25-Nov-20
L-107-07/3	Urabe, Masashi		UniQure B.V.	25-Nov-20

(b) (4), (b) (3) (A), (b) (6)

**NIH Patent Licensing Activities
NHLBI
December 2020**

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
L-104-18/0	Ding, Chuan-Tian	(b)(4);	LakePharma	1-Dec-20						(b) (4), (b) (3) (A), (b) (6)
L-104-18/0	Kotin, Robert M.	(b)(6)	LakePharma	1-Dec-20						
L-104-18/0	Urabe, Masashi		LakePharma	1-Dec-20						
L-058-14/0	Chiorini, John A.		Spark Therapeutics Ireland Ltd	2-Dec-20						
L-058-14/0	Kotin, Robert M.		Spark Therapeutics Ireland Ltd	2-Dec-20						
L-127-15/0	Leonard, Warren J.		Stanford University Medical Center	4-Dec-20						
L-127-15/0	Mitra, Suman		Stanford University Medical Center	4-Dec-20						
L-327-14/0	Ding, Chuan-Tian		Voyager Therapeutics	10-Dec-20						
L-327-14/0	Kotin, Robert M.		Voyager Therapeutics	10-Dec-20						
L-327-14/0	Smith, Richard H.		Voyager Therapeutics	10-Dec-20						
L-327-14/0	Urabe, Masashi		Voyager Therapeutics	10-Dec-20						
L-116-11/3	Chiorini, John A.		uniQure B.V.	11-Dec-20						
L-116-11/3	Kotin, Robert M.		uniQure B.V.	11-Dec-20						
L-116-11/3	(b) (4)		uniQure B.V.	11-Dec-20						
<i>Note: L-116-11/3 split between NHLBI; NIDCR</i>										
L-042-06/2	Aletras, Anthony Homer	(b)(4);	Siemens AG, Med. Solutions	14-Dec-20						
L-042-06/2	Kellman, Peter	(b)(6)	Siemens AG, Med. Solutions	14-Dec-20						
L-042-06/2	McVeigh, Elliott R		Siemens AG, Med. Solutions	14-Dec-20						
L-042-06/2	Wen, Han		Siemens AG, Med. Solutions	14-Dec-20						
L-243-16/0	Boehm, Manfred		StemCell Technologies Inc.	14-Dec-20						
L-243-16/0	Chen, Guibin		StemCell Technologies Inc.	14-Dec-20						
L-243-16/0	Larochelle, Andre		StemCell Technologies Inc.	14-Dec-20						
<i>Note: L-243-16/0 split between NHLBI; NIAMS</i>										
L-181-17/0	Ding, Chuan-Tian		Esteve Pharmaceuticals	14-Dec-20						
L-181-17/0	Kotin, Robert M.		Esteve Pharmaceuticals	14-Dec-20						
L-181-17/0	Urabe, Masashi		Esteve Pharmaceuticals	14-Dec-20						

L-042-06/2	NHLBI	Siemens AG, Med. Solutions	21-Dec-20	(b) (4), (b) (3) (A), (b) (6)	
L-010-14/0	Cecchini, Sylvain	(b)(4); Life Technology Corp. (BAC BV)	21-Dec-20		
L-010-14/0	Kotin, Robert M.	(b)(6) Life Technology Corp. (BAC BV)	21-Dec-20		
L-010-14/0	Smith, Richard H.	Life Technology Corp. (BAC BV)	21-Dec-20		
L-214-18/0	Combs, Christian A.	Yokogawa Electric Corporation	28-Dec-20		
<i>Note: L-214-18/0 split between NHLBI; NIBIB</i>					
L-353-14/0	Chiorini, John A.	Takara Bio. Inc.	28-Dec-20		
L-353-14/0	Kotin, Robert M.	Takara Bio. Inc.	28-Dec-20		
L-246-14/2	Nirenberg (b) (6) Marshall	BIOLEGEND	30-Dec-20		
L-246-14/2	Walsh, Frank	BIOLEGEND	30-Dec-20		
<i>Note: L-246-14/2 split between NHLBI; NIAID</i>					
L-275-18/0	Amar, Marcelo A.	Hartis-Pharma Sarl	30-Dec-20		
L-275-18/0	Brewer, H. Bryan	Hartis-Pharma Sarl	30-Dec-20		
L-275-18/0	Demosky, Stephen J.	Hartis-Pharma Sarl	30-Dec-20		
L-275-18/0	Neufeld, Edward B.	Hartis-Pharma Sarl	30-Dec-20		
L-275-18/0	Remaley, Alan T.	Hartis-Pharma Sarl	30-Dec-20		
L-275-18/0	Stonik, John A.	Hartis-Pharma Sarl	30-Dec-20		
L-275-18/0	Thomas, Fairwell	Hartis-Pharma Sarl	30-Dec-20		

NIH Patent Licensing Activities
NHLBI
January 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
L-029-12/0	Derbyshire, John Andrew	(b)(4);	Koninklijke Philips Electronics NV	1-Jan-21						(b) (4), (b) (3) (A), (b) (6)
L-029-12/0	(b) (4)	(b)(6)	Koninklijke Philips Electronics NV	1-Jan-21						
L-029-12/0	McVeigh, Elliott R		Koninklijke Philips Electronics NV	1-Jan-21						
L-029-12/0	Nezafat, Reza		Koninklijke Philips Electronics NV	1-Jan-21						
L-105-12/0	Ding, Chuan-Tian		Genethon	4-Jan-21						
L-105-12/0	Kotin, Robert M.		Genethon	4-Jan-21						
L-105-12/0	Urabe, Masashi		Genethon	4-Jan-21						
L-199-18/1	(b) (4)		Solid Biosciences	4-Jan-21						
L-199-18/1	Kotin, Robert M.		Solid Biosciences	4-Jan-21						
L-199-18/1	Li, Lina		Solid Biosciences	4-Jan-21						
L-158-17/0	Yang, Yanqin		Mokobio Life Science Group, Inc.	5-Jan-21						
L-158-17/0	Zhu, Jun		Mokobio Life Science Group, Inc.	5-Jan-21						
<i>Note: L-158-17/0 split between NCI; NHLBI</i>										
L-097-08/4	Knepper, Mark A		Novus Biologicals, LLC	6-Jan-21						
L-125-12/0	Nirenberg, (b) (6) Marshall		BD Biosciences	11-Jan-21						
L-125-12/0	Walsh, Frank		BD Biosciences	11-Jan-21						
<i>Note: L-125-12/0 split between NHLBI; NIAID</i>										

(b) (4), (b) (3) (A), (b) (6)

L-116-11/3	NHLBI		uniQure B.V.	19-Jan-21
<i>Note: L-116-11/3 split between NHLBI; NIDCR</i>				
L-098-18/3	Cherkasova, Elena A.	(b)(4);	T-Cure Bioscience	21-Jan-21
L-098-18/3	Childs, Richard W.	(b)(6)	T-Cure Bioscience	21-Jan-21
L-098-18/3	(b) (4)		T-Cure Bioscience	21-Jan-21
L-023-21/0	Carlsten, Mattias CV		ONK Therapeutics	25-Jan-21
L-023-21/0	Childs, Richard W.		ONK Therapeutics	25-Jan-21

NIH Patent Licensing Activities
NHLBI
February 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
L-145-19/0	Cannon, Richard O.	(b)(4);	Globin Solutions, Inc	1-Feb-21						(b) (4), (b) (3) (A), (b) (6)
L-145-19/0	Gladwin, Mark T.	(b)(6)	Globin Solutions, Inc	1-Feb-21						
L-145-19/0	Hunter, Christian J		Globin Solutions, Inc	1-Feb-21						
L-145-19/0	(b) (4)		Globin Solutions, Inc	1-Feb-21						
L-145-19/0			Globin Solutions, Inc	1-Feb-21						
L-145-19/0			Globin Solutions, Inc	1-Feb-21						
L-145-19/0			Globin Solutions, Inc	1-Feb-21						
<i>Note: L-145-19/0 split between CC; NHLBI; NIDDK; NINDS</i>										
L-120-12/2	Ding, Chuan-Tian	(b)(4);	Sangamo Biosciences	1-Feb-21						
L-120-12/2	Kotin, Robert M.	(b)(6)	Sangamo Biosciences	1-Feb-21						
L-120-12/2	Urabe, Masashi		Sangamo Biosciences	1-Feb-21						
L-105-17/0	Chiorini, John A.		Genzyme Corporation	2-Feb-21						
L-105-17/0	Kotin, Robert M.		Genzyme Corporation	2-Feb-21						
L-097-08/4	Knepper, Mark A		Novus Biologicals, LLC	4-Feb-21						
L-223-20/0	Chiorini, John A.		Cellular Biomedicine Group, Inc	8-Feb-21						
L-223-20/0	Kotin, Robert M.		Cellular Biomedicine Group, Inc	8-Feb-21						
L-063-15/0	Ding, Chuan-Tian		BioMarin Pharma.	11-Feb-21						
L-063-15/0	Kotin, Robert M.		BioMarin Pharma.	11-Feb-21						
L-063-15/0	Urabe, Masashi		BioMarin Pharma.	11-Feb-21						
L-170-15/0	Chiorini, John A.		BioMarin Pharmaceuticals, Inc.	11-Feb-21						
L-170-15/0	Kotin, Robert M.		BioMarin Pharmaceuticals, Inc.	11-Feb-21						
L-242-20/0	Ding, Chuan-Tian		Amicus Therapeutics, Inc.	12-Feb-21						
L-242-20/0	Kotin, Robert M.		Amicus Therapeutics, Inc.	12-Feb-21						
L-242-20/0	Smith, Richard H.		Amicus Therapeutics, Inc.	12-Feb-21						
L-242-20/0	Urabe, Masashi		Amicus Therapeutics, Inc.	12-Feb-21						
L-104-18/0	Ding, Chuan-Tian		LakePharma	18-Feb-21						
L-104-18/0	Kotin, Robert M.		LakePharma	18-Feb-21						
L-104-18/0	Urabe, Masashi		LakePharma	18-Feb-21						

(b) (4), (b) (3) (A), (b) (6)

L-264-18/0	Arai, Andrew Ernest	(b)(4);	Circle Cardiovascular Imaging Inc.	19-Feb-21
L-264-18/0	Hsu, Li - Yueh	(b)(6)	Circle Cardiovascular Imaging Inc.	19-Feb-21
L-264-18/0	Jacobs, Matthew James		Circle Cardiovascular Imaging Inc.	19-Feb-21
L-264-18/0	Arai, Andrew Ernest		Circle Cardiovascular Imaging Inc.	19-Feb-21
L-264-18/0	Hsu, Li - Yueh		Circle Cardiovascular Imaging Inc.	19-Feb-21
L-264-18/0	Jacobs, Matthew James		Circle Cardiovascular Imaging Inc.	19-Feb-21
L-029-18/0	Ding, Chuan-Tian		Abeona Therapeutics Inc.	22-Feb-21
L-029-18/0	Kotin, Robert M.		Abeona Therapeutics Inc.	22-Feb-21
L-029-18/0	Urabe, Masashi		Abeona Therapeutics Inc.	22-Feb-21
L-243-16/0	Boehm, Manfred		StemCell Technologies Inc.	23-Feb-21
L-243-16/0	Chen, Guibin		StemCell Technologies Inc.	23-Feb-21
L-243-16/0	Larochelle, Andre		StemCell Technologies Inc.	23-Feb-21

Note: L-243-16/0 split between NHLBI; NIAMS

NIH Patent Licensing Activities
NHLBI
March 2021

License	Inventor	Inventor Share %	Inventor Licensee	Date of Deposit	% of Sales/Ann. Min	Patent	Total March	License Cumulative	Inventor Awards	Net Remaining to
L-029-12/0	Derbyshire, John Andrew	(b)(4);	Koninklijke Philips Electronics NV	1-Mar-21						(b) (4), (b) (3) (A), (b) (6)
L-029-12/0	(b) (4)	(b)(6)	Koninklijke Philips Electronics NV	1-Mar-21						
L-029-12/0	McVeigh, Elliott R		Koninklijke Philips Electronics NV	1-Mar-21						
L-029-12/0	Nezafat, Reza		Koninklijke Philips Electronics NV	1-Mar-21						
L-209-17/0	NHLBI		General Electric Co.	1-Mar-21						
L-044-08/1	Nirenberg (b) (6) Marshall	(b)(4);	Miltenyi Biotec GMBH	2-Mar-21						
L-044-08/1	Walsh, Frank	(b)(6)	Miltenyi Biotec GMBH	2-Mar-21						
Note: L-044-08/1 split between NHLBI; NIAID										
L-209-17/0	Derbyshire, John Andrew		General Electric Co.	2-Mar-21						
L-209-17/0	(b) (4)		General Electric Co.	2-Mar-21						
L-209-17/0	McVeigh, Elliott R		General Electric Co.	2-Mar-21						
L-209-17/0	Nezafat, Reza		General Electric Co.	2-Mar-21						
L-228-96/3	Adelstein, Robert		Biolegend, Inc.	5-Mar-21						
L-228-96/3	Kelley, Christine A		Biolegend, Inc.	5-Mar-21						
L-088-12/0	Chiorini, John A.		Sangamo BioSciences Inc	5-Mar-21						
L-088-12/0	Kotin, Robert M.		Sangamo BioSciences Inc	5-Mar-21						
L-088-12/0	(b) (4)		Sangamo BioSciences Inc	5-Mar-21						
Note: L-088-12/0 split between NHLBI; NIDCR										
L-102-07/1	Nirenberg (b) (6) Marshall		Life Technologies Corporation	9-Mar-21						
L-102-07/1	Walsh, Frank		Life Technologies Corporation	9-Mar-21						
Note: L-102-07/1 split between NHLBI; NIAID										
L-010-14/0	Cecchini, Sylvain		Life Technology Corp. (BAC BV)	9-Mar-21						

(b) (4), (b) (3) (A), (b) (6)

L-010-14/0	Kotin, Robert M.	(b)(4);	Life Technology Corp. (BAC BV)	9-Mar-21
L-010-14/0	Smith, Richard H.	(b)(6)	Life Technology Corp. (BAC BV)	9-Mar-21
L-140-18/0	Haque, Nazmul		Millipore Sigma	10-Mar-21
L-140-18/0	Hogg, John Robert		Millipore Sigma	10-Mar-21
L-052-96/3	Leonard, Warren J.		Millipore Sigma	10-Mar-21
L-052-96/3	Lin, Jian-Xin		Millipore Sigma	10-Mar-21
L-138-10/0	Adelstein, Robert		Millipore Corp	10-Mar-21
L-138-10/0	Kawamoto, Sachiyo		Millipore Corp	10-Mar-21
L-138-10/0	Kim, Kee Kwang		Millipore Corp	10-Mar-21
L-051-13/0	Leonard, Warren J.		Cell Signaling Technology Inc	15-Mar-21
L-051-13/0	Russell, Sarah M		Cell Signaling Technology Inc	15-Mar-21

Note: L-051-13/0 split between NCI; NHLBI; NIAMS

L-264-18/0	Arai, Andrew Ernest	(b)(4);	Circle Cardiovascular Imaging Inc.	19-Mar-21
L-264-18/0	Hsu, Li - Yueh	(b)(6)	Circle Cardiovascular Imaging Inc.	19-Mar-21
L-264-18/0	Jacobs, Matthew James		Circle Cardiovascular Imaging Inc.	19-Mar-21
L-264-18/0	Arai, Andrew Ernest		Circle Cardiovascular Imaging Inc.	19-Mar-21
L-264-18/0	Hsu, Li - Yueh		Circle Cardiovascular Imaging Inc.	19-Mar-21
L-264-18/0	Jacobs, Matthew James		Circle Cardiovascular Imaging Inc.	19-Mar-21

Note: L-243-16/0 split between NHLBI; NIAMS

L-243-16/0	NHLBI		StemCell Technologies Inc.	23-Mar-21
------------	-------	--	----------------------------	-----------

L-074-12/0	Chiorini, John A.	(b)(4);	Vector BioLabs-TGDC	26-Mar-21
L-074-12/0	Kotin, Robert M.	(b)(6)	Vector BioLabs-TGDC	26-Mar-21

Note: L-214-18/0 split between NHLBI; NIBIB

L-214-18/0	NHLBI		Yokogawa Electric Corporation	30-Mar-21
------------	-------	--	-------------------------------	-----------

L-214-18/0	Combs, Christian A.	(b)(4);	Yokogawa Electric Corporation	30-Mar-21
------------	---------------------	---------	-------------------------------	-----------

Note: L-214-18/0 split between NHLBI; NIBIB

\$1,100,349.26	\$84,263.43	\$1,184,612.69	\$471,077.28	\$713,535.41
----------------	-------------	----------------	--------------	--------------

NIH Patent Licensing Activities
NIA
October 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-025-17/1	Moaddel, Ruin	(b)(4);	ocris Bioscience	9-Oct-20						(b) (4), (b) (3) (A), (b) (6)
L-122-18/1	NIA		Peptron	13-Oct-20						
L-132-17/0	NIA		CereDx Inc.	26-Oct-20						

Note: L-132-17/0 split between NIA; NINDS; NINR

NIH Patent Licensing Activities
NIA
November 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
L-012-12/2	Holloway, Harold	(b)(6)	Raptor Pharmaceuticals Corp.	1-Nov-20						
L-012-12/2	Ingram, Donald		Raptor Pharmaceuticals Corp.	1-Nov-20						
L-012-12/2	Shaw, Karen		Raptor Pharmaceuticals Corp.	1-Nov-20						
L-012-12/2	Yu, Qian-sheng		Raptor Pharmaceuticals Corp.	1-Nov-20						
L-270-18/0	Ferrucci, Luigi		The Regents of the University of Califor	17-Nov-20						

NIH Patent Licensing Activities
NIA
December 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
<i>Note: L-117-95/2 split between NCI; NIA</i>		(b)(6)								
L-132-17/0	Matarin Jimenez, Maria Del Ma		CereDx Inc.	8-Dec-20						(b) (4), (b) (3) (A), (b) (6)
L-132-17/0	Singleton, Andrew B.		CereDx Inc.	8-Dec-20						
<i>Note: L-132-17/0 split between NIA; NINDS; NINR</i>										
L-012-12/2	Greig, Nigel H		Raptor Pharmaceuticals Corp.	9-Dec-20						(b) (4), (b) (3) (A), (b) (6)
L-012-12/2	Holloway, Harold		Raptor Pharmaceuticals Corp.	9-Dec-20						
L-012-12/2	Ingram, Donald		Raptor Pharmaceuticals Corp.	9-Dec-20						
L-012-12/2	Shaw, Karen		Raptor Pharmaceuticals Corp.	9-Dec-20						
L-012-12/2	Yu, Qian-sheng		Raptor Pharmaceuticals Corp.	9-Dec-20						
L-166-16/0	Falco, Geppino		Elixirgen, LLC	10-Dec-20						(b) (4), (b) (3) (A), (b) (6)
L-166-16/0	Ko, Minoru S.		Elixirgen, LLC	10-Dec-20						
L-166-16/0	Lee, Sung-Lim		Elixirgen, LLC	10-Dec-20						
L-166-16/0	Monti, Manuela		Elixirgen, LLC	10-Dec-20						
L-166-16/0	Sharova, Lioudmila V.		Elixirgen, LLC	10-Dec-20						
L-166-16/0	Stanghellini, Ilaria		Elixirgen, LLC	10-Dec-20						
L-166-16/0	Zalzman, Michal		Elixirgen, LLC	10-Dec-20						
L-281-14/1	Doyle, Maire E		Peptron	30-Dec-20						(b) (4), (b) (3) (A), (b) (6)
L-281-14/1	Egan, Josephine M		Peptron	30-Dec-20						
L-281-14/1	Greig, Nigel H		Peptron	30-Dec-20						
L-281-14/1	Holloway, Harold		Peptron	30-Dec-20						
L-281-14/1	Perry, Tracy Ann		Peptron	30-Dec-20						
L-122-18/1	Greig, Nigel H		Peptron	30-Dec-20						(b) (4), (b) (3) (A), (b) (6)
L-122-18/1	Kim, Dong Seok		Peptron	30-Dec-20						
L-122-18/1	Li, Yazhou		Peptron	30-Dec-20						

NIH Patent Licensing Activities
NIA
January 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
L-131-18/0	Bagrov, Alexei	(b)(4);	CTS Biopharma	4-Jan-21						(b) (4), (b) (3) (A), (b) (6)
L-131-18/0	Fedorova, Olga V.	(b)(6)	CTS Biopharma	4-Jan-21						
L-131-18/0	Lakatta, Edward G.		CTS Biopharma	4-Jan-21						

NIH Patent Licensing Activities
NIA
February 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
NIA
March 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
L-073-21/0	Goetzl, Edward	(b)(4);	AevisBio, Inc	1-Mar-21						(b) (4), (b) (3) (A), (b) (6)
L-073-21/0	Greig, Nigel H	(b)(6)	AevisBio, Inc	1-Mar-21						
L-073-21/0	Holloway, Harold		AevisBio, Inc	1-Mar-21						
L-073-21/0	Luo, Weiming		AevisBio, Inc	1-Mar-21						
L-073-21/0	Tweedie, David		AevisBio, Inc	1-Mar-21						
L-073-21/0	(b) (4)		AevisBio, Inc	1-Mar-21						
L-073-21/0	Yu, Qian-sheng		AevisBio, Inc	1-Mar-21						
<i>Note: L-073-21/0 split between NCI; NIA</i>										
L-160-07/0	Shin, Soojung		Life Technologies	9-Mar-21						
L-025-17/1	Moaddel, Ruin		Tocris Bioscience	18-Mar-21						
<i>Note: L-025-17/1 split between NCATS; NIA; NIMH</i>										
					\$160,932.58	\$2,845.29	\$163,777.87		\$42,094.27	\$121,683.60

NIH Patent Licensing Activities
NIAAA
October 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-162-16/3	NIAAA		Inversago Pharma Inc.	23-Oct-20						(b) (4), (b) (3) (A), (b) (6)

Note: L-162-16/3 split between NIAAA; NIDA

L-162-16/3	Cinar, Resat	(b)(4);	Inversago Pharma Inc.	26-Oct-20	(b) (4), (b) (3) (A), (b) (6)
L-162-16/3	Iyer, Malliga R.	(b)(6)	Inversago Pharma Inc.	26-Oct-20	
L-162-16/3	Kunos, George I		Inversago Pharma Inc.	26-Oct-20	

Note: L-162-16/3 split between NIAAA; NIDA

NIH Patent Licensing Activities
NIAAA
November 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
NIAAA
December 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
L-257-19/0	Cinar, Resat	(b)(4);	Inversago Pharma Inc	10-Dec-20						(b) (4), (b) (3) (A), (b) (6)
L-257-19/0	Iyer, Malliga R.	(b)(6)	Inversago Pharma Inc	10-Dec-20						
L-257-19/0	Kunos, George I		Inversago Pharma Inc	10-Dec-20						

Note: L-257-19/0 split between NIAAA; NIDA

L-162-16/3	Cinar, Resat		Inversago Pharma Inc.	17-Dec-20						
L-162-16/3	Iyer, Malliga R.		Inversago Pharma Inc.	17-Dec-20						
L-162-16/3	Kunos, George I		Inversago Pharma Inc.	17-Dec-20						

Note: L-162-16/3 split between NIAAA; NIDA

NIH Patent Licensing Activities
NIAAA
January 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
L-276-17/0	Cinar, Resat	(b)(4);	Vital Spark Inc.	4-Jan-21						(b) (4), (b) (3) (A), (b) (6)
L-276-17/0	Iyer, Malliga R.	(b)(6)	Vital Spark Inc.	4-Jan-21						
L-276-17/0	Kunos, George I		Vital Spark Inc.	4-Jan-21						

Note: L-276-17/0 split between NIAAA; NIDA

NIH Patent Licensing Activities
NIAAA
February 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
NIAAA

March 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
L-194-05/1	Kunos, George I	(b)(4); (b)(6)	Tocris Bioscience	18-Mar-21						(b) (4), (b) (3) (A), (b) (6)
					\$76,048.50	\$9,700.37	\$85,748.87		\$17,658.75	\$68,090.12

NIH Patent Licensing Activities

NIAID

October 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-231-20/0	Purcell, Robert H	(b)(4); (b)(6)	ZeptoMetrix Corporation	1-Oct-20						(b) (4), (b) (3) (A), (b) (6)
L-155-18/2	NIAID		Icosavax	1-Oct-20						
L-155-18/2	Baxa, Ulrich	(b)(4); (b)(6)	Icosavax	1-Oct-20						
L-155-18/2	Boyington, Jeffrey C.	(b)(6)	Icosavax	1-Oct-20						
L-155-18/2	Buchholz, Ursula		Icosavax	1-Oct-20						
L-155-18/2	Chen, Lei		Icosavax	1-Oct-20						
L-155-18/2	Chen, Man		Icosavax	1-Oct-20						
L-155-18/2	Chuang, Gwo-Yu		Icosavax	1-Oct-20						
L-155-18/2	Collins, Peter L.		Icosavax	1-Oct-20						
L-155-18/2	Druz, Aliaksandr A.		Icosavax	1-Oct-20						
L-155-18/2	Galen, Joseph Van		Icosavax	1-Oct-20						
L-155-18/2	Georgiev, Ivelin S.		Icosavax	1-Oct-20						
L-155-18/2	Gorman, Jason		Icosavax	1-Oct-20						
L-155-18/2	Graham, Barney		Icosavax	1-Oct-20						
L-155-18/2	Joyce, Michael G.		Icosavax	1-Oct-20						
L-155-18/2	Kanekiyo, Masaru		Icosavax	1-Oct-20						
L-155-18/2	Kong, Wing-pui		Icosavax	1-Oct-20						
L-155-18/2	Kwong, Peter D.		Icosavax	1-Oct-20						
L-155-18/2	Mascola, John R.		Icosavax	1-Oct-20						
L-155-18/2	McLellan, Jason Scott		Icosavax	1-Oct-20						
L-155-18/2	OFEK, GILAD A		Icosavax	1-Oct-20						
L-155-18/2	Ou, Li		Icosavax	1-Oct-20						
L-155-18/2	Pancera, Marie L.		Icosavax	1-Oct-20						
L-155-18/2	Rundlet, Emily J		Icosavax	1-Oct-20						
L-155-18/2	Sastry, Mallika		Icosavax	1-Oct-20						
L-155-18/2	Soto, Cinque		Icosavax	1-Oct-20						
L-155-18/2	Srivatsan, Sanjay R.		Icosavax	1-Oct-20						
L-155-18/2	Stewart-Jones, Guillaume		Icosavax	1-Oct-20						
L-155-18/2	Thomas, Paul V.		Icosavax	1-Oct-20						
L-155-18/2	Tsybovsky, Yaroslav		Icosavax	1-Oct-20						
L-155-18/2	(b) (4)		Icosavax	1-Oct-20						
L-155-18/2	YANG, YONGPING		Icosavax	1-Oct-20						
L-155-18/2	Zhang, Baoshan		Icosavax	1-Oct-20						
L-155-18/2	Zhou, Tongqing		Icosavax	1-Oct-20						
L-189-20/0	Clouse, Thomas		Texcell - North America, Inc	1-Oct-20						

L-189-20/0	Folks, Thomas M	(b)(4);	Texcell - North America, Inc	1-Oct-20
L-189-20/0	Powell, Douglas M	(b)(6)	Texcell - North America, Inc	1-Oct-20
L-207-20/0	Abisola Abiona, Olubukola Marj		The Binding Site Group Ltd.	1-Oct-20
L-207-20/0	Corbett, Kizzmekia		The Binding Site Group Ltd.	1-Oct-20
L-207-20/0	(b) (4)		The Binding Site Group Ltd.	1-Oct-20
L-207-20/0	Graham, Barney		The Binding Site Group Ltd.	1-Oct-20
L-207-20/0	Hutchinson, Geoffrey Bain		The Binding Site Group Ltd.	1-Oct-20
L-207-20/0	Joyce, Michael G.		The Binding Site Group Ltd.	1-Oct-20
L-207-20/0	Kanekiyo, Masaru		The Binding Site Group Ltd.	1-Oct-20
L-207-20/0	(b) (4)		The Binding Site Group Ltd.	1-Oct-20
L-207-20/0	(b) (4)		The Binding Site Group Ltd.	1-Oct-20
L-207-20/0	Yassine, Hadi M.		The Binding Site Group Ltd.	1-Oct-20
L-241-13/0	Shevach, Ethan M		Tonbo Biotechnologies Corp	2-Oct-20
L-111-15/1	NIAID		Codagenix Inc.	2-Oct-20
L-111-15/1	NIAID		Codagenix Inc.	2-Oct-20
L-111-15/1	NIAID		Codagenix Inc.	2-Oct-20
L-074-91/3	Harriman, Gregory R.	(b)(4);	Becton, Dickson and Company	7-Oct-20
L-074-91/3	Kunimoto, Dennis Y.	(b)(6)	Becton, Dickson and Company	7-Oct-20
L-074-91/3	Paul, (b) (6) William E.		Becton, Dickson and Company	7-Oct-20
L-074-91/3	Strober, Warren		Becton, Dickson and Company	7-Oct-20
L-079-93/2	Ohara, Junichi		BD Biosciences - BD PharMingen	7-Oct-20
L-079-93/2	Paul, (b) (6) William E.		BD Biosciences - BD PharMingen	7-Oct-20
L-093-05/4	NIAID		Janssen Vaccines & Prevention BV	14-Oct-20
<i>Note: L-093-05/4 split between CDC; NIAID</i>				
L-124-18/0	Garboczi, David	(b)(4);	Abcam plc	14-Oct-20
L-124-18/0	Lantz, Larry	(b)(6)	Abcam plc	14-Oct-20
L-124-18/0	Leppa, Stephen H.		Abcam plc	14-Oct-20
L-124-18/0	Leysath, Clinton E.		Abcam plc	14-Oct-20
L-124-18/0	Phillips, Damilola D.		Abcam plc	14-Oct-20
L-162-08/2	Sun, Peter D		Biolegend, Inc	16-Oct-20
L-162-08/2	Zou, Zhongcheng		Biolegend, Inc	16-Oct-20
L-231-20/0	Purcell, Robert H		ZeptoMetrix Corporation	20-Oct-20
L-246-14/2	Eisenbarth, (b) (6) George		BIOLEGEND	21-Oct-20
<i>Note: L-246-14/2 split between NHLBI; NIAID</i>				
L-068-04/2	NIAID		Sillajen Biotherapeutics, Inc	22-Oct-20
<i>Note: L-068-04/2 split between NCI; NIAID</i>				
L-001-15/2	NIAID		Merck Sharp & Dohme, Corp.	26-Oct-20
<i>Note: L-001-15/2 split between FDA; NIAID</i>				
L-158-20/0	Abisola Abiona, Olubukola Marj	(b)(4);	AbCellera Biologics Inc.	27-Oct-20
L-158-20/0	Corbett, Kizzmekia	(b)(6)	AbCellera Biologics Inc.	27-Oct-20

L-158-20/0	Graham, Barney	(b)(4);	AbCellera Biologics Inc.	27-Oct-20
L-158-20/0	Kong, Wing-pui	(b)(6)	AbCellera Biologics Inc.	27-Oct-20
L-158-20/0	Ledgerwood, Julie		AbCellera Biologics Inc.	27-Oct-20
L-158-20/0	Mascola, John R.		AbCellera Biologics Inc.	27-Oct-20
L-158-20/0	Shi, Wei		AbCellera Biologics Inc.	27-Oct-20
L-158-20/0	Wang, Lingshu		AbCellera Biologics Inc.	27-Oct-20
L-158-20/0	Zhang, Yi-Ming		AbCellera Biologics Inc.	27-Oct-20

(b) (4), (b) (3) (A), (b) (6)

NIH Patent Licensing Activities
NIAID
November 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
L-203-20/0	Blaney, Jr., Joseph E	(b)(4);	Janssen Pharmaceutica, N.V.	1-Nov-20						(b) (4), (b) (3) (A), (b) (6)
L-203-20/0	Hanley, Kathryn	(b)(6)	Janssen Pharmaceutica, N.V.	1-Nov-20						
L-203-20/0	Lai, Ching-Juh		Janssen Pharmaceutica, N.V.	1-Nov-20						
L-203-20/0	Murphy, Brian R.		Janssen Pharmaceutica, N.V.	1-Nov-20						
L-203-20/0	Whitehead, Stephen S.		Janssen Pharmaceutica, N.V.	1-Nov-20						
<i>Note: L-203-20/0 split between FDA; NIAID</i>										
L-078-11/0	Mackett, Michael		CEVA Biomune	4-Nov-20						
L-078-11/0	Moss, Bernard		CEVA Biomune	4-Nov-20						
L-078-11/0	Smith, Geoffrey L		CEVA Biomune	4-Nov-20						
L-101-09/1	Akin, Cem		Takeda Chemical Industries	9-Nov-20						
L-101-09/1	Kirshenbaum, Arnold		Takeda Chemical Industries	9-Nov-20						
L-101-09/1	Metcalfe, Dean D		Takeda Chemical Industries	9-Nov-20						
L-028-19/0	Graham, Barney	(b) (4)	Ridgeback Biotherapeutics	10-Nov-20						
L-028-19/0			Ridgeback Biotherapeutics	10-Nov-20						
L-028-19/0			Ridgeback Biotherapeutics	10-Nov-20						
L-028-19/0	Ledgerwood, Julie		Ridgeback Biotherapeutics	10-Nov-20						
L-028-19/0	Mulangu, Sabue		Ridgeback Biotherapeutics	10-Nov-20						
L-028-19/0	Muyembe-Tamfun, Jean-Jacque		Ridgeback Biotherapeutics	10-Nov-20						
L-028-19/0	Stanley, Daphne Amanda		Ridgeback Biotherapeutics	10-Nov-20						
L-028-19/0	Sullivan, Nancy J		Ridgeback Biotherapeutics	10-Nov-20						
L-028-19/0	United States Army		Ridgeback Biotherapeutics	10-Nov-20						
L-202-15/0	Akin, Cem		Genentech Inc.	12-Nov-20						
L-202-15/0	Kirshenbaum, Arnold		Genentech Inc.	12-Nov-20						
L-202-15/0	Metcalfe, Dean D		Genentech Inc.	12-Nov-20						
L-070-16/1	NIAID		Emergent Biosolutions	13-Nov-20						
<i>Note: L-070-16/1 split between CDC; NIAID</i>										
L-262-20/0	Abisola Abiona, Olubukola Marj	(b)(4);	Sanofi Pasteur	16-Nov-20						
L-262-20/0	Corbett, Kizzmekia	(b)(6)	Sanofi Pasteur	16-Nov-20						
L-262-20/0		(b) (4)	Sanofi Pasteur	16-Nov-20						
L-262-20/0	Graham, Barney		Sanofi Pasteur	16-Nov-20						
L-262-20/0	Hutchinson, Geoffrey Bain		Sanofi Pasteur	16-Nov-20						
L-262-20/0	Joyce, Michael G.		Sanofi Pasteur	16-Nov-20						
L-262-20/0	Kaneikiyo, Masaru		Sanofi Pasteur	16-Nov-20						

L-262-20/0	Kong, Wing-pui	(b)(4);	Sanofi Pasteur	16-Nov-20
L-262-20/0	Mascola, John R.	(b)(6)	Sanofi Pasteur	16-Nov-20
L-262-20/0	(b) (4)		Sanofi Pasteur	16-Nov-20
L-262-20/0	(b) (4)		Sanofi Pasteur	16-Nov-20
L-262-20/0	Wang, Lingshu		Sanofi Pasteur	16-Nov-20
L-262-20/0	Yassine, Hadi M.		Sanofi Pasteur	16-Nov-20
L-209-20/0	Shevach, Ethan M		Proteintech Group, Inc.	16-Nov-20
L-211-14/2	Biacchesi, Stephanie		ViraTree, LLC	17-Nov-20
L-211-14/2	Buchholz, Ursula		ViraTree, LLC	17-Nov-20
L-211-14/2	Bukreyev, Alexander		ViraTree, LLC	17-Nov-20
L-211-14/2	Collins, Peter L.		ViraTree, LLC	17-Nov-20
L-211-14/2	Luongo, Cindy L.		ViraTree, LLC	17-Nov-20
L-211-14/2	Murphy, Brian R.		ViraTree, LLC	17-Nov-20
L-211-14/2	Nutt, Anne S.		ViraTree, LLC	17-Nov-20
L-211-14/2	(b) (4)		ViraTree, LLC	17-Nov-20
L-211-14/2	Skiadopoulos, Mario		ViraTree, LLC	17-Nov-20
L-211-14/2	(b) (4)		ViraTree, LLC	17-Nov-20
L-142-07/2	Mackett, Michael		Transgene S A.	18-Nov-20
L-142-07/2	Moss, Bernard		Transgene S A.	18-Nov-20
L-142-07/2	Smith, Geoffrey L		Transgene S A.	18-Nov-20
L-188-20/0	Kim, Yong Chan		Teraimmune Inc.	18-Nov-20
L-188-20/0	Shevach, Ethan M		Teraimmune Inc.	18-Nov-20
L-231-20/0	Purcell, Robert H		ZeptoMetrix Corporation	19-Nov-20
L-250-20/0	Abisola Abiona, Olubukola Mar		Thermo Fisher Scientific Inc.	19-Nov-20
L-250-20/0	Corbett, Kizzmekia		Thermo Fisher Scientific Inc.	19-Nov-20
L-250-20/0	(b) (4)		Thermo Fisher Scientific Inc.	19-Nov-20
L-250-20/0	Graham, Barney		Thermo Fisher Scientific Inc.	19-Nov-20
L-250-20/0	Hutchinson, Geoffrey Bain		Thermo Fisher Scientific Inc.	19-Nov-20
L-250-20/0	Joyce, Michael G.		Thermo Fisher Scientific Inc.	19-Nov-20
L-250-20/0	Kanekiyo, Masaru		Thermo Fisher Scientific Inc.	19-Nov-20
L-250-20/0	(b) (4)		Thermo Fisher Scientific Inc.	19-Nov-20
L-250-20/0	(b) (4)		Thermo Fisher Scientific Inc.	19-Nov-20
L-250-20/0	Yassine, Hadi M.		Thermo Fisher Scientific Inc.	19-Nov-20
L-061-13/0	Chen, Zhao Chun		BioFactura, Inc.	19-Nov-20
L-061-13/0	Emerson, Suzanne U.		BioFactura, Inc.	19-Nov-20
L-061-13/0	Moss, Bernard		BioFactura, Inc.	19-Nov-20
L-061-13/0	Purcell, Robert H		BioFactura, Inc.	19-Nov-20
L-061-13/0	NIAID		BioFactura, Inc.	19-Nov-20
L-021-21/0	Akin, Cem	(b)(4);	IgGenix, Inc.	20-Nov-20
L-021-21/0	Kirshenbaum, Arnold	(b)(6)	IgGenix, Inc.	20-Nov-20
L-021-21/0	Metcalfe, Dean D		IgGenix, Inc.	20-Nov-20
L-021-21/0	Akin, Cem		IgGenix, Inc.	20-Nov-20
L-021-21/0	Kirshenbaum, Arnold		IgGenix, Inc.	20-Nov-20
L-021-21/0	Metcalfe, Dean D		IgGenix, Inc.	20-Nov-20

(b) (4), (b) (3) (A), (b) (6)

L-021-21/0	Akin, Cem	(b)(4);	IgGenix, Inc.	20-Nov-20
L-021-21/0	Kirshenbaum, Arnold	(b)(6)	IgGenix, Inc.	20-Nov-20
L-021-21/0	Metcalfe, Dean D		IgGenix, Inc.	20-Nov-20
L-093-05/4	Chakrabarti, Bimal K		Janssen Vaccines & Prevention BV	24-Nov-20
L-093-05/4	Cheng, Cheng		Janssen Vaccines & Prevention BV	24-Nov-20
L-093-05/4	(b) (6) Clement K. Asiedu		Janssen Vaccines & Prevention BV	24-Nov-20
L-093-05/4	Huang, (b) (6) Yue		Janssen Vaccines & Prevention BV	24-Nov-20
L-093-05/4	Mackett, Michael		Janssen Vaccines & Prevention BV	24-Nov-20
L-093-05/4	Moss, Bernard		Janssen Vaccines & Prevention BV	24-Nov-20
L-093-05/4	Nabel, Gary J		Janssen Vaccines & Prevention BV	24-Nov-20
L-093-05/4	Smith, Geoffrey L		Janssen Vaccines & Prevention BV	24-Nov-20
L-093-05/4	Sullivan, Nancy J		Janssen Vaccines & Prevention BV	24-Nov-20
L-093-05/4	Ward, Lucy A.		Janssen Vaccines & Prevention BV	24-Nov-20
L-093-05/4	Yang, Zhi-Yong		Janssen Vaccines & Prevention BV	24-Nov-20
<i>Note: L-093-05/4 split between CDC; NIAID</i>				
L-066-20/0	Akahata, Wataru		The Native Antigen Company	24-Nov-20
L-066-20/0	Nabel, Gary J		The Native Antigen Company	24-Nov-20
L-066-20/0	Rao, Srinivas		The Native Antigen Company	24-Nov-20
L-135-17/3	Boyington, Jeffrey C.		Emergent Product Development	25-Nov-20
L-135-17/3	Corbett, Kizzmekia		Emergent Product Development	25-Nov-20
L-135-17/3	Graham, Barney		Emergent Product Development	25-Nov-20
L-135-17/3	Kanekiyo, Masaru		Emergent Product Development	25-Nov-20
L-135-17/3	Kong, Wing-pui		Emergent Product Development	25-Nov-20
L-135-17/3	Kwong, Peter D.		Emergent Product Development	25-Nov-20
L-135-17/3	Mascola, John R.		Emergent Product Development	25-Nov-20
L-135-17/3	McTamney, Patrick		Emergent Product Development	25-Nov-20
L-135-17/3	Moin, Syed M.		Emergent Product Development	25-Nov-20
L-135-17/3	Nabel, Gary J		Emergent Product Development	25-Nov-20
L-135-17/3	Wang, Lingshu		Emergent Product Development	25-Nov-20
L-135-17/3	Wei, Chih-Jen		Emergent Product Development	25-Nov-20
L-135-17/3	Whittle, James R R		Emergent Product Development	25-Nov-20
L-135-17/3	Yang, Zhi-Yong		Emergent Product Development	25-Nov-20
L-135-17/3	Yassine, Hadi M.		Emergent Product Development	25-Nov-20
L-126-11/0	Cheung, Yiu Chong Gordon		Emergent Biodefense	25-Nov-20
L-126-11/0	Gupta, Pradeep K.		Emergent Biodefense	25-Nov-20
L-126-11/0	Hu, Haijing		Emergent Biodefense	25-Nov-20
L-126-11/0	Leppla, Stephen H.		Emergent Biodefense	25-Nov-20
L-126-11/0	Moayeri, Mahtab		Emergent Biodefense	25-Nov-20
L-126-11/0	Pomerantsev, Andrei P		Emergent Biodefense	25-Nov-20
L-152-02/3	Hsu, Su-Cheng Dana		Emergent BioDefense	25-Nov-20
L-152-02/3	Leppla, Stephen H.		Emergent BioDefense	25-Nov-20
L-152-02/3	Pomerantsev, Andrei P		Emergent BioDefense	25-Nov-20
<i>Note: L-152-02/3 split between NIAID; NIDCR</i>				
L-208-20/0	Guatam, Rejeev		Gilead Sciences, Inc.	25-Nov-20
L-208-20/0	Martin, Malcolm A		Gilead Sciences, Inc.	25-Nov-20
L-208-20/0	Nishimura, Michael		Gilead Sciences, Inc.	25-Nov-20
L-208-20/0	Sadjadpour, Reza		Gilead Sciences, Inc.	25-Nov-20
L-208-20/0	Shingai, Masashi		Gilead Sciences, Inc.	25-Nov-20

(b) (4), (b) (3) (A), (b) (6)

L-073-18/0	Guatam, Rejeev	(b)(4);	Gilead Sciences, Inc.	25-Nov-20
L-073-18/0	Martin, Malcolm A	(b)(6)	Gilead Sciences, Inc.	25-Nov-20
L-073-18/0	Nishimura, Michael		Gilead Sciences, Inc.	25-Nov-20
L-073-18/0	Sadjadpour, Reza		Gilead Sciences, Inc.	25-Nov-20
L-073-18/0	Shingai, Masashi		Gilead Sciences, Inc.	25-Nov-20
L-303-19/1	Chuang, Gwo-Yu		TaiMed Biologics USA, Inc	25-Nov-20
L-303-19/1	Connors, Mark		TaiMed Biologics USA, Inc	25-Nov-20
L-303-19/1	Georgiev, Ivelin S.		TaiMed Biologics USA, Inc	25-Nov-20
L-303-19/1	Kwon, Young Do		TaiMed Biologics USA, Inc	25-Nov-20
L-303-19/1	Kwong, Peter D.		TaiMed Biologics USA, Inc	25-Nov-20
L-303-19/1	Mascola, John R.		TaiMed Biologics USA, Inc	25-Nov-20
L-303-19/1	Nabel, Gary J		TaiMed Biologics USA, Inc	25-Nov-20
L-303-19/1	Rudicell, Rebecca S.		TaiMed Biologics USA, Inc	25-Nov-20
L-303-19/1	Shi, Wei		TaiMed Biologics USA, Inc	25-Nov-20
L-303-19/1	Wu, Xueling		TaiMed Biologics USA, Inc	25-Nov-20
L-303-19/1	YANG, YONGPING		TaiMed Biologics USA, Inc	25-Nov-20
L-303-19/1	Yang, Zhi-Yong		TaiMed Biologics USA, Inc	25-Nov-20
L-303-19/1	Zhang, Baoshan		TaiMed Biologics USA, Inc	25-Nov-20
L-303-19/1	Zhou, Tongqing		TaiMed Biologics USA, Inc	25-Nov-20
L-303-19/1	Zhu, Jiang		TaiMed Biologics USA, Inc	25-Nov-20
L-080-04/1	Green, Kim Y.		R-Biopharm AG	27-Nov-20
L-080-04/1	Sosnovtsev, Stanislav V		R-Biopharm AG	27-Nov-20
L-170-98/2	Conrad, John T.		R-Biopharm GmbH	27-Nov-20
L-170-98/2	Lujan, Hugo D		R-Biopharm GmbH	27-Nov-20
L-170-98/2	Mowatt, Michael		R-Biopharm GmbH	27-Nov-20
L-170-98/2	Nash, Theodore		R-Biopharm GmbH	27-Nov-20
L-249-20/0	Akin, Cem		Laboratorios Liomont, S.A. de C.V	27-Nov-20
L-249-20/0	Kirshenbaum, Arnold		Laboratorios Liomont, S.A. de C.V	27-Nov-20
L-249-20/0	Metcalfe, Dean D		Laboratorios Liomont, S.A. de C.V	27-Nov-20
L-018-18/2	Datta, Sandip Kumar		Forte Biosciences Inc	27-Nov-20
L-018-18/2	Myles, Ian		Forte Biosciences Inc	27-Nov-20

NIH Patent Licensing Activities
NIAID
December 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
L-118-11/1	Alexander, Robert M.	(b)(4);	Transwall	1-Dec-20						(b) (4), (b) (3) (A), (b) (6)
L-118-11/1	Jenkins, John P.	(b)(6)	Transwall	1-Dec-20						
L-118-11/1	Koh, Franklin		Transwall	1-Dec-20						
L-118-11/1	O'Brien, Daniel P.		Transwall	1-Dec-20						
L-118-11/1	Quasney, Judit A.		Transwall	1-Dec-20						
L-024-19/1	Akin, Cem		Kyowa Kirin Pharmaceutical Research, Inc	1-Dec-20						
L-024-19/1	Kirshenbaum, Arnold		Kyowa Kirin Pharmaceutical Research, Inc	1-Dec-20						
L-024-19/1	Metcalfe, Dean D		Kyowa Kirin Pharmaceutical Research, Inc	1-Dec-20						

L-251-20/0	Abisola Abiona, Olubukola Mar	(b)(4);	Thermo Fisher Scientific Inc.	1-Dec-20
L-251-20/0	Corbett, Kizzmekia	(b)(6)	Thermo Fisher Scientific Inc.	1-Dec-20
L-251-20/0	(b) (4)		Thermo Fisher Scientific Inc.	1-Dec-20
L-251-20/0	Graham, Barney		Thermo Fisher Scientific Inc.	1-Dec-20
L-251-20/0	Hutchinson, Geoffrey Bain		Thermo Fisher Scientific Inc.	1-Dec-20
L-251-20/0	Joyce, Michael G.		Thermo Fisher Scientific Inc.	1-Dec-20
L-251-20/0	Kanekiyo, Masaru		Thermo Fisher Scientific Inc.	1-Dec-20
L-251-20/0	(b) (4)		Thermo Fisher Scientific Inc.	1-Dec-20
L-251-20/0	(b) (4)		Thermo Fisher Scientific Inc.	1-Dec-20
L-251-20/0	Yassine, Hadi M.		Thermo Fisher Scientific Inc.	1-Dec-20
L-120-95/3	Shevach, Ethan M		Southern Biotechnology Associates, Inc.	7-Dec-20
L-031-20/0	Angermann, Bastian R		Kleo Pharmaceuticals, Inc.	7-Dec-20
L-031-20/0	Meier-Schellersheim, Martin		Kleo Pharmaceuticals, Inc.	7-Dec-20
L-169-07/2	Folks, Thomas M		Gilead Sciences, Inc.	8-Dec-20
L-169-07/2	Justement, Jesse S		Gilead Sciences, Inc.	8-Dec-20
L-169-07/2	Kinter, Audrey L		Gilead Sciences, Inc.	8-Dec-20
L-122-08/0	Mackett, Michael		Vaccinex Inc	8-Dec-20
L-122-08/0	Moss, Bernard		Vaccinex Inc	8-Dec-20
L-122-08/0	Smith, Geoffrey L		Vaccinex Inc	8-Dec-20
L-190-05/2	Bennink, Jack R.		GeoVax, Inc.	9-Dec-20
L-190-05/2	Broder, Christopher		GeoVax, Inc.	9-Dec-20
L-190-05/2	Chesebro, Bruce		GeoVax, Inc.	9-Dec-20
L-190-05/2	Cox, Josephine H		GeoVax, Inc.	9-Dec-20
L-190-05/2	Doms, Robert W.		GeoVax, Inc.	9-Dec-20
L-190-05/2	Earl, Patricia L.		GeoVax, Inc.	9-Dec-20
L-190-05/2	Moss, Bernard		GeoVax, Inc.	9-Dec-20
L-190-05/2	Wehrly, Kathryn		GeoVax, Inc.	9-Dec-20
L-190-05/2	Yewdell, Jonathan W.		GeoVax, Inc.	9-Dec-20
<i>Note: L-190-05/2 split between NCI; NIAID</i>				
L-150-20/0	Abisola Abiona, Olubukola Mar		Medigen Vaccine Biologics Corp	10-Dec-20
L-150-20/0	Corbett, Kizzmekia		Medigen Vaccine Biologics Corp	10-Dec-20
L-150-20/0	(b) (4)		Medigen Vaccine Biologics Corp	10-Dec-20
L-150-20/0	Graham, Barney		Medigen Vaccine Biologics Corp	10-Dec-20
L-150-20/0	Hutchinson, Geoffrey Bain		Medigen Vaccine Biologics Corp	10-Dec-20
L-150-20/0	Joyce, Michael G.		Medigen Vaccine Biologics Corp	10-Dec-20
L-150-20/0	Kanekiyo, Masaru		Medigen Vaccine Biologics Corp	10-Dec-20
L-150-20/0	Kong, Wing-pui		Medigen Vaccine Biologics Corp	10-Dec-20
L-150-20/0	Mascola, John R.		Medigen Vaccine Biologics Corp	10-Dec-20
L-150-20/0	(b) (4)		Medigen Vaccine Biologics Corp	10-Dec-20
L-150-20/0	(b) (4)		Medigen Vaccine Biologics Corp	10-Dec-20
L-150-20/0	Wang, Lingshu		Medigen Vaccine Biologics Corp	10-Dec-20
L-150-20/0	Yassine, Hadi M.		Medigen Vaccine Biologics Corp	10-Dec-20
L-150-20/0	Abisola Abiona, Olubukola Mar		Medigen Vaccine Biologics Corp	10-Dec-20
L-150-20/0	Corbett, Kizzmekia		Medigen Vaccine Biologics Corp	10-Dec-20
L-150-20/0	(b) (4)		Medigen Vaccine Biologics Corp	10-Dec-20
L-150-20/0	Graham, Barney		Medigen Vaccine Biologics Corp	10-Dec-20
L-150-20/0	Hutchinson, Geoffrey Bain		Medigen Vaccine Biologics Corp	10-Dec-20
L-150-20/0	Joyce, Michael G.		Medigen Vaccine Biologics Corp	10-Dec-20

L-150-20/0	Kanekiyo, Masaru	(b)(4);	Medigen Vaccine Biologics Corp	10-Dec-20
L-150-20/0	Kong, Wing-pui	(b)(6)	Medigen Vaccine Biologics Corp	10-Dec-20
L-150-20/0	Mascola, John R.		Medigen Vaccine Biologics Corp	10-Dec-20
L-150-20/0	(b) (4)		Medigen Vaccine Biologics Corp	10-Dec-20
L-150-20/0	Wang, Lingshu		Medigen Vaccine Biologics Corp	10-Dec-20
L-150-20/0	Yassine, Hadi M.		Medigen Vaccine Biologics Corp	10-Dec-20
L-200-05/6	Chanock, (b) (6) Robert		Wuhan Institute of Bio. Prod.	10-Dec-20
L-200-05/6	Hoshino, Yasutaka		Wuhan Institute of Bio. Prod.	10-Dec-20
L-200-05/6	Kapikian, (b) (6) Albert Z		Wuhan Institute of Bio. Prod.	10-Dec-20
L-015-21/0	Abisola Abiona, Olubukola Marj		ExcellGene SA	10-Dec-20
L-015-21/0	Corbett, Kizzmekia		ExcellGene SA	10-Dec-20
L-015-21/0	(b) (4)		ExcellGene SA	10-Dec-20
L-015-21/0	Graham, Barney		ExcellGene SA	10-Dec-20
L-015-21/0	Hutchinson, Geoffrey Bain		ExcellGene SA	10-Dec-20
L-015-21/0	Joyce, Michael G.		ExcellGene SA	10-Dec-20
L-015-21/0	Kanekiyo, Masaru		ExcellGene SA	10-Dec-20
L-015-21/0	(b) (4)		ExcellGene SA	10-Dec-20
L-015-21/0	Yassine, Hadi M.		ExcellGene SA	10-Dec-20
L-015-21/0	Abisola Abiona, Olubukola Marj		ExcellGene SA	10-Dec-20
L-015-21/0	Corbett, Kizzmekia		ExcellGene SA	10-Dec-20
L-015-21/0	(b) (4)		ExcellGene SA	10-Dec-20
L-015-21/0	Graham, Barney		ExcellGene SA	10-Dec-20
L-015-21/0	Hutchinson, Geoffrey Bain		ExcellGene SA	10-Dec-20
L-015-21/0	Joyce, Michael G.		ExcellGene SA	10-Dec-20
L-015-21/0	Kanekiyo, Masaru		ExcellGene SA	10-Dec-20
L-015-21/0	(b) (4)		ExcellGene SA	10-Dec-20
L-015-21/0	Yassine, Hadi M.		ExcellGene SA	10-Dec-20
L-015-21/0	Abisola Abiona, Olubukola Marj		ExcellGene SA	10-Dec-20
L-015-21/0	Corbett, Kizzmekia		ExcellGene SA	10-Dec-20
L-015-21/0	(b) (4)		ExcellGene SA	10-Dec-20
L-015-21/0	Graham, Barney		ExcellGene SA	10-Dec-20
L-015-21/0	Hutchinson, Geoffrey Bain		ExcellGene SA	10-Dec-20
L-015-21/0	Joyce, Michael G.		ExcellGene SA	10-Dec-20
L-015-21/0	Kanekiyo, Masaru		ExcellGene SA	10-Dec-20
L-015-21/0	(b) (4)		ExcellGene SA	10-Dec-20
L-015-21/0	Yassine, Hadi M.		ExcellGene SA	10-Dec-20
L-040-13/0	NIAID		Baxter Akiengesellschaft Industr	11-Dec-20
L-056-18/1	Akin, Cem	(b)(4);	ActivX Biosciences	11-Dec-20
L-056-18/1	Kirshenbaum, Arnold	(b)(6)	ActivX Biosciences	11-Dec-20
L-056-18/1	Metcalfe, Dean D		ActivX Biosciences	11-Dec-20
L-217-16/0	Blaney, Jr., Joseph E		Indian Immunologicals Ltd	15-Dec-20
L-217-16/0	Hanley, Kathryn		Indian Immunologicals Ltd	15-Dec-20
L-217-16/0	Lai, Ching-Juh		Indian Immunologicals Ltd	15-Dec-20
L-217-16/0	Murphy, Brian R.		Indian Immunologicals Ltd	15-Dec-20

(b) (4), (b) (3) (A), (b) (6)

L-217-16/0	Whitehead, Stephen S.	(b)(4); (b)(6)	Indian Immunologicals Ltd	15-Dec-20
<i>Note: L-217-16/0 split between FDA; NIAID</i>				
L-188-18/0	Cohen, Jeffrey		Indian Immunologicals Limited	15-Dec-20
L-188-18/0	Pesnicak, Lesley M		Indian Immunologicals Limited	15-Dec-20
L-253-15/0	Chanock, (b) (6) Robert		Sun Biotech Pte., Ltd.	15-Dec-20
L-253-15/0	Hoshino, Yasutaka		Sun Biotech Pte., Ltd.	15-Dec-20
L-253-15/0	Kapikian (b) (6) Albert Z		Sun Biotech Pte., Ltd.	15-Dec-20
L-190-20/0	Abisola Abiona, Olubukola Mary		Meso Scale Diagnostics, LLC	15-Dec-20
L-190-20/0	Boyington, Jeffrey C.		Meso Scale Diagnostics, LLC	15-Dec-20
L-190-20/0	Chen, Lei		Meso Scale Diagnostics, LLC	15-Dec-20
L-190-20/0	Chen, Man		Meso Scale Diagnostics, LLC	15-Dec-20
L-190-20/0	Chuang, Gwo-Yu		Meso Scale Diagnostics, LLC	15-Dec-20
L-190-20/0	Corbett, Kizzmekia		Meso Scale Diagnostics, LLC	15-Dec-20
L-190-20/0	(b) (4)		Meso Scale Diagnostics, LLC	15-Dec-20
L-190-20/0	Georgiev, Ivelin S.		Meso Scale Diagnostics, LLC	15-Dec-20
L-190-20/0	Gorman, Jason		Meso Scale Diagnostics, LLC	15-Dec-20
L-190-20/0	Graham, Barney		Meso Scale Diagnostics, LLC	15-Dec-20
L-190-20/0	Hutchinson, Geoffrey Bain		Meso Scale Diagnostics, LLC	15-Dec-20
L-190-20/0	Joyce, Michael G.		Meso Scale Diagnostics, LLC	15-Dec-20
L-190-20/0	Kanekiyo, Masaru		Meso Scale Diagnostics, LLC	15-Dec-20
L-190-20/0	Kwong, Peter D.		Meso Scale Diagnostics, LLC	15-Dec-20
L-190-20/0	McLellan, Jason Scott		Meso Scale Diagnostics, LLC	15-Dec-20
L-190-20/0	OFEK, GILAD A		Meso Scale Diagnostics, LLC	15-Dec-20
L-190-20/0	Pancera, Marie L.		Meso Scale Diagnostics, LLC	15-Dec-20
L-190-20/0	Sastry, Mallika		Meso Scale Diagnostics, LLC	15-Dec-20
L-190-20/0	(b) (4)		Meso Scale Diagnostics, LLC	15-Dec-20
L-190-20/0	Soto, Cinque		Meso Scale Diagnostics, LLC	15-Dec-20
L-190-20/0	Srivatsan, Sanjay R.		Meso Scale Diagnostics, LLC	15-Dec-20
L-190-20/0	Stewart-Jones, Guillaume BE		Meso Scale Diagnostics, LLC	15-Dec-20
L-190-20/0	(b) (4)		Meso Scale Diagnostics, LLC	15-Dec-20
L-190-20/0	YANG, YONGPING		Meso Scale Diagnostics, LLC	15-Dec-20
L-190-20/0	Yassine, Hadi M.		Meso Scale Diagnostics, LLC	15-Dec-20
L-190-20/0	Zhang, Baoshan		Meso Scale Diagnostics, LLC	15-Dec-20
L-190-20/0	Zhou, Tongqing		Meso Scale Diagnostics, LLC	15-Dec-20
L-138-16/1	Biacchesi, Stephanie		Merck Sharp & Dohme Corp.	16-Dec-20
L-138-16/1	Buchholz, Ursula		Merck Sharp & Dohme Corp.	16-Dec-20
L-138-16/1	Collins, Peter L.		Merck Sharp & Dohme Corp.	16-Dec-20
L-016-21/0	David, Alexandre		Biogen, Inc	16-Dec-20
L-016-21/0	Yewdell, Jonathan W.		Biogen, Inc	16-Dec-20
L-016-21/0	David, Alexandre		Biogen, Inc	16-Dec-20
L-016-21/0	Yewdell, Jonathan W.		Biogen, Inc	16-Dec-20
L-246-20/0	Ohara, Junichi		Leinco Technologies, Inc.	16-Dec-20
L-246-20/0	Paul (b) (6) William E.		Leinco Technologies, Inc.	16-Dec-20
L-131-20/0	Adachi, Akio		AbbVie	16-Dec-20
L-131-20/0	Folks, Thomas M		AbbVie	16-Dec-20
L-131-20/0	Leonard, John M.		AbbVie	16-Dec-20
L-131-20/0	Martin, Malcolm A		AbbVie	16-Dec-20

L-131-20/0	Rabson, Arnold B.	(b)(4);	AbbVie	16-Dec-20
L-131-20/0	Rutledge, Rosamond A.	(b)(6)	AbbVie	16-Dec-20
L-131-20/0	Theodore, (b) (6) Theodore S		AbbVie	16-Dec-20
L-131-20/0	Willey, Ronald L.		AbbVie	16-Dec-20
L-116-18/0	NIAID		Katholieke	17-Dec-20
L-208-14/1	NIAID		Grifols Therapeutics, Inc.	18-Dec-20
L-119-09/2	Blaney, Jr., Joseph E	(b)(4);	Fundacao Butantan	21-Dec-20
L-119-09/2	Hanley, Kathryn	(b)(6)	Fundacao Butantan	21-Dec-20
L-119-09/2	Lai, Ching-Juh		Fundacao Butantan	21-Dec-20
L-119-09/2	Murphy, Brian R.		Fundacao Butantan	21-Dec-20
L-119-09/2	Whitehead, Stephen S.		Fundacao Butantan	21-Dec-20
<i>Note: L-119-09/2 split between FDA; NIAID</i>				
L-054-06/0	Germain, Ronald N.		eBioscience	21-Dec-20
L-054-06/0	Porgador, Angel		eBioscience	21-Dec-20
L-049-00/1	Shevach, Ethan M		eBioscience, Inc..	21-Dec-20
<i>Note: L-049-00/1 split between NCI; NIAID</i>				
L-093-05/4	Chakrabarti, Bimal K		Janssen Vaccines & Prevention BV	23-Dec-20
L-093-05/4	Cheng, Cheng		Janssen Vaccines & Prevention BV	23-Dec-20
L-093-05/4	(b) (6) Clement K. Asiedu		Janssen Vaccines & Prevention BV	23-Dec-20
L-093-05/4	Huang, (b) (6) Yue		Janssen Vaccines & Prevention BV	23-Dec-20
L-093-05/4	Mackett, Michael		Janssen Vaccines & Prevention BV	23-Dec-20
L-093-05/4	Moss, Bernard		Janssen Vaccines & Prevention BV	23-Dec-20
L-093-05/4	Nabel, Gary J		Janssen Vaccines & Prevention BV	23-Dec-20
L-093-05/4	Smith, Geoffrey L		Janssen Vaccines & Prevention BV	23-Dec-20
L-093-05/4	Sullivan, Nancy J		Janssen Vaccines & Prevention BV	23-Dec-20
L-093-05/4	Ward, Lucy A.		Janssen Vaccines & Prevention BV	23-Dec-20
L-093-05/4	Yang, Zhi-Yong		Janssen Vaccines & Prevention BV	23-Dec-20
<i>Note: L-093-05/4 split between CDC; NIAID</i>				
L-251-20/0	Abisola Abiona, Olubukola Marj		Thermo Fisher Scientific Inc.	23-Dec-20
L-251-20/0	Corbett, Kizzmekia		Thermo Fisher Scientific Inc.	23-Dec-20
L-251-20/0	(b) (4)		Thermo Fisher Scientific Inc.	23-Dec-20
L-251-20/0	Graham, Barney		Thermo Fisher Scientific Inc.	23-Dec-20
L-251-20/0	Hutchinson, Geoffrey Bain		Thermo Fisher Scientific Inc.	23-Dec-20
L-251-20/0	Joyce, Michael G.		Thermo Fisher Scientific Inc.	23-Dec-20
L-251-20/0	Kanekiyo, Masaru		Thermo Fisher Scientific Inc.	23-Dec-20
L-251-20/0	(b) (4)		Thermo Fisher Scientific Inc.	23-Dec-20
L-251-20/0	(b) (4)		Thermo Fisher Scientific Inc.	23-Dec-20
L-251-20/0	Yassine, Hadi M.		Thermo Fisher Scientific Inc.	23-Dec-20
L-251-20/0	Abisola Abiona, Olubukola Marj		Thermo Fisher Scientific Inc.	23-Dec-20
L-251-20/0	Corbett, Kizzmekia		Thermo Fisher Scientific Inc.	23-Dec-20
L-251-20/0	(b) (4)		Thermo Fisher Scientific Inc.	23-Dec-20
L-251-20/0	Graham, Barney		Thermo Fisher Scientific Inc.	23-Dec-20
L-251-20/0	Hutchinson, Geoffrey Bain		Thermo Fisher Scientific Inc.	23-Dec-20
L-251-20/0	Joyce, Michael G.		Thermo Fisher Scientific Inc.	23-Dec-20
L-251-20/0	Kanekiyo, Masaru		Thermo Fisher Scientific Inc.	23-Dec-20
L-251-20/0	(b) (4)		Thermo Fisher Scientific Inc.	23-Dec-20
L-251-20/0	(b) (4)		Thermo Fisher Scientific Inc.	23-Dec-20

L-251-20/0	Yassine, Hadi M.	(b)(4); L-251-20/0	Thermo Fisher Scientific Inc.	23-Dec-20
L-257-20/0	NIAID		GeoVax, Inc.	23-Dec-20
L-257-20/0	NIAID		GeoVax, Inc.	23-Dec-20
L-257-20/0	Abisola Abiona, Olubukola Mar	(b)(4);	GeoVax, Inc.	23-Dec-20
L-257-20/0	Corbett, Kizzmekia	(b)(6)	GeoVax, Inc.	23-Dec-20
L-257-20/0	(b) (4)		GeoVax, Inc.	23-Dec-20
L-257-20/0	Earl, Patricia L.		GeoVax, Inc.	23-Dec-20
L-257-20/0	Graham, Barney		GeoVax, Inc.	23-Dec-20
L-257-20/0	Hutchinson, Geoffrey Bain		GeoVax, Inc.	23-Dec-20
L-257-20/0	Joyce, Michael G.		GeoVax, Inc.	23-Dec-20
L-257-20/0	Kanekiyo, Masaru		GeoVax, Inc.	23-Dec-20
L-257-20/0	Mackett, Michael		GeoVax, Inc.	23-Dec-20
L-257-20/0	Moss, Bernard		GeoVax, Inc.	23-Dec-20
L-257-20/0	(b) (4)		GeoVax, Inc.	23-Dec-20
L-257-20/0	Smith, Geoffrey L		GeoVax, Inc.	23-Dec-20
L-257-20/0	(b) (4)		GeoVax, Inc.	23-Dec-20
L-257-20/0	Wyatt, Linda S.		GeoVax, Inc.	23-Dec-20
L-257-20/0	Yassine, Hadi M.		GeoVax, Inc.	23-Dec-20
L-205-20/0	Collins, Peter L.		Vir Biotechnology, Inc	24-Dec-20
L-205-20/0	(b) (4)		Vir Biotechnology, Inc	24-Dec-20
L-005-19/0	Brock, Linda G.		Medigen Vaccine Biologics Corp	28-Dec-20
L-005-19/0	Buchholz, Ursula		Medigen Vaccine Biologics Corp	28-Dec-20
L-005-19/0	Collins, Peter L.		Medigen Vaccine Biologics Corp	28-Dec-20
L-005-19/0	Munir, Shirin		Medigen Vaccine Biologics Corp	28-Dec-20
L-244-19/0	De Wit, Emmie		Public Health Vaccines, LLC.	28-Dec-20
L-244-19/0	DeBuyssscher, Blair Lynn		Public Health Vaccines, LLC.	28-Dec-20
L-244-19/0	Feldmann, Heinrich Ulrich		Public Health Vaccines, LLC.	28-Dec-20
L-244-19/0	Marzi, Andrea Maria		Public Health Vaccines, LLC.	28-Dec-20
L-244-19/0	Prescott, Joseph		Public Health Vaccines, LLC.	28-Dec-20
L-152-19/1	Akin, Cem		Celltrion, Inc.	29-Dec-20
L-152-19/1	Kirshenbaum, Arnold		Celltrion, Inc.	29-Dec-20
L-152-19/1	Metcalfe, Dean D		Celltrion, Inc.	29-Dec-20
L-261-19/0	Coligan, John		Bristol-Myers Squibb Company	29-Dec-20
L-261-19/0	Krzewski, Konrad		Bristol-Myers Squibb Company	29-Dec-20
L-261-19/0	Lee, Ha Na		Bristol-Myers Squibb Company	29-Dec-20
L-261-19/0	Tian, Lirjie		Bristol-Myers Squibb Company	29-Dec-20
L-261-19/0	Voss, Oliver		Bristol-Myers Squibb Company	29-Dec-20
L-236-16/1	Akin, Cem		IRBM	29-Dec-20
L-236-16/1	Kirshenbaum, Arnold		IRBM	29-Dec-20
L-236-16/1	Metcalfe, Dean D		IRBM	29-Dec-20
L-003-11/0	Germain, Ronald N.		Biolegend	30-Dec-20
L-003-11/0	Porgador, Angel		Biolegend	30-Dec-20
L-246-14/2	Eisenbarth, (b) (6) George		BIOLEGEND	30-Dec-20

Note: L-246-14/2 split between NHLBI; NIAID

(b) (4), (b) (3) (A), (b) (6)

License	Inventor	Inventor Share %	Licensee	Date of Deposit	(b) (4), (b) (3) (A), (b) (6)
L-005-03/1	Ohara, Junichi	(b)(4);	Biolegend Inc	30-Dec-20	
L-005-03/1	Paul, (b) (6) William E.	(b)(6)	Biolegend Inc	30-Dec-20	
L-011-08/2	Shevach, Ethan M		BioLegend	30-Dec-20	
L-016-21/0	David, Alexandre		Biolegend, Inc	30-Dec-20	
L-016-21/0	Yewdell, Jonathan W.		Biolegend, Inc	30-Dec-20	
L-069-14/0	Mchugh, Rebecca S		BioLegend	30-Dec-20	
L-069-14/0	Shevach, Ethan M		BioLegend	30-Dec-20	
L-069-14/0	Stephens, Geoffrey L.		BioLegend	30-Dec-20	
L-071-10/1	DeVico, Angela M.		BioLegend	30-Dec-20	
L-071-10/1	Korty, Patricia E.		BioLegend	30-Dec-20	
L-071-10/1	Shevach, Ethan M		BioLegend	30-Dec-20	
L-072-09/1	Long, Eric O.		BioLegend	30-Dec-20	
L-072-09/1	Rajagopalan, Sumati		BioLegend	30-Dec-20	
L-110-17/0	Shevach, Ethan M		BioLegend Inc.	30-Dec-20	
L-162-08/2	Sun, Peter D		Biolegend, Inc	30-Dec-20	
L-162-08/2	Zou, Zhongcheng		Biolegend, Inc	30-Dec-20	
L-207-13/2	Cheng, Cheng		Hookipa Biotech AG	30-Dec-20	
L-207-13/2	Mangalampalli, Venkata R.		Hookipa Biotech AG	30-Dec-20	
L-207-13/2	Merritt, Joshua S.		Hookipa Biotech AG	30-Dec-20	
L-207-13/2	Schwartz, Richard M.		Hookipa Biotech AG	30-Dec-20	
L-207-13/2	Wycuff, Diane L.		Hookipa Biotech AG	30-Dec-20	

NIH Patent Licensing Activities
NIAID
January 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC	
L-197-05/5	Chanock, (b) (6) Robert	(b)(4);	Serum Institute of India	4-Jan-21						(b) (4), (b) (3) (A), (b) (6)	
L-197-05/5	Hoshino, Yasutaka	(b)(6)	Serum Institute of India	4-Jan-21							
L-197-05/5	Kapikian, (b) (6) Albert Z		Serum Institute of India	4-Jan-21							
L-200-18/0	Chanock, (b) (6) Robert		Shandong Yidu Biotechnology Co., Ltd.	4-Jan-21							
L-200-18/0	Hoshino, Yasutaka		Shandong Yidu Biotechnology Co., Ltd.	4-Jan-21							
L-200-18/0	Kapikian, (b) (6) Albert Z		Shandong Yidu Biotechnology Co., Ltd.	4-Jan-21							
L-114-09/0	Blaney, Jr., Joseph E		Co for Vaccine and Bio Productin	4-Jan-21							
L-114-09/0	Hanley, Kathryn		Co for Vaccine and Bio Productin	4-Jan-21							
L-114-09/0	Lai, Ching-Juh		Co for Vaccine and Bio Productin	4-Jan-21							
L-114-09/0	Murphy, Brian R.		Co for Vaccine and Bio Productin	4-Jan-21							
L-114-09/0	Whitehead, Stephen S.		Co for Vaccine and Bio Productin	4-Jan-21							
<i>Note: L-114-09/0 split between FDA; NIAID</i>											
L-149-15/1	Blaney, Jr., Joseph E		Serum Institute of India Ltd.	4-Jan-21							

L-149-15/1	Hanley, Kathryn	(b)(4);	Serum Institute of India Ltd.	4-Jan-21
L-149-15/1	Lai, Ching-Juh	(b)(6)	Serum Institute of India Ltd.	4-Jan-21
L-149-15/1	Murphy, Brian R.		Serum Institute of India Ltd.	4-Jan-21
L-149-15/1	Whitehead, Stephen S.		Serum Institute of India Ltd.	4-Jan-21
<i>Note: L-149-15/1 split between FDA; NIAID</i>				
L-036-06/0	NIAID		Hawaii Biotechnology Group, Inc.	4-Jan-21
L-034-20/0	(b) (4)	(b)(4);	Helocyte, Inc	5-Jan-21
L-034-20/0	Mackett, Michael	(b)(6)	Helocyte, Inc	5-Jan-21
L-034-20/0	Moss, Bernard		Helocyte, Inc	5-Jan-21
L-034-20/0	Smith, Geoffrey L		Helocyte, Inc	5-Jan-21
L-120-95/3	Shevach, Ethan M		Southern Biotechnology Associates, Inc.	5-Jan-21
L-248-15/1	Marques, Adriana		InBios International, Inc.	5-Jan-21
<i>Note: L-248-15/1 split between NIAID; NIDCR</i>				
L-181-14/0	Fink, Doran		InBios International Inc	5-Jan-21
L-181-14/0	Kubofcik, Joseph		InBios International Inc	5-Jan-21
L-181-14/0	Nutman, Thomas B.		InBios International Inc	5-Jan-21
<i>Note: L-181-14/0 split between NIAID; NIDCR</i>				
L-154-06/0	Mackett, Michael		Boehringer Ingleheim Animal Health USA I	6-Jan-21
L-154-06/0	Moss, Bernard		Boehringer Ingleheim Animal Health USA I	6-Jan-21
L-154-06/0	Smith, Geoffrey L		Boehringer Ingleheim Animal Health USA I	6-Jan-21
L-245-19/0	Akin, Cem		Escient Pharmaceuticals	6-Jan-21
L-245-19/0	Kirshenbaum, Arnold		Escient Pharmaceuticals	6-Jan-21
L-245-19/0	Metcalf, Dean D		Escient Pharmaceuticals	6-Jan-21
L-125-12/0	Eisenbarth, (b) (6) George		BD Biosciences	11-Jan-21
<i>Note: L-125-12/0 split between NHLBI; NIAID</i>				
L-074-91/3	Harriman, Gregory R.		Becton, Dickson and Company	11-Jan-21
L-074-91/3	Kunimoto, Dennis Y.		Becton, Dickson and Company	11-Jan-21
L-074-91/3	Paul, (b) (6) William E.		Becton, Dickson and Company	11-Jan-21
L-074-91/3	Strober, Warren		Becton, Dickson and Company	11-Jan-21
L-048-21/0	Abisola Abiona, Olubukola Mar		ModernaTx, Inc.	11-Jan-21
L-048-21/0	Corbett, Kizzmekia		ModernaTx, Inc.	11-Jan-21
L-048-21/0	Graham, Barney		ModernaTx, Inc.	11-Jan-21
L-048-21/0	Kong, Wing-pui		ModernaTx, Inc.	11-Jan-21
L-048-21/0	Leung, Kwanyee		ModernaTx, Inc.	11-Jan-21
L-048-21/0	Mascola, John R.		ModernaTx, Inc.	11-Jan-21
L-048-21/0	Shi, Wei		ModernaTx, Inc.	11-Jan-21
L-048-21/0	Wang, Lingshu		ModernaTx, Inc.	11-Jan-21
L-048-21/0	Yang, Eun Sung		ModernaTx, Inc.	11-Jan-21
L-048-21/0	Zhang, Yi		ModernaTx, Inc.	11-Jan-21
L-200-19/0	NIAID		Octapharma Biopharmaceuticals GmbH	11-Jan-21
L-243-20/0	Earl, Patricia L.		GeoVax, Inc.	11-Jan-21
L-243-20/0	Mackett, Michael		GeoVax, Inc.	11-Jan-21
L-243-20/0	Moss, Bernard		GeoVax, Inc.	11-Jan-21


L-243-20/0	Smith, Geoffrey L	(b)(4);	GeoVax, Inc.	11-Jan-21
L-243-20/0	Wyatt, Linda S.	(b)(6)	GeoVax, Inc.	11-Jan-21
L-079-93/2	Ohara, Junichi		BD Biosciences - BD PharMingen	11-Jan-21
L-079-93/2	Paul, (b) (6) William E.		BD Biosciences - BD PharMingen	11-Jan-21
L-033-21/0	Abisola Abiona, Olubukola Marj		ACROBiosystems Inc.	13-Jan-21
L-033-21/0	Corbett, Kizzmekia		ACROBiosystems Inc.	13-Jan-21
L-033-21/0	(b) (4)		ACROBiosystems Inc.	13-Jan-21
L-033-21/0	Graham, Barney		ACROBiosystems Inc.	13-Jan-21
L-033-21/0	Hutchinson, Geoffrey Bain		ACROBiosystems Inc.	13-Jan-21
L-033-21/0	Joyce, Michael G.		ACROBiosystems Inc.	13-Jan-21
L-033-21/0	Kanekiyo, Masaru		ACROBiosystems Inc.	13-Jan-21
L-033-21/0	(b) (4)		ACROBiosystems Inc.	13-Jan-21
L-033-21/0	(b) (4)		ACROBiosystems Inc.	13-Jan-21
L-033-21/0	Yassine, Hadi M.		ACROBiosystems Inc.	13-Jan-21
L-033-21/0	Abisola Abiona, Olubukola Marj		ACROBiosystems Inc.	13-Jan-21
L-033-21/0	Corbett, Kizzmekia		ACROBiosystems Inc.	13-Jan-21
L-033-21/0	(b) (4)		ACROBiosystems Inc.	13-Jan-21
L-033-21/0	Graham, Barney		ACROBiosystems Inc.	13-Jan-21
L-033-21/0	Hutchinson, Geoffrey Bain		ACROBiosystems Inc.	13-Jan-21
L-033-21/0	Joyce, Michael G.		ACROBiosystems Inc.	13-Jan-21
L-033-21/0	Kanekiyo, Masaru		ACROBiosystems Inc.	13-Jan-21
L-033-21/0	(b) (4)		ACROBiosystems Inc.	13-Jan-21
L-033-21/0	(b) (4)		ACROBiosystems Inc.	13-Jan-21
L-033-21/0	Yassine, Hadi M.		ACROBiosystems Inc.	13-Jan-21
L-033-21/0	Abisola Abiona, Olubukola Marj		ACROBiosystems Inc.	13-Jan-21
L-033-21/0	Corbett, Kizzmekia		ACROBiosystems Inc.	13-Jan-21
L-033-21/0	(b) (4)		ACROBiosystems Inc.	13-Jan-21
L-033-21/0	Graham, Barney		ACROBiosystems Inc.	13-Jan-21
L-033-21/0	Hutchinson, Geoffrey Bain		ACROBiosystems Inc.	13-Jan-21
L-033-21/0	Joyce, Michael G.		ACROBiosystems Inc.	13-Jan-21
L-033-21/0	Kanekiyo, Masaru		ACROBiosystems Inc.	13-Jan-21
L-033-21/0	(b) (4)		ACROBiosystems Inc.	13-Jan-21
L-033-21/0	(b) (4)		ACROBiosystems Inc.	13-Jan-21
L-033-21/0	Yassine, Hadi M.		ACROBiosystems Inc.	13-Jan-21
L-119-20/0	Leppla, Stephen H.		Cure Therapeutics	14-Jan-21
L-119-20/0	Leppla, Stephen H.		Cure Therapeutics	14-Jan-21
L-346-14/0	Blaney, Jr., Joseph E		Exxell BIO, Inc.	19-Jan-21
L-346-14/0	Jahrling, Peter B.		Exxell BIO, Inc.	19-Jan-21
L-346-14/0	Johnson, Reed F.		Exxell BIO, Inc.	19-Jan-21
L-346-14/0	Paragas, Jason J.		Exxell BIO, Inc.	19-Jan-21
L-346-14/0	(b) (4)		Exxell BIO, Inc.	19-Jan-21
L-346-14/0	NIAID		Exxell BIO, Inc.	19-Jan-21
L-203-20/0	Blaney, Jr., Joseph E	(b)(4);	Janssen Pharmaceutica, N.V.	21-Jan-21
L-203-20/0	Hanley, Kathryn	(b)(6)	Janssen Pharmaceutica, N.V.	21-Jan-21
L-203-20/0	Lai, Ching-Juh		Janssen Pharmaceutica, N.V.	21-Jan-21
L-203-20/0	Murphy, Brian R.		Janssen Pharmaceutica, N.V.	21-Jan-21

(b) (4), (b) (3) (A), (b) (6)

L-203-20/0	Whitehead, Stephen S.	(b)(4); (b)(6)	Janssen Pharmaceutica, N.V.	21-Jan-21
<i>Note: L-203-20/0 split between FDA; NIAID</i>				
L-249-20/0	Akin, Cem		Laboratorios Liomont, S.A. de C.V	21-Jan-21
L-249-20/0	Kirshenbaum, Arnold		Laboratorios Liomont, S.A. de C.V	21-Jan-21
L-249-20/0	Metcalfe, Dean D		Laboratorios Liomont, S.A. de C.V	21-Jan-21
L-048-21/0	Abisola Abiona, Olubukola Marj		ModernaTx, Inc.	21-Jan-21
L-048-21/0	Corbett, Kizzmekia		ModernaTx, Inc.	21-Jan-21
L-048-21/0	Graham, Barney		ModernaTx, Inc.	21-Jan-21
L-048-21/0	Kong, Wing-pui		ModernaTx, Inc.	21-Jan-21
L-048-21/0	Leung, Kwanyee		ModernaTx, Inc.	21-Jan-21
L-048-21/0	Mascola, John R.		ModernaTx, Inc.	21-Jan-21
L-048-21/0	Shi, Wei		ModernaTx, Inc.	21-Jan-21
L-048-21/0	Wang, Lingshu		ModernaTx, Inc.	21-Jan-21
L-048-21/0	Yang, Eun Sung		ModernaTx, Inc.	21-Jan-21
L-048-21/0	Zhang, Yi		ModernaTx, Inc.	21-Jan-21
L-144-14/1	NIAID		GlaxoSmithKline Biologicals SA	22-Jan-21
L-063-06/3	Barry, Clifton E	(b)(4);	Sequella, Inc.	22-Jan-21
L-063-06/3	Lee, Richard E.	(b)(6)	Sequella, Inc.	22-Jan-21
L-063-06/3	Slayden, Richard A		Sequella, Inc.	22-Jan-21
L-124-18/0	Garboczi, David		Abcam plc	22-Jan-21
L-124-18/0	Lantz, Larry		Abcam plc	22-Jan-21
L-124-18/0	Leppla, Stephen H.		Abcam plc	22-Jan-21
L-124-18/0	Leysath, Clinton E.		Abcam plc	22-Jan-21
L-124-18/0	Phillips, Damilola D.		Abcam plc	22-Jan-21
L-046-17/1	Blaney, Jr., Joseph E		Medigen Vaccine Biologics Corp	25-Jan-21
L-046-17/1	Hanley, Kathryn		Medigen Vaccine Biologics Corp	25-Jan-21
L-046-17/1	Lai, Ching-Juh		Medigen Vaccine Biologics Corp	25-Jan-21
L-046-17/1	Murphy, Brian R.		Medigen Vaccine Biologics Corp	25-Jan-21
L-046-17/1	Whitehead, Stephen S.		Medigen Vaccine Biologics Corp	25-Jan-21
<i>Note: L-046-17/1 split between FDA; NIAID</i>				
L-271-18/0	NIAID		Medigen Vaccine Biologics Corp	25-Jan-21
L-046-17/1	Blaney, Jr., Joseph E	(b)(4);	Medigen Vaccine Biologics Corp	25-Jan-21
L-046-17/1	Hanley, Kathryn	(b)(6)	Medigen Vaccine Biologics Corp	25-Jan-21
L-046-17/1	Lai, Ching-Juh		Medigen Vaccine Biologics Corp	25-Jan-21
L-046-17/1	Murphy, Brian R.		Medigen Vaccine Biologics Corp	25-Jan-21
L-046-17/1	Whitehead, Stephen S.		Medigen Vaccine Biologics Corp	25-Jan-21
<i>Note: L-046-17/1 split between FDA; NIAID</i>				
L-207-20/0	Abisola Abiona, Olubukola Marj		The Binding Site Group Ltd.	26-Jan-21
L-207-20/0	Corbett, Kizzmekia		The Binding Site Group Ltd.	26-Jan-21
L-207-20/0	(b)(4)		The Binding Site Group Ltd.	26-Jan-21
L-207-20/0	Graham, Barney		The Binding Site Group Ltd.	26-Jan-21
L-207-20/0	Hutchinson, Geoffrey Bain		The Binding Site Group Ltd.	26-Jan-21
L-207-20/0	Joyce, Michael G.		The Binding Site Group Ltd.	26-Jan-21
L-207-20/0	Kanekiyo, Masaru		The Binding Site Group Ltd.	26-Jan-21
L-207-20/0	(b)(4)		The Binding Site Group Ltd.	26-Jan-21
L-207-20/0	(b)(4)		The Binding Site Group Ltd.	26-Jan-21

(b) (4), (b) (3) (A), (b) (6)

L-207-20/0	Yassine, Hadi M.	(b)(4); (b)(6)	The Binding Site Group Ltd.	26-Jan-21
L-179-20/0	Abisola Abiona, Olubukola Marj		BioNTech AG	28-Jan-21
L-179-20/0	Corbett, Kizzmekia		BioNTech AG	28-Jan-21
L-179-20/0	(b) (4)		BioNTech AG	28-Jan-21
L-179-20/0	Graham, Barney		BioNTech AG	28-Jan-21
L-179-20/0	Hutchinson, Geoffrey Bain		BioNTech AG	28-Jan-21
L-179-20/0	Joyce, Michael G.		BioNTech AG	28-Jan-21
L-179-20/0	Kaneikiyo, Masaru		BioNTech AG	28-Jan-21
L-179-20/0	(b) (4)		BioNTech AG	28-Jan-21
L-179-20/0	(b) (4)		BioNTech AG	28-Jan-21
L-179-20/0	Yassine, Hadi M.		BioNTech AG	28-Jan-21
L-149-15/1	NIAID		Serum Institute of India Ltd.	28-Jan-21
<i>Note: L-149-15/1 split between FDA; NIAID</i>				
L-246-20/0	Ohara, Junichi	(b)(4);	Leinco Technologies, Inc.	28-Jan-21
L-246-20/0	Paul, (b) (6) William E.	(b)(6)	Leinco Technologies, Inc.	28-Jan-21



(b) (4), (b) (3) (A), (b) (6)

NIH Patent Licensing Activities
NIAID
February 2021


License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
L-115-00/2	Cheung, Yiu Chong Gordon	(b)(4);	List Biological Laboratories, Inc.	1-Feb-21						(b) (4), (b) (3) (A), (b) (6)
L-115-00/2	Gupta, Pradeep K.	(b)(6)	List Biological Laboratories, Inc.	1-Feb-21						
L-115-00/2	Hsu, Su-Cheng Dana		List Biological Laboratories, Inc.	1-Feb-21						
L-115-00/2	Hu, Haijing		List Biological Laboratories, Inc.	1-Feb-21						
L-115-00/2	Leppla, Stephen H.		List Biological Laboratories, Inc.	1-Feb-21						
L-115-00/2	Leysath, Clinton E.		List Biological Laboratories, Inc.	1-Feb-21						
L-115-00/2	Moayeri, Mahtab		List Biological Laboratories, Inc.	1-Feb-21						
L-115-00/2	Pomerantsev, Andrei P		List Biological Laboratories, Inc.	1-Feb-21						
<i>Note: L-115-00/2 split between NIAID; NIDCR</i>										
L-158-20/0	Abisola Abiona, Olubukola Marj		AbCellera Biologics Inc.	1-Feb-21						
L-158-20/0	Corbett, Kizzmekia		AbCellera Biologics Inc.	1-Feb-21						
L-158-20/0	Graham, Barney		AbCellera Biologics Inc.	1-Feb-21						
L-158-20/0	Kong, Wing-pui		AbCellera Biologics Inc.	1-Feb-21						
L-158-20/0	Ledgerwood, Julie		AbCellera Biologics Inc.	1-Feb-21						
L-158-20/0	Mascola, John R.		AbCellera Biologics Inc.	1-Feb-21						
L-158-20/0	Shi, Wei		AbCellera Biologics Inc.	1-Feb-21						
L-158-20/0	Wang, Lingshu		AbCellera Biologics Inc.	1-Feb-21						
L-158-20/0	Zhang, Yi-Ming		AbCellera Biologics Inc.	1-Feb-21						
L-064-21/0	Leppla, Stephen H.		Oncorus, Inc.	2-Feb-21						
L-064-21/0	Liu, Shi-Hui		Oncorus, Inc.	2-Feb-21						
L-111-15/1	NIAID		Codagenix Inc.	3-Feb-21						
L-043-18/0	Boyington, Jeffrey C.	(b)(4);	MedImmune	4-Feb-21						
L-043-18/0	Chen, Lei	(b)(6)	MedImmune	4-Feb-21						
L-043-18/0	Chen, Man		MedImmune	4-Feb-21						



L-043-18/0	Chuang, Gwo-Yu	(b)(4);	MedImmune	4-Feb-21
L-043-18/0	Georgiev, Ivelin S.	(b)(6)	MedImmune	4-Feb-21
L-043-18/0	Gorman, Jason		MedImmune	4-Feb-21
L-043-18/0	Graham, Barney		MedImmune	4-Feb-21
L-043-18/0	Joyce, Michael G.		MedImmune	4-Feb-21
L-043-18/0	Kanekiyo, Masaru		MedImmune	4-Feb-21
L-043-18/0	Kwong, Peter D.		MedImmune	4-Feb-21
L-043-18/0	McLellan, Jason Scott		MedImmune	4-Feb-21
L-043-18/0	OFEK, GILAD A		MedImmune	4-Feb-21
L-043-18/0	Pancera, Marie L.		MedImmune	4-Feb-21
L-043-18/0	Sastry, Mallika		MedImmune	4-Feb-21
L-043-18/0	Soto, Cinque		MedImmune	4-Feb-21
L-043-18/0	Srivatsan, Sanjay R.		MedImmune	4-Feb-21
L-043-18/0	Stewart-Jones, Guillaume BE		MedImmune	4-Feb-21
L-043-18/0	YANG, YONGPING		MedImmune	4-Feb-21
L-043-18/0	Zhang, Baoshan		MedImmune	4-Feb-21
L-043-18/0	Zhou, Tongqing		MedImmune	4-Feb-21
L-054-21/0	Chakrabarti, Sekhar		Simcere Innovation, Inc	10-Feb-21
L-054-21/0	Mackett, Michael		Simcere Innovation, Inc	10-Feb-21
L-054-21/0	Moss, Bernard		Simcere Innovation, Inc	10-Feb-21
L-054-21/0	Smith, Geoffrey L		Simcere Innovation, Inc	10-Feb-21
L-059-20/0	Akin, Cem		Merck Sharp & Dohme Corp.	11-Feb-21
L-059-20/0	Kirshenbaum, Arnold		Merck Sharp & Dohme Corp.	11-Feb-21
L-059-20/0	Metcalfe, Dean D		Merck Sharp & Dohme Corp.	11-Feb-21
L-047-20/0	Morse III, Herbert		Genentech, Inc.	11-Feb-21
L-119-09/2	NIAID		Fundacao Butantan	11-Feb-21
<i>Note: L-119-09/2 split between FDA; NIAID</i>				
L-013-20/0	Chanock, (b) (6) Robert	(b)(4);	Excell BIO, Inc	11-Feb-21
L-013-20/0	Hoshino, Yasutaka	(b)(6)	Excell BIO, Inc	11-Feb-21
L-013-20/0	Kapikian, (b) (6) Albert Z		Excell BIO, Inc	11-Feb-21
L-094-13/1	Ohta, Akio		Redoxtherapies Inc	11-Feb-21
L-094-13/1	Sitkovsky, Michail V.		Redoxtherapies Inc	11-Feb-21
L-298-19/0	Connors, Mark		GlaxoSmithKline Intellectual Property Li	12-Feb-21
L-298-19/0	Huang, Jinghe		GlaxoSmithKline Intellectual Property Li	12-Feb-21
L-298-19/0	Ishida, Elise H.		GlaxoSmithKline Intellectual Property Li	12-Feb-21
L-298-19/0	Kang, Byong Ha		GlaxoSmithKline Intellectual Property Li	12-Feb-21
L-298-19/0	Kwong, Peter D.		GlaxoSmithKline Intellectual Property Li	12-Feb-21
L-298-19/0	Mascola, John R.		GlaxoSmithKline Intellectual Property Li	12-Feb-21
L-298-19/0	Zheng, Anqi		GlaxoSmithKline Intellectual Property Li	12-Feb-21
L-298-19/0	Zhou, Tongqing		GlaxoSmithKline Intellectual Property Li	12-Feb-21
L-140-98/1	Beeler, Judy A.		SmithKline Beecham	12-Feb-21
L-140-98/1	Chanock, (b) (6) Robert		SmithKline Beecham	12-Feb-21
L-140-98/1	Coelingh, Kathleen L.		SmithKline Beecham	12-Feb-21
L-140-98/1	Collins, Peter L.		SmithKline Beecham	12-Feb-21
L-140-98/1	Murphy, Brian R.		SmithKline Beecham	12-Feb-21
L-144-14/1	Baxa, Ulrich		GlaxoSmithKline Biologicals SA	12-Feb-21

(b) (4), (b) (3) (A), (b) (6)

L-144-14/1	Boyington, Jeffrey C.	(b)(4);	GlaxoSmithKline Biologicals SA	12-Feb-21
L-144-14/1	Chen, Lei	(b)(6)	GlaxoSmithKline Biologicals SA	12-Feb-21
L-144-14/1	Chen, Man		GlaxoSmithKline Biologicals SA	12-Feb-21
L-144-14/1	Chuang, Gwo-Yu		GlaxoSmithKline Biologicals SA	12-Feb-21
L-144-14/1	Druz, Aliaksandr A.		GlaxoSmithKline Biologicals SA	12-Feb-21
L-144-14/1	Galen, Joseph Van		GlaxoSmithKline Biologicals SA	12-Feb-21
L-144-14/1	Georgiev, Ivelin S.		GlaxoSmithKline Biologicals SA	12-Feb-21
L-144-14/1	Gorman, Jason		GlaxoSmithKline Biologicals SA	12-Feb-21
L-144-14/1	Graham, Barney		GlaxoSmithKline Biologicals SA	12-Feb-21
L-144-14/1	Joyce, Michael G.		GlaxoSmithKline Biologicals SA	12-Feb-21
L-144-14/1	Kanekiyo, Masaru		GlaxoSmithKline Biologicals SA	12-Feb-21
L-144-14/1	Kong, Wing-pui		GlaxoSmithKline Biologicals SA	12-Feb-21
L-144-14/1	Kwong, Peter D.		GlaxoSmithKline Biologicals SA	12-Feb-21
L-144-14/1	Mascola, John R.		GlaxoSmithKline Biologicals SA	12-Feb-21
L-144-14/1	McLellan, Jason Scott		GlaxoSmithKline Biologicals SA	12-Feb-21
L-144-14/1	OFEK, GILAD A		GlaxoSmithKline Biologicals SA	12-Feb-21
L-144-14/1	Ou, Li		GlaxoSmithKline Biologicals SA	12-Feb-21
L-144-14/1	Pancera, Marie L.		GlaxoSmithKline Biologicals SA	12-Feb-21
L-144-14/1	Rundlet, Emily J		GlaxoSmithKline Biologicals SA	12-Feb-21
L-144-14/1	Sastry, Mallika		GlaxoSmithKline Biologicals SA	12-Feb-21
L-144-14/1	Soto, Cinque		GlaxoSmithKline Biologicals SA	12-Feb-21
L-144-14/1	Srivatsan, Sanjay R.		GlaxoSmithKline Biologicals SA	12-Feb-21
L-144-14/1	Stewart-Jones, Guillaume BE		GlaxoSmithKline Biologicals SA	12-Feb-21
L-144-14/1	Thomas, Paul V.		GlaxoSmithKline Biologicals SA	12-Feb-21
L-144-14/1	Tsybovsky, Yaroslav		GlaxoSmithKline Biologicals SA	12-Feb-21
L-144-14/1	YANG, YONGPING		GlaxoSmithKline Biologicals SA	12-Feb-21
L-144-14/1	Zhang, Baoshan		GlaxoSmithKline Biologicals SA	12-Feb-21
L-144-14/1	Zhou, Tongqing		GlaxoSmithKline Biologicals SA	12-Feb-21
L-207-13/3	Cheng, Cheng		Hookipa Biotech AG	22-Feb-21
L-207-13/3	Mangalampalli, Venkata R.		Hookipa Biotech AG	22-Feb-21
L-207-13/3	Merritt, Joshua S.		Hookipa Biotech AG	22-Feb-21
L-207-13/3	Schwartz, Richard M.		Hookipa Biotech AG	22-Feb-21
L-207-13/3	Wycuff, Diane L.		Hookipa Biotech AG	22-Feb-21
L-207-13/2	Cheng, Cheng		Hookipa Biotech AG	22-Feb-21
L-207-13/2	Mangalampalli, Venkata R.		Hookipa Biotech AG	22-Feb-21
L-207-13/2	Merritt, Joshua S.		Hookipa Biotech AG	22-Feb-21
L-207-13/2	Schwartz, Richard M.		Hookipa Biotech AG	22-Feb-21
L-207-13/2	Wycuff, Diane L.		Hookipa Biotech AG	22-Feb-21
L-169-07/2	Folks, Thomas M		Gilead Sciences, Inc.	23-Feb-21
L-169-07/2	Justement, Jesse S		Gilead Sciences, Inc.	23-Feb-21
L-169-07/2	Kinter, Audrey L		Gilead Sciences, Inc.	23-Feb-21
L-279-19/0	Boyington, Jeffrey C.		BlueWillow Biologics, Inc.	23-Feb-21
L-279-19/0	Carey, Elizabeth		BlueWillow Biologics, Inc.	23-Feb-21
L-279-19/0	Chen, Lei		BlueWillow Biologics, Inc.	23-Feb-21
L-279-19/0	Chen, Man		BlueWillow Biologics, Inc.	23-Feb-21
L-279-19/0	Chen, Mingzong		BlueWillow Biologics, Inc.	23-Feb-21
L-279-19/0	Chen, Peifeng		BlueWillow Biologics, Inc.	23-Feb-21
L-279-19/0	Chuang, Gwo-Yu		BlueWillow Biologics, Inc.	23-Feb-21
L-279-19/0	Georgiev, Ivelin S.		BlueWillow Biologics, Inc.	23-Feb-21
L-279-19/0	Ghosh, Mridul K.		BlueWillow Biologics, Inc.	23-Feb-21
L-279-19/0	Gorman, Jason		BlueWillow Biologics, Inc.	23-Feb-21



(b) (4), (b) (3) (A), (b) (6)

L-279-19/0	Graham, Barney	(b)(4);	BlueWillow Biologics,Inc.	23-Feb-21
L-279-19/0	Horwitz, Joseph	(b)(6)	BlueWillow Biologics,Inc.	23-Feb-21
L-279-19/0	Joyce, Michael G.		BlueWillow Biologics,Inc.	23-Feb-21
L-279-19/0	Kanekiyo, Masaru		BlueWillow Biologics,Inc.	23-Feb-21
L-279-19/0	Kwong, Peter D.		BlueWillow Biologics,Inc.	23-Feb-21
L-279-19/0	McLellan, Jason Scott		BlueWillow Biologics,Inc.	23-Feb-21
L-279-19/0	Nagy, Attila		BlueWillow Biologics,Inc.	23-Feb-21
L-279-19/0	OFEK, GILAD A		BlueWillow Biologics,Inc.	23-Feb-21
L-279-19/0	Pancera, Marie L.		BlueWillow Biologics,Inc.	23-Feb-21
L-279-19/0	Sastry, Mallika		BlueWillow Biologics,Inc.	23-Feb-21
L-279-19/0	Soto, Cinque		BlueWillow Biologics,Inc.	23-Feb-21
L-279-19/0	Srivatsan, Sanjay R.		BlueWillow Biologics,Inc.	23-Feb-21
L-279-19/0	Stewart-Jones, Guillaume BE		BlueWillow Biologics,Inc.	23-Feb-21
L-279-19/0	(b) (4)		BlueWillow Biologics,Inc.	23-Feb-21
L-279-19/0	YANG, YONGPING		BlueWillow Biologics,Inc.	23-Feb-21
L-279-19/0	Zhang, Baoshan		BlueWillow Biologics,Inc.	23-Feb-21
L-279-19/0	Zhou, Tongqing		BlueWillow Biologics,Inc.	23-Feb-21
L-099-14/2	Garboczi, David		KeraFAST	23-Feb-21
L-099-14/2	Lantz, Larry		KeraFAST	23-Feb-21
L-099-14/2	Leppla, Stephen H.		KeraFAST	23-Feb-21
L-099-14/2	Leysath, Clinton E.		KeraFAST	23-Feb-21
L-099-14/2	Phillips, Damilola D.		KeraFAST	23-Feb-21
L-057-18/0	Akin, Cem		Opsidio, LLC	24-Feb-21
L-057-18/0	Kirshenbaum, Arnold		Opsidio, LLC	24-Feb-21
L-057-18/0	Metcalfe, Dean D		Opsidio, LLC	24-Feb-21
L-057-18/0	Akin, Cem		Opsidio, LLC	24-Feb-21
L-057-18/0	Kirshenbaum, Arnold		Opsidio, LLC	24-Feb-21
L-057-18/0	Metcalfe, Dean D		Opsidio, LLC	24-Feb-21
L-099-14/3	Leppla, Stephen H.		KeraFAST	25-Feb-21
L-099-14/3	Leysath, Clinton E.		KeraFAST	25-Feb-21
L-099-14/3	Phillips, Damilola D.		KeraFAST	25-Feb-21
L-154-06/0	Mackett, Michael		Boehringer Ingelheim Animal Health USA I	25-Feb-21
L-154-06/0	Moss, Bernard		Boehringer Ingelheim Animal Health USA I	25-Feb-21
L-154-06/0	Smith, Geoffrey L		Boehringer Ingelheim Animal Health USA I	25-Feb-21
L-020-15/1	Leppla, Stephen H.		KeraFAST	25-Feb-21

NIH Patent Licensing Activities


NIAID

March 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
L-190-20/0	Boyington, Jeffrey C.	(b)(4);	Meso Scale Diagnostics, LLC	1-Mar-21						(b) (4), (b) (3) (A), (b) (6)
L-190-20/0	Chen, Lei	(b)(6)	Meso Scale Diagnostics, LLC	1-Mar-21						
L-190-20/0	Chen, Man		Meso Scale Diagnostics, LLC	1-Mar-21						
L-190-20/0	Chuang, Gwo-Yu		Meso Scale Diagnostics, LLC	1-Mar-21						
L-190-20/0	(b) (4)		Meso Scale Diagnostics, LLC	1-Mar-21						

L-190-20/0	Georgiev, Ivelin S.	(b)(4);	Meso Scale Diagnostics, LLC	1-Mar-21
L-190-20/0	Gorman, Jason	(b)(6)	Meso Scale Diagnostics, LLC	1-Mar-21
L-190-20/0	Hutchinson, Geoffrey Bain		Meso Scale Diagnostics, LLC	1-Mar-21
L-190-20/0	Joyce, Michael G.		Meso Scale Diagnostics, LLC	1-Mar-21
L-190-20/0	Kanekiyo, Masaru		Meso Scale Diagnostics, LLC	1-Mar-21
L-190-20/0	Kwong, Peter D.		Meso Scale Diagnostics, LLC	1-Mar-21
L-190-20/0	McLellan, Jason Scott		Meso Scale Diagnostics, LLC	1-Mar-21
L-190-20/0	OFEK, GILAD A		Meso Scale Diagnostics, LLC	1-Mar-21
L-190-20/0	Pancera, Marie L.		Meso Scale Diagnostics, LLC	1-Mar-21
L-190-20/0	Sastry, Mallika		Meso Scale Diagnostics, LLC	1-Mar-21
L-190-20/0	(b) (4)		Meso Scale Diagnostics, LLC	1-Mar-21
L-190-20/0	Soto, Cinque		Meso Scale Diagnostics, LLC	1-Mar-21
L-190-20/0	Srivatsan, Sanjay R.		Meso Scale Diagnostics, LLC	1-Mar-21
L-190-20/0	Stewart-Jones, Guillaume BE		Meso Scale Diagnostics, LLC	1-Mar-21
L-190-20/0	(b) (4)		Meso Scale Diagnostics, LLC	1-Mar-21
L-190-20/0	YANG, YONGPING		Meso Scale Diagnostics, LLC	1-Mar-21
L-190-20/0	Yassine, Hadi M.		Meso Scale Diagnostics, LLC	1-Mar-21
L-190-20/0	Zhang, Baoshan		Meso Scale Diagnostics, LLC	1-Mar-21
L-190-20/0	Zhou, Tongqing		Meso Scale Diagnostics, LLC	1-Mar-21
L-070-16/1	Akahata, Wataru		Emergent Biosolutions	1-Mar-21
L-070-16/1	Nabel, Gary J		Emergent Biosolutions	1-Mar-21
L-070-16/1	Rao, Srinivas		Emergent Biosolutions	1-Mar-21
L-070-16/1	Sullivan, Nancy J		Emergent Biosolutions	1-Mar-21
L-070-16/1	Yang, Zhi-Yong		Emergent Biosolutions	1-Mar-21
<i>Note: L-070-16/1 split between CDC; NIAID</i>				
L-068-16/1	Cheng, Cheng		Emergent Biosolutions	1-Mar-21
L-068-16/1	Merritt, Joshua S.		Emergent Biosolutions	1-Mar-21
L-068-16/1	Schwartz, Richard M.		Emergent Biosolutions	1-Mar-21
L-089-12/0	Shevach, Ethan M		Miltenyi Biotec GMBH	2-Mar-21
L-044-08/1	Eisenbarth, (b) (6) George		Miltenyi Biotec GMBH	2-Mar-21
<i>Note: L-044-08/1 split between NHLBI; NIAID</i>				
L-098-10/0	Germain, Ronald N.		Miltenyi Biotec GmbH	2-Mar-21
L-098-10/0	Porgador, Angel		Miltenyi Biotec GmbH	2-Mar-21
L-051-11/0	DeVico, Angela M.		Miltenyi Biotec GmbH	2-Mar-21
L-051-11/0	Korty, Patricia E.		Miltenyi Biotec GmbH	2-Mar-21
L-051-11/0	Shevach, Ethan M		Miltenyi Biotec GmbH	2-Mar-21
L-084-02/1	Shevach, Ethan M		Miltenyi Biotec GMBH	2-Mar-21
L-303-19/1	NIAID		TaiMed Biologics USA, Inc	2-Mar-21
L-197-05/6	Chanock, (b) (6) Robert	(b)(4);	Serum Institute of India PVT. LTD	4-Mar-21
L-197-05/6	Hoshino, Yasutaka	(b)(6)	Serum Institute of India PVT. LTD	4-Mar-21
L-197-05/6	Kapikian, (b) (6) Albert Z		Serum Institute of India PVT. LTD	4-Mar-21
L-005-03/1	Ohara, Junichi		Biolegend Inc	5-Mar-21
L-005-03/1	Paul, (b) (6) William E.		Biolegend Inc	5-Mar-21
L-011-08/2	Shevach, Ethan M		BioLegend	5-Mar-21

L-072-09/1	Long, Eric O.	(b)(4);	BioLegend	5-Mar-21
L-072-09/1	Rajagopalan, Sumati	(b)(6)	BioLegend	5-Mar-21
L-162-08/2	Sun, Peter D		Biolegend, Inc	5-Mar-21
L-162-08/2	Zou, Zhongcheng		Biolegend, Inc	5-Mar-21
L-071-10/1	DeVico, Angela M.		BioLegend	5-Mar-21
L-071-10/1	Korty, Patricia E.		BioLegend	5-Mar-21
L-071-10/1	Shevach, Ethan M		BioLegend	5-Mar-21
L-003-11/0	Germain, Ronald N.		Biolegend	5-Mar-21
L-003-11/0	Porgador, Angel		Biolegend	5-Mar-21
L-226-14/1	Nutman, Thomas B.		Quest Diagnostic, Inc	5-Mar-21
L-341-17/0	Garboczi, David		Active Motif, Inc.	5-Mar-21
L-341-17/0	Lantz, Larry		Active Motif, Inc.	5-Mar-21
L-341-17/0	Leppla, Stephen H.		Active Motif, Inc.	5-Mar-21
L-341-17/0	Leysath, Clinton E.		Active Motif, Inc.	5-Mar-21
L-341-17/0	Phillips, Damilola D.		Active Motif, Inc.	5-Mar-21
L-019-20/1	Connors, Mark		ViiV Healthcare UK (No.6) Ltd	8-Mar-21
L-019-20/1	Huang, Jinghe		ViiV Healthcare UK (No.6) Ltd	8-Mar-21
L-019-20/1	Ishida, Elise H.		ViiV Healthcare UK (No.6) Ltd	8-Mar-21
L-019-20/1	Kang, Byong Ha		ViiV Healthcare UK (No.6) Ltd	8-Mar-21
L-019-20/1	Kwong, Peter D.		ViiV Healthcare UK (No.6) Ltd	8-Mar-21
L-019-20/1	Zheng, Anqi		ViiV Healthcare UK (No.6) Ltd	8-Mar-21
L-019-20/1	Zhou, Tongqing		ViiV Healthcare UK (No.6) Ltd	8-Mar-21
L-094-10/0	DeVico, Angela M.		eBioscience	8-Mar-21
L-094-10/0	Korty, Patricia E.		eBioscience	8-Mar-21
L-094-10/0	Shevach, Ethan M		eBioscience	8-Mar-21
L-049-00/1	Shevach, Ethan M		eBioscience, Inc..	8-Mar-21
<i>Note: L-049-00/1 split between NCI; NIAID</i>				
L-153-00/1	Ohara, Junichi		eBioscience	8-Mar-21
L-153-00/1	Paul, (b) (6) William E.		eBioscience	8-Mar-21
L-054-06/0	Germain, Ronald N.		eBioscience	8-Mar-21
L-054-06/0	Porgador, Angel		eBioscience	8-Mar-21
L-102-07/1	Eisenbarth, (b) (6) George		Life Technologies Corporation	9-Mar-21
<i>Note: L-102-07/1 split between NHLBI; NIAID</i>				
L-014-15/0	DeVico, Angela M.		EMD Millipore Corporation	10-Mar-21
L-014-15/0	Korty, Patricia E.		EMD Millipore Corporation	10-Mar-21
L-014-15/0	Shevach, Ethan M		EMD Millipore Corporation	10-Mar-21
L-119-13/0	Jeang, (b) (6) Kuan-Teh		Millipore Sigma	10-Mar-21
L-235-15/0	Best, Sonja M.		EMD Millipore Corp.	10-Mar-21
L-235-15/0	Lubick, Kirk		EMD Millipore Corp.	10-Mar-21
L-235-15/0	Robertson, Shelly J.		EMD Millipore Corp.	10-Mar-21



L-225-94/4	Siebenlist, Ulrich	(b)(4); (b)(6)	Millipore	10-Mar-21
L-050-18/0	Caldwell, Harlan D		Millipore Sigma	10-Mar-21
L-063-18/0	Shevach, Ethan M		Millipore Sigma	10-Mar-21
L-225-94/4	Siebenlist, Ulrich		Millipore	10-Mar-21
L-165-15/0	Davey, Richard T.		Millipore Sigma	10-Mar-21
L-165-15/0	Nutman, Thomas B.		Millipore Sigma	10-Mar-21
L-011-15/1	Garboczi, David		Millipore Sigma	10-Mar-21
L-011-15/1	Lantz, Larry		Millipore Sigma	10-Mar-21
L-011-15/1	Leppla, Stephen H.		Millipore Sigma	10-Mar-21
L-011-15/1	Leysath, Clinton E.		Millipore Sigma	10-Mar-21
L-011-15/1	Phillips, Damilola D.		Millipore Sigma	10-Mar-21
L-179-15/0	Mackett, Michael		Regeneron Pharmaceuticals, Inc.	11-Mar-21
L-179-15/0	Moss, Bernard		Regeneron Pharmaceuticals, Inc.	11-Mar-21
L-179-15/0	Smith, Geoffrey L		Regeneron Pharmaceuticals, Inc.	11-Mar-21
L-001-98/2	Shevach, Ethan M		BD Biosciences	12-Mar-21
L-056-12/0	DeVico, Angela M.		BD Biosciences	12-Mar-21
L-056-12/0	Korty, Patricia E.		BD Biosciences	12-Mar-21
L-056-12/0	Shevach, Ethan M		BD Biosciences	12-Mar-21
L-113-04/1	Jeang, (b) (6) Kuan-Teh		Cell Signaling Technology, Inc.	15-Mar-21
L-113-04/1	Jeang, (b) (6) Kuan-Teh		Cell Signaling Technology, Inc.	15-Mar-21
L-200-18/0	NIAID		Shandong Yidu Biotechnology Co., Ltd.	15-Mar-21
L-117-20/0	Emerson, Suzanne U.	(b)(4); (b)(6)	Southern Research Institute	15-Mar-21
L-117-20/0	Nguyen, Hanh T.		Southern Research Institute	15-Mar-21
L-117-20/0	Purcell, Robert H		Southern Research Institute	15-Mar-21
L-117-20/0	Shukla Bajpai, Priyanka		Southern Research Institute	15-Mar-21
L-117-20/0	Torian, Udana M		Southern Research Institute	15-Mar-21
L-155-18/2	Baxa, Ulrich		Icosavax	18-Mar-21
L-155-18/2	Boyington, Jeffrey C.		Icosavax	18-Mar-21
L-155-18/2	Buchholz, Ursula		Icosavax	18-Mar-21
L-155-18/2	Chen, Lei		Icosavax	18-Mar-21
L-155-18/2	Chen, Man		Icosavax	18-Mar-21
L-155-18/2	Chuang, Gwo-Yu		Icosavax	18-Mar-21
L-155-18/2	Collins, Peter L.		Icosavax	18-Mar-21
L-155-18/2	Druz, Aliaksandr A.		Icosavax	18-Mar-21
L-155-18/2	Galen, Joseph Van		Icosavax	18-Mar-21
L-155-18/2	Georgiev, Ivelin S.		Icosavax	18-Mar-21
L-155-18/2	Gorman, Jason		Icosavax	18-Mar-21
L-155-18/2	Joyce, Michael G.		Icosavax	18-Mar-21
L-155-18/2	Kanekiyo, Masaru		Icosavax	18-Mar-21
L-155-18/2	Kwong, Peter D.		Icosavax	18-Mar-21
L-155-18/2	McLellan, Jason Scott		Icosavax	18-Mar-21

L-155-18/2	OFEK, GILAD A	(b)(4);	Icosavax	18-Mar-21
L-155-18/2	Ou, Li	(b)(6)	Icosavax	18-Mar-21
L-155-18/2	Pancera, Marie L.		Icosavax	18-Mar-21
L-155-18/2	Rundlet, Emily J		Icosavax	18-Mar-21
L-155-18/2	Sastry, Mallika		Icosavax	18-Mar-21
L-155-18/2	Soto, Cinque		Icosavax	18-Mar-21
L-155-18/2	Srivatsan, Sanjay R.		Icosavax	18-Mar-21
L-155-18/2	Stewart-Jones, Guillaume		Icosavax	18-Mar-21
L-155-18/2	Thomas, Paul V.		Icosavax	18-Mar-21
L-155-18/2	Tsybovsky, Yaroslav		Icosavax	18-Mar-21
L-155-18/2	(b) (4)		Icosavax	18-Mar-21
L-155-18/2	YANG, YONGPING		Icosavax	18-Mar-21
L-155-18/2	Zhang, Baoshan		Icosavax	18-Mar-21
L-155-18/2	Zhou, Tongqing		Icosavax	18-Mar-21
L-155-18/2	NIAID		Icosavax	18-Mar-21
L-158-20/0	Abisola Abiona, Olubukola Mar	(b)(4);	AbCellera Biologics Inc.	23-Mar-21
L-158-20/0	Corbett, Kizzmekia	(b)(6)	AbCellera Biologics Inc.	23-Mar-21
L-158-20/0	Graham, Barney		AbCellera Biologics Inc.	23-Mar-21
L-158-20/0	Kong, Wing-pui		AbCellera Biologics Inc.	23-Mar-21
L-158-20/0	Ledgerwood, Julie		AbCellera Biologics Inc.	23-Mar-21
L-158-20/0	Mascola, John R.		AbCellera Biologics Inc.	23-Mar-21
L-158-20/0	Shi, Wei		AbCellera Biologics Inc.	23-Mar-21
L-158-20/0	Wang, Lingshu		AbCellera Biologics Inc.	23-Mar-21
L-158-20/0	Zhang, Yi-Ming		AbCellera Biologics Inc.	23-Mar-21
L-019-08/0	Schubert, Ulrich K		Institut Pasteur	25-Mar-21
L-019-08/0	Yewdell, Jonathan W.		Institut Pasteur	25-Mar-21
<i>Note: L-019-08/0 split between FDA; NCI; NIAID; NIBIB; NIDDK</i>				
L-150-20/0	(b) (4)	(b)(4);	Medigen Vaccine Biologics Corp	25-Mar-21
L-150-20/0	Hutchinson, Geoffrey Bain	(b)(6)	Medigen Vaccine Biologics Corp	25-Mar-21
L-150-20/0	Joyce, Michael G.		Medigen Vaccine Biologics Corp	25-Mar-21
L-150-20/0	Kanekiyo, Masaru		Medigen Vaccine Biologics Corp	25-Mar-21
L-150-20/0	(b) (4).		Medigen Vaccine Biologics Corp	25-Mar-21
L-150-20/0	(b) (4)		Medigen Vaccine Biologics Corp	25-Mar-21
L-150-20/0	Yassine, Hadi M.		Medigen Vaccine Biologics Corp	25-Mar-21
L-258-19/0	Ishizuka, Andrew S		Avidea Technologies	25-Mar-21
L-258-19/0	Seder, Robert		Avidea Technologies	25-Mar-21
L-258-19/0	Zhu, Yaling		Avidea Technologies	25-Mar-21
L-245-94/1	Folks, Thomas M		SearCare Life Sciences	26-Mar-21
L-245-94/1	Martin, Malcolm A		SearCare Life Sciences	26-Mar-21
L-245-94/1	Powell, Douglas M		SearCare Life Sciences	26-Mar-21
<i>Note: L-245-94/1 split between NCI; NIAID</i>				
L-144-14/1	Baxa, Ulrich		GlaxoSmithKline Biologicals SA	29-Mar-21
L-144-14/1	Boyington, Jeffrey C.		GlaxoSmithKline Biologicals SA	29-Mar-21
L-144-14/1	Chen, Lei		GlaxoSmithKline Biologicals SA	29-Mar-21
L-144-14/1	Chen, Man		GlaxoSmithKline Biologicals SA	29-Mar-21
L-144-14/1	Chuang, Gwo-Yu		GlaxoSmithKline Biologicals SA	29-Mar-21
L-144-14/1	Druz, Aliaksandr A.		GlaxoSmithKline Biologicals SA	29-Mar-21
L-144-14/1	Galen, Joseph Van		GlaxoSmithKline Biologicals SA	29-Mar-21

L-144-14/1	Georgiev, Ivelin S.	(b)(4);	GlaxoSmithKline Biologicals SA	29-Mar-21
L-144-14/1	Gorman, Jason	(b)(6)	GlaxoSmithKline Biologicals SA	29-Mar-21
L-144-14/1	Graham, Barney		GlaxoSmithKline Biologicals SA	29-Mar-21
L-144-14/1	Joyce, Michael G.		GlaxoSmithKline Biologicals SA	29-Mar-21
L-144-14/1	Kanekiyo, Masaru		GlaxoSmithKline Biologicals SA	29-Mar-21
L-144-14/1	Kong, Wing-pui		GlaxoSmithKline Biologicals SA	29-Mar-21
L-144-14/1	Kwong, Peter D.		GlaxoSmithKline Biologicals SA	29-Mar-21
L-144-14/1	Mascola, John R.		GlaxoSmithKline Biologicals SA	29-Mar-21
L-144-14/1	McLellan, Jason Scott		GlaxoSmithKline Biologicals SA	29-Mar-21
L-144-14/1	OFEK, GILAD A		GlaxoSmithKline Biologicals SA	29-Mar-21
L-144-14/1	Ou, Li		GlaxoSmithKline Biologicals SA	29-Mar-21
L-144-14/1	Pancera, Marie L.		GlaxoSmithKline Biologicals SA	29-Mar-21
L-144-14/1	Rundlet, Emily J		GlaxoSmithKline Biologicals SA	29-Mar-21
L-144-14/1	Sastry, Mallika		GlaxoSmithKline Biologicals SA	29-Mar-21
L-144-14/1	Soto, Cinque		GlaxoSmithKline Biologicals SA	29-Mar-21
L-144-14/1	Srivatsan, Sanjay R.		GlaxoSmithKline Biologicals SA	29-Mar-21
L-144-14/1	Stewart-Jones, Guillaume BE		GlaxoSmithKline Biologicals SA	29-Mar-21
L-144-14/1	Thomas, Paul V.		GlaxoSmithKline Biologicals SA	29-Mar-21
L-144-14/1	Tsybovsky, Yaroslav		GlaxoSmithKline Biologicals SA	29-Mar-21
L-144-14/1	YANG, YONGPING		GlaxoSmithKline Biologicals SA	29-Mar-21
L-144-14/1	Zhang, Baoshan		GlaxoSmithKline Biologicals SA	29-Mar-21
L-144-14/1	Zhou, Tongqing		GlaxoSmithKline Biologicals SA	29-Mar-21
L-221-16/1	Birmingham, Alison		Sanofi Pasteur	29-Mar-21
L-221-16/1	Buchholz, Ursula		Sanofi Pasteur	29-Mar-21
L-221-16/1	Collins, Peter L.		Sanofi Pasteur	29-Mar-21
L-221-16/1	Graham, Barney		Sanofi Pasteur	29-Mar-21
L-221-16/1	Kwong, Peter D.		Sanofi Pasteur	29-Mar-21
L-221-16/1	Liang, Bo		Sanofi Pasteur	29-Mar-21
L-221-16/1	Luongo, Cindy L.		Sanofi Pasteur	29-Mar-21
L-221-16/1	McCarty, Thomas Charles		Sanofi Pasteur	29-Mar-21
L-221-16/1	McLellan, Jason Scott		Sanofi Pasteur	29-Mar-21
L-221-16/1	Munir, Shirin		Sanofi Pasteur	29-Mar-21
L-221-16/1	Murphy, Brian R.		Sanofi Pasteur	29-Mar-21
L-221-16/1	Nutt, Anne S.		Sanofi Pasteur	29-Mar-21
L-262-20/0	NIAID		Sanofi Pasteur	29-Mar-21
L-262-20/0	(b) (4)	(b)(4);	Sanofi Pasteur	29-Mar-21
L-262-20/0	Hutchinson, Geoffrey Bain	(b)(6)	Sanofi Pasteur	29-Mar-21
L-262-20/0	Joyce, Michael G.		Sanofi Pasteur	29-Mar-21
L-262-20/0	Kanekiyo, Masaru		Sanofi Pasteur	29-Mar-21
L-262-20/0	(b) (4)		Sanofi Pasteur	29-Mar-21
L-262-20/0			Sanofi Pasteur	29-Mar-21
L-262-20/0	Yassine, Hadi M.		Sanofi Pasteur	29-Mar-21
L-132-20/0	Chen, Zhao Chun		Absolute Antibody Ltd.	30-Mar-21
L-132-20/0	Emerson, Suzanne U.		Absolute Antibody Ltd.	30-Mar-21
L-132-20/0	Leppla, Stephen H.		Absolute Antibody Ltd.	30-Mar-21
L-132-20/0	Purcell, Robert H		Absolute Antibody Ltd.	30-Mar-21
<i>Note: L-132-20/0 split between NIAID; NICHD; NIDCR</i>				
L-079-93/2	Ohara, Junichi	(b)(4);	3D Biosciences - BD PharMingen	31-Mar-21
L-079-93/2	Paul, (b) (6) William E.	(b)(6)	3D Biosciences - BD PharMingen	31-Mar-21

L-074-91/3	Harriman, Gregory R.	(b)(4);	Becton, Dickson and Company	31-Mar-21
L-074-91/3	Kunimoto, Dennis Y.	(b)(6)	Becton, Dickson and Company	31-Mar-21
L-074-91/3	Paul, (b)(6) William E.		Becton, Dickson and Company	31-Mar-21
L-074-91/3	Strober, Warren		Becton, Dickson and Company	31-Mar-21

(b) (4), (b) (3) (A), (b) (6)				
\$34,069,858.61	\$518,542.84	\$34,588,401.45	\$3,372,739.01	\$31,215,662.44

NIH Patent Licensing Activities
NIAMS
October 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	----------------------	---------------------------	-------------------------	---------------------

NIH Patent Licensing Activities
NIAMS
November 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
L-006-21/0 <i>Note: L-006-21/0 split between NHGRI; NIAMS</i>	Kong, Heidi H.	(b)(4); (b)(6)	Federation Bio	9-Nov-20						(b) (4), (b) (3) (A), (b) (6)
L-006-21/0 <i>Note: L-006-21/0 split between NHGRI; NIAMS</i>	Kong, Heidi H.		Federation Bio	9-Nov-20						
L-006-21/0 <i>Note: L-006-21/0 split between NHGRI; NIAMS</i>	Kong, Heidi H.		Federation Bio	9-Nov-20						
L-202-18/0	Brydges, Susannah Diane		University of California, San Diego	13-Nov-20						
L-202-18/0	Kastner, Daniel L		University of California, San Diego	13-Nov-20						

NIH Patent Licensing Activities
NIAMS
December 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
L-243-16/0 <i>Note: L-243-16/0 split between NHLBI; NIAMS</i>	Rao, Mahendra S	(b)(4); (b)(6)	StemCell Technologies Inc.	14-Dec-20						(b) (4), (b) (3) (A), (b) (6)

NIH Patent Licensing Activities
NIAMS
January 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
L-066-05/1	Kinet, Jean-Pierre	(b)(4); (b)(6)	President and Fellows of Harvard College	21-Jan-21						(b) (4), (b) (3) (A), (b) (6)

Note: (b) (4) split between NIAMS; NIDCR

NIH Patent Licensing Activities
NIAMS
February 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
L-243-16/0	Rao, Mahendra S	(b)(4);	StemCell Technologies Inc.	23-Feb-21						(b) (4), (b) (3) (A), (b) (6)
Note: L-243-16/0 split between NHLBI; NIAMS		(b)(6)								
L-076-21/0	Chu, Emily Yin		Petragen Inc.	23-Feb-21						
L-076-21/0	Foster, Brian Lee		Petragen Inc.	23-Feb-21						
L-076-21/0	Nociti, Francisco		Petragen Inc.	23-Feb-21						
L-076-21/0	Somerman, Martha J		Petragen Inc.	23-Feb-21						
L-076-21/0	Thumbigere-Math, Vivek		Petragen Inc.	23-Feb-21						
L-076-21/0	(b) (4)		Petragen Inc.	23-Feb-21						

NIH Patent Licensing Activities
NIAMS
March 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
L-051-13/0	Johnston, James A.	(b)(4);	Cell Signaling Technology Inc	15-Mar-21						(b) (4), (b) (3) (A), (b) (6)
Note: L-051-13/0 split between NCI; NHLBI; NIAMS										
L-243-16/0	NIAMS		StemCell Technologies Inc.	23-Mar-21						
Note: L-243-16/0 split between NHLBI; NIAMS										
					\$45,648.00	\$0.00	\$45,648.00		\$17,652.87	\$27,995.13

NIH Patent Licensing Activities
NIBIB
October 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	----------------------	---------------------------	-------------------------	---------------------

NIH Patent Licensing Activities
NIBIB
November 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
NIBIB

December 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	December 2020			License Cumulative Income	Inventor Awards December	Net Remaining to IC						
					% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income									
L-004-19/0	Chen, Xiaoyuan	(b)(4);	Sinotau Pharmaceutical Group	2-Dec-20						(b) (4), (b) (3) (A), (b) (6)						
L-004-19/0	Weiss, Orit Jacobson	(b)(6)	Sinotau Pharmaceutical Group	2-Dec-20												
L-214-18/0	Parekh, Sapun		Yokogawa Electric Corporation	28-Dec-20												
L-214-18/0	Shroff, Hari		Yokogawa Electric Corporation	28-Dec-20												
L-214-18/0	York, Andrew G.		Yokogawa Electric Corporation	28-Dec-20												
<i>Note: L-214-18/0 split between NHLBI; NIBIB</i>																
L-315-19/0	Chen, Xiaoyuan		Molecular Targeting Technologies, Inc	29-Dec-20												
L-315-19/0	Weiss, Orit Jacobson		Molecular Targeting Technologies, Inc	29-Dec-20												
L-276-18/1	Chen, Xiaoyuan		Molecular Targeting Technologies, Inc	29-Dec-20												
L-276-18/1	Weiss, Orit Jacobson		Molecular Targeting Technologies, Inc	29-Dec-20												
L-022-21/0	Chen, Xiaoyuan		Molecular Targeting Technologies, Inc	29-Dec-20												
L-022-21/0	Weiss, Orit Jacobson		Molecular Targeting Technologies, Inc	29-Dec-20												
L-276-18/1	NIBIB		Molecular Targeting Technologies, Inc	29-Dec-20												

NIH Patent Licensing Activities

NIBIB

January 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	January 2021			License Cumulative Income	Inventor Awards January	Net Remaining to IC
					% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income			

NIH Patent Licensing Activities

NIBIB

February 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	February 2021			License Cumulative Income	Inventor Awards February	Net Remaining to IC
					% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income			

NIH Patent Licensing Activities

NIBIB

March 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	March 2021			License Cumulative Income	Inventor Awards March	Net Remaining to IC						
					% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income									
L-019-08/0	Phillips, Terence M	(b)(4);	Institut Pasteur	25-Mar-21						(b) (4), (b) (3) (A), (b) (6)						
<i>Note: L-019-08/0 split between FDA; NCI; NIAID; NIBIB; NIDDK</i>																
L-214-18/0	NIBIB		Yokogawa Electric Corporation	30-Mar-21												
<i>Note: L-214-18/0 split between NHLBI; NIBIB</i>																
L-214-18/0	Parekh, Sapun	(b)(4);	Yokogawa Electric Corporation	30-Mar-21												

L-214-18/0 Shroff, Hari
 L-214-18/0 York, Andrew G.
 Note: L-214-18/0 split between NHLBI; NIBIB

(b)(4); (b)
 (6) okogawa Electric Corporation
 okogawa Electric Corporation

30-Mar-21
 30-Mar-21

(b) (4), (b) (3) (A), (b) (6)

\$225,209.64 \$19,965.05 \$245,174.69 \$60,405.23 \$184,769.46

NIH Patent Licensing Activities
NICHD
October 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-280-14/1	NICHD		Arche Opitex Biomedical, Inc.	1-Oct-20						(b) (4), (b) (3) (A), (b) (6)
<i>Note: L-280-14/1 split between NICHD; NINDS</i>										
L-280-14/1	NICHD		Arche Opitex Biomedical, Inc.	1-Oct-20						
<i>Note: L-280-14/1 split between NICHD; NINDS</i>										
L-033-97/2	Dressler, Gregory R.	(b)(4); (b)(6)	Biolegend, Inc	7-Oct-20						

NIH Patent Licensing Activities
NICHD
November 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
L-280-14/1	Gandjbakhche, Amir H	(b)(4);	Arche Opitex Biomedical, Inc.	2-Nov-20						(b) (4), (b) (3) (A), (b) (6)
L-280-14/1	(b) (4)	(b)(6)	Arche Opitex Biomedical, Inc.	2-Nov-20						
L-280-14/1	Riley, Jason D.		Arche Opitex Biomedical, Inc.	2-Nov-20						
<i>Note: L-280-14/1 split between NICHD; NINDS</i>										
L-138-93/2	Crouch, Robert J.		Agilent Technologies, Inc.	9-Nov-20						
*L-076-08/0	Robbins, John B.		Emergent Product Development Gaithersbur	12-Nov-20						
*L-076-08/0	Schneerson, Rachel		Emergent Product Development Gaithersbur	12-Nov-20						
<i>Note: L-076-08/0 split between NICHD; NIDCR; NIDDK</i>										

NIH Patent Licensing Activities
NICHD
December 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
L-061-19/0	Chou, Janice Yang	(b)(4); (b)(6)	Ultragenyx Pharmaceutical Inc	4-Dec-20						(b) (4), (b) (3) (A), (b) (6)
L-096-17/0	Chou, Janice Yang		Dimension Therapeutics	4-Dec-20						
L-008-15/1	NICHD		xMD Diagnostics, LLC	10-Dec-20						
<i>Note: L-008-15/1 split between CIT; NCI; NICHD</i>										

L-027-21/0	Chou, Janice Yang	(b)(4); (b)(6)	Intellia Therapeutics, Inc.	17-Dec-20	(b) (4), (b) (3) (A), (b) (6)
L-027-21/0	Chou, Janice Yang	(b)(4); (b)(6)	Intellia Therapeutics, Inc.	17-Dec-20	(b) (4), (b) (3) (A), (b) (6)
L-027-21/0	Chou, Janice Yang	(b)(4); (b)(6)	Intellia Therapeutics, Inc.	17-Dec-20	(b) (4), (b) (3) (A), (b) (6)
L-172-19/0	Romero, Roberto	(b)(4); (b)(6)	Genesis Theranostix Ltd.,	17-Dec-20	(b) (4), (b) (3) (A), (b) (6)
L-002-09/1	Dressler, Gregory R.	(b)(4); (b)(6)	Life Tech	21-Dec-20	(b) (4), (b) (3) (A), (b) (6)

NIH Patent Licensing Activities
NICHD
January 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	----------------------	---------------------------	-------------------------	---------------------

NIH Patent Licensing Activities
NICHD
February 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
L-322-17/0	Chou, Janice Yang	(b)(4); (b)(6)	CRISPR Therapeutics AG	4-Feb-21						(b) (4), (b) (3) (A), (b) (6)
L-138-93/2	Crouch, Robert J.	(b)(4); (b)(6)	Agilent Technologies, Inc.	11-Feb-21						(b) (4), (b) (3) (A), (b) (6)
L-009-05/1	Robbins, John B.	(b)(4); (b)(6)	Snaofi Pasteur	19-Feb-21						(b) (4), (b) (3) (A), (b) (6)
L-009-05/1	Schneerson, Rachel	(b)(4); (b)(6)	Snaofi Pasteur	19-Feb-21						(b) (4), (b) (3) (A), (b) (6)
L-009-05/1	Szu, Shousun C	(b)(4); (b)(6)	Snaofi Pasteur	19-Feb-21						(b) (4), (b) (3) (A), (b) (6)

Note: L-009-05/1 split between NCI; NICHD; NIDDK

NIH Patent Licensing Activities
NICHD
March 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
L-033-97/2	Dressler, Gregory R.	(b)(4); (b)(6)	Biogen, Inc	5-Mar-21						(b) (4), (b) (3) (A), (b) (6)
L-002-09/1	Dressler, Gregory R.	(b)(4); (b)(6)	Life Tech	9-Mar-21						(b) (4), (b) (3) (A), (b) (6)
L-075-14/0	Huang, Freesia	(b)(4); (b)(6)	Millipore Sigma	10-Mar-21						(b) (4), (b) (3) (A), (b) (6)
L-075-14/0	Huang, Kuo-Ping	(b)(4); (b)(6)	Millipore Sigma	10-Mar-21						(b) (4), (b) (3) (A), (b) (6)
L-180-14/0	Dey, Anup K	(b)(4); (b)(6)	Millipore Sigma	10-Mar-21						(b) (4), (b) (3) (A), (b) (6)
L-180-14/0	Ozato Dawid, Keiko	(b)(4); (b)(6)	Millipore Sigma	10-Mar-21						(b) (4), (b) (3) (A), (b) (6)
L-018-99/1	Dawid, Igor	(b)(4); (b)(6)	Millipore Sigma	10-Mar-21						(b) (4), (b) (3) (A), (b) (6)

L-018-99/1	Karavanov, Alex A. or Irina	(b)(4); (b)(6)	Millipore Sigma	10-Mar-21
L-254-02/2	Deligiannidis, Kristina M Galarn	(b)(4)	Millipore Sigma	10-Mar-21
L-254-02/2	Klein, David C.		Millipore Sigma	10-Mar-21
L-254-02/2	(b)(4)		Millipore Sigma	10-Mar-21
L-254-02/2	Weller, Joan		Millipore Sigma	10-Mar-21
L-255-02/2	Huang, Freesia	(b)(4)	Millipore	10-Mar-21
L-255-02/2	Huang, Kuo-Ping		Millipore	10-Mar-21
L-101-21/0	Chou, Janice Yang	(b)(4)	Sangamo Therapeutics, Inc.	17-Mar-21
L-105-21/0	Chou, Janice Yang		GeneSpire	30-Mar-21
L-132-20/0	Dai, Lily Zhongdong		Absolute Antibody Ltd.	30-Mar-21
L-132-20/0	Kubler-Kielb, Joanna	(b)(4)	Absolute Antibody Ltd.	30-Mar-21
L-132-20/0	Schneerson, Rachel		Absolute Antibody Ltd.	30-Mar-21
<i>Note: L-132-20/0 split between NIAID; NICHD; NIDCR</i>				
L-313-19/0	NICHD	(b)(4)	Circumvent Pharmaceuticals, Inc.	30-Mar-21



(b) (4), (b) (3) (A), (b) (6)

\$130,791.19	\$12,261.20	\$143,052.39	\$41,381.68	\$101,670.71
--------------	-------------	--------------	-------------	--------------

* denotes an adjustment to fix a problem from a previous month

NIH Patent Licensing Activities
NIDA
October 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-070-03/2	Wise, Roy A	(b)(4);	Brainsway, Inc.	2-Oct-20	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	(b) (4), (b) (3) (A), (b) (6)
L-070-03/2	Zangen, Abraham	(b)(6)	Brainsway, Inc.	2-Oct-20						
<i>Note: L-070-03/2 split between NIDA; NINDS</i>										
L-070-03/2	Wise, Roy A	(b)(4);	Brainsway, Inc.	13-Oct-20						
L-070-03/2	Zangen, Abraham	(b)(6)	Brainsway, Inc.	13-Oct-20						
<i>Note: L-070-03/2 split between NIDA; NINDS</i>										
L-226-17/0	NIDA		EncepHeal Therapeutics, Inc	19-Oct-20						
L-226-17/0	Cao, Jianjing	(b)(4);	EncepHeal Therapeutics, Inc	19-Oct-20						
L-226-17/0	Newman, Amy H.	(b)(6)	EncepHeal Therapeutics, Inc	19-Oct-20						
L-226-17/0	Okunola-Bakare, Oluyomi M.	(b)(4);	EncepHeal Therapeutics, Inc	19-Oct-20						
L-162-16/3	NIDA		Inversago Pharma Inc.	23-Oct-20						
<i>Note: L-162-16/3 split between NIAAA; NIDA</i>										
L-162-16/3	Rice, Kenner C.	(b)(4);	Inversago Pharma Inc.	26-Oct-20						
<i>Note: L-162-16/3 split between NIAAA; NIDA</i>										

NIH Patent Licensing Activities
NIDA

November 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
L-070-03/2	NIDA		Brainsway, Inc.	10-Nov-20						(b) (4), (b) (3) (A), (b) (6)
<i>Note: L-070-03/2 split between NIDA; NINDS</i>										
L-070-03/2	Wise, Roy A	(b)(4);	Brainsway, Inc.	10-Nov-20						
L-070-03/2	Zangen, Abraham	(b)(6)	Brainsway, Inc.	10-Nov-20						
<i>Note: L-070-03/2 split between NIDA; NINDS</i>										
L-206-18/0	Backman, Christina M	(b)(4);	F. Hoffmann-La Roche Ltd	20-Nov-20						
L-206-18/0	Tomac, Andreas C	(b)(6)	F. Hoffmann-La Roche Ltd	20-Nov-20						

NIH Patent Licensing Activities

NIDA

December 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
L-070-03/2	Wise, Roy A	(b)(4);	Brainsway, Inc.	2-Dec-20						(b) (4), (b) (3) (A), (b) (6)
L-070-03/2	Zangen, Abraham	(b)(6)	Brainsway, Inc.	2-Dec-20						
<i>Note: L-070-03/2 split between NIDA; NINDS</i>										
L-070-03/2	Wise, Roy A	(b)(4);	Brainsway, Inc.	9-Dec-20						
L-070-03/2	Zangen, Abraham	(b)(6)	Brainsway, Inc.	9-Dec-20						
<i>Note: L-070-03/2 split between NIDA; NINDS</i>										
L-257-19/0	Rice, Kenner C.	(b)(4);	Inversago Pharma Inc	10-Dec-20						
<i>Note: L-257-19/0 split between NIAAAA; NIDA</i>										
L-162-16/3	Rice, Kenner C.	(b)(4);	Inversago Pharma Inc.	17-Dec-20						
<i>Note: L-162-16/3 split between NIAAAA; NIDA</i>										

NIH Patent Licensing Activities

NIDA

January 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
L-276-17/0	Rice, Kenner C.	(b)(4);	Vital Spark Inc.	4-Jan-21						(b) (4), (b) (3) (A), (b) (6)
<i>Note: L-276-17/0 split between NIAAAA; NIDA</i>										
L-245-17/1	Cao, Jianjing		Braeburn Pharmaceuticals Inc.	6-Jan-21						
L-245-17/1	Cyriac, George C.		Braeburn Pharmaceuticals Inc.	6-Jan-21						
L-245-17/1	Grundt, Peter		Braeburn Pharmaceuticals Inc.	6-Jan-21						
L-245-17/1	Newman, Amy H.		Braeburn Pharmaceuticals Inc.	6-Jan-21						
L-245-17/1	(b) (4)		Braeburn Pharmaceuticals Inc.	6-Jan-21						
L-220-17/1	Kumar, Vivek		Braeburn Pharmaceuticals Inc.	7-Jan-21						

L-220-17/1	Newman, Amy H.	(b)(4);	Braeburn Pharmaceuticals Inc.	7-Jan-21	(b) (4), (b) (3) (A), (b) (6)
L-220-17/1	Shaik, Anerbasha	(b)(6)	Braeburn Pharmaceuticals Inc.	7-Jan-21	
L-226-17/0	Cao, Jianjing		EncepHeal Therapeutics, Inc	17-Jan-21	
L-226-17/0	Newman, Amy H.		EncepHeal Therapeutics, Inc	17-Jan-21	
L-226-17/0	Okunola-Bakare, Oluyomi M.		EncepHeal Therapeutics, Inc	17-Jan-21	
L-055-20/0	Backman, Christina M		Kallyope, Inc	22-Jan-21	
L-055-20/0	Tomac, Andreas C		Kallyope, Inc	22-Jan-21	
L-067-21/0	Backman, Christina M		Cajal Neuroscience, Inc.	25-Jan-21	
L-067-21/0	Tomac, Andreas C		Cajal Neuroscience, Inc.	25-Jan-21	

**NIH Patent Licensing Activities
NIDA
February 2021**

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

**NIH Patent Licensing Activities
NIDA
March 2021**

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
L-186-20/0	Backman, Christina M	(b)(4);	Maplight Therapeutics	1-Mar-21						(b) (4), (b) (3) (A), (b) (6)
L-186-20/0	Tomac, Andreas C	(b)(6)	Maplight Therapeutics	1-Mar-21						
					\$165,873.50	\$20,895.26	\$186,768.76		\$45,553.25	\$141,215.51

**NIH Patent Licensing Activities
NIDCD
October 2020**

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-084-10/0	Drayna, Dennis T.	(b)(4);	Firmenich Inc.	29-Oct-20						(b) (4), (b) (3) (A), (b) (6)
L-084-10/0	Kim, Un-kyung	(b)(6)	Firmenich Inc.	29-Oct-20						
L-084-10/0	(b) (4)		Firmenich Inc.	29-Oct-20						

**NIH Patent Licensing Activities
NIDCD
November 2020**

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
NIDCD
December 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
L-078-18/0	Chen, Zhong	(b)(4);	miRecule	20-Dec-20						(b) (4), (b) (3) (A), (b) (6)
L-078-18/0	Cheng, Hui	(b)(6)	miRecule	20-Dec-20						
L-078-18/0	Saleh, Anthony		miRecule	20-Dec-20						
L-078-18/0	Van Waes, Carter		miRecule	20-Dec-20						
L-111-06/0	NIDCD		ICAD Inc	23-Dec-20						

Note: L-111-06/0 split between CC; CIT; NIDCD

NIH Patent Licensing Activities
NIDCD
January 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC

NIH Patent Licensing Activities
NIDCD
February 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
L-111-06/0	Selbie, W. Scott	(b)(4);	ICAD Inc	12-Feb-21						(b) (4), (b) (3) (A), (b) (6)
		(b)(6)								
L-154-16/0	Griffith, Andrew J.		Millipore Sigma	17-Feb-21						
L-154-16/0	Labay, Valentia		Millipore Sigma	17-Feb-21						
L-154-16/0	Makishima, Tomoko		Millipore Sigma	17-Feb-21						

NIH Patent Licensing Activities
NIDCD
March 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
L-214-92/8	RJ Wenthold (b) (6)	(b)(4);	EMD Chemicals	10-Mar-21						(b) (4), (b) (3) (A), (b) (6)
		(b)(6)								
L-179-14/0	Montcouquiol, Mireille		Millipore Sigma	10-Mar-21						
					\$40,207.94	\$0.00	\$40,207.94		\$12,375.63	\$27,832.31

NIH Patent Licensing Activities
NIDCR

October 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-032-11/1	NIDCR		Sorrento Therapeutics, Inc	22-Oct-20						(b) (4), (b) (3) (A), (b) (6)
L-072-10/0	NIDCR		Mesoblast Inc.	23-Oct-20						
L-116-11/3	Chiorini, John A.	(b)(4);	uniQure B.V.	28-Oct-20						

Note: L-116-11/3 split between NHLBI; NIDCR

NIH Patent Licensing Activities
NIDCR
November 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
*L-076-08/0	Hsu, Su-Cheng Dana	(b)(4);	Emergent Product Development Gaithersbur	12-Nov-20						(b) (4), (b) (3) (A), (b) (6)
*L-076-08/0	Leppla, Stephen H.	(b)(6)	Emergent Product Development Gaithersbur	12-Nov-20						
*L-076-08/0	Rosovitz, Mary Jo		Emergent Product Development Gaithersbur	12-Nov-20						

Note: L-076-08/0 split between NICHD; NIDCR; NIDDK

L-152-17/0	Akiyama, Steven	(b)(4);	Millipore Sigma	18-Nov-20						
L-152-17/0	Yamada, Kenneth	(b)(6)	Millipore Sigma	18-Nov-20						
L-152-17/0	Yamada, Susan Sleeper		Millipore Sigma	18-Nov-20						
L-152-02/3	Leppla, Stephen H.		Emergent BioDefense	25-Nov-20						
L-152-02/3	Park, Sukjoon		Emergent BioDefense	25-Nov-20						
L-152-02/3	Quinn, Conrad P.		Emergent BioDefense	25-Nov-20						
L-152-02/3	Singh, Yogendra		Emergent BioDefense	25-Nov-20						

Note: L-152-02/3 split between NIAID; NIDCR

NIH Patent Licensing Activities
NIDCR
December 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
L-116-11/3	Chiorini, John A.	(b)(4);	uniQure B.V.	11-Dec-20						(b) (4), (b) (3) (A), (b) (6)

Note: L-116-11/3 split between NHLBI; NIDCR

L-102-17/0	Keith, Jerry M	(b)(4);	Inventprise LLC	14-Dec-20						
L-102-17/0	Merkel, Todd J.	(b)(6)	Inventprise LLC	14-Dec-20						
L-102-17/0	Yang, Xiaoming		Inventprise LLC	14-Dec-20						
L-182-17/0	Kulkarni, Ashok		Freeline Therapeutics Limited	24-Dec-20						
L-182-17/0	Ohshima, Toshio		Freeline Therapeutics Limited	24-Dec-20						

Note: L-182-17/0 split between NIDCR; NINDS

NIH Patent Licensing Activities
NIDCR
January 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC	
L-248-15/1	Burbelo, Peter D.	(b)(4);	InBios International, Inc.	5-Jan-21						(b) (4), (b) (3) (A), (b) (6)	
L-248-15/1	Iadarola, Michael J.	(b)(6)	InBios International, Inc.	5-Jan-21							
<i>Note: L-248-15/1 split between NIAID; NIDCR</i>											
L-181-14/0	Burbelo, Peter D.	(b)(4);	InBios International Inc	5-Jan-21							
<i>Note: L-181-14/0 split between NIAID; NIDCR</i>											
L-171-08/1	Siraganian, Reuben		BD Biosciences	11-Jan-21							
L-111-17/0	Akiyama, Steven		BD Biosciences	11-Jan-21							
L-111-17/0	Yamada, Kenneth		BD Biosciences	11-Jan-21							
L-116-11/3	NIDCR		uniQure B.V.	19-Jan-21							
<i>Note: L-116-11/3 split between NHLBI; NIDCR</i>											
L-066-05/1	Siraganian, Reuben	(b)(4);	President and Fellows of Harvard College	21-Jan-21							
<i>Note: L-066-05/1 split between NIAMS; NIDCR</i>											
L-048-03/1	Elkin, Michael		Lees Pharmaceutical (HK) LTD	22-Jan-21							
L-048-03/1	Kleinman, Hynda		Lees Pharmaceutical (HK) LTD	22-Jan-21							
L-048-03/1	Philp, Deborah		Lees Pharmaceutical (HK) LTD	22-Jan-21							
L-102-09/1	Siraganian, Reuben		Bio-Rad AbD	22-Jan-21							
L-115-20/0	Chiorini, John A.		Kriya Therapeutics, Inc.	22-Jan-21							
L-115-20/0	Pasquale, Giovanni Di		Kriya Therapeutics, Inc.	22-Jan-21							
L-078-15/0	Chiorini, John A.		Spark Therapeutics, Inc.	27-Jan-21							
L-078-15/0	Kaludov, Nikola		Spark Therapeutics, Inc.	27-Jan-21							

NIH Patent Licensing Activities
NIDCR
February 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC	
L-115-00/2	Leppla, Stephen H.	(b)(4);	List Biological Laboratories, Inc.	1-Feb-21						(b) (4), (b) (3) (A), (b) (6)	
<i>Note: L-115-00/2 split between NIAID; NIDCR</i>											
L-343-01/0	Keith, Jerry M		List Biological Laboratories, Inc.	1-Feb-21							
L-343-01/0	Merkel, Todd J.		List Biological Laboratories, Inc.	1-Feb-21							
L-343-01/0	Yang, Xiaoming		List Biological Laboratories, Inc.	1-Feb-21							
L-078-15/0	Chiorini, John A.		Spark Therapeutics, Inc.	18-Feb-21							
L-078-15/0	Kaludov, Nikola		Spark Therapeutics, Inc.	18-Feb-21							

L-074-21/0	Chiorini, John A.	(b)(4);	Atsena Therapeutics, Inc	18-Feb-21
L-074-21/0	Pasquale, Giovanni Di	(b)(6)	Atsena Therapeutics, Inc	18-Feb-21
L-074-21/0	Chiorini, John A.		Atsena Therapeutics, Inc	18-Feb-21
L-074-21/0	Pasquale, Giovanni Di		Atsena Therapeutics, Inc	18-Feb-21
L-074-21/0	NIDCR		Atsena Therapeutics, Inc	18-Feb-21
L-024-17/1	Fisher, Larry	(b)(4);	KeraFAST	23-Feb-21

(b) (4), (b) (3) (A), (b) (6)

NIH Patent Licensing Activities
NIDCR
March 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
L-088-12/0	Chiorini, John A.	(b)(4);	Sangamo BioSciences Inc	5-Mar-21						(b) (4), (b) (3) (A), (b) (6)
<i>Note: L-088-12/0 split between NHLBI; NIDCR</i>										
L-233-14/0	Fisher, Larry	(b)(6)	Millipore Sigma	10-Mar-21						
L-152-17/0	Akiyama, Steven		Millipore Sigma	10-Mar-21						
L-152-17/0	Yamada, Kenneth		Millipore Sigma	10-Mar-21						
L-152-17/0	Yamada, Susan Sleeper		Millipore Sigma	10-Mar-21						
L-111-17/0	Akiyama, Steven		BD Biosciences	12-Mar-21						
L-111-17/0	Yamada, Kenneth		BD Biosciences	12-Mar-21						
L-132-20/0	Moayeri, Mahtab		Absolute Antibody Ltd.	30-Mar-21						
<i>Note: L-132-20/0 split between NIAID; NICHD; NIDCR</i>										
					\$288,599.97	\$131,271.35	\$419,871.32		\$70,269.34	\$349,601.98

* denotes an adjustment to fix a problem from a previous month

NIH Patent Licensing Activities
NIEHS
October 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-063-93/2	Eddy, Edward	(b)(4);	ThermoFisher Scientific	29-Oct-20						(b) (4), (b) (3) (A), (b) (6)

NIH Patent Licensing Activities
NIEHS
November 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
NIEHS
December 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
L-244-16/1	(b) (4)	(b)(4);	Sumitomo Pharmaceuticals	18-Dec-20						(b) (4), (b) (3) (A), (b) (6)
L-244-16/1	Moore, Rickie	(b)(6)	Sumitomo Pharmaceuticals	18-Dec-20						
L-244-16/1	Negishi, Masahiko		Sumitomo Pharmaceuticals	18-Dec-20						
L-134-13/1	Mishina, Yuji		Clementia Pharmaceuticals Inc	18-Dec-20						
L-134-13/1	Ray, Manas K.		Clementia Pharmaceuticals Inc	18-Dec-20						
L-134-13/1	Scott, Gregory J.		Clementia Pharmaceuticals Inc	18-Dec-20						

NIH Patent Licensing Activities
NIEHS
January 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
L-060-21/0	Jensen, Patricia	(b)(4);	Vesigen Therapeutics, Inc	21-Jan-21						(b) (4), (b) (3) (A), (b) (6)
L-060-21/0	Plummer, Nicholas W.	(b)(6)	Vesigen Therapeutics, Inc	21-Jan-21						

NIH Patent Licensing Activities
NIEHS
February 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
L-144-04/3	Ehrenshaft, Marilyn I	(b)(4);	Cayman Chemical Company	9-Feb-21						(b) (4), (b) (3) (A), (b) (6)
L-144-04/3	Mason, Ronald P.	(b)(6)	Cayman Chemical Company	9-Feb-21						
L-191-17/0	Jetten, Anton M.		KeraFAST	23-Feb-21						
L-191-17/0	(b) (4)		KeraFAST	23-Feb-21						

NIH Patent Licensing Activities
NIEHS
March 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
L-042-01/3	Beckley, Amy J.	(b)(4);	Pierce Biotechnology	9-Mar-21						(b) (4), (b) (3) (A), (b) (6)
L-042-01/3	Cidlowski, John A.	(b)(6)	Pierce Biotechnology	9-Mar-21						
L-023-15/0	Bradbury, Jennifer Alyce		EMD Millipore Corp.	10-Mar-21						
L-023-15/0	Zeldin, Darryl C		EMD Millipore Corp.	10-Mar-21						

Note: L-023-15/0 split between NCI; NIEHS

L-021-15/0	Bradbury, Jennifer Alyce	(b)(4);	EMD Millipore Corp.	10-Mar-21	(b) (4), (b) (3) (A), (b) (6)
L-021-15/0	Graves, Joan P.	(b)(6)	EMD Millipore Corp.	10-Mar-21	
L-021-15/0	Zeldin, Darryl C		EMD Millipore Corp.	10-Mar-21	
L-063-93/2	Eddy, Edward		hermoFisher Scientific	24-Mar-21	

\$53,861.91	\$0.00	\$53,861.91	\$22,428.91	\$31,433.00
-------------	--------	-------------	-------------	-------------

NIH Patent Licensing Activities
NIMH
October 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-252-20/0	Ginns, Edward I.	(b)(4);	GT Gain Therapeutics SA	5-Oct-20						(b) (4), (b) (3) (A), (b) (6)
L-252-20/0	LaMarca, Mary	(b)(6)	GT Gain Therapeutics SA	5-Oct-20						
L-252-20/0	Ginns, Edward I.		GT Gain Therapeutics SA	5-Oct-20						
L-252-20/0	LaMarca, Mary		GT Gain Therapeutics SA	5-Oct-20						
L-252-20/0	Ginns, Edward I.		GT Gain Therapeutics SA	5-Oct-20						
L-252-20/0	LaMarca, Mary		GT Gain Therapeutics SA	5-Oct-20						
L-252-20/0	Ginns, Edward I.		GT Gain Therapeutics SA	5-Oct-20						
L-252-20/0	LaMarca, Mary		GT Gain Therapeutics SA	5-Oct-20						
L-025-17/1	Zarate, Carlos A.		Tocris Bioscience	9-Oct-20						

Note: L-025-17/1 split between NCATS; NIA; NIMH

NIH Patent Licensing Activities
NIMH
November 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
L-018-10/0	Manji, Hussein K.	(b)(4);	Mount Sinai Med Cntr	3-Nov-20						(b) (4), (b) (3) (A), (b) (6)
L-018-10/0	Zarate, Carlos A.	(b)(6)	Mount Sinai Med Cntr	3-Nov-20						
L-236-18/0	Ginns, Edward I.		Idorsia Pharmaceuticals	10-Nov-20						
L-236-18/0	LaMarca, Mary		Idorsia Pharmaceuticals	10-Nov-20						
L-018-10/0	Manji, Hussein K.		Mount Sinai Med Cntr	13-Nov-20						
L-018-10/0	Zarate, Carlos A.		Mount Sinai Med Cntr	13-Nov-20						
L-050-11/3	Dold, George R.		Passy-Muir	24-Nov-20						
L-050-11/3	Morgan, Newlin T.		Passy-Muir	24-Nov-20						

Note: L-050-11/3 split between NIMH; NINDS

NIH Patent Licensing Activities
NIMH

December 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
NIMH
January 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
L-018-10/0	Manji, Husseini K.	(b)(4);	Mount Sinai Med Cntr	1-Jan-21						(b) (4), (b) (3) (A), (b) (6)
L-018-10/0	Zarate, Carlos A.	(b)(6)	Mount Sinai Med Cntr	1-Jan-21						
L-252-20/0	Ginns, Edward I.		GT Gain Therapeutics SA	7-Jan-21						
L-252-20/0	LaMarca, Mary		GT Gain Therapeutics SA	7-Jan-21						

NIH Patent Licensing Activities
NIMH
February 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
L-261-16/0	Eiden, Maribeth V.	(b)(4);	Fred Hutchinson Cancer Research Center	4-Feb-21						(b) (4), (b) (3) (A), (b) (6)
L-261-16/0	Wilson, Carolyn A.	(b)(6)	Fred Hutchinson Cancer Research Center	4-Feb-21						
L-032-21/0	Ginns, Edward I.		GlaxoSmithKline Research & Development L	12-Feb-21						
L-032-21/0	LaMarca, Mary		GlaxoSmithKline Research & Development L	12-Feb-21						
L-066-21/0	Cohen, Robert M.		Codiak BioSciences, Inc.	23-Feb-21						
L-066-21/0	Ye, Daniel		Codiak BioSciences, Inc.	23-Feb-21						
L-327-02/0	Kowalak, Jeffrey A.		Shimadzu Corp.	24-Feb-21						
L-327-02/0	Markey, Sanford P.		Shimadzu Corp.	24-Feb-21						
L-327-02/0	Masuda, Junichi		Shimadzu Corp.	24-Feb-21						
L-327-02/0	Unsworth, Edward J.		Shimadzu Corp.	24-Feb-21						

NIH Patent Licensing Activities
NIMH
March 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
L-185-20/0	Drevets, Wayne C	(b)(4);	Defender Pharmaceuticals, Inc	1-Mar-21						(b) (4), (b) (3) (A), (b) (6)
L-185-20/0	Furey, Maura L.	(b)(6)	Defender Pharmaceuticals, Inc	1-Mar-21						
L-025-17/1	Zarate, Carlos A.		Tocris Bioscience	18-Mar-21						

Note: L-025-17/1 split between NCATS; NIA; NIMH

\$488,109.74	\$0.00	\$488,109.74	\$114,268.62	\$373,841.12
--------------	--------	--------------	--------------	--------------

NIH Patent Licensing Activities
NINDS
October 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-280-14/1	NINDS		Arche Opitex Biomedical, Inc.	1-Oct-20						(b) (4), (b) (3) (A), (b) (6)
<i>Note: L-280-14/1 split between NICHD; NINDS</i>										
L-280-14/1	NINDS		Arche Opitex Biomedical, Inc.	1-Oct-20						
<i>Note: L-280-14/1 split between NICHD; NINDS</i>										
L-070-03/2	Hallett, Mark	(b)(4);	Brainsway, Inc.	2-Oct-20						
L-070-03/2	Miranda, Pedro	(b)(6)	Brainsway, Inc.	2-Oct-20						
L-070-03/2	Roth, Yiftach		Brainsway, Inc.	2-Oct-20						
<i>Note: L-070-03/2 split between NIDA; NINDS</i>										
L-070-03/2	Hallett, Mark		Brainsway, Inc.	13-Oct-20						
L-070-03/2	Miranda, Pedro		Brainsway, Inc.	13-Oct-20						
L-070-03/2	Roth, Yiftach		Brainsway, Inc.	13-Oct-20						
<i>Note: L-070-03/2 split between NIDA; NINDS</i>										
L-007-19/0	Hsu, Yite		Abcam plc	26-Oct-20						
L-007-19/0	Youle, Richard J.		Abcam plc	26-Oct-20						
L-132-17/0	NINDS		CereDx Inc.	26-Oct-20						
<i>Note: L-132-17/0 split between NIA; NINDS; NINR</i>										
L-170-17/0	NINDS		AestasRx	27-Oct-20						

NIH Patent Licensing Activities
NINDS
November 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
L-280-14/1	Amyot, Franck	(b)(4);	Arche Opitex Biomedical, Inc.	2-Nov-20						(b) (4), (b) (3) (A), (b) (6)
L-280-14/1	Wasserman, Eric M.	(b)(6)	Arche Opitex Biomedical, Inc.	2-Nov-20						
<i>Note: L-280-14/1 split between NICHD; NINDS</i>										
L-070-03/2	NINDS		Brainsway, Inc.	10-Nov-20						
<i>Note: L-070-03/2 split between NIDA; NINDS</i>										
L-070-03/2	Hallett, Mark	(b)(4);	Brainsway, Inc.	10-Nov-20						
L-070-03/2	Miranda, Pedro	(b)(6)	Brainsway, Inc.	10-Nov-20						
L-070-03/2	Roth, Yiftach		Brainsway, Inc.	10-Nov-20						
<i>Note: L-070-03/2 split between NIDA; NINDS</i>										
L-159-07/2	Oldfield, (b) (6) Edward H.		Hope Pharmaceuticals	16-Nov-20						

(b) (4), (b) (3) (A), (b) (6)

L-159-07/2 Pluta, Ryszard M (b)(4); Hope Pharmaceuticals 16-Nov-20
Note: L-159-07/2 split between CC; NHLBI; NIDDK; NINDS

L-050-11/3 Humbert, Ianessa A (b)(4); Passy-Muir 24-Nov-20
L-050-11/3 Lowell, Soren Y (b)(6) Passy-Muir 24-Nov-20
L-050-11/3 Ludlow, Christy L. Passy-Muir 24-Nov-20
L-050-11/3 Poletto, Christopher J. Passy-Muir 24-Nov-20
Note: L-050-11/3 split between NIMH; NINDS

NIH Patent Licensing Activities
NINDS
December 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
L-070-03/2	Hallett, Mark	(b)(4);	Brainsway, Inc.	2-Dec-20						(b) (4), (b) (3) (A), (b) (6)
L-070-03/2	Miranda, Pedro	(b)(6)	Brainsway, Inc.	2-Dec-20						
L-070-03/2	Roth, Yiftach		Brainsway, Inc.	2-Dec-20						
Note: L-070-03/2 split between NIDA; NINDS										
L-132-17/0	Warach, Steven J.		CereDx Inc.	8-Dec-20						
Note: L-132-17/0 split between NIA; NINDS; NINR										
L-070-03/2	Hallett, Mark		Brainsway, Inc.	9-Dec-20						
L-070-03/2	Miranda, Pedro		Brainsway, Inc.	9-Dec-20						
L-070-03/2	Roth, Yiftach		Brainsway, Inc.	9-Dec-20						
Note: L-070-03/2 split between NIDA; NINDS										
L-144-08/1	Hou, Jean		Affymetrix, Inc.	21-Dec-20						
L-144-08/1	Major, Eugene O		Affymetrix, Inc.	21-Dec-20						
L-144-08/1	Messam, Conrad A		Affymetrix, Inc.	21-Dec-20						
L-182-17/0	Brady, (b) (6) Roscoe O		Freeline Therapeutics Limited	24-Dec-20						
L-182-17/0	Murray, Gary J		Freeline Therapeutics Limited	24-Dec-20						
Note: L-182-17/0 split between NIDCR; NINDS										
L-058-13/2	Hou, Jean		BioLegend	30-Dec-20						
L-058-13/2	Major, Eugene O		BioLegend	30-Dec-20						
L-058-13/2	Messam, Conrad A		BioLegend	30-Dec-20						
L-008-08/1	Hsu, Yite		BioLegend	30-Dec-20						
L-008-08/1	Youle, Richard J.		BioLegend	30-Dec-20						
L-198-17/0	Dobersen, Michael J		BioLegend	30-Dec-20						
L-198-17/0	Hammer, Jeffrey A.		BioLegend	30-Dec-20						
L-198-17/0	Noronha, Antonio B		BioLegend	30-Dec-20						
L-198-17/0	Quarles, Richard H.		BioLegend	30-Dec-20						
L-125-04/1	Hou, Jean		BIOLEGEND INC	30-Dec-20						
L-125-04/1	Major, Eugene O		BIOLEGEND INC	30-Dec-20						
L-125-04/1	Messam, Conrad A		BIOLEGEND INC	30-Dec-20						
L-083-11/0	Bielekova, Bibiana B		AbbVie Biotherapeutics, Inc.	30-Dec-20						

(b) (4), (b) (3) (A), (b) (6)

L-083-11/0 Martin, Roland (b)(4); AbbVie Biotherapeutics, Inc. 30-Dec-20
L-083-11/0 McFarland, Henry F. (b)(6) AbbVie Biotherapeutics, Inc. 30-Dec-20

Note: L-083-11/0 split between NCI; NINDS

NIH Patent Licensing Activities

NINDS

January 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
L-170-17/0	NINDS		AestasRx	3-Jan-21						(b) (4), (b) (3) (A), (b) (6)
L-235-97/2	Hsu, Yite	(b)(4);	Southern Biotechnology Assoc.	5-Jan-21						
L-235-97/2	Youle, Richard J.	(b)(6)	Southern Biotechnology Assoc.	5-Jan-21						
L-182-04/2	Hou, Jean		Novus Biologicals Inc	6-Jan-21						
L-182-04/2	Major, Eugene O		Novus Biologicals Inc	6-Jan-21						
L-182-04/2	Messam, Conrad A		Novus Biologicals Inc	6-Jan-21						
L-084-97/4	Hsu, Yite		BD Biosciences	11-Jan-21						
L-084-97/4	Youle, Richard J.		BD Biosciences	11-Jan-21						
L-007-19/0	Hsu, Yite		Abcam plc	25-Jan-21						
L-007-19/0	Youle, Richard J.		Abcam plc	25-Jan-21						

NIH Patent Licensing Activities

NINDS

February 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
L-145-19/0	Oldfield, Estate of Edward H.	(b)(4);	Globin Solutions, Inc	1-Feb-21						(b) (4), (b) (3) (A), (b) (6)
L-145-19/0	Pluta, Ryszard M	(b)(6)	Globin Solutions, Inc	1-Feb-21						
Note: L-145-19/0 split between CC; NHLBI; NIDDK; NINDS										
L-083-11/0	Bielekova, Bibiana B	(b)(4);	AbbVie Biotherapeutics, Inc.	2-Feb-21						
L-083-11/0	Martin, Roland	(b)(6)	AbbVie Biotherapeutics, Inc.	2-Feb-21						
L-083-11/0	McFarland, Henry F.		AbbVie Biotherapeutics, Inc.	2-Feb-21						
Note: L-083-11/0 split between NCI; NINDS										
L-083-11/0	Bielekova, Bibiana B		AbbVie Biotherapeutics, Inc.	17-Feb-21						
L-083-11/0	Martin, Roland		AbbVie Biotherapeutics, Inc.	17-Feb-21						
L-083-11/0	McFarland, Henry F.		AbbVie Biotherapeutics, Inc.	17-Feb-21						
Note: L-083-11/0 split between NCI; NINDS										
L-002-19/0	Lee, Myoung Hwa		Geneuro SA	23-Feb-21						
L-002-19/0	Li, Wenxue		Geneuro SA	23-Feb-21						
L-002-19/0	Nath, Avindra		Geneuro SA	23-Feb-21						
L-002-19/0	Steiner, Joseph Perry		Geneuro SA	23-Feb-21						

NIH Patent Licensing Activities
 NINDS
 March 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
L-050-21/0	Bharti, Kapil	(b)(4);	CellRay, LLC	4-Mar-21						(b) (4), (b) (3) (A), (b) (6)
<i>Note: L-050-21/0 split between NEI; NINDS</i>										
L-012-01/2	Hsu, Yite	(b)(6)	NeoMarkers, Inc.	5-Mar-21						
L-012-01/2	Youle, Richard J.		NeoMarkers, Inc.	5-Mar-21						
L-091-98/3	Hsu, Yite		NeoMarkers, Inc.	5-Mar-21						
L-091-98/3	Youle, Richard J.		NeoMarkers, Inc.	5-Mar-21						
L-065-03/2	Hsu, Yite		Biolegend	5-Mar-21						
L-065-03/2	Youle, Richard J.		Biolegend	5-Mar-21						
L-008-08/1	Hsu, Yite		Biolegend	5-Mar-21						
L-008-08/1	Youle, Richard J.		Biolegend	5-Mar-21						
L-125-04/1	Hou, Jean		BIOLEGEND INC	5-Mar-21						
L-125-04/1	Major, Eugene O		BIOLEGEND INC	5-Mar-21						
L-125-04/1	Messam, Conrad A		BIOLEGEND INC	5-Mar-21						
L-058-13/2	Hou, Jean		BioLegend	5-Mar-21						
L-058-13/2	Major, Eugene O		BioLegend	5-Mar-21						
L-058-13/2	Messam, Conrad A		BioLegend	5-Mar-21						
L-144-08/1	Hou, Jean		Affymetrix, Inc.	8-Mar-21						
L-144-08/1	Major, Eugene O		Affymetrix, Inc.	8-Mar-21						
L-144-08/1	Messam, Conrad A		Affymetrix, Inc.	8-Mar-21						
L-091-15/0	Hsu, Yite		Millipore Sigma	10-Mar-21						
L-091-15/0	Youle, Richard J.		Millipore Sigma	10-Mar-21						
L-264-14/0	Gainer, Harold		Millipore Sigma	10-Mar-21						
L-309-02/2	Hou, Jean		Millipore Sigma	10-Mar-21						
L-309-02/2	Major, Eugene O		Millipore Sigma	10-Mar-21						
L-309-02/2	Messam, Conrad A		Millipore Sigma	10-Mar-21						
L-304-17/3	Youle, Richard J.		Genentech, Inc.	29-Mar-21						
L-208-01/3	Hou, Jean		Millipore Sigma	29-Mar-21						
L-208-01/3	Major, Eugene O		Millipore Sigma	29-Mar-21						
L-208-01/3	Messam, Conrad A		Millipore Sigma	29-Mar-21						
					\$448,231.60	\$12,543.00	\$460,774.60		\$122,836.99	\$337,937.61

NIH Patent Licensing Activities
 NINR
 October 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-132-17/0	NINR		CereDx Inc.	26-Oct-20						(b) (4), (b) (3) (A)

Note: L-132-17/0 split between NIA; NINDS; NINR

NIH Patent Licensing Activities
NINR
November 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
NINR
December 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
L-132-17/0	Barr, Taura L.	(b)(4);	CereDx Inc.	8-Dec-20						(b) (4), (b) (3) (A), (b) (6)

L-132-17/0 University of Pittsburgh (b)(6) CereDx Inc. 8-Dec-20
Note: L-132-17/0 split between NIA; NINDS; NINR

NIH Patent Licensing Activities
NINR
January 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	----------------------	---------------------------	-------------------------	---------------------

NIH Patent Licensing Activities
NINR
February 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities
NINR
March 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	--------------------	---------------------------	-----------------------	---------------------

(b) (4), (b) (3) (A), (b) (6)

NIH Patent Licensing Activities
NLM

October 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total October Income	License Cumulative Income	Inventor Awards October	Net Remaining to IC
L-010-18/0	Lu, Zhiyong	(b)(4);	Ping An Technology (Shenzen) Company LTD	1-Oct-20						(b) (4), (b) (3) (A), (b) (6)
L-010-18/0	Pang, Yifan	(b)(6)	Ping An Technology (Shenzen) Company LTD	1-Oct-20						

Note: L-010-18/0 split between CC; NLM

NIH Patent Licensing Activities

NLM

November 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total November Income	License Cumulative Income	Inventor Awards November	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities

NLM

December 2020

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total December Income	License Cumulative Income	Inventor Awards December	Net Remaining to IC
L-010-18/0	Lu, Zhiyong	(b)(4);	Ping An Technology (Shenzen) Company LTD	23-Dec-20						(b) (4), (b) (3) (A), (b) (6)
L-010-18/0	Pang, Yifan	(b)(6)	Ping An Technology (Shenzen) Company LTD	23-Dec-20						

Note: L-010-18/0 split between CC; NLM

NIH Patent Licensing Activities

NLM

January 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total January Income	License Cumulative Income	Inventor Awards January	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	----------------------	---------------------------	-------------------------	---------------------

NIH Patent Licensing Activities

NLM

February 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total February Income	License Cumulative Income	Inventor Awards February	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-----------------------	---------------------------	--------------------------	---------------------

NIH Patent Licensing Activities

NLM

March 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total March Income	License Cumulative Income	Inventor Awards March	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	--------------------	---------------------------	-----------------------	---------------------

— (b) (4), (b) (3) (A), (b) (6)

National Institutes of Health

Office of Financial Management

Royalties Semiannual Report -- Payments due to Inventors by IC -- Period ending: September 2021

CC

\$7,866.24

Jin, Jianjian

(b) (4), (b) (3) (A),
(b) (6)

Kwak, Jin Tae

Sabatino, Marianna V.

Stroncek, David F.

Summers, Ronald

Wood, Bradford J

Xu, Sheng

CDC

\$155,584.54

Ades, Edwin W.

(b) (4), (b) (3)
(A), (b) (6)

Albarino, Cesar G.

Alisio, Carol H.

Aloisio, Carol H.

Amador, Manuel

Anderson, Burt E.

Anderson, Larry J.

Barclay, Leslie

Barrera, Roberto

Bellini, William J.

Bird, Brian H.

Black, Charlotte M.

Candal, Francisco (Paco) J.

CDC

Chang, Gwong-Jen J.

Chhabra, Preeti

Cox, Nancy J.

Crill, Wayne D.

Davis, Brent S.

Dawson, Jacqueline E.

Devos, Joshua R.

Donis, Ruben O.
Fields, Patricia
Folks, Thomas M
Freeman, Charlotte
Galland, Gale G.
Garcia Lerma, Jose Gerardo
Garcia-Lerma, J. Geraldo
Gentsch, Jon R.
Glass, Roger I.
Granade, Timothy C.
Gregoricus, Nicole
Harmon, Maurice
Heneine, Walid M.
Hierholzer, John C.
Hughes, Holly R
Janssen, Robert
Jiang, Baoming
Katz, Jacqueline M.
Kendal, Alan P.
Kent, Rebekah J.
Khudyakov, Yury E
Klimov, Alexander I.
Komar, Nicholas
Ksiazek, Thomas G.
Leaumont, Collette F.
Lewis, Daniel M.
Lindstrom, Stephen
Loftin, Lamorris
Mackay, Andrew J.
Maher, Kaija
Mark W. Reimer, (b) (6)
McQuiston, John R.
Moore, Deborah D.
Nichol, Stuart T.

(b) (4), (b) (3) (A),
(b) (6)

Olson, Victoria Ann
Otten, Ronald
Pallansch, Mark A.
Panella, Nicholas A.
Parekh, Bharat S.
Pau, Chou-Pong
Phillips, Donald
Reimer, Charles B.
Roehrig, John T.
Rupprecht, Charles E.
Saluzzo, Jean-francious
Schmechel, Detlef
Stockdale, Carol
Tripp, Ralph A.
Tsou, Cecelia

(b) (4)

Vinje, Jan
Wagar, Nicholas
Walls, Harriet
Wang, Yuhuan
Wang, Zhongde
Wells, Thomas
Wu, Xianfu
Yang, Chunfu (Dustin)
Yang, Yong
Zhou, Zhiyong

CIT

\$0.00

FDA

\$21,014.00

Falgout, Barry
Golding, Hana
Khurana, Surender
Markoff, Lewis

(b) (4), (b) (3)
(A), (b) (6)

NCATS

\$243,518.96

Alimardanov, Asaf R

(b) (4), (b) (3) (A),
(b) (6)

Austin, Christopher P.
Deng, Tao
Grewal, Gurmit S
Huang, Junfeng
Huang, Wenwei
Huang, Xiuli
Inglese, James
Jang, Sung-Wook
Jiang, Jian-kang
Lee, Arthur
Liu, Ke
Marugan, Juan J.
McKew, John C.
Morris, Patrick
Patel, Paresma Rasiklal
Patnaik, Samarjit
Sanderson, Philip Edward
Shamim, Khalida
Shen, Min
Simeonov, Anton
Singec, Ilyas
Southall, Noel T.
Svaren, John
Swaroop, Manju
Tawa, Gregory
Thomas, Craig J.
Xiao, Jingbo
Xu, Miao
Xu, Xin
Zheng, Wei
NCI
Aaronson, Stuart A.
Ahlers, Jeffrey D
Aloia, Amanda

(b) (4), (b) (3) (A),
(b) (6)

\$1,872,479.59

(b) (4), (b) (3) (A),
(b) (6)

(b) (4)

Aplan, Peter D.
Austin, Faye C.
Bang, Sook-Hee
Barry, Todd
Baskar, Sivasubramanian
Beers, Richard
Bergamaschi, Cristina
Berzofsky, Jay A.
Beyer*, Rachel
Beyer, Rachel K. B.
Bluestone, Jeffrey A
Bonomi, Carrie A.
Borgel, Suzanne D.

(b) (4)

Brechbiel, Martin W.
Brinkmann, Ulrich
Broadt, Trevor L.
Buck, Christopher
Bustin, Michael
Cafri, Gal
Cao, Boliang (Brian)
Caplen, Natasha

(b) (4)

Chang, Kai
Chang, Nancy T.
Cheng, Sheue-Yann
Choyke, Peter L
Chung-YIn Yang*, James
Colcher, David
Copeland, Amy
Copeland, Neal
Costantino, Nina
Court, Donald

(b) (4), (b) (3) (A), (b)
(6)

Cowan, Kenneth H.
Crowl, Robert
Datta, Simanti
Deniger, Drew
Dimitrov, Dimiter S.
Dougherty*, Kelly
Dougherty, Kelly
Dudley, Mark
Eberle, Jaime A
Eil, Robert Langland
Ellis, Hilary Moyed
Ellmore, Nelson
Esposito, Dominic
Felber, Barbara K.
Feldman, Steven A
Feng, Mingqian
Feng, Yang
Finch, Paul W.
Fisher, Amanda G.
Fitzgerald, David J.
Fitzgerald, Peter C.
Franchini, Genoveffa
Fry, Terry
Gao, Wei
Garmestani, Kayhan
Gartner, Suzanne
Gattinoni, Luca
Gazdar, (b) (6) Adi
Gelboin, (b) (6) Harry
(b) (4)
Giard, Donald
Gillette, William K.
Gonzalez, Frank J
Good, Meghan

(b) (4), (b) (3) (A), (b) (6)

Gottesman, Michael M.
Greiner, John W.
Gros, Alena
Grose, Carissa L.
Hahn, Beatrice
Hamilton, Thomas C
Hanada, Kenichi
Hand, Patricia H
Hassan, Raffit
Hathcock, Karen
Hinrichs, Christian S.
Ho, Mitchell
Hodes, Richard J
Hodge, James W.
Holderfield, Matthew T.
Hollingshead, Melinda G.
Hopkins, Ralph F.
(b) (4)
Islam, S M Rafiqul
Ito, Hiroyasu
Jenkins Copeland, Nancy A
Jensen, Roy A.
Jin*, Benjamin Yongzu
Jin, Benjamin Yongzu
Johnson, Bruce E
JONES, JENNIFER
Jung, Sun-Hee
Kalyanaraman, Vaniambadi S.
Kawakami, Yutaka
Kawamura, Masaru
Kaye, Frederic J
Kheif*, Samir
Khleif*, Samir N.
Khleif, Samir N.

(b) (4), (b) (3) (A), (b)
(6)

Kim, Heungnam
Kim, Jung-Hwan
Kim, Sanghyun
King, Charles R.
Kirnbauer, Reinhard
Kishton, Rigel Joseph
Klemen, Nicholas Donald
Klinman, Dennis
Kozlov, Serguei
Kraus, (b) (6) Matthias
Krausz, Kristopher W.
Kreitman, Robert J
Krishna, Sri
Kuan, Chien-Tsun
Lacal, Juan C.
Lam, Norris
LaRochelle, William
Laszlo, Gloria
Lee, Byungkook
Lee, E-Chiang
Leo, Oberdan
Levin, Noam
Li, Dan
Li, Nan
Lin, Ying-Wei
Liu, Pentao
Liu, Wenhai
Lo, Winifred Margaret
Lorenzi, Philipp
Lori, Franco C.
Lowery, Frank
Lowy, Douglas R.
Lu, Yong-Chen
Maeda, Takuya

(b) (4), (b) (3) (A),
(b) (6)

Malekzadeh, Parisa
Mansfield, Elizabeth
Markham, Phillip D.
Mason, Llewellyn H.
Matsui, Toshimitsu
Mazor, Ronit
McVicar, Daniel W
Minna, John D.
Mitra, Guatam (George)
Morgan, Richard A.
Nagata, Satoshi
Nara, Peter L
Nuti, Marianna
O'Shea, John J.
Oie, (b) (6) Herbert K
Onda, Masanori
Ortaldo, John R.
Ozols, Robert F
Palmer, Douglas
Paria, Biman
Parkhurst, Maria
Parks, Wade P
Pasetto, Anna
Pass, Harvey I
Pastan, Ira H
Pastrana, Diana V
Patel, Shashankkumar
Pavlakis, George N
Pendleton, Charles D.
Phung, Yen T.
Pierce, Jacalyn
Pinto, Peter A
Popovic, Mikulas
Potter, (b) (6) Michael

(b) (4), (b) (3) (A),
(b) (6)

Qasba, Pradman
Qin, Haiying
Rader, Christoph
Ramakrishnan, Boopathy
Reddy, E. Premkumar.
Rein, Alan
Reitz, Jr., Marvin S.
Restifo, Nicholas P.
Robbins, Keith
Robbins, Paul F
Roberts, Veronica Ann
Roden, Richard B
Rosenberg, Steven A.
Rosenwald, Andreas
Rubin, Jeffrey S
Salahuddin, Syed Z.
Salvatore, Giuliana
Sarngadharan, Mangalasseril
Sato, Takashi
Schiller, John T
Schlom, Jeffrey
Shaban, Samir H.
Sharan, Shyam K
Shaw, George M
Shirai, Mutsunori
Shoemaker, Robert H
Slape, Christopher I.
Somerville, Robert P.
Soppet, Dan
Spiese, Paul J
Staudt, Louis M
Stewart, Colin L.
Swaminathan, Srividya
Tamaoki, Naritaka

(b) (4), (b) (3) (A), (b)
(6)

Tang, Zhewei
Tran, Eric
Tsang, Kwong-Yok
Turkbey, Ismail B.
Ueda, Kazumitsu
(b) (4)
Valentin, Antonio L.
Vande Woude, George
Vassall, Aaron
Vizcardo Sakoda, Raul Eduardo
Vodnala, Suman Kumar
Vos, Michele
Wang, Qiong
Warming, Soren
Weinstein, John N.
Weldon, John
Welsh, Joshua
Wiestner, Adrian
Willingham, Mark C.
Wilson, Wyndham H.
Wunderlich, John
Xie, Yueqing
Yang, James C
Yao, Xin
Yim, Sun Hee
Yoseph, Rami
Yu, Daiguan
Yu, Zhiya
Zacharakis, Nikolaos
Zhang, Yifan
Zhang, ZhenHua
Zhao, Chihao
Zheng, Zhili
Zhu, Jianwei

(b) (4), (b) (3) (A),
(b) (6)

Zhu, Shiqui

(b) (4), (b) (3) (A),
(b) (6)

NEI

\$105,504.09

Amaral, Juan A

(b) (4), (b) (3) (A),
(b) (6)

Bharti, Kapil

Charles, Steven Thomas

Gentleman, Susan B.

Hotaling, Nathan

Khristov, Vladimir R.

Maminishkis, Arvydas

National Inst. of Standards and Tech.

Redmond, Thomas M.

Ruchi, Fnu

NHGRI

\$27,097.26

Chandler, Randy J.

(b) (4), (b) (3) (A),
(b) (6)

Goldin, Ehud M.

Manoli*, Eirini

Manoli, Eirini

Motabar, Omid

Sidransky, Ellen

Venditti, Charles P.

Westbroek, Wendy

NHLBI

\$233,488.96

Arai, Andrew Ernest

(b) (4), (b) (3) (A),
(b) (6)

(b) (4)

Childs, Richard W.

Combs, Christian A.

Derbyshire, John Andrew

Ding*, Chuan-Tian

Fitzhugh, Courtney

Hsieh, Matthew M.

Hsu, Li - Yueh

Igarashi, Takehito

Jacobs, Matthew James

(b) (4)

Knepper, Mark A	(b) (4), (b) (3) (A), (b) (6)
Kotin, Robert M.	
Leonard, Alexis	
Leonard, Warren J.	
Li, Lina	
Lin, Jian-Xin	
McVeigh, Elliott R	
Mitra, Suman	
Nezafat, Reza	
Nirenberg, (b) (6) Marshall	
Remaley, Alan T.	
Russell, Sarah M	
Sviridov, Denis O.	
Tisdale, John	
Urabe, Masashi	
Walsh, Frank	
Wolska, Anna	
Wynberg, Jason	
NIA	\$1,344.82
Hodes, Richard J	(b) (4), (b) (3) (A), (b) (6)
Matarin Jimenez, Maria Del Mar	
Moaddel, Ruin	
Singleton, Andrew B.	(b) (4), (b) (3) (A), (b) (6)
NIAAA	
NIAID	\$611,766.95
Akahata, Wataru	(b) (4), (b) (3) (A), (b) (6)
Akin, Cem	
Baxa, Ulrich	
Berminham, Alison	
Blaney, Jr., Joseph E	
Boyington, Jeffrey C.	
Bray, Michael	
Buchholz, Ursula	
Caldwell, Harlan D	

Carey, Elizabeth
Chanock, (b) (6) Robert
Chen, Lei
Chen, Man
Chen, Mingzong
Chen, Peifeng
Cheng, Cheng
Cheung, Yiu Chong Gordon
Chuang, Gwo-Yu
Collins, Peter L.
Connors, Mark
(b) (4)
DeVico, Angela M.
Douek, Daniel
Druz, Aliaksandr A.
Eckels, Kenneth H
Eisenbarth, (b) (6) George
Fauci, Anthony
Folks, Thomas M
Fuerst, Thomas R.
Galen, Joseph Van
Garboczi, David
Georgiev, Ivelin S.
Germain, Ronald N.
Gerner, Michael Y
Ghosh, Mridul K.
Gorman, Jason
Green, Kim Y.
Gupta, Pradeep K.
Hanley, Kathryn
Harriman, Gregory R.
Haynes, Barton F.
Henry, Amy R
Hirsch, Vanessa M.

(b) (4), (b) (3) (A), (b)
(6)

Horwitz, Joseph
Hoshino, Yasutaka
Hsu, Su-Cheng Dana
Hu, Haijing
(b) (4)
Hutchinson, Geoffrey Bain
(b) (4)
Jeang, (b) (6) Kuan-Teh
Joyce, Michael G.
Kanekiyo, Masaru
Kapikian, (b) (6) Albert Z
Kirshenbaum, Arnold
Korty, Patricia E.
Kunimoto, Dennis Y.
Kwon, Young Do
Kwong, Peter D.
Lai, Ching-Juh
Lantz, Larry
Leppla, Stephen H.
Leysath, Clinton E.
Li, Weizhe
Liang, Bo
Long, Eric O.
Lugli, Enrico
Luongo, Cindy L.
Mackett, Michael
Mangalampalli, Venkata R.
Martin, Malcolm A
Mason, Rosemarie D.
McCarty, Thomas Charles
McLellan, Jason Scott
McTamney, Patrick
Men, Ruhe
Merritt, Joshua S.

(b) (4), (b) (3) (A),
(b) (6)

Metcalfe, Dean D
MISASI, JOHN
Moayeri, Mahtab
Moin, Syed M.
Morrison, Richard P.
Moss, Bernard
Mulangu, Sabue
Munir, Shirin
Murphy, Brian R.
Muyembe-Tamfun, Jean-Jacques
Nabel, Gary J
Nagy, Attila
Nutman, Thomas B.
Nutt, Anne S.
OFEK, GILAD A
Ohara, Junichi
Ou, Li
Pancera, Marie L.
Paul, (b) (6) William E.
Pegu, Amarendra
Phillips, Damilola D.
Pletnev, Alexander G
Pomerantsev, Andrei P
Porgador, Angel
Powell, Douglas M
Rajagopalan, Sumati
Rao, Srinivas
Roederer, Mario
Rudicell, Rebecca S.
Rundlet, Emily J
Sastry, Mallika
Schramm, Chaim
Schubert, Ulrich K
Schwartz, Richard M.

(b) (4), (b) (3) (A), (b)
(6)

(b) (4)

Shevach, Ethan M

Smith, Geoffrey L

Sosnovtsev, Stanislav V

Soto, Cinque

Srivatsan, Sanjay R.

Stanley, Daphne Amanda

Stewart-Jones, Guillaume

Stewart-Jones, Guillaume BE

Strober, Warren

Sullivan, Nancy J

(b) (4)

Thomas, Paul V.

Tsybovsky, Yaroslav

United States Army

(b) (4)

(b) (4)

(b) (4)

Wei, Chih-Jen

Whitehead, Stephen S.

Whittle, James R R

Wu, Xueling

Wycuff, Diane L.

(b) (4)

Yang, Eun Sung

YANG, YONGPING

Yang, Zhi-Yong

Yassine, Hadi M.

Yewdell, Jonathan W.

Zhang, Baoshan

Zhang, Yi

Zhou*, Tongqing

Zhou, Tongqing

Zhu, Jiang

(b) (4), (b) (3) (A), (b) (6)

NIAMS

Johnston, James A.
Kinet, Jean-Pierre
Meylan, Francoise
Plotz, Paul H.
Raben, Nina
Siegel, Richard
Song, Yun-Jeong

\$9,595.01

(b) (4), (b) (3)
(A), (b) (6)

NIBIB

Parekh, Sapun
Phillips, Terence M
Shroff, Hari
York, Andrew G.

\$9,939.00

(b) (4), (b) (3) (A),
(b) (6)

NICHD

Blithe, Diana L.
Bridson, William E.
Chou, Janice Yang
Chumakov, Ekaterina
Crouch, Robert J.
Deligiannidis, Kristina M Galarneau
Gandjbakhche, Amir H

\$48,094.32

(b) (4), (b) (3) (A),
(b) (6)

(b) (4)

Hertz, Roy
Kingfield, Joyce G.
Klein, David C.
Kohler, Peter O

(b) (4)

Lawson, Nathan
McDonald, John
Moffett, John R
Namboodiri, Aryan M
Nieman, Lynnette K.
Riley, Jason D.
Roseboom, Patrick

Weinstein, Brant
Weller, Joan
Westphal, Heinrich
Woodgate, Roger

NIDA

Gomez, Juan Luis

(b) (4)

Michaelides, Michael
Morera, Jordi Bonaventura
Wise, Roy A
Zangen, Abraham

NIDCD

Canseco De Kalinec, Gilda Mabel
De Kalinec, Gilda Mabel Canseco
Drayna, Dennis T.
Kalinec, Federico
Kim, Un-kyung
RJ Wenthold, (b) (6)
(b) (4)

NIDCR

Akiyama, Steven
Chiorini, John A.
Fisher, Larry
Gronthos, Stan
Kaludov, Nikola
Keith, Jerry M
Kulkarni, Ashok
Leppla, Stephen H.
Merkel, Todd J.
Miura, Masako
Ohshima, Toshio
Robey, Pamela G.
Seo, Byoung-Moo
Shi, Songtao

(b) (4), (b) (3) (A),
(b) (6)

\$24,398.95

(b) (4), (b) (3) (A),
(b) (6)

\$8,909.08

(b) (4), (b) (3) (A),
(b) (6)

\$136,280.06

(b) (4), (b) (3) (A), (b)
(6)

Siraganian, Reuben

Yamada, Kenneth

Yamada, Susan Sleeper

Yang, Xiaoming

NIDDK

Daly, (b) (6) John W

Goldsmith, Paul K

Jacobson, Kenneth A

Kopp, Jeffrey B

Oral, Elif A.

Ravi, Rama Suresh

Spiegel, Allen M.

Taylor, Simeon

NIEHS

Baek, Seung Joon

Eddy, Edward

Eling, Thomas E

NIMH

Bonner, Tom I

Buckley, Noel

Drevets, Wayne C

Eiden, Maribeth V.

Furey, Maura L.

Mahan, Lawrence C.

Manji, Hussein K.

Wilson, Carolyn A.

Zarate, Carlos A.

NINDS

Amyot, Franck

Bankiewicz, Krystof S.

Brady, (b) (6) Roscoe O

Brann, (b) (6) Mark R

Hallett, Mark

Hou, Jean

(b) (4), (b) (3)
(A), (b) (6)

\$32,852.22

(b) (4), (b) (3)
(A), (b) (6)

\$4,029.01

(b) (4), (b) (3) (A),
(b) (6)

\$102,540.65

(b) (4), (b) (3) (A),
(b) (6)

\$119,606.50

(b) (4), (b) (3) (A),
(b) (6)

Hsu, Yite
Lonser, Russell R
Major, Eugene O
McVittie, Loris D.
Messam, Conrad A
Miranda, Pedro
Monsma, Jr., Frederick J.
Murray, Gary J
Oldfield, (b) (6) Edward H.
Roth, Yiftach
Sanchez Soto, Marta
Sibley, David R.
Warach, Steven J.
Wasserman, Eric M.
Youle, Richard J.

NINR

Barr, Taura L.

(b) (4)

OD

Davis, Matthew T.

Meyer, Payam

Santangelo, George Michael

(b) (4), (b) (3) (A),
(b) (6)

\$2,000.00

(b) (4), (b) (3)
(A), (b) (6)

NIH Patent Licensing Activities
CC
April 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
L-028-18/1	CC		Scanmed LLC	13-Apr-21						(b) (4), (b) (3) (A)

Note: L-028-18/1 split between CC; CIT; NCI

NIH Patent Licensing Activities
CC
May 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
(b) (4)	CC		Scanmed LLC	18-May-21						(b) (4), (b) (3) (A)

Note: L-028-18/1 split between CC; CIT; NCI

NIH Patent Licensing Activities
CC
June 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
L-159-07/2	CC		Hope Pharmaceuticals	17-Jun-21						(b) (4), (b) (3) (A)
L-160-18/0	CC		Advanced Imaging Projects, LLC (AIP)	17-Jun-21						
L-107-15/2	CC		Iovance Biotherapeutics, Inc.	17-Jun-21						
L-028-18/1	CC		Scanmed LLC	30-Jun-21						

Note: L-159-07/2 split between CC; NHLBI; NIDDK; NINDS
Note: L-160-18/0 split between CC; NCI
Note: L-107-15/2 split between CC; NCI
Note: L-028-18/1 split between CC; CIT; NCI

NIH Patent Licensing Activities
CC
July 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
L-107-15/2	Jin, Jianjian	(b)(4)	Iovance Biotherapeutics, Inc.	30-Jul-21						(b) (4), (b) (3) (A), (b) (6)
L-107-15/2	Sabatino, Marianna V.	(b)(6)	Iovance Biotherapeutics, Inc.	30-Jul-21						
L-107-15/2	Stroncek, David F.		Iovance Biotherapeutics, Inc.	30-Jul-21						

Note: L-107-15/2 split between CC; NCI

L-107-15/2 CC
 Note: L-107-15/2 split between CC; NCI

Iovance Biotherapeutics, Inc.

30-Jul-21

(b) (4), (b) (3) (A)

NIH Patent Licensing Activities
 CC
 August 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
L-122-17/0	Kwak, Jin Tae	(b)(4)	Koninklijke Philips N.V.	27-Aug-21						(b) (4), (b) (3) (A), (b) (6)
L-122-17/0	Summers, Ronald	(b)(6)	Koninklijke Philips N.V.	27-Aug-21						
L-122-17/0	Wood, Bradford J		Koninklijke Philips N.V.	27-Aug-21						
L-122-17/0	Xu, Sheng		Koninklijke Philips N.V.	27-Aug-21						

Note (b) (4) split between CC; NCI

NIH Patent Licensing Activities
 CC
 September 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
					\$34,494.73	\$15,910.91	\$50,405.64		\$7,866.24	\$42,539.40

NIH Patent Licensing Activities
 CIT
 April 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
L-028-18/1	CIT		Scanmed LLC	13-Apr-21						(b) (4), (b) (3) (A)

Note: L-028-18/1 split between CC; CIT; NCI

NIH Patent Licensing Activities
 CIT
 May 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
L-028-18/1	CIT		Scanmed LLC	18-May-21						(b) (4), (b) (3) (A)
L-008-15/1	CIT		xMD Diagnostics, LLC	18-May-21						

Note: L-008-15/1 split between CIT; NCI; NICHD

NIH Patent Licensing Activities
CIT
June 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
L-232-14/1	CIT		NanoString Technologies, Inc.	17-Jun-21						(b) (4), (b) (3) (A)
<i>Note: L-232-14/1 split between CIT; NCI</i>										
L-028-18/1	CIT		Scanmed LLC	30-Jun-21						
<i>Note: L-028-18/1 split between CC; CIT; NCI</i>										

NIH Patent Licensing Activities
CIT
July 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-------------------	---------------------------	----------------------	---------------------

NIH Patent Licensing Activities
CIT
August 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	---------------------	---------------------------	------------------------	---------------------

NIH Patent Licensing Activities
CIT
September 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
						\$0.00	\$0.00	\$0.00	\$0.00	\$0.00

NIH Patent Licensing Activities
NCATS
April 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
L-099-21/0	NCATS		Grunenthal GmbH	19-Apr-21						(b) (4), (b) (3) (A), (b) (6)
L-099-21/0	Deng, Tao	(b)(4);	Grunenthal GmbH	19-Apr-21						
L-099-21/0	Simeonov, Anton	(b)(6)	Grunenthal GmbH	19-Apr-21						
L-099-21/0	Singec, Ilyas		Grunenthal GmbH	19-Apr-21						

NIH Patent Licensing Activities

NCATS
May 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
L-055-15/1	Marugan, Juan J.	(b)(4);	Bial-BioTech Investments, Inc.	13-May-21						(b) (4), (b) (3) (A), (b) (6)
L-055-15/1	Patnaik, Samarjit	(b)(6)	Bial-BioTech Investments, Inc.	13-May-21						
L-055-15/1	Southall, Noel T.		Bial-BioTech Investments, Inc.	13-May-21						
L-055-15/1	Zheng, Wei		Bial-BioTech Investments, Inc.	13-May-21						

Note: L-055-15/1 split between NCATS; NHGRI

NIH Patent Licensing Activities

NCATS
June 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
L-076-18/1	Inglese, James	(b)(4); (b)(6)	Lead Discovery Center GmbH	23-Jun-21						(b) (4), (b) (3) (A), (b) (6)
L-076-18/1	Jang, Sung-Wook		Lead Discovery Center GmbH	23-Jun-21						
L-076-18/1	Svaren, John		Lead Discovery Center GmbH	23-Jun-21						

NIH Patent Licensing Activities

NCATS
July 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
L-016-16/0	Marugan, Juan J.	(b)(4);	The General Hospital Corporation	16-Jul-21						(b) (4), (b) (3) (A), (b) (6)

NIH Patent Licensing Activities

NCATS
August 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
L-057-15/0	Austin, Christopher P.	(b)(4);	Vtesse, Inc	31-Aug-21						(b) (4), (b) (3) (A), (b) (6)
L-057-15/0	Liu, Ke	(b)(6)	Vtesse, Inc	31-Aug-21						
L-057-15/0	Marugan, Juan J.		Vtesse, Inc	31-Aug-21						
L-057-15/0	McKew, John C.		Vtesse, Inc	31-Aug-21						
L-057-15/0	Southall, Noel T.		Vtesse, Inc	31-Aug-21						
L-057-15/0	Swaroop, Manju		Vtesse, Inc	31-Aug-21						
L-057-15/0	Xiao, Jingbo		Vtesse, Inc	31-Aug-21						
L-057-15/0	Xu, Miao		Vtesse, Inc	31-Aug-21						

L-057-15/0 Zheng, Wei (b)(4); Vtesse, Inc
 Note: L-057-15/0 split between NCATS; NHGRI

31-Aug-21

(b) (4), (b) (3) (A), (b) (6)

NIH Patent Licensing Activities
 NCATS
 September 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
L-025-17/1	Morris, Patrick	(b)(4);	Tocris Bioscience	16-Sep-21						(b) (4), (b) (3) (A), (b) (6)
L-025-17/1	Thomas, Craig J.	(b)(6)	Tocris Bioscience	16-Sep-21						
Note: L-025-17/1 split between NCATS; NIA; NIMH										
L-128-16/0	Alimardanov, Asaf R	(b)(4);	Massachusetts General Hospital	22-Sep-21						
L-128-16/0	Grewal, Gurmit S	(b)(6)	Massachusetts General Hospital	22-Sep-21						
L-128-16/0	Huang, Xiuli		Massachusetts General Hospital	22-Sep-21						
L-128-16/0	Lee, Arthur		Massachusetts General Hospital	22-Sep-21						
L-128-16/0	McKew, John C.		Massachusetts General Hospital	22-Sep-21						
L-128-16/0	Patel, Paresma Rasiklal		Massachusetts General Hospital	22-Sep-21						
L-128-16/0	Sanderson, Philip Edward		Massachusetts General Hospital	22-Sep-21						
L-128-16/0	Shen, Min		Massachusetts General Hospital	22-Sep-21						
L-128-16/0	Xu, Xin		Massachusetts General Hospital	22-Sep-21						
L-128-16/0	Zheng, Wei		Massachusetts General Hospital	22-Sep-21						
L-128-16/0	Alimardanov, Asaf R		Massachusetts General Hospital	22-Sep-21						
L-128-16/0	Grewal, Gurmit S		Massachusetts General Hospital	22-Sep-21						
L-128-16/0	Huang, Xiuli		Massachusetts General Hospital	22-Sep-21						
L-128-16/0	Lee, Arthur		Massachusetts General Hospital	22-Sep-21						
L-128-16/0	McKew, John C.		Massachusetts General Hospital	22-Sep-21						
L-128-16/0	Patel, Paresma Rasiklal		Massachusetts General Hospital	22-Sep-21						
L-128-16/0	Sanderson, Philip Edward		Massachusetts General Hospital	22-Sep-21						
L-128-16/0	Shen, Min		Massachusetts General Hospital	22-Sep-21						
L-128-16/0	Xu, Xin		Massachusetts General Hospital	22-Sep-21						
L-128-16/0	Zheng, Wei		Massachusetts General Hospital	22-Sep-21						
L-128-16/0	Alimardanov, Asaf R		Massachusetts General Hospital	22-Sep-21						
L-128-16/0	Grewal, Gurmit S		Massachusetts General Hospital	22-Sep-21						
L-128-16/0	Huang, Xiuli		Massachusetts General Hospital	22-Sep-21						
L-128-16/0	Lee, Arthur		Massachusetts General Hospital	22-Sep-21						
L-128-16/0	McKew, John C.		Massachusetts General Hospital	22-Sep-21						

L-128-16/0	Patel, Paresma Rasiklal	(b)(4):	Massachusetts General Hospital	22-Sep-21
L-128-16/0	Sanderson, Philip Edward	(b)(6)	Massachusetts General Hospital	22-Sep-21
L-128-16/0	Shen, Min		Massachusetts General Hospital	22-Sep-21
L-128-16/0	Xu, Xin		Massachusetts General Hospital	22-Sep-21
L-128-16/0	Zheng, Wei		Massachusetts General Hospital	22-Sep-21
L-128-16/0	Alimardanov, Asaf R		Massachusetts General Hospital	22-Sep-21
L-128-16/0	Grewal, Gurmit S		Massachusetts General Hospital	22-Sep-21
L-128-16/0	Huang, Xiuli		Massachusetts General Hospital	22-Sep-21
L-128-16/0	Lee, Arthur		Massachusetts General Hospital	22-Sep-21
L-128-16/0	McKew, John C.		Massachusetts General Hospital	22-Sep-21
L-128-16/0	Patel, Paresma Rasiklal		Massachusetts General Hospital	22-Sep-21
L-128-16/0	Sanderson, Philip Edward		Massachusetts General Hospital	22-Sep-21
L-128-16/0	Shen, Min		Massachusetts General Hospital	22-Sep-21
L-128-16/0	Xu, Xin		Massachusetts General Hospital	22-Sep-21
L-128-16/0	Zheng, Wei		Massachusetts General Hospital	22-Sep-21
L-066-19/0	Alimardanov, Asaf R		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Huang, Junfeng		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Huang, Wenwei		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Huang, Xiuli		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Jiang, Jian-kang		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Lee, Arthur		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Sanderson, Philip Edward		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Shamim, Khalida		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Tawa, Gregory		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Zheng, Wei		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Alimardanov, Asaf R		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Huang, Junfeng		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Huang, Wenwei		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Huang, Xiuli		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Jiang, Jian-kang		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Lee, Arthur		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Sanderson, Philip Edward		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Shamim, Khalida		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Tawa, Gregory		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Zheng, Wei		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Alimardanov, Asaf R		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Huang, Junfeng		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Huang, Wenwei		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Huang, Xiuli		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Jiang, Jian-kang		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Lee, Arthur		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Sanderson, Philip Edward		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Shamim, Khalida		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Tawa, Gregory		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Zheng, Wei		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Alimardanov, Asaf R		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Huang, Junfeng		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Huang, Wenwei		Brigham and Women's Hospital	22-Sep-21

(b) (4), (b) (3) (A), (b) (6)

L-066-19/0	Huang, Xiuli	(b)(4):	Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Jiang, Jian-kang	(b)(6)	Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Lee, Arthur		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Sanderson, Philip Edward		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Shamim, Khalida		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Tawa, Gregory		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Zheng, Wei		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Alimardanov, Asaf R		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Huang, Junfeng		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Huang, Wenwei		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Huang, Xiuli		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Jiang, Jian-kang		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Lee, Arthur		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Sanderson, Philip Edward		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Shamim, Khalida		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Tawa, Gregory		Brigham and Women's Hospital	22-Sep-21
L-066-19/0	Zheng, Wei		Brigham and Women's Hospital	22-Sep-21

\$995,619.83	\$3,977.00	\$999,596.83	\$243,518.96	\$756,077.87
--------------	------------	--------------	--------------	--------------

NIH Patent Licensing Activities

NCI

April 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
L-106-21/0	Copeland, Neal	(b)(4):	Theolytics Ltd	1-Apr-21						(b) (4), (b) (3) (A), (b) (6)
L-106-21/0	Costantino, Nina	(b)(6)	Theolytics Ltd	1-Apr-21						
L-106-21/0	Court, Donald		Theolytics Ltd	1-Apr-21						
L-106-21/0	Ellis, Hilary Moyed		Theolytics Ltd	1-Apr-21						
L-106-21/0	Jenkins Copeland, Nancy A		Theolytics Ltd	1-Apr-21						
L-106-21/0	Lee, E-Chiang		Theolytics Ltd	1-Apr-21						
L-106-21/0	Sharan, Shyam K		Theolytics Ltd	1-Apr-21						
L-106-21/0	Swaminathan, Srividya		Theolytics Ltd	1-Apr-21						
L-106-21/0	Warming, Soren		Theolytics Ltd	1-Apr-21						
L-106-21/0	Yu, Daiguan		Theolytics Ltd	1-Apr-21						
L-075-13/0	Franchini, Genoveffa		Wuxi Apptec Inc	2-Apr-21						
L-075-13/0	Kalyanaraman, Vaniambadi		Wuxi Apptec Inc	2-Apr-21						
L-075-13/0	Markham, Phillip D.		Wuxi Apptec Inc	2-Apr-21						
L-075-13/0	Salahuddin, Syed Z.		Wuxi Apptec Inc	2-Apr-21						
L-091-11/0	Chang, Nancy T.		Quest Diagnostics, Inc.	2-Apr-21						
L-091-11/0	Fisher, Amanda G.		Quest Diagnostics, Inc.	2-Apr-21						
L-091-11/0	Hahn, Beatrice		Quest Diagnostics, Inc.	2-Apr-21						
L-091-11/0	(b) (4)		Quest Diagnostics, Inc.	2-Apr-21						
L-091-11/0	Sarngadharan, Mangalasse		Quest Diagnostics, Inc.	2-Apr-21						
L-024-18/0	Gazdar, (b) (6) Adi		SeraCare Life	2-Apr-21						

L-024-18/0	Johnson, Bruce E	(b)(4);	SeraCare Life	2-Apr-21
L-024-18/0	Kaye, Frederic J	(b)(6)	SeraCare Life	2-Apr-21
L-024-18/0	Khleif*, Samir N.		SeraCare Life	2-Apr-21
L-024-18/0	Minna, John D.		SeraCare Life	2-Apr-21
L-024-18/0	Oie, (b) (6) Herbert K		SeraCare Life	2-Apr-21
L-024-18/0	Pass, Harvey I		SeraCare Life	2-Apr-21
L-161-04/1	(b) (4)		SeraCare Life Sciences, Inc.	2-Apr-21
L-161-04/1	Popovic, Mikulas		SeraCare Life Sciences, Inc.	2-Apr-21
L-161-04/1	Sarngadharan, Mangalasse		SeraCare Life Sciences, Inc.	2-Apr-21
L-161-19/0	Gazdar, (b) (6) Adi		SearCare Life Sciences	2-Apr-21
L-161-19/0	Johnson, Bruce E		SearCare Life Sciences	2-Apr-21
L-161-19/0	Kaye, Frederic J		SearCare Life Sciences	2-Apr-21
L-161-19/0	Khleif*, Samir N.		SearCare Life Sciences	2-Apr-21
L-161-19/0	Minna, John D.		SearCare Life Sciences	2-Apr-21
L-161-19/0	Oie, (b) (6) Herbert K		SearCare Life Sciences	2-Apr-21
L-161-19/0	Pass, Harvey I		SearCare Life Sciences	2-Apr-21
L-081-18/0	NCI		PathoVax LLV	2-Apr-21
L-245-94/1	Sarngadharan, Mangalasse	(b)(4);	SearCare Life Sciences	2-Apr-21
<i>Note: L-245-94/1 split between NCI; NIAID</i>		(b)(6)		
L-140-20/0	Bonomi, Carrie A.		Zymeworks Inc.	5-Apr-21
L-140-20/0	Borgel, Suzanne D.		Zymeworks Inc.	5-Apr-21
L-140-20/0	Dougherty, Kelly		Zymeworks Inc.	5-Apr-21
L-140-20/0	Hollingshead, Melinda G.		Zymeworks Inc.	5-Apr-21
L-138-20/0	Gazdar (b) (6) Adi		Zymeworks Inc.	5-Apr-21
L-138-20/0	Johnson, Bruce E		Zymeworks Inc.	5-Apr-21
L-138-20/0	Kaye, Frederic J		Zymeworks Inc.	5-Apr-21
L-138-20/0	Kheif*, Samir		Zymeworks Inc.	5-Apr-21
L-138-20/0	Minna, John D.		Zymeworks Inc.	5-Apr-21
L-138-20/0	Oie, (b) (6) Herbert K		Zymeworks Inc.	5-Apr-21
L-138-20/0	Pass, Harvey I		Zymeworks Inc.	5-Apr-21
L-138-20/0	Gazdar, (b) (6) Adi		Zymeworks Inc.	5-Apr-21
L-138-20/0	Johnson, Bruce E		Zymeworks Inc.	5-Apr-21
L-138-20/0	Kaye, Frederic J		Zymeworks Inc.	5-Apr-21
L-138-20/0	Kheif*, Samir		Zymeworks Inc.	5-Apr-21
L-138-20/0	Minna, John D.		Zymeworks Inc.	5-Apr-21
L-138-20/0	Oie, (b) (6) Herbert K		Zymeworks Inc.	5-Apr-21
L-138-20/0	Pass, Harvey I		Zymeworks Inc.	5-Apr-21
L-273-14/0	Chang, Nancy T.		Grifols Worldwide Operations Ltd.	6-Apr-21
L-273-14/0	Crowl, Robert		Grifols Worldwide Operations Ltd.	6-Apr-21
L-273-14/0	Fisher, Amanda G.		Grifols Worldwide Operations Ltd.	6-Apr-21
L-273-14/0	Hahn, Beatrice		Grifols Worldwide Operations Ltd.	6-Apr-21
L-273-14/0	Popovic, Mikulas		Grifols Worldwide Operations Ltd.	6-Apr-21
L-273-14/0	Reddy, E. Premkumar.		Grifols Worldwide Operations Ltd.	6-Apr-21
L-273-14/0	Sarngadharan, Mangalasse		Grifols Worldwide Operations Ltd.	6-Apr-21
L-273-14/0	Shaw, George M		Grifols Worldwide Operations Ltd.	6-Apr-21

L-026-05/8	Bang, Sook-Hee	(b)(4);	MedImmune, Inc.	6-Apr-21
L-026-05/8	Beers, Richard	(b)(6)	MedImmune, Inc.	6-Apr-21
L-026-05/8	Brinkmann, Ulrich		MedImmune, Inc.	6-Apr-21
L-026-05/8	Fitzgerald, David J.		MedImmune, Inc.	6-Apr-21
L-026-05/8	Ho, Mitchell		MedImmune, Inc.	6-Apr-21
L-026-05/8	Jung, Sun-Hee		MedImmune, Inc.	6-Apr-21
L-026-05/8	Kreitman, Robert J		MedImmune, Inc.	6-Apr-21
L-026-05/8	Kuan, Chien-Tsun		MedImmune, Inc.	6-Apr-21
L-026-05/8	Lee, Byungkook		MedImmune, Inc.	6-Apr-21
L-026-05/8	Mansfield, Elizabeth		MedImmune, Inc.	6-Apr-21
L-026-05/8	Pastan, Ira H		MedImmune, Inc.	6-Apr-21
L-026-05/8	Salvatore, Giuliana		MedImmune, Inc.	6-Apr-21
L-094-20/1	NCI		Innovative Cellular Therapeutics	6-Apr-21
L-331-17/1	(b) (4)	(b)(4);	Istari Oncology Inc	6-Apr-21
L-331-17/1	Broadt, Trevor L.	(b)(6)	Istari Oncology Inc	6-Apr-21
L-331-17/1	Mitra, Guatam (George)		Istari Oncology Inc	6-Apr-21
L-331-17/1	Shaban, Samir H.		Istari Oncology Inc	6-Apr-21
L-331-17/1	Xie, Yueqing		Istari Oncology Inc	6-Apr-21
L-331-17/1	Zhu, Jianwei		Istari Oncology Inc	6-Apr-21
L-154-18/0	Caplen, Natasha		ERYtech Pharma	6-Apr-21
L-154-18/0	Lorenzi, Philipp		ERYtech Pharma	6-Apr-21
L-154-18/0	Weinstein, John N.		ERYtech Pharma	6-Apr-21
L-136-20/0	Dudley, Mark		Intima Bioscience Inc.	6-Apr-21
L-136-20/0	Fitzgerald, Peter C.		Intima Bioscience Inc.	6-Apr-21
L-136-20/0	Gros, Alena		Intima Bioscience Inc.	6-Apr-21
L-136-20/0	Lu, Yong-Chen		Intima Bioscience Inc.	6-Apr-21
L-136-20/0	Palmer, Douglas		Intima Bioscience Inc.	6-Apr-21
L-136-20/0	Restifo, Nicholas P.		Intima Bioscience Inc.	6-Apr-21
L-136-20/0	Robbins, Paul F		Intima Bioscience Inc.	6-Apr-21
L-136-20/0	Rosenberg, Steven A.		Intima Bioscience Inc.	6-Apr-21
L-136-20/0	Tran, Eric		Intima Bioscience Inc.	6-Apr-21
L-136-20/0	Wunderlich, John		Intima Bioscience Inc.	6-Apr-21
L-136-20/0	Zheng, Zhili		Intima Bioscience Inc.	6-Apr-21
L-013-01/2	Austin, Faye C.		NeoMarkers, Inc.	7-Apr-21
L-013-01/2	Colcher, David		NeoMarkers, Inc.	7-Apr-21
L-013-01/2	Hand, Patricia H		NeoMarkers, Inc.	7-Apr-21
L-013-01/2	Nuti, Marianna		NeoMarkers, Inc.	7-Apr-21
L-013-01/2	Schlom, Jeffrey		NeoMarkers, Inc.	7-Apr-21
L-153-19/1	Beyer, Rachel K. B.		Novartis Institutes for BioMedical Resea	7-Apr-21
L-153-19/1	(b) (4)		Novartis Institutes for BioMedical Resea	7-Apr-21
L-153-19/1	Holderfield, Matthew T.		Novartis Institutes for BioMedical Resea	7-Apr-21
L-153-19/1	Soppet, Dan		Novartis Institutes for BioMedical Resea	7-Apr-21
L-108-19/0	Bonomi, Carrie A.		GB006 (Gossamer Bio, Inc.)	8-Apr-21
L-108-19/0	Borgel, Suzanne D.		GB006 (Gossamer Bio, Inc.)	8-Apr-21
L-108-19/0	Dougherty, Kelly		GB006 (Gossamer Bio, Inc.)	8-Apr-21

L-108-19/0	Hollingshead, Melinda G.	(b)(4); (b)(6)	GB006 (Gossamer Bio, Inc.)	8-Apr-21
L-215-19/0	Gottesman, Michael M.		Vertex Pharmaceuticals Inc	8-Apr-21
L-215-19/0	Pastan, Ira H		Vertex Pharmaceuticals Inc	8-Apr-21
L-215-19/0	Ueda, Kazumitsu		Vertex Pharmaceuticals Inc	8-Apr-21
L-072-20/0	Ho, Mitchell		Janssen Pharmaceutica, N.V.	8-Apr-21
L-072-20/0	Kim, Heungnam		Janssen Pharmaceutica, N.V.	8-Apr-21
L-072-20/0	Pastan, Ira H		Janssen Pharmaceutica, N.V.	8-Apr-21
L-018-20/0	Bonomi, Carrie A.		Recursion Pharmaceuticals, Inc.	8-Apr-21
L-018-20/0	Borgel, Suzanne D.		Recursion Pharmaceuticals, Inc.	8-Apr-21
L-018-20/0	Dougherty, Kelly		Recursion Pharmaceuticals, Inc.	8-Apr-21
L-018-20/0	Hollingshead, Melinda G.		Recursion Pharmaceuticals, Inc.	8-Apr-21
L-099-20/0	Rosenberg, Steven A.		Kite Pharma	8-Apr-21
L-218-19/0	Gazdar, (b) (6) Adi		Kintai Therapeutics	9-Apr-21
L-218-19/0	Johnson, Bruce E		Kintai Therapeutics	9-Apr-21
L-218-19/0	Kaye, Frederic J		Kintai Therapeutics	9-Apr-21
L-218-19/0	Khleif*, Samir N.		Kintai Therapeutics	9-Apr-21
L-218-19/0	Minna, John D.		Kintai Therapeutics	9-Apr-21
L-218-19/0	Oie (b) (6) Herbert K		Kintai Therapeutics	9-Apr-21
L-218-19/0	Pass, Harvey I		Kintai Therapeutics	9-Apr-21
L-218-19/0	Gazdar, (b) (6) Adi		Kintai Therapeutics	9-Apr-21
L-218-19/0	Johnson, Bruce E		Kintai Therapeutics	9-Apr-21
L-218-19/0	Kaye, Frederic J		Kintai Therapeutics	9-Apr-21
L-218-19/0	Khleif*, Samir N.		Kintai Therapeutics	9-Apr-21
L-218-19/0	Minna, John D.		Kintai Therapeutics	9-Apr-21
L-218-19/0	Oie, (b) (6) Herbert K		Kintai Therapeutics	9-Apr-21
L-218-19/0	Pass, Harvey I		Kintai Therapeutics	9-Apr-21
L-213-20/0	Beyer, Rachel K. B.		Bristol Myers Squibb Company	9-Apr-21
L-213-20/0	(b) (4)		Bristol Myers Squibb Company	9-Apr-21
L-213-20/0	Holderfield, Matthew T.		Bristol Myers Squibb Company	9-Apr-21
L-213-20/0	Soppet, Dan		Bristol Myers Squibb Company	9-Apr-21
L-259-19/0	Bonomi, Carrie A.		Senda Biosciences, Inc	9-Apr-21
L-259-19/0	Borgel, Suzanne D.		Senda Biosciences, Inc	9-Apr-21
L-259-19/0	Dougherty, Kelly		Senda Biosciences, Inc	9-Apr-21
L-259-19/0	Hollingshead, Melinda G.		Senda Biosciences, Inc	9-Apr-21
L-097-21/0	Gao, Wei		Senti Biosciences, Inc.	12-Apr-21
L-097-21/0	Ho, Mitchell		Senti Biosciences, Inc.	12-Apr-21
L-097-21/0	Phung, Yen T.		Senti Biosciences, Inc.	12-Apr-21
L-097-21/0	Zhang, Yifan		Senti Biosciences, Inc.	12-Apr-21
L-097-21/0	Gao, Wei		Senti Biosciences, Inc.	12-Apr-21
L-097-21/0	Ho, Mitchell		Senti Biosciences, Inc.	12-Apr-21
L-097-21/0	Phung, Yen T.		Senti Biosciences, Inc.	12-Apr-21
L-097-21/0	Zhang, Yifan		Senti Biosciences, Inc.	12-Apr-21



L-086-11/0	Baskar, Sivasubramanian	(b)(4);	Miltenyi Biotec GMBH	12-Apr-21
L-086-11/0	Rader, Christoph	(b)(6)	Miltenyi Biotec GMBH	12-Apr-21
L-028-18/1	NCI		Scanmed LLC	13-Apr-21
<i>Note: L-028-18/1 split between CC; CIT; NCI</i>				
L-169-15/2	Gottesman, Michael M.	(b)(4);	Enanta Pharmaceuticals, Inc.	13-Apr-21
L-169-15/2	Pastan, Ira H	(b)(6)	Enanta Pharmaceuticals, Inc.	13-Apr-21
L-169-15/2	Ueda, Kazumitsu		Enanta Pharmaceuticals, Inc.	13-Apr-21
L-092-12/2	Bergamaschi, Cristina		Admune Therapeutics LLC	13-Apr-21
L-092-12/2	Felber, Barbara K.		Admune Therapeutics LLC	13-Apr-21
L-092-12/2	Pavlakis, George N		Admune Therapeutics LLC	13-Apr-21
L-092-12/2	Valentin, Antonio L.		Admune Therapeutics LLC	13-Apr-21
L-102-21/0	Felber, Barbara K.		Biolegend, Inc	15-Apr-21
L-102-21/0	Pavlakis, George N		Biolegend, Inc	15-Apr-21
L-102-21/0	Valentin, Antonio L.		Biolegend, Inc	15-Apr-21
L-318-17/0	Onda, Masanori		Millipore Sigma	15-Apr-21
L-318-17/0	Pastan, Ira H		Millipore Sigma	15-Apr-21
L-120-21/0	Bonomi, Carrie A.		pH Pharma Inc.	15-Apr-21
L-120-21/0	Borgel, Suzanne D.		pH Pharma Inc.	15-Apr-21
L-120-21/0	Dougherty, Kelly		pH Pharma Inc.	15-Apr-21
L-120-21/0	Hollingshead, Melinda G.		pH Pharma Inc.	15-Apr-21
L-120-21/0	Bonomi, Carrie A.		pH Pharma Inc.	15-Apr-21
L-120-21/0	Borgel, Suzanne D.		pH Pharma Inc.	15-Apr-21
L-120-21/0	Dougherty, Kelly		pH Pharma Inc.	15-Apr-21
L-120-21/0	Hollingshead, Melinda G.		pH Pharma Inc.	15-Apr-21
L-097-21/0	NCI		Senti Biosciences, Inc.	15-Apr-21
L-052-18/1	Gros, Alena	(b)(4);	MedGene Therapeutics, Inc.	15-Apr-21
		(b)(6)		
L-142-18/0	Gottesman, Michael M.		Takeda California	16-Apr-21
L-142-18/0	Pastan, Ira H		Takeda California	16-Apr-21
L-142-18/0	Ueda, Kazumitsu		Takeda California	16-Apr-21
L-189-16/0	Kirnbauer, Reinhard		HIPRA Scientific	20-Apr-21
L-189-16/0	Lowy, Douglas R.		HIPRA Scientific	20-Apr-21
L-189-16/0	Roden, Richard B		HIPRA Scientific	20-Apr-21
L-189-16/0	Schiller, John T		HIPRA Scientific	20-Apr-21
L-071-19/1	NCI		Atara Biotherapeutics Inc.	22-Apr-21
L-130-19/0	Bonomi, Carrie A.	(b)(4);	Exelixis, Inc.	23-Apr-21
L-130-19/0	Borgel, Suzanne D.	(b)(6)	Exelixis, Inc.	23-Apr-21
L-130-19/0	Dougherty, Kelly		Exelixis, Inc.	23-Apr-21
L-130-19/0	Hollingshead, Melinda G.		Exelixis, Inc.	23-Apr-21
L-139-21/0	Aaronson, Stuart A.		CLS Cell Lines Service GmbH	23-Apr-21

L-139-21/0	Ellmore, Nelson	(b)(4); (b)(6)	CLS Cell Lines Service GmbH	23-Apr-21
L-190-19/3	Cafri, Gal		ZioPharm Oncology, Inc.	23-Apr-21
L-190-19/3	Deniger, Drew		ZioPharm Oncology, Inc.	23-Apr-21
L-190-19/3	Feldman, Steven A		ZioPharm Oncology, Inc.	23-Apr-21
L-190-19/3	Fitzgerald, Peter C.		ZioPharm Oncology, Inc.	23-Apr-21
L-190-19/3	Hanada, Kenichi		ZioPharm Oncology, Inc.	23-Apr-21
L-190-19/3	Levin, Noam		ZioPharm Oncology, Inc.	23-Apr-21
L-190-19/3	Lo, Winifred Margaret		ZioPharm Oncology, Inc.	23-Apr-21
L-190-19/3	Lowery, Frank		ZioPharm Oncology, Inc.	23-Apr-21
L-190-19/3	Lu, Yong-Chen		ZioPharm Oncology, Inc.	23-Apr-21
L-190-19/3	Malekzadeh, Parisa		ZioPharm Oncology, Inc.	23-Apr-21
L-190-19/3	Paria, Biman		ZioPharm Oncology, Inc.	23-Apr-21
L-190-19/3	Parkhurst, Maria		ZioPharm Oncology, Inc.	23-Apr-21
L-190-19/3	Pasetto, Anna		ZioPharm Oncology, Inc.	23-Apr-21
L-190-19/3	Robbins, Paul F		ZioPharm Oncology, Inc.	23-Apr-21
L-190-19/3	Tran, Eric		ZioPharm Oncology, Inc.	23-Apr-21
L-190-19/3	Wang, Qiong		ZioPharm Oncology, Inc.	23-Apr-21
L-190-19/3	Yang, James C		ZioPharm Oncology, Inc.	23-Apr-21
L-190-19/3	Yoseph, Rami		ZioPharm Oncology, Inc.	23-Apr-21
L-190-19/3	Yu, Zhiya		ZioPharm Oncology, Inc.	23-Apr-21
L-190-19/3	Zhao, Chihao		ZioPharm Oncology, Inc.	23-Apr-21
L-190-19/3	Zheng, Zhili		ZioPharm Oncology, Inc.	23-Apr-21
L-032-16/0	NCI		Novartis International Pharmaceuticals	26-Apr-21
L-040-20/0	Greiner, John W.	(b)(4);	Pfizer Inc.	27-Apr-21
L-040-20/0	Schlom, Jeffrey	(b)(6)	Pfizer Inc.	27-Apr-21
L-162-14/0	Gottesman, Michael M.		Pfizer	27-Apr-21
L-162-14/0	Pastan, Ira H		Pfizer	27-Apr-21
L-162-14/0	Ueda, Kazumitsu		Pfizer	27-Apr-21
L-136-21/0	Gazdar, (b) (6) Adi		Vibliome Operations, LLC.	27-Apr-21
L-136-21/0	Johnson, Bruce E		Vibliome Operations, LLC.	27-Apr-21
L-136-21/0	Kaye, Frederic J		Vibliome Operations, LLC.	27-Apr-21
L-136-21/0	Kheif*, Samir		Vibliome Operations, LLC.	27-Apr-21
L-136-21/0	Minna, John D.		Vibliome Operations, LLC.	27-Apr-21
L-136-21/0	Oie, (b) (6) Herbert K		Vibliome Operations, LLC.	27-Apr-21
L-136-21/0	Pass, Harvey I		Vibliome Operations, LLC.	27-Apr-21
L-136-21/0	Gazdar, (b) (6) Adi		Vibliome Operations, LLC.	27-Apr-21
L-136-21/0	Johnson, Bruce E		Vibliome Operations, LLC.	27-Apr-21
L-136-21/0	Kaye, Frederic J		Vibliome Operations, LLC.	27-Apr-21
L-136-21/0	Kheif*, Samir		Vibliome Operations, LLC.	27-Apr-21
L-136-21/0	Minna, John D.		Vibliome Operations, LLC.	27-Apr-21
L-136-21/0	Oie, (b) (6) Herbert K		Vibliome Operations, LLC.	27-Apr-21
L-136-21/0	Pass, Harvey I		Vibliome Operations, LLC.	27-Apr-21
L-116-21/0	Bonomi, Carrie A.		Agenus, Inc.	28-Apr-21
L-116-21/0	Dougherty, Kelly		Agenus, Inc.	28-Apr-21
L-116-21/0	Hollingshead, Melinda G.		Agenus, Inc.	28-Apr-21

(b) (4), (b) (3) (A), (b) (6)

License	Inventor	Share %	Licensee	Date of Deposit	(b) (4), (b) (3) (A), (b) (6)
L-197-94/3	Cheng, Sheue-Yann	(b)(4); (b)(6)	Santa Cruz Biotechnology, Inc.	28-Apr-21	
L-138-05/3	Chang, Kai		Santa Cruz Biotechnology Inc	28-Apr-21	
L-138-05/3	Pastan, Ira H		Santa Cruz Biotechnology Inc	28-Apr-21	
L-138-05/3	Willingham, Mark C.		Santa Cruz Biotechnology Inc	28-Apr-21	
L-031-07/2	Aaronson, Stuart A.		Santa Cruz Biotechnology	28-Apr-21	
L-031-07/2	Lacal, Juan C.		Santa Cruz Biotechnology	28-Apr-21	
L-111-21/0	Hamilton, Thomas C		Engine Biosciences, Inc.	28-Apr-21	
L-111-21/0	Ozols, Robert F		Engine Biosciences, Inc.	28-Apr-21	
L-111-21/0	Hamilton, Thomas C		Engine Biosciences, Inc.	28-Apr-21	
L-111-21/0	Ozols, Robert F		Engine Biosciences, Inc.	28-Apr-21	
L-113-06/1	Kawakami, Yutaka		Santa Cruz Biotechnology Inc	28-Apr-21	
L-165-99/1	Crowl, Robert		Trinity Biotech	29-Apr-21	
L-165-99/1	(b) (4)		Trinity Biotech	29-Apr-21	
L-165-99/1	Reddy, E. Premkumar.		Trinity Biotech	29-Apr-21	
L-165-99/1	Sargadharan, Mangalasse		Trinity Biotech	29-Apr-21	
L-024-21/0	NCI		Vor Biopharma, Inc.	29-Apr-21	
L-079-21/0	Ito, Hiroyasu		Six Therapeutics Inc.	30-Apr-21	
L-079-21/0	Klinman, Dennis		Six Therapeutics Inc.	30-Apr-21	
L-079-21/0	Sato, Takashi		Six Therapeutics Inc.	30-Apr-21	

NIH Patent Licensing Activities
NCI
May 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
L-084-19/0	Gelboin, (b) (6) Harry	(b)(4);	Biopredic U.S., Inc.	1-May-21						(b) (4), (b) (3) (A), (b) (6)
L-084-19/0	Gonzalez, Frank J	(b)(6)	Biopredic U.S., Inc.	1-May-21						
L-084-19/0	Krausz, Kristopher W.		Biopredic U.S., Inc.	1-May-21						
L-086-21/0	Gazdar, (b) (6) Adi		Ocello B.V.	3-May-21						
L-086-21/0	Johnson, Bruce E		Ocello B.V.	3-May-21						
L-086-21/0	Kaye, Frederic J		Ocello B.V.	3-May-21						
L-086-21/0	Kheif*, Samir		Ocello B.V.	3-May-21						
L-086-21/0	Minna, John D.		Ocello B.V.	3-May-21						
L-086-21/0	Oie, (b) (6) Herbert K		Ocello B.V.	3-May-21						
L-086-21/0	Pass, Harvey I		Ocello B.V.	3-May-21						
L-089-18/0	Franchini, Genoveffa		AGC Biologics	3-May-21						
L-089-18/0	Kalyanaraman, Vaniambadi		AGC Biologics	3-May-21						
L-089-18/0	Markham, Phillip D.		AGC Biologics	3-May-21						
L-089-18/0	Salahuddin, Syed Z.		AGC Biologics	3-May-21						

L-224-15/0	NCI	Bluebird Bio	4-May-21
L-116-21/0	Bonomi, Carrie A.	(b)(4); Agenus, Inc.	5-May-21
L-116-21/0	Dougherty, Kelly	(b)(6) Agenus, Inc.	5-May-21
L-116-21/0	Hollingshead, Melinda G.	Agenus, Inc.	5-May-21
L-130-20/1	Hamilton, Thomas C	Janssen Research and Development, LLC	5-May-21
L-130-20/1	Ozols, Robert F	Janssen Research and Development, LLC	5-May-21
L-229-17/0	Bonomi, Carrie A.	Covance Laboratories Inc.	5-May-21
L-229-17/0	Borgel, Suzanne D.	Covance Laboratories Inc.	5-May-21
L-229-17/0	Dougherty, Kelly	Covance Laboratories Inc.	5-May-21
L-229-17/0	Hollingshead, Melinda G.	Covance Laboratories Inc.	5-May-21
L-055-12/1	Gazdar, (b) (6) Adi	Covance Laboratories Inc.	5-May-21
L-055-12/1	Johnson, Bruce E	Covance Laboratories Inc.	5-May-21
L-055-12/1	Kaye, Frederic J	Covance Laboratories Inc.	5-May-21
L-055-12/1	Khleif*, Samir N.	Covance Laboratories Inc.	5-May-21
L-055-12/1	Minna, John D.	Covance Laboratories Inc.	5-May-21
L-055-12/1	Oie, (b) (6) Herbert K	Covance Laboratories Inc.	5-May-21
L-055-12/1	Pass, Harvey I	Covance Laboratories Inc.	5-May-21
L-046-20/0	Bluestone, Jeffrey A	Proteintech Group, Inc.	5-May-21
L-046-20/0	Leo, Oberdan	Proteintech Group, Inc.	5-May-21
L-046-20/0	Vos, Michele	Proteintech Group, Inc.	5-May-21
L-135-21/0	Bonomi, Carrie A.	Arcus Biosciences	6-May-21
L-135-21/0	Dougherty, Kelly	Arcus Biosciences	6-May-21
L-135-21/0	Hollingshead, Melinda G.	Arcus Biosciences	6-May-21
L-128-21/0	Bonomi, Carrie A.	Clovis Oncology, Inc.	6-May-21
L-128-21/0	Borgel, Suzanne D.	Clovis Oncology, Inc.	6-May-21
L-128-21/0	Dougherty, Kelly	Clovis Oncology, Inc.	6-May-21
L-128-21/0	Hollingshead, Melinda G.	Clovis Oncology, Inc.	6-May-21
L-131-21/0	Bonomi, Carrie A.	Orion Corporation	6-May-21
L-131-21/0	Borgel, Suzanne D.	Orion Corporation	6-May-21
L-131-21/0	Dougherty, Kelly	Orion Corporation	6-May-21
L-131-21/0	Hollingshead, Melinda G.	Orion Corporation	6-May-21
L-250-17/0	Bonomi, Carrie A.	Aragen Bioscience, Inc.	7-May-21
L-250-17/0	Borgel, Suzanne D.	Aragen Bioscience, Inc.	7-May-21
L-250-17/0	Dougherty, Kelly	Aragen Bioscience, Inc.	7-May-21
L-250-17/0	Hollingshead, Melinda G.	Aragen Bioscience, Inc.	7-May-21
L-138-20/0	Gazdar, (b) (6) Adi	Zymeworks Inc.	10-May-21
L-138-20/0	Johnson, Bruce E	Zymeworks Inc.	10-May-21
L-138-20/0	Kaye, Frederic J	Zymeworks Inc.	10-May-21
L-138-20/0	Kheif*, Samir	Zymeworks Inc.	10-May-21
L-138-20/0	Minna, John D.	Zymeworks Inc.	10-May-21
L-138-20/0	Oie, (b) (6) Herbert K	Zymeworks Inc.	10-May-21
L-138-20/0	Pass, Harvey I	Zymeworks Inc.	10-May-21

L-132-21/0	Beyer*, Rachel	(b)(4);	Elicio Therapeutics	10-May-21
L-132-21/0	(b) (4)	(b)(6)	Elicio Therapeutics	10-May-21
L-132-21/0	Holderfield, Matthew T.		Elicio Therapeutics	10-May-21
L-132-21/0	Soppet, Dan		Elicio Therapeutics	10-May-21
L-068-18/1	Bonomi, Carrie A.		Dicerna Pharmaceuticals	11-May-21
L-068-18/1	Dougherty, Kelly		Dicerna Pharmaceuticals	11-May-21
L-068-18/1	Hollingshead, Melinda G.		Dicerna Pharmaceuticals	11-May-21
L-248-19/0	Hinrichs, Christian S.		Regeneron Pharmaceuticals, Inc.	11-May-21
L-248-19/0	Jin*, Benjamin Yongzu		Regeneron Pharmaceuticals, Inc.	11-May-21
L-002-16/1	NCI		Kite Pharma, Inc.	11-May-21
L-125-21/0	Beyer*, Rachel	(b)(4);	Relay Therapeutics, Inc	11-May-21
L-125-21/0	(b) (4)	(b)(6)	Relay Therapeutics, Inc	11-May-21
L-125-21/0	Holderfield, Matthew T.		Relay Therapeutics, Inc	11-May-21
L-125-21/0	Soppet, Dan		Relay Therapeutics, Inc	11-May-21
L-126-21/0	Bonomi, Carrie A.		Calico Lfe Sciences	11-May-21
L-126-21/0	Borgel, Suzanne D.		Calico Lfe Sciences	11-May-21
L-126-21/0	Dougherty, Kelly		Calico Lfe Sciences	11-May-21
L-126-21/0	Hollingshead, Melinda G.		Calico Lfe Sciences	11-May-21
L-126-21/0	Bonomi, Carrie A.		Calico Lfe Sciences	11-May-21
L-126-21/0	Borgel, Suzanne D.		Calico Lfe Sciences	11-May-21
L-126-21/0	Dougherty, Kelly		Calico Lfe Sciences	11-May-21
L-126-21/0	Hollingshead, Melinda G.		Calico Lfe Sciences	11-May-21
L-035-19/1	Greiner, John W.		EnGene Inc.	12-May-21
L-035-19/1	Schlom, Jeffrey		EnGene Inc.	12-May-21
L-239-16/1	Bonomi, Carrie A.		Alkermes, Inc.	13-May-21
L-239-16/1	Borgel, Suzanne D.		Alkermes, Inc.	13-May-21
L-239-16/1	Dougherty, Kelly		Alkermes, Inc.	13-May-21
L-239-16/1	Hollingshead, Melinda G.		Alkermes, Inc.	13-May-21
L-289-19/0	Bonomi, Carrie A.		Alkermes	13-May-21
L-289-19/0	Dougherty, Kelly		Alkermes	13-May-21
L-289-19/0	Hollingshead, Melinda G.		Alkermes	13-May-21
L-086-16/0	Bonomi, Carrie A.		Compass Therapeutics, LLC	13-May-21
L-086-16/0	Dougherty, Kelly		Compass Therapeutics, LLC	13-May-21
L-086-16/0	Hollingshead, Melinda G.		Compass Therapeutics, LLC	13-May-21
L-143-21/0	Bonomi, Carrie A.		Senda Biosciences, Inc.	14-May-21
L-143-21/0	Borgel, Suzanne D.		Senda Biosciences, Inc.	14-May-21
L-143-21/0	Dougherty, Kelly		Senda Biosciences, Inc.	14-May-21
L-143-21/0	Hollingshead, Melinda G.		Senda Biosciences, Inc.	14-May-21
L-279-17/0	Bonomi, Carrie A.		OncodesignBiotechnology	17-May-21
L-279-17/0	Borgel, Suzanne D.		OncodesignBiotechnology	17-May-21
L-279-17/0	Dougherty, Kelly		OncodesignBiotechnology	17-May-21

(b) (4), (b) (3) (A), (b) (6)

L-279-17/0	Hollingshead, Melinda G.	(b)(4); (b)(6)	OncodesignBiotechnology	17-May-21
L-039-11/0	Onda, Masanori		Rockland Immunochemicals, Inc.	17-May-21
L-039-11/0	Pastan, Ira H		Rockland Immunochemicals, Inc.	17-May-21
L-224-15/0	NCI		Bluebird Bio	17-May-21
L-028-18/1	NCI		Scanmed LLC	18-May-21
<i>Note: L-028-18/1 split between CC; CIT; NCI</i>				
L-008-15/1	NCI		xMD Diagnostics, LLC	18-May-21
<i>Note: L-008-15/1 split between CIT; NCI; NICHD</i>				
L-063-11/0	Aaronson, Stuart A.	(b)(4);	Eptiomcs Inc	19-May-21
L-063-11/0	King, Charles R.	(b)(6)	Eptiomcs Inc	19-May-21
L-063-11/0	Kraus, (b) (6) Matthias		Eptiomcs Inc	19-May-21
L-261-18/0	Bonomi, Carrie A.		CureVac AG	19-May-21
L-261-18/0	Borgel, Suzanne D.		CureVac AG	19-May-21
L-261-18/0	Dougherty, Kelly		CureVac AG	19-May-21
L-261-18/0	Hollingshead, Melinda G.		CureVac AG	19-May-21
L-259-16/5	NCI		Kite Pharma	20-May-21
L-146-21/0	Bonomi, Carrie A.	(b)(4);	Pharmacology Discovery Services Taiwa	20-May-21
L-146-21/0	Borgel, Suzanne D.	(b)(6)	Pharmacology Discovery Services Taiwa	20-May-21
L-146-21/0	Dougherty, Kelly		Pharmacology Discovery Services Taiwa	20-May-21
L-146-21/0	Hollingshead, Melinda G.		Pharmacology Discovery Services Taiwa	20-May-21
L-181-18/1	Bonomi, Carrie A.		ModernaTX, Inc.	20-May-21
L-181-18/1	Borgel, Suzanne D.		ModernaTX, Inc.	20-May-21
L-181-18/1	Dougherty, Kelly		ModernaTX, Inc.	20-May-21
L-181-18/1	Hollingshead, Melinda G.		ModernaTX, Inc.	20-May-21
L-116-16/1	(b) (4)		Relay Therapeutics, Inc	21-May-21
L-116-16/1	Esposito, Dominic		Relay Therapeutics, Inc	21-May-21
L-116-16/1	Gillette, William K.		Relay Therapeutics, Inc	21-May-21
L-116-16/1	Grose, Carissa L.		Relay Therapeutics, Inc	21-May-21
L-116-16/1	Hopkins, Ralph F.		Relay Therapeutics, Inc	21-May-21
L-116-16/1	Roberts, Veronica Ann		Relay Therapeutics, Inc	21-May-21
L-063-16/2	Gazdar, (b) (6) Adi		GlaxoSmithKline	24-May-21
L-063-16/2	Johnson, Bruce E		GlaxoSmithKline	24-May-21
L-063-16/2	Kaye, Frederic J		GlaxoSmithKline	24-May-21
L-063-16/2	Khleif*, Samir N.		GlaxoSmithKline	24-May-21
L-063-16/2	Minna, John D.		GlaxoSmithKline	24-May-21
L-063-16/2	Oie, (b) (6) Herbert K		GlaxoSmithKline	24-May-21
L-063-16/2	Pass, Harvey I		GlaxoSmithKline	24-May-21
L-129-21/0	Bonomi, Carrie A.		Crown Bioscience Inc.	24-May-21
L-129-21/0	Borgel, Suzanne D.		Crown Bioscience Inc.	24-May-21
L-129-21/0	Buck, Christopher		Crown Bioscience Inc.	24-May-21
L-129-21/0	Dougherty*, Kelly		Crown Bioscience Inc.	24-May-21

(b) (4), (b) (3) (A), (b) (6)

L-129-21/0	Gazdar (b) (6) Adi	(b)(4);	Crown Bioscience Inc.	24-May-21
L-129-21/0	Hamilton, Thomas C	(b)(6)	Crown Bioscience Inc.	24-May-21
L-129-21/0	Hollingshead, Melinda G.		Crown Bioscience Inc.	24-May-21
L-129-21/0	Johnson, Bruce E		Crown Bioscience Inc.	24-May-21
L-129-21/0	Kaye, Frederic J		Crown Bioscience Inc.	24-May-21
L-129-21/0	Kheif*, Samir		Crown Bioscience Inc.	24-May-21
L-129-21/0	Minna, John D.		Crown Bioscience Inc.	24-May-21
L-129-21/0	Oie, (b) (6) Herbert K		Crown Bioscience Inc.	24-May-21
L-129-21/0	Ozols, Robert F		Crown Bioscience Inc.	24-May-21
L-129-21/0	Pass, Harvey I		Crown Bioscience Inc.	24-May-21
L-129-21/0	Schiller, John T		Crown Bioscience Inc.	24-May-21
L-129-21/0	Bonomi, Carrie A.		Crown Bioscience Inc.	24-May-21
L-129-21/0	Borgel, Suzanne D.		Crown Bioscience Inc.	24-May-21
L-129-21/0	Buck, Christopher		Crown Bioscience Inc.	24-May-21
L-129-21/0	Dougherty*, Kelly		Crown Bioscience Inc.	24-May-21
L-129-21/0	Gazdar, (b) (6) Adi		Crown Bioscience Inc.	24-May-21
L-129-21/0	Hamilton, Thomas C		Crown Bioscience Inc.	24-May-21
L-129-21/0	Hollingshead, Melinda G.		Crown Bioscience Inc.	24-May-21
L-129-21/0	Johnson, Bruce E		Crown Bioscience Inc.	24-May-21
L-129-21/0	Kaye, Frederic J		Crown Bioscience Inc.	24-May-21
L-129-21/0	Kheif*, Samir		Crown Bioscience Inc.	24-May-21
L-129-21/0	Minna, John D.		Crown Bioscience Inc.	24-May-21
L-129-21/0	Oie, (b) (6) Herbert K		Crown Bioscience Inc.	24-May-21
L-129-21/0	Ozols, Robert F		Crown Bioscience Inc.	24-May-21
L-129-21/0	Pass, Harvey I		Crown Bioscience Inc.	24-May-21
L-129-21/0	Schiller, John T		Crown Bioscience Inc.	24-May-21
L-329-17/1	Gao, Wei		Abpro	24-May-21
L-329-17/1	Ho, Mitchell		Abpro	24-May-21
L-329-17/1	Phung, Yen T.		Abpro	24-May-21
L-329-17/1	Zhang, Yifan		Abpro	24-May-21
L-059-19/0	Chung-Yln Yang*, James		Regeneron Pharmaceuticals, Inc	25-May-21
L-059-19/0	Spiese, Paul J		Regeneron Pharmaceuticals, Inc	25-May-21
L-146-21/0	Bonomi, Carrie A.		Pharmacology Discovery Services Taiwa	26-May-21
L-146-21/0	Borgel, Suzanne D.		Pharmacology Discovery Services Taiwa	26-May-21
L-146-21/0	Dougherty, Kelly		Pharmacology Discovery Services Taiwa	26-May-21
L-146-21/0	Hollingshead, Melinda G.		Pharmacology Discovery Services Taiwa	26-May-21
L-134-21/0	Bonomi, Carrie A.		Yuhan R&D Institute	27-May-21
L-134-21/0	Dougherty, Kelly		Yuhan R&D Institute	27-May-21
L-134-21/0	Hollingshead, Melinda G.		Yuhan R&D Institute	27-May-21
L-271-01/8	NCI		Millennium Pharmaceuticals, Inc.	27-May-21
L-157-21/0	Bonomi, Carrie A.	(b)(4);	Pyxis Oncology Inc	28-May-21
L-157-21/0	Borgel, Suzanne D.	(b)(6)	Pyxis Oncology Inc	28-May-21
L-157-21/0	Dougherty, Kelly		Pyxis Oncology Inc	28-May-21
L-157-21/0	Hollingshead, Melinda G.		Pyxis Oncology Inc	28-May-21

NIH Patent Licensing Activities
 NCI
 June 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min /Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
L-194-19/0	Buck, Christopher	(b)(4)	Etna Biotech Srl	1-Jun-21						(b) (4), (b) (3) (A), (b) (6)
L-194-19/0	(b) (4)	(b)(6)	Etna Biotech Srl	1-Jun-21						
L-194-19/0	Lowy, Douglas R.		Etna Biotech Srl	1-Jun-21						
L-194-19/0	Pastrana, Diana V		Etna Biotech Srl	1-Jun-21						
L-194-19/0	Roden, Richard B		Etna Biotech Srl	1-Jun-21						
L-194-19/0	Schiller, John T		Etna Biotech Srl	1-Jun-21						
L-083-18/1	Bonomi, Carrie A.		Evotec SAS	1-Jun-21						
L-083-18/1	Borgel, Suzanne D.		Evotec SAS	1-Jun-21						
L-083-18/1	Dougherty, Kelly		Evotec SAS	1-Jun-21						
L-083-18/1	Hollingshead, Melinda G.		Evotec SAS	1-Jun-21						
L-153-19/1	Beyer, Rachel K. B.		Novartis Institutes for BioMedical Resea	1-Jun-21						
L-153-19/1	(b) (4)		Novartis Institutes for BioMedical Resea	1-Jun-21						
L-153-19/1	Holderfield, Matthew T.		Novartis Institutes for BioMedical Resea	1-Jun-21						
L-153-19/1	Soppet, Dan		Novartis Institutes for BioMedical Resea	1-Jun-21						
L-151-21/0	Bonomi, Carrie A.		Anaveon AG	1-Jun-21						
L-151-21/0	Borgel, Suzanne D.		Anaveon AG	1-Jun-21						
L-151-21/0	Dougherty, Kelly		Anaveon AG	1-Jun-21						
L-151-21/0	Hollingshead, Melinda G.		Anaveon AG	1-Jun-21						
L-151-21/0	Bonomi, Carrie A.		Anaveon AG	1-Jun-21						
L-151-21/0	Borgel, Suzanne D.		Anaveon AG	1-Jun-21						
L-151-21/0	Dougherty, Kelly		Anaveon AG	1-Jun-21						
L-151-21/0	Hollingshead, Melinda G.		Anaveon AG	1-Jun-21						
L-209-15/0	Gazdar, (b) (6) Adi		HistoCyte Laboratories	1-Jun-21						
L-209-15/0	Johnson, Bruce E		HistoCyte Laboratories	1-Jun-21						
L-209-15/0	Kaye, Frederic J		HistoCyte Laboratories	1-Jun-21						
L-209-15/0	Khleif, Samir N.		HistoCyte Laboratories	1-Jun-21						
L-209-15/0	Minna, John D.		HistoCyte Laboratories	1-Jun-21						
L-209-15/0	Oie, (b) (6) Herbert K		HistoCyte Laboratories	1-Jun-21						
L-209-15/0	Pass, Harvey I		HistoCyte Laboratories	1-Jun-21						
L-154-97/2	Mason, Llewellyn H.		BD Biosciences - BD PharMingen	3-Jun-21						
L-154-97/2	Ortaldo, John R.		BD Biosciences - BD PharMingen	3-Jun-21						
L-097-00/3	Austin, Faye C.		BD Biosciences, PharMingen	3-Jun-21						
L-097-00/3	Colcher, David		BD Biosciences, PharMingen	3-Jun-21						
L-097-00/3	Hand, Patricia H		BD Biosciences, PharMingen	3-Jun-21						
L-097-00/3	Nuti, Marianna		BD Biosciences, PharMingen	3-Jun-21						
L-097-00/3	Schlom, Jeffrey		BD Biosciences, PharMingen	3-Jun-21						
L-184-19/0	Bonomi, Carrie A.		Kowa Company LTD	3-Jun-21						
L-184-19/0	Borgel, Suzanne D.		Kowa Company LTD	3-Jun-21						

L-184-19/0	Dougherty, Kelly	(b)(4);	Kowa Company LTD	3-Jun-21
L-184-19/0	Hollingshead, Melinda G.	(b)(6)	Kowa Company LTD	3-Jun-21
L-045-19/1	Bonomi, Carrie A.		Alligator Bioscience AB	3-Jun-21
L-045-19/1	Borgel, Suzanne D.		Alligator Bioscience AB	3-Jun-21
L-045-19/1	Dougherty, Kelly		Alligator Bioscience AB	3-Jun-21
L-045-19/1	Hollingshead, Melinda G.		Alligator Bioscience AB	3-Jun-21
L-045-19/1	Schlom, Jeffrey		Alligator Bioscience AB	3-Jun-21
L-086-19/0	Bonomi, Carrie A.		Pionyr Immunotherapeutics, Inc.	3-Jun-21
L-086-19/0	Dougherty, Kelly		Pionyr Immunotherapeutics, Inc.	3-Jun-21
L-086-19/0	Hollingshead, Melinda G.		Pionyr Immunotherapeutics, Inc.	3-Jun-21
L-151-20/0	Gazdar, (b) (6) Adi		Harpoon Therapeutics	3-Jun-21
L-151-20/0	Johnson, Bruce E		Harpoon Therapeutics	3-Jun-21
L-151-20/0	Kaye, Frederic J		Harpoon Therapeutics	3-Jun-21
L-151-20/0	Khleif*, Samir N.		Harpoon Therapeutics	3-Jun-21
L-151-20/0	Minna, John D.		Harpoon Therapeutics	3-Jun-21
L-151-20/0	Oie, (b) (6) Herbert K		Harpoon Therapeutics	3-Jun-21
L-151-20/0	Pass, Harvey I		Harpoon Therapeutics	3-Jun-21
L-138-21/0	Hathcock, Karen		Proteintech Group, Inc.	3-Jun-21
L-138-21/0	Hodes, Richard J		Proteintech Group, Inc.	3-Jun-21
L-138-21/0	Laszlo, Gloria		Proteintech Group, Inc.	3-Jun-21
L-253-18/3	Bonomi, Carrie A.		Yuhan R&D Institute	8-Jun-21
L-253-18/3	Borgel, Suzanne D.		Yuhan R&D Institute	8-Jun-21
L-253-18/3	Dougherty, Kelly		Yuhan R&D Institute	8-Jun-21
L-253-18/3	Hollingshead, Melinda G.		Yuhan R&D Institute	8-Jun-21
L-271-01/8	NCI		Millennium Pharmaceuticals, Inc.	8-Jun-21
L-094-21/0	Cao, Boliang (Brian)	(b)(4);	Cymeta Biopharmaceutical	8-Jun-21
L-094-21/0	Vande Woude, George	(b)(6)	Cymeta Biopharmaceutical	8-Jun-21
L-051-13/0	Kawamura, Masaru		Cell Signaling Technology Inc	9-Jun-21
L-051-13/0	McVicar, Daniel W		Cell Signaling Technology Inc	9-Jun-21
L-051-13/0	O'Shea, John J.		Cell Signaling Technology Inc	9-Jun-21
<i>Note: L-051-13/0 split between NCI; NHLBI; NIAMS</i>				
L-168-21/0	Aaronson, Stuart A.	(b)(4);	Genentech, Inc	10-Jun-21
L-168-21/0	Ellmore, Nelson	(b)(6)	Genentech, Inc	10-Jun-21
L-179-16/1	Gazdar (b) (6) Adi		Janssen Research Foundation	10-Jun-21
L-179-16/1	Johnson, Bruce E		Janssen Research Foundation	10-Jun-21
L-179-16/1	Kaye, Frederic J		Janssen Research Foundation	10-Jun-21
L-179-16/1	Khleif, Samir N.		Janssen Research Foundation	10-Jun-21
L-179-16/1	Minna, John D.		Janssen Research Foundation	10-Jun-21
L-179-16/1	Oie, (b) (6) Herbert K		Janssen Research Foundation	10-Jun-21
L-179-16/1	Pass, Harvey I		Janssen Research Foundation	10-Jun-21
L-140-21/0	Bonomi, Carrie A.		TXINNO Bioscience Inc	11-Jun-21
L-140-21/0	Borgel, Suzanne D.		TXINNO Bioscience Inc	11-Jun-21

(b) (4), (b) (3) (A), (b) (6)

L-140-21/0	Dougherty, Kelly	(b)(4);	TXINNO Bioscience Inc	11-Jun-21
L-140-21/0	Hollingshead, Melinda G.	(b)(6)	TXINNO Bioscience Inc	11-Jun-21
L-168-21/0	Aaronson, Stuart A.		Genentech, Inc	11-Jun-21
L-168-21/0	Ellmore, Nelson		Genentech, Inc	11-Jun-21
L-192-19/0	Bonomi, Carrie A.		Hookipa Biotech GmbH	11-Jun-21
L-192-19/0	Borgel, Suzanne D.		Hookipa Biotech GmbH	11-Jun-21
L-192-19/0	Dougherty, Kelly		Hookipa Biotech GmbH	11-Jun-21
L-192-19/0	Hollingshead, Melinda G.		Hookipa Biotech GmbH	11-Jun-21
L-132-19/0	Bonomi, Carrie A.		Shattuck Labs, Inc	14-Jun-21
L-132-19/0	Borgel, Suzanne D.		Shattuck Labs, Inc	14-Jun-21
L-132-19/0	Dougherty, Kelly		Shattuck Labs, Inc	14-Jun-21
L-132-19/0	Hollingshead, Melinda G.		Shattuck Labs, Inc	14-Jun-21
L-161-21/0	Kozlov, Serguei		Nuevocor Pte. Ltd.	15-Jun-21
L-161-21/0	Stewart, Colin L.		Nuevocor Pte. Ltd.	15-Jun-21
L-157-21/0	Bonomi, Carrie A.		Pyxis Oncology Inc	15-Jun-21
L-157-21/0	Borgel, Suzanne D.		Pyxis Oncology Inc	15-Jun-21
L-157-21/0	Dougherty, Kelly		Pyxis Oncology Inc	15-Jun-21
L-157-21/0	Hollingshead, Melinda G.		Pyxis Oncology Inc	15-Jun-21
L-165-21/0	Gazdar, (b) (6) Adi		Vibliome Operations, LLC.	15-Jun-21
L-165-21/0	Johnson, Bruce E		Vibliome Operations, LLC.	15-Jun-21
L-165-21/0	Kaye, Frederic J		Vibliome Operations, LLC.	15-Jun-21
L-165-21/0	Khleif, Samir N.		Vibliome Operations, LLC.	15-Jun-21
L-165-21/0	Minna, John D.		Vibliome Operations, LLC.	15-Jun-21
L-165-21/0	Oie, (b) (6) Herbert K		Vibliome Operations, LLC.	15-Jun-21
L-165-21/0	Pass, Harvey I		Vibliome Operations, LLC.	15-Jun-21
L-165-21/0	Gazdar, (b) (6) Adi		Vibliome Operations, LLC.	15-Jun-21
L-165-21/0	Johnson, Bruce E		Vibliome Operations, LLC.	15-Jun-21
L-165-21/0	Kaye, Frederic J		Vibliome Operations, LLC.	15-Jun-21
L-165-21/0	Khleif, Samir N.		Vibliome Operations, LLC.	15-Jun-21
L-165-21/0	Minna, John D.		Vibliome Operations, LLC.	15-Jun-21
L-165-21/0	Oie, (b) (6) Herbert K		Vibliome Operations, LLC.	15-Jun-21
L-165-21/0	Pass, Harvey I		Vibliome Operations, LLC.	15-Jun-21
L-232-14/1	NCI		NanoString Technologies, Inc.	17-Jun-21
<i>Note: L-232-14/1 split between CIT; NCI</i>				
L-155-21/0	Gazdar, (b) (6) Adi	(b)(4);	Sanofi-Aventis Recherche & Develop	17-Jun-21
L-155-21/0	Johnson, Bruce E	(b)(6)	Sanofi-Aventis Recherche & Develop	17-Jun-21
L-155-21/0	Kaye, Frederic J		Sanofi-Aventis Recherche & Develop	17-Jun-21
L-155-21/0	Kheif*, Samir		Sanofi-Aventis Recherche & Develop	17-Jun-21
L-155-21/0	Minna, John D.		Sanofi-Aventis Recherche & Develop	17-Jun-21
L-155-21/0	Oie, (b) (6) Herbert K		Sanofi-Aventis Recherche & Develop	17-Jun-21
L-155-21/0	Pass, Harvey I		Sanofi-Aventis Recherche & Develop	17-Jun-21
L-160-18/0	NCI		Advanced Imaging Projects, LLC (AIP)	17-Jun-21
<i>Note: L-160-18/0 split between CC; NCI</i>				

(b) (4), (b) (3) (A), (b) (6)

L-107-15/2	NCI		Iovance Biotherapeutics, Inc.	17-Jun-21
<i>Note: L-107-15/2 split between CC; NCI</i>				
L-147-18/0	Bonomi, Carrie A.	(b)(4);	Genentech	18-Jun-21
L-147-18/0	Borgel, Suzanne D.	(b)(6)	Genentech	18-Jun-21
L-147-18/0	Dougherty, Kelly		Genentech	18-Jun-21
L-147-18/0	Hollingshead, Melinda G.		Genentech	18-Jun-21
L-179-16/1	Gazdar, (b) (6) Adi		Janssen Research Foundation	22-Jun-21
L-179-16/1	Johnson, Bruce E		Janssen Research Foundation	22-Jun-21
L-179-16/1	Kaye, Frederic J		Janssen Research Foundation	22-Jun-21
L-179-16/1	Khleif, Samir N.		Janssen Research Foundation	22-Jun-21
L-179-16/1	Minna, John D.		Janssen Research Foundation	22-Jun-21
L-179-16/1	Oie, (b) (6) Herbert K		Janssen Research Foundation	22-Jun-21
L-179-16/1	Pass, Harvey I		Janssen Research Foundation	22-Jun-21
L-190-19/4	Cafri, Gal		ZioPharm Oncology, Inc.	22-Jun-21
L-190-19/4	Deniger, Drew		ZioPharm Oncology, Inc.	22-Jun-21
L-190-19/4	Feldman, Steven A		ZioPharm Oncology, Inc.	22-Jun-21
L-190-19/4	Fitzgerald, Peter C.		ZioPharm Oncology, Inc.	22-Jun-21
L-190-19/4	Hanada, Kenichi		ZioPharm Oncology, Inc.	22-Jun-21
L-190-19/4	Kim, Sanghyun		ZioPharm Oncology, Inc.	22-Jun-21
L-190-19/4	Levin, Noam		ZioPharm Oncology, Inc.	22-Jun-21
L-190-19/4	Lo, Winifred Margaret		ZioPharm Oncology, Inc.	22-Jun-21
L-190-19/4	Lowery, Frank		ZioPharm Oncology, Inc.	22-Jun-21
L-190-19/4	Lu, Yong-Chen		ZioPharm Oncology, Inc.	22-Jun-21
L-190-19/4	Malekzadeh, Parisa		ZioPharm Oncology, Inc.	22-Jun-21
L-190-19/4	Paria, Biman		ZioPharm Oncology, Inc.	22-Jun-21
L-190-19/4	Parkhurst, Maria		ZioPharm Oncology, Inc.	22-Jun-21
L-190-19/4	Pasetto, Anna		ZioPharm Oncology, Inc.	22-Jun-21
L-190-19/4	Robbins, Paul F		ZioPharm Oncology, Inc.	22-Jun-21
L-190-19/4	Tran, Eric		ZioPharm Oncology, Inc.	22-Jun-21
L-190-19/4	Wang, Qiong		ZioPharm Oncology, Inc.	22-Jun-21
L-190-19/4	Yang, James C		ZioPharm Oncology, Inc.	22-Jun-21
L-190-19/4	Yoseph, Rami		ZioPharm Oncology, Inc.	22-Jun-21
L-190-19/4	Yu, Zhiya		ZioPharm Oncology, Inc.	22-Jun-21
L-190-19/4	Zacharakis, Nikolaos		ZioPharm Oncology, Inc.	22-Jun-21
L-190-19/4	Zhao, Chihao		ZioPharm Oncology, Inc.	22-Jun-21
L-190-19/4	Zheng, Zhili		ZioPharm Oncology, Inc.	22-Jun-21
L-201-20/0	Gao, Wei		Navrogen Inc	23-Jun-21
L-201-20/0	Hassan, Raffit		Navrogen Inc	23-Jun-21
L-201-20/0	Ho, Mitchell		Navrogen Inc	23-Jun-21
L-201-20/0	Pastan, Ira H		Navrogen Inc	23-Jun-21
L-201-20/0	Phung, Yen T.		Navrogen Inc	23-Jun-21
L-201-20/0	Zhang, Yifan		Navrogen Inc	23-Jun-21
L-201-20/0	NCI		Navrogen Inc	23-Jun-21
L-239-15/0	Gazdar, (b) (6) Adi	(b)(4);	Dako North America	25-Jun-21
L-239-15/0	Johnson, Bruce E	(b)(6)	Dako North America	25-Jun-21
L-239-15/0	Kaye, Frederic J		Dako North America	25-Jun-21

L-239-15/0	Khleif, Samir N.	(b)(4);	Dako North America	25-Jun-21
L-239-15/0	Minna, John D.	(b)(6)	Dako North America	25-Jun-21
L-239-15/0	Oie, (b) (6) Herbert K		Dako North America	25-Jun-21
L-239-15/0	Pass, Harvey I		Dako North America	25-Jun-21
L-164-13/3	NCI		Aura Biosciences, Inc.	25-Jun-21
L-249-14/0	Copeland, Neal	(b)(4);	Merck Sharp & Dohme Corp.	28-Jun-21
L-249-14/0	Costantino, Nina	(b)(6)	Merck Sharp & Dohme Corp.	28-Jun-21
L-249-14/0	Court, Donald		Merck Sharp & Dohme Corp.	28-Jun-21
L-249-14/0	Ellis, Hilary Moyed		Merck Sharp & Dohme Corp.	28-Jun-21
L-249-14/0	Jenkins Copeland, Nancy A		Merck Sharp & Dohme Corp.	28-Jun-21
L-249-14/0	Lee, E-Chiang		Merck Sharp & Dohme Corp.	28-Jun-21
L-249-14/0	Liu, Pentao		Merck Sharp & Dohme Corp.	28-Jun-21
L-249-14/0	Sharan, Shyam K		Merck Sharp & Dohme Corp.	28-Jun-21
L-249-14/0	Swaminathan, Srividya		Merck Sharp & Dohme Corp.	28-Jun-21
L-249-14/0	Warming, Soren		Merck Sharp & Dohme Corp.	28-Jun-21
L-249-14/0	Yu, Daiguan		Merck Sharp & Dohme Corp.	28-Jun-21
L-073-03/3	Gottesman, Michael M.		Genentech	28-Jun-21
L-073-03/3	Pastan, Ira H		Genentech	28-Jun-21
L-073-03/3	Ueda, Kazumitsu		Genentech	28-Jun-21
L-127-20/1	Lam, Norris		Kite Pharma, Inc	29-Jun-21
L-002-16/2	Feldman, Steven A		Kite Pharma	29-Jun-21
L-002-16/2	Morgan, Richard A.		Kite Pharma	29-Jun-21
L-002-16/2	Robbins, Paul F		Kite Pharma	29-Jun-21
L-002-16/2	Yao, Xin		Kite Pharma	29-Jun-21
L-002-16/2	Zhu, Shiqui		Kite Pharma	29-Jun-21
L-259-16/6	Cafri, Gal		Kite Pharma	29-Jun-21
L-259-16/6	Hanada, Kenichi		Kite Pharma	29-Jun-21
L-259-16/6	Levin, Noam		Kite Pharma	29-Jun-21
L-259-16/6	Lowery, Frank		Kite Pharma	29-Jun-21
L-259-16/6	Lu, Yong-Chen		Kite Pharma	29-Jun-21
L-259-16/6	Paria, Biman		Kite Pharma	29-Jun-21
L-259-16/6	Parkhurst, Maria		Kite Pharma	29-Jun-21
L-259-16/6	Pasetto, Anna		Kite Pharma	29-Jun-21
L-259-16/6	Robbins, Paul F		Kite Pharma	29-Jun-21
L-259-16/6	Tran, Eric		Kite Pharma	29-Jun-21
L-259-16/6	Wang, Qiong		Kite Pharma	29-Jun-21
L-259-16/6	Yang, James C		Kite Pharma	29-Jun-21
L-259-16/6	Yoseph, Rami		Kite Pharma	29-Jun-21
L-259-16/6	Yu, Zhiya		Kite Pharma	29-Jun-21
L-259-16/6	Zheng, Zhili		Kite Pharma	29-Jun-21
L-277-14/2	NCI		Kite Pharma, Inc.	29-Jun-21
L-028-18/1	NCI		Scanmed LLC	30-Jun-21

Note: L-028-18/1 split between CC; CIT; NCI

(b) (4), (b) (3) (A), (b) (6)

NIH Patent Licensing Activities
 NCI
 July 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
L-080-93/3	Hathcock, Karen	(b)(4);	BD Biosciences - BD PharMingen, Inc.	1-Jul-21						(b) (4), (b) (3) (A), (b) (6)
L-080-93/3	Hodes, Richard J	(b)(6)	BD Biosciences - BD PharMingen, Inc.	1-Jul-21						
L-080-93/3	Laszlo, Gloria		BD Biosciences - BD PharMingen, Inc.	1-Jul-21						
L-163-18/0	Bonomi, Carrie A.		Japan Tobacco	1-Jul-21						
L-163-18/0	Borgel, Suzanne D.		Japan Tobacco	1-Jul-21						
L-163-18/0	Dougherty, Kelly		Japan Tobacco	1-Jul-21						
L-163-18/0	Hollingshead, Melinda G.		Japan Tobacco	1-Jul-21						
L-137-10/1	Potter, (b) (6) Michael		Exbio	1-Jul-21						
L-003-12/1	Potter, (b) (6) Michael		Exbio Praha AS	1-Jul-21						
L-092-13/1	Potter, (b) (6) Michael		EXBIO Praha	1-Jul-21						
L-170-21/0	Copeland, Amy		Fresh Wind Biotechnologies USA, Inc.	1-Jul-21						
L-170-21/0	Gros, Alena		Fresh Wind Biotechnologies USA, Inc.	1-Jul-21						
L-170-21/0	Hanada, Kenichi		Fresh Wind Biotechnologies USA, Inc.	1-Jul-21						
L-170-21/0	Krishna, Sri		Fresh Wind Biotechnologies USA, Inc.	1-Jul-21						
L-170-21/0	Lowery, Frank		Fresh Wind Biotechnologies USA, Inc.	1-Jul-21						
L-170-21/0	Robbins, Paul F		Fresh Wind Biotechnologies USA, Inc.	1-Jul-21						
L-170-21/0	Yang, James C		Fresh Wind Biotechnologies USA, Inc.	1-Jul-21						
L-170-21/0	Yoseph, Rami		Fresh Wind Biotechnologies USA, Inc.	1-Jul-21						
L-102-13/1	Hathcock, Karen		EXBIO Praha	1-Jul-21						
L-102-13/1	Hodes, Richard J		EXBIO Praha	1-Jul-21						
L-102-13/1	Laszlo, Gloria		EXBIO Praha	1-Jul-21						
<i>Note: L-102-13/1 split between NCI; NIA</i>										
L-273-14/0	Chang, Nancy T.		Grifols Worldwide Operations Ltd.	2-Jul-21						
L-273-14/0	Crowl, Robert		Grifols Worldwide Operations Ltd.	2-Jul-21						
L-273-14/0	Fisher, Amanda G.		Grifols Worldwide Operations Ltd.	2-Jul-21						
L-273-14/0	Hahn, Beatrice		Grifols Worldwide Operations Ltd.	2-Jul-21						
L-273-14/0	Reddy, E. Premkumar.		Grifols Worldwide Operations Ltd.	2-Jul-21						
L-273-14/0	Sarnagadharan, Mangalasse		Grifols Worldwide Operations Ltd.	2-Jul-21						
L-185-21/0	Bonomi, Carrie A.		Anwita Biosciences Inc.	2-Jul-21						
L-185-21/0	Borgel, Suzanne D.		Anwita Biosciences Inc.	2-Jul-21						
L-185-21/0	Dougherty, Kelly		Anwita Biosciences Inc.	2-Jul-21						
L-185-21/0	Hollingshead, Melinda G.		Anwita Biosciences Inc.	2-Jul-21						
L-117-21/1	Schlom, Jeffrey		Piramal Pharma Solutions UK Ltd.	6-Jul-21						
L-052-18/1	NCI		MedGene Therapeutics, Inc.	6-Jul-21						
L-319-14/1	Gottesman, Michael M.	(b)(4); (b)(6)	WuXi AppTec (Shanghai) Co., Ltd.	9-Jul-21						

L-319-14/1	Pastan, Ira H	(b)(4);	WuXi AppTec (Shanghai) Co., Ltd.	9-Jul-21
L-319-14/1	Ueda, Kazumitsu	(b)(6)	WuXi AppTec (Shanghai) Co., Ltd.	9-Jul-21
L-186-21/0	Esposito, Dominic		Vector Y	9-Jul-21
L-186-21/0	Hopkins, Ralph F.		Vector Y	9-Jul-21
L-185-21/0	Bonomi, Carrie A.		Anwita Biosciences Inc.	11-Jul-21
L-185-21/0	Borgel, Suzanne D.		Anwita Biosciences Inc.	11-Jul-21
L-185-21/0	Dougherty, Kelly		Anwita Biosciences Inc.	11-Jul-21
L-185-21/0	Hollingshead, Melinda G.		Anwita Biosciences Inc.	11-Jul-21
L-149-08/2	NCI		Bavarian Nordic	13-Jul-21
L-158-21/0	NCI		Kyverna Therapeutics	13-Jul-21
L-159-21/0	NCI		Kyverna Therapeutics	13-Jul-21
L-159-21/0	NCI		Kyverna Therapeutics	13-Jul-21
L-158-21/0	NCI		Kyverna Therapeutics	13-Jul-21
L-121-08/0	Brechbiel, Martin W.	(b)(4);	Medtronic Inc	14-Jul-21
L-121-08/0	Garmestani, Kayhan	(b)(6)	Medtronic Inc	14-Jul-21
<i>Note: L-121-08/0 split between NCI; NINDS</i>				
L-065-21/1	Eil, Robert Langland	(b)(4);	Lyell Immunopharma, Inc.	19-Jul-21
L-065-21/1	Gattinoni, Luca	(b)(6)	Lyell Immunopharma, Inc.	19-Jul-21
L-065-21/1	Good, Meghan		Lyell Immunopharma, Inc.	19-Jul-21
L-065-21/1	Islam, S M Rafiqul		Lyell Immunopharma, Inc.	19-Jul-21
L-065-21/1	Kishton, Rigel Joseph		Lyell Immunopharma, Inc.	19-Jul-21
L-065-21/1	Klemen, Nicholas Donald		Lyell Immunopharma, Inc.	19-Jul-21
L-065-21/1	Maeda, Takuya		Lyell Immunopharma, Inc.	19-Jul-21
L-065-21/1	Patel, Shashankkumar		Lyell Immunopharma, Inc.	19-Jul-21
L-065-21/1	Restifo, Nicholas P.		Lyell Immunopharma, Inc.	19-Jul-21
L-065-21/1	Tamaoki, Naritaka		Lyell Immunopharma, Inc.	19-Jul-21
L-065-21/1	Vizcardo Sakoda, Raul Edua		Lyell Immunopharma, Inc.	19-Jul-21
L-065-21/1	Vodnala, Suman Kumar		Lyell Immunopharma, Inc.	19-Jul-21
<i>Note: L-065-21/1 split between NCI; NIAID</i>				
L-319-14/1	Gottesman, Michael M.		WuXi AppTec (Shanghai) Co., Ltd.	20-Jul-21
L-319-14/1	Pastan, Ira H		WuXi AppTec (Shanghai) Co., Ltd.	20-Jul-21
L-319-14/1	Ueda, Kazumitsu		WuXi AppTec (Shanghai) Co., Ltd.	20-Jul-21
L-147-21/0	Bonomi, Carrie A.		LG Chem, Ltd	22-Jul-21
L-147-21/0	Borgel, Suzanne D.		LG Chem, Ltd	22-Jul-21
L-147-21/0	Dougherty, Kelly		LG Chem, Ltd	22-Jul-21
L-147-21/0	Hollingshead, Melinda G.		LG Chem, Ltd	22-Jul-21
L-094-20/1	NCI		Innovative Cellular Therapeutics	23-Jul-21
L-252-17/0	Bonomi, Carrie A.	(b)(4);	Champions Oncology, Inc.	23-Jul-21
L-252-17/0	Borgel, Suzanne D.	(b)(6)	Champions Oncology, Inc.	23-Jul-21
L-252-17/0	Dougherty, Kelly		Champions Oncology, Inc.	23-Jul-21

L-252-17/0	Hollingshead, Melinda G.	(b)(4); (b)(6)	Champions Oncology, Inc.	23-Jul-21
L-179-21/0	Beyer, Rachel K. B.		Treeline Biosciences, Inc.	23-Jul-21
L-179-21/0	(b) (4)		Treeline Biosciences, Inc.	23-Jul-21
L-179-21/0	Holderfield, Matthew T.		Treeline Biosciences, Inc.	23-Jul-21
L-179-21/0	Soppet, Dan		Treeline Biosciences, Inc.	23-Jul-21
L-010-20/0	Bonomi, Carrie A.		Genentech, Inc.	26-Jul-21
L-010-20/0	Dougherty, Kelly		Genentech, Inc.	26-Jul-21
L-010-20/0	Hollingshead, Melinda G.		Genentech, Inc.	26-Jul-21
L-239-15/0	Gazdar, (b) (6) Adi		Dako North America	26-Jul-21
L-239-15/0	Johnson, Bruce E		Dako North America	26-Jul-21
L-239-15/0	Kaye, Frederic J		Dako North America	26-Jul-21
L-239-15/0	Khleif, Samir N.		Dako North America	26-Jul-21
L-239-15/0	Minna, John D.		Dako North America	26-Jul-21
L-239-15/0	Oie, (b) (6) Herbert K		Dako North America	26-Jul-21
L-239-15/0	Pass, Harvey I		Dako North America	26-Jul-21
L-267-18/0	Dimitrov, Dimiter S.		Memorial Sloan-Kettering Cancer Cente	27-Jul-21
L-267-18/0	Feng, Yang		Memorial Sloan-Kettering Cancer Cente	27-Jul-21
L-175-21/0	Bonomi, Carrie A.		Prokarium Ltd.	27-Jul-21
L-175-21/0	Borgel, Suzanne D.		Prokarium Ltd.	27-Jul-21
L-175-21/0	Dougherty, Kelly		Prokarium Ltd.	27-Jul-21
L-175-21/0	Hollingshead, Melinda G.		Prokarium Ltd.	27-Jul-21
L-053-21/0	Shoemaker, Robert H		GLG Pharma, LLC	27-Jul-21
L-182-21/0	Beers, Richard		Navrogen Inc	28-Jul-21
L-182-21/0	Eberle, Jaime A		Navrogen Inc	28-Jul-21
L-182-21/0	Fitzgerald, David J.		Navrogen Inc	28-Jul-21
L-182-21/0	Kreitman, Robert J		Navrogen Inc	28-Jul-21
L-182-21/0	Lee, Byungkook		Navrogen Inc	28-Jul-21
L-182-21/0	Liu, Wenhai		Navrogen Inc	28-Jul-21
L-182-21/0	Mazor, Ronit		Navrogen Inc	28-Jul-21
L-182-21/0	Nagata, Satoshi		Navrogen Inc	28-Jul-21
L-182-21/0	Onda, Masanori		Navrogen Inc	28-Jul-21
L-182-21/0	Pastan, Ira H		Navrogen Inc	28-Jul-21
L-182-21/0	Vassall, Aaron		Navrogen Inc	28-Jul-21
L-182-21/0	Weldon, John		Navrogen Inc	28-Jul-21
L-202-21/0	Bonomi, Carrie A.		Good Therapeutics, Inc.	28-Jul-21
L-202-21/0	Dougherty, Kelly		Good Therapeutics, Inc.	28-Jul-21
L-202-21/0	Hollingshead, Melinda G.		Good Therapeutics, Inc.	28-Jul-21
L-202-21/0	Bonomi, Carrie A.		Good Therapeutics, Inc.	28-Jul-21
L-202-21/0	Dougherty, Kelly		Good Therapeutics, Inc.	28-Jul-21
L-202-21/0	Hollingshead, Melinda G.		Good Therapeutics, Inc.	28-Jul-21
L-329-17/1	NCI		Abpro	28-Jul-21
L-267-18/0	NCI		Memorial Sloan-Kettering Cancer Cente	29-Jul-21

(b) (4), (b) (3) (A), (b) (6)

L-064-11/0	Barry, Todd	(b)(4);	Eptiomics Inc	29-Jul-21
L-064-11/0	Rosenwald, Andreas	(b)(6)	Eptiomics Inc	29-Jul-21
L-064-11/0	Staudt, Louis M		Eptiomics Inc	29-Jul-21
L-064-11/0	Wiestner, Adrian		Eptiomics Inc	29-Jul-21
L-064-11/0	Wilson, Wyndham H.		Eptiomics Inc	29-Jul-21
L-127-21/0	Gazdar, (b) (6) Adi		ALECTOR, LLC	29-Jul-21
L-127-21/0	Johnson, Bruce E		ALECTOR, LLC	29-Jul-21
L-127-21/0	Kaye, Frederic J		ALECTOR, LLC	29-Jul-21
L-127-21/0	Kheif*, Samir		ALECTOR, LLC	29-Jul-21
L-127-21/0	Minna, John D.		ALECTOR, LLC	29-Jul-21
L-127-21/0	Oie (b) (6) Herbert K		ALECTOR, LLC	29-Jul-21
L-127-21/0	Pass, Harvey I		ALECTOR, LLC	29-Jul-21
L-106-18/0	Bonomi, Carrie A.		KSQ Therapeutics	30-Jul-21
L-106-18/0	Dougherty, Kelly		KSQ Therapeutics	30-Jul-21
L-106-18/0	Hollingshead, Melinda G.		KSQ Therapeutics	30-Jul-21
L-104-20/1	NCI		T-Cure Bioscience, Inc.	30-Jul-21
L-107-15/2	Dudley, Mark	(b)(4);	lovance Biotherapeutics. Inc.	30-Jul-21
L-107-15/2	Hinrichs, Christian S.	(b)(6)	lovance Biotherapeutics. Inc.	30-Jul-21
L-107-15/2	Jin, Benjamin Yongzu		lovance Biotherapeutics. Inc.	30-Jul-21
L-107-15/2	Somerville, Robert P.		lovance Biotherapeutics. Inc.	30-Jul-21
L-107-15/2	Wunderlich, John		lovance Biotherapeutics. Inc.	30-Jul-21
<i>Note: L-107-15/2 split between CC; NCI</i>				
L-107-15/2	NCI		lovance Biotherapeutics. Inc.	30-Jul-21
<i>Note: L-107-15/2 split between CC; NCI</i>				



(b) (4), (b) (3) (A), (b) (6)

NIH Patent Licensing Activities
NCI
August 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
L-172-21/0	Ozols, Robert F	(b)(6)	Genentech, Inc.	1-Aug-21						
L-156-21/0	Fry, Terry		Senti Biosciences, Inc.	2-Aug-21						
L-156-21/0	Qin, Haiying		Senti Biosciences, Inc.	2-Aug-21						
L-156-21/0	NCI		Senti Biosciences, Inc.	2-Aug-21						
L-065-21/0	NCI		Lyell Immunopharma, Inc.	3-Aug-21						
L-091-11/0	Chang, Nancy T.	(b)(4);	Quest Diagnostics, Inc.	3-Aug-21						
L-091-11/0	Fisher, Amanda G.	(b)(6)	Quest Diagnostics, Inc.	3-Aug-21						
L-091-11/0	Hahn, Beatrice		Quest Diagnostics, Inc.	3-Aug-21						
L-091-11/0	(b) (4)		Quest Diagnostics, Inc.	3-Aug-21						

L-091-11/0	Sarnagadharan, Mangalasse	(b)(4); (b)(6)	Quest Diagnostics, Inc.	3-Aug-21
L-172-21/0	Hamilton, Thomas C		Genentech, Inc.	3-Aug-21
L-172-21/0	Ozols, Robert F		Genentech, Inc.	3-Aug-21
L-127-20/1	NCI		Kite Pharma, Inc	3-Aug-21
L-039-11/0	Onda, Masanori	(b)(4); (b)(6)	Rockland Immunochemicals, Inc.	3-Aug-21
L-039-11/0	Pastan, Ira H		Rockland Immunochemicals, Inc.	3-Aug-21
L-053-21/0	Shoemaker, Robert H		GLG Pharma, LLC	3-Aug-21
L-170-21/0	NCI		Fresh Wind Biotechnologies USA, Inc.	3-Aug-21
L-250-17/0	Bonomi, Carrie A.	(b)(4);	Aragen Bioscience, Inc.	4-Aug-21
L-250-17/0	Borgel, Suzanne D.	(b)(6)	Aragen Bioscience, Inc.	4-Aug-21
L-250-17/0	Dougherty, Kelly		Aragen Bioscience, Inc.	4-Aug-21
L-250-17/0	Hollingshead, Melinda G.		Aragen Bioscience, Inc.	4-Aug-21
L-187-21/0	Bonomi, Carrie A.		Janssen Research & Development, LLC	5-Aug-21
L-187-21/0	Dougherty, Kelly		Janssen Research & Development, LLC	5-Aug-21
L-187-21/0	Hollingshead, Melinda G.		Janssen Research & Development, LLC	5-Aug-21
L-024-21/0	Fry, Terry		Vor Biopharma, Inc.	6-Aug-21
L-024-21/0	Qin, Haiying		Vor Biopharma, Inc.	6-Aug-21
L-203-21/0	NCI		Cabaletta Bio, Inc.	9-Aug-21
L-055-21/0	Aloia, Amanda	(b)(4);	Monogram Biosciences	10-Aug-21
L-055-21/0	Rein, Alan	(b)(6)	Monogram Biosciences	10-Aug-21
L-052-18/1	NCI		MedGene Therapeutics, Inc.	10-Aug-21
L-136-20/0	Dudley, Mark	(b)(4);	Intima Bioscience Inc.	11-Aug-21
L-136-20/0	Fitzgerald, Peter C.	(b)(6)	Intima Bioscience Inc.	11-Aug-21
L-136-20/0	Gros, Alena		Intima Bioscience Inc.	11-Aug-21
L-136-20/0	Lu, Yong-Chen		Intima Bioscience Inc.	11-Aug-21
L-136-20/0	Palmer, Douglas		Intima Bioscience Inc.	11-Aug-21
L-136-20/0	Restifo, Nicholas P.		Intima Bioscience Inc.	11-Aug-21
L-136-20/0	Robbins, Paul F		Intima Bioscience Inc.	11-Aug-21
L-136-20/0	Tran, Eric		Intima Bioscience Inc.	11-Aug-21
L-136-20/0	Wunderlich, John		Intima Bioscience Inc.	11-Aug-21
L-136-20/0	Zheng, Zhili		Intima Bioscience Inc.	11-Aug-21
L-089-16/4	Feng, Mingqian		H2bio	11-Aug-21
L-089-16/4	Gao, Wei		H2bio	11-Aug-21
L-089-16/4	Ho, Mitchell		H2bio	11-Aug-21
L-089-16/4	Pastan, Ira H		H2bio	11-Aug-21
L-089-16/4	Tang, Zhewei		H2bio	11-Aug-21
L-203-15/0	Gazdar, (b)(6) Adi		SOTIO	12-Aug-21
L-203-15/0	Johnson, Bruce E		SOTIO	12-Aug-21
L-203-15/0	Kaye, Frederic J		SOTIO	12-Aug-21

(b) (4), (b) (3) (A), (b) (6)

L-203-15/0	Khleif, Samir N.	(b)(4);	SOTIO	12-Aug-21
L-203-15/0	Minna, John D.	(b)(6)	SOTIO	12-Aug-21
L-203-15/0	Oie, (b) (6) Herbert K		SOTIO	12-Aug-21
L-203-15/0	Pass, Harvey I		SOTIO	12-Aug-21
L-203-15/1	Gazdar, (b) (6) Adi		SOTIO	12-Aug-21
L-203-15/1	Johnson, Bruce E		SOTIO	12-Aug-21
L-203-15/1	Kaye, Frederic J		SOTIO	12-Aug-21
L-203-15/1	Khleif, Samir N.		SOTIO	12-Aug-21
L-203-15/1	Minna, John D.		SOTIO	12-Aug-21
L-203-15/1	Oie, (b) (6) Herbert K		SOTIO	12-Aug-21
L-203-15/1	Pass, Harvey I		SOTIO	12-Aug-21
L-184-21/0	Gazdar, (b) (6) Adi		Vibliome Operations, LLC.	12-Aug-21
L-184-21/0	Johnson, Bruce E		Vibliome Operations, LLC.	12-Aug-21
L-184-21/0	Kaye, Frederic J		Vibliome Operations, LLC.	12-Aug-21
L-184-21/0	Khleif, Samir N.		Vibliome Operations, LLC.	12-Aug-21
L-184-21/0	Minna, John D.		Vibliome Operations, LLC.	12-Aug-21
L-184-21/0	Oie, (b) (6) Herbert K		Vibliome Operations, LLC.	12-Aug-21
L-184-21/0	Pass, Harvey I		Vibliome Operations, LLC.	12-Aug-21
L-184-21/0	Gazdar, (b) (6) Adi		Vibliome Operations, LLC.	12-Aug-21
L-184-21/0	Johnson, Bruce E		Vibliome Operations, LLC.	12-Aug-21
L-184-21/0	Kaye, Frederic J		Vibliome Operations, LLC.	12-Aug-21
L-184-21/0	Khleif, Samir N.		Vibliome Operations, LLC.	12-Aug-21
L-184-21/0	Minna, John D.		Vibliome Operations, LLC.	12-Aug-21
L-184-21/0	Oie, (b) (6) Herbert K		Vibliome Operations, LLC.	12-Aug-21
L-184-21/0	Pass, Harvey I		Vibliome Operations, LLC.	12-Aug-21
L-089-16/4	Feng, Mingqian		H2bio	13-Aug-21
L-089-16/4	Gao, Wei		H2bio	13-Aug-21
L-089-16/4	Ho, Mitchell		H2bio	13-Aug-21
L-089-16/4	Pastan, Ira H		H2bio	13-Aug-21
L-089-16/4	Tang, Zhewei		H2bio	13-Aug-21
L-075-13/1	Franchini, Genoveffa		WuXi Advanced Therapies Inc.	17-Aug-21
L-075-13/1	Kalyanaraman, Vaniambadi		WuXi Advanced Therapies Inc.	17-Aug-21
L-075-13/1	Markham, Phillip D.		WuXi Advanced Therapies Inc.	17-Aug-21
L-075-13/1	Salahuddin, Syed Z.		WuXi Advanced Therapies Inc.	17-Aug-21
L-271-01/8	NCI		Millennium Pharmaceuticals, Inc.	17-Aug-21
L-224-17/0	Costantino, Nina		Delve Therapeutics	17-Aug-21
L-224-17/0	Court, Donald		Delve Therapeutics	17-Aug-21
L-224-17/0	Datta, Simanti		Delve Therapeutics	17-Aug-21
L-194-21/0	Bonomi, Carrie A.		Novasenta Inc.	17-Aug-21
L-194-21/0	Borgel, Suzanne D.		Novasenta Inc.	17-Aug-21
L-194-21/0	Dougherty, Kelly		Novasenta Inc.	17-Aug-21
L-194-21/0	Hollingshead, Melinda G.		Novasenta Inc.	17-Aug-21
L-212-21/0	Robbins, Paul F		BioNTech US, Inc	18-Aug-21
L-212-21/0	Yao, Xin		BioNTech US, Inc	18-Aug-21

L-094-21/0	Cao, Boliang (Brian)	(b)(4);	Cymeta Biopharmaceutical	18-Aug-21
L-094-21/0	Vande Woude, George	(b)(6)	Cymeta Biopharmaceutical	18-Aug-21
L-224-15/0	NCI		Bluebird Bio	18-Aug-21
L-180-21/0	Esposito, Dominic	(b)(4);	Vertex Pharmaceuticals (Europe) Limite	19-Aug-21
L-180-21/0	Grose, Carissa L.	(b)(6)	Vertex Pharmaceuticals (Europe) Limite	19-Aug-21
L-180-21/0	Esposito, Dominic		Vertex Pharmaceuticals (Europe) Limite	19-Aug-21
L-180-21/0	Grose, Carissa L.		Vertex Pharmaceuticals (Europe) Limite	19-Aug-21
L-026-20/0	Bonomi, Carrie A.		Imanis Life Sciences, LLC	19-Aug-21
L-026-20/0	Borgel, Suzanne D.		Imanis Life Sciences, LLC	19-Aug-21
L-026-20/0	Dougherty, Kelly		Imanis Life Sciences, LLC	19-Aug-21
L-026-20/0	Hollingshead, Melinda G.		Imanis Life Sciences, LLC	19-Aug-21
L-053-21/0	NCI		GLG Pharma, LLC	19-Aug-21
L-191-20/0	Bonomi, Carrie A.	(b)(4);	Actym Therapeutics, Inc	23-Aug-21
L-191-20/0	Borgel, Suzanne D.	(b)(6)	Actym Therapeutics, Inc	23-Aug-21
L-191-20/0	Dougherty, Kelly		Actym Therapeutics, Inc	23-Aug-21
L-191-20/0	Hollingshead, Melinda G.		Actym Therapeutics, Inc	23-Aug-21
L-242-02/2	Kawakami, Yutaka		Biocare Medical, LLC	24-Aug-21
L-189-21/0	Bonomi, Carrie A.		Harpoon Therapeutics	24-Aug-21
L-189-21/0	Dougherty, Kelly		Harpoon Therapeutics	24-Aug-21
L-189-21/0	Hollingshead, Melinda G.		Harpoon Therapeutics	24-Aug-21
L-075-11/0	NCI		PDS Biotechnology Corp	24-Aug-21
L-048-15/2	Schlom, Jeffrey	(b)(4);	PDS Biotechnology Corporation	24-Aug-21
L-048-15/2	Tsang, Kwong-Yok	(b)(6)	PDS Biotechnology Corporation	24-Aug-21
L-048-15/2	NCI		PDS Biotechnology Corporation	24-Aug-21
L-053-21/0	Shoemaker, Robert H	(b)(4);	GLG Pharma, LLC	25-Aug-21
L-095-12/0	Baskar, Sivasubramanian	(b)(6)	BioLegend	26-Aug-21
L-095-12/0	Rader, Christoph		BioLegend	26-Aug-21
L-177-19/0	Bonomi, Carrie A.		Gilead Sciences, Inc	26-Aug-21
L-177-19/0	Borgel, Suzanne D.		Gilead Sciences, Inc	26-Aug-21
L-177-19/0	Dougherty, Kelly		Gilead Sciences, Inc	26-Aug-21
L-177-19/0	Hollingshead, Melinda G.		Gilead Sciences, Inc	26-Aug-21
L-240-20/1	Bonomi, Carrie A.		Medytox Inc.	26-Aug-21
L-240-20/1	Borgel, Suzanne D.		Medytox Inc.	26-Aug-21
L-240-20/1	Dougherty, Kelly		Medytox Inc.	26-Aug-21
L-240-20/1	Hollingshead, Melinda G.		Medytox Inc.	26-Aug-21
L-049-01/3	Bustin, Michael		Millipore Sigma	26-Aug-21

L-171-21/0	JONES, JENNIFER	(b)(4);	Cytek Biosciences	26-Aug-21
L-171-21/0	Welsh, Joshua	(b)(6)	Cytek Biosciences	26-Aug-21
L-122-17/0	Choyke, Peter L		Koninklijke Philips N.V.	27-Aug-21
L-122-17/0	Pinto, Peter A		Koninklijke Philips N.V.	27-Aug-21
L-122-17/0	Turkbey, Ismail B.		Koninklijke Philips N.V.	27-Aug-21
<i>Note: L-122-17/0 split between CC; NCI</i>				
L-069-21/0	Gao, Wei		Cytovia Therapeutics	27-Aug-21
L-069-21/0	Ho, Mitchell		Cytovia Therapeutics	27-Aug-21
L-069-21/0	Li, Dan		Cytovia Therapeutics	27-Aug-21
L-069-21/0	Li, Nan		Cytovia Therapeutics	27-Aug-21
L-069-21/0	Phung, Yen T.		Cytovia Therapeutics	27-Aug-21
L-069-21/0	Zhang, Yifan		Cytovia Therapeutics	27-Aug-21
L-270-19/0	Bonomi, Carrie A.		Bluefin Biomedicine, Inc.	27-Aug-21
L-270-19/0	Borgel, Suzanne D.		Bluefin Biomedicine, Inc.	27-Aug-21
L-270-19/0	Dougherty, Kelly		Bluefin Biomedicine, Inc.	27-Aug-21
L-270-19/0	Hollingshead, Melinda G.		Bluefin Biomedicine, Inc.	27-Aug-21
L-004-07/2	Qasba, Pradman		Life Technologies Corp.	27-Aug-21
L-004-07/2	Ramakrishnan, Boopathy		Life Technologies Corp.	27-Aug-21
L-049-91/5	Aaronson, Stuart A.		Biovitium AB (publ)	30-Aug-21
L-049-91/5	Finch, Paul W.		Biovitium AB (publ)	30-Aug-21
L-049-91/5	Rubin, Jeffrey S		Biovitium AB (publ)	30-Aug-21
L-284-19/0	Bonomi, Carrie A.		Molecular Partners AG	30-Aug-21
L-284-19/0	Borgel, Suzanne D.		Molecular Partners AG	30-Aug-21
L-284-19/0	Dougherty, Kelly		Molecular Partners AG	30-Aug-21
L-284-19/0	Hollingshead, Melinda G.		Molecular Partners AG	30-Aug-21
L-224-15/0	NCI		Bluebird Bio	30-Aug-21
L-154-97/2	Mason, Llewellyn H.	(b)(4);	BD Biosciences - BD PharMingen	31-Aug-21
L-154-97/2	Ortaldo, John R.	(b)(6)	BD Biosciences - BD PharMingen	31-Aug-21
L-097-00/3	Austin, Faye C.		BD Biosciences, PharMingen	31-Aug-21
L-097-00/3	Colcher, David		BD Biosciences, PharMingen	31-Aug-21
L-097-00/3	Hand, Patricia H		BD Biosciences, PharMingen	31-Aug-21
L-097-00/3	Nuti, Marianna		BD Biosciences, PharMingen	31-Aug-21
L-097-00/3	Schlom, Jeffrey		BD Biosciences, PharMingen	31-Aug-21
L-210-21/0	Aplan, Peter D.		Agios Pharmaceuticals, Inc	31-Aug-21
L-210-21/0	Lin, Ying-Wei		Agios Pharmaceuticals, Inc	31-Aug-21
L-210-21/0	Slape, Christopher I.		Agios Pharmaceuticals, Inc	31-Aug-21
L-210-21/0	Zhang, ZhenHua		Agios Pharmaceuticals, Inc	31-Aug-21

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
L-081-21/0	Hinrichs, Christian S.	(b)(4); (b)(6)	Rubius Therapeutics, Inc.	1-Sep-21						(b) (4), (b) (3) (A), (b) (6)
L-080-21/0	Hinrichs, Christian S.		Rubius Therapeutics, Inc	1-Sep-21						
L-226-15/3	Hodge, James W.		KeraFAST	1-Sep-21						
L-226-15/3	Schlom, Jeffrey		KeraFAST	1-Sep-21						
L-218-21/0	Cowan, Kenneth H.		Elevation Oncology	2-Sep-21						
L-071-19/1	Pastan, Ira H		Atara Biotherapeutics Inc.	2-Sep-21						
L-140-20/1	Bonomi, Carrie A.		Zymeworks Inc.	3-Sep-21						
L-140-20/1	Borgel, Suzanne D.		Zymeworks Inc.	3-Sep-21						
L-140-20/1	Dougherty, Kelly		Zymeworks Inc.	3-Sep-21						
L-140-20/1	Hollingshead, Melinda G.		Zymeworks Inc.	3-Sep-21						
L-231-21/0	Bonomi, Carrie A.		Delta TpX, Inc.	3-Sep-21						
L-231-21/0	Borgel, Suzanne D.		Delta TpX, Inc.	3-Sep-21						
L-231-21/0	Dougherty, Kelly		Delta TpX, Inc.	3-Sep-21						
L-231-21/0	Hollingshead, Melinda G.		Delta TpX, Inc.	3-Sep-21						
L-273-18/0	Bonomi, Carrie A.		August Bioservices, LLC	3-Sep-21						
L-273-18/0	Borgel, Suzanne D.		August Bioservices, LLC	3-Sep-21						
L-273-18/0	Dougherty, Kelly		August Bioservices, LLC	3-Sep-21						
L-273-18/0	Hollingshead, Melinda G.		August Bioservices, LLC	3-Sep-21						
L-203-94/0	Aaronson, Stuart A.		BD Biosciences - BD PharMingen, Inc.	8-Sep-21						
L-203-94/0	Jensen, Roy A.		BD Biosciences - BD PharMingen, Inc.	8-Sep-21						
L-203-94/0	LaRochelle, William		BD Biosciences - BD PharMingen, Inc.	8-Sep-21						
L-203-94/0	Matsui, Toshimitsu		BD Biosciences - BD PharMingen, Inc.	8-Sep-21						
L-203-94/0	Pierce, Jacalyn		BD Biosciences - BD PharMingen, Inc.	8-Sep-21						
L-203-94/0	Robbins, Keith		BD Biosciences - BD PharMingen, Inc.	8-Sep-21						
L-166-20/0	Bonomi, Carrie A.		Evotec SAS	9-Sep-21						
L-166-20/0	Dougherty, Kelly		Evotec SAS	9-Sep-21						
L-166-20/0	Hollingshead, Melinda G.		Evotec SAS	9-Sep-21						
L-210-21/0	Aplan, Peter D.		Agios Pharmaceuticals, Inc	10-Sep-21						
L-210-21/0	Lin, Ying-Wei		Agios Pharmaceuticals, Inc	10-Sep-21						
L-210-21/0	Slape, Christopher I.		Agios Pharmaceuticals, Inc	10-Sep-21						
L-210-21/0	Zhang, ZhenHua		Agios Pharmaceuticals, Inc	10-Sep-21						
L-128-18/1	Bonomi, Carrie A.		Xencor, Inc.	10-Sep-21						
L-128-18/1	Borgel, Suzanne D.		Xencor, Inc.	10-Sep-21						
L-128-18/1	Dougherty*, Kelly		Xencor, Inc.	10-Sep-21						
L-128-18/1	Hollingshead, Melinda G.		Xencor, Inc.	10-Sep-21						
L-093-21/0	Bonomi, Carrie A.		C4 Therapeutics, Inc	10-Sep-21						
L-093-21/0	Borgel, Suzanne D.		C4 Therapeutics, Inc	10-Sep-21						

L-093-21/0	Dougherty, Kelly	(b)(4):	C4 Therapeutics, Inc	10-Sep-21
L-093-21/0	Hollingshead, Melinda G.	(b)(6)	C4 Therapeutics, Inc	10-Sep-21
L-228-21/0	Beyer, Rachel K. B.		Unnatural Products Inc.	10-Sep-21
L-228-21/0	(b) (4)		Unnatural Products Inc.	10-Sep-21
L-228-21/0	Holderfield, Matthew T.		Unnatural Products Inc.	10-Sep-21
L-228-21/0	Soppet, Dan		Unnatural Products Inc.	10-Sep-21
L-153-19/2	Beyer, Rachel K. B.		Novartis Institutes for BioMedical Resea	14-Sep-21
L-153-19/2	(b) (4)		Novartis Institutes for BioMedical Resea	14-Sep-21
L-153-19/2	Holderfield, Matthew T.		Novartis Institutes for BioMedical Resea	14-Sep-21
L-153-19/2	Soppet, Dan		Novartis Institutes for BioMedical Resea	14-Sep-21
L-082-16/0	Franchini, Genoveffa		Gilead Sciences	14-Sep-21
L-082-16/0	Gartner, Suzanne		Gilead Sciences	14-Sep-21
L-082-16/0	(b) (4)		Gilead Sciences	14-Sep-21
L-082-16/0	Lori, Franco C.		Gilead Sciences	14-Sep-21
L-082-16/0	Markham, Phillip D.		Gilead Sciences	14-Sep-21
L-082-16/0	Reitz, Jr., Marvin S.		Gilead Sciences	14-Sep-21
L-077-21/0	Bonomi, Carrie A.		Minerva Imaging ApS	15-Sep-21
L-077-21/0	Borgel, Suzanne D.		Minerva Imaging ApS	15-Sep-21
L-077-21/0	Dougherty, Kelly		Minerva Imaging ApS	15-Sep-21
L-077-21/0	Gazdar, (b) (6) Adi		Minerva Imaging ApS	15-Sep-21
L-077-21/0	Hollingshead, Melinda G.		Minerva Imaging ApS	15-Sep-21
L-077-21/0	Johnson, Bruce E		Minerva Imaging ApS	15-Sep-21
L-077-21/0	Kaye, Frederic J		Minerva Imaging ApS	15-Sep-21
L-077-21/0	Kheif*, Samir		Minerva Imaging ApS	15-Sep-21
L-077-21/0	Minna, John D.		Minerva Imaging ApS	15-Sep-21
L-077-21/0	Oie, (b) (6) Herbert K		Minerva Imaging ApS	15-Sep-21
L-077-21/0	Pass, Harvey I		Minerva Imaging ApS	15-Sep-21
L-062-18/1	Bonomi, Carrie A.		Constellation Pharmaceuticals, Inc.	15-Sep-21
L-062-18/1	Borgel, Suzanne D.		Constellation Pharmaceuticals, Inc.	15-Sep-21
L-062-18/1	Dougherty, Kelly		Constellation Pharmaceuticals, Inc.	15-Sep-21
L-062-18/1	Hollingshead, Melinda G.		Constellation Pharmaceuticals, Inc.	15-Sep-21
L-236-21/0	Gonzalez, Frank J		Jnana Therapeutics	15-Sep-21
L-236-21/0	Kim, Jung-Hwan		Jnana Therapeutics	15-Sep-21
L-236-21/0	Yim, Sun Hee		Jnana Therapeutics	15-Sep-21
L-247-17/1	Beyer, Rachel K. B.		Revolution Medicines, Inc.	16-Sep-21
L-247-17/1	(b) (4)		Revolution Medicines, Inc.	16-Sep-21
L-247-17/1	Holderfield, Matthew T.		Revolution Medicines, Inc.	16-Sep-21
L-247-17/1	Soppet, Dan		Revolution Medicines, Inc.	16-Sep-21
L-217-21/0	Bonomi, Carrie A.		Sotio Biotech	17-Sep-21
L-217-21/0	Dougherty, Kelly		Sotio Biotech	17-Sep-21
L-217-21/0	Hollingshead, Melinda G.		Sotio Biotech	17-Sep-21
L-225-21/0	Aaronson, Stuart A.		Univercells SA	20-Sep-21
L-225-21/0	Giard, Donald		Univercells SA	20-Sep-21
L-225-21/0	Parks, Wade P		Univercells SA	20-Sep-21

(b) (4), (b) (3) (A), (b) (6)

L-019-08/0	Ahlers, Jeffrey D	(b)(4);	Institut Pasteur	20-Sep-21
L-019-08/0	Berzofsky, Jay A.	(b)(6)	Institut Pasteur	20-Sep-21
L-019-08/0	Chang, Nancy T.		Institut Pasteur	20-Sep-21
L-019-08/0	Crowl, Robert		Institut Pasteur	20-Sep-21
L-019-08/0	Fisher, Amanda G.		Institut Pasteur	20-Sep-21
L-019-08/0	Hahn, Beatrice		Institut Pasteur	20-Sep-21
L-019-08/0	Nara, Peter L		Institut Pasteur	20-Sep-21
L-019-08/0	Pendleton, Charles D.		Institut Pasteur	20-Sep-21
L-019-08/0	Reddy, E. Premkumar.		Institut Pasteur	20-Sep-21
L-019-08/0	Sarngadharan, Mangalasse		Institut Pasteur	20-Sep-21
L-019-08/0	Shirai, Mutsunori		Institut Pasteur	20-Sep-21

Note: L-019-08/0 split between FDA; NCI; NIAID; NIBIB; NIDDK

L-053-21/0	NCI		GLG Pharma, LLC	20-Sep-21
L-206-21/0	Gazdar, (b) (6) Adi	(b)(4);	ARC Therapeutics, LLC	21-Sep-21
L-206-21/0	Johnson, Bruce E	(b)(6)	ARC Therapeutics, LLC	21-Sep-21
L-206-21/0	Kaye, Frederic J		ARC Therapeutics, LLC	21-Sep-21
L-206-21/0	Khleif, Samir N.		ARC Therapeutics, LLC	21-Sep-21
L-206-21/0	Minna, John D.		ARC Therapeutics, LLC	21-Sep-21
L-206-21/0	Oie, (b) (6) Herbert K		ARC Therapeutics, LLC	21-Sep-21
L-206-21/0	Pass, Harvey I		ARC Therapeutics, LLC	21-Sep-21
L-212-21/0	Robbins, Paul F		BioNTech US, Inc	22-Sep-21
L-212-21/0	Yao, Xin		BioNTech US, Inc	22-Sep-21
L-081-18/0	NCI		PathoVax LLV	22-Sep-21
L-308-19/0	Bonomi, Carrie A.	(b)(4);	Microbiotica Ltd.	22-Sep-21
L-308-19/0	Borgel, Suzanne D.	(b)(6)	Microbiotica Ltd.	22-Sep-21
L-308-19/0	Dougherty, Kelly		Microbiotica Ltd.	22-Sep-21
L-308-19/0	Hollingshead, Melinda G.		Microbiotica Ltd.	22-Sep-21
L-049-18/1	Bonomi, Carrie A.		BrightPath Biotherapeutics Co., Ltd.	24-Sep-21
L-049-18/1	Borgel, Suzanne D.		BrightPath Biotherapeutics Co., Ltd.	24-Sep-21
L-049-18/1	Dougherty, Kelly		BrightPath Biotherapeutics Co., Ltd.	24-Sep-21
L-049-18/1	Hollingshead, Melinda G.		BrightPath Biotherapeutics Co., Ltd.	24-Sep-21
L-232-21/0	Gazdar, (b) (6) Adi		August Bioservices, LLC	28-Sep-21
L-232-21/0	Johnson, Bruce E		August Bioservices, LLC	28-Sep-21
L-232-21/0	Kaye, Frederic J		August Bioservices, LLC	28-Sep-21
L-232-21/0	Khleif, Samir N.		August Bioservices, LLC	28-Sep-21
L-232-21/0	Minna, John D.		August Bioservices, LLC	28-Sep-21
L-232-21/0	Oie, (b) (6) Herbert K		August Bioservices, LLC	28-Sep-21
L-232-21/0	Pass, Harvey I		August Bioservices, LLC	28-Sep-21
L-232-21/0	Gazdar, (b) (6) Adi		August Bioservices, LLC	28-Sep-21
L-232-21/0	Johnson, Bruce E		August Bioservices, LLC	28-Sep-21
L-232-21/0	Kaye, Frederic J		August Bioservices, LLC	28-Sep-21
L-232-21/0	Khleif, Samir N.		August Bioservices, LLC	28-Sep-21
L-232-21/0	Minna, John D.		August Bioservices, LLC	28-Sep-21
L-232-21/0	Oie, (b) (6) Herbert K		August Bioservices, LLC	28-Sep-21

L-232-21/0	Pass, Harvey I	(b)(4); (b)(6)	August Bioservices, LLC	28-Sep-21	(b) (4), (b) (3) (A), (b) (6)
L-220-21/0	Buck, Christopher	(b) (4)	Vaccine Center for Assisting Safety & Te	29-Sep-21	
L-220-21/0			Vaccine Center for Assisting Safety & Te	29-Sep-21	
L-220-21/0	Lowy, Douglas R.		Vaccine Center for Assisting Safety & Te	29-Sep-21	
L-220-21/0	Pastrana, Diana V		Vaccine Center for Assisting Safety & Te	29-Sep-21	
L-220-21/0	Roden, Richard B		Vaccine Center for Assisting Safety & Te	29-Sep-21	
L-220-21/0	Schiller, John T		Vaccine Center for Assisting Safety & Te	29-Sep-21	

\$16,324,469.43 \$1,290,994.38 \$17,615,463.81 \$1,872,479.59 \$15,742,984.22

NIH Patent Licensing Activities

NEI

April 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
L-187-20/0	Bharti, Kapil	(b)(4);	Regeneron Pharmaceuticals, Inc.	19-Apr-21						(b) (4), (b) (3) (A), (b) (6)
L-187-20/0	Ruchi, Fnu	(b)(6)	Regeneron Pharmaceuticals, Inc.	19-Apr-21						

NIH Patent Licensing Activities

NEI

May 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
L-020-21/0	Amaral, Juan A	(b)(4);	Opis Therapeutics, LLC	13-May-21						(b) (4), (b) (3) (A), (b) (6)
L-020-21/0	Bharti, Kapil	(b)(6)	Opis Therapeutics, LLC	13-May-21						
L-020-21/0	Charles, Steven Thomas		Opis Therapeutics, LLC	13-May-21						
L-020-21/0	Hotaling, Nathan		Opis Therapeutics, LLC	13-May-21						
L-020-21/0	Khristov, Vladimir R.		Opis Therapeutics, LLC	13-May-21						
L-020-21/0	Maminishkis, Arvydas		Opis Therapeutics, LLC	13-May-21						
L-020-21/0	National Inst. of Standards		Opis Therapeutics, LLC	13-May-21						
L-020-21/0	NEI		Opis Therapeutics, LLC	13-May-21						

NIH Patent Licensing Activities

NEI

June 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
L-162-21/0	Gentleman, Susan B.	(b)(4);	Frontera Therapeutics, Inc.	2-Jun-21						(b) (4), (b) (3) (A), (b) (6)
L-162-21/0	Redmond, Thomas M.	(b)(6)	Frontera Therapeutics, Inc.	2-Jun-21						
L-162-21/0	Gentleman, Susan B.		Frontera Therapeutics, Inc.	2-Jun-21						
L-162-21/0	Redmond, Thomas M.		Frontera Therapeutics, Inc.	2-Jun-21						

NIH Patent Licensing Activities

NEI

July 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
L-050-21/0	NEI		CellRay, LLC	23-Jul-21						(b) (4), (b) (3) (A)

Note: L-050-21/0 split between NEI; NINDS

NIH Patent Licensing Activities

NEI

August 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC

NIH Patent Licensing Activities

NEI

September 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
L-230-02/1	NEI		Bausch & Lomb	1-Sep-21						(b) (4), (b) (3) (A)
					\$4,123,156.48	\$233,084.45	\$4,356,240.93		\$105,504.09	\$4,250,736.84

NIH Patent Licensing Activities

NHGRI

April 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC

NIH Patent Licensing Activities

NHGRI

May 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
L-055-15/1	Goldin, Ehud M.	(b)(4);	ial-BioTech Investments, Inc.	13-May-21						(b) (4), (b) (3) (A), (b) (6)
L-055-15/1	Motabar, Omid	(b)(6)	ial-BioTech Investments, Inc.	13-May-21						
L-055-15/1	Sidransky, Ellen		ial-BioTech Investments, Inc.	13-May-21						
L-055-15/1	Westbroek, Wendy		ial-BioTech Investments, Inc.	13-May-21						

Note: L-055-15/1 split between NCATS; NHGRI

NIH Patent Licensing Activities
NHGRI
June 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-------------------	---------------------------	----------------------	---------------------

NIH Patent Licensing Activities
NHGRI
July 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
L-069-19/0	NHGRI		LogicBio Therapeutics, Inc.	1-Jul-21						(b) (4), (b) (3) (A)

NIH Patent Licensing Activities
NHGRI
August 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
L-196-21/0	Manoli*, Eirini	(b)(4);	Selecta Biosciences Inc.	31-Aug-21						(b) (4), (b) (3) (A), (b) (6)
L-196-21/0	Venditti, Charles P.	(b)(6)	Selecta Biosciences Inc.	31-Aug-21						
L-197-21/0	Manoli, Eirini		Selecta Biosciences Inc.	31-Aug-21						
L-197-21/0	Venditti, Charles P.		Selecta Biosciences Inc.	31-Aug-21						
L-197-21/0	Manoli, Eirini		Selecta Biosciences Inc.	31-Aug-21						
L-197-21/0	Venditti, Charles P.		Selecta Biosciences Inc.	31-Aug-21						
L-196-21/0	Manoli*, Eirini		Selecta Biosciences Inc.	31-Aug-21						
L-196-21/0	Venditti, Charles P.		Selecta Biosciences Inc.	31-Aug-21						
L-057-15/0	NHGRI		Vtesse, Inc	31-Aug-21						

Note: L-057-15/0 split between NCATS; NHGRI

NIH Patent Licensing Activities
NHGRI
September 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
L-069-19/0	Chandler, Randy J.	(b)(4);	LogicBio Therapeutics, Inc.	22-Sep-21						(b) (4), (b) (3) (A), (b) (6)
L-069-19/0	Venditti, Charles P.	(b)(6)	LogicBio Therapeutics, Inc.	22-Sep-21						

\$138,646.32	\$593.00	\$139,239.32	\$27,097.26	\$112,142.06
--------------	----------	--------------	-------------	--------------

NIH Patent Licensing Activities
NHLBI
April 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
L-258-18/0	Derbyshire, John Andrew	(b)(4);	: Siemens Healthcare GmbH	12-Apr-21						(b) (4), (b) (3) (A), (b) (6)
L-258-18/0	(b) (4)	(b)(6)	: Siemens Healthcare GmbH	12-Apr-21						
L-258-18/0	McVeigh, Elliott R		: Siemens Healthcare GmbH	12-Apr-21						
L-258-18/0	Nezafat, Reza		: Siemens Healthcare GmbH	12-Apr-21						
L-256-14/0	Combs, Christian A.		VisiTech International	19-Apr-21						
<i>Note: L-256-14/0 split between NHLBI; NIBIB</i>										
L-258-18/0	NHLBI		: Siemens Healthcare GmbH	22-Apr-21						
L-097-08/4	Knepper, Mark A	(b)(4); (b)(6)	Novus Biologicals, LLC	28-Apr-21						
L-124-17/1	(b) (4)		Generation Bio Co	28-Apr-21						
L-124-17/1	Kotin, Robert M.		Generation Bio Co	28-Apr-21						
L-124-17/1	Li, Lina		Generation Bio Co	28-Apr-21						
L-234-18/0	Kotin, Robert M.		Generation Bio	28-Apr-21						
L-234-18/0	Li, Lina		Generation Bio	28-Apr-21						

NIH Patent Licensing Activities
NHLBI
May 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
L-058-14/0	NHLBI		Spark Therapeutics Ireland Ltd	11-May-21						(b) (4), (b) (3) (A), (b) (6)
L-186-18/0	Ding*, Chuan-Tian	(b)(4);	Casebia Therapeutics	21-May-21						
L-186-18/0	Kotin, Robert M.	(b)(6)	Casebia Therapeutics	21-May-21						
L-186-18/0	Urabe, Masashi		Casebia Therapeutics	21-May-21						
L-259-02/0	Nirenberg, (b) (6) Marsh.		R & D Systems, Inc.	28-May-21						
L-259-02/0	Walsh, Frank		R & D Systems, Inc.	28-May-21						
<i>Note: L-259-02/0 split between NHLBI; NIAID</i>										

NIH Patent Licensing Activities
NHLBI
June 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
L-109-21/0	NHLBI		ONK Therapeutics	1-Jun-21						(b) (4), (b) (3) (A), (b) (6)
L-109-21/0	Childs, Richard W.	(b)(4);	ONK Therapeutics	1-Jun-21						
L-109-21/0	Igarashi, Takehito	(b)(6)	ONK Therapeutics	1-Jun-21						
L-109-21/0	Wynberg, Jason		ONK Therapeutics	1-Jun-21						
L-072-18/0	Remaley, Alan T.		Corvidia Therapeutics	1-Jun-21						
L-072-18/0	Sviridov, Denis O.		Corvidia Therapeutics	1-Jun-21						
L-072-18/0	Wolska, Anna		Corvidia Therapeutics	1-Jun-21						
L-051-13/0	Leonard, Warren J.		Cell Signaling Technology Inc	9-Jun-21						
L-051-13/0	Russell, Sarah M		Cell Signaling Technology Inc	9-Jun-21						
<i>Note: L-051-13/0 split between NCI; NHLBI; NIAMS</i>										
L-159-07/2	NHLBI		Hope Pharmaceuticals	17-Jun-21						
<i>Note: L-159-07/2 split between CC; NHLBI; NIDDK; NINDS</i>										
L-150-21/0	Childs, Richard W.	(b)(4);	Senti Biosciences, Inc.	22-Jun-21						
L-150-21/0	Igarashi, Takehito	(b)(6)	Senti Biosciences, Inc.	22-Jun-21						
L-150-21/0	Wynberg, Jason		Senti Biosciences, Inc.	22-Jun-21						

NIH Patent Licensing Activities
NHLBI
July 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
L-116-11/3	Kotin, Robert M.	(b)(4);	uniQure B.V.	29-Jul-21						(b) (4), (b) (3) (A), (b) (6)
<i>Note: L-116-11/3 split between NHLBI; NIDCR</i>										
L-116-11/3	NHLBI		uniQure B.V.	29-Jul-21						
<i>Note: L-116-11/3 split between NHLBI; NIDCR</i>										
L-116-11/3	NHLBI		uniQure B.V.	29-Jul-21						
<i>Note: L-116-11/3 split between NHLBI; NIDCR</i>										

NIH Patent Licensing Activities
NHLBI
August 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
L-198-21/0	Fitzhugh, Courtney	(b)(4);	Graphite Bio, Inc.	10-Aug-21						(b) (4), (b) (3) (A), (b) (6)
L-198-21/0	Hsieh, Matthew M.	(b)(6)	Graphite Bio, Inc.	10-Aug-21						
L-198-21/0	Leonard, Alexis		Graphite Bio, Inc.	10-Aug-21						
L-198-21/0	Tisdale, John		Graphite Bio, Inc.	10-Aug-21						

L-209-17/0	Derbyshire, John Andrew	(b)(4);	General Electric Co.	11-Aug-21	(b) (4), (b) (3) (A), (b) (6)
L-209-17/0	(b) (4)	(b)(6)	General Electric Co.	11-Aug-21	
L-209-17/0	McVeigh, Elliott R		General Electric Co.	11-Aug-21	
L-209-17/0	Nezafat, Reza		General Electric Co.	11-Aug-21	
L-264-18/0	Arai, Andrew Ernest		Circle Cardiovascular Imaging Inc.	20-Aug-21	
L-264-18/0	Hsu, Li - Yueh		Circle Cardiovascular Imaging Inc.	20-Aug-21	
L-264-18/0	Jacobs, Matthew James		Circle Cardiovascular Imaging Inc.	20-Aug-21	
L-052-96/3	Leonard, Warren J.		Millipore Sigma	26-Aug-21	
L-052-96/3	Lin, Jian-Xin		Millipore Sigma	26-Aug-21	

NIH Patent Licensing Activities

NHLBI

September 2021

License	Inventor	Inventor Share %	Licensor	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
L-327-14/0	NHLBI		Voyager Therapeutics	3-Sep-21						(b) (4), (b) (3) (A), (b) (6)
L-105-17/0	NHLBI		Genzyme Corporation	13-Sep-21						
L-127-15/0	Leonard, Warren J.	(b)(4);	Stanford University Medical Center	21-Sep-21						
L-127-15/0	Mitra, Suman	(b)(6)	Stanford University Medical Center	21-Sep-21						
L-088-12/0	NHLBI		Sangamo BioSciences Inc	23-Sep-21						
<i>Note: L-088-12/0 split between NHLBI; NIDCR</i>										
L-258-18/0	Derbyshire, John Andrew	(b)(4);	Siemens Healthcare GmbH	24-Sep-21						
L-258-18/0	(b) (4)	(b)(6)	Siemens Healthcare GmbH	24-Sep-21						
L-258-18/0	McVeigh, Elliott R		Siemens Healthcare GmbH	24-Sep-21						
L-258-18/0	Nezafat, Reza		Siemens Healthcare GmbH	24-Sep-21						
					\$6,791,743.91	\$58,878.50	\$6,850,622.41		\$233,488.96	\$6,617,133.45

NIH Patent Licensing Activities

NIA

April 2021

License	Inventor	Inventor Share %	Licensor	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
L-079-17/0	Matarin Jimenez, Maria De	(b)(4);	VuEssence, Inc.	5-Apr-21						(b) (4), (b) (3) (A), (b) (6)
L-079-17/0	Singleton, Andrew B.	(b)(6)	VuEssence, Inc.	5-Apr-21						
<i>Note: L-079-17/0 split between NIA; NINDS; NINR</i>										

NIH Patent Licensing Activities

NIA

May 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	------------------	---------------------------	---------------------	---------------------

NIH Patent Licensing Activities

NIA

June 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-------------------	---------------------------	----------------------	---------------------

NIH Patent Licensing Activities

NIA

July 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
L-102-13/1	Hodes, Richard J	(b)(4);	EXBIO Praha	1-Jul-21						(b) (4), (b) (3) (A), (b) (6)

Note: L-102-13/1 split between NCI; NIA

NIH Patent Licensing Activities

NIA

August 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
L-281-14/1	NIA		Peptron	1-Aug-21						(b) (4), (b) (3) (A)

NIH Patent Licensing Activities

NIA

September 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
L-025-17/1	Moaddel, Ruin	(b)(4);	Tocris Bioscience	16-Sep-21						(b) (4), (b) (3) (A), (b) (6)

Note: L-025-17/1 split between NCATS; NIA; NIMH

\$3,217.54	\$15,527.00	\$18,744.54	\$1,344.82	\$17,399.72
------------	-------------	-------------	------------	-------------

NIH Patent Licensing Activities

NIAAAA

April 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	--------------------	---------------------------	-----------------------	---------------------

NIH Patent Licensing Activities
NIAAA
May 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
L-257-19/0	NIAAA		Inversago Pharma Inc	11-May-21						(b) (4), (b) (3) (A)
<i>Note: L-257-19/0 split between NIAAA; NIDA</i>										
L-162-16/3	NIAAA		Inversago Pharma Inc.	11-May-21						
<i>Note: L-162-16/3 split between NIAAA; NIDA</i>										

NIH Patent Licensing Activities
NIAAA
June 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
L-276-17/0	NIAAA		Vital Spark Inc.	4-Jun-21						(b) (4), (b) (3) (A)
<i>Note: L-276-17/0 split between NIAAA; NIDA</i>										

NIH Patent Licensing Activities
NIAAA
July 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-------------------	---------------------------	----------------------	---------------------

NIH Patent Licensing Activities
NIAAA
August 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	---------------------	---------------------------	------------------------	---------------------

NIH Patent Licensing Activities
NIAAA
September 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	------------------------	---------------------------	---------------------------	---------------------

\$0.00	\$61,375.76	\$61,375.76	\$0.00	\$61,375.76
--------	-------------	-------------	--------	-------------

NIH Patent Licensing Activities
NIAID
April 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min /Exec Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
L-001-15/2	Blaney, Jr., Joseph E	(b)(4);	Merck Sharp & Dohme, Corp.	1-Apr-21						(b) (4), (b) (3) (A), (b) (6)
L-001-15/2	Bray, Michael	(b)(6)	Merck Sharp & Dohme, Corp.	1-Apr-21						
L-001-15/2	Chanock, (b) (6) Robert		Merck Sharp & Dohme, Corp.	1-Apr-21						
L-001-15/2	Eckels, Kenneth H		Merck Sharp & Dohme, Corp.	1-Apr-21						
L-001-15/2	Hanley, Kathryn		Merck Sharp & Dohme, Corp.	1-Apr-21						
L-001-15/2	Lai, Ching-Juh		Merck Sharp & Dohme, Corp.	1-Apr-21						
L-001-15/2	Men, Ruhe		Merck Sharp & Dohme, Corp.	1-Apr-21						
L-001-15/2	Murphy, Brian R.		Merck Sharp & Dohme, Corp.	1-Apr-21						
L-001-15/2	Pletnev, Alexander G		Merck Sharp & Dohme, Corp.	1-Apr-21						
L-001-15/2	Whitehead, Stephen S.		Merck Sharp & Dohme, Corp.	1-Apr-21						
L-001-15/2	Zhang, Yi-Ming		Merck Sharp & Dohme, Corp.	1-Apr-21						
<i>Note: L-001-15/2 split between FDA; NIAID</i>										
L-162-15/2	Baxa, Ulrich	(b)(4);	Merck Sharp and dohme	1-Apr-21						
L-162-15/2	Boyington, Jeffrey C.	(b)(6)	Merck Sharp and dohme	1-Apr-21						
L-162-15/2	Chen, Lei		Merck Sharp and dohme	1-Apr-21						
L-162-15/2	Chen, Man		Merck Sharp and dohme	1-Apr-21						
L-162-15/2	Chuang, Gwo-Yu		Merck Sharp and dohme	1-Apr-21						
L-162-15/2	Druz, Aliaksandr A.		Merck Sharp and dohme	1-Apr-21						
L-162-15/2	Galen, Joseph Van		Merck Sharp and dohme	1-Apr-21						
L-162-15/2	Georgiev, Ivelin S.		Merck Sharp and dohme	1-Apr-21						
L-162-15/2	Gorman, Jason		Merck Sharp and dohme	1-Apr-21						
L-162-15/2	Joyce, Michael G.		Merck Sharp and dohme	1-Apr-21						
L-162-15/2	Kanekiyo, Masaru		Merck Sharp and dohme	1-Apr-21						
L-162-15/2	Kwong, Peter D.		Merck Sharp and dohme	1-Apr-21						
L-162-15/2	McLellan, Jason Scott		Merck Sharp and dohme	1-Apr-21						
L-162-15/2	OFEK, GILAD A		Merck Sharp and dohme	1-Apr-21						
L-162-15/2	Ou, Li		Merck Sharp and dohme	1-Apr-21						
L-162-15/2	Pancera, Marie L.		Merck Sharp and dohme	1-Apr-21						
L-162-15/2	Rundlet, Emily J		Merck Sharp and dohme	1-Apr-21						
L-162-15/2	Sastry, Mallika		Merck Sharp and dohme	1-Apr-21						
L-162-15/2	Soto, Cinque		Merck Sharp and dohme	1-Apr-21						
L-162-15/2	Srivatsan, Sanjay R.		Merck Sharp and dohme	1-Apr-21						
L-162-15/2	Stewart-Jones, Guillaume B		Merck Sharp and dohme	1-Apr-21						
L-162-15/2	Thomas, Paul V.		Merck Sharp and dohme	1-Apr-21						
L-162-15/2	Tsybovsky, Yaroslav		Merck Sharp and dohme	1-Apr-21						
L-162-15/2	YANG, YONGPING		Merck Sharp and dohme	1-Apr-21						
L-162-15/2	Zhang, Baoshan		Merck Sharp and dohme	1-Apr-21						
L-162-15/2	Zhou, Tongqing		Merck Sharp and dohme	1-Apr-21						
L-241-13/0	Shevach, Ethan M	(b)(4); (b)	Tonbo Biotechnologies Corp	1-Apr-21						

L-121-20/0	(b) (4)	(b)(4);	Noachis Terra Inc	1-Apr-21
L-121-20/0	Hutchinson, Geoffrey Bain	(b)(6)	Noachis Terra Inc	1-Apr-21
L-121-20/0	Joyce, Michael G.		Noachis Terra Inc	1-Apr-21
L-121-20/0	Kanekiyo, Masaru		Noachis Terra Inc	1-Apr-21
L-121-20/0	(b) (4)		Noachis Terra Inc	1-Apr-21
L-121-20/0	(b) (4)		Noachis Terra Inc	1-Apr-21
L-121-20/0	Yassine, Hadi M.		Noachis Terra Inc	1-Apr-21
L-096-20/0	Akin, Cem		Ardelyx, Inc.	2-Apr-21
L-096-20/0	Kirshenbaum, Arnold		Ardelyx, Inc.	2-Apr-21
L-096-20/0	Metcalfe, Dean D		Ardelyx, Inc.	2-Apr-21
L-245-94/1	Folks, Thomas M		SearCare Life Sciences	2-Apr-21
L-245-94/1	Martin, Malcolm A		SearCare Life Sciences	2-Apr-21
L-245-94/1	Powell, Douglas M		SearCare Life Sciences	2-Apr-21
<i>Note: L-245-94/1 split between NCI; NIAID</i>				
L-155-20/0	Akahata, Wataru		Emergent Product Development Gaithe	7-Apr-21
L-155-20/0	Nabel, Gary J		Emergent Product Development Gaithe	7-Apr-21
L-155-20/0	Rao, Srinivas		Emergent Product Development Gaithe	7-Apr-21
L-155-20/0	Yang, Zhi-Yong		Emergent Product Development Gaithe	7-Apr-21
L-078-21/0	(b) (4)		Icosagen AS	9-Apr-21
L-078-21/0	Hutchinson, Geoffrey Bain		Icosagen AS	9-Apr-21
L-078-21/0	Joyce, Michael G.		Icosagen AS	9-Apr-21
L-078-21/0	Kanekiyo, Masaru		Icosagen AS	9-Apr-21
L-078-21/0	(b) (4)		Icosagen AS	9-Apr-21
L-078-21/0	(b) (4)		Icosagen AS	9-Apr-21
L-078-21/0	Yassine, Hadi M.		Icosagen AS	9-Apr-21
L-197-05/6	Chanock, (b) (6) Robert		Serum Institute of India PVT. LTD	9-Apr-21
L-197-05/6	Hoshino, Yasutaka		Serum Institute of India PVT. LTD	9-Apr-21
L-197-05/6	Kapikian, Estate of Albert Z		Serum Institute of India PVT. LTD	9-Apr-21
L-078-11/0	Mackett, Michael		CEVA Biomune	9-Apr-21
L-078-11/0	Moss, Bernard		CEVA Biomune	9-Apr-21
L-078-11/0	Smith, Geoffrey L		CEVA Biomune	9-Apr-21
L-084-02/1	Shevach, Ethan M		Miltenyi Biotec GMBH	12-Apr-21
L-044-18/1	NIAID		ModernaTX, Inc.	15-Apr-21
L-115-00/2	Cheung, Yiu Chong Gordon	(b)(4);	List Biological Laboratories, Inc.	15-Apr-21
L-115-00/2	Gupta, Pradeep K.	(b)(6)	List Biological Laboratories, Inc.	15-Apr-21
L-115-00/2	Hsu, Su-Cheng Dana		List Biological Laboratories, Inc.	15-Apr-21
L-115-00/2	Hu, Haijing		List Biological Laboratories, Inc.	15-Apr-21
L-115-00/2	Leplla, Stephen H.		List Biological Laboratories, Inc.	15-Apr-21
L-115-00/2	Leysath, Clinton E.		List Biological Laboratories, Inc.	15-Apr-21
L-115-00/2	Moayeri, Mahtab		List Biological Laboratories, Inc.	15-Apr-21
L-115-00/2	Pomerantsev, Andrei P		List Biological Laboratories, Inc.	15-Apr-21
<i>Note: L-115-00/2 split between NIAID; NIDCR</i>				
L-165-13/1	Mackett, Michael	(b)(4);	Sillajen Biotherapeutics, Inc	16-Apr-21

(b) (4), (b) (3) (A), (b) (6)

L-165-13/1	Moss, Bernard	(b)(4);	Sillajen Biotherapeutics, Inc	16-Apr-21
L-165-13/1	Smith, Geoffrey L	(b)(6)	Sillajen Biotherapeutics, Inc	16-Apr-21
L-124-18/0	Garboczi, David		Abcam plc	21-Apr-21
L-124-18/0	Lantz, Larry		Abcam plc	21-Apr-21
L-124-18/0	Leppla, Stephen H.		Abcam plc	21-Apr-21
L-124-18/0	Leysath, Clinton E.		Abcam plc	21-Apr-21
L-124-18/0	Phillips, Damilola D.		Abcam plc	21-Apr-21
L-012-07/2	Eisenbarth, (b) (6) Georg		Santa Cruz Biotechnology Inc	28-Apr-21
L-012-07/2	Fauci, Anthony		Santa Cruz Biotechnology Inc	28-Apr-21
L-012-07/2	Haynes, Barton F.		Santa Cruz Biotechnology Inc	28-Apr-21
L-108-07/1	Caldwell, Harlan D		Santa Cruz Biot., Inc.	28-Apr-21
L-108-07/1	Morrison, Richard P.		Santa Cruz Biot., Inc.	28-Apr-21
L-106-06/1	Shevach, Ethan M		Affymetrix, Inc.	28-Apr-21
L-137-21/0	Douek, Daniel		AbCellera Biologics Inc.	29-Apr-21
L-137-21/0	Henry, Amy R		AbCellera Biologics Inc.	29-Apr-21
L-137-21/0	Kwong, Peter D.		AbCellera Biologics Inc.	29-Apr-21
L-137-21/0	Mason, Rosemarie D.		AbCellera Biologics Inc.	29-Apr-21
L-137-21/0	MISASI, JOHN		AbCellera Biologics Inc.	29-Apr-21
L-137-21/0	Pegu, Amarendra		AbCellera Biologics Inc.	29-Apr-21
L-137-21/0	Roederer, Mario		AbCellera Biologics Inc.	29-Apr-21
L-137-21/0	Schramm, Chaim		AbCellera Biologics Inc.	29-Apr-21
L-137-21/0	Sullivan, Nancy J		AbCellera Biologics Inc.	29-Apr-21
L-137-21/0	Yang, Eun Sung		AbCellera Biologics Inc.	29-Apr-21
L-137-21/0	Zhang, Yi		AbCellera Biologics Inc.	29-Apr-21
L-137-21/0	Zhou, Tongqing		AbCellera Biologics Inc.	29-Apr-21

(b) (4), (b) (3) (A), (b) (6)

NIH Patent Licensing Activities
NIAID
May 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min /Exec Fee	Patent Prosecution Costs	Total May Income	License	Inventor Awards May	Net Remaining to IC
								Cumulative Income		
L-035-18/0	DeVico, Angela M.	(b)(4); (b)(6)	Celgene Corporation	12-May-21						(b) (4), (b) (3) (A), (b) (6)
L-035-18/0	Shevach, Ethan M	(b)(6)	Celgene Corporation	12-May-21						
L-226-14/2	Nutman, Thomas B.		Quest Distribution Inc.	17-May-21						
L-028-19/0	NIAID		Ridgeback Biotherapeutics	19-May-21						
L-065-18/0	Akin, Cem	(b)(4); (b)(6)	Sanofi-Aventis	20-May-21						
L-065-18/0	Kirshenbaum, Arnold	(b)(6)	Sanofi-Aventis	20-May-21						
L-065-18/0	Metcalfe, Dean D	(b)(6)	Sanofi-Aventis	20-May-21						
L-089-21/0	Akin, Cem		Engitix Limited	20-May-21						
L-089-21/0	Kirshenbaum, Arnold		Engitix Limited	20-May-21						
L-089-21/0	Metcalfe, Dean D		Engitix Limited	20-May-21						

L-028-19/0	(b) (4)	(b)(4);	Ridgeback Biotherapeutics	20-May-21	(b) (4), (b) (3) (A), (b) (6)
L-028-19/0	(b) (4)	(b)(6)	Ridgeback Biotherapeutics	20-May-21	
L-028-19/0	Mulang, Sabue		Ridgeback Biotherapeutics	20-May-21	
L-028-19/0	Muyembe-Tamfun, Jean-Ja		Ridgeback Biotherapeutics	20-May-21	
L-028-19/0	Stanley, Daphne Amanda		Ridgeback Biotherapeutics	20-May-21	
L-028-19/0	Sullivan, Nancy J		Ridgeback Biotherapeutics	20-May-21	
L-028-19/0	United States Army		Ridgeback Biotherapeutics	20-May-21	
L-057-18/1	Akin, Cem		Opsidio, LLC	21-May-21	
L-057-18/1	Kirshenbaum, Arnold		Opsidio, LLC	21-May-21	
L-057-18/1	Metcalfe, Dean D		Opsidio, LLC	21-May-21	
L-066-20/0	NIAID		The Native Antigen Company	25-May-21	
L-122-08/0	Mackett, Michael	(b)(4);	Vaccinex Inc	27-May-21	
L-122-08/0	Moss, Bernard	(b)(6)	Vaccinex Inc	27-May-21	
L-122-08/0	Smith, Geoffrey L		Vaccinex Inc	27-May-21	
L-259-02/0	Eisenbarth, (b) (6) Georg		R & D Systems, Inc.	28-May-21	

Note: L-259-02/0 split between NHLBI; NIAID

NIH Patent Licensing Activities
NIAID
June 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
L-221-16/2	Birmingham, Alison	(b)(4);	Sanofi Pasteur	8-Jun-21						(b) (4), (b) (3) (A), (b) (6)
L-221-16/2	Buchholz, Ursula	(b)(6)	Sanofi Pasteur	8-Jun-21						
L-221-16/2	Collins, Peter L.		Sanofi Pasteur	8-Jun-21						
L-221-16/2	Kwong, Peter D.		Sanofi Pasteur	8-Jun-21						
L-221-16/2	Liang, Bo		Sanofi Pasteur	8-Jun-21						
L-221-16/2	Luongo, Cindy L.		Sanofi Pasteur	8-Jun-21						
L-221-16/2	McCarty, Thomas Charles		Sanofi Pasteur	8-Jun-21						
L-221-16/2	McLellan, Jason Scott		Sanofi Pasteur	8-Jun-21						
L-221-16/2	Munir, Shirin		Sanofi Pasteur	8-Jun-21						
L-221-16/2	Murphy, Brian R.		Sanofi Pasteur	8-Jun-21						
L-221-16/2	Nutt, Anne S.		Sanofi Pasteur	8-Jun-21						
L-113-04/1	Jeang, (b) (6) Kuan-Teh		Cell Signaling Technology, Inc.	9-Jun-21						
L-204-20/0	NIAID		Blue Water Vaccines Inc.	15-Jun-21						
L-162-15/2	NIAID		Merck Sharp and dohme	16-Jun-21						
L-273-16/1	Akin, Cem	(b)(4);	Heptares Therapeutics	16-Jun-21						
L-273-16/1	Kirshenbaum, Arnold	(b)(6)	Heptares Therapeutics	16-Jun-21						
L-273-16/1	Metcalfe, Dean D		Heptares Therapeutics	16-Jun-21						
L-303-19/1	Chuang, Gwo-Yu		TaiMed Biologics USA, Inc	18-Jun-21						

L-303-19/1	Connors, Mark	(b)(4);	TaiMed Biologics USA, Inc	18-Jun-21
L-303-19/1	Georgiev, Ivelin S.	(b)(6)	TaiMed Biologics USA, Inc	18-Jun-21
L-303-19/1	Kwon, Young Do		TaiMed Biologics USA, Inc	18-Jun-21
L-303-19/1	Kwong, Peter D.		TaiMed Biologics USA, Inc	18-Jun-21
L-303-19/1	Nabel, Gary J		TaiMed Biologics USA, Inc	18-Jun-21
L-303-19/1	Rudicell, Rebecca S.		TaiMed Biologics USA, Inc	18-Jun-21
L-303-19/1	Wu, Xueling		TaiMed Biologics USA, Inc	18-Jun-21
L-303-19/1	YANG, YONGPING		TaiMed Biologics USA, Inc	18-Jun-21
L-303-19/1	Yang, Zhi-Yong		TaiMed Biologics USA, Inc	18-Jun-21
L-303-19/1	Zhang, Baoshan		TaiMed Biologics USA, Inc	18-Jun-21
L-303-19/1	Zhou*, Tongqing		TaiMed Biologics USA, Inc	18-Jun-21
L-303-19/1	Zhu, Jiang		TaiMed Biologics USA, Inc	18-Jun-21
L-093-05/4	NIAID		Janssen Vaccines & Prevention BV	24-Jun-21
<i>Note: L-093-05/4 split between CDC; NIAID</i>				
L-275-14/0	NIAID		CSL Behring (Australia)	25-Jun-21
L-099-17/1	Akin, Cem	(b)(4);	Ei Lilly and Company	28-Jun-21
L-099-17/1	Kirshenbaum, Arnold	(b)(6)	Ei Lilly and Company	28-Jun-21
L-099-17/1	Metcalfe, Dean D		Ei Lilly and Company	28-Jun-21



(b) (4), (b) (3) (A), (b) (6)

NIH Patent Licensing Activities

NIAID

July 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
L-079-93/2	Ohara, Junichi	(b)(4);	BD Biosciences - BD PharMingen	1-Jul-21						(b) (4), (b) (3) (A), (b) (6)
L-079-93/2	Paul, (b) (6) William E.	(b)(6)	BD Biosciences - BD PharMingen	1-Jul-21						
L-074-91/3	Harriman, Gregory R.		Becton, Dickson and Company	1-Jul-21						
L-074-91/3	Kunimoto, Dennis Y.		Becton, Dickson and Company	1-Jul-21						
L-074-91/3	Paul, (b) (6) William E.		Becton, Dickson and Company	1-Jul-21						
L-074-91/3	Strober, Warren		Becton, Dickson and Company	1-Jul-21						
L-101-14/1	DeVico, Angela M.		EXBIO Praha	1-Jul-21						
L-101-14/1	Korty, Patricia E.		EXBIO Praha	1-Jul-21						
L-101-14/1	Shevach, Ethan M		EXBIO Praha	1-Jul-21						
L-021-10/1	Long, Eric O.		EXBIO Praha	1-Jul-21						
L-021-10/1	Rajagopalan, Sumati		EXBIO Praha	1-Jul-21						
L-221-16/2	Bermingham, Alison		Sanofi Pasteur	6-Jul-21						
L-221-16/2	Buchholz, Ursula		Sanofi Pasteur	6-Jul-21						
L-221-16/2	Collins, Peter L.		Sanofi Pasteur	6-Jul-21						
L-221-16/2	Kwong, Peter D.		Sanofi Pasteur	6-Jul-21						
L-221-16/2	Liang, Bo		Sanofi Pasteur	6-Jul-21						
L-221-16/2	Luongo, Cindy L.		Sanofi Pasteur	6-Jul-21						
L-221-16/2	McCarty, Thomas Charles		Sanofi Pasteur	6-Jul-21						
L-221-16/2	McLellan, Jason Scott		Sanofi Pasteur	6-Jul-21						

L-221-16/2	Munir, Shirin	(b)(4);	Sanofi Pasteur	6-Jul-21
L-221-16/2	Murphy, Brian R.	(b)(6)	Sanofi Pasteur	6-Jul-21
L-221-16/2	Nutt, Anne S.		Sanofi Pasteur	6-Jul-21
L-207-13/4	Cheng, Cheng		Hookipa Biotech, AG	7-Jul-21
L-207-13/4	Mangalampalli, Venkata R.		Hookipa Biotech, AG	7-Jul-21
L-207-13/4	Merritt, Joshua S.		Hookipa Biotech, AG	7-Jul-21
L-207-13/4	Schwartz, Richard M.		Hookipa Biotech, AG	7-Jul-21
L-207-13/4	Wycuff, Diane L.		Hookipa Biotech, AG	7-Jul-21
L-149-21/0	Ohara, Junichi		Proteintech Group Inc.	8-Jul-21
L-149-21/0	Paul, (b) (6) William E.		Proteintech Group Inc.	8-Jul-21
L-303-19/2	Chuang, Gwo-Yu		TaiMed Biologics USA, Inc.	13-Jul-21
L-303-19/2	Connors, Mark		TaiMed Biologics USA, Inc.	13-Jul-21
L-303-19/2	Georgiev, Ivelin S.		TaiMed Biologics USA, Inc.	13-Jul-21
L-303-19/2	Kwon, Young Do		TaiMed Biologics USA, Inc.	13-Jul-21
L-303-19/2	Kwong, Peter D.		TaiMed Biologics USA, Inc.	13-Jul-21
L-303-19/2	Nabel, Gary J		TaiMed Biologics USA, Inc.	13-Jul-21
L-303-19/2	Rudicell, Rebecca S.		TaiMed Biologics USA, Inc.	13-Jul-21
L-303-19/2	Wu, Xueling		TaiMed Biologics USA, Inc.	13-Jul-21
L-303-19/2	YANG, YONGPING		TaiMed Biologics USA, Inc.	13-Jul-21
L-303-19/2	Yang, Zhi-Yong		TaiMed Biologics USA, Inc.	13-Jul-21
L-303-19/2	Zhang, Baoshan		TaiMed Biologics USA, Inc.	13-Jul-21
L-303-19/2	Zhou, Tongqing		TaiMed Biologics USA, Inc.	13-Jul-21
L-303-19/2	Zhu, Jiang		TaiMed Biologics USA, Inc.	13-Jul-21
L-124-18/0	Garboczi, David		Abcam plc	14-Jul-21
L-124-18/0	Lantz, Larry		Abcam plc	14-Jul-21
L-124-18/0	Leppla, Stephen H.		Abcam plc	14-Jul-21
L-124-18/0	Leysath, Clinton E.		Abcam plc	14-Jul-21
L-124-18/0	Phillips, Damilola D.		Abcam plc	14-Jul-21
L-080-06/4	Blaney, Jr., Joseph E		Panacea Biotech Ltd	16-Jul-21
L-080-06/4	Hanley, Kathryn		Panacea Biotech Ltd	16-Jul-21
L-080-06/4	Lai, Ching-Juh		Panacea Biotech Ltd	16-Jul-21
L-080-06/4	Murphy, Brian R.		Panacea Biotech Ltd	16-Jul-21
L-080-06/4	Whitehead, Stephen S.		Panacea Biotech Ltd	16-Jul-21
<i>Note: L-080-06/4 split between FDA; NIAID</i>				
L-173-21/0	Germain, Ronald N.		Becton, Dickinson and Company	19-Jul-21
L-173-21/0	Porgador, Angel		Becton, Dickinson and Company	19-Jul-21
L-065-21/1	Lugli, Enrico		Lyell Immunopharma, Inc.	19-Jul-21
L-065-21/1	Roederer, Mario		Lyell Immunopharma, Inc.	19-Jul-21
<i>Note: L-065-21/1 split between NCI; NIAID</i>				
L-048-10/1	Akin, Cem		Novartis Horsham Research Centre	20-Jul-21
L-048-10/1	Kirshenbaum, Arnold		Novartis Horsham Research Centre	20-Jul-21
L-048-10/1	Metcalf, Dean D		Novartis Horsham Research Centre	20-Jul-21
L-048-10/0	Akin, Cem		Novartis Horsham Research Center	20-Jul-21
L-048-10/0	Kirshenbaum, Arnold		Novartis Horsham Research Center	20-Jul-21

(b) (4), (b) (3) (A), (b) (6)

L-048-10/0	Metcalf, Dean D	(b)(4); (b)(6)	Novartis Horsham Research Center	20-Jul-21	(b) (4), (b) (3) (A), (b) (6)
L-312-01/0	Ohara, Junichi		Mabtech AB	23-Jul-21	
L-312-01/0	Paul, (b) (6) William E.		Mabtech AB	23-Jul-21	
L-111-15/1	NIAID		Codagenix Inc.	23-Jul-21	

NIH Patent Licensing Activities

NIAID

August 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
L-115-00/2	Cheung, Yiu Chong Gordon	(b)(4);	List Biological Laboratories, Inc.	3-Aug-21						(b) (4), (b) (3) (A), (b) (6)
L-115-00/2	Gupta, Pradeep K.	(b)(6)	List Biological Laboratories, Inc.	3-Aug-21						
L-115-00/2	Hsu, Su-Cheng Dana		List Biological Laboratories, Inc.	3-Aug-21						
L-115-00/2	Hu, Haijing		List Biological Laboratories, Inc.	3-Aug-21						
L-115-00/2	Leppla, Stephen H.		List Biological Laboratories, Inc.	3-Aug-21						
L-115-00/2	Leysath, Clinton E.		List Biological Laboratories, Inc.	3-Aug-21						
L-115-00/2	Moayeri, Mahtab		List Biological Laboratories, Inc.	3-Aug-21						
L-115-00/2	Pomerantsev, Andrei P		List Biological Laboratories, Inc.	3-Aug-21						
<i>Note: L-115-00/2 split between NIAID; NIDCR</i>										
L-226-14/2	Nutman, Thomas B.		Quest Distribution Inc.	3-Aug-21						
L-279-19/0	Boyington, Jeffrey C.		BlueWillow Biologics, Inc.	4-Aug-21						
L-279-19/0	Carey, Elizabeth		BlueWillow Biologics, Inc.	4-Aug-21						
L-279-19/0	Chen, Lei		BlueWillow Biologics, Inc.	4-Aug-21						
L-279-19/0	Chen, Man		BlueWillow Biologics, Inc.	4-Aug-21						
L-279-19/0	Chen, Mingzong		BlueWillow Biologics, Inc.	4-Aug-21						
L-279-19/0	Chen, Peifeng		BlueWillow Biologics, Inc.	4-Aug-21						
L-279-19/0	Chuang, Gwo-Yu		BlueWillow Biologics, Inc.	4-Aug-21						
L-279-19/0	Georgiev, Ivelin S.		BlueWillow Biologics, Inc.	4-Aug-21						
L-279-19/0	Ghosh, Mridul K.		BlueWillow Biologics, Inc.	4-Aug-21						
L-279-19/0	Gorman, Jason		BlueWillow Biologics, Inc.	4-Aug-21						
L-279-19/0	Horwitz, Joseph		BlueWillow Biologics, Inc.	4-Aug-21						
L-279-19/0	Joyce, Michael G.		BlueWillow Biologics, Inc.	4-Aug-21						
L-279-19/0	Kanekiyo, Masaru		BlueWillow Biologics, Inc.	4-Aug-21						
L-279-19/0	Kwong, Peter D.		BlueWillow Biologics, Inc.	4-Aug-21						
L-279-19/0	McLellan, Jason Scott		BlueWillow Biologics, Inc.	4-Aug-21						
L-279-19/0	Nagy, Attila		BlueWillow Biologics, Inc.	4-Aug-21						
L-279-19/0	OFEK, GILAD A		BlueWillow Biologics, Inc.	4-Aug-21						
L-279-19/0	Pancera, Marie L.		BlueWillow Biologics, Inc.	4-Aug-21						
L-279-19/0	Sastry, Mallika		BlueWillow Biologics, Inc.	4-Aug-21						
L-279-19/0	Soto, Cinque		BlueWillow Biologics, Inc.	4-Aug-21						
L-279-19/0	Srivatsan, Sanjay R.		BlueWillow Biologics, Inc.	4-Aug-21						
L-279-19/0	Stewart-Jones, Guillaume B		BlueWillow Biologics, Inc.	4-Aug-21						
L-279-19/0	(b) (4)		BlueWillow Biologics, Inc.	4-Aug-21						
L-279-19/0	YANG, YONGPING		BlueWillow Biologics, Inc.	4-Aug-21						
L-279-19/0	Zhang, Baoshan		BlueWillow Biologics, Inc.	4-Aug-21						
L-279-19/0	Zhou, Tongqing		BlueWillow Biologics, Inc.	4-Aug-21						

L-126-15/1	NIAID	GlaxoSmithKline Biologicals, S.A.	5-Aug-21
<i>Note: L-126-15/1 split between CDC; NIAID</i>			
L-009-06/0	Collins, Peter L.	(b)(4); (b)(6) Apath, LLC	5-Aug-21
L-190-20/0	Boyington, Jeffrey C.	Meso Scale Diagnostics, LLC	16-Aug-21
L-190-20/0	Chen, Lei	Meso Scale Diagnostics, LLC	16-Aug-21
L-190-20/0	Chen, Man	Meso Scale Diagnostics, LLC	16-Aug-21
L-190-20/0	Chuang, Gwo-Yu	Meso Scale Diagnostics, LLC	16-Aug-21
L-190-20/0	(b) (4)	Meso Scale Diagnostics, LLC	16-Aug-21
L-190-20/0	Georgiev, Ivelin S.	Meso Scale Diagnostics, LLC	16-Aug-21
L-190-20/0	Gorman, Jason	Meso Scale Diagnostics, LLC	16-Aug-21
L-190-20/0	Hutchinson, Geoffrey Bain	Meso Scale Diagnostics, LLC	16-Aug-21
L-190-20/0	Joyce, Michael G.	Meso Scale Diagnostics, LLC	16-Aug-21
L-190-20/0	Kanekiyo, Masaru	Meso Scale Diagnostics, LLC	16-Aug-21
L-190-20/0	Kwong, Peter D.	Meso Scale Diagnostics, LLC	16-Aug-21
L-190-20/0	McLellan, Jason Scott	Meso Scale Diagnostics, LLC	16-Aug-21
L-190-20/0	OFEK, GILAD A	Meso Scale Diagnostics, LLC	16-Aug-21
L-190-20/0	Pancera, Marie L.	Meso Scale Diagnostics, LLC	16-Aug-21
L-190-20/0	Sastry, Mallika	Meso Scale Diagnostics, LLC	16-Aug-21
L-190-20/0	(b) (4)	Meso Scale Diagnostics, LLC	16-Aug-21
L-190-20/0	Soto, Cinque	Meso Scale Diagnostics, LLC	16-Aug-21
L-190-20/0	Srivatsan, Sanjay R.	Meso Scale Diagnostics, LLC	16-Aug-21
L-190-20/0	Stewart-Jones, Guillaume B	Meso Scale Diagnostics, LLC	16-Aug-21
L-190-20/0	(b) (4)	Meso Scale Diagnostics, LLC	16-Aug-21
L-190-20/0	YANG, YONGPING	Meso Scale Diagnostics, LLC	16-Aug-21
L-190-20/0	Yassine, Hadi M.	Meso Scale Diagnostics, LLC	16-Aug-21
L-190-20/0	Zhang, Baoshan	Meso Scale Diagnostics, LLC	16-Aug-21
L-190-20/0	Zhou, Tongqing	Meso Scale Diagnostics, LLC	16-Aug-21
L-298-19/0	NIAID	GlaxoSmithKline Intellectual Property Li	19-Aug-21
L-191-16/3	Akin, Cem	(b)(4); GlaxoSmithKline LLC	20-Aug-21
L-191-16/3	Kirshenbaum, Arnold	(b)(6) GlaxoSmithKline LLC	20-Aug-21
L-191-16/3	Metcalf, Dean D	GlaxoSmithKline LLC	20-Aug-21
L-072-09/1	Long, Eric O.	BioLegend	26-Aug-21
L-072-09/1	Rajagopalan, Sumati	BioLegend	26-Aug-21
L-157-20/0	Germain, Ronald N.	Biologend, Inc.	26-Aug-21
L-157-20/0	Gerner, Michael Y	Biologend, Inc.	26-Aug-21
L-157-20/0	Li, Weizhe	Biologend, Inc.	26-Aug-21
L-164-21/0	Akin, Cem	Eurofins Beacon Discovery, Inc.	27-Aug-21
L-164-21/0	Kirshenbaum, Arnold	Eurofins Beacon Discovery, Inc.	27-Aug-21
L-164-21/0	Metcalf, Dean D	Eurofins Beacon Discovery, Inc.	27-Aug-21
L-251-20/0	(b) (4)	Remel Europe Limited	30-Aug-21
L-251-20/0	Hutchinson, Geoffrey Bain	Remel Europe Limited	30-Aug-21
L-251-20/0	Joyce, Michael G.	Remel Europe Limited	30-Aug-21
L-251-20/0	Kanekiyo, Masaru	Remel Europe Limited	30-Aug-21
L-251-20/0	(b) (4)	Remel Europe Limited	30-Aug-21

L-251-20/0	(b) (4)	(b)(4);	Remel Europe Limited	30-Aug-21	(b) (4), (b) (3) (A), (b) (6)
L-251-20/0	Yassine, Hadi M.	(b)(6)	Remel Europe Limited	30-Aug-21	
L-154-06/0	Mackett, Michael		Boehringer Ingelheim Animal Health US	31-Aug-21	
L-154-06/0	Moss, Bernard		Boehringer Ingelheim Animal Health US	31-Aug-21	
L-154-06/0	Smith, Geoffrey L		Boehringer Ingelheim Animal Health US	31-Aug-21	
L-121-20/0	NIAID		Noachis Terra Inc	31-Aug-21	

NIH Patent Licensing Activities
NIAID
September 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
L-099-14/2	Garboczi, David	(b)(4);	KeraFAST	2-Sep-21						(b) (4), (b) (3) (A), (b) (6)
L-099-14/2	Lantz, Larry	(b)(6)	KeraFAST	2-Sep-21						
L-099-14/2	Leppla, Stephen H.		KeraFAST	2-Sep-21						
L-099-14/2	Leysath, Clinton E.		KeraFAST	2-Sep-21						
L-099-14/2	Phillips, Damilola D.		KeraFAST	2-Sep-21						
L-262-20/0	(b) (4)		Sanofi Pasteur	7-Sep-21						
L-262-20/0	Hutchinson, Geoffrey Bain		Sanofi Pasteur	7-Sep-21						
L-262-20/0	Joyce, Michael G.		Sanofi Pasteur	7-Sep-21						
L-262-20/0	Kanekiyo, Masaru		Sanofi Pasteur	7-Sep-21						
L-262-20/0	(b) (4)		Sanofi Pasteur	7-Sep-21						
L-262-20/0	Yassine, Hadi M.		Sanofi Pasteur	7-Sep-21						
L-158-20/1	Zhang, Yi		AbCellera Biologics Inc.	8-Sep-21						
L-074-20/0	Baxa, Ulrich		China National Biotec Group Company I	9-Sep-21						
L-074-20/0	Boyington, Jeffrey C.		China National Biotec Group Company I	9-Sep-21						
L-074-20/0	Chen, Lei		China National Biotec Group Company I	9-Sep-21						
L-074-20/0	Chen, Man		China National Biotec Group Company I	9-Sep-21						
L-074-20/0	Chuang, Gwo-Yu		China National Biotec Group Company I	9-Sep-21						
L-074-20/0	Druz, Aliaksandr A.		China National Biotec Group Company I	9-Sep-21						
L-074-20/0	Galen, Joseph Van		China National Biotec Group Company I	9-Sep-21						
L-074-20/0	Georgiev, Ivelin S.		China National Biotec Group Company I	9-Sep-21						
L-074-20/0	Gorman, Jason		China National Biotec Group Company I	9-Sep-21						
L-074-20/0	Joyce, Michael G.		China National Biotec Group Company I	9-Sep-21						
L-074-20/0	Kanekiyo, Masaru		China National Biotec Group Company I	9-Sep-21						
L-074-20/0	Kwong, Peter D.		China National Biotec Group Company I	9-Sep-21						
L-074-20/0	McLellan, Jason Scott		China National Biotec Group Company I	9-Sep-21						
L-074-20/0	OFEK, GILAD A		China National Biotec Group Company I	9-Sep-21						
L-074-20/0	Ou, Li		China National Biotec Group Company I	9-Sep-21						
L-074-20/0	Pancera, Marie L.		China National Biotec Group Company I	9-Sep-21						
L-074-20/0	Rundlet, Emily J		China National Biotec Group Company I	9-Sep-21						
L-074-20/0	Sastry, Mallika		China National Biotec Group Company I	9-Sep-21						
L-074-20/0	Soto, Cinque		China National Biotec Group Company I	9-Sep-21						
L-074-20/0	Srivatsan, Sanjay R.		China National Biotec Group Company I	9-Sep-21						

L-074-20/0	Stewart-Jones, Guillaume	(b)(4);	China National Biotec Group Company I	9-Sep-21
L-074-20/0	Thomas, Paul V.	(b)(6)	China National Biotec Group Company I	9-Sep-21
L-074-20/0	Tsybovsky, Yaroslav		China National Biotec Group Company I	9-Sep-21
L-074-20/0	YANG, YONGPING		China National Biotec Group Company I	9-Sep-21
L-074-20/0	Zhang, Baoshan		China National Biotec Group Company I	9-Sep-21
L-074-20/0	Zhou, Tongqing		China National Biotec Group Company I	9-Sep-21
L-191-16/3	Akin, Cem		GlaxoSmithKline LLC	10-Sep-21
L-191-16/3	Kirshenbaum, Arnold		GlaxoSmithKline LLC	10-Sep-21
L-191-16/3	Metcalfe, Dean D		GlaxoSmithKline LLC	10-Sep-21
L-150-20/0	NIAID		Medigen Vaccine Biologics Corp	10-Sep-21
L-191-16/3	Akin, Cem	(b)(4);	GlaxoSmithKline LLC	13-Sep-21
L-191-16/3	Kirshenbaum, Arnold	(b)(6)	GlaxoSmithKline LLC	13-Sep-21
L-191-16/3	Metcalfe, Dean D		GlaxoSmithKline LLC	13-Sep-21
L-080-06/4	NIAID		Panacea Biotech Ltd	14-Sep-21
<i>Note: L-080-06/4 split between FDA; NIAID</i>				
L-203-19/2	Akin, Cem	(b)(4);	AstraZeneca AB	15-Sep-21
L-203-19/2	Kirshenbaum, Arnold	(b)(6)	AstraZeneca AB	15-Sep-21
L-203-19/2	Metcalfe, Dean D		AstraZeneca AB	15-Sep-21
L-158-20/1	Zhang, Yi		AbCellera Biologics Inc.	15-Sep-21 \$
L-135-17/4	Boyington, Jeffrey C.		Emergent Product Development Gaithe	15-Sep-21
L-135-17/4	Kanekiyo, Masaru		Emergent Product Development Gaithe	15-Sep-21
L-135-17/4	Kwong, Peter D.		Emergent Product Development Gaithe	15-Sep-21
L-135-17/4	McTamney, Patrick		Emergent Product Development Gaithe	15-Sep-21
L-135-17/4	Moin, Syed M.		Emergent Product Development Gaithe	15-Sep-21
L-135-17/4	Nabel, Gary J		Emergent Product Development Gaithe	15-Sep-21
L-135-17/4	Wei, Chih-Jen		Emergent Product Development Gaithe	15-Sep-21
L-135-17/4	Whittle, James R R		Emergent Product Development Gaithe	15-Sep-21
L-135-17/4	Yang, Zhi-Yong		Emergent Product Development Gaithe	15-Sep-21
L-135-17/4	Yassine, Hadi M.		Emergent Product Development Gaithe	15-Sep-21
L-080-04/1	Green, Kim Y.		R-Biopharm AG	17-Sep-21
L-080-04/1	Sosnovtsev, Stanislav V		R-Biopharm AG	17-Sep-21
L-199-17/0	Akahata, Wataru		Infectious Disease Research Institute	20-Sep-21
L-199-17/0	Nabel, Gary J		Infectious Disease Research Institute	20-Sep-21
L-199-17/0	Rao, Srinivas		Infectious Disease Research Institute	20-Sep-21
L-199-17/0	Yang, Zhi-Yong		Infectious Disease Research Institute	20-Sep-21
L-199-17/0	NIAID		Infectious Disease Research Institute	20-Sep-21
L-019-08/0	Schubert, Ulrich K	(b)(4);	Institut Pasteur	20-Sep-21
L-019-08/0	Yewdell, Jonathan W.	(b)(6)	Institut Pasteur	20-Sep-21
<i>Note: L-019-08/0 split between FDA; NCI; NIAID; NIBIB; NIDDK</i>				
L-059-21/0	Akahata, Wataru	(b)(4);	BIOMERIEUX S. A.	21-Sep-21
L-059-21/0	Nabel, Gary J	(b)(6)	BIOMERIEUX S. A.	21-Sep-21

L-059-21/0	Rao, Srinivas	(b)(4); (b)(6)	BIOMERIEUX S. A.	21-Sep-21	(b) (4), (b) (3) (A), (b) (6)				
L-059-21/0	NIAID		BIOMERIEUX S. A.	21-Sep-21					
L-163-21/0	Stewart-Jones, Guillaume B	(b)(4); (b)(6)	MEVOX Ltd.	27-Sep-21					
L-106-06/1	Shevach, Ethan M		Affymetrix, Inc.	28-Sep-21					
L-106-06/1	Shevach, Ethan M		Affymetrix, Inc.	28-Sep-21					
L-211-21/0	Fuerst, Thomas R.		Gilead Sciences Inc.	28-Sep-21					
L-211-21/0	Hirsch, Vanessa M.		Gilead Sciences Inc.	28-Sep-21					
					\$24,802,452.42	\$242,171.54	\$25,044,623.96	\$612,946.26	\$24,431,677.70

NIH Patent Licensing Activities
NIAMS
April 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	--------------------	---------------------------	-----------------------	---------------------

NIH Patent Licensing Activities
NIAMS
May 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
L-171-19/0	Meylan, Francoise	(b)(4);	Bio X Cell	10-May-21						(b) (4), (b) (3) (A), (b) (6)
L-171-19/0	Siegel, Richard	(b)(6)	Bio X Cell	10-May-21						
L-171-19/0	Song, Yun-Jeong		Bio X Cell	10-May-21						

NIH Patent Licensing Activities
NIAMS
June 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
L-054-18/0	Plotz, Paul H.	(b)(4);	AVROBIO, Inc	7-Jun-21						(b) (4), (b) (3) (A), (b) (6)
L-054-18/0	Raben, Nina	(b)(6)	AVROBIO, Inc	7-Jun-21						
L-051-13/0	Johnston, James A.	(b)(4);	Cell Signaling Technology Inc	9-Jun-21						

Note: L-051-13/0 split between NCI; NHLBI; NIAMS

NIH Patent Licensing Activities
NIAMS
July 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-------------------	---------------------------	----------------------	---------------------

NIH Patent Licensing Activities
NIAMS
August 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
L-066-05/1	Kinet, Jean-Pierre	(b)(4);	President and Fellows of Harvard Colleg	3-Aug-21						(b) (4), (b) (3) (A), (b) (6)

Note: L-066-05/1 split between NIAMS; NIDCR

NIH Patent Licensing Activities
NIAMS
September 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
						\$36,630.61	\$0.00	\$36,630.61	\$9,595.01	\$27,035.60

NIH Patent Licensing Activities
NIBIB
April 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
L-256-14/0	Parekh, Sapun	(b)(4);	VisiTech International	19-Apr-21						(b) (4), (b) (3) (A), (b) (6)
L-256-14/0	Shroff, Hari	(b)(6)	VisiTech International	19-Apr-21						
L-256-14/0	York, Andrew G.		VisiTech International	19-Apr-21						

Note: L-256-14/0 split between NHLBI; NIBIB

NIH Patent Licensing Activities
NIBIB
May 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	------------------	---------------------------	---------------------	---------------------

NIH Patent Licensing Activities
NIBIB
June 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-------------------	---------------------------	----------------------	---------------------

NIH Patent Licensing Activities
NIBIB
July 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-------------------	---------------------------	----------------------	---------------------

NIH Patent Licensing Activities
NIBIB
August 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	---------------------	---------------------------	------------------------	---------------------

NIH Patent Licensing Activities
NIBIB
September 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	------------------------	---------------------------	---------------------------	---------------------

L-019-08/0 Phillips, Terence M (b)(4); Institut Pasteur 20-Sep-21
Note: L-019-08/0 split between FDA; NCI; NIAID; NIBIB; NIDDK

(b) (4), (b) (3) (A), (b) (6)

\$26,607.80 \$0.00 \$26,607.80 \$9,939.00 \$16,668.80

NIH Patent Licensing Activities
NICHD
April 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	--------------------	---------------------------	-----------------------	---------------------

L-215-14/0 Bridson, William E. (b)(4); Quest Diagnostics, Inc. 2-Apr-21
L-215-14/0 Hertz, Roy (b)(6) Quest Diagnostics, Inc. 2-Apr-21
L-215-14/0 Kingfield, Joyce G. Quest Diagnostics, Inc. 2-Apr-21
L-215-14/0 Kohler, Peter O. Quest Diagnostics, Inc. 2-Apr-21

L-240-02/2 Deligiannidis, Kristina M Ga Novus Biologicals Inc 7-Apr-21
L-240-02/2 Klein, David C. Novus Biologicals Inc 7-Apr-21
L-240-02/2 (b) (4) Novus Biologicals Inc 7-Apr-21
L-240-02/2 Weller, Joan Novus Biologicals Inc 7-Apr-21

L-204-02/2 Chumakov, Ekaterina Novus Biologicals, LLC 7-Apr-21
L-204-02/2 McDonald, John Novus Biologicals, LLC 7-Apr-21
L-204-02/2 Woodgate, Roger Novus Biologicals, LLC 7-Apr-21

(b) (4), (b) (3) (A), (b) (6)

L-101-21/0	Chou, Janice Yang	(b)(4); (b)(6)	Sangamo Therapeutics, Inc.	13-Apr-21	(b) (4), (b) (3) (A), (b) (6)
L-132-04/2	Klein, David C.		Santa Cruz Biotechnology Inc	28-Apr-21	
L-132-04/2	Moffett, John R		Santa Cruz Biotechnology Inc	28-Apr-21	
L-132-04/2	Namboodiri, Aryan M		Santa Cruz Biotechnology Inc	28-Apr-21	
L-132-04/2	Roseboom, Patrick		Santa Cruz Biotechnology Inc	28-Apr-21	
L-132-04/2	Weller, Joan		Santa Cruz Biotechnology Inc	28-Apr-21	
L-207-18/0	Chou, Janice Yang		Generation Bio	28-Apr-21	

NIH Patent Licensing Activities
NICHD
May 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
L-124-21/0	Chou, Janice Yang	(b)(4); (b)(6)	Poseidon Innovation, LLC	14-May-21						(b) (4), (b) (3) (A), (b) (6)
L-124-21/0	Chou, Janice Yang		Poseidon Innovation, LLC	14-May-21						
L-008-15/1	NICHD		xMD Diagnostics, LLC	18-May-21						

Note: L-008-15/1 split between CIT; NCI; NICHD

NIH Patent Licensing Activities
NICHD
June 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC

NIH Patent Licensing Activities
NICHD
July 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC

NIH Patent Licensing Activities
NICHD
August 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
L-313-19/0	NICHD		Circumvent Pharmaceuticals, Inc.	11-Aug-21						(b) (4), (b) (3) (A), (b) (6)
L-138-93/2	Crouch, Robert J.	(b)(4); (b)(6)	Agilent Technologies, Inc.	16-Aug-21						

(b) (4), (b) (3) (A), (b) (6)

L-192-21/0	Westphal, Heinrich	(b)(4); (b)(6)	Morphic Therapeutic	17-Aug-21
L-280-14/1	Gandjbakhche, Amir H		Arche Opitex Biomedical, Inc.	18-Aug-21
L-280-14/1		(b) (4)	Arche Opitex Biomedical, Inc.	18-Aug-21
L-280-14/1	Riley, Jason D.		Arche Opitex Biomedical, Inc.	18-Aug-21
<i>Note: L-280-14/1 split between NICHD; NIND</i>				
L-153-21/0	Lawson, Nathan		Regeneron Pharmaceuticals, Inc.	19-Aug-21
L-153-21/0	Weinstein, Brant		Regeneron Pharmaceuticals, Inc.	19-Aug-21
L-153-21/0	Lawson, Nathan		Regeneron Pharmaceuticals, Inc.	30-Aug-21
L-153-21/0	Weinstein, Brant		Regeneron Pharmaceuticals, Inc.	30-Aug-21

NIH Patent Licensing Activities
NICHD
September 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
L-026-13/1	Blithe, Diana L.	(b)(4);	Preglem SA	21-Sep-21						(b) (4), (b) (3) (A), (b) (6)
L-026-13/1	Nieman, Lynnette K.	(b)(6)	Preglem SA	21-Sep-21						
					\$214,486.89	\$25,525.51	\$240,012.40		\$48,094.32	\$191,918.08

NIH Patent Licensing Activities
NIDA
April 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC

NIH Patent Licensing Activities
NIDA
May 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
L-257-19/0	NIDA		Inversago Pharma Inc	11-May-21						(b) (4), (b) (3) (A)
<i>Note: L-257-19/0 split between NIAAA; NIDA</i>										
L-162-16/3	NIDA		Inversago Pharma Inc.	11-May-21						
<i>Note: L-162-16/3 split between NIAAA; NIDA</i>										

NIH Patent Licensing Activities
NIDA
June 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
L-276-17/0	NIDA		Vital Spark Inc.	4-Jun-21						(b) (4), (b) (3) (A)

Note: L-276-17/0 split between NIAAA; NIDA

NIH Patent Licensing Activities
NIDA
July 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
L-250-18/1	NIDA		Hello Bio Ltd.	28-Jul-21						(b) (4), (b) (3) (A)

Note: L-250-18/1 split between NIDA; NINDS

NIH Patent Licensing Activities
NIDA
August 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
L-250-18/1	Gomez, Juan Luis	(b)(4);	Hello Bio Ltd.	12-Aug-21						(b) (4), (b) (3) (A), (b) (6)
L-250-18/1	(b) (4)	(b)(6)	Hello Bio Ltd.	12-Aug-21						
L-250-18/1	Michaelides, Michael		Hello Bio Ltd.	12-Aug-21						
L-250-18/1	Moreira, Jordi Bonaventura		Hello Bio Ltd.	12-Aug-21						

Note: L-250-18/1 split between NIDA; NINDS

NIH Patent Licensing Activities
NIDA
September 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
L-070-03/2	Wise, Roy A	(b)(4);	Brainsway, Inc.	1-Sep-21						(b) (4), (b) (3) (A), (b) (6)
L-070-03/2	Zangen, Abraham	(b)(6)	Brainsway, Inc.	1-Sep-21						

Note: L-070-03/2 split between NIDA; NINDS

L-070-03/2	Wise, Roy A	(b)(4);	Brainsway, Inc.	13-Sep-21						
L-070-03/2	Zangen, Abraham	(b)(6)	Brainsway, Inc.	13-Sep-21						

Note: L-070-03/2 split between NIDA; NINDS

\$92,755.17	\$786.25	\$93,541.42	\$24,398.95	\$69,142.47
-------------	----------	-------------	-------------	-------------

NIH Patent Licensing Activities
NIDCD

April 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	--------------------	---------------------------	-----------------------	---------------------

NIH Patent Licensing Activities
NIDCD
May 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
L-084-10/0	NIDCD		Firmenich Inc.	7-May-21						(b) (4), (b) (3) (A), (b) (6)
L-084-10/0	Drayna, Dennis T.	(b)(4);	irmenich Inc.	7-May-21						
L-084-10/0	Kim, Un-kyung	(b)(6)	irmenich Inc.	7-May-21						
L-084-10/0	(b) (4)		irmenich Inc.	7-May-21						
L-016-20/0	Canseco De Kalinec, Gilda M		Regeneron Pharmaceuticals, Inc	11-May-21						
L-016-20/0	Kalinec, Federico		Regeneron Pharmaceuticals, Inc	11-May-21						
L-036-20/0	De Kalinec, Gilda Mabel Ca		Regeneron Pharmaceuticals, Inc	11-May-21						
L-036-20/0	Kalinec, Federico		Regeneron Pharmaceuticals, Inc	11-May-21						

NIH Patent Licensing Activities
NIDCD
June 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-------------------	---------------------------	----------------------	---------------------

NIH Patent Licensing Activities
NIDCD
July 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-------------------	---------------------------	----------------------	---------------------

NIH Patent Licensing Activities
NIDCD
August 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
L-214-92/8	RJ Wenthold (b) (6)	(b)(4); (b) (6)	Millipore Sigma	26-Aug-21						(b) (4), (b) (3) (A), (b) (6)

NIH Patent Licensing Activities

NIDCD
September 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
					\$32,560.36	\$7,680.53	\$40,240.89		\$8,909.08	\$31,331.81

NIH Patent Licensing Activities
NIDCR
April 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC	
L-072-10/0	Gronthos, Stan	(b)(4);	Mesoblast Inc.	13-Apr-21						(b) (4), (b) (3) (A), (b) (6)	
L-072-10/0	Miura, Masako	(b)(6)	Mesoblast Inc.	13-Apr-21							
L-072-10/0	Robey, Pamela G.		Mesoblast Inc.	13-Apr-21							
L-072-10/0	Seo, Byoung-Moo		Mesoblast Inc.	13-Apr-21							
L-072-10/0	Shi, Songtao		Mesoblast Inc.	13-Apr-21							
L-179-19/0	Kulkarni, Ashok		Codexis, Inc.	15-Apr-21							
L-179-19/0	Ohshima, Toshio		Codexis, Inc.	15-Apr-21							
<i>Note: L-179-19/0 split between NIDCR; NINDS</i>											
L-115-00/2	Leppla, Stephen H.	(b)(4);	List Biological Laboratories, Inc.	15-Apr-21							
<i>Note: L-115-00/2 split between NIAID; NIDCR</i>											
L-153-07/2	Fisher, Larry	(b)(6)	Santa Cruz Biotech., Inc.	28-Apr-21							
L-153-07/2	Fisher, Larry		Santa Cruz Biotech., Inc.	28-Apr-21							

NIH Patent Licensing Activities
NIDCR
May 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
L-152-17/0	Akiyama, Steven	(b)(4);	Millipore Sigma	26-May-21						(b) (4), (b) (3) (A), (b) (6)
L-152-17/0	Yamada, Kenneth	(b)(6)	Millipore Sigma	26-May-21						
L-152-17/0	Yamada, Susan Sleeper		Millipore Sigma	26-May-21						

NIH Patent Licensing Activities
NIDCR
June 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-------------------	---------------------------	----------------------	---------------------

NIH Patent Licensing Activities
NIDCR
July 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
L-048-03/1	NIDCR		Lees Pharmaceutical (HK) LTD	20-Jul-21						(b) (4), (b) (3) (A), (b) (6)
L-116-11/3	Chiorini, John A.	(b)(4);	uniQure B.V.	29-Jul-21						
<i>Note: L-116-11/3 split between NHLBI; NIDCR</i>										
L-116-11/3	NIDCR		uniQure B.V.	29-Jul-21						
<i>Note: L-116-11/3 split between NHLBI; NIDCR</i>										
L-116-11/3	NIDCR		uniQure B.V.	29-Jul-21						
<i>Note: L-116-11/3 split between NHLBI; NIDCR</i>										

NIH Patent Licensing Activities
NIDCR
August 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
L-115-00/2	Leppla, Stephen H.	(b)(4);	List Biological Laboratories, Inc.	3-Aug-21						(b) (4), (b) (3) (A), (b) (6)
<i>Note: L-115-00/2 split between NIAID; NIDCR</i>										
L-343-01/0	Keith, Jerry M	(b)(4);	List Biological Laboratories, Inc.	3-Aug-21						
L-343-01/0	Merkel, Todd J.	(b)(6)	List Biological Laboratories, Inc.	3-Aug-21						
L-343-01/0	Yang, Xiaoming		List Biological Laboratories, Inc.	3-Aug-21						
L-066-05/1	Siraganian, Reuben		President and Fellows of Harvard Colleg	3-Aug-21						
<i>Note: L-066-05/1 split between NIAMS; NIDCR</i>										
L-152-17/0	Akiyama, Steven	(b)(4);	Millipore Sigma	26-Aug-21						
L-152-17/0	Yamada, Kenneth	(b)(6)	Millipore Sigma	26-Aug-21						
L-152-17/0	Yamada, Susan Sleeper		Millipore Sigma	26-Aug-21						
L-078-15/0	Kaludov, Nikola		Spark Therapeutics, Inc.	30-Aug-21						

NIH Patent Licensing Activities
NIDCR
September 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
L-263-18/0	NIDCR		MeiraGTx	8-Sep-21						(b) (4), (b) (3) (A)

L-088-12/0 NIDCR
 Note: L-088-12/0 split between NHLBI; NIDCR

Sangamo BioSciences Inc

23-Sep-21

(b) (4), (b) (3) (A)

\$2,376,539.41 \$1,702.00 \$2,378,241.41 \$136,280.06 \$2,241,961.35

NIH Patent Licensing Activities
NIDDK
April 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
L-033-19/0	Goldsmith, Paul K	(b)(4):	Bio-Techne Corporation	7-Apr-21						(b) (4), (b) (3) (A), (b) (6)
L-033-19/0	Spiegel, Allen M.	(b)(6)	Bio-Techne Corporation	7-Apr-21						

NIH Patent Licensing Activities
NIDDK
May 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	------------------	---------------------------	---------------------	---------------------

NIH Patent Licensing Activities
NIDDK
June 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
L-155-07/1	Daly, (b) (4) John W	(b)(4): (b)(6)	Latoxan S.A.S.	15-Jun-21						(b) (4), (b) (3) (A), (b) (6)
L-155-07/1	Daly, (b) (4) John W	(b)(4): (b)(6)	Latoxan S.A.S.	15-Jun-21						
L-159-07/2	NIDDK		Hope Pharmaceuticals	17-Jun-21						
<i>Note: L-159-07/2 split between CC; NHLBI; NIDDK; NINDS</i>										
L-132-12/2	NIDDK		Metalogics Corp	30-Jun-21						

NIH Patent Licensing Activities
NIDDK
July 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-------------------	---------------------------	----------------------	---------------------

NIH Patent Licensing Activities
NIDDK
August 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
L-097-20/1	Jacobson, Kenneth A	(b)(4);	Astrocyte Pharmaceuticals, Inc	9-Aug-21						(b) (4), (b) (3) (A), (b) (6)
L-097-20/1	Ravi, Rama Suresh	(b)(6)	Astrocyte Pharmaceuticals, Inc	9-Aug-21						
L-149-17/0	Oral, Elif A.		Aegerion Pharmaceuticals, Inc.	16-Aug-21						
L-149-17/0	Taylor, Simeon		Aegerion Pharmaceuticals, Inc.	16-Aug-21						
L-097-20/1	Jacobson, Kenneth A		Astrocyte Pharmaceuticals, Inc	26-Aug-21						
L-097-20/1	Ravi, Rama Suresh		Astrocyte Pharmaceuticals, Inc	26-Aug-21						

NIH Patent Licensing Activities

NIDDK

September 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
L-019-08/0	Kopp, Jeffrey B	(b)(4);	Institut Pasteur	20-Sep-21						(b) (4), (b) (3) (A), (b) (6)
<i>Note: L-019-08/0 split between FDA; NCI; NIAID; NIBIB; NIDDK</i>										
					\$144,220.16	\$401.50	\$144,621.66		\$32,852.22	\$111,769.44

NIH Patent Licensing Activities

NIEHS

April 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	--------------------	---------------------------	-----------------------	---------------------

NIH Patent Licensing Activities

NIEHS

May 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	------------------	---------------------------	---------------------	---------------------

NIH Patent Licensing Activities

NIEHS

June 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-------------------	---------------------------	----------------------	---------------------

NIH Patent Licensing Activities

NIEHS

July 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
L-079-16/2	Baek, Seung Joon	(b)(4);	Janssen Research & Development	22-Jul-21						(b) (4), (b) (3) (A), (b) (6)
L-079-16/2	Eling, Thomas E	(b)(6)	Janssen Research & Development	22-Jul-21						

NIH Patent Licensing Activities

NIEHS

August 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC

NIH Patent Licensing Activities

NIEHS

September 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
L-063-93/2	Eddy, Edward	(b)(4);	ThermoFisher Scientific	22-Sep-21						(b) (4), (b) (3) (A), (b) (6)
							\$14,229.01		\$4,029.01	\$10,200.00

NIH Patent Licensing Activities

NIMH

April 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
L-018-10/0	Manji, Hussein K.	(b)(4);	Mount Sinai Med Cntr	1-Apr-21						(b) (4), (b) (3) (A), (b) (6)
L-018-10/0	Zarate, Carlos A.	(b)(6)	Mount Sinai Med Cntr	1-Apr-21						
L-018-10/0	Manji, Hussein K.		Mount Sinai Med Cntr	12-Apr-21						
L-018-10/0	Zarate, Carlos A.		Mount Sinai Med Cntr	12-Apr-21						

NIH Patent Licensing Activities

NIMH

May 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
L-213-94/1	Mahan, Lawrence C.	(b)(4);	Eurofins Panlabs	1-May-21						(b) (4), (b) (3) (A), (b) (6)
	<i>Note: L-213-94/1 split between NIMH; NINDS</i>	(b)(6)								
L-261-16/0	Eiden, Maribeth V.		Fred Hutchinson Cancer Research Cente	7-May-21						

L-261-16/0 Wilson, Carolyn A. (b)(4); (b)(6) Fred Hutchinson Cancer Research Cente 7-May-21 (b) (4), (b) (6), (b) (3) (A)

NIH Patent Licensing Activities
NIMH
June 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
L-042-91/0	Bonner, Tom I	(b)(4);	BioSignal, Inc.	1-Jun-21						(b) (4), (b) (3) (A), (b) (6)
L-042-91/0	Buckley, Noel	(b)(6)	BioSignal, Inc.	1-Jun-21						

Note: L-042-91/0 split between NIMH; NINDS

NIH Patent Licensing Activities
NIMH
July 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-------------------	---------------------------	----------------------	---------------------

NIH Patent Licensing Activities
NIMH
August 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
L-261-16/0	Eiden, Maribeth V.	(b)(4);	Fred Hutchinson Cancer Research Cente	2-Aug-21						(b) (4), (b) (3) (A), (b) (6)
L-261-16/0	Wilson, Carolyn A.	(b)(6)	Fred Hutchinson Cancer Research Cente	2-Aug-21						
L-185-20/0	Drevets, Wayne C		Defender Pharmaceuticals, Inc	13-Aug-21						
L-185-20/0	Furey, Maura L.		Defender Pharmaceuticals, Inc	13-Aug-21						

NIH Patent Licensing Activities
NIMH
September 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
L-025-17/1	Zarate, Carlos A.	(b)(4);	Tocris Bioscience	16-Sep-21						(b) (4), (b) (3) (A), (b) (6)

Note: L-025-17/1 split between NCATS; NIA; NIMH

\$431,502.40	\$0.00	\$431,502.40	\$102,540.65	\$328,961.75
--------------	--------	--------------	--------------	--------------

NIH Patent Licensing Activities

NINDS
April 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
L-079-17/0	Warach, Steven J.	(b)(4);	VuEssence, Inc.	5-Apr-21						(b) (4), (b) (3) (A), (b) (6)
<i>Note: L-079-17/0 split between NIA; NINDS; NINR</i>										
L-182-04/2	Hou, Jean	(b)(4);	Novus Biologicals Inc	7-Apr-21						
L-182-04/2	Major, Eugene O	(b)(6)	Novus Biologicals Inc	7-Apr-21						
L-182-04/2	Messam, Conrad A		Novus Biologicals Inc	7-Apr-21						
L-012-01/2	Hsu, Yite		NeoMarkers, Inc.	15-Apr-21						
L-012-01/2	Youle, Richard J.		NeoMarkers, Inc.	15-Apr-21						
L-179-19/0	Brady, (b) (6) Roscoe O		Codexis, Inc.	15-Apr-21						
L-179-19/0	Murray, Gary J		Codexis, Inc.	15-Apr-21						
<i>Note: L-179-19/0 split between NIDCR; NINDS</i>										
L-007-19/0	Hsu, Yite	(b)(4);	Abcam plc	22-Apr-21						
L-007-19/0	Youle, Richard J.	(b)(6)	Abcam plc	22-Apr-21						
L-130-02/1	Hsu, Yite		Santa Cruz Biotechnology Inc	28-Apr-21						
L-130-02/1	Youle, Richard J.		Santa Cruz Biotechnology Inc	28-Apr-21						
L-130-02/1	Hsu, Yite		Santa Cruz Biotechnology Inc	28-Apr-21						
L-130-02/1	Youle, Richard J.		Santa Cruz Biotechnology Inc	28-Apr-21						
L-123-04/2	Hsu, Yite		Santa Cruz Biotechnology Inc	28-Apr-21						
L-123-04/2	Youle, Richard J.		Santa Cruz Biotechnology Inc	28-Apr-21						

NIH Patent Licensing Activities

NINDS
May 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
L-213-94/1	McVittie, Loris D.	(b)(4);	Eurofins Panlabs	1-May-21						(b) (4), (b) (3) (A), (b) (6)
L-213-94/1	Monsma, Jr., Frederick J.	(b)(6)	Eurofins Panlabs	1-May-21						
L-213-94/1	Sibley, David R.		Eurofins Panlabs	1-May-21						
<i>Note: L-213-94/1 split between NIMH; NINDS</i>										

NIH Patent Licensing Activities

NINDS
June 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-------------------	---------------------------	----------------------	---------------------

(b) (4), (b) (3) (A), (b) (6)

L-042-91/0 Brann, (b) (6) Mark R (b)(4); BioSignal, Inc. 1-Jun-21
Note: L-042-91/0 split between NIMH; NINDS (b)(6)

L-181-04/2 Hou, Jean Immuquest Ltd 14-Jun-21
 L-181-04/2 Major, Eugene O Immuquest Ltd 14-Jun-21
 L-181-04/2 Messam, Conrad A Immuquest Ltd 14-Jun-21

L-159-07/2 NINDS Hope Pharmaceuticals 17-Jun-21
Note: L-159-07/2 split between CC; NHLBI; NIDDK; NINDS

NIH Patent Licensing Activities
NINDS
July 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
L-121-08/0	Bankiewicz, Krystof S.	(b)(4);	Medtronic Inc	14-Jul-21						(b) (4), (b) (3) (A), (b) (6)
L-121-08/0	Lonser, Russell R	(b)(6)	Medtronic Inc	14-Jul-21						
L-121-08/0	Oldfield, (b) (6) Edward I	(b)(6)	Medtronic Inc	14-Jul-21						
<i>Note: L-121-08/0 split between NCI; NINDS</i>										
L-050-21/0	NINDS		CellRay, LLC	23-Jul-21						
<i>Note: L-050-21/0 split between NEI; NINDS</i>										
L-250-18/1	NINDS		Hello Bio Ltd.	28-Jul-21						
<i>Note: L-250-18/1 split between NIDA; NINDS</i>										
L-007-19/0	Hsu, Yite	(b)(4);	Abcam plc	29-Jul-21						
L-007-19/0	Youle, Richard J.	(b)(6)	Abcam plc	29-Jul-21						

NIH Patent Licensing Activities
NINDS
August 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
L-250-18/1	Sanchez Soto, Marta	(b)(4);	Hello Bio Ltd.	12-Aug-21						(b) (4), (b) (3) (A), (b) (6)
<i>Note: L-250-18/1 split between NIDA; NINDS</i>										
L-280-14/1	Amyot, Franck	(b)(4);	Arche Opitex Biomedical, Inc.	18-Aug-21						
L-280-14/1	Wasserman, Eric M.	(b)(6)	Arche Opitex Biomedical, Inc.	18-Aug-21						
<i>Note: L-280-14/1 split between NICHD; NINDS</i>										
L-208-01/3	Hou, Jean	(b)(4);	Millipore Sigma	27-Aug-21						
L-208-01/3	Major, Eugene O	(b)(6)	Millipore Sigma	27-Aug-21						
L-208-01/3	Messam, Conrad A	(b)(6)	Millipore Sigma	27-Aug-21						

NIH Patent Licensing Activities

NINDS
September 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
L-070-03/2	Hallett, Mark	(b)(4);	Brainsway, Inc.	1-Sep-21						(b) (4), (b) (3) (A), (b) (6)
L-070-03/2	Miranda, Pedro	(b)(6)	Brainsway, Inc.	1-Sep-21						
L-070-03/2	Roth, Yiftach		Brainsway, Inc.	1-Sep-21						
<i>Note: L-070-03/2 split between NIDA; NINDS</i>										
L-208-01/3	Hou, Jean		Millipore Sigma	2-Sep-21						
L-208-01/3	Major, Eugene O		Millipore Sigma	2-Sep-21						
L-208-01/3	Messam, Conrad A		Millipore Sigma	2-Sep-21						
L-070-03/2	Miranda, Pedro		Brainsway, Inc.	13-Sep-21						
L-070-03/2	Roth, Yiftach		Brainsway, Inc.	13-Sep-21						
<i>Note: L-070-03/2 split between NIDA; NINDS</i>										

\$459,987.59	\$0.00	\$459,987.59	\$119,606.50	\$340,381.09
--------------	--------	--------------	--------------	--------------

NIH Patent Licensing Activities
NINR
April 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
L-079-17/0	Barr, Taura L.	(b)(4);	VuEssence, Inc.	5-Apr-21						(b) (4), (b) (3) (A), (b) (6)
L-079-17/0	University of Pittsburgh	(b)(6)	VuEssence, Inc.	5-Apr-21						
<i>Note: L-079-17/0 split between NIA; NINDS; NINR</i>										

NIH Patent Licensing Activities
NINR
May 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	------------------	---------------------------	---------------------	---------------------

NIH Patent Licensing Activities
NINR
June 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-------------------	---------------------------	----------------------	---------------------

NIH Patent Licensing Activities
NINR
July 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-------------------	---------------------------	----------------------	---------------------

NIH Patent Licensing Activities
NINR
August 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	---------------------	---------------------------	------------------------	---------------------

NIH Patent Licensing Activities
NINR
September 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	------------------------	---------------------------	---------------------------	---------------------

(b) (4), (b) (3) (A), (b) (6)

NIH Patent Licensing Activities
OD
April 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total April Income	License Cumulative Income	Inventor Awards April	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	--------------------	---------------------------	-----------------------	---------------------

NIH Patent Licensing Activities
OD
May 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total May Income	License Cumulative Income	Inventor Awards May	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	------------------	---------------------------	---------------------	---------------------

NIH Patent Licensing Activities
OD
June 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total June Income	License Cumulative Income	Inventor Awards June	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	-------------------	---------------------------	----------------------	---------------------

NIH Patent Licensing Activities
OD
July 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total July Income	License Cumulative Income	Inventor Awards July	Net Remaining to IC
L-199-21/0	Davis, Matthew T.	(b)(4);	Atomwise	26-Jul-21						(b) (4), (b) (3) (A), (b) (6)
L-199-21/0	Meyer, Payam	(b)(6)	Atomwise	26-Jul-21						
L-199-21/0	Santangelo, George Michae		Atomwise	26-Jul-21						

NIH Patent Licensing Activities
OD
August 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total August Income	License Cumulative Income	Inventor Awards August	Net Remaining to IC
---------	----------	------------------	----------	-----------------	--------------------------------	--------------------------	---------------------	---------------------------	------------------------	---------------------

NIH Patent Licensing Activities
OD
September 2021

License	Inventor	Inventor Share %	Licensee	Date of Deposit	% of Sales/Ann. Min./Exec. Fee	Patent Prosecution Costs	Total September Income	License Cumulative Income	Inventor Awards September	Net Remaining to IC
					\$2,000.00	\$0.00	\$2,000.00		\$2,000.00	\$0.00